ID,report_name,ticker,report_date,arguments_clean,label,Processed_arguments_clean_list,Processed_arguments_clean_str,p_matches_without_negate,n_matches_without_negate,score_without_negate,p_matches_with_negate,n_matches_with_negate,score_with_negate,compound_score
1,"Ambarella, Inc._Attachment1(2).pdf",AMBA,1/30/2018,ambarella is well known for its market leading high performance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers in a move to diversify its business and lower its dependency on gopro ambarella has forayed into the vr camera space by launching h3 soc in january this year the company claims that the chip will work wonderfully for highend drones and vr cameras although it will be very tough for ambarella to compete against well established players such as nvidia and advanced micro we believe that given its track record of innovation the company has the potential to strengthen its position in the space nearly all automakers are now in various stages of developing selfdriving cars this has been creating huge demand for camera based socs as well as computer vision technology notably ambarella already has deep technical knowledge in camerabased socs and to enhance its computer vision capabilities the company acquired vislab in jul 2015 vislab developed the concept of computer vision and intelligent control systems for automotive and other commercial applications using the technology of vislab ambarella is planning to make chips for internetconnected security camera companies and drone manufacturers initially after that ambarella may target auto manufacturers,sell,"['ambarella', 'know', 'market', 'lead', 'high', 'performance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'diversify', 'business', 'lower', 'dependency', 'gopro', 'ambarella', 'foray', 'vr', 'camera', 'space', 'launch', 'h3', 'soc', 'january', 'year', 'company', 'claim', 'chip', 'work', 'wonderfully', 'highend', 'drone', 'vr', 'camera', 'tough', 'ambarella', 'compete', 'establish', 'player', 'nvidia', 'advanced', 'micro', 'believe', 'give', 'track', 'record', 'innovation', 'company', 'potential', 'strengthen', 'position', 'space', 'nearly', 'automaker', 'stage', 'develop', 'selfdriving', 'car', 'create', 'huge', 'demand', 'camera', 'base', 'soc', 'computer', 'vision', 'technology', 'notably', 'ambarella', 'deep', 'technical', 'knowledge', 'camerabased', 'soc', 'enhance', 'computer', 'vision', 'capabilitie', 'company', 'acquire', 'vislab', 'jul', '2015', 'vislab', 'develop', 'concept', 'computer', 'vision', 'intelligent', 'control', 'system', 'automotive', 'commercial', 'application', 'technology', 'vislab', 'ambarella', 'plan', 'chip', 'internetconnected', 'security', 'camera', 'company', 'drone', 'manufacturer', 'initially', 'ambarella', 'target', 'auto', 'manufacturer']",ambarella know market lead high performance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker diversify business lower dependency gopro ambarella foray vr camera space launch h3 soc january year company claim chip work wonderfully highend drone vr camera tough ambarella compete establish player nvidia advanced micro believe give track record innovation company potential strengthen position space nearly automaker stage develop selfdriving car create huge demand camera base soc computer vision technology notably ambarella deep technical knowledge camerabased soc enhance computer vision capabilitie company acquire vislab jul 2015 vislab develop concept computer vision intelligent control system automotive commercial application technology vislab ambarella plan chip internetconnected security camera company drone manufacturer initially ambarella target auto manufacturer,9,6,0.1875,9,6,0.1875,0.9666
2,"Ambarella, Inc._Attachment1(2).pdf",AMBA,6/11/2018,ambarella is well known for its market leading high performance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers ambarella has a broad portfolio of products that are tailored for meeting the specific needs of various end markets the companys h2 soc is one of the widely used technologies in the sports camera market which provide features such as flying camera flight control video analytics and wireless networking its sseries solutions are used in majority of the digital ip cameras apart from the aforementioned the company provides soc solutions for drone automotive dashboard and wearable cameras the company in 2018 started providing socs for virtualreality vr cameras new technologies internet penetration and invention of smart devices are driving demand for different kinds of cameras and broadcast infrastructure equipment mainly centered on highdefinition video and image quality along with advanced features transmission and analytics highdefinition cameras are now used in varied fields such as sports medical automobiles or mobiles etc with advancement in technology advancing video processing becoming a musthave feature across various end markets the industry has huge growth potential being one of the most cost and power efficient soc providers we believe ambarella is well positioned to grab the growing opportunity in this space,sell,"['ambarella', 'know', 'market', 'lead', 'high', 'performance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'ambarella', 'broad', 'portfolio', 'product', 'tailor', 'meet', 'specific', 'need', 'end', 'market', 'companys', 'h2', 'soc', 'widely', 'technology', 'sport', 'camera', 'market', 'provide', 'feature', 'fly', 'camera', 'flight', 'control', 'video', 'analytic', 'wireless', 'network', 'sserie', 'solution', 'majority', 'digital', 'ip', 'camera', 'apart', 'aforementioned', 'company', 'provide', 'soc', 'solution', 'drone', 'automotive', 'dashboard', 'wearable', 'camera', 'company', '2018', 'start', 'provide', 'soc', 'virtualreality', 'vr', 'camera', 'new', 'technology', 'internet', 'penetration', 'invention', 'smart', 'device', 'drive', 'demand', 'different', 'kind', 'camera', 'broadcast', 'infrastructure', 'equipment', 'mainly', 'center', 'highdefinition', 'video', 'image', 'quality', 'advanced', 'feature', 'transmission', 'analytic', 'highdefinition', 'camera', 'varied', 'field', 'sport', 'medical', 'automobile', 'mobile', 'etc', 'advancement', 'technology', 'advance', 'video', 'processing', 'musthave', 'feature', 'end', 'market', 'industry', 'huge', 'growth', 'potential', 'cost', 'power', 'efficient', 'soc', 'provider', 'believe', 'ambarella', 'positioned', 'grab', 'grow', 'opportunity', 'space']",ambarella know market lead high performance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker ambarella broad portfolio product tailor meet specific need end market companys h2 soc widely technology sport camera market provide feature fly camera flight control video analytic wireless network sserie solution majority digital ip camera apart aforementioned company provide soc solution drone automotive dashboard wearable camera company 2018 start provide soc virtualreality vr camera new technology internet penetration invention smart device drive demand different kind camera broadcast infrastructure equipment mainly center highdefinition video image quality advanced feature transmission analytic highdefinition camera varied field sport medical automobile mobile etc advancement technology advance video processing musthave feature end market industry huge growth potential cost power efficient soc provider believe ambarella positioned grab grow opportunity space,10,9,0.05,10,9,0.05,0.9678
3,"Ambarella, Inc._Attachment1(3).pdf",AMBA,10/30/2018,ambarella is making steady progress on the development and delivery of computer video solution based on its cvflow architecture the company released cvflow software developed kits supporting its cv2 and cv22 socs attracting positive consumer feedback ambarella is well known for its market leading high performance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers ambarella has a broad portfolio of products that are tailored for meeting the specific needs of various end markets the companys h2 soc is one of the widely used technologies in the sports camera market which provide features such as flying camera flight control video analytics and wireless networking its sseries solutions are used in majority of the digital ip cameras apart from the aforementioned the company provides soc solutions for drone automotive dashboard and wearable cameras in 2018 the company started providing socs for virtualreality vr cameras new technologies internet penetration and invention of smart devices are driving demand for different kinds of cameras and broadcast infrastructure equipment mainly centered on highdefinition video and image quality along with advanced features transmission and analytics highdefinition cameras are now used in varied fields such as sports medical automobiles or mobiles etc with advancement in technology advancing video processing becoming a musthave feature across various end markets the industry has huge growth potential being one of the most cost and power efficient soc providers we believe ambarella is well positioned to grab the growing opportunity in this space in a move to diversify its business and lower its dependency on gopro ambarella has forayed into the vr camera space by launching h3 soc in january 2017 the company claims that the chip will work wonderfully for highend drones and vr cameras although it will be very tough for ambarella to compete against well established players such as nvidia and advanced micro we believe that given its track record of innovation the company has the potential to strengthen its position in the space nearly all automakers are now in various stages of developing selfdriving cars this has been creating huge demand for camera based socs as well as computer vision technology notably ambarella already has deep technical knowledge in camerabased socs and to enhance its computer vision capabilities it acquired vislab in 2015 thus expanding its capabilities in making chips for internetconnected security cameras and automotive vision cameras ambarella expects the demand for security cameras with computer vision capability to continue to grow giving it an opportunity to increase its value contribution per camera and hence boost topline,buy,"['ambarella', 'make', 'steady', 'progress', 'development', 'delivery', 'computer', 'video', 'solution', 'base', 'cvflow', 'architecture', 'company', 'release', 'cvflow', 'software', 'develop', 'kit', 'support', 'cv2', 'cv22', 'soc', 'attract', 'positive', 'consumer', 'feedback', 'ambarella', 'know', 'market', 'lead', 'high', 'performance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'ambarella', 'broad', 'portfolio', 'product', 'tailor', 'meet', 'specific', 'need', 'end', 'market', 'companys', 'h2', 'soc', 'widely', 'technology', 'sport', 'camera', 'market', 'provide', 'feature', 'fly', 'camera', 'flight', 'control', 'video', 'analytic', 'wireless', 'network', 'sserie', 'solution', 'majority', 'digital', 'ip', 'camera', 'apart', 'aforementioned', 'company', 'provide', 'soc', 'solution', 'drone', 'automotive', 'dashboard', 'wearable', 'camera', '2018', 'company', 'start', 'provide', 'soc', 'virtualreality', 'vr', 'camera', 'new', 'technology', 'internet', 'penetration', 'invention', 'smart', 'device', 'drive', 'demand', 'different', 'kind', 'camera', 'broadcast', 'infrastructure', 'equipment', 'mainly', 'center', 'highdefinition', 'video', 'image', 'quality', 'advanced', 'feature', 'transmission', 'analytic', 'highdefinition', 'camera', 'varied', 'field', 'sport', 'medical', 'automobile', 'mobile', 'etc', 'advancement', 'technology', 'advance', 'video', 'processing', 'musthave', 'feature', 'end', 'market', 'industry', 'huge', 'growth', 'potential', 'cost', 'power', 'efficient', 'soc', 'provider', 'believe', 'ambarella', 'positioned', 'grab', 'grow', 'opportunity', 'space', 'diversify', 'business', 'lower', 'dependency', 'gopro', 'ambarella', 'foray', 'vr', 'camera', 'space', 'launch', 'h3', 'soc', 'january', '2017', 'company', 'claim', 'chip', 'work', 'wonderfully', 'highend', 'drone', 'vr', 'camera', 'tough', 'ambarella', 'compete', 'establish', 'player', 'nvidia', 'advanced', 'micro', 'believe', 'give', 'track', 'record', 'innovation', 'company', 'potential', 'strengthen', 'position', 'space', 'nearly', 'automaker', 'stage', 'develop', 'selfdriving', 'car', 'create', 'huge', 'demand', 'camera', 'base', 'soc', 'computer', 'vision', 'technology', 'notably', 'ambarella', 'deep', 'technical', 'knowledge', 'camerabased', 'soc', 'enhance', 'computer', 'vision', 'capability', 'acquire', 'vislab', '2015', 'expand', 'capability', 'make', 'chip', 'internetconnected', 'security', 'camera', 'automotive', 'vision', 'camera', 'ambarella', 'expect', 'demand', 'security', 'camera', 'computer', 'vision', 'capability', 'continue', 'grow', 'give', 'opportunity', 'increase', 'value', 'contribution', 'camera', 'boost', 'topline']",ambarella make steady progress development delivery computer video solution base cvflow architecture company release cvflow software develop kit support cv2 cv22 soc attract positive consumer feedback ambarella know market lead high performance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker ambarella broad portfolio product tailor meet specific need end market companys h2 soc widely technology sport camera market provide feature fly camera flight control video analytic wireless network sserie solution majority digital ip camera apart aforementioned company provide soc solution drone automotive dashboard wearable camera 2018 company start provide soc virtualreality vr camera new technology internet penetration invention smart device drive demand different kind camera broadcast infrastructure equipment mainly center highdefinition video image quality advanced feature transmission analytic highdefinition camera varied field sport medical automobile mobile etc advancement technology advance video processing musthave feature end market industry huge growth potential cost power efficient soc provider believe ambarella positioned grab grow opportunity space diversify business lower dependency gopro ambarella foray vr camera space launch h3 soc january 2017 company claim chip work wonderfully highend drone vr camera tough ambarella compete establish player nvidia advanced micro believe give track record innovation company potential strengthen position space nearly automaker stage develop selfdriving car create huge demand camera base soc computer vision technology notably ambarella deep technical knowledge camerabased soc enhance computer vision capability acquire vislab 2015 expand capability make chip internetconnected security camera automotive vision camera ambarella expect demand security camera computer vision capability continue grow give opportunity increase value contribution camera boost topline,19,11,0.25806451612903225,19,11,0.25806451612903225,0.9963
4,"Ambarella, Inc._Attachment1(3).pdf",AMBA,11/26/2020,ambarella is making steady progress on the development and delivery of computer video solution based on its cvflow architecture the company released cvflow software developed kits supporting its cv2 and cv22 socs attracting positive consumer feedback ambarella is well known for its market leading highperformance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers new technologies internet penetration and invention of smart devices are driving demand for different kinds of cameras and broadcast infrastructure equipment mainly centered on highdefinition video and image quality along with advanced features transmission and analytics highdefinition cameras are now used in varied fields such as sports medical automobiles or mobiles etc with advancement in technology advancing video processing becoming a musthave feature across various end markets the industry has huge growth potential being one of the most cost and power efficient soc providers we believe ambarella is well positioned to grab the growing opportunity in this space in a move to diversify its business and lower its dependency on gopro ambarella has forayed into the vr camera space by launching h3 soc in january 2017 since then the company has been continuously expanding its product portfolio in the highend drones and vr cameras space although it will be very tough for ambarella to compete against well established players such as nvidia and advanced micro we believe that given its track record of innovation the company has the potential to strengthen its position in the space nearly all automakers are now in various stages of developing selfdriving cars this has been creating huge demand for camerabased socs as well as computer vision technology notably ambarella already has deep technical knowledge in camerabased socs and to enhance its computer vision capabilities growing demand for automated driver assistant systems adas is a main driver design wins for automated parking systems are a positive ambarella expects the demand for security cameras with computer vision capability to continue to grow giving it an opportunity to increase its value contribution per camera and hence boost topline ambarella has a strong balance sheet with ample liquidity position and less debt obligations as of oct 31 2020 the company had cash and cash equivalents marketable securities of 424 million compared with 411 million as of jul 31 moreover operation lease liabilities at the end of its fiscal thirdquarter 2021 were only 95 million,sell,"['ambarella', 'make', 'steady', 'progress', 'development', 'delivery', 'computer', 'video', 'solution', 'base', 'cvflow', 'architecture', 'company', 'release', 'cvflow', 'software', 'develop', 'kit', 'support', 'cv2', 'cv22', 'soc', 'attract', 'positive', 'consumer', 'feedback', 'ambarella', 'know', 'market', 'lead', 'highperformance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'new', 'technology', 'internet', 'penetration', 'invention', 'smart', 'device', 'drive', 'demand', 'different', 'kind', 'camera', 'broadcast', 'infrastructure', 'equipment', 'mainly', 'center', 'highdefinition', 'video', 'image', 'quality', 'advanced', 'feature', 'transmission', 'analytic', 'highdefinition', 'camera', 'varied', 'field', 'sport', 'medical', 'automobile', 'mobile', 'etc', 'advancement', 'technology', 'advance', 'video', 'processing', 'musthave', 'feature', 'end', 'market', 'industry', 'huge', 'growth', 'potential', 'cost', 'power', 'efficient', 'soc', 'provider', 'believe', 'ambarella', 'positioned', 'grab', 'grow', 'opportunity', 'space', 'diversify', 'business', 'lower', 'dependency', 'gopro', 'ambarella', 'foray', 'vr', 'camera', 'space', 'launch', 'h3', 'soc', 'january', '2017', 'company', 'continuously', 'expand', 'product', 'portfolio', 'highend', 'drone', 'vr', 'camera', 'space', 'tough', 'ambarella', 'compete', 'establish', 'player', 'nvidia', 'advanced', 'micro', 'believe', 'give', 'track', 'record', 'innovation', 'company', 'potential', 'strengthen', 'position', 'space', 'nearly', 'automaker', 'stage', 'develop', 'selfdriving', 'car', 'create', 'huge', 'demand', 'camerabased', 'soc', 'computer', 'vision', 'technology', 'notably', 'ambarella', 'deep', 'technical', 'knowledge', 'camerabased', 'soc', 'enhance', 'computer', 'vision', 'capabilitie', 'grow', 'demand', 'automate', 'driver', 'assistant', 'system', 'adas', 'main', 'driver', 'design', 'win', 'automate', 'parking', 'system', 'positive', 'ambarella', 'expect', 'demand', 'security', 'camera', 'computer', 'vision', 'capability', 'continue', 'grow', 'give', 'opportunity', 'increase', 'value', 'contribution', 'camera', 'boost', 'topline', 'ambarella', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'debt', 'obligation', 'oct', '31', '2020', 'company', 'cash', 'cash', 'equivalent', 'marketable', 'security', '424', 'million', 'compare', '411', 'million', 'jul', '31', 'operation', 'lease', 'liability', 'end', 'fiscal', 'thirdquarter', '2021', '95', 'million']",ambarella make steady progress development delivery computer video solution base cvflow architecture company release cvflow software develop kit support cv2 cv22 soc attract positive consumer feedback ambarella know market lead highperformance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker new technology internet penetration invention smart device drive demand different kind camera broadcast infrastructure equipment mainly center highdefinition video image quality advanced feature transmission analytic highdefinition camera varied field sport medical automobile mobile etc advancement technology advance video processing musthave feature end market industry huge growth potential cost power efficient soc provider believe ambarella positioned grab grow opportunity space diversify business lower dependency gopro ambarella foray vr camera space launch h3 soc january 2017 company continuously expand product portfolio highend drone vr camera space tough ambarella compete establish player nvidia advanced micro believe give track record innovation company potential strengthen position space nearly automaker stage develop selfdriving car create huge demand camerabased soc computer vision technology notably ambarella deep technical knowledge camerabased soc enhance computer vision capabilitie grow demand automate driver assistant system adas main driver design win automate parking system positive ambarella expect demand security camera computer vision capability continue grow give opportunity increase value contribution camera boost topline ambarella strong balance sheet ample liquidity position debt obligation oct 31 2020 company cash cash equivalent marketable security 424 million compare 411 million jul 31 operation lease liability end fiscal thirdquarter 2021 95 million,21,12,0.2647058823529412,21,12,0.2647058823529412,0.996
5,"Ambarella, Inc._Attachment1(4).pdf",AMBA,12/3/2018,ambarella is making steady progress on the development and delivery of computer video solution based on its cvflow architecture the company released cvflow software developed kits supporting its cv2 and cv22 socs attracting positive consumer feedback ambarella is well known for its market leading high performance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers ambarella has a broad portfolio of products that are tailored for meeting the specific needs of various end markets the companys h2 soc is one of the widely used technologies in the sports camera market which provide features such as flying camera flight control video analytics and wireless networking its sseries solutions are used in majority of the digital ip cameras apart from the aforementioned the company provides soc solutions for drone automotive dashboard and wearable cameras in 2018 the company started providing socs for virtualreality vr cameras new technologies internet penetration and invention of smart devices are driving demand for different kinds of cameras and broadcast infrastructure equipment mainly centered on highdefinition video and image quality along with advanced features transmission and analytics highdefinition cameras are now used in varied fields such as sports medical automobiles or mobiles etc with advancement in technology advancing video processing becoming a musthave feature across various end markets the industry has huge growth potential being one of the most cost and power efficient soc providers we believe ambarella is well positioned to grab the growing opportunity in this space in a move to diversify its business and lower its dependency on gopro ambarella has forayed into the vr camera space by launching h3 soc in january 2017 the company claims that the chip will work wonderfully for highend drones and vr cameras although it will be very tough for ambarella to compete against well established players such as nvidia and advanced micro we believe that given its track record of innovation the company has the potential to strengthen its position in the space nearly all automakers are now in various stages of developing selfdriving cars this has been creating huge demand for camera based socs as well as computer vision technology notably ambarella already has deep technical knowledge in camerabased socs and to enhance its computer vision capabilities it acquired vislab in 2015 thus expanding its capabilities in making chips for internetconnected security cameras and automotive vision cameras ambarella expects the demand for security cameras with computer vision capability to continue to grow giving it an opportunity to increase its value contribution per camera and hence boost topline,buy,"['ambarella', 'make', 'steady', 'progress', 'development', 'delivery', 'computer', 'video', 'solution', 'base', 'cvflow', 'architecture', 'company', 'release', 'cvflow', 'software', 'develop', 'kit', 'support', 'cv2', 'cv22', 'soc', 'attract', 'positive', 'consumer', 'feedback', 'ambarella', 'know', 'market', 'lead', 'high', 'performance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'ambarella', 'broad', 'portfolio', 'product', 'tailor', 'meet', 'specific', 'need', 'end', 'market', 'companys', 'h2', 'soc', 'widely', 'technology', 'sport', 'camera', 'market', 'provide', 'feature', 'fly', 'camera', 'flight', 'control', 'video', 'analytic', 'wireless', 'network', 'sserie', 'solution', 'majority', 'digital', 'ip', 'camera', 'apart', 'aforementioned', 'company', 'provide', 'soc', 'solution', 'drone', 'automotive', 'dashboard', 'wearable', 'camera', '2018', 'company', 'start', 'provide', 'soc', 'virtualreality', 'vr', 'camera', 'new', 'technology', 'internet', 'penetration', 'invention', 'smart', 'device', 'drive', 'demand', 'different', 'kind', 'camera', 'broadcast', 'infrastructure', 'equipment', 'mainly', 'center', 'highdefinition', 'video', 'image', 'quality', 'advanced', 'feature', 'transmission', 'analytic', 'highdefinition', 'camera', 'varied', 'field', 'sport', 'medical', 'automobile', 'mobile', 'etc', 'advancement', 'technology', 'advance', 'video', 'processing', 'musthave', 'feature', 'end', 'market', 'industry', 'huge', 'growth', 'potential', 'cost', 'power', 'efficient', 'soc', 'provider', 'believe', 'ambarella', 'positioned', 'grab', 'grow', 'opportunity', 'space', 'diversify', 'business', 'lower', 'dependency', 'gopro', 'ambarella', 'foray', 'vr', 'camera', 'space', 'launch', 'h3', 'soc', 'january', '2017', 'company', 'claim', 'chip', 'work', 'wonderfully', 'highend', 'drone', 'vr', 'camera', 'tough', 'ambarella', 'compete', 'establish', 'player', 'nvidia', 'advanced', 'micro', 'believe', 'give', 'track', 'record', 'innovation', 'company', 'potential', 'strengthen', 'position', 'space', 'nearly', 'automaker', 'stage', 'develop', 'selfdriving', 'car', 'create', 'huge', 'demand', 'camera', 'base', 'soc', 'computer', 'vision', 'technology', 'notably', 'ambarella', 'deep', 'technical', 'knowledge', 'camerabased', 'soc', 'enhance', 'computer', 'vision', 'capability', 'acquire', 'vislab', '2015', 'expand', 'capability', 'make', 'chip', 'internetconnected', 'security', 'camera', 'automotive', 'vision', 'camera', 'ambarella', 'expect', 'demand', 'security', 'camera', 'computer', 'vision', 'capability', 'continue', 'grow', 'give', 'opportunity', 'increase', 'value', 'contribution', 'camera', 'boost', 'topline']",ambarella make steady progress development delivery computer video solution base cvflow architecture company release cvflow software develop kit support cv2 cv22 soc attract positive consumer feedback ambarella know market lead high performance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker ambarella broad portfolio product tailor meet specific need end market companys h2 soc widely technology sport camera market provide feature fly camera flight control video analytic wireless network sserie solution majority digital ip camera apart aforementioned company provide soc solution drone automotive dashboard wearable camera 2018 company start provide soc virtualreality vr camera new technology internet penetration invention smart device drive demand different kind camera broadcast infrastructure equipment mainly center highdefinition video image quality advanced feature transmission analytic highdefinition camera varied field sport medical automobile mobile etc advancement technology advance video processing musthave feature end market industry huge growth potential cost power efficient soc provider believe ambarella positioned grab grow opportunity space diversify business lower dependency gopro ambarella foray vr camera space launch h3 soc january 2017 company claim chip work wonderfully highend drone vr camera tough ambarella compete establish player nvidia advanced micro believe give track record innovation company potential strengthen position space nearly automaker stage develop selfdriving car create huge demand camera base soc computer vision technology notably ambarella deep technical knowledge camerabased soc enhance computer vision capability acquire vislab 2015 expand capability make chip internetconnected security camera automotive vision camera ambarella expect demand security camera computer vision capability continue grow give opportunity increase value contribution camera boost topline,19,11,0.25806451612903225,19,11,0.25806451612903225,0.9963
6,"Ambarella, Inc._Attachment1.pdf",AMBA,6/14/2017,ambarella is well known for its market leading high performance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers ambarella has a broad portfolio of products that are tailored for meeting the specific needs of various end markets the companys h2 soc is one of the widely used technologies in the sports camera market which provide features such as flying camera flight control video analytics and wireless networking its sseries solutions are used in majority of the digital ip cameras apart from the aforementioned the company provides soc solutions for drone automotive dashboard and wearable cameras the company has recently started providing socs for virtualreality vr cameras new technologies internet penetration and invention of smart devices are driving demand for different kinds of cameras and broadcast infrastructure equipment mainly centered on highdefinition video and image quality along with advanced features transmission and analytics highdefinition cameras are now used in varied fields such as sports medical automobiles or mobiles etc with advancement in technology advancing video processing becoming a musthave feature across various end markets the industry has huge growth potential being one of the most cost and power efficient soc providers we believe ambarella is well positioned to grab the growing opportunity in this space in a move to diversify its business and lower its dependency on gopro ambarella has forayed into the vr camera space by launching h3 soc in january this year the company claims that the chip will work wonderfully for highend drones and vr cameras although it will be very tough for ambarella to compete against well established players such as nvidia and advanced micro we believe that given its track record of innovation the company has the potential to strengthen its position in the space nearly all automakers are now in various stages of developing selfdriving cars this has been creating huge demand for camera based socs as well as computer vision technology notably ambarella already has deep technical knowledge in camerabased socs and to enhance its computer vision capabilities the company acquired vislab in jul 2015 vislab developed the concept of computer vision and intelligent control systems for automotive and other commercial applications using the technology of vislab ambarella is planning to make chips for internetconnected security camera companies and drone manufacturers initially after that ambarella may target auto manufacturers,buy,"['ambarella', 'know', 'market', 'lead', 'high', 'performance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'ambarella', 'broad', 'portfolio', 'product', 'tailor', 'meet', 'specific', 'need', 'end', 'market', 'companys', 'h2', 'soc', 'widely', 'technology', 'sport', 'camera', 'market', 'provide', 'feature', 'fly', 'camera', 'flight', 'control', 'video', 'analytic', 'wireless', 'network', 'sserie', 'solution', 'majority', 'digital', 'ip', 'camera', 'apart', 'aforementioned', 'company', 'provide', 'soc', 'solution', 'drone', 'automotive', 'dashboard', 'wearable', 'camera', 'company', 'recently', 'start', 'provide', 'soc', 'virtualreality', 'vr', 'camera', 'new', 'technology', 'internet', 'penetration', 'invention', 'smart', 'device', 'drive', 'demand', 'different', 'kind', 'camera', 'broadcast', 'infrastructure', 'equipment', 'mainly', 'center', 'highdefinition', 'video', 'image', 'quality', 'advanced', 'feature', 'transmission', 'analytic', 'highdefinition', 'camera', 'varied', 'field', 'sport', 'medical', 'automobile', 'mobile', 'etc', 'advancement', 'technology', 'advance', 'video', 'processing', 'musthave', 'feature', 'end', 'market', 'industry', 'huge', 'growth', 'potential', 'cost', 'power', 'efficient', 'soc', 'provider', 'believe', 'ambarella', 'positioned', 'grab', 'grow', 'opportunity', 'space', 'diversify', 'business', 'lower', 'dependency', 'gopro', 'ambarella', 'foray', 'vr', 'camera', 'space', 'launch', 'h3', 'soc', 'january', 'year', 'company', 'claim', 'chip', 'work', 'wonderfully', 'highend', 'drone', 'vr', 'camera', 'tough', 'ambarella', 'compete', 'establish', 'player', 'nvidia', 'advanced', 'micro', 'believe', 'give', 'track', 'record', 'innovation', 'company', 'potential', 'strengthen', 'position', 'space', 'nearly', 'automaker', 'stage', 'develop', 'selfdriving', 'car', 'create', 'huge', 'demand', 'camera', 'base', 'soc', 'computer', 'vision', 'technology', 'notably', 'ambarella', 'deep', 'technical', 'knowledge', 'camerabased', 'soc', 'enhance', 'computer', 'vision', 'capabilitie', 'company', 'acquire', 'vislab', 'jul', '2015', 'vislab', 'develop', 'concept', 'computer', 'vision', 'intelligent', 'control', 'system', 'automotive', 'commercial', 'application', 'technology', 'vislab', 'ambarella', 'plan', 'chip', 'internetconnected', 'security', 'camera', 'company', 'drone', 'manufacturer', 'initially', 'ambarella', 'target', 'auto', 'manufacturer']",ambarella know market lead high performance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker ambarella broad portfolio product tailor meet specific need end market companys h2 soc widely technology sport camera market provide feature fly camera flight control video analytic wireless network sserie solution majority digital ip camera apart aforementioned company provide soc solution drone automotive dashboard wearable camera company recently start provide soc virtualreality vr camera new technology internet penetration invention smart device drive demand different kind camera broadcast infrastructure equipment mainly center highdefinition video image quality advanced feature transmission analytic highdefinition camera varied field sport medical automobile mobile etc advancement technology advance video processing musthave feature end market industry huge growth potential cost power efficient soc provider believe ambarella positioned grab grow opportunity space diversify business lower dependency gopro ambarella foray vr camera space launch h3 soc january year company claim chip work wonderfully highend drone vr camera tough ambarella compete establish player nvidia advanced micro believe give track record innovation company potential strengthen position space nearly automaker stage develop selfdriving car create huge demand camera base soc computer vision technology notably ambarella deep technical knowledge camerabased soc enhance computer vision capabilitie company acquire vislab jul 2015 vislab develop concept computer vision intelligent control system automotive commercial application technology vislab ambarella plan chip internetconnected security camera company drone manufacturer initially ambarella target auto manufacturer,15,10,0.19230769230769232,15,10,0.19230769230769232,0.9908
7,"Ambarella, Inc._Attachment1.pdf",AMBA,1/5/2018,ambarella is well known for its market leading high performance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers ambarella has a broad portfolio of products that are tailored for meeting the specific needs of various end markets the companys h2 soc is one of the widely used technologies in the sports camera market which provide features such as flying camera flight control video analytics and wireless networking its sseries solutions are used in majority of the digital ip cameras apart from the aforementioned the company provides soc solutions for drone automotive dashboard and wearable cameras the company has recently started providing socs for virtualreality vr cameras new technologies internet penetration and invention of smart devices are driving demand for different kinds of cameras and broadcast infrastructure equipment mainly centered on highdefinition video and image quality along with advanced features transmission and analytics highdefinition cameras are now used in varied fields such as sports medical automobiles or mobiles etc with advancement in technology advancing video processing becoming a musthave feature across various end markets the industry has huge growth potential being one of the most cost and power efficient soc providers we believe ambarella is well positioned to grab the growing opportunity in this space in a move to diversify its business and lower its dependency on gopro ambarella has forayed into the vr camera space by launching h3 soc in january 2017 the company claims that the chip will work wonderfully for highend drones and vr cameras although it will be very tough for ambarella to compete against well established players such as nvidia and advanced micro we believe that given its track record of innovation the company has the potential to strengthen its position in the space nearly all automakers are now in various stages of developing selfdriving cars this has been creating huge demand for camera based socs as well as computer vision technology notably ambarella already has deep technical knowledge in camerabased socs and to enhance its computer vision capabilities the company acquired vislab in jul 2015 vislab developed the concept of computer vision and intelligent control systems for automotive and other commercial applications using the technology of vislab ambarella is planning to make chips for internetconnected security camera companies and drone manufacturers initially after that ambarella may target auto manufacturers,buy,"['ambarella', 'know', 'market', 'lead', 'high', 'performance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'ambarella', 'broad', 'portfolio', 'product', 'tailor', 'meet', 'specific', 'need', 'end', 'market', 'companys', 'h2', 'soc', 'widely', 'technology', 'sport', 'camera', 'market', 'provide', 'feature', 'fly', 'camera', 'flight', 'control', 'video', 'analytic', 'wireless', 'network', 'sserie', 'solution', 'majority', 'digital', 'ip', 'camera', 'apart', 'aforementioned', 'company', 'provide', 'soc', 'solution', 'drone', 'automotive', 'dashboard', 'wearable', 'camera', 'company', 'recently', 'start', 'provide', 'soc', 'virtualreality', 'vr', 'camera', 'new', 'technology', 'internet', 'penetration', 'invention', 'smart', 'device', 'drive', 'demand', 'different', 'kind', 'camera', 'broadcast', 'infrastructure', 'equipment', 'mainly', 'center', 'highdefinition', 'video', 'image', 'quality', 'advanced', 'feature', 'transmission', 'analytic', 'highdefinition', 'camera', 'varied', 'field', 'sport', 'medical', 'automobile', 'mobile', 'etc', 'advancement', 'technology', 'advance', 'video', 'processing', 'musthave', 'feature', 'end', 'market', 'industry', 'huge', 'growth', 'potential', 'cost', 'power', 'efficient', 'soc', 'provider', 'believe', 'ambarella', 'positioned', 'grab', 'grow', 'opportunity', 'space', 'diversify', 'business', 'lower', 'dependency', 'gopro', 'ambarella', 'foray', 'vr', 'camera', 'space', 'launch', 'h3', 'soc', 'january', '2017', 'company', 'claim', 'chip', 'work', 'wonderfully', 'highend', 'drone', 'vr', 'camera', 'tough', 'ambarella', 'compete', 'establish', 'player', 'nvidia', 'advanced', 'micro', 'believe', 'give', 'track', 'record', 'innovation', 'company', 'potential', 'strengthen', 'position', 'space', 'nearly', 'automaker', 'stage', 'develop', 'selfdriving', 'car', 'create', 'huge', 'demand', 'camera', 'base', 'soc', 'computer', 'vision', 'technology', 'notably', 'ambarella', 'deep', 'technical', 'knowledge', 'camerabased', 'soc', 'enhance', 'computer', 'vision', 'capabilitie', 'company', 'acquire', 'vislab', 'jul', '2015', 'vislab', 'develop', 'concept', 'computer', 'vision', 'intelligent', 'control', 'system', 'automotive', 'commercial', 'application', 'technology', 'vislab', 'ambarella', 'plan', 'chip', 'internetconnected', 'security', 'camera', 'company', 'drone', 'manufacturer', 'initially', 'ambarella', 'target', 'auto', 'manufacturer']",ambarella know market lead high performance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker ambarella broad portfolio product tailor meet specific need end market companys h2 soc widely technology sport camera market provide feature fly camera flight control video analytic wireless network sserie solution majority digital ip camera apart aforementioned company provide soc solution drone automotive dashboard wearable camera company recently start provide soc virtualreality vr camera new technology internet penetration invention smart device drive demand different kind camera broadcast infrastructure equipment mainly center highdefinition video image quality advanced feature transmission analytic highdefinition camera varied field sport medical automobile mobile etc advancement technology advance video processing musthave feature end market industry huge growth potential cost power efficient soc provider believe ambarella positioned grab grow opportunity space diversify business lower dependency gopro ambarella foray vr camera space launch h3 soc january 2017 company claim chip work wonderfully highend drone vr camera tough ambarella compete establish player nvidia advanced micro believe give track record innovation company potential strengthen position space nearly automaker stage develop selfdriving car create huge demand camera base soc computer vision technology notably ambarella deep technical knowledge camerabased soc enhance computer vision capabilitie company acquire vislab jul 2015 vislab develop concept computer vision intelligent control system automotive commercial application technology vislab ambarella plan chip internetconnected security camera company drone manufacturer initially ambarella target auto manufacturer,15,10,0.19230769230769232,15,10,0.19230769230769232,0.9908
8,"Ambarella, Inc._Attachment1.pdf",AMBA,6/4/2018,ambarella is well known for its market leading high performance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers ambarella has a broad portfolio of products that are tailored for meeting the specific needs of various end markets the companys h2 soc is one of the widely used technologies in the sports camera market which provide features such as flying camera flight control video analytics and wireless networking its sseries solutions are used in majority of the digital ip cameras apart from the aforementioned the company provides soc solutions for drone automotive dashboard and wearable cameras the company in 2018 started providing socs for virtualreality vr cameras new technologies internet penetration and invention of smart devices are driving demand for different kinds of cameras and broadcast infrastructure equipment mainly centered on highdefinition video and image quality along with advanced features transmission and analytics highdefinition cameras are now used in varied fields such as sports medical automobiles or mobiles etc with advancement in technology advancing video processing becoming a musthave feature across various end markets the industry has huge growth potential being one of the most cost and power efficient soc providers we believe ambarella is well positioned to grab the growing opportunity in this space in a move to diversify its business and lower its dependency on gopro ambarella has forayed into the vr camera space by launching h3 soc in january 2017 the company claims that the chip will work wonderfully for highend drones and vr cameras although it will be very tough for ambarella to compete against well established players such as nvidia and advanced micro we believe that given its track record of innovation the company has the potential to strengthen its position in the space nearly all automakers are now in various stages of developing selfdriving cars this has been creating huge demand for camera based socs as well as computer vision technology notably ambarella already has deep technical knowledge in camerabased socs and to enhance its computer vision capabilities the company acquired vislab in jul 2015 vislab developed the concept of computer vision and intelligent control systems for automotive and other commercial applications the acquisition of vislab has expanded ambarellas capabilities in making chips for internetconnected security cameras and automotive vision cameras,buy,"['ambarella', 'know', 'market', 'lead', 'high', 'performance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'ambarella', 'broad', 'portfolio', 'product', 'tailor', 'meet', 'specific', 'need', 'end', 'market', 'companys', 'h2', 'soc', 'widely', 'technology', 'sport', 'camera', 'market', 'provide', 'feature', 'fly', 'camera', 'flight', 'control', 'video', 'analytic', 'wireless', 'network', 'sserie', 'solution', 'majority', 'digital', 'ip', 'camera', 'apart', 'aforementioned', 'company', 'provide', 'soc', 'solution', 'drone', 'automotive', 'dashboard', 'wearable', 'camera', 'company', '2018', 'start', 'provide', 'soc', 'virtualreality', 'vr', 'camera', 'new', 'technology', 'internet', 'penetration', 'invention', 'smart', 'device', 'drive', 'demand', 'different', 'kind', 'camera', 'broadcast', 'infrastructure', 'equipment', 'mainly', 'center', 'highdefinition', 'video', 'image', 'quality', 'advanced', 'feature', 'transmission', 'analytic', 'highdefinition', 'camera', 'varied', 'field', 'sport', 'medical', 'automobile', 'mobile', 'etc', 'advancement', 'technology', 'advance', 'video', 'processing', 'musthave', 'feature', 'end', 'market', 'industry', 'huge', 'growth', 'potential', 'cost', 'power', 'efficient', 'soc', 'provider', 'believe', 'ambarella', 'positioned', 'grab', 'grow', 'opportunity', 'space', 'diversify', 'business', 'lower', 'dependency', 'gopro', 'ambarella', 'foray', 'vr', 'camera', 'space', 'launch', 'h3', 'soc', 'january', '2017', 'company', 'claim', 'chip', 'work', 'wonderfully', 'highend', 'drone', 'vr', 'camera', 'tough', 'ambarella', 'compete', 'establish', 'player', 'nvidia', 'advanced', 'micro', 'believe', 'give', 'track', 'record', 'innovation', 'company', 'potential', 'strengthen', 'position', 'space', 'nearly', 'automaker', 'stage', 'develop', 'selfdriving', 'car', 'create', 'huge', 'demand', 'camera', 'base', 'soc', 'computer', 'vision', 'technology', 'notably', 'ambarella', 'deep', 'technical', 'knowledge', 'camerabased', 'soc', 'enhance', 'computer', 'vision', 'capabilitie', 'company', 'acquire', 'vislab', 'jul', '2015', 'vislab', 'develop', 'concept', 'computer', 'vision', 'intelligent', 'control', 'system', 'automotive', 'commercial', 'application', 'acquisition', 'vislab', 'expand', 'ambarella', 'capability', 'make', 'chip', 'internetconnected', 'security', 'camera', 'automotive', 'vision', 'camera']",ambarella know market lead high performance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker ambarella broad portfolio product tailor meet specific need end market companys h2 soc widely technology sport camera market provide feature fly camera flight control video analytic wireless network sserie solution majority digital ip camera apart aforementioned company provide soc solution drone automotive dashboard wearable camera company 2018 start provide soc virtualreality vr camera new technology internet penetration invention smart device drive demand different kind camera broadcast infrastructure equipment mainly center highdefinition video image quality advanced feature transmission analytic highdefinition camera varied field sport medical automobile mobile etc advancement technology advance video processing musthave feature end market industry huge growth potential cost power efficient soc provider believe ambarella positioned grab grow opportunity space diversify business lower dependency gopro ambarella foray vr camera space launch h3 soc january 2017 company claim chip work wonderfully highend drone vr camera tough ambarella compete establish player nvidia advanced micro believe give track record innovation company potential strengthen position space nearly automaker stage develop selfdriving car create huge demand camera base soc computer vision technology notably ambarella deep technical knowledge camerabased soc enhance computer vision capabilitie company acquire vislab jul 2015 vislab develop concept computer vision intelligent control system automotive commercial application acquisition vislab expand ambarella capability make chip internetconnected security camera automotive vision camera,15,10,0.19230769230769232,15,10,0.19230769230769232,0.9921
9,"Ambarella, Inc._Attachment1.pdf",AMBA,9/6/2018,ambarellas efforts toward expanding its reach in other markets such as ip security automotive nongopro wearable and dronesflying cameras and simultaneously lower dependency on gopro will drive longterm growth the company is making steady progress on the development and delivery of computer video solution based on its cvflow architecture the company released cvflow software developed kits supporting its cv2 and cv22 socs attracting positive consumer feedback ambarella is well known for its market leading high performance video processing socs which consume lowest power in this space the companys proprietary video and image processing socs are highly configurable providing it a cost and power advantage against its rivals which uses multiple expensive semiconductors in their video and image processing solutions this makes ambarella a suitable choice for wearable camera ip camera automotive dashboard cameras and drone camera makers ambarella has a broad portfolio of products that are tailored for meeting the specific needs of various end markets the companys h2 soc is one of the widely used technologies in the sports camera market which provide features such as flying camera flight control video analytics and wireless networking its sseries solutions are used in majority of the digital ip cameras apart from the aforementioned the company provides soc solutions for drone automotive dashboard and wearable cameras in 2018 the company started providing socs for virtualreality vr cameras new technologies internet penetration and invention of smart devices are driving demand for different kinds of cameras and broadcast infrastructure equipment mainly centered on highdefinition video and image quality along with advanced features transmission and analytics highdefinition cameras are now used in varied fields such as sports medical automobiles or mobiles etc with advancement in technology advancing video processing becoming a musthave feature across various end markets the industry has huge growth potential being one of the most cost and power efficient soc providers we believe ambarella is well positioned to grab the growing opportunity in this space in a move to diversify its business and lower its dependency on gopro ambarella has forayed into the vr camera space by launching h3 soc in january 2017 the company claims that the chip will work wonderfully for highend drones and vr cameras although it will be very tough for ambarella to compete against well established players such as nvidia and advanced micro we believe that given its track record of innovation the company has the potential to strengthen its position in the space nearly all automakers are now in various stages of developing selfdriving cars this has been creating huge demand for camera based socs as well as computer vision technology notably ambarella already has deep technical knowledge in camerabased socs and to enhance its computer vision capabilities the company acquired vislab in jul 2015 thus expanding its capabilities in making chips for internetconnected security cameras and automotive vision cameras ambarella expects the demand for security cameras with computer vision capability to continue to grow giving it an opportunity to increase its value contribution per camera and hence boost topline,sell,"['ambarella', 'effort', 'expand', 'reach', 'market', 'ip', 'security', 'automotive', 'nongopro', 'wearable', 'dronesflying', 'camera', 'simultaneously', 'low', 'dependency', 'gopro', 'drive', 'longterm', 'growth', 'company', 'make', 'steady', 'progress', 'development', 'delivery', 'computer', 'video', 'solution', 'base', 'cvflow', 'architecture', 'company', 'release', 'cvflow', 'software', 'develop', 'kit', 'support', 'cv2', 'cv22', 'soc', 'attract', 'positive', 'consumer', 'feedback', 'ambarella', 'know', 'market', 'lead', 'high', 'performance', 'video', 'processing', 'soc', 'consume', 'low', 'power', 'space', 'companys', 'proprietary', 'video', 'image', 'processing', 'soc', 'highly', 'configurable', 'provide', 'cost', 'power', 'advantage', 'rival', 'use', 'multiple', 'expensive', 'semiconductor', 'video', 'image', 'processing', 'solution', 'make', 'ambarella', 'suitable', 'choice', 'wearable', 'camera', 'ip', 'camera', 'automotive', 'dashboard', 'camera', 'drone', 'camera', 'maker', 'ambarella', 'broad', 'portfolio', 'product', 'tailor', 'meet', 'specific', 'need', 'end', 'market', 'companys', 'h2', 'soc', 'widely', 'technology', 'sport', 'camera', 'market', 'provide', 'feature', 'fly', 'camera', 'flight', 'control', 'video', 'analytic', 'wireless', 'network', 'sserie', 'solution', 'majority', 'digital', 'ip', 'camera', 'apart', 'aforementioned', 'company', 'provide', 'soc', 'solution', 'drone', 'automotive', 'dashboard', 'wearable', 'camera', '2018', 'company', 'start', 'provide', 'soc', 'virtualreality', 'vr', 'camera', 'new', 'technology', 'internet', 'penetration', 'invention', 'smart', 'device', 'drive', 'demand', 'different', 'kind', 'camera', 'broadcast', 'infrastructure', 'equipment', 'mainly', 'center', 'highdefinition', 'video', 'image', 'quality', 'advanced', 'feature', 'transmission', 'analytic', 'highdefinition', 'camera', 'varied', 'field', 'sport', 'medical', 'automobile', 'mobile', 'etc', 'advancement', 'technology', 'advance', 'video', 'processing', 'musthave', 'feature', 'end', 'market', 'industry', 'huge', 'growth', 'potential', 'cost', 'power', 'efficient', 'soc', 'provider', 'believe', 'ambarella', 'positioned', 'grab', 'grow', 'opportunity', 'space', 'diversify', 'business', 'lower', 'dependency', 'gopro', 'ambarella', 'foray', 'vr', 'camera', 'space', 'launch', 'h3', 'soc', 'january', '2017', 'company', 'claim', 'chip', 'work', 'wonderfully', 'highend', 'drone', 'vr', 'camera', 'tough', 'ambarella', 'compete', 'establish', 'player', 'nvidia', 'advanced', 'micro', 'believe', 'give', 'track', 'record', 'innovation', 'company', 'potential', 'strengthen', 'position', 'space', 'nearly', 'automaker', 'stage', 'develop', 'selfdriving', 'car', 'create', 'huge', 'demand', 'camera', 'base', 'soc', 'computer', 'vision', 'technology', 'notably', 'ambarella', 'deep', 'technical', 'knowledge', 'camerabased', 'soc', 'enhance', 'computer', 'vision', 'capabilitie', 'company', 'acquire', 'vislab', 'jul', '2015', 'expand', 'capability', 'make', 'chip', 'internetconnected', 'security', 'camera', 'automotive', 'vision', 'camera', 'ambarella', 'expect', 'demand', 'security', 'camera', 'computer', 'vision', 'capability', 'continue', 'grow', 'give', 'opportunity', 'increase', 'value', 'contribution', 'camera', 'boost', 'topline']",ambarella effort expand reach market ip security automotive nongopro wearable dronesflying camera simultaneously low dependency gopro drive longterm growth company make steady progress development delivery computer video solution base cvflow architecture company release cvflow software develop kit support cv2 cv22 soc attract positive consumer feedback ambarella know market lead high performance video processing soc consume low power space companys proprietary video image processing soc highly configurable provide cost power advantage rival use multiple expensive semiconductor video image processing solution make ambarella suitable choice wearable camera ip camera automotive dashboard camera drone camera maker ambarella broad portfolio product tailor meet specific need end market companys h2 soc widely technology sport camera market provide feature fly camera flight control video analytic wireless network sserie solution majority digital ip camera apart aforementioned company provide soc solution drone automotive dashboard wearable camera 2018 company start provide soc virtualreality vr camera new technology internet penetration invention smart device drive demand different kind camera broadcast infrastructure equipment mainly center highdefinition video image quality advanced feature transmission analytic highdefinition camera varied field sport medical automobile mobile etc advancement technology advance video processing musthave feature end market industry huge growth potential cost power efficient soc provider believe ambarella positioned grab grow opportunity space diversify business lower dependency gopro ambarella foray vr camera space launch h3 soc january 2017 company claim chip work wonderfully highend drone vr camera tough ambarella compete establish player nvidia advanced micro believe give track record innovation company potential strengthen position space nearly automaker stage develop selfdriving car create huge demand camera base soc computer vision technology notably ambarella deep technical knowledge camerabased soc enhance computer vision capabilitie company acquire vislab jul 2015 expand capability make chip internetconnected security camera automotive vision camera ambarella expect demand security camera computer vision capability continue grow give opportunity increase value contribution camera boost topline,19,13,0.18181818181818182,19,13,0.18181818181818182,0.9967
10,"Ambarella, Inc._Attachment1.pdf",AMBA,11/18/2020,ambarella is making steady progress on the development and delivery of computer video solution based on its cvflow architecture the company released cvflow software,buy,"['ambarella', 'make', 'steady', 'progress', 'development', 'delivery', 'computer', 'video', 'solution', 'base', 'cvflow', 'architecture', 'company', 'release', 'cvflow', 'software']",ambarella make steady progress development delivery computer video solution base cvflow architecture company release cvflow software,1,1,0.0,1,1,0.0,0.6249
11,AVEO Pharmaceuticals Inc_Attachment1(3).pdf,AVEO,7/2/2020,fotivda approval a positive aveo got a boost with the eu approval of its lead product fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval was based on data from tivo1 study and was a huge boost to aveo given the lucrative firstline rcc market in europe it also triggered a payment of 4 million from eusa pharma to aveo the company also receives additional milestone fees on the reimbursement approval obtained by eusa,sell,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'product', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'base', 'datum', 'tivo1', 'study', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'company', 'receive', 'additional', 'milestone', 'fee', 'reimbursement', 'approval', 'obtain', 'eusa']",fotivda approval positive aveo get boost eu approval lead product fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval base datum tivo1 study huge boost aveo give lucrative firstline rcc market europe trigger payment 4 million eusa pharma aveo company receive additional milestone fee reimbursement approval obtain eusa,6,2,0.4444444444444444,6,2,0.4444444444444444,0.9732
12,AVEO Pharmaceuticals Inc_Attachment1.pdf,AVEO,8/19/2020,fotivda approval a positive aveo got a boost with the eu approval of its lead product fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval was based on data from tivo1 study and was a huge boost to aveo given the lucrative firstline rcc market in europe it also triggered a payment of 4 million from eusa pharma to aveo the company also receives additional milestone fees on the reimbursement approval obtained by eusa,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'product', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'base', 'datum', 'tivo1', 'study', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'company', 'receive', 'additional', 'milestone', 'fee', 'reimbursement', 'approval', 'obtain', 'eusa']",fotivda approval positive aveo get boost eu approval lead product fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval base datum tivo1 study huge boost aveo give lucrative firstline rcc market europe trigger payment 4 million eusa pharma aveo company receive additional milestone fee reimbursement approval obtain eusa,6,2,0.4444444444444444,6,2,0.4444444444444444,0.9732
13,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,5/24/2017,tivozanib progress encouraging aveo has made significant progress with its lead pipeline candidate tivozanib it is currently under review in the eu for the firstline treatment of advanced rcc the regulatory application was submitted by aveos partner eusa pharma a final response on the approval status of the candidate is expected in the first half of 2017 the candidates approval will be a huge boost for aveo given the lucrative firstline rcc market in europe meanwhile tivozanib is being evaluated in a couple of additional studies for the thirdline treatment of rcc and advanced rcc zacks equity research aveo wwwzackscom page 3 of 8,sell,"['tivozanib', 'progress', 'encourage', 'aveo', 'significant', 'progress', 'lead', 'pipeline', 'candidate', 'tivozanib', 'currently', 'review', 'eu', 'firstline', 'treatment', 'advanced', 'rcc', 'regulatory', 'application', 'submit', 'aveos', 'partner', 'eusa', 'pharma', 'final', 'response', 'approval', 'status', 'candidate', 'expect', 'half', '2017', 'candidate', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'tivozanib', 'evaluate', 'couple', 'additional', 'study', 'thirdline', 'treatment', 'rcc', 'advanced', 'rcc', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",tivozanib progress encourage aveo significant progress lead pipeline candidate tivozanib currently review eu firstline treatment advanced rcc regulatory application submit aveos partner eusa pharma final response approval status candidate expect half 2017 candidate approval huge boost aveo give lucrative firstline rcc market europe tivozanib evaluate couple additional study thirdline treatment rcc advanced rcc zacks equity research aveo wwwzackscom page 3 8,8,3,0.4166666666666667,8,3,0.4166666666666667,0.9716
14,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,12/6/2017,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the first quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in june 2017 the company announced that the study has progressed to phase ii based on successful completion of the phase i dose escalation study the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av 380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications zacks equity research aveo wwwzackscom page 3 of 7,sell,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'june', '2017', 'company', 'announce', 'study', 'progress', 'phase', 'ii', 'base', 'successful', 'completion', 'phase', 'dose', 'escalation', 'study', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av', '380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '7']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc june 2017 company announce study progress phase ii base successful completion phase dose escalation study phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av 380 related antibody bind gdf15 treatment prevention disease condition indication zacks equity research aveo wwwzackscom page 3 7,21,12,0.2647058823529412,21,12,0.2647058823529412,0.9967
15,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,1/9/2018,share price outperformance aveos share price movement shows that the stock has significantly outperformed the industry in the past year in fact aveo has gained 4592 during this period compared with an increase of 23 for the industry fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the first quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in june 2017 the company announced that the study has progressed to phase ii based on successful completion of the phase i dose escalation study the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments in the absence of any approved product meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63990 new cases of rcc will be diagnosed in the united states in 2017 however prognosis of the disease is weak given that approximately 14400 patients are expected to die from the disease in the united states in 2017 indicating the need for newer therapies moreover as per may 2017 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'past', 'year', 'fact', 'aveo', 'gain', '4592', 'period', 'compare', 'increase', '23', 'industry', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'june', '2017', 'company', 'announce', 'study', 'progress', 'phase', 'ii', 'base', 'successful', 'completion', 'phase', 'dose', 'escalation', 'study', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'absence', 'approve', 'product', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63990', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2017', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14400', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2017', 'indicate', 'need', 'new', 'therapy', '2017', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock significantly outperform industry past year fact aveo gain 4592 period compare increase 23 industry fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc june 2017 company announce study progress phase ii base successful completion phase dose escalation study phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment absence approve product company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63990 new case rcc diagnose united states 2017 prognosis disease weak give approximately 14400 patient expect die disease united states 2017 indicate need new therapy 2017 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,24,20,0.08888888888888889,24,20,0.08888888888888889,0.9962
16,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,5/30/2018,share price outperformance aveos share price movement shows that the stock has significantly outperformed the industry in the past year in fact aveo has gained 2071 during this period compared with an decrease of 72 for the industry fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified topline data is expected in the third quarter of 2018 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'past', 'year', 'fact', 'aveo', 'gain', '2071', 'period', 'compare', 'decrease', '72', 'industry', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodified', 'topline', 'datum', 'expect', 'quarter', '2018', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock significantly outperform industry past year fact aveo gain 2071 period compare decrease 72 industry fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodified topline datum expect quarter 2018 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,24,20,0.08888888888888889,24,20,0.08888888888888889,0.9954
17,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,10/10/2018,share price outperformance aveos share price movement shows that the stock has outperformed the industry so far this year shares of aveo have gained 25 compared with the industrys decrease of 114 fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified topline data is expected in the fourth quarter of 2018 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'outperform', 'industry', 'far', 'year', 'share', 'aveo', 'gain', '25', 'compare', 'industrys', 'decrease', '114', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodified', 'topline', 'datum', 'expect', 'fourth', 'quarter', '2018', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock outperform industry far year share aveo gain 25 compare industrys decrease 114 fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodified topline datum expect fourth quarter 2018 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,25,22,0.0625,25,22,0.0625,0.996
18,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,10/10/2018,string of pipeline setbacks aveo has suffered a string of pipeline setbacks in the past tivozanib had received a complete response letter crl from the fda in jun 2013 for the firstline treatment of advanced rcc citing concerns regarding the negative trend in overall survival in the pivotal phase iii study we note that the company is currently conducting the tivo3 study on tivozanib to address the concerns raised by the regulatory agency in its crl timely approval would have allowed the company to start generating revenues from tivozanib meanwhile aveo does not plan to conduct further studies on tivozanib for the treatment of metastatic colorectal cancer till the time an assay used to measure serum neuropilin1 in firstline colorectal cancer patients is identified we note that the phase ii baton breast cancer study on tivozanib was stopped due to insufficient enrollment meanwhile a phase ii study that evaluated ficlatuzumab in combination with iressa for the treatment of firstline nonsmall cell lung cancer nsclc demonstrated disappointing results based on the findings from the interim analysis and slow enrollment aveo and biodesix discontinued the phase ii focal study that was conducted to evaluate ficlatuzumab in combination with tarceva in the subset of patients with firstline advanced nsclc in september 2016 similar setbacks in the future could hinder the companys pipeline progress and have an adverse impact on the stock dependence on partners aveo is heavily dependent on partnerships for the development and commercialization of its pipeline zacks equity research aveo wwwzackscom page 3 of 8,sell,"['string', 'pipeline', 'setback', 'aveo', 'suffer', 'string', 'pipeline', 'setback', 'past', 'tivozanib', 'receive', 'complete', 'response', 'letter', 'crl', 'fda', 'jun', '2013', 'firstline', 'treatment', 'advanced', 'rcc', 'cite', 'concern', 'negative', 'trend', 'overall', 'survival', 'pivotal', 'phase', 'iii', 'study', 'note', 'company', 'currently', 'conduct', 'tivo3', 'study', 'tivozanib', 'address', 'concern', 'raise', 'regulatory', 'agency', 'crl', 'timely', 'approval', 'allow', 'company', 'start', 'generate', 'revenue', 'tivozanib', 'aveo', 'plan', 'conduct', 'study', 'tivozanib', 'treatment', 'metastatic', 'colorectal', 'cancer', 'till', 'time', 'assay', 'measure', 'serum', 'neuropilin1', 'firstline', 'colorectal', 'cancer', 'patient', 'identify', 'note', 'phase', 'ii', 'baton', 'breast', 'cancer', 'study', 'tivozanib', 'stop', 'insufficient', 'enrollment', 'phase', 'ii', 'study', 'evaluate', 'ficlatuzumab', 'combination', 'iressa', 'treatment', 'firstline', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'demonstrate', 'disappointing', 'result', 'base', 'finding', 'interim', 'analysis', 'slow', 'enrollment', 'aveo', 'biodesix', 'discontinue', 'phase', 'ii', 'focal', 'study', 'conduct', 'evaluate', 'ficlatuzumab', 'combination', 'tarceva', 'subset', 'patient', 'firstline', 'advanced', 'nsclc', 'september', '2016', 'similar', 'setback', 'future', 'hinder', 'company', 'pipeline', 'progress', 'adverse', 'impact', 'stock', 'dependence', 'partner', 'aveo', 'heavily', 'dependent', 'partnership', 'development', 'commercialization', 'pipeline', 'zack', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",string pipeline setback aveo suffer string pipeline setback past tivozanib receive complete response letter crl fda jun 2013 firstline treatment advanced rcc cite concern negative trend overall survival pivotal phase iii study note company currently conduct tivo3 study tivozanib address concern raise regulatory agency crl timely approval allow company start generate revenue tivozanib aveo plan conduct study tivozanib treatment metastatic colorectal cancer till time assay measure serum neuropilin1 firstline colorectal cancer patient identify note phase ii baton breast cancer study tivozanib stop insufficient enrollment phase ii study evaluate ficlatuzumab combination iressa treatment firstline nonsmall cell lung cancer nsclc demonstrate disappointing result base finding interim analysis slow enrollment aveo biodesix discontinue phase ii focal study conduct evaluate ficlatuzumab combination tarceva subset patient firstline advanced nsclc september 2016 similar setback future hinder company pipeline progress adverse impact stock dependence partner aveo heavily dependent partnership development commercialization pipeline zack equity research aveo wwwzackscom page 3 8,4,18,-0.6086956521739131,4,18,-0.6086956521739131,-0.9747
19,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,2/11/2019,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified in november 2018 aveo announced positive topline data from the phase iii tivo3 study which compared fotivda with nexavar in patients suffering highly refractory advanced or metastatic rcc the study met primary endpoint by demonstrating a statistically significant benefit in progressionfree survival pfsthe company plans to submit a new drug application nda in the next six months data from this study along with the previously completed tivo1 evaluation will support the filing of a regulatory application for fotivdas approval in the united states as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 in october 2018 aveo along with eusa pharma presented updated interim results from the phase ii portion of the tinivo program the study which evaluated fotivda in combination with opdivo demonstrated a favorable safety and efficacy profile pertaining to the treatment of advancedmetastatic rcc the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab aveo is developing ficlatuzumab in combination with lillys erbitux in a phase ii study for treating metastatic head and neck squamous cell carcinoma in december 2018 aveo enetred into a collaboration with astrazeneca to evalute the latters imfinzi in combination with aveos fotivda the phase iii study will evaluate the combo for treating firstline hepatocellular carcinoma the phase i part of the study is expected to begin in 2019 such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodifie', 'november', '2018', 'aveo', 'announce', 'positive', 'topline', 'datum', 'phase', 'iii', 'tivo3', 'study', 'compare', 'fotivda', 'nexavar', 'patient', 'suffer', 'highly', 'refractory', 'advanced', 'metastatic', 'rcc', 'study', 'meet', 'primary', 'endpoint', 'demonstrate', 'statistically', 'significant', 'benefit', 'progressionfree', 'survival', 'pfsthe', 'company', 'plan', 'submit', 'new', 'drug', 'application', 'nda', 'month', 'datum', 'study', 'previously', 'complete', 'tivo1', 'evaluation', 'support', 'filing', 'regulatory', 'application', 'fotivdas', 'approval', 'united', 'states', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'october', '2018', 'aveo', 'eusa', 'pharma', 'present', 'update', 'interim', 'result', 'phase', 'ii', 'portion', 'tinivo', 'program', 'study', 'evaluate', 'fotivda', 'combination', 'opdivo', 'demonstrate', 'favorable', 'safety', 'efficacy', 'profile', 'pertain', 'treatment', 'advancedmetastatic', 'rcc', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'aveo', 'develop', 'ficlatuzumab', 'combination', 'lillys', 'erbitux', 'phase', 'ii', 'study', 'treat', 'metastatic', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'december', '2018', 'aveo', 'enetre', 'collaboration', 'astrazeneca', 'evalute', 'latter', 'imfinzi', 'combination', 'aveo', 'fotivda', 'phase', 'iii', 'study', 'evaluate', 'combo', 'treat', 'firstline', 'hepatocellular', 'carcinoma', 'phase', 'study', 'expect', 'begin', '2019', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodifie november 2018 aveo announce positive topline datum phase iii tivo3 study compare fotivda nexavar patient suffer highly refractory advanced metastatic rcc study meet primary endpoint demonstrate statistically significant benefit progressionfree survival pfsthe company plan submit new drug application nda month datum study previously complete tivo1 evaluation support filing regulatory application fotivdas approval united states firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 october 2018 aveo eusa pharma present update interim result phase ii portion tinivo program study evaluate fotivda combination opdivo demonstrate favorable safety efficacy profile pertain treatment advancedmetastatic rcc phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab aveo develop ficlatuzumab combination lillys erbitux phase ii study treat metastatic head neck squamous cell carcinoma december 2018 aveo enetre collaboration astrazeneca evalute latter imfinzi combination aveo fotivda phase iii study evaluate combo treat firstline hepatocellular carcinoma phase study expect begin 2019 deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,29,26,0.05357142857142857,29,26,0.05357142857142857,0.9968
20,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,3/19/2019,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in october 2018 aveo along with eusa pharma presented updated interim results from the phase ii portion of the tinivo program the study showed a favorable safety and efficacy profile pertaining to the treatment of advancedmetastatic rcc the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc aveo is planning to further develop tivozanib as a combination therapy with immune checkpoint inhibitors for the treatment of rcc and hcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab aveo is developing ficlatuzumab in combination with lillys erbitux in a phase ii study for treating metastatic head and neck squamous cell carcinoma such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 73820 new cases of rcc will be diagnosed in the united states in 2019 however prognosis of the disease is weak given that approximately 14770 patients are expected to die from the disease in the united states indicating the need for newer therapies once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'october', '2018', 'aveo', 'eusa', 'pharma', 'present', 'update', 'interim', 'result', 'phase', 'ii', 'portion', 'tinivo', 'program', 'study', 'show', 'favorable', 'safety', 'efficacy', 'profile', 'pertain', 'treatment', 'advancedmetastatic', 'rcc', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'aveo', 'plan', 'develop', 'tivozanib', 'combination', 'therapy', 'immune', 'checkpoint', 'inhibitor', 'treatment', 'rcc', 'hcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'aveo', 'develop', 'ficlatuzumab', 'combination', 'lillys', 'erbitux', 'phase', 'ii', 'study', 'treat', 'metastatic', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '73820', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2019', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14770', 'patient', 'expect', 'die', 'disease', 'united', 'states', 'indicate', 'need', 'new', 'therapy', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc october 2018 aveo eusa pharma present update interim result phase ii portion tinivo program study show favorable safety efficacy profile pertain treatment advancedmetastatic rcc phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc aveo plan develop tivozanib combination therapy immune checkpoint inhibitor treatment rcc hcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab aveo develop ficlatuzumab combination lillys erbitux phase ii study treat metastatic head neck squamous cell carcinoma deal provide aveo need fund form license fee upfront milestone payment lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 73820 new case rcc diagnose united states 2019 prognosis disease weak give approximately 14770 patient expect die disease united states indicate need new therapy approve tivozanib provide alternative treatment option patient huge boost company,22,18,0.0975609756097561,22,18,0.0975609756097561,0.9965
21,"AVEO Pharmaceuticals, Inc._Attachment1(2).pdf",AVEO,3/19/2019,string of pipeline setbacks aveo has suffered a string of pipeline setbacks in the past tivozanib had received a complete response letter crl from the fda in jun 2013 for the firstline treatment of advanced rcc citing concerns regarding the negative trend in overall survival in the pivotal phase iii study we note that the company is currently conducting the tivo3 study on tivozanib to address the concerns raised by the regulatory agency in its crl timely approval would have allowed the company to start generating revenues from tivozanib in january 2019 aveo faced a major setback when it had to delay its nda seeking an approval for fotivda the company decided not to file an nda in the united states after the fda informed that it was not satisfied with the preliminary os data reported along with the topline tivo3 study data on progressionfreesurvival last november the phase iii tivo3 study evaluated fotivda in highly refractory advanced or metastatic rcc patients compared with bayer ags nexavar previously the company intended to submit the nda in the first half of 2019 aveo had planned a final analysis of os last august data from this interim analysis will be available during the fourth quarter of 2019 meanwhile aveo does not plan to conduct further studies on tivozanib for the treatment of metastatic colorectal cancer till the time an assay used to measure serum neuropilin1 in firstline colorectal cancer patients is identified we note that the phase ii baton breast cancer study on tivozanib was stopped due to insufficient enrollment meanwhile a phase ii study that evaluated ficlatuzumab in combination with iressa for the treatment of firstline nonsmall cell lung cancer nsclc demonstrated disappointing results based on the findings from the interim analysis and slow enrollment aveo and biodesix discontinued the phase ii focal study that was conducted to evaluate ficlatuzumab in combination with tarceva in the subset of patients with firstline advanced nsclc in september 2016 similar setbacks in the future could hinder the companys pipeline progress and have an adverse impact on the stock dependence on partners aveo is heavily dependent on partnerships for the development and commercialization of its pipeline candidates if any of the companys partners fails to receive regulatory approvals or terminates a deal aveos future prospects zacks equity research aveo wwwzackscom page 3 of 7,sell,"['string', 'pipeline', 'setback', 'aveo', 'suffer', 'string', 'pipeline', 'setback', 'past', 'tivozanib', 'receive', 'complete', 'response', 'letter', 'crl', 'fda', 'jun', '2013', 'firstline', 'treatment', 'advanced', 'rcc', 'cite', 'concern', 'negative', 'trend', 'overall', 'survival', 'pivotal', 'phase', 'iii', 'study', 'note', 'company', 'currently', 'conduct', 'tivo3', 'study', 'tivozanib', 'address', 'concern', 'raise', 'regulatory', 'agency', 'crl', 'timely', 'approval', 'allow', 'company', 'start', 'generate', 'revenue', 'tivozanib', 'january', '2019', 'aveo', 'face', 'major', 'setback', 'delay', 'nda', 'seek', 'approval', 'fotivda', 'company', 'decide', 'file', 'nda', 'united', 'states', 'fda', 'inform', 'satisfied', 'preliminary', 'os', 'datum', 'report', 'topline', 'tivo3', 'study', 'datum', 'progressionfreesurvival', 'november', 'phase', 'iii', 'tivo3', 'study', 'evaluate', 'fotivda', 'highly', 'refractory', 'advanced', 'metastatic', 'rcc', 'patient', 'compare', 'bayer', 'ags', 'nexavar', 'previously', 'company', 'intend', 'submit', 'nda', 'half', '2019', 'aveo', 'plan', 'final', 'analysis', 'os', 'august', 'datum', 'interim', 'analysis', 'available', 'fourth', 'quarter', '2019', 'aveo', 'plan', 'conduct', 'study', 'tivozanib', 'treatment', 'metastatic', 'colorectal', 'cancer', 'till', 'time', 'assay', 'measure', 'serum', 'neuropilin1', 'firstline', 'colorectal', 'cancer', 'patient', 'identify', 'note', 'phase', 'ii', 'baton', 'breast', 'cancer', 'study', 'tivozanib', 'stop', 'insufficient', 'enrollment', 'phase', 'ii', 'study', 'evaluate', 'ficlatuzumab', 'combination', 'iressa', 'treatment', 'firstline', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'demonstrate', 'disappointing', 'result', 'base', 'finding', 'interim', 'analysis', 'slow', 'enrollment', 'aveo', 'biodesix', 'discontinue', 'phase', 'ii', 'focal', 'study', 'conduct', 'evaluate', 'ficlatuzumab', 'combination', 'tarceva', 'subset', 'patient', 'firstline', 'advanced', 'nsclc', 'september', '2016', 'similar', 'setback', 'future', 'hinder', 'company', 'pipeline', 'progress', 'adverse', 'impact', 'stock', 'dependence', 'partner', 'aveo', 'heavily', 'dependent', 'partnership', 'development', 'commercialization', 'pipeline', 'candidate', 'company', 'partner', 'fail', 'receive', 'regulatory', 'approval', 'terminate', 'deal', 'aveo', 'future', 'prospect', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '7']",string pipeline setback aveo suffer string pipeline setback past tivozanib receive complete response letter crl fda jun 2013 firstline treatment advanced rcc cite concern negative trend overall survival pivotal phase iii study note company currently conduct tivo3 study tivozanib address concern raise regulatory agency crl timely approval allow company start generate revenue tivozanib january 2019 aveo face major setback delay nda seek approval fotivda company decide file nda united states fda inform satisfied preliminary os datum report topline tivo3 study datum progressionfreesurvival november phase iii tivo3 study evaluate fotivda highly refractory advanced metastatic rcc patient compare bayer ags nexavar previously company intend submit nda half 2019 aveo plan final analysis os august datum interim analysis available fourth quarter 2019 aveo plan conduct study tivozanib treatment metastatic colorectal cancer till time assay measure serum neuropilin1 firstline colorectal cancer patient identify note phase ii baton breast cancer study tivozanib stop insufficient enrollment phase ii study evaluate ficlatuzumab combination iressa treatment firstline nonsmall cell lung cancer nsclc demonstrate disappointing result base finding interim analysis slow enrollment aveo biodesix discontinue phase ii focal study conduct evaluate ficlatuzumab combination tarceva subset patient firstline advanced nsclc september 2016 similar setback future hinder company pipeline progress adverse impact stock dependence partner aveo heavily dependent partnership development commercialization pipeline candidate company partner fail receive regulatory approval terminate deal aveo future prospect zacks equity research aveo wwwzackscom page 3 7,9,28,-0.5,9,28,-0.5,-0.9403
22,"AVEO Pharmaceuticals, Inc._Attachment1(3).pdf",AVEO,6/27/2017,tivozanib progress encouraging aveo has made significant progress with its lead pipeline candidate tivozanib it is currently under review in the eu for the firstline treatment of advanced rcc the regulatory application was submitted by aveos partner eusa pharma in jun 2017 the chmphas recommended the approval of the candidate a final response on the approval status of the candidate is expected in the third quarter of 2017the candidates approval will be a huge boost for aveo given the lucrative firstline rcc market in europe meanwhile tivozanib is being evaluated in a couple of additional studies for the thirdline treatment of rcc and advanced rcc in may 2016 aveo started a pivotal phase iii study tivo comparing tivozanib to nexavar sorafenib for the thirdline treatment of patients with refractory rcc the study is evaluating patients with recurrent or metastatic rcc who have failed at least two prior regimens including vegfrtki therapy other than nexavar in feb 2017 aveo announced that tivo3 to zacks equity research aveo wwwzackscom page 3 of 8,sell,"['tivozanib', 'progress', 'encourage', 'aveo', 'significant', 'progress', 'lead', 'pipeline', 'candidate', 'tivozanib', 'currently', 'review', 'eu', 'firstline', 'treatment', 'advanced', 'rcc', 'regulatory', 'application', 'submit', 'aveos', 'partner', 'eusa', 'pharma', 'jun', '2017', 'chmpha', 'recommend', 'approval', 'candidate', 'final', 'response', 'approval', 'status', 'candidate', 'expect', 'quarter', '2017the', 'candidate', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'tivozanib', 'evaluate', 'couple', 'additional', 'study', 'thirdline', 'treatment', 'rcc', 'advanced', 'rcc', '2016', 'aveo', 'start', 'pivotal', 'phase', 'iii', 'study', 'tivo', 'compare', 'tivozanib', 'nexavar', 'sorafenib', 'thirdline', 'treatment', 'patient', 'refractory', 'rcc', 'study', 'evaluate', 'patient', 'recurrent', 'metastatic', 'rcc', 'fail', 'prior', 'regimen', 'include', 'vegfrtki', 'therapy', 'nexavar', 'feb', '2017', 'aveo', 'announce', 'tivo3', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",tivozanib progress encourage aveo significant progress lead pipeline candidate tivozanib currently review eu firstline treatment advanced rcc regulatory application submit aveos partner eusa pharma jun 2017 chmpha recommend approval candidate final response approval status candidate expect quarter 2017the candidate approval huge boost aveo give lucrative firstline rcc market europe tivozanib evaluate couple additional study thirdline treatment rcc advanced rcc 2016 aveo start pivotal phase iii study tivo compare tivozanib nexavar sorafenib thirdline treatment patient refractory rcc study evaluate patient recurrent metastatic rcc fail prior regimen include vegfrtki therapy nexavar feb 2017 aveo announce tivo3 zacks equity research aveo wwwzackscom page 3 8,8,4,0.3076923076923077,8,4,0.3076923076923077,0.975
23,"AVEO Pharmaceuticals, Inc._Attachment1(3).pdf",AVEO,2/9/2018,share price outperformance aveos share price movement shows that the stock has significantly outperformed the industry in the past year in fact aveo has gained 4056 during this period compared with an decrease of 33 for the industry fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the first quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in june 2017 the company announced that the study has progressed to phase ii based on successful completion of the phase i dose escalation study the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments in the absence of any approved product meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63990 new cases of rcc will be diagnosed in the united states in 2017 however prognosis of the disease is weak given that approximately 14400 patients are expected to die from the disease in the united states in 2017 indicating the need for newer therapies moreover as per may 2017 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'past', 'year', 'fact', 'aveo', 'gain', '4056', 'period', 'compare', 'decrease', '33', 'industry', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'june', '2017', 'company', 'announce', 'study', 'progress', 'phase', 'ii', 'base', 'successful', 'completion', 'phase', 'dose', 'escalation', 'study', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'absence', 'approve', 'product', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63990', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2017', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14400', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2017', 'indicate', 'need', 'new', 'therapy', '2017', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock significantly outperform industry past year fact aveo gain 4056 period compare decrease 33 industry fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc june 2017 company announce study progress phase ii base successful completion phase dose escalation study phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment absence approve product company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63990 new case rcc diagnose united states 2017 prognosis disease weak give approximately 14400 patient expect die disease united states 2017 indicate need new therapy 2017 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,24,20,0.08888888888888889,24,20,0.08888888888888889,0.996
24,"AVEO Pharmaceuticals, Inc._Attachment1(3).pdf",AVEO,7/2/2018,share price outperformance aveos share price movement shows that the stock has outperformed the industry in the past year in fact aveo has gained 18 during this period compared with an decrease of 104 for the industry fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified topline data is expected in the third quarter of 2018 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'outperform', 'industry', 'past', 'year', 'fact', 'aveo', 'gain', '18', 'period', 'compare', 'decrease', '104', 'industry', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodified', 'topline', 'datum', 'expect', 'quarter', '2018', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock outperform industry past year fact aveo gain 18 period compare decrease 104 industry fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodified topline datum expect quarter 2018 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,24,20,0.08888888888888889,24,20,0.08888888888888889,0.9954
25,"AVEO Pharmaceuticals, Inc._Attachment1(3).pdf",AVEO,10/23/2018,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified topline data is expected in the fourth quarter of 2018 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodified', 'topline', 'datum', 'expect', 'fourth', 'quarter', '2018', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodified topline datum expect fourth quarter 2018 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,23,19,0.09302325581395349,23,19,0.09302325581395349,0.9947
26,"AVEO Pharmaceuticals, Inc._Attachment1(4).pdf",AVEO,4/28/2017,tivozanib progress encouraging aveo has made significant progress with its lead pipeline candidate tivozanib it is currently under review in the eu for the firstline treatment of advanced rcc the regulatory application was submitted by aveos partner eusa pharma a final response on the approval status of the candidate is expected in the first half of 2017 the candidates approval will be a huge boost for aveo given the lucrative firstline rcc market in europe meanwhile tivozanib is being evaluated in a couple of additional studies for the thirdline treatment of rcc and advanced rcc in may 2016 aveo started a pivotal phase iii study tivo comparing tivozanib to nexavar sorafenib for the thirdline treatment of patients with refractory rcc the study is evaluating patients with recurrent or metastatic rcc who have failed at least two prior regimens including vegfrtki therapy other than nexavar in feb 2017 aveo announced that tivo3 to compare lead candidate tivozanib to nexavar in patients with refractory advanced renal cell carcinoma rcc has successfully completed the first safety review by safety monitoring committee smc the committee ruled no safety concern was observed for tivozanib and recommended that the study can replace the small number of patients who dropped out prior to starting treatment following the smc recommendation to replace early dropouts the company expects to complete enrolment in jun 2017 ahead of its prior guidance of aug 2017 a preplanned futility analysis of the trial is expected around mid 2017 with topline data expected in the first quarter of 2018 the company expects that the tivo3 trial together with the previously completed tivo1 trial on tivozanib in the firstline treatment of rcc will support potential regulatory approval of tivozanib in the us as a third and firstline treatment for rcc the trial is being conducted to address the overall survival concerns from the tivo1 trial the concerns were identified by the zacks equity research aveo page 3 of 8,sell,"['tivozanib', 'progress', 'encourage', 'aveo', 'significant', 'progress', 'lead', 'pipeline', 'candidate', 'tivozanib', 'currently', 'review', 'eu', 'firstline', 'treatment', 'advanced', 'rcc', 'regulatory', 'application', 'submit', 'aveos', 'partner', 'eusa', 'pharma', 'final', 'response', 'approval', 'status', 'candidate', 'expect', 'half', '2017', 'candidate', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'tivozanib', 'evaluate', 'couple', 'additional', 'study', 'thirdline', 'treatment', 'rcc', 'advanced', 'rcc', '2016', 'aveo', 'start', 'pivotal', 'phase', 'iii', 'study', 'tivo', 'compare', 'tivozanib', 'nexavar', 'sorafenib', 'thirdline', 'treatment', 'patient', 'refractory', 'rcc', 'study', 'evaluate', 'patient', 'recurrent', 'metastatic', 'rcc', 'fail', 'prior', 'regimen', 'include', 'vegfrtki', 'therapy', 'nexavar', 'feb', '2017', 'aveo', 'announce', 'tivo3', 'compare', 'lead', 'candidate', 'tivozanib', 'nexavar', 'patient', 'refractory', 'advanced', 'renal', 'cell', 'carcinoma', 'rcc', 'successfully', 'complete', 'safety', 'review', 'safety', 'monitoring', 'committee', 'smc', 'committee', 'rule', 'safety', 'concern', 'observe', 'tivozanib', 'recommend', 'study', 'replace', 'small', 'number', 'patient', 'drop', 'prior', 'start', 'treatment', 'follow', 'smc', 'recommendation', 'replace', 'early', 'dropout', 'company', 'expect', 'complete', 'enrolment', 'jun', '2017', 'ahead', 'prior', 'guidance', 'aug', '2017', 'preplanned', 'futility', 'analysis', 'trial', 'expect', 'mid', '2017', 'topline', 'datum', 'expect', 'quarter', '2018', 'company', 'expect', 'tivo3', 'trial', 'previously', 'complete', 'tivo1', 'trial', 'tivozanib', 'firstline', 'treatment', 'rcc', 'support', 'potential', 'regulatory', 'approval', 'tivozanib', 'firstline', 'treatment', 'rcc', 'trial', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'concern', 'identify', 'zack', 'equity', 'research', 'aveo', 'page', '3', '8']",tivozanib progress encourage aveo significant progress lead pipeline candidate tivozanib currently review eu firstline treatment advanced rcc regulatory application submit aveos partner eusa pharma final response approval status candidate expect half 2017 candidate approval huge boost aveo give lucrative firstline rcc market europe tivozanib evaluate couple additional study thirdline treatment rcc advanced rcc 2016 aveo start pivotal phase iii study tivo compare tivozanib nexavar sorafenib thirdline treatment patient refractory rcc study evaluate patient recurrent metastatic rcc fail prior regimen include vegfrtki therapy nexavar feb 2017 aveo announce tivo3 compare lead candidate tivozanib nexavar patient refractory advanced renal cell carcinoma rcc successfully complete safety review safety monitoring committee smc committee rule safety concern observe tivozanib recommend study replace small number patient drop prior start treatment follow smc recommendation replace early dropout company expect complete enrolment jun 2017 ahead prior guidance aug 2017 preplanned futility analysis trial expect mid 2017 topline datum expect quarter 2018 company expect tivo3 trial previously complete tivo1 trial tivozanib firstline treatment rcc support potential regulatory approval tivozanib firstline treatment rcc trial conduct address overall survival concern tivo1 trial concern identify zack equity research aveo page 3 8,11,17,-0.20689655172413793,11,17,-0.20689655172413793,0.9895
27,"AVEO Pharmaceuticals, Inc._Attachment1(4).pdf",AVEO,7/24/2017,share price outperformance aveos share price movement shows that the stock has significantly outperformed the zacks classified medicalbiomedical and genetics industry so far this year in fact aveo has gained 3592 during this period compared with an increase of 117 for the industry tivozanib progress encouraging aveo has made significant progress with its lead pipeline candidate tivozanib it is currently under review in the eu for the firstline treatment of advanced rcc the regulatory application was submitted by aveos partner eusa pharma in jun 2017 the chmp has recommended the approval of the candidate a final response on the approval status of the candidate is expected in the third quarter of 2017the candidates approval will be a huge boost for aveo given the lucrative firstline rcc market in europe meanwhile tivozanib is being evaluated in a couple of additional studies for the thirdline treatment of rcc and advanced rcc in may 2016 aveo started a pivotal phase iii study tivo comparing tivozanib to nexavar sorafenib for the thirdline treatment of patients with refractory rcc the study is evaluating patients with recurrent or metastatic rcc who have failed at least two prior regimens including vegfrtki therapy other than nexavar in feb 2017 aveo announced that tivo3 to compare lead candidate tivozanib to nexavar in patients with refractory advanced renal cell carcinoma rcc has successfully completed the first safety review by safety monitoring committee smc the committee ruled no safety concern was observed for tivozanib and recommended that the study can replace the small number of patients who dropped out prior to starting treatment following the smc recommendation to replace early dropouts the company has completed enrolment in jun 2017 ahead of its prior guidance of aug 2017 a preplanned futility analysis of the trial is expected around mid 2017 with topline data expected in the first quarter of 2018 the trial is being conducted to address the overall survival concerns from the tivo1 trial the concerns were identified by the fda in the complete response letter issued in jun 2013 the tivo3 trial together with the previously completed tivo1 trial is also intended to support a request for regulatory approval of tivozanib in the us as a thirdline treatment and as a firstline treatment for rcc in aug 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in jun 2017 the company announced that the study has progressed to phase ii based on successful completion of the phase i dose escalation study the phase ii study will evaluate 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in mar 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the us canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in dec 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand aveo will receive 4 million as research and development reimbursement payment from eusa upon approval of tivozanib followed by 12 million as additional milestone payments based on member state reimbursement and regulatory approvals in aug 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in apr 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments in the absence of any approved product meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63990 new cases of rcc will be diagnosed in the us in 2017 however prognosis of the disease is weak given that approximately 14400 patients are expected to die from the disease in the us in 2017 indicating the need for newer therapies moreover as per may 2017 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'zack', 'classify', 'medicalbiomedical', 'genetic', 'industry', 'far', 'year', 'fact', 'aveo', 'gain', '3592', 'period', 'compare', 'increase', '117', 'industry', 'tivozanib', 'progress', 'encourage', 'aveo', 'significant', 'progress', 'lead', 'pipeline', 'candidate', 'tivozanib', 'currently', 'review', 'eu', 'firstline', 'treatment', 'advanced', 'rcc', 'regulatory', 'application', 'submit', 'aveos', 'partner', 'eusa', 'pharma', 'jun', '2017', 'chmp', 'recommend', 'approval', 'candidate', 'final', 'response', 'approval', 'status', 'candidate', 'expect', 'quarter', '2017the', 'candidate', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'tivozanib', 'evaluate', 'couple', 'additional', 'study', 'thirdline', 'treatment', 'rcc', 'advanced', 'rcc', '2016', 'aveo', 'start', 'pivotal', 'phase', 'iii', 'study', 'tivo', 'compare', 'tivozanib', 'nexavar', 'sorafenib', 'thirdline', 'treatment', 'patient', 'refractory', 'rcc', 'study', 'evaluate', 'patient', 'recurrent', 'metastatic', 'rcc', 'fail', 'prior', 'regimen', 'include', 'vegfrtki', 'therapy', 'nexavar', 'feb', '2017', 'aveo', 'announce', 'tivo3', 'compare', 'lead', 'candidate', 'tivozanib', 'nexavar', 'patient', 'refractory', 'advanced', 'renal', 'cell', 'carcinoma', 'rcc', 'successfully', 'complete', 'safety', 'review', 'safety', 'monitoring', 'committee', 'smc', 'committee', 'rule', 'safety', 'concern', 'observe', 'tivozanib', 'recommend', 'study', 'replace', 'small', 'number', 'patient', 'drop', 'prior', 'start', 'treatment', 'follow', 'smc', 'recommendation', 'replace', 'early', 'dropout', 'company', 'complete', 'enrolment', 'jun', '2017', 'ahead', 'prior', 'guidance', 'aug', '2017', 'preplanned', 'futility', 'analysis', 'trial', 'expect', 'mid', '2017', 'topline', 'datum', 'expect', 'quarter', '2018', 'trial', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'concern', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'jun', '2013', 'tivo3', 'trial', 'previously', 'complete', 'tivo1', 'trial', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'aug', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'jun', '2017', 'company', 'announce', 'study', 'progress', 'phase', 'ii', 'base', 'successful', 'completion', 'phase', 'dose', 'escalation', 'study', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'mar', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'dec', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'aveo', 'receive', '4', 'million', 'research', 'development', 'reimbursement', 'payment', 'eusa', 'approval', 'tivozanib', 'follow', '12', 'million', 'additional', 'milestone', 'payment', 'base', 'member', 'state', 'reimbursement', 'regulatory', 'approval', 'aug', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'apr', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'absence', 'approve', 'product', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63990', 'new', 'case', 'rcc', 'diagnose', '2017', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14400', 'patient', 'expect', 'die', 'disease', '2017', 'indicate', 'need', 'new', 'therapy', '2017', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock significantly outperform zack classify medicalbiomedical genetic industry far year fact aveo gain 3592 period compare increase 117 industry tivozanib progress encourage aveo significant progress lead pipeline candidate tivozanib currently review eu firstline treatment advanced rcc regulatory application submit aveos partner eusa pharma jun 2017 chmp recommend approval candidate final response approval status candidate expect quarter 2017the candidate approval huge boost aveo give lucrative firstline rcc market europe tivozanib evaluate couple additional study thirdline treatment rcc advanced rcc 2016 aveo start pivotal phase iii study tivo compare tivozanib nexavar sorafenib thirdline treatment patient refractory rcc study evaluate patient recurrent metastatic rcc fail prior regimen include vegfrtki therapy nexavar feb 2017 aveo announce tivo3 compare lead candidate tivozanib nexavar patient refractory advanced renal cell carcinoma rcc successfully complete safety review safety monitoring committee smc committee rule safety concern observe tivozanib recommend study replace small number patient drop prior start treatment follow smc recommendation replace early dropout company complete enrolment jun 2017 ahead prior guidance aug 2017 preplanned futility analysis trial expect mid 2017 topline datum expect quarter 2018 trial conduct address overall survival concern tivo1 trial concern identify fda complete response letter issue jun 2013 tivo3 trial previously complete tivo1 trial intend support request regulatory approval tivozanib thirdline treatment firstline treatment rcc aug 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc jun 2017 company announce study progress phase ii base successful completion phase dose escalation study phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering mar 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib dec 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand aveo receive 4 million research development reimbursement payment eusa approval tivozanib follow 12 million additional milestone payment base member state reimbursement regulatory approval aug 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world apr 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment absence approve product company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63990 new case rcc diagnose 2017 prognosis disease weak give approximately 14400 patient expect die disease 2017 indicate need new therapy 2017 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,27,34,-0.11290322580645161,27,34,-0.11290322580645161,0.9969
28,"AVEO Pharmaceuticals, Inc._Attachment1(4).pdf",AVEO,7/24/2017,string of pipeline setbacks aveo has suffered a string of pipeline setbacks in the last couple of years tivozanib had received a complete response letter crl from the fda in jun 2013 for the firstline treatment of advanced rcc citing concerns regarding the negative trend in overall survival in the pivotal phase iii study we note that the company is currently conducting the tivo3 study on tivozanib to address the concerns raised by the regulatory agency in its crl timely approval would have allowed the company to start generating revenues from tivozanib zacks equity research aveo wwwzackscom page 3 of 8,sell,"['string', 'pipeline', 'setback', 'aveo', 'suffer', 'string', 'pipeline', 'setback', 'couple', 'year', 'tivozanib', 'receive', 'complete', 'response', 'letter', 'crl', 'fda', 'jun', '2013', 'firstline', 'treatment', 'advanced', 'rcc', 'cite', 'concern', 'negative', 'trend', 'overall', 'survival', 'pivotal', 'phase', 'iii', 'study', 'note', 'company', 'currently', 'conduct', 'tivo3', 'study', 'tivozanib', 'address', 'concern', 'raise', 'regulatory', 'agency', 'crl', 'timely', 'approval', 'allow', 'company', 'start', 'generate', 'revenue', 'tivozanib', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",string pipeline setback aveo suffer string pipeline setback couple year tivozanib receive complete response letter crl fda jun 2013 firstline treatment advanced rcc cite concern negative trend overall survival pivotal phase iii study note company currently conduct tivo3 study tivozanib address concern raise regulatory agency crl timely approval allow company start generate revenue tivozanib zacks equity research aveo wwwzackscom page 3 8,2,10,-0.6153846153846154,2,10,-0.6153846153846154,-0.296
29,"AVEO Pharmaceuticals, Inc._Attachment1(4).pdf",AVEO,3/9/2018,share price outperformance aveos share price movement shows that the stock has significantly outperformed the industry in the past year in fact aveo has gained 2302 during this period compared with an decrease of 4 for the industry fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the first quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in june 2017 the company announced that the study has progressed to phase ii based on successful completion of the phase i dose escalation study the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments in the absence of any approved product meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63990 new cases of rcc will be diagnosed in the united states in 2017 however prognosis of the disease is weak given that approximately 14400 patients are expected to die from the disease in the united states in 2017 indicating the need for newer therapies moreover as per may 2017 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'past', 'year', 'fact', 'aveo', 'gain', '2302', 'period', 'compare', 'decrease', '4', 'industry', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'june', '2017', 'company', 'announce', 'study', 'progress', 'phase', 'ii', 'base', 'successful', 'completion', 'phase', 'dose', 'escalation', 'study', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'absence', 'approve', 'product', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63990', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2017', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14400', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2017', 'indicate', 'need', 'new', 'therapy', '2017', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock significantly outperform industry past year fact aveo gain 2302 period compare decrease 4 industry fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc june 2017 company announce study progress phase ii base successful completion phase dose escalation study phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment absence approve product company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63990 new case rcc diagnose united states 2017 prognosis disease weak give approximately 14400 patient expect die disease united states 2017 indicate need new therapy 2017 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,24,20,0.08888888888888889,24,20,0.08888888888888889,0.996
30,"AVEO Pharmaceuticals, Inc._Attachment1(4).pdf",AVEO,11/8/2018,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified aveo announced topline data in november 2018 from the tivo3 study which met the primary endpoint the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodified', 'aveo', 'announce', 'topline', 'datum', 'november', '2018', 'tivo3', 'study', 'meet', 'primary', 'endpoint', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodified aveo announce topline datum november 2018 tivo3 study meet primary endpoint datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,23,19,0.09302325581395349,23,19,0.09302325581395349,0.9947
31,"AVEO Pharmaceuticals, Inc._Attachment1(4).pdf",AVEO,11/8/2018,string of pipeline setbacks aveo has suffered a string of pipeline setbacks in the past tivozanib had received a complete response letter crl from the fda in jun 2013 for the firstline treatment of advanced rcc citing concerns regarding the negative trend in overall survival in the pivotal phase iii study we note that the company is currently conducting the tivo3 study on tivozanib to address the concerns raised by the regulatory agency in its crl timely approval would have allowed the company to start generating revenues from tivozanib meanwhile aveo does not plan to conduct further studies on tivozanib for the treatment of metastatic colorectal cancer till the time an assay used to measure serum neuropilin1 in firstline colorectal cancer patients is identified we note that the phase ii baton breast cancer study on tivozanib was stopped due to insufficient enrollment meanwhile a phase ii study that evaluated ficlatuzumab in combination with iressa for the treatment of firstline nonsmall cell lung cancer nsclc demonstrated disappointing results based on the findings from the interim analysis and slow enrollment aveo and biodesix discontinued the phase ii focal study that was conducted to evaluate ficlatuzumab in combination with tarceva in the subset of patients with firstline advanced nsclc in september 2016 similar setbacks in the future could hinder the companys pipeline progress and have an adverse impact on the stock dependence on partners aveo is heavily dependent on partnerships for the development and commercialization of its pipeline candidates if any of the companys partners fails to receive regulatory approvals or terminates a deal aveos future prospects would be severely hampered for instance tivozanib was returned to aveo by astellas pharma in august 2014 aveo had a zacks equity research aveo wwwzackscom page 3 of 8,sell,"['string', 'pipeline', 'setback', 'aveo', 'suffer', 'string', 'pipeline', 'setback', 'past', 'tivozanib', 'receive', 'complete', 'response', 'letter', 'crl', 'fda', 'jun', '2013', 'firstline', 'treatment', 'advanced', 'rcc', 'cite', 'concern', 'negative', 'trend', 'overall', 'survival', 'pivotal', 'phase', 'iii', 'study', 'note', 'company', 'currently', 'conduct', 'tivo3', 'study', 'tivozanib', 'address', 'concern', 'raise', 'regulatory', 'agency', 'crl', 'timely', 'approval', 'allow', 'company', 'start', 'generate', 'revenue', 'tivozanib', 'aveo', 'plan', 'conduct', 'study', 'tivozanib', 'treatment', 'metastatic', 'colorectal', 'cancer', 'till', 'time', 'assay', 'measure', 'serum', 'neuropilin1', 'firstline', 'colorectal', 'cancer', 'patient', 'identify', 'note', 'phase', 'ii', 'baton', 'breast', 'cancer', 'study', 'tivozanib', 'stop', 'insufficient', 'enrollment', 'phase', 'ii', 'study', 'evaluate', 'ficlatuzumab', 'combination', 'iressa', 'treatment', 'firstline', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'demonstrate', 'disappointing', 'result', 'base', 'finding', 'interim', 'analysis', 'slow', 'enrollment', 'aveo', 'biodesix', 'discontinue', 'phase', 'ii', 'focal', 'study', 'conduct', 'evaluate', 'ficlatuzumab', 'combination', 'tarceva', 'subset', 'patient', 'firstline', 'advanced', 'nsclc', 'september', '2016', 'similar', 'setback', 'future', 'hinder', 'company', 'pipeline', 'progress', 'adverse', 'impact', 'stock', 'dependence', 'partner', 'aveo', 'heavily', 'dependent', 'partnership', 'development', 'commercialization', 'pipeline', 'candidate', 'company', 'partner', 'fail', 'receive', 'regulatory', 'approval', 'terminate', 'deal', 'aveo', 'future', 'prospect', 'severely', 'hamper', 'instance', 'tivozanib', 'return', 'aveo', 'astella', 'pharma', 'august', '2014', 'aveo', 'zack', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",string pipeline setback aveo suffer string pipeline setback past tivozanib receive complete response letter crl fda jun 2013 firstline treatment advanced rcc cite concern negative trend overall survival pivotal phase iii study note company currently conduct tivo3 study tivozanib address concern raise regulatory agency crl timely approval allow company start generate revenue tivozanib aveo plan conduct study tivozanib treatment metastatic colorectal cancer till time assay measure serum neuropilin1 firstline colorectal cancer patient identify note phase ii baton breast cancer study tivozanib stop insufficient enrollment phase ii study evaluate ficlatuzumab combination iressa treatment firstline nonsmall cell lung cancer nsclc demonstrate disappointing result base finding interim analysis slow enrollment aveo biodesix discontinue phase ii focal study conduct evaluate ficlatuzumab combination tarceva subset patient firstline advanced nsclc september 2016 similar setback future hinder company pipeline progress adverse impact stock dependence partner aveo heavily dependent partnership development commercialization pipeline candidate company partner fail receive regulatory approval terminate deal aveo future prospect severely hamper instance tivozanib return aveo astella pharma august 2014 aveo zack equity research aveo wwwzackscom page 3 8,4,23,-0.6785714285714286,4,23,-0.6785714285714286,-0.9779
32,"AVEO Pharmaceuticals, Inc._Attachment1(5).pdf",AVEO,10/11/2017,share price outperformance aveos share price movement shows that the stock has significantly outperformed the zacks classified medicalbiomedical and genetics industry so far this year in fact aveo has gained 5982 during this period compared with an increase of 143 for the industry fotivda approval a positive aveo got a boost with the approval of its lead pipeline candidate tivozanib fotivda in august 2017 fotivda a tyrosine kinase inhibitor is approved in the eu for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the first quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 the study from the both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in june 2017 the company announced that the study has progressed to phase ii based on successful completion of the phase i dose escalation study the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments in the absence of any approved product meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63990 new cases of rcc will be diagnosed in the united states in 2017 however prognosis of the disease is weak given that approximately 14400 patients are expected to die from the disease in the united states in 2017 indicating the need for newer therapies moreover as per may 2017 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'zack', 'classify', 'medicalbiomedical', 'genetic', 'industry', 'far', 'year', 'fact', 'aveo', 'gain', '5982', 'period', 'compare', 'increase', '143', 'industry', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'approval', 'lead', 'pipeline', 'candidate', 'tivozanib', 'fotivda', 'august', '2017', 'fotivda', 'tyrosine', 'kinase', 'inhibitor', 'approve', 'eu', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'study', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'june', '2017', 'company', 'announce', 'study', 'progress', 'phase', 'ii', 'base', 'successful', 'completion', 'phase', 'dose', 'escalation', 'study', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'absence', 'approve', 'product', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63990', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2017', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14400', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2017', 'indicate', 'need', 'new', 'therapy', '2017', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock significantly outperform zack classify medicalbiomedical genetic industry far year fact aveo gain 5982 period compare increase 143 industry fotivda approval positive aveo get boost approval lead pipeline candidate tivozanib fotivda august 2017 fotivda tyrosine kinase inhibitor approve eu firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 study study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc june 2017 company announce study progress phase ii base successful completion phase dose escalation study phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment absence approve product company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63990 new case rcc diagnose united states 2017 prognosis disease weak give approximately 14400 patient expect die disease united states 2017 indicate need new therapy 2017 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,24,20,0.08888888888888889,24,20,0.08888888888888889,0.9967
33,"AVEO Pharmaceuticals, Inc._Attachment1(5).pdf",AVEO,3/23/2018,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the second quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminiary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer zacks equity research aveo wwwzackscom page 3 of 8,sell,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'second', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodifie', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminiary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'zack', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect second quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodifie datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminiary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer zack equity research aveo wwwzackscom page 3 8,18,8,0.37037037037037035,18,8,0.37037037037037035,0.9944
34,"AVEO Pharmaceuticals, Inc._Attachment1(5).pdf",AVEO,8/3/2018,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified topline data is expected in the fourth quarter of 2018 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodified', 'topline', 'datum', 'expect', 'fourth', 'quarter', '2018', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodified topline datum expect fourth quarter 2018 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,22,17,0.125,22,17,0.125,0.9941
35,"AVEO Pharmaceuticals, Inc._Attachment1(5).pdf",AVEO,4/3/2019,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in october 2018 aveo along with eusa pharma presented updated interim results from the phase ii portion of the tinivo program the study showed a favorable safety and efficacy profile pertaining to the treatment of advancedmetastatic rcc the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc aveo is planning to further develop tivozanib as a combination therapy with immune checkpoint inhibitors for the treatment of rcc and hcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab in april 2019 aveo announced positive results from phase ib expansion cohort of ficlatuzumab in combination with cytarabine for treating patients with relapsed and refractory acute myeloid leukemia aveo is also developing ficlatuzumab in combination with lillys erbitux in a phase ii study for treating metastatic head and neck squamous cell carcinoma such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 73820 new cases of rcc will be diagnosed in the united states in 2019 however prognosis of the disease is weak given that approximately 14770 patients are expected to die from the disease in the united states indicating the need for newer therapies once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'october', '2018', 'aveo', 'eusa', 'pharma', 'present', 'update', 'interim', 'result', 'phase', 'ii', 'portion', 'tinivo', 'program', 'study', 'show', 'favorable', 'safety', 'efficacy', 'profile', 'pertain', 'treatment', 'advancedmetastatic', 'rcc', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'aveo', 'plan', 'develop', 'tivozanib', 'combination', 'therapy', 'immune', 'checkpoint', 'inhibitor', 'treatment', 'rcc', 'hcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'april', '2019', 'aveo', 'announce', 'positive', 'result', 'phase', 'ib', 'expansion', 'cohort', 'ficlatuzumab', 'combination', 'cytarabine', 'treat', 'patient', 'relapsed', 'refractory', 'acute', 'myeloid', 'leukemia', 'aveo', 'develop', 'ficlatuzumab', 'combination', 'lillys', 'erbitux', 'phase', 'ii', 'study', 'treat', 'metastatic', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '73820', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2019', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14770', 'patient', 'expect', 'die', 'disease', 'united', 'states', 'indicate', 'need', 'new', 'therapy', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc october 2018 aveo eusa pharma present update interim result phase ii portion tinivo program study show favorable safety efficacy profile pertain treatment advancedmetastatic rcc phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc aveo plan develop tivozanib combination therapy immune checkpoint inhibitor treatment rcc hcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab april 2019 aveo announce positive result phase ib expansion cohort ficlatuzumab combination cytarabine treat patient relapsed refractory acute myeloid leukemia aveo develop ficlatuzumab combination lillys erbitux phase ii study treat metastatic head neck squamous cell carcinoma deal provide aveo need fund form license fee upfront milestone payment lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 73820 new case rcc diagnose united states 2019 prognosis disease weak give approximately 14770 patient expect die disease united states indicate need new therapy approve tivozanib provide alternative treatment option patient huge boost company,23,22,0.021739130434782608,23,22,0.021739130434782608,0.9971
36,"AVEO Pharmaceuticals, Inc._Attachment1(5).pdf",AVEO,4/3/2019,string of pipeline setbacks aveo has suffered a string of pipeline setbacks in the past tivozanib had received a complete response letter crl from the fda in jun 2013 for the firstline treatment of advanced rcc citing concerns regarding the negative trend in overall survival in the pivotal phase iii study we note that the company is currently conducting the tivo3 study on tivozanib to address the concerns raised by the regulatory agency in its crl timely approval would have allowed the company to start generating revenues from tivozanib in january 2019 aveo faced a major setback when it had to delay its nda seeking an approval for fotivda the company decided not to file an nda in the united states after the fda informed that it was not satisfied with the preliminary os data reported along with the topline tivo3 study data on progressionfreesurvival last november the phase iii tivo3 study evaluated fotivda in highly refractory advanced or metastatic rcc patients compared with bayer ags nexavar previously the company intended to submit the nda in the first half of 2019 aveo had planned a final analysis of os last august data from this interim analysis will be available during the fourth quarter of 2019 meanwhile aveo does not plan to conduct further studies on tivozanib for the treatment of metastatic colorectal cancer till the time an assay used to measure serum neuropilin1 in firstline colorectal cancer patients is identified we note that the phase ii baton breast cancer study on tivozanib was stopped due to insufficient enrollment meanwhile a phase ii study that evaluated ficlatuzumab in combination with iressa for the treatment of firstline nonsmall cell lung cancer nsclc demonstrated disappointing results based on the findings from the interim analysis and slow enrollment aveo and biodesix discontinued the phase ii focal study that was conducted to evaluate ficlatuzumab in combination with tarceva in the subset of patients with firstline advanced nsclc in september 2016 similar setbacks in the future could hinder the companys pipeline progress and have an adverse impact on the stock zacks equity research aveo wwwzackscom page 3 of 7,sell,"['string', 'pipeline', 'setback', 'aveo', 'suffer', 'string', 'pipeline', 'setback', 'past', 'tivozanib', 'receive', 'complete', 'response', 'letter', 'crl', 'fda', 'jun', '2013', 'firstline', 'treatment', 'advanced', 'rcc', 'cite', 'concern', 'negative', 'trend', 'overall', 'survival', 'pivotal', 'phase', 'iii', 'study', 'note', 'company', 'currently', 'conduct', 'tivo3', 'study', 'tivozanib', 'address', 'concern', 'raise', 'regulatory', 'agency', 'crl', 'timely', 'approval', 'allow', 'company', 'start', 'generate', 'revenue', 'tivozanib', 'january', '2019', 'aveo', 'face', 'major', 'setback', 'delay', 'nda', 'seek', 'approval', 'fotivda', 'company', 'decide', 'file', 'nda', 'united', 'states', 'fda', 'inform', 'satisfied', 'preliminary', 'os', 'datum', 'report', 'topline', 'tivo3', 'study', 'datum', 'progressionfreesurvival', 'november', 'phase', 'iii', 'tivo3', 'study', 'evaluate', 'fotivda', 'highly', 'refractory', 'advanced', 'metastatic', 'rcc', 'patient', 'compare', 'bayer', 'ags', 'nexavar', 'previously', 'company', 'intend', 'submit', 'nda', 'half', '2019', 'aveo', 'plan', 'final', 'analysis', 'os', 'august', 'datum', 'interim', 'analysis', 'available', 'fourth', 'quarter', '2019', 'aveo', 'plan', 'conduct', 'study', 'tivozanib', 'treatment', 'metastatic', 'colorectal', 'cancer', 'till', 'time', 'assay', 'measure', 'serum', 'neuropilin1', 'firstline', 'colorectal', 'cancer', 'patient', 'identify', 'note', 'phase', 'ii', 'baton', 'breast', 'cancer', 'study', 'tivozanib', 'stop', 'insufficient', 'enrollment', 'phase', 'ii', 'study', 'evaluate', 'ficlatuzumab', 'combination', 'iressa', 'treatment', 'firstline', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'demonstrate', 'disappointing', 'result', 'base', 'finding', 'interim', 'analysis', 'slow', 'enrollment', 'aveo', 'biodesix', 'discontinue', 'phase', 'ii', 'focal', 'study', 'conduct', 'evaluate', 'ficlatuzumab', 'combination', 'tarceva', 'subset', 'patient', 'firstline', 'advanced', 'nsclc', 'september', '2016', 'similar', 'setback', 'future', 'hinder', 'company', 'pipeline', 'progress', 'adverse', 'impact', 'stock', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '7']",string pipeline setback aveo suffer string pipeline setback past tivozanib receive complete response letter crl fda jun 2013 firstline treatment advanced rcc cite concern negative trend overall survival pivotal phase iii study note company currently conduct tivo3 study tivozanib address concern raise regulatory agency crl timely approval allow company start generate revenue tivozanib january 2019 aveo face major setback delay nda seek approval fotivda company decide file nda united states fda inform satisfied preliminary os datum report topline tivo3 study datum progressionfreesurvival november phase iii tivo3 study evaluate fotivda highly refractory advanced metastatic rcc patient compare bayer ags nexavar previously company intend submit nda half 2019 aveo plan final analysis os august datum interim analysis available fourth quarter 2019 aveo plan conduct study tivozanib treatment metastatic colorectal cancer till time assay measure serum neuropilin1 firstline colorectal cancer patient identify note phase ii baton breast cancer study tivozanib stop insufficient enrollment phase ii study evaluate ficlatuzumab combination iressa treatment firstline nonsmall cell lung cancer nsclc demonstrate disappointing result base finding interim analysis slow enrollment aveo biodesix discontinue phase ii focal study conduct evaluate ficlatuzumab combination tarceva subset patient firstline advanced nsclc september 2016 similar setback future hinder company pipeline progress adverse impact stock zacks equity research aveo wwwzackscom page 3 7,9,26,-0.4722222222222222,9,26,-0.4722222222222222,-0.9477
37,"AVEO Pharmaceuticals, Inc._Attachment1(5).pdf",AVEO,10/23/2019,string of pipeline setbacks aveo has suffered a string of pipeline setbacks in the past in january 2019 aveo faced a major setback when it had to delay its nda seeking an approval for fotivda the company decided not to file an nda in the united states after the fda informed that it was not satisfied with the preliminary os data reported along with the topline tivo3 study data on progressionfree survival last november the phase iii tivo3 study evaluated fotivda in highly refractory advanced or metastatic rcc patients compared with bayer ags nexavar previously the company intended to submit the nda in the first half of 2019 aveo had planned a final,sell,"['string', 'pipeline', 'setback', 'aveo', 'suffer', 'string', 'pipeline', 'setback', 'past', 'january', '2019', 'aveo', 'face', 'major', 'setback', 'delay', 'nda', 'seek', 'approval', 'fotivda', 'company', 'decide', 'file', 'nda', 'united', 'states', 'fda', 'inform', 'satisfied', 'preliminary', 'os', 'datum', 'report', 'topline', 'tivo3', 'study', 'datum', 'progressionfree', 'survival', 'november', 'phase', 'iii', 'tivo3', 'study', 'evaluate', 'fotivda', 'highly', 'refractory', 'advanced', 'metastatic', 'rcc', 'patient', 'compare', 'bayer', 'ags', 'nexavar', 'previously', 'company', 'intend', 'submit', 'nda', 'half', '2019', 'aveo', 'plan', 'final']",string pipeline setback aveo suffer string pipeline setback past january 2019 aveo face major setback delay nda seek approval fotivda company decide file nda united states fda inform satisfied preliminary os datum report topline tivo3 study datum progressionfree survival november phase iii tivo3 study evaluate fotivda highly refractory advanced metastatic rcc patient compare bayer ags nexavar previously company intend submit nda half 2019 aveo plan final,4,11,-0.4375,4,11,-0.4375,0.6344
38,"AVEO Pharmaceuticals, Inc._Attachment1(6).pdf",AVEO,4/24/2018,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the second quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminiary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered zacks equity research aveo wwwzackscom page 3 of 8,sell,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'second', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodifie', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminiary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect second quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodifie datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminiary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter zacks equity research aveo wwwzackscom page 3 8,19,11,0.25806451612903225,19,11,0.25806451612903225,0.9954
39,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,5/23/2017,share price outperformance aveos share price movement shows that the stock has significantly outperformed the zacks classified medicalbiomedical and genetics industry so far this year in fact aveo has gained 508 during this period in comparison to a gain of 04 for the industry tivozanib progress encouraging aveo has made significant progress with its lead pipeline candidate tivozanib it is currently under review in the eu for the firstline treatment of advanced rcc the regulatory application was submitted by aveos partner eusa pharma a final response on the approval status of the candidate is expected in the first half of 2017 the candidates approval will be a huge boost for aveo given the lucrative firstline rcc market in europe meanwhile tivozanib is being evaluated in a couple of additional studies for the thirdline treatment of rcc and advanced rcc in may 2016 aveo started a pivotal phase iii study tivo comparing tivozanib to nexavar sorafenib for the thirdline treatment of patients with refractory rcc the study is evaluating patients with recurrent or metastatic rcc who have failed at least two prior regimens including vegfrtki therapy other than nexavar in feb 2017 aveo announced that tivo3 to compare lead candidate tivozanib to nexavar in patients with refractory advanced renal cell carcinoma rcc has successfully completed the first safety review by safety monitoring committee smc the committee ruled no safety concern was observed for tivozanib and recommended that the study can replace the small number of patients who dropped out prior to starting treatment following the smc recommendation to replace early dropouts the company expects to complete enrolment in jun 2017 ahead of its prior guidance of aug 2017 a preplanned futility analysis of the trial is expected around mid 2017 with topline data expected in the first quarter of 2018 the company expects that the tivo3 trial together with the previously completed tivo1 trial on tivozanib in the firstline treatment of rcc will support potential regulatory approval of tivozanib in the us as a third and firstline treatment for rcc the trial is being conducted to address the overall survival concerns from the tivo1 trial the concerns were identified by the fda in the complete response letter issued in jun 2013 the tivo3 trial is also intended to support a request for regulatory approval of tivozanib in the us as a thirdline treatment and as a firstline treatment for rcc in aug 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc the phase i study will evaluate tivozanib in combination with opdivo at escalating doses in patients with advanced rcc and will be followed by an expansion phase ii cohort at the established combination dose initial safety results from the phase i portion of the tinivo study should be out in the first half of 2017 the goal is to combine vegf inhibitors with immune checkpoint inhibitors to improve outcomes with tolerable safety profiles in mar 2017 aveo announced that it has completed the first dose cohort and initiation of enrollment in the second and final dose cohort of the phase i portion of the study lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63990 new cases of rcc will be diagnosed in the us in 2017 however prognosis for the disease is weak given that approximately 14400 patients are expected to die from the disease in the us in 2017 indicating the need for newer therapies once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company positive on collaborations aveo has been quite active on the partnering front in mar 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the us canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in dec 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in aug 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in apr 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments in the absence of any approved product meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'zack', 'classify', 'medicalbiomedical', 'genetic', 'industry', 'far', 'year', 'fact', 'aveo', 'gain', '508', 'period', 'comparison', 'gain', '04', 'industry', 'tivozanib', 'progress', 'encourage', 'aveo', 'significant', 'progress', 'lead', 'pipeline', 'candidate', 'tivozanib', 'currently', 'review', 'eu', 'firstline', 'treatment', 'advanced', 'rcc', 'regulatory', 'application', 'submit', 'aveos', 'partner', 'eusa', 'pharma', 'final', 'response', 'approval', 'status', 'candidate', 'expect', 'half', '2017', 'candidate', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'tivozanib', 'evaluate', 'couple', 'additional', 'study', 'thirdline', 'treatment', 'rcc', 'advanced', 'rcc', '2016', 'aveo', 'start', 'pivotal', 'phase', 'iii', 'study', 'tivo', 'compare', 'tivozanib', 'nexavar', 'sorafenib', 'thirdline', 'treatment', 'patient', 'refractory', 'rcc', 'study', 'evaluate', 'patient', 'recurrent', 'metastatic', 'rcc', 'fail', 'prior', 'regimen', 'include', 'vegfrtki', 'therapy', 'nexavar', 'feb', '2017', 'aveo', 'announce', 'tivo3', 'compare', 'lead', 'candidate', 'tivozanib', 'nexavar', 'patient', 'refractory', 'advanced', 'renal', 'cell', 'carcinoma', 'rcc', 'successfully', 'complete', 'safety', 'review', 'safety', 'monitoring', 'committee', 'smc', 'committee', 'rule', 'safety', 'concern', 'observe', 'tivozanib', 'recommend', 'study', 'replace', 'small', 'number', 'patient', 'drop', 'prior', 'start', 'treatment', 'follow', 'smc', 'recommendation', 'replace', 'early', 'dropout', 'company', 'expect', 'complete', 'enrolment', 'jun', '2017', 'ahead', 'prior', 'guidance', 'aug', '2017', 'preplanned', 'futility', 'analysis', 'trial', 'expect', 'mid', '2017', 'topline', 'datum', 'expect', 'quarter', '2018', 'company', 'expect', 'tivo3', 'trial', 'previously', 'complete', 'tivo1', 'trial', 'tivozanib', 'firstline', 'treatment', 'rcc', 'support', 'potential', 'regulatory', 'approval', 'tivozanib', 'firstline', 'treatment', 'rcc', 'trial', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'concern', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'jun', '2013', 'tivo3', 'trial', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'aug', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'phase', 'study', 'evaluate', 'tivozanib', 'combination', 'opdivo', 'escalate', 'dose', 'patient', 'advanced', 'rcc', 'follow', 'expansion', 'phase', 'ii', 'cohort', 'establish', 'combination', 'dose', 'initial', 'safety', 'result', 'phase', 'portion', 'tinivo', 'study', 'half', '2017', 'goal', 'combine', 'vegf', 'inhibitor', 'immune', 'checkpoint', 'inhibitor', 'improve', 'outcome', 'tolerable', 'safety', 'profile', 'mar', '2017', 'aveo', 'announce', 'complete', 'dose', 'cohort', 'initiation', 'enrollment', 'second', 'final', 'dose', 'cohort', 'phase', 'portion', 'study', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63990', 'new', 'case', 'rcc', 'diagnose', '2017', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14400', 'patient', 'expect', 'die', 'disease', '2017', 'indicate', 'need', 'new', 'therapy', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'mar', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'dec', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'aug', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'apr', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'absence', 'approve', 'product', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah']",share price outperformance aveo share price movement show stock significantly outperform zack classify medicalbiomedical genetic industry far year fact aveo gain 508 period comparison gain 04 industry tivozanib progress encourage aveo significant progress lead pipeline candidate tivozanib currently review eu firstline treatment advanced rcc regulatory application submit aveos partner eusa pharma final response approval status candidate expect half 2017 candidate approval huge boost aveo give lucrative firstline rcc market europe tivozanib evaluate couple additional study thirdline treatment rcc advanced rcc 2016 aveo start pivotal phase iii study tivo compare tivozanib nexavar sorafenib thirdline treatment patient refractory rcc study evaluate patient recurrent metastatic rcc fail prior regimen include vegfrtki therapy nexavar feb 2017 aveo announce tivo3 compare lead candidate tivozanib nexavar patient refractory advanced renal cell carcinoma rcc successfully complete safety review safety monitoring committee smc committee rule safety concern observe tivozanib recommend study replace small number patient drop prior start treatment follow smc recommendation replace early dropout company expect complete enrolment jun 2017 ahead prior guidance aug 2017 preplanned futility analysis trial expect mid 2017 topline datum expect quarter 2018 company expect tivo3 trial previously complete tivo1 trial tivozanib firstline treatment rcc support potential regulatory approval tivozanib firstline treatment rcc trial conduct address overall survival concern tivo1 trial concern identify fda complete response letter issue jun 2013 tivo3 trial intend support request regulatory approval tivozanib thirdline treatment firstline treatment rcc aug 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc phase study evaluate tivozanib combination opdivo escalate dose patient advanced rcc follow expansion phase ii cohort establish combination dose initial safety result phase portion tinivo study half 2017 goal combine vegf inhibitor immune checkpoint inhibitor improve outcome tolerable safety profile mar 2017 aveo announce complete dose cohort initiation enrollment second final dose cohort phase portion study lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63990 new case rcc diagnose 2017 prognosis disease weak give approximately 14400 patient expect die disease 2017 indicate need new therapy approve tivozanib provide alternative treatment option patient huge boost company positive collaboration aveo active partnering mar 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib dec 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand aug 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world apr 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment absence approve product company currently seek partner global development commercialization av353 treatment pah,27,35,-0.12698412698412698,27,35,-0.12698412698412698,0.9977
40,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,11/13/2017,share price outperformance aveos share price movement shows that the stock has significantly outperformed the industry so far this year in fact aveo has gained 4592 during this period compared with an increase of 23 for the industry fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the first quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in june 2017 the company announced that the study has progressed to phase ii based on successful completion of the phase i dose escalation study the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments in the absence of any approved product meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63990 new cases of rcc will be diagnosed in the united states in 2017 however prognosis of the disease is weak given that approximately 14400 patients are expected to die from the disease in the united states in 2017 indicating the need for newer therapies moreover as per may 2017 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'far', 'year', 'fact', 'aveo', 'gain', '4592', 'period', 'compare', 'increase', '23', 'industry', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'june', '2017', 'company', 'announce', 'study', 'progress', 'phase', 'ii', 'base', 'successful', 'completion', 'phase', 'dose', 'escalation', 'study', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'absence', 'approve', 'product', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63990', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2017', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14400', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2017', 'indicate', 'need', 'new', 'therapy', '2017', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock significantly outperform industry far year fact aveo gain 4592 period compare increase 23 industry fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc june 2017 company announce study progress phase ii base successful completion phase dose escalation study phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment absence approve product company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63990 new case rcc diagnose united states 2017 prognosis disease weak give approximately 14400 patient expect die disease united states 2017 indicate need new therapy 2017 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,24,20,0.08888888888888889,24,20,0.08888888888888889,0.9962
41,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,1/8/2018,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data on thirdline refractory rcc is expected in the first quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a third line treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in june 2017 the company announced that the study has progressed to phase ii based on successful completion of the phase i dose escalation study the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av 380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications zacks equity research aveo wwwzackscom page 3 of 8,sell,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'thirdline', 'refractory', 'rcc', 'expect', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'line', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'june', '2017', 'company', 'announce', 'study', 'progress', 'phase', 'ii', 'base', 'successful', 'completion', 'phase', 'dose', 'escalation', 'study', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av', '380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum thirdline refractory rcc expect quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 datum study intend support request regulatory approval tivozanib united states line treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc june 2017 company announce study progress phase ii base successful completion phase dose escalation study phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av 380 related antibody bind gdf15 treatment prevention disease condition indication zacks equity research aveo wwwzackscom page 3 8,21,13,0.22857142857142856,21,13,0.22857142857142856,0.9967
42,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,5/4/2018,share price outperformance aveos share price movement shows that the stock has significantly outperformed the industry in the past year in fact aveo has gained 297 during this period compared with an decrease of 143 for the industry fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo3 study which demonstrated that the drug achieved superior pfs topline data is expected in the second quarter of 2018 it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals tivo3 is being conducted to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminiary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments in the absence of any approved product meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per may 2017 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'past', 'year', 'fact', 'aveo', 'gain', '297', 'period', 'compare', 'decrease', '143', 'industry', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo3', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'topline', 'datum', 'expect', 'second', 'quarter', '2018', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'tivo3', 'conduct', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodifie', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminiary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'absence', 'approve', 'product', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2017', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock significantly outperform industry past year fact aveo gain 297 period compare decrease 143 industry fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo3 study demonstrate drug achieve superior pfs topline datum expect second quarter 2018 trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval tivo3 conduct address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodifie datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminiary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment absence approve product company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2017 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,24,21,0.06521739130434782,24,21,0.06521739130434782,0.996
43,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,9/4/2018,share price outperformance aveos share price movement shows that the stock has outperformed the industry so far this year shares of aveo have gained 72 compared with the industrys decrease of 17 fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified topline data is expected in the fourth quarter of 2018 the data from both the studies is also intended to support a request for regulatory approval of tivozanib in the united states as a thirdline treatment and as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['share', 'price', 'outperformance', 'aveo', 'share', 'price', 'movement', 'show', 'stock', 'outperform', 'industry', 'far', 'year', 'share', 'aveo', 'gain', '72', 'compare', 'industrys', 'decrease', '17', 'fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodified', 'topline', 'datum', 'expect', 'fourth', 'quarter', '2018', 'datum', 'study', 'intend', 'support', 'request', 'regulatory', 'approval', 'tivozanib', 'united', 'states', 'thirdline', 'treatment', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",share price outperformance aveo share price movement show stock outperform industry far year share aveo gain 72 compare industrys decrease 17 fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodified topline datum expect fourth quarter 2018 datum study intend support request regulatory approval tivozanib united states thirdline treatment firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,25,22,0.0625,25,22,0.0625,0.996
44,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,12/7/2018,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified in november 2018 aveo announced positive topline data from the phase iii tivo3 study which compared fotivda with nexavar in patients suffering highly refractory advanced or metastatic rcc the study met primary endpoint by demonstrating a statistically significant benefit in progressionfree survival pfsthe company plans to submit a new drug application nda in the next six monthsdata from this study along with the previously completed tivo1 evaluation will support the filing of a regulatory application for fotivdas approval in the united states as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 in october 2018 aveo along with eusa pharma presented updated interim results from the phase ii portion of the tinivo program the study which evaluated fotivda in combination with opdivo demonstrated a favorable safety and efficacy profile pertaining to the treatment of advancedmetastatic rcc the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab aveo is developing ficlatuzumab in combination with lillys erbitux in a phase ii study for treating metastatic head and neck squamous cell carcinoma such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodifie', 'november', '2018', 'aveo', 'announce', 'positive', 'topline', 'datum', 'phase', 'iii', 'tivo3', 'study', 'compare', 'fotivda', 'nexavar', 'patient', 'suffer', 'highly', 'refractory', 'advanced', 'metastatic', 'rcc', 'study', 'meet', 'primary', 'endpoint', 'demonstrate', 'statistically', 'significant', 'benefit', 'progressionfree', 'survival', 'pfsthe', 'company', 'plan', 'submit', 'new', 'drug', 'application', 'nda', 'monthsdata', 'study', 'previously', 'complete', 'tivo1', 'evaluation', 'support', 'filing', 'regulatory', 'application', 'fotivdas', 'approval', 'united', 'states', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'october', '2018', 'aveo', 'eusa', 'pharma', 'present', 'update', 'interim', 'result', 'phase', 'ii', 'portion', 'tinivo', 'program', 'study', 'evaluate', 'fotivda', 'combination', 'opdivo', 'demonstrate', 'favorable', 'safety', 'efficacy', 'profile', 'pertain', 'treatment', 'advancedmetastatic', 'rcc', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'aveo', 'develop', 'ficlatuzumab', 'combination', 'lillys', 'erbitux', 'phase', 'ii', 'study', 'treat', 'metastatic', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodifie november 2018 aveo announce positive topline datum phase iii tivo3 study compare fotivda nexavar patient suffer highly refractory advanced metastatic rcc study meet primary endpoint demonstrate statistically significant benefit progressionfree survival pfsthe company plan submit new drug application nda monthsdata study previously complete tivo1 evaluation support filing regulatory application fotivdas approval united states firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 october 2018 aveo eusa pharma present update interim result phase ii portion tinivo program study evaluate fotivda combination opdivo demonstrate favorable safety efficacy profile pertain treatment advancedmetastatic rcc phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab aveo develop ficlatuzumab combination lillys erbitux phase ii study treat metastatic head neck squamous cell carcinoma deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,28,25,0.05555555555555555,28,25,0.05555555555555555,0.9966
45,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,12/7/2018,string of pipeline setbacks aveo has suffered a string of pipeline setbacks in the past tivozanib had received a complete response letter crl from the fda in jun 2013 for the firstline treatment of advanced rcc citing concerns regarding the negative trend in overall survival in the pivotal phase iii study we note that the company is currently conducting the tivo3 study on tivozanib to address the concerns raised by the regulatory agency in its crl timely approval would have allowed the company to start generating revenues from tivozanib meanwhile aveo does not plan to conduct further studies on tivozanib for the treatment of metastatic colorectal cancer till the time an assay used to measure serum neuropilin1 in firstline colorectal cancer patients is identified we note that the phase ii baton breast cancer study on tivozanib was stopped due to insufficient enrollment meanwhile a phase ii study that evaluated ficlatuzumab in combination with iressa for the treatment of firstline nonsmall cell lung cancer nsclc demonstrated disappointing results based on the findings from the interim analysis and slow enrollment aveo and biodesix discontinued the phase ii focal study that was conducted to evaluate ficlatuzumab in combination with tarceva in the subset of patients with zacks equity research aveo wwwzackscom page 3 of 8,sell,"['string', 'pipeline', 'setback', 'aveo', 'suffer', 'string', 'pipeline', 'setback', 'past', 'tivozanib', 'receive', 'complete', 'response', 'letter', 'crl', 'fda', 'jun', '2013', 'firstline', 'treatment', 'advanced', 'rcc', 'cite', 'concern', 'negative', 'trend', 'overall', 'survival', 'pivotal', 'phase', 'iii', 'study', 'note', 'company', 'currently', 'conduct', 'tivo3', 'study', 'tivozanib', 'address', 'concern', 'raise', 'regulatory', 'agency', 'crl', 'timely', 'approval', 'allow', 'company', 'start', 'generate', 'revenue', 'tivozanib', 'aveo', 'plan', 'conduct', 'study', 'tivozanib', 'treatment', 'metastatic', 'colorectal', 'cancer', 'till', 'time', 'assay', 'measure', 'serum', 'neuropilin1', 'firstline', 'colorectal', 'cancer', 'patient', 'identify', 'note', 'phase', 'ii', 'baton', 'breast', 'cancer', 'study', 'tivozanib', 'stop', 'insufficient', 'enrollment', 'phase', 'ii', 'study', 'evaluate', 'ficlatuzumab', 'combination', 'iressa', 'treatment', 'firstline', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'demonstrate', 'disappointing', 'result', 'base', 'finding', 'interim', 'analysis', 'slow', 'enrollment', 'aveo', 'biodesix', 'discontinue', 'phase', 'ii', 'focal', 'study', 'conduct', 'evaluate', 'ficlatuzumab', 'combination', 'tarceva', 'subset', 'patient', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",string pipeline setback aveo suffer string pipeline setback past tivozanib receive complete response letter crl fda jun 2013 firstline treatment advanced rcc cite concern negative trend overall survival pivotal phase iii study note company currently conduct tivo3 study tivozanib address concern raise regulatory agency crl timely approval allow company start generate revenue tivozanib aveo plan conduct study tivozanib treatment metastatic colorectal cancer till time assay measure serum neuropilin1 firstline colorectal cancer patient identify note phase ii baton breast cancer study tivozanib stop insufficient enrollment phase ii study evaluate ficlatuzumab combination iressa treatment firstline nonsmall cell lung cancer nsclc demonstrate disappointing result base finding interim analysis slow enrollment aveo biodesix discontinue phase ii focal study conduct evaluate ficlatuzumab combination tarceva subset patient zacks equity research aveo wwwzackscom page 3 8,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.9781
46,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,1/8/2019,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals aveo is conducting another phase iii study tivo3 to address the overall survival concerns from the tivo1 trial identified by the fda in the complete response letter issued in june 2013 interim data from tivo3 study announced in october 2017 supports continuation of the study unmodified in november 2018 aveo announced positive topline data from the phase iii tivo3 study which compared fotivda with nexavar in patients suffering highly refractory advanced or metastatic rcc the study met primary endpoint by demonstrating a statistically significant benefit in progressionfree survival pfsthe company plans to submit a new drug application nda in the next six monthsdata from this study along with the previously completed tivo1 evaluation will support the filing of a regulatory application for fotivdas approval in the united states as a firstline treatment for rcc in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in february 2018 the company announced preliminary data from the phase ii portion of the study which showed that 64 patients achieved orr the disease control rate achieved by the combination therapy was 100 in october 2018 aveo along with eusa pharma presented updated interim results from the phase ii portion of the tinivo program the study which evaluated fotivda in combination with opdivo demonstrated a favorable safety and efficacy profile pertaining to the treatment of advancedmetastatic rcc the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab aveo is developing ficlatuzumab in combination with lillys erbitux in a phase ii study for treating metastatic head and neck squamous cell carcinoma in december 2018 aveo enetred into a collaboration with astrazeneca to evalute the latters imfinzi in combination with aveos fotivda the phase iii study will evaluate the combo for treating firstline hepatocellular carcinoma the phase i part of the study is expected to begin in 2019 such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments meanwhile the company is currently seeking a partner for the global development and commercialization of av353 for the treatment of pah lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 63340 new cases of rcc will be diagnosed in the united states in 2018 however prognosis of the disease is weak given that approximately 14 970 patients are expected to die from the disease in the united states in 2018 indicating the need for newer therapies moreover as per 2012 data of cancer research uk rcc is the most common form of kidney cancer which causes an estimated 49000 deaths in europe each year once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'aveo', 'conduct', 'phase', 'iii', 'study', 'tivo3', 'address', 'overall', 'survival', 'concern', 'tivo1', 'trial', 'identify', 'fda', 'complete', 'response', 'letter', 'issue', 'june', '2013', 'interim', 'datum', 'tivo3', 'study', 'announce', 'october', '2017', 'support', 'continuation', 'study', 'unmodifie', 'november', '2018', 'aveo', 'announce', 'positive', 'topline', 'datum', 'phase', 'iii', 'tivo3', 'study', 'compare', 'fotivda', 'nexavar', 'patient', 'suffer', 'highly', 'refractory', 'advanced', 'metastatic', 'rcc', 'study', 'meet', 'primary', 'endpoint', 'demonstrate', 'statistically', 'significant', 'benefit', 'progressionfree', 'survival', 'pfsthe', 'company', 'plan', 'submit', 'new', 'drug', 'application', 'nda', 'monthsdata', 'study', 'previously', 'complete', 'tivo1', 'evaluation', 'support', 'filing', 'regulatory', 'application', 'fotivdas', 'approval', 'united', 'states', 'firstline', 'treatment', 'rcc', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'february', '2018', 'company', 'announce', 'preliminary', 'datum', 'phase', 'ii', 'portion', 'study', 'show', '64', 'patient', 'achieve', 'orr', 'disease', 'control', 'rate', 'achieve', 'combination', 'therapy', '100', 'october', '2018', 'aveo', 'eusa', 'pharma', 'present', 'update', 'interim', 'result', 'phase', 'ii', 'portion', 'tinivo', 'program', 'study', 'evaluate', 'fotivda', 'combination', 'opdivo', 'demonstrate', 'favorable', 'safety', 'efficacy', 'profile', 'pertain', 'treatment', 'advancedmetastatic', 'rcc', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'aveo', 'develop', 'ficlatuzumab', 'combination', 'lillys', 'erbitux', 'phase', 'ii', 'study', 'treat', 'metastatic', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'december', '2018', 'aveo', 'enetre', 'collaboration', 'astrazeneca', 'evalute', 'latter', 'imfinzi', 'combination', 'aveo', 'fotivda', 'phase', 'iii', 'study', 'evaluate', 'combo', 'treat', 'firstline', 'hepatocellular', 'carcinoma', 'phase', 'study', 'expect', 'begin', '2019', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'company', 'currently', 'seek', 'partner', 'global', 'development', 'commercialization', 'av353', 'treatment', 'pah', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '63340', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2018', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14', '970', 'patient', 'expect', 'die', 'disease', 'united', 'states', '2018', 'indicate', 'need', 'new', 'therapy', '2012', 'datum', 'cancer', 'research', 'uk', 'rcc', 'common', 'form', 'kidney', 'cancer', 'cause', 'estimate', '49000', 'death', 'europe', 'year', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval aveo conduct phase iii study tivo3 address overall survival concern tivo1 trial identify fda complete response letter issue june 2013 interim datum tivo3 study announce october 2017 support continuation study unmodifie november 2018 aveo announce positive topline datum phase iii tivo3 study compare fotivda nexavar patient suffer highly refractory advanced metastatic rcc study meet primary endpoint demonstrate statistically significant benefit progressionfree survival pfsthe company plan submit new drug application nda monthsdata study previously complete tivo1 evaluation support filing regulatory application fotivdas approval united states firstline treatment rcc august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc february 2018 company announce preliminary datum phase ii portion study show 64 patient achieve orr disease control rate achieve combination therapy 100 october 2018 aveo eusa pharma present update interim result phase ii portion tinivo program study evaluate fotivda combination opdivo demonstrate favorable safety efficacy profile pertain treatment advancedmetastatic rcc phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab aveo develop ficlatuzumab combination lillys erbitux phase ii study treat metastatic head neck squamous cell carcinoma december 2018 aveo enetre collaboration astrazeneca evalute latter imfinzi combination aveo fotivda phase iii study evaluate combo treat firstline hepatocellular carcinoma phase study expect begin 2019 deal provide aveo need fund form license fee upfront milestone payment company currently seek partner global development commercialization av353 treatment pah lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 63340 new case rcc diagnose united states 2018 prognosis disease weak give approximately 14 970 patient expect die disease united states 2018 indicate need new therapy 2012 datum cancer research uk rcc common form kidney cancer cause estimate 49000 death europe year approve tivozanib provide alternative treatment option patient huge boost company,29,26,0.05357142857142857,29,26,0.05357142857142857,0.9968
47,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,1/8/2019,string of pipeline setbacks aveo has suffered a string of pipeline setbacks in the past tivozanib had received a complete response letter crl from the fda in jun 2013 for the firstline treatment of advanced rcc citing concerns regarding the negative trend in overall survival in the pivotal phase iii study we note that the company is currently conducting the tivo3 study on tivozanib to address the concerns raised by the regulatory agency in its crl timely approval would have allowed the company to start generating revenues from tivozanib meanwhile aveo does not plan to conduct further studies on tivozanib for the treatment of metastatic colorectal cancer till the time an assay used to measure serum neuropilin1 in firstline colorectal cancer patients is identified we note that the phase ii baton breast cancer study on tivozanib was stopped due to insufficient enrollment meanwhile a phase ii study that evaluated ficlatuzumab in combination with iressa for the treatment of firstline nonsmall cell lung cancer nsclc demonstrated zacks equity research aveo wwwzackscom page 3 of 8,sell,"['string', 'pipeline', 'setback', 'aveo', 'suffer', 'string', 'pipeline', 'setback', 'past', 'tivozanib', 'receive', 'complete', 'response', 'letter', 'crl', 'fda', 'jun', '2013', 'firstline', 'treatment', 'advanced', 'rcc', 'cite', 'concern', 'negative', 'trend', 'overall', 'survival', 'pivotal', 'phase', 'iii', 'study', 'note', 'company', 'currently', 'conduct', 'tivo3', 'study', 'tivozanib', 'address', 'concern', 'raise', 'regulatory', 'agency', 'crl', 'timely', 'approval', 'allow', 'company', 'start', 'generate', 'revenue', 'tivozanib', 'aveo', 'plan', 'conduct', 'study', 'tivozanib', 'treatment', 'metastatic', 'colorectal', 'cancer', 'till', 'time', 'assay', 'measure', 'serum', 'neuropilin1', 'firstline', 'colorectal', 'cancer', 'patient', 'identify', 'note', 'phase', 'ii', 'baton', 'breast', 'cancer', 'study', 'tivozanib', 'stop', 'insufficient', 'enrollment', 'phase', 'ii', 'study', 'evaluate', 'ficlatuzumab', 'combination', 'iressa', 'treatment', 'firstline', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'demonstrate', 'zacks', 'equity', 'research', 'aveo', 'wwwzackscom', 'page', '3', '8']",string pipeline setback aveo suffer string pipeline setback past tivozanib receive complete response letter crl fda jun 2013 firstline treatment advanced rcc cite concern negative trend overall survival pivotal phase iii study note company currently conduct tivo3 study tivozanib address concern raise regulatory agency crl timely approval allow company start generate revenue tivozanib aveo plan conduct study tivozanib treatment metastatic colorectal cancer till time assay measure serum neuropilin1 firstline colorectal cancer patient identify note phase ii baton breast cancer study tivozanib stop insufficient enrollment phase ii study evaluate ficlatuzumab combination iressa treatment firstline nonsmall cell lung cancer nsclc demonstrate zacks equity research aveo wwwzackscom page 3 8,2,12,-0.6666666666666666,2,12,-0.6666666666666666,-0.9719
48,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,5/15/2019,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals in august 2016 aveo initiated a phase iii study tinivo on tivozanib in combination with bristolmyers opdivo an immune checkpoint pd1 inhibitor for the treatment of advanced rcc in october 2018 aveo along with eusa pharma presented updated interim results from the phase ii portion of the tinivo program the study showed a favorable safety and efficacy profile pertaining to the treatment of advancedmetastatic rcc the phase ii study is evaluating a 15 mg dose of tivozanib in combination with opdivo daily in patients with advanced rcc aveo is planning to further develop tivozanib as a combination therapy with immune checkpoint inhibitors for the treatment of rcc and hcc positive on collaborations aveo has been quite active on the partnering front in march 2016 aveo entered into an exclusive collaboration and license agreement granting canbridge the exclusive right to develop manufacture and commercialize av203 in all countries other than the united states canada and mexico canbridge plans to develop the candidate for the treatment of squamous cell esophagus cancer aveo received a 2million milestone payment from canbridge life sciences following the acceptance of investigational new drug ind application for a phase ibiii study of can017 av by china national drug administration cnda aveo has also inked several agreements for tivozanib in december 2015 aveo entered into an exclusive license agreement granting eusa pharma rights to develop manufacture and commercialize tivozanib for all diseases and conditions in humans excluding nononcologic diseases or conditions of the eye in europe excluding russia ukraine and the commonwealth of independent states latin america excluding mexico africa australasia and new zealand in august 2015 aveo entered into an exclusive worldwide license agreement with novartis granting the latter the development and commercialization of av380 and related antibodies that bind to gdf15 for the treatment and prevention of diseases and other conditions in all indications in humans under this agreement novartis is responsible for all activities and costs associated with the further development regulatory filing and commercialization of av380 across the world in april 2014 aveo entered into an agreement with biodesix a molecular diagnostics company to develop and commercialize ficlatuzumab in april 2019 aveo announced positive results from phase ib expansion cohort of ficlatuzumab in combination with cytarabine for treating patients with relapsed and refractory acute myeloid leukemia the company is also developing ficlatuzumab combined with lillys erbitux in a phase ii probe for treating metastatic head and neck squamous cell carcinoma ficlatuzumab is also being evaluated in combination with cytosar cytarabine for acute myeloid leukemia and in combination with nabpaclitaxel and gemcitabine for pancreatic cancer such deals provide aveo with much needed funds in the form of license fees upfront and milestone and other payments lucrative rcc market as per the american cancer society rcc is among the 10 most common cancers in both men and women it has been estimated that approximately 73820 new cases of rcc will be diagnosed in the united states in 2019 however prognosis of the disease is weak given that approximately 14770 patients are expected to die from the disease in the united states indicating the need for newer therapies once approved tivozanib will provide an alternative treatment option to these patients and will be a huge boost for the company,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval', 'august', '2016', 'aveo', 'initiate', 'phase', 'iii', 'study', 'tinivo', 'tivozanib', 'combination', 'bristolmyer', 'opdivo', 'immune', 'checkpoint', 'pd1', 'inhibitor', 'treatment', 'advanced', 'rcc', 'october', '2018', 'aveo', 'eusa', 'pharma', 'present', 'update', 'interim', 'result', 'phase', 'ii', 'portion', 'tinivo', 'program', 'study', 'show', 'favorable', 'safety', 'efficacy', 'profile', 'pertain', 'treatment', 'advancedmetastatic', 'rcc', 'phase', 'ii', 'study', 'evaluate', '15', 'mg', 'dose', 'tivozanib', 'combination', 'opdivo', 'daily', 'patient', 'advanced', 'rcc', 'aveo', 'plan', 'develop', 'tivozanib', 'combination', 'therapy', 'immune', 'checkpoint', 'inhibitor', 'treatment', 'rcc', 'hcc', 'positive', 'collaboration', 'aveo', 'active', 'partnering', 'march', '2016', 'aveo', 'enter', 'exclusive', 'collaboration', 'license', 'agreement', 'grant', 'canbridge', 'exclusive', 'right', 'develop', 'manufacture', 'commercialize', 'av203', 'country', 'united', 'states', 'canada', 'mexico', 'canbridge', 'plan', 'develop', 'candidate', 'treatment', 'squamous', 'cell', 'esophagus', 'cancer', 'aveo', 'receive', '2million', 'milestone', 'payment', 'canbridge', 'life', 'science', 'follow', 'acceptance', 'investigational', 'new', 'drug', 'ind', 'application', 'phase', 'ibiii', 'study', 'can017', 'av', 'china', 'national', 'drug', 'administration', 'cnda', 'aveo', 'ink', 'agreement', 'tivozanib', 'december', '2015', 'aveo', 'enter', 'exclusive', 'license', 'agreement', 'grant', 'eusa', 'pharma', 'right', 'develop', 'manufacture', 'commercialize', 'tivozanib', 'disease', 'condition', 'human', 'exclude', 'nononcologic', 'disease', 'condition', 'eye', 'europe', 'exclude', 'russia', 'ukraine', 'commonwealth', 'independent', 'states', 'latin', 'america', 'exclude', 'mexico', 'africa', 'australasia', 'new', 'zealand', 'august', '2015', 'aveo', 'enter', 'exclusive', 'worldwide', 'license', 'agreement', 'novartis', 'grant', 'development', 'commercialization', 'av380', 'related', 'antibody', 'bind', 'gdf15', 'treatment', 'prevention', 'disease', 'condition', 'indication', 'human', 'agreement', 'novartis', 'responsible', 'activity', 'cost', 'associate', 'development', 'regulatory', 'filing', 'commercialization', 'av380', 'world', 'april', '2014', 'aveo', 'enter', 'agreement', 'biodesix', 'molecular', 'diagnostic', 'company', 'develop', 'commercialize', 'ficlatuzumab', 'april', '2019', 'aveo', 'announce', 'positive', 'result', 'phase', 'ib', 'expansion', 'cohort', 'ficlatuzumab', 'combination', 'cytarabine', 'treat', 'patient', 'relapsed', 'refractory', 'acute', 'myeloid', 'leukemia', 'company', 'develop', 'ficlatuzumab', 'combine', 'lillys', 'erbitux', 'phase', 'ii', 'probe', 'treat', 'metastatic', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'ficlatuzumab', 'evaluate', 'combination', 'cytosar', 'cytarabine', 'acute', 'myeloid', 'leukemia', 'combination', 'nabpaclitaxel', 'gemcitabine', 'pancreatic', 'cancer', 'deal', 'provide', 'aveo', 'need', 'fund', 'form', 'license', 'fee', 'upfront', 'milestone', 'payment', 'lucrative', 'rcc', 'market', 'american', 'cancer', 'society', 'rcc', '10', 'common', 'cancer', 'man', 'woman', 'estimate', 'approximately', '73820', 'new', 'case', 'rcc', 'diagnose', 'united', 'states', '2019', 'prognosis', 'disease', 'weak', 'give', 'approximately', '14770', 'patient', 'expect', 'die', 'disease', 'united', 'states', 'indicate', 'need', 'new', 'therapy', 'approve', 'tivozanib', 'provide', 'alternative', 'treatment', 'option', 'patient', 'huge', 'boost', 'company']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval august 2016 aveo initiate phase iii study tinivo tivozanib combination bristolmyer opdivo immune checkpoint pd1 inhibitor treatment advanced rcc october 2018 aveo eusa pharma present update interim result phase ii portion tinivo program study show favorable safety efficacy profile pertain treatment advancedmetastatic rcc phase ii study evaluate 15 mg dose tivozanib combination opdivo daily patient advanced rcc aveo plan develop tivozanib combination therapy immune checkpoint inhibitor treatment rcc hcc positive collaboration aveo active partnering march 2016 aveo enter exclusive collaboration license agreement grant canbridge exclusive right develop manufacture commercialize av203 country united states canada mexico canbridge plan develop candidate treatment squamous cell esophagus cancer aveo receive 2million milestone payment canbridge life science follow acceptance investigational new drug ind application phase ibiii study can017 av china national drug administration cnda aveo ink agreement tivozanib december 2015 aveo enter exclusive license agreement grant eusa pharma right develop manufacture commercialize tivozanib disease condition human exclude nononcologic disease condition eye europe exclude russia ukraine commonwealth independent states latin america exclude mexico africa australasia new zealand august 2015 aveo enter exclusive worldwide license agreement novartis grant development commercialization av380 related antibody bind gdf15 treatment prevention disease condition indication human agreement novartis responsible activity cost associate development regulatory filing commercialization av380 world april 2014 aveo enter agreement biodesix molecular diagnostic company develop commercialize ficlatuzumab april 2019 aveo announce positive result phase ib expansion cohort ficlatuzumab combination cytarabine treat patient relapsed refractory acute myeloid leukemia company develop ficlatuzumab combine lillys erbitux phase ii probe treat metastatic head neck squamous cell carcinoma ficlatuzumab evaluate combination cytosar cytarabine acute myeloid leukemia combination nabpaclitaxel gemcitabine pancreatic cancer deal provide aveo need fund form license fee upfront milestone payment lucrative rcc market american cancer society rcc 10 common cancer man woman estimate approximately 73820 new case rcc diagnose united states 2019 prognosis disease weak give approximately 14770 patient expect die disease united states indicate need new therapy approve tivozanib provide alternative treatment option patient huge boost company,23,23,0.0,23,23,0.0,0.9967
49,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,8/19/2019,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval is a huge boost for aveo given the lucrative firstline rcc market in europe the decision was primarily based on data from tivo1 study which demonstrated that the drug achieved superior pfs it also triggered a payment of 4 million from eusa pharma to aveo the latter is also eligible for additional 12 million based on reimbursement and regulatory approvals,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'decision', 'primarily', 'base', 'datum', 'tivo1', 'study', 'demonstrate', 'drug', 'achieve', 'superior', 'pfs', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'eligible', 'additional', '12', 'million', 'base', 'reimbursement', 'regulatory', 'approval']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval huge boost aveo give lucrative firstline rcc market europe decision primarily base datum tivo1 study demonstrate drug achieve superior pfs trigger payment 4 million eusa pharma aveo eligible additional 12 million base reimbursement regulatory approval,8,2,0.5454545454545454,8,2,0.5454545454545454,0.9796
50,"AVEO Pharmaceuticals, Inc._Attachment1.pdf",AVEO,4/30/2020,fotivda approval a positive aveo got a boost with the eu approval of its lead pipeline candidate fotivda in august 2017 for the firstline treatment of advanced rcc in adult patients who have not received any vegfr and mtor pathway inhibitor treatment the approval was based on data from tivo1 study and was a huge boost to aveo given the lucrative firstline rcc market in europe it also triggered a payment of 4 million from eusa pharma to aveo the company also receives additional milestone fees on the,buy,"['fotivda', 'approval', 'positive', 'aveo', 'get', 'boost', 'eu', 'approval', 'lead', 'pipeline', 'candidate', 'fotivda', 'august', '2017', 'firstline', 'treatment', 'advanced', 'rcc', 'adult', 'patient', 'receive', 'vegfr', 'mtor', 'pathway', 'inhibitor', 'treatment', 'approval', 'base', 'datum', 'tivo1', 'study', 'huge', 'boost', 'aveo', 'give', 'lucrative', 'firstline', 'rcc', 'market', 'europe', 'trigger', 'payment', '4', 'million', 'eusa', 'pharma', 'aveo', 'company', 'receive', 'additional', 'milestone', 'fee']",fotivda approval positive aveo get boost eu approval lead pipeline candidate fotivda august 2017 firstline treatment advanced rcc adult patient receive vegfr mtor pathway inhibitor treatment approval base datum tivo1 study huge boost aveo give lucrative firstline rcc market europe trigger payment 4 million eusa pharma aveo company receive additional milestone fee,6,2,0.4444444444444444,6,2,0.4444444444444444,0.9652
51,Box Inc_Attachment1(3).pdf,BOX,6/2/2020,box has been incurring losses since it went public in 2005 as of jan 31 2018 the company had an accumulated deficit of 104 billion boxs current focus is on scaling its business through making significant investments in cloud infrastructure development,sell,"['box', 'incur', 'loss', 'go', 'public', '2005', 'jan', '31', '2018', 'company', 'accumulate', 'deficit', '104', 'billion', 'box', 'current', 'focus', 'scale', 'business', 'make', 'significant', 'investment', 'cloud', 'infrastructure', 'development']",box incur loss go public 2005 jan 31 2018 company accumulate deficit 104 billion box current focus scale business make significant investment cloud infrastructure development,1,3,-0.4,1,3,-0.4,-0.4939
52,Box Inc_Attachment1.pdf,BOX,10/21/2020,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base further it is witnessing winning clientele and extension of contracts with its existing clients,buy,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'witness', 'win', 'clientele', 'extension', 'contract', 'exist', 'client']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base witness win clientele extension contract exist client,5,4,0.1,5,4,0.1,0.936
53,"Box, Inc._Attachment1(2).pdf",BOX,6/18/2018,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base that includes more than 60 million registered users further it is witnessing winning clientele and extension of contracts with its existing clients box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate free cash flow is an important measure of boxs liquidity and provides vital information to investors regarding the amount of cash available for investment in business box sees significant improvements in free cash flow through efficient working capital management retention rate is an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of more than 100 through user expansion both enterprise as well as small and medium business customers,buy,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'include', '60', 'million', 'register', 'user', 'witness', 'win', 'clientele', 'extension', 'contract', 'exist', 'client', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'box', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rate', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base include 60 million register user witness win clientele extension contract exist client box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate free cash flow important measure boxs liquidity provide vital information investor cash available investment business box see significant improvement free cash flow efficient work capital management retention rate efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,10,17,-0.25,10,17,-0.25,0.9939
54,"Box, Inc._Attachment1(2).pdf",BOX,3/8/2019,box has been incurring losses since it went public in 2005 as of jan 31 2018 the company had an accumulated deficit of 104 billion boxs current focus is on scaling its business through making significant investments in cloud infrastructure development professional services sales marketing and so on the company said that it will continue making such investments and as result does not expect profit in the foreseeable future however the company reported profiys in the last reported fiscal fourth quarter box operates in an intensely competitive market and most of the players in the space are operationally superior they are bigger brands with greater resources and longer history of operation some of the major competitors of the company include google microsoft opentext and dropbox additionally the market is characterized by lower entry barriers and frequent technological improvements that increase the chances of price competition pricing pressure makes box susceptible to reduced sales and lower margins the business is concentrated in the us box so far has not received much success in its international business moreover operating in international markets involves economic regulatory geographical and political risks under the current circumstances box faces considerable difficulties in creating demand and improving revenues in these markets moreover its limited international operations make it vulnerable to foreign exchange risk appreciation or depreciation of the us dollar versus foreign currencies could impact the companys financial results,sell,"['box', 'incur', 'loss', 'go', 'public', '2005', 'jan', '31', '2018', 'company', 'accumulate', 'deficit', '104', 'billion', 'box', 'current', 'focus', 'scale', 'business', 'make', 'significant', 'investment', 'cloud', 'infrastructure', 'development', 'professional', 'service', 'sale', 'marketing', 'company', 'say', 'continue', 'make', 'investment', 'result', 'expect', 'profit', 'foreseeable', 'future', 'company', 'report', 'profiys', 'report', 'fiscal', 'fourth', 'quarter', 'box', 'operate', 'intensely', 'competitive', 'market', 'player', 'space', 'operationally', 'superior', 'big', 'brand', 'great', 'resource', 'long', 'history', 'operation', 'major', 'competitor', 'company', 'include', 'google', 'microsoft', 'opentext', 'dropbox', 'additionally', 'market', 'characterize', 'low', 'entry', 'barrier', 'frequent', 'technological', 'improvement', 'increase', 'chance', 'price', 'competition', 'pricing', 'pressure', 'make', 'box', 'susceptible', 'reduce', 'sale', 'low', 'margin', 'business', 'concentrate', 'box', 'far', 'receive', 'success', 'international', 'business', 'operate', 'international', 'market', 'involve', 'economic', 'regulatory', 'geographical', 'political', 'risk', 'current', 'circumstance', 'box', 'face', 'considerable', 'difficulty', 'create', 'demand', 'improve', 'revenue', 'market', 'limited', 'international', 'operation', 'vulnerable', 'foreign', 'exchange', 'risk', 'appreciation', 'depreciation', 'dollar', 'versus', 'foreign', 'currency', 'impact', 'companys', 'financial', 'result']",box incur loss go public 2005 jan 31 2018 company accumulate deficit 104 billion box current focus scale business make significant investment cloud infrastructure development professional service sale marketing company say continue make investment result expect profit foreseeable future company report profiys report fiscal fourth quarter box operate intensely competitive market player space operationally superior big brand great resource long history operation major competitor company include google microsoft opentext dropbox additionally market characterize low entry barrier frequent technological improvement increase chance price competition pricing pressure make box susceptible reduce sale low margin business concentrate box far receive success international business operate international market involve economic regulatory geographical political risk current circumstance box face considerable difficulty create demand improve revenue market limited international operation vulnerable foreign exchange risk appreciation depreciation dollar versus foreign currency impact companys financial result,6,21,-0.5357142857142857,6,21,-0.5357142857142857,0.9152
55,"Box, Inc._Attachment1(3).pdf",BOX,2/13/2018,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base that includes more than 52 million registered users tens of thousands of thirdparty developers have used boxs platform as the secure content layer for their applications box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate billings were 4542 million up 23 from fiscal 3691 million up 50 from fiscal and 2464 million up 41 from fiscal in fiscal 2017 2016 and 2015 respectively given the consistent rise in billings the companys top line is expected to stay strong free cash flow is an important measure of boxs profitability and liquidity and provides vital information to investors regarding the amount of cash available for investment in business free cash flow increased 914 million from fiscal 2016 to fiscal 2017 mainly driven by significant decrease in capital expenditures and cash used in operations box sees significant improvements in free cash flow through efficient working capital management retention rate is an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of more than 100 through user expansion both enterprise as well as small and medium business customers,sell,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'include', '52', 'million', 'register', 'user', 'ten', 'thousand', 'thirdparty', 'developer', 'boxs', 'platform', 'secure', 'content', 'layer', 'application', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'billing', '4542', 'million', '23', 'fiscal', '3691', 'million', '50', 'fiscal', '2464', 'million', '41', 'fiscal', 'fiscal', '2017', '2016', '2015', 'respectively', 'give', 'consistent', 'rise', 'billing', 'company', 'line', 'expect', 'stay', 'strong', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'profitability', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'free', 'cash', 'flow', 'increase', '914', 'million', 'fiscal', '2016', 'fiscal', '2017', 'mainly', 'drive', 'significant', 'decrease', 'capital', 'expenditure', 'cash', 'operation', 'box', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rate', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base include 52 million register user ten thousand thirdparty developer boxs platform secure content layer application box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate billing 4542 million 23 fiscal 3691 million 50 fiscal 2464 million 41 fiscal fiscal 2017 2016 2015 respectively give consistent rise billing company line expect stay strong free cash flow important measure boxs profitability liquidity provide vital information investor cash available investment business free cash flow increase 914 million fiscal 2016 fiscal 2017 mainly drive significant decrease capital expenditure cash operation box see significant improvement free cash flow efficient work capital management retention rate efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,11,20,-0.28125,11,20,-0.28125,0.9959
56,"Box, Inc._Attachment1(3).pdf",BOX,3/12/2019,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base further it is witnessing winning clientele and extension of contracts with its existing clients box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate free cash flow is an important measure of boxs profitability and liquidity and provides vital information to investors regarding the amount of cash available for investment in business the company sees significant improvements in free cash flow through efficient working capital management retention rate is an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of over 100 through user expansion both enterprise as well as small and medium business customers,buy,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'witness', 'win', 'clientele', 'extension', 'contract', 'exist', 'client', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'profitability', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'company', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rate', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base witness win clientele extension contract exist client box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate free cash flow important measure boxs profitability liquidity provide vital information investor cash available investment business company see significant improvement free cash flow efficient work capital management retention rate efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,11,18,-0.23333333333333334,11,18,-0.23333333333333334,0.9943
57,"Box, Inc._Attachment1(4).pdf",BOX,12/3/2018,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base further it is witnessing winning clientele and extension of contracts with its existing clients box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate box should continue to benefit from partnerships with enterprise software companies and large public cloud providers among others according to the company approximately 30 of new bookings come through boxs partner channel ibm is one of the most significant partners of box and has been part of many large deals over the past year with particular strength internationally other partnerships with technology giants like microsoft amazon facebook and google have increasingly been adding ai capacities to boxs platform thus aiding its topline growth these partnerships should continue to be incremental to boxs business free cash flow is an important measure of boxs liquidity and provides vital information to investors regarding the amount of cash available for investment in business box sees significant improvements in free cash flow through efficient working capital management retention rate is an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of more than 100 through user expansion both enterprise as well as small and medium business customers,sell,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'witness', 'win', 'clientele', 'extension', 'contract', 'exist', 'client', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'box', 'continue', 'benefit', 'partnership', 'enterprise', 'software', 'company', 'large', 'public', 'cloud', 'provider', 'accord', 'company', 'approximately', '30', 'new', 'booking', 'come', 'boxs', 'partner', 'channel', 'ibm', 'significant', 'partner', 'box', 'large', 'deal', 'past', 'year', 'particular', 'strength', 'internationally', 'partnership', 'technology', 'giant', 'like', 'microsoft', 'amazon', 'facebook', 'google', 'increasingly', 'add', 'ai', 'capacity', 'boxs', 'platform', 'aid', 'topline', 'growth', 'partnership', 'continue', 'incremental', 'boxs', 'business', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'box', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rate', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base witness win clientele extension contract exist client box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate box continue benefit partnership enterprise software company large public cloud provider accord company approximately 30 new booking come boxs partner channel ibm significant partner box large deal past year particular strength internationally partnership technology giant like microsoft amazon facebook google increasingly add ai capacity boxs platform aid topline growth partnership continue incremental boxs business free cash flow important measure boxs liquidity provide vital information investor cash available investment business box see significant improvement free cash flow efficient work capital management retention rate efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,13,19,-0.18181818181818182,13,19,-0.18181818181818182,0.9961
58,"Box, Inc._Attachment1.pdf",BOX,6/13/2017,box has been developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base that includes more than 52 million registered users tens of thousands of thirdparty developers have used boxs platform as the secure content layer for their applications box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate billings were 4542 million up 23 from fiscal 3691 million up 50 from fiscal and 2464 million up 41 from fiscal in fiscal 2017 2016 and 2015 respectively given the consistent rise in billings the companys top line is expected to stay strong free cash flow is an important measure of boxs profitability and liquidity and provides vital information to investors regarding the amount of cash available for investment in business free cash flow increased 914 million from fiscal 2016 to fiscal 2017 mainly driven by significant decrease in capital expenditures and cash used in operations box sees significant improvements in free cash flow through efficient working capital management retention rateis an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of over 100 through user expansion both enterprise as well as small and medium business customers,buy,"['box', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'include', '52', 'million', 'register', 'user', 'ten', 'thousand', 'thirdparty', 'developer', 'boxs', 'platform', 'secure', 'content', 'layer', 'application', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'billing', '4542', 'million', '23', 'fiscal', '3691', 'million', '50', 'fiscal', '2464', 'million', '41', 'fiscal', 'fiscal', '2017', '2016', '2015', 'respectively', 'give', 'consistent', 'rise', 'billing', 'company', 'line', 'expect', 'stay', 'strong', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'profitability', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'free', 'cash', 'flow', 'increase', '914', 'million', 'fiscal', '2016', 'fiscal', '2017', 'mainly', 'drive', 'significant', 'decrease', 'capital', 'expenditure', 'cash', 'operation', 'box', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rateis', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base include 52 million register user ten thousand thirdparty developer boxs platform secure content layer application box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate billing 4542 million 23 fiscal 3691 million 50 fiscal 2464 million 41 fiscal fiscal 2017 2016 2015 respectively give consistent rise billing company line expect stay strong free cash flow important measure boxs profitability liquidity provide vital information investor cash available investment business free cash flow increase 914 million fiscal 2016 fiscal 2017 mainly drive significant decrease capital expenditure cash operation box see significant improvement free cash flow efficient work capital management retention rateis efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,10,19,-0.3,10,19,-0.3,0.9959
59,"Box, Inc._Attachment1.pdf",BOX,11/8/2017,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base that includes more than 52 million registered users tens of thousands of thirdparty developers have used boxs platform as the secure content layer for their applications box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate billings were 4542 million up 23 from fiscal 3691 million up 50 from fiscal and 2464 million up 41 from fiscal in fiscal 2017 2016 and 2015 respectively given the consistent rise in billings the companys top line is expected to stay strong free cash flow is an important measure of boxs profitability and liquidity and provides vital information to investors regarding the amount of cash available for investment in business free cash flow increased 914 million from fiscal 2016 to fiscal 2017 mainly driven by significant decrease in capital expenditures and cash used in operations box sees significant improvements in free cash flow through efficient working capital management retention rate is an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of over 100 through user expansion both enterprise as well as small and medium business customers,buy,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'include', '52', 'million', 'register', 'user', 'ten', 'thousand', 'thirdparty', 'developer', 'boxs', 'platform', 'secure', 'content', 'layer', 'application', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'billing', '4542', 'million', '23', 'fiscal', '3691', 'million', '50', 'fiscal', '2464', 'million', '41', 'fiscal', 'fiscal', '2017', '2016', '2015', 'respectively', 'give', 'consistent', 'rise', 'billing', 'company', 'line', 'expect', 'stay', 'strong', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'profitability', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'free', 'cash', 'flow', 'increase', '914', 'million', 'fiscal', '2016', 'fiscal', '2017', 'mainly', 'drive', 'significant', 'decrease', 'capital', 'expenditure', 'cash', 'operation', 'box', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rate', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base include 52 million register user ten thousand thirdparty developer boxs platform secure content layer application box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate billing 4542 million 23 fiscal 3691 million 50 fiscal 2464 million 41 fiscal fiscal 2017 2016 2015 respectively give consistent rise billing company line expect stay strong free cash flow important measure boxs profitability liquidity provide vital information investor cash available investment business free cash flow increase 914 million fiscal 2016 fiscal 2017 mainly drive significant decrease capital expenditure cash operation box see significant improvement free cash flow efficient work capital management retention rate efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,11,20,-0.28125,11,20,-0.28125,0.9959
60,"Box, Inc._Attachment1.pdf",BOX,1/8/2018,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base that includes more than 52 million registered users tens of thousands of thirdparty developers have used boxs platform as the secure content layer for their applications box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate billings were 4542 million up 23 from fiscal 3691 million up 50 from fiscal and 2464 million up 41 from fiscal in fiscal 2017 2016 and 2015 respectively given the consistent rise in billings the companys top line is expected to stay strong free cash flow is an important measure of boxs profitability and liquidity and provides vital information to investors regarding the amount of cash available for investment in business free cash flow increased 914 million from fiscal 2016 to fiscal 2017 mainly driven by significant decrease in capital expenditures and cash used in operations box sees significant improvements in free cash flow through efficient working capital management retention rate is an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of more than 100 through user expansion both enterprise as well as small and medium business customers,buy,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'include', '52', 'million', 'register', 'user', 'ten', 'thousand', 'thirdparty', 'developer', 'boxs', 'platform', 'secure', 'content', 'layer', 'application', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'billing', '4542', 'million', '23', 'fiscal', '3691', 'million', '50', 'fiscal', '2464', 'million', '41', 'fiscal', 'fiscal', '2017', '2016', '2015', 'respectively', 'give', 'consistent', 'rise', 'billing', 'company', 'line', 'expect', 'stay', 'strong', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'profitability', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'free', 'cash', 'flow', 'increase', '914', 'million', 'fiscal', '2016', 'fiscal', '2017', 'mainly', 'drive', 'significant', 'decrease', 'capital', 'expenditure', 'cash', 'operation', 'box', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rate', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base include 52 million register user ten thousand thirdparty developer boxs platform secure content layer application box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate billing 4542 million 23 fiscal 3691 million 50 fiscal 2464 million 41 fiscal fiscal 2017 2016 2015 respectively give consistent rise billing company line expect stay strong free cash flow important measure boxs profitability liquidity provide vital information investor cash available investment business free cash flow increase 914 million fiscal 2016 fiscal 2017 mainly drive significant decrease capital expenditure cash operation box see significant improvement free cash flow efficient work capital management retention rate efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,11,20,-0.28125,11,20,-0.28125,0.9959
61,"Box, Inc._Attachment1.pdf",BOX,5/15/2018,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base that includes more than 52 million registered users tens of thousands of thirdparty developers have used boxs platform as the secure content layer for their applications box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate free cash flow is an important measure of boxs liquidity and provides vital information to investors regarding the amount of cash available for investment in business box sees significant improvements in free cash flow through efficient working capital management retention rate is an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of more than 100 through user expansion both enterprise as well as small and medium business customers,buy,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'include', '52', 'million', 'register', 'user', 'ten', 'thousand', 'thirdparty', 'developer', 'boxs', 'platform', 'secure', 'content', 'layer', 'application', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'box', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rate', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base include 52 million register user ten thousand thirdparty developer boxs platform secure content layer application box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate free cash flow important measure boxs liquidity provide vital information investor cash available investment business box see significant improvement free cash flow efficient work capital management retention rate efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,9,17,-0.2962962962962963,9,17,-0.2962962962962963,0.9934
62,"Box, Inc._Attachment1.pdf",BOX,9/24/2018,box is currently enriching its cloud content management and ai platforms by developing a rich technology partner ecosystem and its platform today integrates with some of the biggest enterprise technology providers such as microsoft apple ibm google and salesforce the company enables inhouse enterprise developers and independent software developers create industry and market focused applications with ease as a result the company has a strong user base further it is witnessing winning clientele and extension of contracts with its existing clients box says billings are a better metric to gauge its sales activity since it recognizes subscription revenues ratably over the subscription item the billings figure is derived by adding change in deferred revenues with the revenue figure year over year the company has been doing well on this front with billings growing at a handsome rate box should continue to benefit from partnerships with enterprise software companies and large public cloud providers among others according to the company approximately 30 of new bookings come through boxs partner channel ibm is one of the most significant partners of box and has been part of many large deals over the past year with particular strength internationally other partnerships with technology giants like microsoft amazon facebook and google have increasingly been adding ai capacities to boxs platform thus aiding its topline growth these partnerships should continue to be incremental to boxs business free cash flow is an important measure of boxs liquidity and provides vital information to investors regarding the amount of cash available for investment in business box sees significant improvements in free cash flow through efficient working capital management retention rate is an efficient indicator of longterm value of boxs subscription agreements and its ability to improve upon revenues derived from customers box determines retention rate as of a period end by starting with the annual contract value acv from customers with contract value of 5000 or more as of 12 months prior to such period end prior period acv and a subscription term of at least 12 months it then determines acv from the same customers as of the current period end current period acv the retention rate is obtained by dividing the aggregate current period acv for the trailing 12 month period by the aggregate prior period acv for the trailing 12month period box has been maintaining retention rates of more than 100 through user expansion both enterprise as well as small and medium business customers,buy,"['box', 'currently', 'enrich', 'cloud', 'content', 'management', 'ai', 'platform', 'develop', 'rich', 'technology', 'partner', 'ecosystem', 'platform', 'today', 'integrate', 'big', 'enterprise', 'technology', 'provider', 'microsoft', 'apple', 'ibm', 'google', 'salesforce', 'company', 'enable', 'inhouse', 'enterprise', 'developer', 'independent', 'software', 'developer', 'create', 'industry', 'market', 'focus', 'application', 'ease', 'result', 'company', 'strong', 'user', 'base', 'witness', 'win', 'clientele', 'extension', 'contract', 'exist', 'client', 'box', 'say', 'billing', 'well', 'metric', 'gauge', 'sale', 'activity', 'recognize', 'subscription', 'revenue', 'ratably', 'subscription', 'item', 'billing', 'figure', 'derive', 'add', 'change', 'defer', 'revenue', 'revenue', 'figure', 'year', 'year', 'company', 'billing', 'grow', 'handsome', 'rate', 'box', 'continue', 'benefit', 'partnership', 'enterprise', 'software', 'company', 'large', 'public', 'cloud', 'provider', 'accord', 'company', 'approximately', '30', 'new', 'booking', 'come', 'boxs', 'partner', 'channel', 'ibm', 'significant', 'partner', 'box', 'large', 'deal', 'past', 'year', 'particular', 'strength', 'internationally', 'partnership', 'technology', 'giant', 'like', 'microsoft', 'amazon', 'facebook', 'google', 'increasingly', 'add', 'ai', 'capacity', 'boxs', 'platform', 'aid', 'topline', 'growth', 'partnership', 'continue', 'incremental', 'boxs', 'business', 'free', 'cash', 'flow', 'important', 'measure', 'boxs', 'liquidity', 'provide', 'vital', 'information', 'investor', 'cash', 'available', 'investment', 'business', 'box', 'see', 'significant', 'improvement', 'free', 'cash', 'flow', 'efficient', 'work', 'capital', 'management', 'retention', 'rate', 'efficient', 'indicator', 'longterm', 'value', 'boxs', 'subscription', 'agreement', 'ability', 'improve', 'revenue', 'derive', 'customer', 'box', 'determine', 'retention', 'rate', 'period', 'end', 'start', 'annual', 'contract', 'value', 'acv', 'customer', 'contract', 'value', '5000', '12', 'month', 'prior', 'period', 'end', 'prior', 'period', 'acv', 'subscription', 'term', '12', 'month', 'determine', 'acv', 'customer', 'current', 'period', 'end', 'current', 'period', 'acv', 'retention', 'rate', 'obtain', 'divide', 'aggregate', 'current', 'period', 'acv', 'trailing', '12', 'month', 'period', 'aggregate', 'prior', 'period', 'acv', 'trailing', '12month', 'period', 'box', 'maintain', 'retention', 'rate', '100', 'user', 'expansion', 'enterprise', 'small', 'medium', 'business', 'customer']",box currently enrich cloud content management ai platform develop rich technology partner ecosystem platform today integrate big enterprise technology provider microsoft apple ibm google salesforce company enable inhouse enterprise developer independent software developer create industry market focus application ease result company strong user base witness win clientele extension contract exist client box say billing well metric gauge sale activity recognize subscription revenue ratably subscription item billing figure derive add change defer revenue revenue figure year year company billing grow handsome rate box continue benefit partnership enterprise software company large public cloud provider accord company approximately 30 new booking come boxs partner channel ibm significant partner box large deal past year particular strength internationally partnership technology giant like microsoft amazon facebook google increasingly add ai capacity boxs platform aid topline growth partnership continue incremental boxs business free cash flow important measure boxs liquidity provide vital information investor cash available investment business box see significant improvement free cash flow efficient work capital management retention rate efficient indicator longterm value boxs subscription agreement ability improve revenue derive customer box determine retention rate period end start annual contract value acv customer contract value 5000 12 month prior period end prior period acv subscription term 12 month determine acv customer current period end current period acv retention rate obtain divide aggregate current period acv trailing 12 month period aggregate prior period acv trailing 12month period box maintain retention rate 100 user expansion enterprise small medium business customer,13,19,-0.18181818181818182,13,19,-0.18181818181818182,0.9961
63,Clovis Oncology Inc_Attachment1(2).pdf,CLVS,10/19/2020,rubraca holds potential in ovarian cancer rubraca is the sole marketed product in clovis portfolio and has bright prospects given the immense commercial potential in the,buy,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'sole', 'market', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential']",rubraca hold potential ovarian cancer rubraca sole market product clovis portfolio bright prospect give immense commercial potential,0,0,0.0,0,0,0.0,-0.0772
64,"Clovis Oncology, Inc._Attachment1(10).pdf",CLVS,4/22/2019,share price outperformance clovis shares have outperformed the industry so far this year the stock has rallied 162 compared with the industrys increase of 23 rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in january 2019 the european commission approved rubraca in maintenance setting based on data from the ariel3 study with the expanded label as well as expansion in europe the commercial uptake of the drug is likely to improve moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the parp inhibitor market and its share in it boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 the company is also developing the drug as monotherapy or in combination with other therapies for lung bladder pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22530 cases of ovarian cancer will be diagnosed in the united states in 2019 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 174650 newly diagnosed prostate cancer patients in the united stated in 2019 per the american cancer society according to the national cancer institute 80470 patients will be diagnosed with bladder cancer in 2019,buy,"['share', 'price', 'outperformance', 'clovis', 'share', 'outperform', 'industry', 'far', 'year', 'stock', 'rally', '162', 'compare', 'industrys', 'increase', '23', 'rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'expand', 'label', 'expansion', 'europe', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'parp', 'inhibitor', 'market', 'share', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'company', 'develop', 'drug', 'monotherapy', 'combination', 'therapy', 'lung', 'bladder', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22530', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2019', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '174650', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2019', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '80470', 'patient', 'diagnose', 'bladder', 'cancer', '2019']",share price outperformance clovis share outperform industry far year stock rally 162 compare industrys increase 23 rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor january 2019 european commission approve rubraca maintenance setting base datum ariel3 study expand label expansion europe commercial uptake drug likely improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase parp inhibitor market share boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 company develop drug monotherapy combination therapy lung bladder pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22530 case ovarian cancer diagnose united states 2019 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 174650 newly diagnose prostate cancer patient united state 2019 american cancer society accord national cancer institute 80470 patient diagnose bladder cancer 2019,8,11,-0.15,8,11,-0.15,-0.9966
65,"Clovis Oncology, Inc._Attachment1(2).pdf",CLVS,6/20/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the zacks classified medicalbiomedical and genetics industry having surged 5559 in the past one year while the industry increased 20 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the fda was expected to render a final decision on rubraca by feb 23 2017 the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors successful commercialization will significantly boost clovis top line going forward meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in late 2017 or early 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in jun 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer patientsthe positive results may expand rubracas label which could improve the commercial uptake of the drug clovis plans to file a regulatory application for label expansion to include a second line or later maintenance treatment for ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study within the next four months meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis is also collaborating with companies like roche for the evaluation of rubraca in combination with other regimens including pdl clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22000 cases of ovarian cancer are diagnosed in the us each year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'zack', 'classify', 'medicalbiomedical', 'genetic', 'industry', 'having', 'surge', '5559', 'past', 'year', 'industry', 'increase', '20', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'fda', 'expect', 'render', 'final', 'decision', 'rubraca', 'feb', '23', '2017', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'significantly', 'boost', 'clovis', 'line', 'go', 'forward', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'late', '2017', 'early', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'jun', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'patientsthe', 'positive', 'result', 'expand', 'rubracas', 'label', 'improve', 'commercial', 'uptake', 'drug', 'clovis', 'plan', 'file', 'regulatory', 'application', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'month', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'collaborate', 'company', 'like', 'roche', 'evaluation', 'rubraca', 'combination', 'regimen', 'include', 'pdl', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22000', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform zack classify medicalbiomedical genetic industry having surge 5559 past year industry increase 20 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule fda expect render final decision rubraca feb 23 2017 approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization significantly boost clovis line go forward rubraca review eu comparable ovarian cancer indication clovis expect approval eu late 2017 early 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present jun 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer patientsthe positive result expand rubracas label improve commercial uptake drug clovis plan file regulatory application label expansion include second line late maintenance treatment ovarian cancer patient undergo prior therapy base ariel3 study month second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis collaborate company like roche evaluation rubraca combination regimen include pdl clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22000 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,19,22,-0.07142857142857142,19,22,-0.07142857142857142,-0.9786
66,"Clovis Oncology, Inc._Attachment1(2).pdf",CLVS,12/4/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the industry having increased 381 so far this year while the industry rose 26 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in december 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in june 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in early 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer are diagnosed in the united states this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'having', 'increase', '381', 'far', 'year', 'industry', 'rise', '26', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'december', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'june', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'early', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform industry having increase 381 far year industry rise 26 rubraca approval boost clovis get boost accelerated fda approval rubraca december 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present june 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study approve expand label commercial uptake drug improve clovis plan file marketing authorization application early 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,16,15,0.03125,16,15,0.03125,-0.9887
67,"Clovis Oncology, Inc._Attachment1(2).pdf",CLVS,1/16/2018,rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in december 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same promising progressionfree survival pfs and safety results from the ariel3 study were presented in june 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study the snda has been granted priority review by the fda with decision expected on apr 6 2018 if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in the second quarter of 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer,sell,"['rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'december', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'june', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'snda', 'grant', 'priority', 'review', 'fda', 'decision', 'expect', 'apr', '6', '2018', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'second', 'quarter', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer']",rubraca approval boost clovis get boost accelerated fda approval rubraca december 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure promising progressionfree survival pfs safety result ariel3 study present june 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study snda grant priority review fda decision expect apr 6 2018 approve expand label commercial uptake drug improve clovis plan file marketing authorization application second quarter 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer,13,13,0.0,13,13,0.0,-0.8625
68,"Clovis Oncology, Inc._Attachment1(2).pdf",CLVS,6/29/2018,rubraca progressing well rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer the drug got approved in the eu as monotherapy for treating recurring ovarian cancer in third or later line setting in june 2018 in april 2018 clovis announced fda approval for the label expansion of rubraca the drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinumbased chemotherapy based on data from ariel3 study the drug can now also be prescribed irrespective of brcamutation in the secondline setting with the expanded label the commercial uptake of the drug may improve a label expansion application in maintenance setting is under review data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study the snda has been granted priority review by the fda with decision expected on apr 6 2018 if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in the second quarter of 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations a phase ii atlas study is evaluating rubraca in bladder cancer other ongoing studies include the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer will be diagnosed in the united states in 2018 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 164000 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society according to the national cancer institute 79000 patients were diagnosed with bladder cancer in 2017,buy,"['rubraca', 'progress', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'drug', 'get', 'approve', 'eu', 'monotherapy', 'treat', 'recur', 'ovarian', 'cancer', 'later', 'line', 'setting', 'june', '2018', 'april', '2018', 'clovis', 'announce', 'fda', 'approval', 'label', 'expansion', 'rubraca', 'drug', 'approve', 'maintenance', 'treatment', 'recurrent', 'ovarian', 'cancer', 'patient', 'receive', 'prior', 'platinumbase', 'chemotherapy', 'base', 'datum', 'ariel3', 'study', 'drug', 'prescribe', 'irrespective', 'brcamutation', 'secondline', 'set', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'snda', 'grant', 'priority', 'review', 'fda', 'decision', 'expect', 'apr', '6', '2018', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'second', 'quarter', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'ongoing', 'study', 'include', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '164000', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '79000', 'patient', 'diagnose', 'bladder', 'cancer', '2017']",rubraca progress rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer drug get approve eu monotherapy treat recur ovarian cancer later line setting june 2018 april 2018 clovis announce fda approval label expansion rubraca drug approve maintenance treatment recurrent ovarian cancer patient receive prior platinumbase chemotherapy base datum ariel3 study drug prescribe irrespective brcamutation secondline set expand label commercial uptake drug improve label expansion application maintenance setting review datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study snda grant priority review fda decision expect apr 6 2018 approve expand label commercial uptake drug improve clovis plan file marketing authorization application second quarter 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation phase ii atlas study evaluate rubraca bladder cancer ongoing study include investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states 2018 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 164000 newly diagnose prostate cancer patient united state 2018 american cancer society accord national cancer institute 79000 patient diagnose bladder cancer 2017,10,19,-0.3,10,19,-0.3,-0.9986
69,"Clovis Oncology, Inc._Attachment1(2).pdf",CLVS,10/16/2018,rubraca progressing well rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors the drug got approved in the eu for treating brcamutant ovarian cancer in third or later line setting in june 2018 data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer in april 2018 clovis announced fda approval for the label expansion of rubraca the drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinum based chemotherapy based on data from ariel3 study the drug can now also be prescribed irrespective of brcamutation in the secondline setting with the expanded label the commercial uptake of the drug may improve a label expansion application in maintenance setting is under review in europe meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitorsfor treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier will return exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor,sell,"['rubraca', 'progress', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'drug', 'get', 'approve', 'eu', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'setting', 'june', '2018', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'april', '2018', 'clovis', 'announce', 'fda', 'approval', 'label', 'expansion', 'rubraca', 'drug', 'approve', 'maintenance', 'treatment', 'recurrent', 'ovarian', 'cancer', 'patient', 'receive', 'prior', 'platinum', 'base', 'chemotherapy', 'base', 'datum', 'ariel3', 'study', 'drug', 'prescribe', 'irrespective', 'brcamutation', 'secondline', 'set', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitorsfor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor']",rubraca progress rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor drug get approve eu treat brcamutant ovarian cancer later line setting june 2018 datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer april 2018 clovis announce fda approval label expansion rubraca drug approve maintenance treatment recurrent ovarian cancer patient receive prior platinum base chemotherapy base datum ariel3 study drug prescribe irrespective brcamutation secondline set expand label commercial uptake drug improve label expansion application maintenance setting review europe second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitorsfor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor,5,14,-0.45,5,14,-0.45,-0.9633
70,"Clovis Oncology, Inc._Attachment1(2).pdf",CLVS,1/4/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in december 2016 the drug was approved for treating brcamutant ovarian cancer in third or later line setting the drug was approved in the eu for similar indication in june 2018 in april 2018 rubraca was approved as maintenance treatment of ovarian cancer irrespective of brcamutation in second line setting based on data from the ariel3 study in decemeber 2018 the chmp has recommended approval of rubraca in similar indication a decision in europe is expected in the first quarter 2019 data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer a label expansion application in maintenance setting is under review in europe in december the chmp has recommended rubracas approval in this indication with the expanded label the commercial uptake of the drug is likely to improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier has returned exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22240 cases of ovarian cancer will be diagnosed in the united states in 2018 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 164690 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society according to the national cancer institute 81190 patients will be diagnosed with bladder cancer in 2018,buy,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'december', '2016', 'drug', 'approve', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'set', 'drug', 'approve', 'eu', 'similar', 'indication', 'june', '2018', 'april', '2018', 'rubraca', 'approve', 'maintenance', 'treatment', 'ovarian', 'cancer', 'irrespective', 'brcamutation', 'second', 'line', 'set', 'base', 'datum', 'ariel3', 'study', 'decemeber', '2018', 'chmp', 'recommend', 'approval', 'rubraca', 'similar', 'indication', 'decision', 'europe', 'expect', 'quarter', '2019', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'december', 'chmp', 'recommend', 'rubracas', 'approval', 'indication', 'expand', 'label', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22240', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '164690', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '81190', 'patient', 'diagnose', 'bladder', 'cancer', '2018']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor december 2016 drug approve treat brcamutant ovarian cancer later line set drug approve eu similar indication june 2018 april 2018 rubraca approve maintenance treatment ovarian cancer irrespective brcamutation second line set base datum ariel3 study decemeber 2018 chmp recommend approval rubraca similar indication decision europe expect quarter 2019 datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer label expansion application maintenance setting review europe december chmp recommend rubracas approval indication expand label commercial uptake drug likely improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22240 case ovarian cancer diagnose united states 2018 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 164690 newly diagnose prostate cancer patient united state 2018 american cancer society accord national cancer institute 81190 patient diagnose bladder cancer 2018,7,16,-0.375,7,16,-0.375,-0.9976
71,"Clovis Oncology, Inc._Attachment1(2).pdf",CLVS,3/11/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in january 2019 the european commission approved rubraca in maintenance setting based on data from the ariel3 study with the expanded label as well as expansion in europe the commercial uptake of the drug is likely to improve moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the parp inhibitor market and its share in it boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 a phase ii atlas study is evaluating rubraca in bladder cancer the company is also developing the drug for lung pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor,sell,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'expand', 'label', 'expansion', 'europe', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'parp', 'inhibitor', 'market', 'share', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'company', 'develop', 'drug', 'lung', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor january 2019 european commission approve rubraca maintenance setting base datum ariel3 study expand label expansion europe commercial uptake drug likely improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase parp inhibitor market share boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 phase ii atlas study evaluate rubraca bladder cancer company develop drug lung pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor,6,9,-0.1875,6,9,-0.1875,-0.9657
72,"Clovis Oncology, Inc._Attachment1(2).pdf",CLVS,4/30/2019,rubraca sales disappoint although the company is progressing well with label expansion of rubraca sales are not improving in tandem although sales of rubraca improved in the fourth quarter of 2018 the drug faced challenges in adoption in secondline maintenance setting hence we prefer to keep a wait and see approach although clovis is developing the drug for several indications beyond ovarian cancer it will face competition upon successful development and launch in those indications too lynparza one of its competitors is already approved for breast cancer and has successfully completed a latestage study targeting pancreatic cancer pipeline setbacks in april 2019 clovis discontinued phase ii atlas study evaluating rubraca monotherapy for metastatic bladder cancer as preliminary data suggested that it was unlikely to provide a meaningful clinical benefit to patients in the second quarter of 2016 clovis received a crl for the nda for rociletinib which was submitted during the third quarter of 2015 post the receipt of the crl clovis terminated enrollment in all ongoing sponsored studies on rociletinib however clovis continues to provide rociletinib to patients whose clinicians recommend continuing rociletinib therapy clovis was seeking fda approval for rociletinib for the treatment of patients with mutant egfr nonsmall cell lung cancer who have been previously treated with an egfrtargeted therapy and have the egfr t790m mutation clovis is continuing with its analyses to see whether certain patient populations represent an opportunity for a partner committed to investing in further and specific clinical development additionally clovis has withdrawn its regulatory application for rociletinib that was previously filed with european regulatory authorities zacks equity research clvs wwwzackscom page 4 of 9,sell,"['rubraca', 'sale', 'disappoint', 'company', 'progress', 'label', 'expansion', 'rubraca', 'sale', 'improve', 'tandem', 'sale', 'rubraca', 'improve', 'fourth', 'quarter', '2018', 'drug', 'face', 'challenge', 'adoption', 'secondline', 'maintenance', 'set', 'prefer', 'wait', 'approach', 'clovis', 'develop', 'drug', 'indication', 'ovarian', 'cancer', 'face', 'competition', 'successful', 'development', 'launch', 'indication', 'lynparza', 'competitor', 'approve', 'breast', 'cancer', 'successfully', 'complete', 'latestage', 'study', 'target', 'pancreatic', 'cancer', 'pipeline', 'setback', 'april', '2019', 'clovis', 'discontinue', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'monotherapy', 'metastatic', 'bladder', 'cancer', 'preliminary', 'datum', 'suggest', 'unlikely', 'provide', 'meaningful', 'clinical', 'benefit', 'patient', 'second', 'quarter', '2016', 'clovis', 'receive', 'crl', 'nda', 'rociletinib', 'submit', 'quarter', '2015', 'post', 'receipt', 'crl', 'clovis', 'terminate', 'enrollment', 'ongoing', 'sponsor', 'study', 'rociletinib', 'clovis', 'continue', 'provide', 'rociletinib', 'patient', 'clinician', 'recommend', 'continue', 'rociletinib', 'therapy', 'clovis', 'seek', 'fda', 'approval', 'rociletinib', 'treatment', 'patient', 'mutant', 'egfr', 'nonsmall', 'cell', 'lung', 'cancer', 'previously', 'treat', 'egfrtargeted', 'therapy', 'egfr', 't790', 'm', 'mutation', 'clovis', 'continue', 'analysis', 'certain', 'patient', 'population', 'represent', 'opportunity', 'partner', 'commit', 'invest', 'specific', 'clinical', 'development', 'additionally', 'clovis', 'withdraw', 'regulatory', 'application', 'rociletinib', 'previously', 'file', 'european', 'regulatory', 'authority', 'zack', 'equity', 'research', 'clvs', 'wwwzackscom', 'page', '4', '9']",rubraca sale disappoint company progress label expansion rubraca sale improve tandem sale rubraca improve fourth quarter 2018 drug face challenge adoption secondline maintenance set prefer wait approach clovis develop drug indication ovarian cancer face competition successful development launch indication lynparza competitor approve breast cancer successfully complete latestage study target pancreatic cancer pipeline setback april 2019 clovis discontinue phase ii atlas study evaluate rubraca monotherapy metastatic bladder cancer preliminary datum suggest unlikely provide meaningful clinical benefit patient second quarter 2016 clovis receive crl nda rociletinib submit quarter 2015 post receipt crl clovis terminate enrollment ongoing sponsor study rociletinib clovis continue provide rociletinib patient clinician recommend continue rociletinib therapy clovis seek fda approval rociletinib treatment patient mutant egfr nonsmall cell lung cancer previously treat egfrtargeted therapy egfr t790 m mutation clovis continue analysis certain patient population represent opportunity partner commit invest specific clinical development additionally clovis withdraw regulatory application rociletinib previously file european regulatory authority zack equity research clvs wwwzackscom page 4 9,8,14,-0.2608695652173913,8,14,-0.2608695652173913,0.802
73,"Clovis Oncology, Inc._Attachment1(3).pdf",CLVS,7/12/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the zacks classified medicalbiomedical and genetics industry having surged 1118 so far this year while the industry increased 71 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the fda was expected to render a final decision on rubraca by feb 23 2017 the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors successful commercialization will significantly boost clovis top line going forward meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in late 2017 or early 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in jun 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer patientsthe positive results may expand rubracas label which could improve the commercial uptake of the drug clovis plans to file a regulatory application for label expansion to include a second line or later maintenance treatment for ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study within the next four months meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis is also collaborating with companies like roche for the evaluation of rubraca in combination with other regimens including pdl clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22000 cases of ovarian cancer are diagnosed in the us each year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'zack', 'classify', 'medicalbiomedical', 'genetic', 'industry', 'having', 'surge', '1118', 'far', 'year', 'industry', 'increase', '71', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'fda', 'expect', 'render', 'final', 'decision', 'rubraca', 'feb', '23', '2017', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'significantly', 'boost', 'clovis', 'line', 'go', 'forward', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'late', '2017', 'early', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'jun', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'patientsthe', 'positive', 'result', 'expand', 'rubracas', 'label', 'improve', 'commercial', 'uptake', 'drug', 'clovis', 'plan', 'file', 'regulatory', 'application', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'month', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'collaborate', 'company', 'like', 'roche', 'evaluation', 'rubraca', 'combination', 'regimen', 'include', 'pdl', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22000', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform zack classify medicalbiomedical genetic industry having surge 1118 far year industry increase 71 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule fda expect render final decision rubraca feb 23 2017 approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization significantly boost clovis line go forward rubraca review eu comparable ovarian cancer indication clovis expect approval eu late 2017 early 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present jun 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer patientsthe positive result expand rubracas label improve commercial uptake drug clovis plan file regulatory application label expansion include second line late maintenance treatment ovarian cancer patient undergo prior therapy base ariel3 study month second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis collaborate company like roche evaluation rubraca combination regimen include pdl clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22000 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,19,22,-0.07142857142857142,19,22,-0.07142857142857142,-0.9786
74,"Clovis Oncology, Inc._Attachment1(3).pdf",CLVS,7/12/2017,rociletinib investment discontinued in the second quarter of 2016 clovis received a crl for the nda for rociletinib which was submitted during the third quarter of 2015 post the receipt of the crl clovis terminated enrollment in all ongoing sponsored studies on rociletinib however clovis continues to provide rociletinib to patients whose clinicians recommend continuing rociletinib therapy clovis was seeking fda approval for rociletinib for the treatment of patients with mutant egfr nonsmall cell lung cancer who have been previously treated with an egfrtargeted therapy and have the egfr t790m mutation clovis is continuing with its analyses to see whether certain patient populations represent an opportunity for a partner committed to investing in further and specific clinical development additionally clovis has withdrawn its regulatory application for rociletinib that was previously filed with european regulatory authorities fierce competition in target market while the ovarian cancer market provides immense commercial potential we note that rubraca will face intense competition from currently marketed parp inhibitors approved treatments include astrazenecas ovarian cancer treatment lynparza and tesaros niraparib which has been approved recently there are a number of parp inhibitors in clinical development including abbvies veliparib and abt767 and pfizers talazoparib meanwhile the oncology market is attracting a lot of attention with several companies inking deals and working on bringing their candidates to this high revenue potential market pipeline setbacks would weigh heavily clovis has suffered its share of pipeline setbacks in nov 2012 the company reported disappointing results from a pivotal metastatic pancreatic cancer study leap on co101 based on these negative results the company decided to discontinue the development of the candidate clovis also discontinued enrollment in the company sponsored phase ii study on lucitanib in advanced lung cancer patients with fgfr aberrations citing it as a very challenging study lucitanib was also previously being evaluated for breast cancer development in lung and breast cancers has been discontinued however clovis continues to provide lucitanib to patients whose clinicians recommend continuing lucitanib therapy along with partner servier clovis is evaluating whether to pursue any further development of lucitanib any further development or regulatory setback would have an adverse impact on shares and the companys growth prospects,sell,"['rociletinib', 'investment', 'discontinue', 'second', 'quarter', '2016', 'clovis', 'receive', 'crl', 'nda', 'rociletinib', 'submit', 'quarter', '2015', 'post', 'receipt', 'crl', 'clovis', 'terminate', 'enrollment', 'ongoing', 'sponsor', 'study', 'rociletinib', 'clovis', 'continue', 'provide', 'rociletinib', 'patient', 'clinician', 'recommend', 'continue', 'rociletinib', 'therapy', 'clovis', 'seek', 'fda', 'approval', 'rociletinib', 'treatment', 'patient', 'mutant', 'egfr', 'nonsmall', 'cell', 'lung', 'cancer', 'previously', 'treat', 'egfrtargeted', 'therapy', 'egfr', 't790', 'm', 'mutation', 'clovis', 'continue', 'analysis', 'certain', 'patient', 'population', 'represent', 'opportunity', 'partner', 'commit', 'invest', 'specific', 'clinical', 'development', 'additionally', 'clovis', 'withdraw', 'regulatory', 'application', 'rociletinib', 'previously', 'file', 'european', 'regulatory', 'authority', 'fierce', 'competition', 'target', 'market', 'ovarian', 'cancer', 'market', 'provide', 'immense', 'commercial', 'potential', 'note', 'rubraca', 'face', 'intense', 'competition', 'currently', 'market', 'parp', 'inhibitor', 'approve', 'treatment', 'include', 'astrazenecas', 'ovarian', 'cancer', 'treatment', 'lynparza', 'tesaros', 'niraparib', 'approve', 'recently', 'number', 'parp', 'inhibitor', 'clinical', 'development', 'include', 'abbvie', 'veliparib', 'abt767', 'pfizer', 'talazoparib', 'oncology', 'market', 'attract', 'lot', 'attention', 'company', 'ink', 'deal', 'work', 'bring', 'candidate', 'high', 'revenue', 'potential', 'market', 'pipeline', 'setback', 'weigh', 'heavily', 'clovis', 'suffer', 'share', 'pipeline', 'setback', 'nov', '2012', 'company', 'report', 'disappointing', 'result', 'pivotal', 'metastatic', 'pancreatic', 'cancer', 'study', 'leap', 'co101', 'base', 'negative', 'result', 'company', 'decide', 'discontinue', 'development', 'candidate', 'clovis', 'discontinue', 'enrollment', 'company', 'sponsor', 'phase', 'ii', 'study', 'lucitanib', 'advanced', 'lung', 'cancer', 'patient', 'fgfr', 'aberration', 'cite', 'challenging', 'study', 'lucitanib', 'previously', 'evaluate', 'breast', 'cancer', 'development', 'lung', 'breast', 'cancer', 'discontinue', 'clovis', 'continue', 'provide', 'lucitanib', 'patient', 'clinician', 'recommend', 'continue', 'lucitanib', 'therapy', 'partner', 'servi', 'clovis', 'evaluate', 'pursue', 'development', 'lucitanib', 'development', 'regulatory', 'setback', 'adverse', 'impact', 'share', 'company', 'growth', 'prospect']",rociletinib investment discontinue second quarter 2016 clovis receive crl nda rociletinib submit quarter 2015 post receipt crl clovis terminate enrollment ongoing sponsor study rociletinib clovis continue provide rociletinib patient clinician recommend continue rociletinib therapy clovis seek fda approval rociletinib treatment patient mutant egfr nonsmall cell lung cancer previously treat egfrtargeted therapy egfr t790 m mutation clovis continue analysis certain patient population represent opportunity partner commit invest specific clinical development additionally clovis withdraw regulatory application rociletinib previously file european regulatory authority fierce competition target market ovarian cancer market provide immense commercial potential note rubraca face intense competition currently market parp inhibitor approve treatment include astrazenecas ovarian cancer treatment lynparza tesaros niraparib approve recently number parp inhibitor clinical development include abbvie veliparib abt767 pfizer talazoparib oncology market attract lot attention company ink deal work bring candidate high revenue potential market pipeline setback weigh heavily clovis suffer share pipeline setback nov 2012 company report disappointing result pivotal metastatic pancreatic cancer study leap co101 base negative result company decide discontinue development candidate clovis discontinue enrollment company sponsor phase ii study lucitanib advanced lung cancer patient fgfr aberration cite challenging study lucitanib previously evaluate breast cancer development lung breast cancer discontinue clovis continue provide lucitanib patient clinician recommend continue lucitanib therapy partner servi clovis evaluate pursue development lucitanib development regulatory setback adverse impact share company growth prospect,5,19,-0.56,5,19,-0.56,-0.9595
75,"Clovis Oncology, Inc._Attachment1(3).pdf",CLVS,2/19/2018,rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in december 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same promising progressionfree survival pfs and safety results from the ariel3 study were presented in june 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study the snda has been granted priority review by the fda with decision expected on apr 6 2018 if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in the second quarter of 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to zacks equity research clvs wwwzackscom page 3 of 7,sell,"['rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'december', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'june', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'snda', 'grant', 'priority', 'review', 'fda', 'decision', 'expect', 'apr', '6', '2018', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'second', 'quarter', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'zacks', 'equity', 'research', 'clvs', 'wwwzackscom', 'page', '3', '7']",rubraca approval boost clovis get boost accelerated fda approval rubraca december 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure promising progressionfree survival pfs safety result ariel3 study present june 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study snda grant priority review fda decision expect apr 6 2018 approve expand label commercial uptake drug improve clovis plan file marketing authorization application second quarter 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 zacks equity research clvs wwwzackscom page 3 7,13,14,-0.03571428571428571,13,14,-0.03571428571428571,0.0516
76,"Clovis Oncology, Inc._Attachment1(3).pdf",CLVS,7/10/2018,rubraca progressing well rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer the drug got approved in the eu as monotherapy for treating recurring ovarian cancer in third or later line setting in june 2018 in april 2018 clovis announced fda approval for the label expansion of rubraca the drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinum based chemotherapy based on data from ariel3 study the drug can now also be prescribed irrespective of brcamutation in the secondline setting with the expanded label the commercial uptake of the drug may improve a label expansion application in maintenance setting is under review in europe additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations a phase ii atlas study is evaluating rubraca in bladder cancer other ongoing studies include the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer,sell,"['rubraca', 'progress', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'drug', 'get', 'approve', 'eu', 'monotherapy', 'treat', 'recur', 'ovarian', 'cancer', 'later', 'line', 'setting', 'june', '2018', 'april', '2018', 'clovis', 'announce', 'fda', 'approval', 'label', 'expansion', 'rubraca', 'drug', 'approve', 'maintenance', 'treatment', 'recurrent', 'ovarian', 'cancer', 'patient', 'receive', 'prior', 'platinum', 'base', 'chemotherapy', 'base', 'datum', 'ariel3', 'study', 'drug', 'prescribe', 'irrespective', 'brcamutation', 'secondline', 'set', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'ongoing', 'study', 'include', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer']",rubraca progress rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer drug get approve eu monotherapy treat recur ovarian cancer later line setting june 2018 april 2018 clovis announce fda approval label expansion rubraca drug approve maintenance treatment recurrent ovarian cancer patient receive prior platinum base chemotherapy base datum ariel3 study drug prescribe irrespective brcamutation secondline set expand label commercial uptake drug improve label expansion application maintenance setting review europe additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation phase ii atlas study evaluate rubraca bladder cancer ongoing study include investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer,6,10,-0.23529411764705882,6,10,-0.23529411764705882,-0.993
77,"Clovis Oncology, Inc._Attachment1(3).pdf",CLVS,11/20/2018,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in december 2016 the drug was approved for treating brcamutant ovarian cancer in third or later line setting the drug was approved in the eu for similar indication in june 2018 in april 2018 rubraca was approved as maintenance treatment of ovarian cancer irrespective of brcamutation in second line setting based on data from the ariel3 study data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer a label expansion application in maintenance setting is under review in europe with the expanded label the commercial uptake of the drug is likely to improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier has returned exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22240 cases of ovarian cancer will be diagnosed in the united states in 2018 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 164690 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society according to the national cancer institute 81190 patients will be diagnosed with bladder cancer in 2018,buy,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'december', '2016', 'drug', 'approve', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'set', 'drug', 'approve', 'eu', 'similar', 'indication', 'june', '2018', 'april', '2018', 'rubraca', 'approve', 'maintenance', 'treatment', 'ovarian', 'cancer', 'irrespective', 'brcamutation', 'second', 'line', 'set', 'base', 'datum', 'ariel3', 'study', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'expand', 'label', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22240', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '164690', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '81190', 'patient', 'diagnose', 'bladder', 'cancer', '2018']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor december 2016 drug approve treat brcamutant ovarian cancer later line set drug approve eu similar indication june 2018 april 2018 rubraca approve maintenance treatment ovarian cancer irrespective brcamutation second line set base datum ariel3 study datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer label expansion application maintenance setting review europe expand label commercial uptake drug likely improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22240 case ovarian cancer diagnose united states 2018 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 164690 newly diagnose prostate cancer patient united state 2018 american cancer society accord national cancer institute 81190 patient diagnose bladder cancer 2018,7,16,-0.375,7,16,-0.375,-0.9981
78,"Clovis Oncology, Inc._Attachment1(3).pdf",CLVS,1/9/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in december 2016 the drug was approved for treating brcamutant ovarian cancer in third or later line setting the drug was approved in the eu for similar indication in june 2018 in april 2018 rubraca was approved as maintenance treatment of ovarian cancer irrespective of brcamutation in second line setting based on data from the ariel3 study in decemeber 2018 the chmp has recommended approval of rubraca in similar indication a decision in europe is expected in the first quarter 2019 data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer a label expansion application in maintenance setting is under review in europe in december the chmp has recommended rubracas approval in this indication with the expanded label the commercial uptake of the drug is likely to improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier has returned exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor,sell,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'december', '2016', 'drug', 'approve', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'set', 'drug', 'approve', 'eu', 'similar', 'indication', 'june', '2018', 'april', '2018', 'rubraca', 'approve', 'maintenance', 'treatment', 'ovarian', 'cancer', 'irrespective', 'brcamutation', 'second', 'line', 'set', 'base', 'datum', 'ariel3', 'study', 'decemeber', '2018', 'chmp', 'recommend', 'approval', 'rubraca', 'similar', 'indication', 'decision', 'europe', 'expect', 'quarter', '2019', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'december', 'chmp', 'recommend', 'rubracas', 'approval', 'indication', 'expand', 'label', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor december 2016 drug approve treat brcamutant ovarian cancer later line set drug approve eu similar indication june 2018 april 2018 rubraca approve maintenance treatment ovarian cancer irrespective brcamutation second line set base datum ariel3 study decemeber 2018 chmp recommend approval rubraca similar indication decision europe expect quarter 2019 datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer label expansion application maintenance setting review europe december chmp recommend rubracas approval indication expand label commercial uptake drug likely improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor,6,15,-0.4090909090909091,6,15,-0.4090909090909091,-0.9741
79,"Clovis Oncology, Inc._Attachment1(3).pdf",CLVS,3/29/2019,share price outperformance clovis shares have outperformed the industry so far this year the stock has rallied 356 compared with the industrys increase of 95 rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in january 2019 the european commission approved rubraca in maintenance setting based on data from the ariel3 study with the expanded label as well as expansion in europe the commercial uptake of the drug is likely to improve moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the parp inhibitor market and its share in it boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 a phase ii atlas study is evaluating rubraca in bladder cancer the company is also developing the drug for lung pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22530 cases of ovarian cancer will be diagnosed in the united states in 2019 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 174650 newly diagnosed prostate cancer patients in the united stated in 2019 per the american cancer society according to the national cancer institute 80470 patients will be diagnosed with bladder cancer in 2019,buy,"['share', 'price', 'outperformance', 'clovis', 'share', 'outperform', 'industry', 'far', 'year', 'stock', 'rally', '356', 'compare', 'industrys', 'increase', '95', 'rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'expand', 'label', 'expansion', 'europe', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'parp', 'inhibitor', 'market', 'share', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'company', 'develop', 'drug', 'lung', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22530', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2019', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '174650', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2019', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '80470', 'patient', 'diagnose', 'bladder', 'cancer', '2019']",share price outperformance clovis share outperform industry far year stock rally 356 compare industrys increase 95 rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor january 2019 european commission approve rubraca maintenance setting base datum ariel3 study expand label expansion europe commercial uptake drug likely improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase parp inhibitor market share boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 phase ii atlas study evaluate rubraca bladder cancer company develop drug lung pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22530 case ovarian cancer diagnose united states 2019 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 174650 newly diagnose prostate cancer patient united state 2019 american cancer society accord national cancer institute 80470 patient diagnose bladder cancer 2019,8,11,-0.15,8,11,-0.15,-0.997
80,"Clovis Oncology, Inc._Attachment1(3).pdf",CLVS,5/13/2019,share price outperformance clovis shares have outperformed the industry so far this year the stock has gained 73 compared with the industrys increase of 24 rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors rubracas label was expanded in secondline maintenance setting based on data from the ariel3 study in the united states in april 2018 and in europe in january 2019 with the expanded label as the commercial uptake of the drug is improving moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the penetration of parp inhibitors and gain 20 share of the parp inhibitor ovarian cancer market boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo in advanced ovarian cancer as firstline maintenance treatment a phase ii study is evaluating the same combination in prostate cancer rubracas potential in other cancers meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 the company is also developing the drug as monotherapy or in combination with other therapies for lung bladder pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22530 cases of ovarian cancer will be diagnosed in the united states in 2019 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 174650 newly diagnosed prostate cancer patients in the united stated in 2019 per the american cancer society according to the national cancer institute 80470 patients will be diagnosed with bladder cancer in 2019,buy,"['share', 'price', 'outperformance', 'clovis', 'share', 'outperform', 'industry', 'far', 'year', 'stock', 'gain', '73', 'compare', 'industrys', 'increase', '24', 'rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'rubracas', 'label', 'expand', 'secondline', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'united', 'states', 'april', '2018', 'europe', 'january', '2019', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'penetration', 'parp', 'inhibitor', 'gain', '20', 'share', 'parp', 'inhibitor', 'ovarian', 'cancer', 'market', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'advanced', 'ovarian', 'cancer', 'firstline', 'maintenance', 'treatment', 'phase', 'ii', 'study', 'evaluate', 'combination', 'prostate', 'cancer', 'rubracas', 'potential', 'cancer', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'company', 'develop', 'drug', 'monotherapy', 'combination', 'therapy', 'lung', 'bladder', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22530', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2019', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '174650', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2019', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '80470', 'patient', 'diagnose', 'bladder', 'cancer', '2019']",share price outperformance clovis share outperform industry far year stock gain 73 compare industrys increase 24 rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor rubracas label expand secondline maintenance setting base datum ariel3 study united states april 2018 europe january 2019 expand label commercial uptake drug improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase penetration parp inhibitor gain 20 share parp inhibitor ovarian cancer market boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo advanced ovarian cancer firstline maintenance treatment phase ii study evaluate combination prostate cancer rubracas potential cancer clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 company develop drug monotherapy combination therapy lung bladder pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22530 case ovarian cancer diagnose united states 2019 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 174650 newly diagnose prostate cancer patient united state 2019 american cancer society accord national cancer institute 80470 patient diagnose bladder cancer 2019,9,14,-0.20833333333333334,9,14,-0.20833333333333334,-0.9969
81,"Clovis Oncology, Inc._Attachment1(4).pdf",CLVS,7/13/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the zacks classified medicalbiomedical and genetics industry having surged 1146 so far this year while the industry increased 79 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the fda was expected to render a final decision on rubraca by feb 23 2017 the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors successful commercialization will significantly boost clovis top line going forward meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in late 2017 or early 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in jun 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer patientsthe positive results may expand rubracas label which could improve the commercial uptake of the drug clovis plans to file a regulatory application for label expansion to include a second line or later maintenance treatment for ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study within the next four months meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis is also collaborating with companies like roche for the evaluation of rubraca in combination with other regimens including pdl clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22400 cases of ovarian cancer are diagnosed in the us this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'zack', 'classify', 'medicalbiomedical', 'genetic', 'industry', 'having', 'surge', '1146', 'far', 'year', 'industry', 'increase', '79', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'fda', 'expect', 'render', 'final', 'decision', 'rubraca', 'feb', '23', '2017', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'significantly', 'boost', 'clovis', 'line', 'go', 'forward', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'late', '2017', 'early', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'jun', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'patientsthe', 'positive', 'result', 'expand', 'rubracas', 'label', 'improve', 'commercial', 'uptake', 'drug', 'clovis', 'plan', 'file', 'regulatory', 'application', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'month', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'collaborate', 'company', 'like', 'roche', 'evaluation', 'rubraca', 'combination', 'regimen', 'include', 'pdl', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22400', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform zack classify medicalbiomedical genetic industry having surge 1146 far year industry increase 79 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule fda expect render final decision rubraca feb 23 2017 approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization significantly boost clovis line go forward rubraca review eu comparable ovarian cancer indication clovis expect approval eu late 2017 early 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present jun 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer patientsthe positive result expand rubracas label improve commercial uptake drug clovis plan file regulatory application label expansion include second line late maintenance treatment ovarian cancer patient undergo prior therapy base ariel3 study month second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis collaborate company like roche evaluation rubraca combination regimen include pdl clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22400 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,19,22,-0.07142857142857142,19,22,-0.07142857142857142,-0.9786
82,"Clovis Oncology, Inc._Attachment1(4).pdf",CLVS,2/21/2018,rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in december 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same promising progressionfree survival pfs and safety results from the ariel3 study were presented in june 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study the snda has been granted priority review by the fda with decision expected on apr 6 2018 if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in the second quarter of 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer are diagnosed in the united states this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'december', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'june', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'snda', 'grant', 'priority', 'review', 'fda', 'decision', 'expect', 'apr', '6', '2018', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'second', 'quarter', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",rubraca approval boost clovis get boost accelerated fda approval rubraca december 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure promising progressionfree survival pfs safety result ariel3 study present june 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study snda grant priority review fda decision expect apr 6 2018 approve expand label commercial uptake drug improve clovis plan file marketing authorization application second quarter 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,14,13,0.03571428571428571,14,13,0.03571428571428571,-0.9936
83,"Clovis Oncology, Inc._Attachment1(4).pdf",CLVS,8/13/2018,rubraca progressing well rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors the drug got approved in the eu for treating brcamutant ovarian cancer in third or later line setting in june 2018 data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer in april 2018 clovis announced fda approval for the label expansion of rubraca the drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinum based chemotherapy based on data from ariel3 study the drug can now also be prescribed irrespective of brcamutation in the secondline setting with the expanded label the commercial uptake of the drug may improve a label expansion application in maintenance setting is under review in europe meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitorsfor treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier will return exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor,sell,"['rubraca', 'progress', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'drug', 'get', 'approve', 'eu', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'setting', 'june', '2018', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'april', '2018', 'clovis', 'announce', 'fda', 'approval', 'label', 'expansion', 'rubraca', 'drug', 'approve', 'maintenance', 'treatment', 'recurrent', 'ovarian', 'cancer', 'patient', 'receive', 'prior', 'platinum', 'base', 'chemotherapy', 'base', 'datum', 'ariel3', 'study', 'drug', 'prescribe', 'irrespective', 'brcamutation', 'secondline', 'set', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitorsfor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor']",rubraca progress rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor drug get approve eu treat brcamutant ovarian cancer later line setting june 2018 datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer april 2018 clovis announce fda approval label expansion rubraca drug approve maintenance treatment recurrent ovarian cancer patient receive prior platinum base chemotherapy base datum ariel3 study drug prescribe irrespective brcamutation secondline set expand label commercial uptake drug improve label expansion application maintenance setting review europe second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitorsfor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor,5,14,-0.45,5,14,-0.45,-0.9698
84,"Clovis Oncology, Inc._Attachment1(4).pdf",CLVS,6/10/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors rubracas label was expanded in secondline maintenance setting based on data from the ariel3 study in the united states in april 2018 and in europe in january 2019 with the expanded label as the commercial uptake of the drug is improving moreover the company is conducting patient focused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the penetration of parp inhibitors and gain 20 share of the parp inhibitor ovarian cancer market boosting rubracas sales,buy,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'rubracas', 'label', 'expand', 'secondline', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'united', 'states', 'april', '2018', 'europe', 'january', '2019', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'company', 'conduct', 'patient', 'focused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'penetration', 'parp', 'inhibitor', 'gain', '20', 'share', 'parp', 'inhibitor', 'ovarian', 'cancer', 'market', 'boost', 'rubracas', 'sale']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor rubracas label expand secondline maintenance setting base datum ariel3 study united states april 2018 europe january 2019 expand label commercial uptake drug improve company conduct patient focused awareness program rubraca parp inhibitor program help company increase penetration parp inhibitor gain 20 share parp inhibitor ovarian cancer market boost rubracas sale,4,3,0.125,4,3,0.125,0.9413
85,"Clovis Oncology, Inc._Attachment1(5).pdf",CLVS,4/17/2017,impressive share price movement shares of clovis touched a 52week high on dec 19 with the fda granting accelerated approval to rubraca clovis share price movement shows that the stock has significantly outperformed the zacks classified medical biomedical and genetics industry having surged 2928 in the past one year while the industry declined 128 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the fda was expected to render a final decision on rubraca by feb 23 2017 the approval was based on the encouraging objective response rate and duration of response the fda concurrently approved foundation medicines foundationfocus cdxbrca companion diagnostic to select patients eligible for treatment with rubraca rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors successful commercialization will significantly boost clovis top line going forward meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in late 2017 or early 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is required to run confirmatory studies clovis has completed enrollment in a pivotal maintenance confirmatory study ariel3 on rubraca data is expected to be available in mid 2017 if the data are positive clovis intends to submit a supplemental new drug application snda for a second line or later maintenance indication for advanced ovarion cancel patient the ariel4 phase iii treatment confirmatory study evaluating rubraca versus chemotherapy is open for enrolment additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis is also collaborating with companies like roche for the evaluation of rubraca in combination with other regimens including pdl clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22000 cases of ovarian cancer are diagnosed in the us each year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'share', 'clovis', 'touch', '52week', 'high', 'dec', '19', 'fda', 'grant', 'accelerate', 'approval', 'rubraca', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'zack', 'classify', 'medical', 'biomedical', 'genetic', 'industry', 'having', 'surge', '2928', 'past', 'year', 'industry', 'decline', '128', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'fda', 'expect', 'render', 'final', 'decision', 'rubraca', 'feb', '23', '2017', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'fda', 'concurrently', 'approve', 'foundation', 'medicine', 'foundationfocus', 'cdxbrca', 'companion', 'diagnostic', 'select', 'patient', 'eligible', 'treatment', 'rubraca', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'significantly', 'boost', 'clovis', 'line', 'go', 'forward', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'late', '2017', 'early', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'require', 'run', 'confirmatory', 'study', 'clovis', 'complete', 'enrollment', 'pivotal', 'maintenance', 'confirmatory', 'study', 'ariel3', 'rubraca', 'datum', 'expect', 'available', 'mid', '2017', 'datum', 'positive', 'clovis', 'intend', 'submit', 'supplemental', 'new', 'drug', 'application', 'snda', 'second', 'line', 'late', 'maintenance', 'indication', 'advanced', 'ovarion', 'cancel', 'patient', 'ariel4', 'phase', 'iii', 'treatment', 'confirmatory', 'study', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'open', 'enrolment', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'collaborate', 'company', 'like', 'roche', 'evaluation', 'rubraca', 'combination', 'regimen', 'include', 'pdl', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22000', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement share clovis touch 52week high dec 19 fda grant accelerate approval rubraca clovis share price movement show stock significantly outperform zack classify medical biomedical genetic industry having surge 2928 past year industry decline 128 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule fda expect render final decision rubraca feb 23 2017 approval base encouraging objective response rate duration response fda concurrently approve foundation medicine foundationfocus cdxbrca companion diagnostic select patient eligible treatment rubraca rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization significantly boost clovis line go forward rubraca review eu comparable ovarian cancer indication clovis expect approval eu late 2017 early 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis require run confirmatory study clovis complete enrollment pivotal maintenance confirmatory study ariel3 rubraca datum expect available mid 2017 datum positive clovis intend submit supplemental new drug application snda second line late maintenance indication advanced ovarion cancel patient ariel4 phase iii treatment confirmatory study evaluate rubraca versus chemotherapy open enrolment additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis collaborate company like roche evaluation rubraca combination regimen include pdl clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22000 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,19,20,-0.025,19,20,-0.025,-0.9601
86,"Clovis Oncology, Inc._Attachment1(5).pdf",CLVS,8/14/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the industry having surged 598 so far this year while the industry increased 62 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in jun 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis plans to file a regulatory application for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study by october this year if approved for the expanded label the commercial uptake of the drug may improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role the company collaborated with bristol myers in jul 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer are diagnosed in the us this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'having', 'surge', '598', 'far', 'year', 'industry', 'increase', '62', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'jun', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'plan', 'file', 'regulatory', 'application', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'october', 'year', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'company', 'collaborate', 'bristol', 'myers', 'jul', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform industry having surge 598 far year industry increase 62 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present jun 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis plan file regulatory application label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study october year approve expand label commercial uptake drug improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role company collaborate bristol myers jul 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,19,21,-0.04878048780487805,19,21,-0.04878048780487805,-0.9876
87,"Clovis Oncology, Inc._Attachment1(5).pdf",CLVS,3/9/2018,rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in december 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the second quarter of 2018 and is establishing the commercial infrastructure for the same data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study the snda has been granted priority review by the fda with decision expected on apr 6 2018 if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in the second quarter of 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations a phase ii atlas study is evaluating rubraca in bladder cancer other ongoing studies include the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer,sell,"['rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'december', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'second', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'snda', 'grant', 'priority', 'review', 'fda', 'decision', 'expect', 'apr', '6', '2018', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'second', 'quarter', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'ongoing', 'study', 'include', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer']",rubraca approval boost clovis get boost accelerated fda approval rubraca december 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor rubraca review eu comparable ovarian cancer indication clovis expect approval eu second quarter 2018 establish commercial infrastructure datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study snda grant priority review fda decision expect apr 6 2018 approve expand label commercial uptake drug improve clovis plan file marketing authorization application second quarter 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation phase ii atlas study evaluate rubraca bladder cancer ongoing study include investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer,9,11,-0.09523809523809523,9,11,-0.09523809523809523,-0.986
88,"Clovis Oncology, Inc._Attachment1(6).pdf",CLVS,9/15/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the industry having surged 577 so far this year while the industry increased 154 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in jun 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis plans to file a regulatory application for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study by october this year if approved for the expanded label the commercial uptake of the drug may improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role the company collaborated with bristol myers in jul 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer are diagnosed in the us this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'having', 'surge', '577', 'far', 'year', 'industry', 'increase', '154', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'jun', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'plan', 'file', 'regulatory', 'application', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'october', 'year', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'company', 'collaborate', 'bristol', 'myers', 'jul', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform industry having surge 577 far year industry increase 154 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present jun 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis plan file regulatory application label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study october year approve expand label commercial uptake drug improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role company collaborate bristol myers jul 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,19,21,-0.04878048780487805,19,21,-0.04878048780487805,-0.9876
89,"Clovis Oncology, Inc._Attachment1(6).pdf",CLVS,1/25/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in december 2016 the drug was approved for treating brcamutant ovarian cancer in third or later line setting the drug was approved in the eu for similar indication in june 2018 in april 2018 rubraca was approved as maintenance treatment of ovarian cancer irrespective of brcamutation in second line setting based on data from the ariel3 study in janurary 2019 the european commission approved rubraca in similar indication data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer with the expanded label the commercial uptake of the drug is likely to improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier has returned exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor,sell,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'december', '2016', 'drug', 'approve', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'set', 'drug', 'approve', 'eu', 'similar', 'indication', 'june', '2018', 'april', '2018', 'rubraca', 'approve', 'maintenance', 'treatment', 'ovarian', 'cancer', 'irrespective', 'brcamutation', 'second', 'line', 'set', 'base', 'datum', 'ariel3', 'study', 'janurary', '2019', 'european', 'commission', 'approve', 'rubraca', 'similar', 'indication', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'expand', 'label', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor december 2016 drug approve treat brcamutant ovarian cancer later line set drug approve eu similar indication june 2018 april 2018 rubraca approve maintenance treatment ovarian cancer irrespective brcamutation second line set base datum ariel3 study janurary 2019 european commission approve rubraca similar indication datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer expand label commercial uptake drug likely improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor,6,14,-0.38095238095238093,6,14,-0.38095238095238093,-0.9871
90,"Clovis Oncology, Inc._Attachment1(6).pdf",CLVS,4/11/2019,share price outperformance clovis shares have outperformed the industry so far this year the stock has rallied 377 compared with the industrys increase of 112 rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in january 2019 the european commission approved rubraca in maintenance setting based on data from the ariel3 study with the expanded label as well as expansion in europe the commercial uptake of the drug is likely to improve moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the parp inhibitor market and its share in it boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 a phase ii atlas study is evaluating rubraca in bladder cancer the company is also developing the drug for lung pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22530 cases of ovarian cancer will be diagnosed in the united states in 2019 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 174650 newly diagnosed prostate cancer patients in the united stated in 2019 per the american cancer society according to the national cancer institute 80470 patients will be diagnosed with bladder cancer in 2019,buy,"['share', 'price', 'outperformance', 'clovis', 'share', 'outperform', 'industry', 'far', 'year', 'stock', 'rally', '377', 'compare', 'industrys', 'increase', '112', 'rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'expand', 'label', 'expansion', 'europe', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'parp', 'inhibitor', 'market', 'share', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'company', 'develop', 'drug', 'lung', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22530', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2019', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '174650', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2019', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '80470', 'patient', 'diagnose', 'bladder', 'cancer', '2019']",share price outperformance clovis share outperform industry far year stock rally 377 compare industrys increase 112 rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor january 2019 european commission approve rubraca maintenance setting base datum ariel3 study expand label expansion europe commercial uptake drug likely improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase parp inhibitor market share boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 phase ii atlas study evaluate rubraca bladder cancer company develop drug lung pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22530 case ovarian cancer diagnose united states 2019 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 174650 newly diagnose prostate cancer patient united state 2019 american cancer society accord national cancer institute 80470 patient diagnose bladder cancer 2019,8,11,-0.15,8,11,-0.15,-0.997
91,"Clovis Oncology, Inc._Attachment1(7).pdf",CLVS,10/3/2017,rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrateresistant setting is also open for enrolment the company is also collaborating with other companies to develop rubraca in combination with their drugs in various oncology indications,sell,"['rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrateresistant', 'setting', 'open', 'enrolment', 'company', 'collaborate', 'company', 'develop', 'rubraca', 'combination', 'drug', 'oncology', 'indication']",rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrateresistant setting open enrolment company collaborate company develop rubraca combination drug oncology indication,10,9,0.05,10,9,0.05,0.9866
92,"Clovis Oncology, Inc._Attachment1(7).pdf",CLVS,4/19/2018,rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in december 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the second quarter of 2018 and is establishing the commercial infrastructure for the same data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study the snda has been granted priority review by the fda with decision expected on apr 6 2018 if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in the second quarter of 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations a phase ii atlas study is evaluating rubraca in bladder cancer other ongoing studies include the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer will be diagnosed in the united states in 2018 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 164000 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society according to the national cancer institute 79000 patients were diagnosed with bladder cancer in 2017,buy,"['rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'december', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'second', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'snda', 'grant', 'priority', 'review', 'fda', 'decision', 'expect', 'apr', '6', '2018', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'second', 'quarter', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'ongoing', 'study', 'include', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '164000', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '79000', 'patient', 'diagnose', 'bladder', 'cancer', '2017']",rubraca approval boost clovis get boost accelerated fda approval rubraca december 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor rubraca review eu comparable ovarian cancer indication clovis expect approval eu second quarter 2018 establish commercial infrastructure datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study snda grant priority review fda decision expect apr 6 2018 approve expand label commercial uptake drug improve clovis plan file marketing authorization application second quarter 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation phase ii atlas study evaluate rubraca bladder cancer ongoing study include investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states 2018 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 164000 newly diagnose prostate cancer patient united state 2018 american cancer society accord national cancer institute 79000 patient diagnose bladder cancer 2017,10,12,-0.08695652173913043,10,12,-0.08695652173913043,-0.9981
93,"Clovis Oncology, Inc._Attachment1(7).pdf",CLVS,1/29/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in december 2016 the drug was approved for treating brcamutant ovarian cancer in third or later line setting the drug was approved in the eu for similar indication in june 2018 in april 2018 rubraca was approved as maintenance treatment of ovarian cancer irrespective of brcamutation in second line setting based on data from the ariel3 study in january 2019 the european commission approved rubraca in similar indication data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer a label expansion application in maintenance setting is under review in europe with the expanded label the commercial uptake of the drug is likely to improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier has returned exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22530 cases of ovarian cancer will be diagnosed in the united states in 2019 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 174650 newly diagnosed prostate cancer patients in the united stated in 2019 per the american cancer society according to the national cancer institute 80470 patients will be diagnosed with bladder cancer in 2019,buy,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'december', '2016', 'drug', 'approve', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'set', 'drug', 'approve', 'eu', 'similar', 'indication', 'june', '2018', 'april', '2018', 'rubraca', 'approve', 'maintenance', 'treatment', 'ovarian', 'cancer', 'irrespective', 'brcamutation', 'second', 'line', 'set', 'base', 'datum', 'ariel3', 'study', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'similar', 'indication', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'expand', 'label', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22530', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2019', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '174650', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2019', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '80470', 'patient', 'diagnose', 'bladder', 'cancer', '2019']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor december 2016 drug approve treat brcamutant ovarian cancer later line set drug approve eu similar indication june 2018 april 2018 rubraca approve maintenance treatment ovarian cancer irrespective brcamutation second line set base datum ariel3 study january 2019 european commission approve rubraca similar indication datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer label expansion application maintenance setting review europe expand label commercial uptake drug likely improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22530 case ovarian cancer diagnose united states 2019 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 174650 newly diagnose prostate cancer patient united state 2019 american cancer society accord national cancer institute 80470 patient diagnose bladder cancer 2019,7,16,-0.375,7,16,-0.375,-0.9981
94,"Clovis Oncology, Inc._Attachment1(7).pdf",CLVS,4/16/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in january 2019 the european commission approved rubraca in maintenance setting based on data from the ariel3 study with the expanded label as well as expansion in europe the commercial uptake of the drug is likely to improve moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the parp inhibitor market and its share in it boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 the company is also developing the drug as monotherapy or in combination with other therapies for lung bladder pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor,sell,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'expand', 'label', 'expansion', 'europe', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'parp', 'inhibitor', 'market', 'share', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'company', 'develop', 'drug', 'monotherapy', 'combination', 'therapy', 'lung', 'bladder', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor january 2019 european commission approve rubraca maintenance setting base datum ariel3 study expand label expansion europe commercial uptake drug likely improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase parp inhibitor market share boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 company develop drug monotherapy combination therapy lung bladder pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor,6,9,-0.1875,6,9,-0.1875,-0.9432
95,"Clovis Oncology, Inc._Attachment1(8).pdf",CLVS,10/5/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the industry having surged 846 so far this year while the industry increased 146 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in jun 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis plans to file a regulatory application for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study by october this year if approved for the expanded label the commercial uptake of the drug may improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role the company collaborated with bristol myers in jul 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer are diagnosed in the us this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'having', 'surge', '846', 'far', 'year', 'industry', 'increase', '146', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'jun', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'plan', 'file', 'regulatory', 'application', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'october', 'year', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'company', 'collaborate', 'bristol', 'myers', 'jul', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform industry having surge 846 far year industry increase 146 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present jun 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis plan file regulatory application label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study october year approve expand label commercial uptake drug improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role company collaborate bristol myers jul 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,19,21,-0.04878048780487805,19,21,-0.04878048780487805,-0.9876
96,"Clovis Oncology, Inc._Attachment1(8).pdf",CLVS,4/17/2019,share price outperformance clovis shares have outperformed the industry so far this year the stock has rallied 181 compared with the industrys increase of 83 rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in january 2019 the european commission approved rubraca in maintenance setting based on data from the ariel3 study with the expanded label as well as expansion in europe the commercial uptake of the drug is likely to improve moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the parp inhibitor market and its share in it boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 the company is also developing the drug as monotherapy or in combination with other therapies for lung bladder pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22530 cases of ovarian cancer will be diagnosed in the united states in 2019 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 174650 newly diagnosed prostate cancer patients in the united stated in 2019 per the american cancer society according to the national cancer institute 80470 patients will be diagnosed with bladder cancer in 2019,buy,"['share', 'price', 'outperformance', 'clovis', 'share', 'outperform', 'industry', 'far', 'year', 'stock', 'rally', '181', 'compare', 'industrys', 'increase', '83', 'rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'expand', 'label', 'expansion', 'europe', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'parp', 'inhibitor', 'market', 'share', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'company', 'develop', 'drug', 'monotherapy', 'combination', 'therapy', 'lung', 'bladder', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22530', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2019', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '174650', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2019', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '80470', 'patient', 'diagnose', 'bladder', 'cancer', '2019']",share price outperformance clovis share outperform industry far year stock rally 181 compare industrys increase 83 rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor january 2019 european commission approve rubraca maintenance setting base datum ariel3 study expand label expansion europe commercial uptake drug likely improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase parp inhibitor market share boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 company develop drug monotherapy combination therapy lung bladder pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22530 case ovarian cancer diagnose united states 2019 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 174650 newly diagnose prostate cancer patient united state 2019 american cancer society accord national cancer institute 80470 patient diagnose bladder cancer 2019,8,11,-0.15,8,11,-0.15,-0.9966
97,"Clovis Oncology, Inc._Attachment1(9).pdf",CLVS,10/17/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the industry having surged 904 so far this year while the industry increased 125 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in jun 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application for label expansion in october 2017 to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in early 2018 in europe for the same indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role the company collaborated with bristol myers in jul 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer are diagnosed in the us this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'having', 'surge', '904', 'far', 'year', 'industry', 'increase', '125', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'jun', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'label', 'expansion', 'october', '2017', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'early', '2018', 'europe', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'company', 'collaborate', 'bristol', 'myers', 'jul', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform industry having surge 904 far year industry increase 125 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present jun 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application label expansion october 2017 include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study approve expand label commercial uptake drug improve clovis plan file marketing authorization application early 2018 europe indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role company collaborate bristol myers jul 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,19,21,-0.04878048780487805,19,21,-0.04878048780487805,-0.9876
98,"Clovis Oncology, Inc._Attachment1(9).pdf",CLVS,10/17/2017,fierce competition in target market while the ovarian cancer market provides immense commercial potential we note that rubraca will face intense competition from currently marketed parp inhibitors approved treatments include astrazenecas ovarian cancer treatment lynparza and tesaros niraparib which has been approved recently there are a number of parp inhibitors in clinical development including abbvies veliparib and abt767 and pfizers talazoparib meanwhile the oncology zacks equity research clvs wwwzackscom page 3 of 8,sell,"['fierce', 'competition', 'target', 'market', 'ovarian', 'cancer', 'market', 'provide', 'immense', 'commercial', 'potential', 'note', 'rubraca', 'face', 'intense', 'competition', 'currently', 'market', 'parp', 'inhibitor', 'approve', 'treatment', 'include', 'astrazenecas', 'ovarian', 'cancer', 'treatment', 'lynparza', 'tesaros', 'niraparib', 'approve', 'recently', 'number', 'parp', 'inhibitor', 'clinical', 'development', 'include', 'abbvie', 'veliparib', 'abt767', 'pfizer', 'talazoparib', 'oncology', 'zack', 'equity', 'research', 'clvs', 'wwwzackscom', 'page', '3', '8']",fierce competition target market ovarian cancer market provide immense commercial potential note rubraca face intense competition currently market parp inhibitor approve treatment include astrazenecas ovarian cancer treatment lynparza tesaros niraparib approve recently number parp inhibitor clinical development include abbvie veliparib abt767 pfizer talazoparib oncology zack equity research clvs wwwzackscom page 3 8,0,2,-0.6666666666666666,0,2,-0.6666666666666666,-0.8689
99,"Clovis Oncology, Inc._Attachment1.pdf",CLVS,5/19/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the zacks classified medicalbiomedical and genetics industry having surged 2768 in the past one year while the industry declined 64 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in dec 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the fda was expected to render a final decision on rubraca by feb 23 2017 the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors successful commercialization will significantly boost clovis top line going forward meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in late 2017 or early 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is required to run confirmatory studies clovis has completed enrollment in a pivotal maintenance confirmatory study ariel3 on rubraca data is expected to be available in mid 2017 if the data are positive clovis intends to submit a supplemental new drug application snda for a second line or later maintenance indication for advanced ovarion cancel patient the ariel4 phase iii treatment confirmatory study evaluating rubraca versus chemotherapy is open for enrolment additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations both inclusive of germline and somatic or other deleterious mutations in other homologous recombination repair genes and all patients will have progressed after receiving one line of taxanebased chemotherapy and one or two lines of androgenreceptor ar targeted therapy in the castrateresistant setting is enrolling patients a phase iii comparative study triton in mcrpc brca mutant and atm mutant both inclusive of germline and somatic patients who have progressed on artargeted therapy and who have not yet received chemotherapy in the castrate resistant setting is also open for enrolment other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis is also collaborating with companies like roche for the evaluation of rubraca in combination with other regimens including pdl clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer rubraca also has the potential to be studied for additional tumor types in which mutations in brca and other dna repair deficiencies play a significant role potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22000 cases of ovarian cancer are diagnosed in the us each year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'zack', 'classify', 'medicalbiomedical', 'genetic', 'industry', 'having', 'surge', '2768', 'past', 'year', 'industry', 'decline', '64', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'dec', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'fda', 'expect', 'render', 'final', 'decision', 'rubraca', 'feb', '23', '2017', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'significantly', 'boost', 'clovis', 'line', 'go', 'forward', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'late', '2017', 'early', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'require', 'run', 'confirmatory', 'study', 'clovis', 'complete', 'enrollment', 'pivotal', 'maintenance', 'confirmatory', 'study', 'ariel3', 'rubraca', 'datum', 'expect', 'available', 'mid', '2017', 'datum', 'positive', 'clovis', 'intend', 'submit', 'supplemental', 'new', 'drug', 'application', 'snda', 'second', 'line', 'late', 'maintenance', 'indication', 'advanced', 'ovarion', 'cancel', 'patient', 'ariel4', 'phase', 'iii', 'treatment', 'confirmatory', 'study', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'open', 'enrolment', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'inclusive', 'germline', 'somatic', 'deleterious', 'mutation', 'homologous', 'recombination', 'repair', 'gene', 'patient', 'progress', 'receive', 'line', 'taxanebased', 'chemotherapy', 'line', 'androgenreceptor', 'ar', 'target', 'therapy', 'castrateresistant', 'setting', 'enrol', 'patient', 'phase', 'iii', 'comparative', 'study', 'triton', 'mcrpc', 'brca', 'mutant', 'atm', 'mutant', 'inclusive', 'germline', 'somatic', 'patient', 'progress', 'artargete', 'therapy', 'receive', 'chemotherapy', 'castrate', 'resistant', 'setting', 'open', 'enrolment', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'collaborate', 'company', 'like', 'roche', 'evaluation', 'rubraca', 'combination', 'regimen', 'include', 'pdl', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'rubraca', 'potential', 'study', 'additional', 'tumor', 'type', 'mutation', 'brca', 'dna', 'repair', 'deficiency', 'play', 'significant', 'role', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22000', 'case', 'ovarian', 'cancer', 'diagnose', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform zack classify medicalbiomedical genetic industry having surge 2768 past year industry decline 64 rubraca approval boost clovis get boost accelerated fda approval rubraca dec 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule fda expect render final decision rubraca feb 23 2017 approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization significantly boost clovis line go forward rubraca review eu comparable ovarian cancer indication clovis expect approval eu late 2017 early 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis require run confirmatory study clovis complete enrollment pivotal maintenance confirmatory study ariel3 rubraca datum expect available mid 2017 datum positive clovis intend submit supplemental new drug application snda second line late maintenance indication advanced ovarion cancel patient ariel4 phase iii treatment confirmatory study evaluate rubraca versus chemotherapy open enrolment additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation inclusive germline somatic deleterious mutation homologous recombination repair gene patient progress receive line taxanebased chemotherapy line androgenreceptor ar target therapy castrateresistant setting enrol patient phase iii comparative study triton mcrpc brca mutant atm mutant inclusive germline somatic patient progress artargete therapy receive chemotherapy castrate resistant setting open enrolment ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis collaborate company like roche evaluation rubraca combination regimen include pdl clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer rubraca potential study additional tumor type mutation brca dna repair deficiency play significant role potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22000 case ovarian cancer diagnose year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,18,19,-0.02631578947368421,18,19,-0.02631578947368421,-0.9779
100,"Clovis Oncology, Inc._Attachment1.pdf",CLVS,11/7/2017,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the industry having surged 63 so far this year while the industry increased 33 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in december 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in june 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in early 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer are diagnosed in the united states this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'having', 'surge', '63', 'far', 'year', 'industry', 'increase', '33', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'december', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'june', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'early', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform industry having surge 63 far year industry increase 33 rubraca approval boost clovis get boost accelerated fda approval rubraca december 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present june 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study approve expand label commercial uptake drug improve clovis plan file marketing authorization application early 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,16,15,0.03125,16,15,0.03125,-0.9887
101,"Clovis Oncology, Inc._Attachment1.pdf",CLVS,1/5/2018,impressive share price movement clovis share price movement shows that the stock has significantly outperformed the industry having increased 471 in the past one year while the industry rose 38 rubraca approval was a boost clovis got a boost with the accelerated fda approval of rubraca in december 2016 for the treatment of advanced brcamutant ovarian cancer the approval came more than two months ahead of schedule the approval was based on the encouraging objective response rate and duration of response rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors with successful commercialization rubraca is registering impressive growth significantly boosting clovis top line meanwhile rubraca is also under review in the eu for a comparable ovarian cancer indication clovis expects an approval in eu in the first quarter of 2018 and is establishing the commercial infrastructure for the same in order to convert the accelerated approval to a continued approval clovis is conducting confirmatory studies including ariel3 and ariel4 promising progressionfree survival pfs and safety results from the ariel3 study were presented in june 2017 data from the study demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study the snda has been granted priority review by the fda with decision expected on apr 6 2018 if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in the second quarter of 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional indications like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations other ongoing studies include the cooperative groupsponsored mito25 study evaluating rucaparib and bevacizumab in combination as a firstline maintenance therapy for advanced ovarian cancer the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer are diagnosed in the united states this year with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors,buy,"['impressive', 'share', 'price', 'movement', 'clovis', 'share', 'price', 'movement', 'show', 'stock', 'significantly', 'outperform', 'industry', 'having', 'increase', '471', 'past', 'year', 'industry', 'rise', '38', 'rubraca', 'approval', 'boost', 'clovis', 'get', 'boost', 'accelerated', 'fda', 'approval', 'rubraca', 'december', '2016', 'treatment', 'advanced', 'brcamutant', 'ovarian', 'cancer', 'approval', 'come', 'month', 'ahead', 'schedule', 'approval', 'base', 'encouraging', 'objective', 'response', 'rate', 'duration', 'response', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'successful', 'commercialization', 'rubraca', 'register', 'impressive', 'growth', 'significantly', 'boost', 'clovis', 'line', 'rubraca', 'review', 'eu', 'comparable', 'ovarian', 'cancer', 'indication', 'clovis', 'expect', 'approval', 'eu', 'quarter', '2018', 'establish', 'commercial', 'infrastructure', 'order', 'convert', 'accelerated', 'approval', 'continue', 'approval', 'clovis', 'conduct', 'confirmatory', 'study', 'include', 'ariel3', 'ariel4', 'promising', 'progressionfree', 'survival', 'pfs', 'safety', 'result', 'ariel3', 'study', 'present', 'june', '2017', 'datum', 'study', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'snda', 'grant', 'priority', 'review', 'fda', 'decision', 'expect', 'apr', '6', '2018', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'second', 'quarter', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'indication', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'ongoing', 'study', 'include', 'cooperative', 'groupsponsore', 'mito25', 'study', 'evaluate', 'rucaparib', 'bevacizumab', 'combination', 'firstline', 'maintenance', 'therapy', 'advanced', 'ovarian', 'cancer', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', 'year', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor']",impressive share price movement clovis share price movement show stock significantly outperform industry having increase 471 past year industry rise 38 rubraca approval boost clovis get boost accelerated fda approval rubraca december 2016 treatment advanced brcamutant ovarian cancer approval come month ahead schedule approval base encouraging objective response rate duration response rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor successful commercialization rubraca register impressive growth significantly boost clovis line rubraca review eu comparable ovarian cancer indication clovis expect approval eu quarter 2018 establish commercial infrastructure order convert accelerated approval continue approval clovis conduct confirmatory study include ariel3 ariel4 promising progressionfree survival pfs safety result ariel3 study present june 2017 datum study demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study snda grant priority review fda decision expect apr 6 2018 approve expand label commercial uptake drug improve clovis plan file marketing authorization application second quarter 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional indication like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation ongoing study include cooperative groupsponsore mito25 study evaluate rucaparib bevacizumab combination firstline maintenance therapy advanced ovarian cancer investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states year standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor,16,15,0.03125,16,15,0.03125,-0.9872
102,"Clovis Oncology, Inc._Attachment1.pdf",CLVS,5/28/2018,rubraca progressing well rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer in april 2018 clovis announced fda approval for the label expansion of rubraca the drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinumbased chemotherapy based on data from ariel3 study the drug can now also be prescribed irrespective of brcamutation in the secondline setting with the expanded label the commercial uptake of the drug may improve data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer clovis filed a regulatory application in october 2017 for label expansion to include a second line or later maintenance treatment for advanced ovarian cancer in patients who have undergone at least one prior therapy based on ariel3 study the snda has been granted priority review by the fda with decision expected on apr 6 2018 if approved for the expanded label the commercial uptake of the drug may improve clovis is planning to file a marketing authorization application in the second quarter of 2018 in europe for the same expanded indication meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations a phase ii atlas study is evaluating rubraca in bladder cancer other ongoing studies include the investigatorinitiated ruby study in women with breast cancer whose tumors have a somatic brca mutation or homologous recombination deficient hrd signature other than a known germline brca mutation and the investigatorinitiated platform study in gastroesophageal cancer in the firstline maintenance setting clovis has a clinical collaboration with roche to evaluate a combination therapy of the latters tecentriq and rubraca for the treatment of gynecological cancers with a focus on ovarian cancer the company collaborated with bristolmyers in july 2017 to evaluate the rubraca opdivo combination in two phase iii studies for ovarian and breast cancer and a phase ii study for prostate cancer potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer will be diagnosed in the united states in 2018 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 164000 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society according to the national cancer institute 79000 patients were diagnosed with bladder cancer in 2017,buy,"['rubraca', 'progress', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'april', '2018', 'clovis', 'announce', 'fda', 'approval', 'label', 'expansion', 'rubraca', 'drug', 'approve', 'maintenance', 'treatment', 'recurrent', 'ovarian', 'cancer', 'patient', 'receive', 'prior', 'platinumbase', 'chemotherapy', 'base', 'datum', 'ariel3', 'study', 'drug', 'prescribe', 'irrespective', 'brcamutation', 'secondline', 'set', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'clovis', 'file', 'regulatory', 'application', 'october', '2017', 'label', 'expansion', 'include', 'second', 'line', 'late', 'maintenance', 'treatment', 'advanced', 'ovarian', 'cancer', 'patient', 'undergo', 'prior', 'therapy', 'base', 'ariel3', 'study', 'snda', 'grant', 'priority', 'review', 'fda', 'decision', 'expect', 'apr', '6', '2018', 'approve', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'clovis', 'plan', 'file', 'marketing', 'authorization', 'application', 'second', 'quarter', '2018', 'europe', 'expand', 'indication', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'ongoing', 'study', 'include', 'investigatorinitiate', 'ruby', 'study', 'woman', 'breast', 'cancer', 'tumor', 'somatic', 'brca', 'mutation', 'homologous', 'recombination', 'deficient', 'hrd', 'signature', 'known', 'germline', 'brca', 'mutation', 'investigatorinitiate', 'platform', 'study', 'gastroesophageal', 'cancer', 'firstline', 'maintenance', 'setting', 'clovis', 'clinical', 'collaboration', 'roche', 'evaluate', 'combination', 'therapy', 'latter', 'tecentriq', 'rubraca', 'treatment', 'gynecological', 'cancer', 'focus', 'ovarian', 'cancer', 'company', 'collaborate', 'bristolmyer', 'july', '2017', 'evaluate', 'rubraca', 'opdivo', 'combination', 'phase', 'iii', 'study', 'ovarian', 'breast', 'cancer', 'phase', 'ii', 'study', 'prostate', 'cancer', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '164000', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '79000', 'patient', 'diagnose', 'bladder', 'cancer', '2017']",rubraca progress rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer april 2018 clovis announce fda approval label expansion rubraca drug approve maintenance treatment recurrent ovarian cancer patient receive prior platinumbase chemotherapy base datum ariel3 study drug prescribe irrespective brcamutation secondline set expand label commercial uptake drug improve datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer clovis file regulatory application october 2017 label expansion include second line late maintenance treatment advanced ovarian cancer patient undergo prior therapy base ariel3 study snda grant priority review fda decision expect apr 6 2018 approve expand label commercial uptake drug improve clovis plan file marketing authorization application second quarter 2018 europe expand indication second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation phase ii atlas study evaluate rubraca bladder cancer ongoing study include investigatorinitiate ruby study woman breast cancer tumor somatic brca mutation homologous recombination deficient hrd signature known germline brca mutation investigatorinitiate platform study gastroesophageal cancer firstline maintenance setting clovis clinical collaboration roche evaluate combination therapy latter tecentriq rubraca treatment gynecological cancer focus ovarian cancer company collaborate bristolmyer july 2017 evaluate rubraca opdivo combination phase iii study ovarian breast cancer phase ii study prostate cancer potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states 2018 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 164000 newly diagnose prostate cancer patient united state 2018 american cancer society accord national cancer institute 79000 patient diagnose bladder cancer 2017,10,16,-0.2222222222222222,10,16,-0.2222222222222222,-0.9985
103,"Clovis Oncology, Inc._Attachment1.pdf",CLVS,9/14/2018,rubraca progressing well rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors the drug got approved in the eu for treating brcamutant ovarian cancer in third or later line setting in june 2018 data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer in april 2018 clovis announced fda approval for the label expansion of rubraca the drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinum based chemotherapy based on data from ariel3 study the drug can now also be prescribed irrespective of brcamutation in the secondline setting with the expanded label the commercial uptake of the drug may improve a label expansion application in maintenance setting is under review in europe meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitorsfor treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier will return exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor,sell,"['rubraca', 'progress', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'drug', 'get', 'approve', 'eu', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'setting', 'june', '2018', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'april', '2018', 'clovis', 'announce', 'fda', 'approval', 'label', 'expansion', 'rubraca', 'drug', 'approve', 'maintenance', 'treatment', 'recurrent', 'ovarian', 'cancer', 'patient', 'receive', 'prior', 'platinum', 'base', 'chemotherapy', 'base', 'datum', 'ariel3', 'study', 'drug', 'prescribe', 'irrespective', 'brcamutation', 'secondline', 'set', 'expand', 'label', 'commercial', 'uptake', 'drug', 'improve', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitorsfor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor']",rubraca progress rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor drug get approve eu treat brcamutant ovarian cancer later line setting june 2018 datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer april 2018 clovis announce fda approval label expansion rubraca drug approve maintenance treatment recurrent ovarian cancer patient receive prior platinum base chemotherapy base datum ariel3 study drug prescribe irrespective brcamutation secondline set expand label commercial uptake drug improve label expansion application maintenance setting review europe second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitorsfor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor,5,14,-0.45,5,14,-0.45,-0.9698
104,"Clovis Oncology, Inc._Attachment1.pdf",CLVS,12/24/2018,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in december 2016 the drug was approved for treating brcamutant ovarian cancer in third or later line setting the drug was approved in the eu for similar indication in june 2018 in april 2018 rubraca was approved as maintenance treatment of ovarian cancer irrespective of brcamutation in second line setting based on data from the ariel3 study in decemeber 2018 the chmp has recommended approval of rubraca in similar indication a decision in europe is expected in the first quarter 2019 data from the ariel 3 study presented in june 2017 demonstrated that rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer a label expansion application in maintenance setting is under review in europe with the expanded label the commercial uptake of the drug is likely to improve meanwhile the second phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 a phase ii atlas study is evaluating rubraca in bladder cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer the companys partner servier has returned exus excluding china rights to the candidate in 2018 following this clovis will own global development rights for lucitanib except china the company has plans to initiate clinical studies before the end of first quarter of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22240 cases of ovarian cancer will be diagnosed in the united states in 2018 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 164690 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society according to the national cancer institute 81190 patients will be diagnosed with bladder cancer in 2018,buy,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'december', '2016', 'drug', 'approve', 'treat', 'brcamutant', 'ovarian', 'cancer', 'later', 'line', 'set', 'drug', 'approve', 'eu', 'similar', 'indication', 'june', '2018', 'april', '2018', 'rubraca', 'approve', 'maintenance', 'treatment', 'ovarian', 'cancer', 'irrespective', 'brcamutation', 'second', 'line', 'set', 'base', 'datum', 'ariel3', 'study', 'decemeber', '2018', 'chmp', 'recommend', 'approval', 'rubraca', 'similar', 'indication', 'decision', 'europe', 'expect', 'quarter', '2019', 'datum', 'ariel', '3', 'study', 'present', 'june', '2017', 'demonstrate', 'rubraca', 'meaningful', 'impact', 'delay', 'disease', 'recurrence', 'advanced', 'ovarian', 'cancer', 'label', 'expansion', 'application', 'maintenance', 'setting', 'review', 'europe', 'expand', 'label', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'second', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'follow', 'clovis', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'end', 'quarter', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22240', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '164690', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '81190', 'patient', 'diagnose', 'bladder', 'cancer', '2018']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor december 2016 drug approve treat brcamutant ovarian cancer later line set drug approve eu similar indication june 2018 april 2018 rubraca approve maintenance treatment ovarian cancer irrespective brcamutation second line set base datum ariel3 study decemeber 2018 chmp recommend approval rubraca similar indication decision europe expect quarter 2019 datum ariel 3 study present june 2017 demonstrate rubraca meaningful impact delay disease recurrence advanced ovarian cancer label expansion application maintenance setting review europe expand label commercial uptake drug likely improve second phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 phase ii atlas study evaluate rubraca bladder cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer company partner servi return exus exclude china right candidate 2018 follow clovis global development right lucitanib china company plan initiate clinical study end quarter 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22240 case ovarian cancer diagnose united states 2018 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 164690 newly diagnose prostate cancer patient united state 2018 american cancer society accord national cancer institute 81190 patient diagnose bladder cancer 2018,7,16,-0.375,7,16,-0.375,-0.9979
105,"Clovis Oncology, Inc._Attachment1.pdf",CLVS,3/6/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in january 2019 the european commission approved rubraca in maintenance setting based on data from the ariel3 study with the expanded label as well as expansion in europe the commercial uptake of the drug is likely to improve moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the parp inhibitor market and its share in it boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 a phase ii atlas study is evaluating rubraca in bladder cancer the company is also developing the drug for lung pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22530 cases of ovarian cancer will be diagnosed in the united states in 2019 with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore rubraca has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 174650 newly diagnosed prostate cancer patients in the united stated in 2019 per the american cancer society according to the national cancer institute 80470 patients will be diagnosed with bladder cancer in 2019,buy,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'expand', 'label', 'expansion', 'europe', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'parp', 'inhibitor', 'market', 'share', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'phase', 'ii', 'atlas', 'study', 'evaluate', 'rubraca', 'bladder', 'cancer', 'company', 'develop', 'drug', 'lung', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22530', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2019', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'rubraca', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '174650', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2019', 'american', 'cancer', 'society', 'accord', 'national', 'cancer', 'institute', '80470', 'patient', 'diagnose', 'bladder', 'cancer', '2019']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor january 2019 european commission approve rubraca maintenance setting base datum ariel3 study expand label expansion europe commercial uptake drug likely improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase parp inhibitor market share boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 phase ii atlas study evaluate rubraca bladder cancer company develop drug lung pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22530 case ovarian cancer diagnose united states 2019 standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation rubraca bright prospect give immense commercial potential target market tremendous demand parp inhibitor 174650 newly diagnose prostate cancer patient united state 2019 american cancer society accord national cancer institute 80470 patient diagnose bladder cancer 2019,7,10,-0.16666666666666666,7,10,-0.16666666666666666,-0.9974
106,"Clovis Oncology, Inc._Attachment1.pdf",CLVS,4/23/2019,rubraca holds potential in ovarian cancer rubraca is not only the first approved product in clovis portfolio but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for parp inhibitors in january 2019 the european commission approved rubraca in maintenance setting based on data from the ariel3 study with the expanded label as well as expansion in europe the commercial uptake of the drug is likely to improve moreover the company is conducting patientfocused awareness programs for rubraca as well as parp inhibitors these programs helped the company to increase the parp inhibitor market and its share in it boosting rubracas sales clovis is evaluating rubraca in several label expansion studies a phase iii confirmatory study ariel4 is evaluating rubraca versus chemotherapy in patients who have failed two prior lines of therapy a phase iii study athena is evaluating rubraca in combination with bristolmyers opdivo as part of collaboration in advanced ovarian cancer additional indications being evaluated meanwhile clovis is looking to expand rubracas label into additional cancer types like prostrate breast and gastroesophageal cancers among others a phase ii triton2 study and a phase iii triton 3 study is evaluating rubraca in metastatic castrateresistant prostate cancer mcrpc patients with tumor with brca mutations and atm mutations the fda granted orphan drug status to the drug for this indication in october 2018 the company plans to file for label expansion of rubraca in prostate cancer in late 2019 the company is also developing the drug as monotherapy or in combination with other therapies for lung bladder pancreatic and gastroesophageal cancer clovis has a collaboration agreement with merck and bristolmyers to develop rubraca in combination with their pd1 pdl1 inhibitors for treating several cancer indications apart from rubraca the company is also developing lucitanib for treating breast and lung cancer in the fourth quarter of 2018 the company expanded its agreement with bristolmyers to include combination studies of lucitanib the companys partner servier returned exus excluding china rights to the candidate in 2018 now clovis owns global development rights for lucitanib except china the company has plans to initiate clinical studies in the first half of 2019 to evaluate lucitanib in combination with rubraca or a pd1 inhibitor zacks equity research clvs wwwzackscom page 4 of 9,sell,"['rubraca', 'hold', 'potential', 'ovarian', 'cancer', 'rubraca', 'approve', 'product', 'clovis', 'portfolio', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'january', '2019', 'european', 'commission', 'approve', 'rubraca', 'maintenance', 'setting', 'base', 'datum', 'ariel3', 'study', 'expand', 'label', 'expansion', 'europe', 'commercial', 'uptake', 'drug', 'likely', 'improve', 'company', 'conduct', 'patientfocused', 'awareness', 'program', 'rubraca', 'parp', 'inhibitor', 'program', 'help', 'company', 'increase', 'parp', 'inhibitor', 'market', 'share', 'boost', 'rubracas', 'sale', 'clovis', 'evaluate', 'rubraca', 'label', 'expansion', 'study', 'phase', 'iii', 'confirmatory', 'study', 'ariel4', 'evaluate', 'rubraca', 'versus', 'chemotherapy', 'patient', 'fail', 'prior', 'line', 'therapy', 'phase', 'iii', 'study', 'athena', 'evaluate', 'rubraca', 'combination', 'bristolmyer', 'opdivo', 'collaboration', 'advanced', 'ovarian', 'cancer', 'additional', 'indication', 'evaluate', 'clovis', 'look', 'expand', 'rubracas', 'label', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'gastroesophageal', 'cancer', 'phase', 'ii', 'triton2', 'study', 'phase', 'iii', 'triton', '3', 'study', 'evaluate', 'rubraca', 'metastatic', 'castrateresistant', 'prostate', 'cancer', 'mcrpc', 'patient', 'tumor', 'brca', 'mutation', 'atm', 'mutation', 'fda', 'grant', 'orphan', 'drug', 'status', 'drug', 'indication', 'october', '2018', 'company', 'plan', 'file', 'label', 'expansion', 'rubraca', 'prostate', 'cancer', 'late', '2019', 'company', 'develop', 'drug', 'monotherapy', 'combination', 'therapy', 'lung', 'bladder', 'pancreatic', 'gastroesophageal', 'cancer', 'clovis', 'collaboration', 'agreement', 'merck', 'bristolmyer', 'develop', 'rubraca', 'combination', 'pd1', 'pdl1', 'inhibitor', 'treat', 'cancer', 'indication', 'apart', 'rubraca', 'company', 'develop', 'lucitanib', 'treat', 'breast', 'lung', 'cancer', 'fourth', 'quarter', '2018', 'company', 'expand', 'agreement', 'bristolmyer', 'include', 'combination', 'study', 'lucitanib', 'company', 'partner', 'servi', 'return', 'exus', 'exclude', 'china', 'right', 'candidate', '2018', 'clovis', 'own', 'global', 'development', 'right', 'lucitanib', 'china', 'company', 'plan', 'initiate', 'clinical', 'study', 'half', '2019', 'evaluate', 'lucitanib', 'combination', 'rubraca', 'pd1', 'inhibitor', 'zacks', 'equity', 'research', 'clvs', 'wwwzackscom', 'page', '4', '9']",rubraca hold potential ovarian cancer rubraca approve product clovis portfolio bright prospect give immense commercial potential target market tremendous demand parp inhibitor january 2019 european commission approve rubraca maintenance setting base datum ariel3 study expand label expansion europe commercial uptake drug likely improve company conduct patientfocused awareness program rubraca parp inhibitor program help company increase parp inhibitor market share boost rubracas sale clovis evaluate rubraca label expansion study phase iii confirmatory study ariel4 evaluate rubraca versus chemotherapy patient fail prior line therapy phase iii study athena evaluate rubraca combination bristolmyer opdivo collaboration advanced ovarian cancer additional indication evaluate clovis look expand rubracas label additional cancer type like prostrate breast gastroesophageal cancer phase ii triton2 study phase iii triton 3 study evaluate rubraca metastatic castrateresistant prostate cancer mcrpc patient tumor brca mutation atm mutation fda grant orphan drug status drug indication october 2018 company plan file label expansion rubraca prostate cancer late 2019 company develop drug monotherapy combination therapy lung bladder pancreatic gastroesophageal cancer clovis collaboration agreement merck bristolmyer develop rubraca combination pd1 pdl1 inhibitor treat cancer indication apart rubraca company develop lucitanib treat breast lung cancer fourth quarter 2018 company expand agreement bristolmyer include combination study lucitanib company partner servi return exus exclude china right candidate 2018 clovis own global development right lucitanib china company plan initiate clinical study half 2019 evaluate lucitanib combination rubraca pd1 inhibitor zacks equity research clvs wwwzackscom page 4 9,6,10,-0.23529411764705882,6,10,-0.23529411764705882,-0.9432
107,"Ellie Mae, Inc._Attachment1(10).pdf",ELLI,2/6/2019,ellie maes total addressable market tam is limited only to the financial mortgage industry this industryconcentric feature is a headwind for the company in our view notably the mortgage origination environment is currently facing hurdles leading to declining amount of closed loans for the company this downward trend is anticipated to continue in 2019 as well the lowered volumes pertain to higher mortgage or interest rates lower housing inventory and ongoing shift to the purchase loan segment catering to just the mortgage industry in such a scenario is a negative for this saas provider though the saas industry has tremendous growth prospects ellie maes frequent acquisitions have escalated integration risks moreover we note that the large acquisitions negatively impacted the companys balance sheet in the form of high level of goodwill and intangible assets which comprised of almost 2285 of total assets as of sep30 2018 ellie mae currently has a trailing oneyear pe ratio of 8162 which compares unfavorably to some extent with what the industry saw last year hence its valuation looks slightly stretched from a pe perspective,sell,"['ellie', 'maes', 'total', 'addressable', 'market', 'tam', 'limit', 'financial', 'mortgage', 'industry', 'industryconcentric', 'feature', 'headwind', 'company', 'view', 'notably', 'mortgage', 'origination', 'environment', 'currently', 'face', 'hurdle', 'lead', 'decline', 'closed', 'loan', 'company', 'downward', 'trend', 'anticipate', 'continue', '2019', 'lower', 'volume', 'pertain', 'high', 'mortgage', 'interest', 'rate', 'low', 'housing', 'inventory', 'ongoing', 'shift', 'purchase', 'loan', 'segment', 'cater', 'mortgage', 'industry', 'scenario', 'negative', 'saas', 'provider', 'saas', 'industry', 'tremendous', 'growth', 'prospect', 'ellie', 'maes', 'frequent', 'acquisition', 'escalate', 'integration', 'risk', 'note', 'large', 'acquisition', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'comprise', '2285', 'total', 'asset', 'sep30', '2018', 'ellie', 'mae', 'currently', 'trail', 'oneyear', 'pe', 'ratio', '8162', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'valuation', 'looks', 'slightly', 'stretch', 'pe', 'perspective']",ellie maes total addressable market tam limit financial mortgage industry industryconcentric feature headwind company view notably mortgage origination environment currently face hurdle lead decline closed loan company downward trend anticipate continue 2019 lower volume pertain high mortgage interest rate low housing inventory ongoing shift purchase loan segment cater mortgage industry scenario negative saas provider saas industry tremendous growth prospect ellie maes frequent acquisition escalate integration risk note large acquisition negatively impact company balance sheet form high level goodwill intangible asset comprise 2285 total asset sep30 2018 ellie mae currently trail oneyear pe ratio 8162 compare unfavorably extent industry see year valuation looks slightly stretch pe perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,0.4019
108,"Ellie Mae, Inc._Attachment1(3).pdf",ELLI,11/2/2018,ellie mae has witnessed accelerated adoption of its solutions its revenues witnessed cagr of 345 since 2013 the company provides endtoend mortgage management solutions the depth in its product portfolio has been the major growth driver in recent times the company has been witnessing robust adoption of the encompass ng lending platform as of dec 31 2017 the company had 184000 professionals using encompass as their mortgage management platform up 115 from the previous year it is aimed at offering a digital mortgage platform that enables seamless workflow along with reduction in cost for lenders and shorter closing times ellie mae is currently working toward its vision of a true digital mortgage platform to support this initiative the company is coming up with upgrades for the encompass platform with solutions like encompass investor connect and encompass data connect which will increase visibility and collaboration between home buyers thirdparty originators and loan officers this will in turn drive demand for the companys platform thereby boosting the top line ellie mae has a huge customer base including the likes of banks credit unions and mortgage companies some of its prominent customers include wyndham capital mortgage american national bank and peoples national bank among others the latest addition to the customer base is td bank one of the top 10 national banks of america notably the companys new enhancements in encompass consumer connect solution is currently in beta phase and changes will be made per lender feedback we believe that these enhancements in accordance with consumers feedback make the companys solutions further lucrative for adoption thereby increasing its customer base apart from innovation the company has been enriching its product suite inorganically with buyouts the most recent acquisition of velocify is worth a mention the integration of the acquired entity is in progress and continues to boost revenues notably the companys previous acquisitions of allregs and mavent have proven to be accretive to its portfolio as well and the product lines of these two entities are being offered separately by the company till now,buy,"['ellie', 'mae', 'witness', 'accelerated', 'adoption', 'solution', 'revenue', 'witness', 'cagr', '345', '2013', 'company', 'provide', 'endtoend', 'mortgage', 'management', 'solution', 'depth', 'product', 'portfolio', 'major', 'growth', 'driver', 'recent', 'time', 'company', 'witness', 'robust', 'adoption', 'encompass', 'ng', 'lending', 'platform', 'dec', '31', '2017', 'company', '184000', 'professional', 'encompass', 'mortgage', 'management', 'platform', '115', 'previous', 'year', 'aim', 'offer', 'digital', 'mortgage', 'platform', 'enable', 'seamless', 'workflow', 'reduction', 'cost', 'lender', 'short', 'closing', 'time', 'ellie', 'mae', 'currently', 'work', 'vision', 'true', 'digital', 'mortgage', 'platform', 'support', 'initiative', 'company', 'come', 'upgrade', 'encompass', 'platform', 'solution', 'like', 'encompass', 'investor', 'connect', 'encompass', 'datum', 'connect', 'increase', 'visibility', 'collaboration', 'home', 'buyer', 'thirdparty', 'originator', 'loan', 'officer', 'turn', 'drive', 'demand', 'company', 'platform', 'boost', 'line', 'ellie', 'mae', 'huge', 'customer', 'base', 'include', 'like', 'bank', 'credit', 'union', 'mortgage', 'company', 'prominent', 'customer', 'include', 'wyndham', 'capital', 'mortgage', 'american', 'national', 'bank', 'peoples', 'national', 'bank', 'late', 'addition', 'customer', 'base', 'td', 'bank', '10', 'national', 'bank', 'america', 'notably', 'company', 'new', 'enhancement', 'encompass', 'consumer', 'connect', 'solution', 'currently', 'beta', 'phase', 'change', 'lender', 'feedback', 'believe', 'enhancement', 'accordance', 'consumer', 'feedback', 'company', 'solution', 'lucrative', 'adoption', 'increase', 'customer', 'base', 'apart', 'innovation', 'company', 'enrich', 'product', 'suite', 'inorganically', 'buyout', 'recent', 'acquisition', 'velocify', 'worth', 'mention', 'integration', 'acquire', 'entity', 'progress', 'continue', 'boost', 'revenue', 'notably', 'company', 'previous', 'acquisition', 'allreg', 'mavent', 'prove', 'accretive', 'portfolio', 'product', 'line', 'entity', 'offer', 'separately', 'company', 'till']",ellie mae witness accelerated adoption solution revenue witness cagr 345 2013 company provide endtoend mortgage management solution depth product portfolio major growth driver recent time company witness robust adoption encompass ng lending platform dec 31 2017 company 184000 professional encompass mortgage management platform 115 previous year aim offer digital mortgage platform enable seamless workflow reduction cost lender short closing time ellie mae currently work vision true digital mortgage platform support initiative company come upgrade encompass platform solution like encompass investor connect encompass datum connect increase visibility collaboration home buyer thirdparty originator loan officer turn drive demand company platform boost line ellie mae huge customer base include like bank credit union mortgage company prominent customer include wyndham capital mortgage american national bank peoples national bank late addition customer base td bank 10 national bank america notably company new enhancement encompass consumer connect solution currently beta phase change lender feedback believe enhancement accordance consumer feedback company solution lucrative adoption increase customer base apart innovation company enrich product suite inorganically buyout recent acquisition velocify worth mention integration acquire entity progress continue boost revenue notably company previous acquisition allreg mavent prove accretive portfolio product line entity offer separately company till,12,15,-0.10714285714285714,12,15,-0.10714285714285714,0.9923
109,"Ellie Mae, Inc._Attachment1(3).pdf",ELLI,1/16/2019,ellie maes total addressable market tam is limited only to the financial mortgage industry this industryconcentric feature is a headwind for the company in our view notably the mortgage origination environment is currently facing hurdles leading to declining amount of closed loans for the company this downward trend is anticipated to continue in 2019 as well the lowered volumes pertain to higher mortgage or interest rates lower housing inventory and ongoing shift to the purchase loan segment catering to just the mortgage industry in such a scenario is a negative for this saas provider though the saas industry has tremendous growth prospects ellie maes frequent acquisitions have escalated integration risks moreover we note that the large acquisitions negatively impacted the companys balance sheet in the form of high level of goodwill and intangible assets which comprised of almost 2285 of total assets as of sep30 2018 ellie mae currently has a trailing oneyear pe ratio of 6762 which compares unfavorably to some extent with what the industry saw last year hence its valuation looks slightly stretched from a pe perspective,sell,"['ellie', 'maes', 'total', 'addressable', 'market', 'tam', 'limit', 'financial', 'mortgage', 'industry', 'industryconcentric', 'feature', 'headwind', 'company', 'view', 'notably', 'mortgage', 'origination', 'environment', 'currently', 'face', 'hurdle', 'lead', 'decline', 'closed', 'loan', 'company', 'downward', 'trend', 'anticipate', 'continue', '2019', 'lower', 'volume', 'pertain', 'high', 'mortgage', 'interest', 'rate', 'low', 'housing', 'inventory', 'ongoing', 'shift', 'purchase', 'loan', 'segment', 'cater', 'mortgage', 'industry', 'scenario', 'negative', 'saas', 'provider', 'saas', 'industry', 'tremendous', 'growth', 'prospect', 'ellie', 'maes', 'frequent', 'acquisition', 'escalate', 'integration', 'risk', 'note', 'large', 'acquisition', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'comprise', '2285', 'total', 'asset', 'sep30', '2018', 'ellie', 'mae', 'currently', 'trail', 'oneyear', 'pe', 'ratio', '6762', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'valuation', 'looks', 'slightly', 'stretch', 'pe', 'perspective']",ellie maes total addressable market tam limit financial mortgage industry industryconcentric feature headwind company view notably mortgage origination environment currently face hurdle lead decline closed loan company downward trend anticipate continue 2019 lower volume pertain high mortgage interest rate low housing inventory ongoing shift purchase loan segment cater mortgage industry scenario negative saas provider saas industry tremendous growth prospect ellie maes frequent acquisition escalate integration risk note large acquisition negatively impact company balance sheet form high level goodwill intangible asset comprise 2285 total asset sep30 2018 ellie mae currently trail oneyear pe ratio 6762 compare unfavorably extent industry see year valuation looks slightly stretch pe perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,0.4019
110,"Ellie Mae, Inc._Attachment1(4).pdf",ELLI,3/5/2019,ellie mae has witnessed accelerated adoption of its solutions its revenues witnessed cagr of 345 since 2013 the company provides endtoend mortgage management solutions the depth in its product portfolio has been the major growth driver in recent times the company has been witnessing robust adoption of the encompass ng lending platform it is aimed at offering a digital mortgage platform that enables seamless workflow along with reduction in cost for lenders and shorter closing times ellie mae is currently working toward its vision of a true digital mortgage platform to support this initiative the company is coming up with upgrades for the encompass platform with solutions like encompass investor connect and encompass data connect which will increase visibility and collaboration between home buyers thirdparty originators and loan officers this will in turn drive demand for the companys platform thereby boosting the top line ellie mae has a huge customer base including the likes of banks credit unions and mortgage companies some of its prominent customers include wyndham capital mortgage american national bank and peoples national bank among others the latest addition to the customer base is td bank one of the top 10 national banks of america notably the companys new enhancements in encompass consumer connect solution is currently in beta phase and changes will be made per lender feedback we believe that these enhancements in accordance with consumers feedback make the companys solutions further lucrative for adoption thereby increasing its customer base apart from innovation the company has been enriching its product suite inorganically with buyouts the most recent acquisition of velocify is worth a mention the integration of the acquired entity is in progress and continues to boost revenues notably the companys previous acquisitions of allregs and mavent have proven to be accretive to its portfolio as well and the product lines of these two entities are being offered separately by the company till now,buy,"['ellie', 'mae', 'witness', 'accelerated', 'adoption', 'solution', 'revenue', 'witness', 'cagr', '345', '2013', 'company', 'provide', 'endtoend', 'mortgage', 'management', 'solution', 'depth', 'product', 'portfolio', 'major', 'growth', 'driver', 'recent', 'time', 'company', 'witness', 'robust', 'adoption', 'encompass', 'ng', 'lending', 'platform', 'aim', 'offer', 'digital', 'mortgage', 'platform', 'enable', 'seamless', 'workflow', 'reduction', 'cost', 'lender', 'short', 'closing', 'time', 'ellie', 'mae', 'currently', 'work', 'vision', 'true', 'digital', 'mortgage', 'platform', 'support', 'initiative', 'company', 'come', 'upgrade', 'encompass', 'platform', 'solution', 'like', 'encompass', 'investor', 'connect', 'encompass', 'datum', 'connect', 'increase', 'visibility', 'collaboration', 'home', 'buyer', 'thirdparty', 'originator', 'loan', 'officer', 'turn', 'drive', 'demand', 'company', 'platform', 'boost', 'line', 'ellie', 'mae', 'huge', 'customer', 'base', 'include', 'like', 'bank', 'credit', 'union', 'mortgage', 'company', 'prominent', 'customer', 'include', 'wyndham', 'capital', 'mortgage', 'american', 'national', 'bank', 'peoples', 'national', 'bank', 'late', 'addition', 'customer', 'base', 'td', 'bank', '10', 'national', 'bank', 'america', 'notably', 'company', 'new', 'enhancement', 'encompass', 'consumer', 'connect', 'solution', 'currently', 'beta', 'phase', 'change', 'lender', 'feedback', 'believe', 'enhancement', 'accordance', 'consumer', 'feedback', 'company', 'solution', 'lucrative', 'adoption', 'increase', 'customer', 'base', 'apart', 'innovation', 'company', 'enrich', 'product', 'suite', 'inorganically', 'buyout', 'recent', 'acquisition', 'velocify', 'worth', 'mention', 'integration', 'acquire', 'entity', 'progress', 'continue', 'boost', 'revenue', 'notably', 'company', 'previous', 'acquisition', 'allreg', 'mavent', 'prove', 'accretive', 'portfolio', 'product', 'line', 'entity', 'offer', 'separately', 'company', 'till']",ellie mae witness accelerated adoption solution revenue witness cagr 345 2013 company provide endtoend mortgage management solution depth product portfolio major growth driver recent time company witness robust adoption encompass ng lending platform aim offer digital mortgage platform enable seamless workflow reduction cost lender short closing time ellie mae currently work vision true digital mortgage platform support initiative company come upgrade encompass platform solution like encompass investor connect encompass datum connect increase visibility collaboration home buyer thirdparty originator loan officer turn drive demand company platform boost line ellie mae huge customer base include like bank credit union mortgage company prominent customer include wyndham capital mortgage american national bank peoples national bank late addition customer base td bank 10 national bank america notably company new enhancement encompass consumer connect solution currently beta phase change lender feedback believe enhancement accordance consumer feedback company solution lucrative adoption increase customer base apart innovation company enrich product suite inorganically buyout recent acquisition velocify worth mention integration acquire entity progress continue boost revenue notably company previous acquisition allreg mavent prove accretive portfolio product line entity offer separately company till,12,14,-0.07407407407407407,12,14,-0.07407407407407407,0.9923
111,"Ellie Mae, Inc._Attachment1(5).pdf",ELLI,1/23/2019,ellie maes total addressable market tam is limited only to the financial mortgage industry this industryconcentric feature is a headwind for the company in our view notably the mortgage origination environment is currently facing hurdles leading to declining amount of closed loans for the company this downward trend is anticipated to continue in 2019 as well the lowered volumes pertain to higher mortgage or interest rates lower housing inventory and ongoing shift to the purchase loan segment catering to just the mortgage industry in such a scenario is a negative for this saas provider though the saas industry has tremendous growth prospects ellie maes frequent acquisitions have escalated integration risks moreover we note that the large acquisitions negatively impacted the companys balance sheet in the form of high level of goodwill and intangible assets which comprised of almost 2285 of total assets as of sep30 2018 ellie mae currently has a trailing oneyear pe ratio of 7131 which compares unfavorably to some extent with what the industry saw last year hence its valuation looks slightly stretched from a pe perspective,sell,"['ellie', 'maes', 'total', 'addressable', 'market', 'tam', 'limit', 'financial', 'mortgage', 'industry', 'industryconcentric', 'feature', 'headwind', 'company', 'view', 'notably', 'mortgage', 'origination', 'environment', 'currently', 'face', 'hurdle', 'lead', 'decline', 'closed', 'loan', 'company', 'downward', 'trend', 'anticipate', 'continue', '2019', 'lower', 'volume', 'pertain', 'high', 'mortgage', 'interest', 'rate', 'low', 'housing', 'inventory', 'ongoing', 'shift', 'purchase', 'loan', 'segment', 'cater', 'mortgage', 'industry', 'scenario', 'negative', 'saas', 'provider', 'saas', 'industry', 'tremendous', 'growth', 'prospect', 'ellie', 'maes', 'frequent', 'acquisition', 'escalate', 'integration', 'risk', 'note', 'large', 'acquisition', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'comprise', '2285', 'total', 'asset', 'sep30', '2018', 'ellie', 'mae', 'currently', 'trail', 'oneyear', 'pe', 'ratio', '7131', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",ellie maes total addressable market tam limit financial mortgage industry industryconcentric feature headwind company view notably mortgage origination environment currently face hurdle lead decline closed loan company downward trend anticipate continue 2019 lower volume pertain high mortgage interest rate low housing inventory ongoing shift purchase loan segment cater mortgage industry scenario negative saas provider saas industry tremendous growth prospect ellie maes frequent acquisition escalate integration risk note large acquisition negatively impact company balance sheet form high level goodwill intangible asset comprise 2285 total asset sep30 2018 ellie mae currently trail oneyear pe ratio 7131 compare unfavorably extent industry see year valuation look slightly stretch pe perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,0.4019
112,"Ellie Mae, Inc._Attachment1(6).pdf",ELLI,1/25/2019,ellie maes total addressable market tam is limited only to the financial mortgage industry this industryconcentric feature is a headwind for the company in our view notably the mortgage origination environment is currently facing hurdles leading to declining amount of closed loans for the company this downward trend is anticipated to continue in 2019 as well the lowered volumes pertain to higher mortgage or interest rates lower housing inventory and ongoing shift to the purchase loan segment catering to just the mortgage industry in such a scenario is a negative for this saas provider though the saas industry has tremendous growth prospects ellie maes frequent acquisitions have escalated integration risks moreover we note that the large acquisitions negatively impacted the companys balance sheet in the form of high level of goodwill and intangible assets which comprised of almost 2285 of total assets as of sep30 2018 ellie mae currently has a trailing oneyear pe ratio of 7124 which compares unfavorably to some extent with what the industry saw last year hence its valuation looks slightly stretched from a pe perspective,sell,"['ellie', 'maes', 'total', 'addressable', 'market', 'tam', 'limit', 'financial', 'mortgage', 'industry', 'industryconcentric', 'feature', 'headwind', 'company', 'view', 'notably', 'mortgage', 'origination', 'environment', 'currently', 'face', 'hurdle', 'lead', 'decline', 'closed', 'loan', 'company', 'downward', 'trend', 'anticipate', 'continue', '2019', 'lower', 'volume', 'pertain', 'high', 'mortgage', 'interest', 'rate', 'low', 'housing', 'inventory', 'ongoing', 'shift', 'purchase', 'loan', 'segment', 'cater', 'mortgage', 'industry', 'scenario', 'negative', 'saas', 'provider', 'saas', 'industry', 'tremendous', 'growth', 'prospect', 'ellie', 'maes', 'frequent', 'acquisition', 'escalate', 'integration', 'risk', 'note', 'large', 'acquisition', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'comprise', '2285', 'total', 'asset', 'sep30', '2018', 'ellie', 'mae', 'currently', 'trail', 'oneyear', 'pe', 'ratio', '7124', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'valuation', 'looks', 'slightly', 'stretch', 'pe', 'perspective']",ellie maes total addressable market tam limit financial mortgage industry industryconcentric feature headwind company view notably mortgage origination environment currently face hurdle lead decline closed loan company downward trend anticipate continue 2019 lower volume pertain high mortgage interest rate low housing inventory ongoing shift purchase loan segment cater mortgage industry scenario negative saas provider saas industry tremendous growth prospect ellie maes frequent acquisition escalate integration risk note large acquisition negatively impact company balance sheet form high level goodwill intangible asset comprise 2285 total asset sep30 2018 ellie mae currently trail oneyear pe ratio 7124 compare unfavorably extent industry see year valuation looks slightly stretch pe perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,0.4019
113,"Ellie Mae, Inc._Attachment1(8).pdf",ELLI,1/29/2019,ellie maes total addressable market tam is limited only to the financial mortgage industry this industryconcentric feature is a headwind for the company in our view notably the mortgage origination environment is currently facing hurdles leading to declining amount of closed loans for the company this downward trend is anticipated to continue in 2019 as well the lowered volumes pertain to higher mortgage or interest rates lower housing inventory and ongoing shift to the purchase loan segment catering to just the mortgage industry in such a scenario is a negative for this saas provider though the saas industry has tremendous growth prospects ellie maes frequent acquisitions have escalated integration risks moreover we note that the large acquisitions negatively impacted the companys balance sheet in the form of high level of goodwill and intangible assets which comprised of almost 2285 of total assets as of sep30 2018 ellie mae currently has a trailing oneyear pe ratio of 7202 which compares unfavorably to some extent with what the industry saw last year hence its valuation looks slightly stretched from a pe perspective,sell,"['ellie', 'maes', 'total', 'addressable', 'market', 'tam', 'limit', 'financial', 'mortgage', 'industry', 'industryconcentric', 'feature', 'headwind', 'company', 'view', 'notably', 'mortgage', 'origination', 'environment', 'currently', 'face', 'hurdle', 'lead', 'decline', 'closed', 'loan', 'company', 'downward', 'trend', 'anticipate', 'continue', '2019', 'lower', 'volume', 'pertain', 'high', 'mortgage', 'interest', 'rate', 'low', 'housing', 'inventory', 'ongoing', 'shift', 'purchase', 'loan', 'segment', 'cater', 'mortgage', 'industry', 'scenario', 'negative', 'saas', 'provider', 'saas', 'industry', 'tremendous', 'growth', 'prospect', 'ellie', 'maes', 'frequent', 'acquisition', 'escalate', 'integration', 'risk', 'note', 'large', 'acquisition', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'comprise', '2285', 'total', 'asset', 'sep30', '2018', 'ellie', 'mae', 'currently', 'trail', 'oneyear', 'pe', 'ratio', '7202', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",ellie maes total addressable market tam limit financial mortgage industry industryconcentric feature headwind company view notably mortgage origination environment currently face hurdle lead decline closed loan company downward trend anticipate continue 2019 lower volume pertain high mortgage interest rate low housing inventory ongoing shift purchase loan segment cater mortgage industry scenario negative saas provider saas industry tremendous growth prospect ellie maes frequent acquisition escalate integration risk note large acquisition negatively impact company balance sheet form high level goodwill intangible asset comprise 2285 total asset sep30 2018 ellie mae currently trail oneyear pe ratio 7202 compare unfavorably extent industry see year valuation look slightly stretch pe perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,0.4019
114,"Ellie Mae, Inc._Attachment1.pdf",ELLI,6/21/2018,ellie mae has witnessed accelerated adoption of its solutions its revenues witnessed cagr of 266 over the last five fiscals the company provides endtoend mortgage management solutions the depth in its product portfolio has been the major growth driver in recent times the companys impressive topline performance boosted investors confidence and the stock has outperformed the industry on a yeartodate basis the company has been witnessing robust adoption of the encompass ng lending platform as of dec 31 2017 the company had 184000 professionals using encompass as their mortgage management platform up 115 from the previous year it is aimed at offering a digital mortgage platform that enables seamless workflow along with reduction in cost for lenders and shorter closing times ellie mae is currently working toward its vision of a true digital mortgage platform to support this initiative the company is coming up with upgrades for the encompass platform with solutions like encompass investor connect and encompass data connect which will increase visibility and collaboration between home buyers thirdparty originators and loan officers this will in turn drive demand for the companys platform thereby boosting the top line ellie mae has a huge customer base including the likes of banks credit unions and mortgage companies some of its prominent customers include wyndham capital mortgage american national bank and peoples national bank among others the latest addition to the customer base is td bank one of the top 10 national banks of america notably the companys new enhancements in encompass consumer connect solution is currently in beta phase and changes will be made per lender feedback we believe that these enhancements in accordance with consumers feedback make the companys solutions further lucrative for adoption thereby increasing its customer base apart from innovation the company has been enriching its product suite inorganically with buyouts the most recent acquisition of velocify is worth a mention the integration of the acquired entity is in progress and its revenue contribution was more than managements expectation in firstquarter 2018 notably the companys previous acquisitions of allregs and mavent have proven to be accretive to its portfolio as well and the product lines of these two entities are being offered separately by the company till now,buy,"['ellie', 'mae', 'witness', 'accelerated', 'adoption', 'solution', 'revenue', 'witness', 'cagr', '266', 'fiscal', 'company', 'provide', 'endtoend', 'mortgage', 'management', 'solution', 'depth', 'product', 'portfolio', 'major', 'growth', 'driver', 'recent', 'time', 'companys', 'impressive', 'topline', 'performance', 'boost', 'investor', 'confidence', 'stock', 'outperform', 'industry', 'yeartodate', 'basis', 'company', 'witness', 'robust', 'adoption', 'encompass', 'ng', 'lending', 'platform', 'dec', '31', '2017', 'company', '184000', 'professional', 'encompass', 'mortgage', 'management', 'platform', '115', 'previous', 'year', 'aim', 'offer', 'digital', 'mortgage', 'platform', 'enable', 'seamless', 'workflow', 'reduction', 'cost', 'lender', 'short', 'closing', 'time', 'ellie', 'mae', 'currently', 'work', 'vision', 'true', 'digital', 'mortgage', 'platform', 'support', 'initiative', 'company', 'come', 'upgrade', 'encompass', 'platform', 'solution', 'like', 'encompass', 'investor', 'connect', 'encompass', 'datum', 'connect', 'increase', 'visibility', 'collaboration', 'home', 'buyer', 'thirdparty', 'originator', 'loan', 'officer', 'turn', 'drive', 'demand', 'company', 'platform', 'boost', 'line', 'ellie', 'mae', 'huge', 'customer', 'base', 'include', 'like', 'bank', 'credit', 'union', 'mortgage', 'company', 'prominent', 'customer', 'include', 'wyndham', 'capital', 'mortgage', 'american', 'national', 'bank', 'peoples', 'national', 'bank', 'late', 'addition', 'customer', 'base', 'td', 'bank', '10', 'national', 'bank', 'america', 'notably', 'company', 'new', 'enhancement', 'encompass', 'consumer', 'connect', 'solution', 'currently', 'beta', 'phase', 'change', 'lender', 'feedback', 'believe', 'enhancement', 'accordance', 'consumer', 'feedback', 'company', 'solution', 'lucrative', 'adoption', 'increase', 'customer', 'base', 'apart', 'innovation', 'company', 'enrich', 'product', 'suite', 'inorganically', 'buyout', 'recent', 'acquisition', 'velocify', 'worth', 'mention', 'integration', 'acquire', 'entity', 'progress', 'revenue', 'contribution', 'management', 'expectation', 'firstquarter', '2018', 'notably', 'company', 'previous', 'acquisition', 'allreg', 'mavent', 'prove', 'accretive', 'portfolio', 'product', 'line', 'entity', 'offer', 'separately', 'company', 'till']",ellie mae witness accelerated adoption solution revenue witness cagr 266 fiscal company provide endtoend mortgage management solution depth product portfolio major growth driver recent time companys impressive topline performance boost investor confidence stock outperform industry yeartodate basis company witness robust adoption encompass ng lending platform dec 31 2017 company 184000 professional encompass mortgage management platform 115 previous year aim offer digital mortgage platform enable seamless workflow reduction cost lender short closing time ellie mae currently work vision true digital mortgage platform support initiative company come upgrade encompass platform solution like encompass investor connect encompass datum connect increase visibility collaboration home buyer thirdparty originator loan officer turn drive demand company platform boost line ellie mae huge customer base include like bank credit union mortgage company prominent customer include wyndham capital mortgage american national bank peoples national bank late addition customer base td bank 10 national bank america notably company new enhancement encompass consumer connect solution currently beta phase change lender feedback believe enhancement accordance consumer feedback company solution lucrative adoption increase customer base apart innovation company enrich product suite inorganically buyout recent acquisition velocify worth mention integration acquire entity progress revenue contribution management expectation firstquarter 2018 notably company previous acquisition allreg mavent prove accretive portfolio product line entity offer separately company till,14,15,-0.03333333333333333,14,15,-0.03333333333333333,0.9941
115,"Ellie Mae, Inc._Attachment1.pdf",ELLI,6/21/2018,ellie maes total addressable market tam is limited only to the financial mortgage industry this industryconcentric feature is a headwind for the company in our view notably the mortgage origination environment is likely to face hurdles with volumes down in midhigh teens in 2018 instead of the industrys expectation of 7 and this downward trend is anticipated to continue in 2019 as well the lowered volumes pertain to higher mortgage or interest rates and ongoing shift to the purchase loan segment catering to just the mortgage industry in such a scenario is a negative for this saas provider though the saas industry has tremendous growth prospects the negative free cash flow is also a concern the company recorded free cash outflow of 193 million in firstquarter 2018 in the yearago quarter the company recorded negative free cash flow of 242 million the negative free cash flow indicates that the company does not have enough cash for investing activities and might have to raise debts for further investments which might hurt profitability ellie maes frequent acquisitions have escalated integration risks moreover we note that the large acquisitions negatively impacted the companys balance sheet in the form of high level of goodwill and intangible assets which comprised of almost 173 of total assets as of mar 31 2018 ellie mae currently has a trailing oneyear pe ratio of 9691 which compares unfavorably to some extent with what the industry saw last year the ratio is higher than the average level of 7988 and is in line with the high end of the valuation range over this period hence its valuation looks slightly stretched from a pe perspective,sell,"['ellie', 'maes', 'total', 'addressable', 'market', 'tam', 'limit', 'financial', 'mortgage', 'industry', 'industryconcentric', 'feature', 'headwind', 'company', 'view', 'notably', 'mortgage', 'origination', 'environment', 'likely', 'face', 'hurdle', 'volume', 'midhigh', 'teen', '2018', 'instead', 'industrys', 'expectation', '7', 'downward', 'trend', 'anticipate', 'continue', '2019', 'lower', 'volume', 'pertain', 'high', 'mortgage', 'interest', 'rate', 'ongoing', 'shift', 'purchase', 'loan', 'segment', 'cater', 'mortgage', 'industry', 'scenario', 'negative', 'saas', 'provider', 'saas', 'industry', 'tremendous', 'growth', 'prospect', 'negative', 'free', 'cash', 'flow', 'concern', 'company', 'record', 'free', 'cash', 'outflow', '193', 'million', 'firstquarter', '2018', 'yearago', 'quarter', 'company', 'record', 'negative', 'free', 'cash', 'flow', '242', 'million', 'negative', 'free', 'cash', 'flow', 'indicate', 'company', 'cash', 'invest', 'activity', 'raise', 'debt', 'investment', 'hurt', 'profitability', 'ellie', 'maes', 'frequent', 'acquisition', 'escalate', 'integration', 'risk', 'note', 'large', 'acquisition', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'comprise', '173', 'total', 'asset', 'mar', '31', '2018', 'ellie', 'mae', 'currently', 'trail', 'oneyear', 'pe', 'ratio', '9691', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'ratio', 'high', 'average', 'level', '7988', 'line', 'high', 'end', 'valuation', 'range', 'period', 'valuation', 'looks', 'slightly', 'stretch', 'pe', 'perspective']",ellie maes total addressable market tam limit financial mortgage industry industryconcentric feature headwind company view notably mortgage origination environment likely face hurdle volume midhigh teen 2018 instead industrys expectation 7 downward trend anticipate continue 2019 lower volume pertain high mortgage interest rate ongoing shift purchase loan segment cater mortgage industry scenario negative saas provider saas industry tremendous growth prospect negative free cash flow concern company record free cash outflow 193 million firstquarter 2018 yearago quarter company record negative free cash flow 242 million negative free cash flow indicate company cash invest activity raise debt investment hurt profitability ellie maes frequent acquisition escalate integration risk note large acquisition negatively impact company balance sheet form high level goodwill intangible asset comprise 173 total asset mar 31 2018 ellie mae currently trail oneyear pe ratio 9691 compare unfavorably extent industry see year ratio high average level 7988 line high end valuation range period valuation looks slightly stretch pe perspective,8,21,-0.43333333333333335,8,21,-0.43333333333333335,0.2732
116,"Ellie Mae, Inc._Attachment1.pdf",ELLI,8/31/2018,ellie mae has witnessed accelerated adoption of its solutions its revenues witnessed cagr of 345 since 2013 the company provides endtoend mortgage management solutions the depth in its product portfolio has been the major growth driver in recent times the companys impressive topline performance boosted investors confidence and the stock has outperformed the industry on a yeartodate basis the company has been witnessing robust adoption of the encompass ng lending platform as of dec 31 2017 the company had 184000 professionals using encompass as their mortgage management platform up 115 from the previous year it is aimed at offering a digital mortgage platform that enables seamless workflow along with reduction in cost for lenders and shorter closing times ellie mae is currently working toward its vision of a true digital mortgage platform to support this initiative the company is coming up with upgrades for the encompass platform with solutions like encompass investor connect and encompass data connect which will increase visibility and collaboration between home buyers thirdparty originators and loan officers this will in turn drive demand for the companys platform thereby boosting the top line ellie mae has a huge customer base including the likes of banks credit unions and mortgage companies some of its prominent customers include wyndham capital mortgage american national bank and peoples national bank among others the latest addition to the customer base is td bank one of the top 10 national banks of america notably the companys new enhancements in encompass consumer connect solution is currently in beta phase and changes will be made per lender feedback we believe that these enhancements in accordance with consumers feedback make the companys solutions further lucrative for adoption thereby increasing its customer base apart from innovation the company has been enriching its product suite inorganically with buyouts the most recent acquisition of velocify is worth a mention the integration of the acquired entity is in progress and its revenue contribution was more than managements expectation in firstquarter 2018 notably the companys previous acquisitions of allregs and mavent have proven to be accretive to its portfolio as well and the product lines of these two entities are being offered separately by the company till now,buy,"['ellie', 'mae', 'witness', 'accelerated', 'adoption', 'solution', 'revenue', 'witness', 'cagr', '345', '2013', 'company', 'provide', 'endtoend', 'mortgage', 'management', 'solution', 'depth', 'product', 'portfolio', 'major', 'growth', 'driver', 'recent', 'time', 'companys', 'impressive', 'topline', 'performance', 'boost', 'investor', 'confidence', 'stock', 'outperform', 'industry', 'yeartodate', 'basis', 'company', 'witness', 'robust', 'adoption', 'encompass', 'ng', 'lending', 'platform', 'dec', '31', '2017', 'company', '184000', 'professional', 'encompass', 'mortgage', 'management', 'platform', '115', 'previous', 'year', 'aim', 'offer', 'digital', 'mortgage', 'platform', 'enable', 'seamless', 'workflow', 'reduction', 'cost', 'lender', 'short', 'closing', 'time', 'ellie', 'mae', 'currently', 'work', 'vision', 'true', 'digital', 'mortgage', 'platform', 'support', 'initiative', 'company', 'come', 'upgrade', 'encompass', 'platform', 'solution', 'like', 'encompass', 'investor', 'connect', 'encompass', 'datum', 'connect', 'increase', 'visibility', 'collaboration', 'home', 'buyer', 'thirdparty', 'originator', 'loan', 'officer', 'turn', 'drive', 'demand', 'company', 'platform', 'boost', 'line', 'ellie', 'mae', 'huge', 'customer', 'base', 'include', 'like', 'bank', 'credit', 'union', 'mortgage', 'company', 'prominent', 'customer', 'include', 'wyndham', 'capital', 'mortgage', 'american', 'national', 'bank', 'peoples', 'national', 'bank', 'late', 'addition', 'customer', 'base', 'td', 'bank', '10', 'national', 'bank', 'america', 'notably', 'company', 'new', 'enhancement', 'encompass', 'consumer', 'connect', 'solution', 'currently', 'beta', 'phase', 'change', 'lender', 'feedback', 'believe', 'enhancement', 'accordance', 'consumer', 'feedback', 'company', 'solution', 'lucrative', 'adoption', 'increase', 'customer', 'base', 'apart', 'innovation', 'company', 'enrich', 'product', 'suite', 'inorganically', 'buyout', 'recent', 'acquisition', 'velocify', 'worth', 'mention', 'integration', 'acquire', 'entity', 'progress', 'revenue', 'contribution', 'management', 'expectation', 'firstquarter', '2018', 'notably', 'company', 'previous', 'acquisition', 'allreg', 'mavent', 'prove', 'accretive', 'portfolio', 'product', 'line', 'entity', 'offer', 'separately', 'company', 'till']",ellie mae witness accelerated adoption solution revenue witness cagr 345 2013 company provide endtoend mortgage management solution depth product portfolio major growth driver recent time companys impressive topline performance boost investor confidence stock outperform industry yeartodate basis company witness robust adoption encompass ng lending platform dec 31 2017 company 184000 professional encompass mortgage management platform 115 previous year aim offer digital mortgage platform enable seamless workflow reduction cost lender short closing time ellie mae currently work vision true digital mortgage platform support initiative company come upgrade encompass platform solution like encompass investor connect encompass datum connect increase visibility collaboration home buyer thirdparty originator loan officer turn drive demand company platform boost line ellie mae huge customer base include like bank credit union mortgage company prominent customer include wyndham capital mortgage american national bank peoples national bank late addition customer base td bank 10 national bank america notably company new enhancement encompass consumer connect solution currently beta phase change lender feedback believe enhancement accordance consumer feedback company solution lucrative adoption increase customer base apart innovation company enrich product suite inorganically buyout recent acquisition velocify worth mention integration acquire entity progress revenue contribution management expectation firstquarter 2018 notably company previous acquisition allreg mavent prove accretive portfolio product line entity offer separately company till,14,15,-0.03333333333333333,14,15,-0.03333333333333333,0.9941
117,"Ellie Mae, Inc._Attachment1.pdf",ELLI,12/26/2018,ellie mae has witnessed accelerated adoption of its solutions its revenues witnessed cagr of 345 since 2013 the company provides endtoend mortgage management solutions the depth in its product portfolio has been the major growth driver in recent times the company has been witnessing robust adoption of the encompass ng lending platform as of dec 31 2017 the company had 184000 professionals using encompass as their mortgage management platform up 115 from the previous year it is aimed at offering a digital mortgage platform that enables seamless workflow along with reduction in cost for lenders and shorter closing times ellie mae is currently working toward its vision of a true digital mortgage platform to support this initiative the company is coming up with upgrades for the encompass platform with solutions like encompass investor connect and encompass data connect which will increase visibility and collaboration between home buyers thirdparty originators and loan officers this will in turn drive demand for the companys platform thereby boosting the top line ellie mae has a huge customer base including the likes of banks credit unions and mortgage companies some of its prominent customers include wyndham capital mortgage american national bank and peoples national bank among others the latest addition to the customer base is td bank one of the top 10 national banks of america notably the companys new enhancements in encompass consumer connect solution is currently in beta phase and changes will be made per lender feedback we believe that these enhancements in accordance with consumers feedback make the companys solutions further lucrative for adoption thereby increasing its customer base apart from innovation the company has been enriching its product suite inorganically with buyouts the most recent acquisition of velocify is worth a mention the integration of the acquired entity is in progress and continues to boost revenues notably the companys previous acquisitions of allregs and mavent have proven to be accretive to its portfolio as well and the product lines of these two entities are being offered separately by the company till now,sell,"['ellie', 'mae', 'witness', 'accelerated', 'adoption', 'solution', 'revenue', 'witness', 'cagr', '345', '2013', 'company', 'provide', 'endtoend', 'mortgage', 'management', 'solution', 'depth', 'product', 'portfolio', 'major', 'growth', 'driver', 'recent', 'time', 'company', 'witness', 'robust', 'adoption', 'encompass', 'ng', 'lending', 'platform', 'dec', '31', '2017', 'company', '184000', 'professional', 'encompass', 'mortgage', 'management', 'platform', '115', 'previous', 'year', 'aim', 'offer', 'digital', 'mortgage', 'platform', 'enable', 'seamless', 'workflow', 'reduction', 'cost', 'lender', 'short', 'closing', 'time', 'ellie', 'mae', 'currently', 'work', 'vision', 'true', 'digital', 'mortgage', 'platform', 'support', 'initiative', 'company', 'come', 'upgrade', 'encompass', 'platform', 'solution', 'like', 'encompass', 'investor', 'connect', 'encompass', 'datum', 'connect', 'increase', 'visibility', 'collaboration', 'home', 'buyer', 'thirdparty', 'originator', 'loan', 'officer', 'turn', 'drive', 'demand', 'company', 'platform', 'boost', 'line', 'ellie', 'mae', 'huge', 'customer', 'base', 'include', 'like', 'bank', 'credit', 'union', 'mortgage', 'company', 'prominent', 'customer', 'include', 'wyndham', 'capital', 'mortgage', 'american', 'national', 'bank', 'peoples', 'national', 'bank', 'late', 'addition', 'customer', 'base', 'td', 'bank', '10', 'national', 'bank', 'america', 'notably', 'company', 'new', 'enhancement', 'encompass', 'consumer', 'connect', 'solution', 'currently', 'beta', 'phase', 'change', 'lender', 'feedback', 'believe', 'enhancement', 'accordance', 'consumer', 'feedback', 'company', 'solution', 'lucrative', 'adoption', 'increase', 'customer', 'base', 'apart', 'innovation', 'company', 'enrich', 'product', 'suite', 'inorganically', 'buyout', 'recent', 'acquisition', 'velocify', 'worth', 'mention', 'integration', 'acquire', 'entity', 'progress', 'continue', 'boost', 'revenue', 'notably', 'company', 'previous', 'acquisition', 'allreg', 'mavent', 'prove', 'accretive', 'portfolio', 'product', 'line', 'entity', 'offer', 'separately', 'company', 'till']",ellie mae witness accelerated adoption solution revenue witness cagr 345 2013 company provide endtoend mortgage management solution depth product portfolio major growth driver recent time company witness robust adoption encompass ng lending platform dec 31 2017 company 184000 professional encompass mortgage management platform 115 previous year aim offer digital mortgage platform enable seamless workflow reduction cost lender short closing time ellie mae currently work vision true digital mortgage platform support initiative company come upgrade encompass platform solution like encompass investor connect encompass datum connect increase visibility collaboration home buyer thirdparty originator loan officer turn drive demand company platform boost line ellie mae huge customer base include like bank credit union mortgage company prominent customer include wyndham capital mortgage american national bank peoples national bank late addition customer base td bank 10 national bank america notably company new enhancement encompass consumer connect solution currently beta phase change lender feedback believe enhancement accordance consumer feedback company solution lucrative adoption increase customer base apart innovation company enrich product suite inorganically buyout recent acquisition velocify worth mention integration acquire entity progress continue boost revenue notably company previous acquisition allreg mavent prove accretive portfolio product line entity offer separately company till,12,15,-0.10714285714285714,12,15,-0.10714285714285714,0.9923
118,"Ellie Mae, Inc._Attachment1.pdf",ELLI,1/8/2019,ellie maes total addressable market tam is limited only to the financial mortgage industry this industryconcentric feature is a headwind for the company in our view notably the mortgage origination environment is currently facing hurdles leading to declining amount of closed loans for the company this downward trend is anticipated to continue in 2019 as well the lowered volumes pertain to higher mortgage or interest rates lower housing inventory and ongoing shift to the purchase loan segment catering to just the mortgage industry in such a scenario is a negative for this saas provider though the saas industry has tremendous growth prospects ellie maes frequent acquisitions have escalated integration risks moreover we note that the large acquisitions negatively impacted the companys balance sheet in the form of high level of goodwill and intangible assets which comprised of almost 2285 of total assets as of sep30 2018 ellie mae currently has a trailing oneyear pe ratio of 6533 which compares unfavorably to some extent with what the industry saw last year hence its valuation looks slightly stretched from a pe perspective,sell,"['ellie', 'maes', 'total', 'addressable', 'market', 'tam', 'limit', 'financial', 'mortgage', 'industry', 'industryconcentric', 'feature', 'headwind', 'company', 'view', 'notably', 'mortgage', 'origination', 'environment', 'currently', 'face', 'hurdle', 'lead', 'decline', 'closed', 'loan', 'company', 'downward', 'trend', 'anticipate', 'continue', '2019', 'lower', 'volume', 'pertain', 'high', 'mortgage', 'interest', 'rate', 'low', 'housing', 'inventory', 'ongoing', 'shift', 'purchase', 'loan', 'segment', 'cater', 'mortgage', 'industry', 'scenario', 'negative', 'saas', 'provider', 'saas', 'industry', 'tremendous', 'growth', 'prospect', 'ellie', 'maes', 'frequent', 'acquisition', 'escalate', 'integration', 'risk', 'note', 'large', 'acquisition', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'comprise', '2285', 'total', 'asset', 'sep30', '2018', 'ellie', 'mae', 'currently', 'trail', 'oneyear', 'pe', 'ratio', '6533', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'valuation', 'looks', 'slightly', 'stretch', 'pe', 'perspective']",ellie maes total addressable market tam limit financial mortgage industry industryconcentric feature headwind company view notably mortgage origination environment currently face hurdle lead decline closed loan company downward trend anticipate continue 2019 lower volume pertain high mortgage interest rate low housing inventory ongoing shift purchase loan segment cater mortgage industry scenario negative saas provider saas industry tremendous growth prospect ellie maes frequent acquisition escalate integration risk note large acquisition negatively impact company balance sheet form high level goodwill intangible asset comprise 2285 total asset sep30 2018 ellie mae currently trail oneyear pe ratio 6533 compare unfavorably extent industry see year valuation looks slightly stretch pe perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,0.4019
119,"Ellie Mae, Inc._Attachment1.pdf",ELLI,2/27/2019,ellie mae has witnessed accelerated adoption of its solutions its revenues witnessed cagr of 345 since 2013 the company provides endtoend mortgage management solutions the depth in its product portfolio has been the major growth driver in recent times the company has been witnessing robust adoption of the encompass ng lending platform it is aimed at offering a digital mortgage platform that enables seamless workflow along with reduction in cost for lenders and shorter closing times ellie mae is currently working toward its vision of a true digital mortgage platform to support this initiative the company is coming up with upgrades for the encompass platform with solutions like encompass investor connect and encompass data connect which will increase visibility and collaboration between home buyers thirdparty originators and loan officers this will in turn drive demand for the companys platform thereby boosting the top line ellie mae has a huge customer base including the likes of banks credit unions and mortgage companies some of its prominent customers include wyndham capital mortgage american national bank and peoples national bank among others the latest addition to the customer base is td bank one of the top 10 national banks of america notably the companys new enhancements in encompass consumer connect solution is currently in beta phase and changes will be made per lender feedback we believe that these enhancements in accordance with consumers feedback make the companys solutions further lucrative for adoption thereby increasing its customer base apart from innovation the company has been enriching its product suite inorganically with buyouts the most recent acquisition of velocify is worth a mention the integration of the acquired entity is in progress and continues to boost revenues notably the companys previous acquisitions of allregs and mavent have proven to be accretive to its portfolio as well and the product lines of these two entities are being offered separately by the company till now,sell,"['ellie', 'mae', 'witness', 'accelerated', 'adoption', 'solution', 'revenue', 'witness', 'cagr', '345', '2013', 'company', 'provide', 'endtoend', 'mortgage', 'management', 'solution', 'depth', 'product', 'portfolio', 'major', 'growth', 'driver', 'recent', 'time', 'company', 'witness', 'robust', 'adoption', 'encompass', 'ng', 'lending', 'platform', 'aim', 'offer', 'digital', 'mortgage', 'platform', 'enable', 'seamless', 'workflow', 'reduction', 'cost', 'lender', 'short', 'closing', 'time', 'ellie', 'mae', 'currently', 'work', 'vision', 'true', 'digital', 'mortgage', 'platform', 'support', 'initiative', 'company', 'come', 'upgrade', 'encompass', 'platform', 'solution', 'like', 'encompass', 'investor', 'connect', 'encompass', 'datum', 'connect', 'increase', 'visibility', 'collaboration', 'home', 'buyer', 'thirdparty', 'originator', 'loan', 'officer', 'turn', 'drive', 'demand', 'company', 'platform', 'boost', 'line', 'ellie', 'mae', 'huge', 'customer', 'base', 'include', 'like', 'bank', 'credit', 'union', 'mortgage', 'company', 'prominent', 'customer', 'include', 'wyndham', 'capital', 'mortgage', 'american', 'national', 'bank', 'peoples', 'national', 'bank', 'late', 'addition', 'customer', 'base', 'td', 'bank', '10', 'national', 'bank', 'america', 'notably', 'company', 'new', 'enhancement', 'encompass', 'consumer', 'connect', 'solution', 'currently', 'beta', 'phase', 'change', 'lender', 'feedback', 'believe', 'enhancement', 'accordance', 'consumer', 'feedback', 'company', 'solution', 'lucrative', 'adoption', 'increase', 'customer', 'base', 'apart', 'innovation', 'company', 'enrich', 'product', 'suite', 'inorganically', 'buyout', 'recent', 'acquisition', 'velocify', 'worth', 'mention', 'integration', 'acquire', 'entity', 'progress', 'continue', 'boost', 'revenue', 'notably', 'company', 'previous', 'acquisition', 'allreg', 'mavent', 'prove', 'accretive', 'portfolio', 'product', 'line', 'entity', 'offer', 'separately', 'company', 'till']",ellie mae witness accelerated adoption solution revenue witness cagr 345 2013 company provide endtoend mortgage management solution depth product portfolio major growth driver recent time company witness robust adoption encompass ng lending platform aim offer digital mortgage platform enable seamless workflow reduction cost lender short closing time ellie mae currently work vision true digital mortgage platform support initiative company come upgrade encompass platform solution like encompass investor connect encompass datum connect increase visibility collaboration home buyer thirdparty originator loan officer turn drive demand company platform boost line ellie mae huge customer base include like bank credit union mortgage company prominent customer include wyndham capital mortgage american national bank peoples national bank late addition customer base td bank 10 national bank america notably company new enhancement encompass consumer connect solution currently beta phase change lender feedback believe enhancement accordance consumer feedback company solution lucrative adoption increase customer base apart innovation company enrich product suite inorganically buyout recent acquisition velocify worth mention integration acquire entity progress continue boost revenue notably company previous acquisition allreg mavent prove accretive portfolio product line entity offer separately company till,12,14,-0.07407407407407407,12,14,-0.07407407407407407,0.9923
120,Enphase Energy Inc_Attachment1(5).pdf,ENPH,7/20/2020,on sep 24 2018 the united states began imposing 10 tariffs on enphases microinverter products and related accessories that are manufactured in china these tariffs per expectations have increased to 25 on 250 billion of imports since mar 1 2019 such tariffs may lead to increased costs of enphases products in the united states thereby hurting its growth trajectory solar panel prices in the united states are 4357 higher than the global average leading to higher prices for customers and reduced overall demand per a report by seia such a slowdown in demand could hurt the companys growth trajectory although the company has outperformed its industry in the past year a comparative analysis of its historical pricecash flow pcf ratio reflects a relatively gloomy picture that might be a cause for investors concern the stock currently has a trailing 12month pcf ratio of 4185 the ratio is higher than the industrys negative average of 1842 since early march 2020 the coronavirus pandemic has resulted in a significant downward pressure on demand due to business restrictionseven though solar installations have been allowed as essential services in some locations the ability to generate new sales has been hindered due to social distancing and economic uncertainty in the united states residential installations started declining in march which further intensified in the month of aprilin the united states management anticipates 30 to 50 drop in residential installations in aprilthis may have impacted the companys secondquarter results since the extent to which the covid19 outbreak will impact the global economy is not known we remain cautious about this companys growth,sell,"['sep', '24', '2018', 'united', 'states', 'begin', 'impose', '10', 'tariff', 'enphase', 'microinverter', 'product', 'relate', 'accessory', 'manufacture', 'china', 'tariff', 'expectation', 'increase', '25', '250', 'billion', 'import', 'mar', '1', '2019', 'tariff', 'lead', 'increase', 'cost', 'enphase', 'product', 'united', 'states', 'hurt', 'growth', 'trajectory', 'solar', 'panel', 'price', 'united', 'states', '4357', 'high', 'global', 'average', 'lead', 'high', 'price', 'customer', 'reduce', 'overall', 'demand', 'report', 'seia', 'slowdown', 'demand', 'hurt', 'company', 'growth', 'trajectory', 'company', 'outperform', 'industry', 'past', 'year', 'comparative', 'analysis', 'historical', 'pricecash', 'flow', 'pcf', 'ratio', 'reflect', 'relatively', 'gloomy', 'picture', 'cause', 'investor', 'concern', 'stock', 'currently', 'trailing', '12month', 'pcf', 'ratio', '4185', 'ratio', 'high', 'industrys', 'negative', 'average', '1842', 'early', 'march', '2020', 'coronavirus', 'pandemic', 'result', 'significant', 'downward', 'pressure', 'demand', 'business', 'restrictionseven', 'solar', 'installation', 'allow', 'essential', 'service', 'location', 'ability', 'generate', 'new', 'sale', 'hinder', 'social', 'distancing', 'economic', 'uncertainty', 'united', 'states', 'residential', 'installation', 'start', 'decline', 'march', 'intensify', 'month', 'aprilin', 'united', 'states', 'management', 'anticipate', '30', '50', 'drop', 'residential', 'installation', 'aprilthis', 'impact', 'company', 'secondquarter', 'result', 'extent', 'covid19', 'outbreak', 'impact', 'global', 'economy', 'know', 'remain', 'cautious', 'company', 'growth']",sep 24 2018 united states begin impose 10 tariff enphase microinverter product relate accessory manufacture china tariff expectation increase 25 250 billion import mar 1 2019 tariff lead increase cost enphase product united states hurt growth trajectory solar panel price united states 4357 high global average lead high price customer reduce overall demand report seia slowdown demand hurt company growth trajectory company outperform industry past year comparative analysis historical pricecash flow pcf ratio reflect relatively gloomy picture cause investor concern stock currently trailing 12month pcf ratio 4185 ratio high industrys negative average 1842 early march 2020 coronavirus pandemic result significant downward pressure demand business restrictionseven solar installation allow essential service location ability generate new sale hinder social distancing economic uncertainty united states residential installation start decline march intensify month aprilin united states management anticipate 30 50 drop residential installation aprilthis impact company secondquarter result extent covid19 outbreak impact global economy know remain cautious company growth,7,19,-0.4444444444444444,7,19,-0.4444444444444444,0.7579
121,"Enphase Energy, Inc._Attachment1(3).pdf",ENPH,12/4/2019,enphase revolutionized the solar industry by pioneering a semiconductorbased microinverter which converts energy at the individual solar module level combined with its proprietary networking and software technologies these microinverters provide advanced energy,buy,"['enphase', 'revolutionize', 'solar', 'industry', 'pioneer', 'semiconductorbase', 'microinverter', 'convert', 'energy', 'individual', 'solar', 'module', 'level', 'combine', 'proprietary', 'networking', 'software', 'technology', 'microinverter', 'provide', 'advanced', 'energy']",enphase revolutionize solar industry pioneer semiconductorbase microinverter convert energy individual solar module level combine proprietary networking software technology microinverter provide advanced energy,2,0,0.6666666666666666,2,0,0.6666666666666666,0.6369
122,"Enphase Energy, Inc._Attachment1.pdf",ENPH,11/26/2019,on sept 24 2018 the united states began assessing 10 tariffs on enphases microinverter products and related accessories that are manufactured in china these tariffs as per expectation might have increased to 25 since mar 1 2019 such tariffs may push up costs of enphases products in the united states thereby hurting its growth trajectory component shortages have been weighing on enphases financial performance lately notably such shortages in 2018 limited the,sell,"['sept', '24', '2018', 'united', 'states', 'begin', 'assess', '10', 'tariff', 'enphase', 'microinverter', 'product', 'relate', 'accessory', 'manufacture', 'china', 'tariff', 'expectation', 'increase', '25', 'mar', '1', '2019', 'tariff', 'push', 'cost', 'enphase', 'product', 'united', 'states', 'hurt', 'growth', 'trajectory', 'component', 'shortage', 'weigh', 'enphase', 'financial', 'performance', 'lately', 'notably', 'shortage', '2018', 'limit']",sept 24 2018 united states begin assess 10 tariff enphase microinverter product relate accessory manufacture china tariff expectation increase 25 mar 1 2019 tariff push cost enphase product united states hurt growth trajectory component shortage weigh enphase financial performance lately notably shortage 2018 limit,0,4,-0.8,0,4,-0.8,0.4767
123,Envestnet Inc_Attachment1.pdf,ENV,10/16/2020,envestnet never declared and currently does not have any plan to payout cash dividends on common stock so the only way to achieve return on investment on the companys stock is share price appreciation which is not guaranteed investors seeking cash,sell,"['envestnet', 'declare', 'currently', 'plan', 'payout', 'cash', 'dividend', 'common', 'stock', 'way', 'achieve', 'return', 'investment', 'company', 'stock', 'share', 'price', 'appreciation', 'guarantee', 'investor', 'seek', 'cash']",envestnet declare currently plan payout cash dividend common stock way achieve return investment company stock share price appreciation guarantee investor seek cash,1,2,-0.25,1,2,-0.25,0.7579
124,EPAM Systems Inc_Attachment1.pdf,EPAM,10/15/2020,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate,buy,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate,3,1,0.4,3,1,0.4,0.8271
125,"EPAM Systems, Inc._Attachment1(11).pdf",EPAM,2/5/2019,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 3915 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '3915', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 3915 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
126,"EPAM Systems, Inc._Attachment1(13).pdf",EPAM,2/13/2019,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 402 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '402', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 402 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
127,"EPAM Systems, Inc._Attachment1(15).pdf",EPAM,2/25/2019,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 3621 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '3621', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 3621 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
128,"EPAM Systems, Inc._Attachment1(2).pdf",EPAM,7/10/2018,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses most recently in march 2018 the company bought bostonbased design firm continuum the acquisition brings a massive talent pool of 150 persons and is expected to contribute approximately 30 million to epams 2018 total revenues these acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 374 trillion in 2018 representing a 62 increase from the 352 billion recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasa service cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloudcomputing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations cash and cash equivalents were 5359 million as of mar 31 2018 which translates to around 40 of the total assets it should be noted that the company has been able to regularly increase its cash and cash equivalents balance which reached 583 million at the end of 2017 from 118 million at the end of 2012 similarly epams cash from operations amounted to approximately 195 million in 2017 a significant increase from 48 million in 2012 the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,sell,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'recently', 'march', '2018', 'company', 'buy', 'bostonbased', 'design', 'firm', 'continuum', 'acquisition', 'bring', 'massive', 'talent', 'pool', '150', 'person', 'expect', 'contribute', 'approximately', '30', 'million', 'epams', '2018', 'total', 'revenue', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '374', 'trillion', '2018', 'represent', '62', 'increase', '352', 'billion', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasa', 'service', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloudcompute', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'cash', 'cash', 'equivalent', '5359', 'million', 'mar', '31', '2018', 'translate', '40', 'total', 'asset', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'reach', '583', 'million', 'end', '2017', '118', 'million', 'end', '2012', 'similarly', 'epam', 'cash', 'operation', 'amount', 'approximately', '195', 'million', '2017', 'significant', 'increase', '48', 'million', '2012', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business recently march 2018 company buy bostonbased design firm continuum acquisition bring massive talent pool 150 person expect contribute approximately 30 million epams 2018 total revenue acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 374 trillion 2018 represent 62 increase 352 billion record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasa service cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloudcompute vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation cash cash equivalent 5359 million mar 31 2018 translate 40 total asset note company able regularly increase cash cash equivalent balance reach 583 million end 2017 118 million end 2012 similarly epam cash operation amount approximately 195 million 2017 significant increase 48 million 2012 increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,24,-0.13953488372093023,18,24,-0.13953488372093023,0.9961
129,"EPAM Systems, Inc._Attachment1(2).pdf",EPAM,1/8/2019,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses most recently in march 2018 the company bought bostonbased design firm continuum the acquisition brings a massive talent pool of 150 persons and is expected to have contributed approximately 30 million to epams 2018 total revenues these acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 38 trillion in 2019 representing a 32 increase from the figure recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasaservice cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloud computing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations cash and cash equivalents were 6581 million as of sep 30 2018 it should be noted that the company has been able to regularly increase its cash and cash equivalents balance and cash from operations the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,buy,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'recently', 'march', '2018', 'company', 'buy', 'bostonbased', 'design', 'firm', 'continuum', 'acquisition', 'bring', 'massive', 'talent', 'pool', '150', 'person', 'expect', 'contribute', 'approximately', '30', 'million', 'epams', '2018', 'total', 'revenue', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '38', 'trillion', '2019', 'represent', '32', 'increase', 'figure', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasaservice', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloud', 'computing', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'cash', 'cash', 'equivalent', '6581', 'million', 'sep', '30', '2018', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'cash', 'operation', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business recently march 2018 company buy bostonbased design firm continuum acquisition bring massive talent pool 150 person expect contribute approximately 30 million epams 2018 total revenue acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 38 trillion 2019 represent 32 increase figure record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasaservice cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloud computing vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation cash cash equivalent 6581 million sep 30 2018 note company able regularly increase cash cash equivalent balance cash operation increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,21,-0.075,18,21,-0.075,0.9954
130,"EPAM Systems, Inc._Attachment1(2).pdf",EPAM,1/8/2019,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 3343 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '3343', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 3343 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
131,"EPAM Systems, Inc._Attachment1(2).pdf",EPAM,5/15/2019,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 38 trillion in 2019 representing a 32 increase from the figure recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasaservice cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloud computing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations cash and cash equivalents were 7625 million as of the last reported quarter it should be noted that the company has been able to regularly increase its cash and cash equivalents balance and cash from operations the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,buy,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '38', 'trillion', '2019', 'represent', '32', 'increase', 'figure', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasaservice', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloud', 'computing', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'cash', 'cash', 'equivalent', '7625', 'million', 'reported', 'quarter', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'cash', 'operation', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 38 trillion 2019 represent 32 increase figure record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasaservice cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloud computing vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation cash cash equivalent 7625 million reported quarter note company able regularly increase cash cash equivalent balance cash operation increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,21,-0.075,18,21,-0.075,0.9949
132,"EPAM Systems, Inc._Attachment1(2).pdf",EPAM,5/15/2019,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 402 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective zacks equity research epam wwwzackscom page 4 of 9,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '402', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective', 'zack', 'equity', 'research', 'epam', 'wwwzackscom', 'page', '4', '9']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 402 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective zack equity research epam wwwzackscom page 4 9,2,16,-0.7368421052631579,2,16,-0.7368421052631579,-0.296
133,"EPAM Systems, Inc._Attachment1(3).pdf",EPAM,7/31/2018,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses most recently in march 2018 the company bought bostonbased design firm continuum the acquisition brings a massive talent pool of 150 persons and is expected to contribute approximately 30 million to epams 2018 total revenues these acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 374 trillion in 2018 representing a 62 increase from the 352 billion recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasa service cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloudcomputing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations it should be noted that the company has been able to regularly increase its cash and cash equivalents balance which reached 583 million at the end of 2017 from 118 million at the end of 2012 similarly epams cash from operations amounted to approximately 195 million in 2017 a significant increase from 48 million in 2012 the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,buy,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'recently', 'march', '2018', 'company', 'buy', 'bostonbased', 'design', 'firm', 'continuum', 'acquisition', 'bring', 'massive', 'talent', 'pool', '150', 'person', 'expect', 'contribute', 'approximately', '30', 'million', 'epams', '2018', 'total', 'revenue', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '374', 'trillion', '2018', 'represent', '62', 'increase', '352', 'billion', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasa', 'service', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloudcompute', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'reach', '583', 'million', 'end', '2017', '118', 'million', 'end', '2012', 'similarly', 'epam', 'cash', 'operation', 'amount', 'approximately', '195', 'million', '2017', 'significant', 'increase', '48', 'million', '2012', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business recently march 2018 company buy bostonbased design firm continuum acquisition bring massive talent pool 150 person expect contribute approximately 30 million epams 2018 total revenue acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 374 trillion 2018 represent 62 increase 352 billion record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasa service cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloudcompute vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation note company able regularly increase cash cash equivalent balance reach 583 million end 2017 118 million end 2012 similarly epam cash operation amount approximately 195 million 2017 significant increase 48 million 2012 increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,24,-0.13953488372093023,18,24,-0.13953488372093023,0.9958
134,"EPAM Systems, Inc._Attachment1(3).pdf",EPAM,11/8/2018,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses most recently in march 2018 the company bought bostonbased design firm continuum the acquisition brings a massive talent pool of 150 persons and is expected to contribute approximately 30 million to epams 2018 total revenues these acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 374 trillion in 2018 representing a 62 increase from the 352 billion recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasaservice cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloud computing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations cash and cash equivalents were 6581 million as of sep 30 2018 it should be noted that the company has been able to regularly increase its cash and cash equivalents balance and cash from operations the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,buy,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'recently', 'march', '2018', 'company', 'buy', 'bostonbased', 'design', 'firm', 'continuum', 'acquisition', 'bring', 'massive', 'talent', 'pool', '150', 'person', 'expect', 'contribute', 'approximately', '30', 'million', 'epams', '2018', 'total', 'revenue', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '374', 'trillion', '2018', 'represent', '62', 'increase', '352', 'billion', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasaservice', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloud', 'computing', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'cash', 'cash', 'equivalent', '6581', 'million', 'sep', '30', '2018', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'cash', 'operation', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business recently march 2018 company buy bostonbased design firm continuum acquisition bring massive talent pool 150 person expect contribute approximately 30 million epams 2018 total revenue acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 374 trillion 2018 represent 62 increase 352 billion record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasaservice cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloud computing vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation cash cash equivalent 6581 million sep 30 2018 note company able regularly increase cash cash equivalent balance cash operation increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,21,-0.075,18,21,-0.075,0.9954
135,"EPAM Systems, Inc._Attachment1(3).pdf",EPAM,11/8/2018,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 3502 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '3502', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 3502 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
136,"EPAM Systems, Inc._Attachment1(4).pdf",EPAM,8/8/2018,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses most recently in march 2018 the company bought bostonbased design firm continuum the acquisition brings a massive talent pool of 150 persons and is expected to contribute approximately 30 million to epams 2018 total revenues these acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 374 trillion in 2018 representing a 62 increase from the 352 billion recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasa service cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloudcomputing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations cash and cash equivalents were 5841 million as of jun 30 2018 it should be noted that the company has been able to regularly increase its cash and cash equivalents balance and cash from operations the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,sell,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'recently', 'march', '2018', 'company', 'buy', 'bostonbased', 'design', 'firm', 'continuum', 'acquisition', 'bring', 'massive', 'talent', 'pool', '150', 'person', 'expect', 'contribute', 'approximately', '30', 'million', 'epams', '2018', 'total', 'revenue', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '374', 'trillion', '2018', 'represent', '62', 'increase', '352', 'billion', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasa', 'service', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloudcompute', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'cash', 'cash', 'equivalent', '5841', 'million', 'jun', '30', '2018', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'cash', 'operation', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business recently march 2018 company buy bostonbased design firm continuum acquisition bring massive talent pool 150 person expect contribute approximately 30 million epams 2018 total revenue acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 374 trillion 2018 represent 62 increase 352 billion record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasa service cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloudcompute vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation cash cash equivalent 5841 million jun 30 2018 note company able regularly increase cash cash equivalent balance cash operation increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,21,-0.075,18,21,-0.075,0.9954
137,"EPAM Systems, Inc._Attachment1(6).pdf",EPAM,1/23/2019,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 3611 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '3611', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 3611 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
138,"EPAM Systems, Inc._Attachment1(7).pdf",EPAM,1/25/2019,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 3682 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '3682', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 3682 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
139,"EPAM Systems, Inc._Attachment1(9).pdf",EPAM,1/29/2019,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 3776 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '3776', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 3776 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
140,"EPAM Systems, Inc._Attachment1.pdf",EPAM,6/14/2018,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses most recently in march 2018 the company bought bostonbased design firm continuum the acquisition brings a massive talent pool of 150 persons and is expected to contribute approximately 30 million to epams 2018 total revenues these acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 374 trillion in 2018 representing a 62 increase from the 352 billion recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasa service cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloudcomputing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations cash and cash equivalents were 5359 million as of mar 31 2018 which translates to around 40 of the total assets it should be noted that the company has been able to regularly increase its cash and cash equivalents balance which reached 583 million at the end of 2017 from 118 million at the end of 2012 similarly epams cash from operations amounted to approximately 195 million in 2017 a significant increase from 48 million in 2012 the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,buy,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'recently', 'march', '2018', 'company', 'buy', 'bostonbased', 'design', 'firm', 'continuum', 'acquisition', 'bring', 'massive', 'talent', 'pool', '150', 'person', 'expect', 'contribute', 'approximately', '30', 'million', 'epams', '2018', 'total', 'revenue', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '374', 'trillion', '2018', 'represent', '62', 'increase', '352', 'billion', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasa', 'service', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloudcompute', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'cash', 'cash', 'equivalent', '5359', 'million', 'mar', '31', '2018', 'translate', '40', 'total', 'asset', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'reach', '583', 'million', 'end', '2017', '118', 'million', 'end', '2012', 'similarly', 'epam', 'cash', 'operation', 'amount', 'approximately', '195', 'million', '2017', 'significant', 'increase', '48', 'million', '2012', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business recently march 2018 company buy bostonbased design firm continuum acquisition bring massive talent pool 150 person expect contribute approximately 30 million epams 2018 total revenue acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 374 trillion 2018 represent 62 increase 352 billion record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasa service cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloudcompute vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation cash cash equivalent 5359 million mar 31 2018 translate 40 total asset note company able regularly increase cash cash equivalent balance reach 583 million end 2017 118 million end 2012 similarly epam cash operation amount approximately 195 million 2017 significant increase 48 million 2012 increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,24,-0.13953488372093023,18,24,-0.13953488372093023,0.9961
141,"EPAM Systems, Inc._Attachment1.pdf",EPAM,9/11/2018,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses most recently in march 2018 the company bought bostonbased design firm continuum the acquisition brings a massive talent pool of 150 persons and is expected to contribute approximately 30 million to epams 2018 total revenues these acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 374 trillion in 2018 representing a 62 increase from the 352 billion recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasa service cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloudcomputing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations cash and cash equivalents were 5841 million as of jun 30 2018 it should be noted that the company has been able to regularly increase its cash and cash equivalents balance and cash from operations the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,buy,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'recently', 'march', '2018', 'company', 'buy', 'bostonbased', 'design', 'firm', 'continuum', 'acquisition', 'bring', 'massive', 'talent', 'pool', '150', 'person', 'expect', 'contribute', 'approximately', '30', 'million', 'epams', '2018', 'total', 'revenue', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '374', 'trillion', '2018', 'represent', '62', 'increase', '352', 'billion', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasa', 'service', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloudcompute', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'cash', 'cash', 'equivalent', '5841', 'million', 'jun', '30', '2018', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'cash', 'operation', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business recently march 2018 company buy bostonbased design firm continuum acquisition bring massive talent pool 150 person expect contribute approximately 30 million epams 2018 total revenue acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 374 trillion 2018 represent 62 increase 352 billion record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasa service cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloudcompute vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation cash cash equivalent 5841 million jun 30 2018 note company able regularly increase cash cash equivalent balance cash operation increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,21,-0.075,18,21,-0.075,0.9954
142,"EPAM Systems, Inc._Attachment1.pdf",EPAM,12/10/2018,as epams majority of its delivery centers are located in central and eastern europe the companys prospects are currently prone to a massive geopolitical risk due to the ongoing conflict between russia and ukraine notably the companys largest delivery centers are located in belarus russia and ukraine any escalation in the ongoing conflict is likely to disrupt the companys overall business operations and therefore hurt its revenues and profitability epams market share and revenues necessarily depend on client relationships and the number of contracts it secures this along with the limited scope for product differentiation makes renegotiation of large contracts extremely important as a result competition from companies like accenture and infosys is a constant pressure competition is particularly tough in the case of resurgent regions like europe since all the major players are fighting for business this naturally also increases pricing pressures we note that the stock currently has a trailing 12 month pe ratio of 3329 this compares unfavorably to some extent with what the industry witnessed during the same time frame hence valuation looks slightly stretched from a pe perspective,sell,"['epams', 'majority', 'delivery', 'center', 'locate', 'central', 'eastern', 'europe', 'company', 'prospect', 'currently', 'prone', 'massive', 'geopolitical', 'risk', 'ongoing', 'conflict', 'russia', 'ukraine', 'notably', 'company', 'large', 'delivery', 'center', 'locate', 'belarus', 'russia', 'ukraine', 'escalation', 'ongoing', 'conflict', 'likely', 'disrupt', 'company', 'overall', 'business', 'operation', 'hurt', 'revenue', 'profitability', 'epam', 'market', 'share', 'revenue', 'necessarily', 'depend', 'client', 'relationship', 'number', 'contract', 'secure', 'limited', 'scope', 'product', 'differentiation', 'make', 'renegotiation', 'large', 'contract', 'extremely', 'important', 'result', 'competition', 'company', 'like', 'accenture', 'infosy', 'constant', 'pressure', 'competition', 'particularly', 'tough', 'case', 'resurgent', 'region', 'like', 'europe', 'major', 'player', 'fight', 'business', 'naturally', 'increase', 'pricing', 'pressure', 'note', 'stock', 'currently', 'trail', '12', 'month', 'pe', 'ratio', '3329', 'compare', 'unfavorably', 'extent', 'industry', 'witness', 'time', 'frame', 'valuation', 'look', 'slightly', 'stretch', 'pe', 'perspective']",epams majority delivery center locate central eastern europe company prospect currently prone massive geopolitical risk ongoing conflict russia ukraine notably company large delivery center locate belarus russia ukraine escalation ongoing conflict likely disrupt company overall business operation hurt revenue profitability epam market share revenue necessarily depend client relationship number contract secure limited scope product differentiation make renegotiation large contract extremely important result competition company like accenture infosy constant pressure competition particularly tough case resurgent region like europe major player fight business naturally increase pricing pressure note stock currently trail 12 month pe ratio 3329 compare unfavorably extent industry witness time frame valuation look slightly stretch pe perspective,2,15,-0.7222222222222222,2,15,-0.7222222222222222,-0.296
143,"EPAM Systems, Inc._Attachment1.pdf",EPAM,2/26/2019,epam mainly serves to the fastest growing areas of it services which include mobile applications and their testing cognitive computing software development and advanced analytics the benefits of operating in these key it services areas can better be understood with the fact that epams revenues have witnessed a compounded annual growth rate cagr of more than 25 over the last six years the demand for these key areas are likely to continue for the next several years as more and more organizations are trying to take advantage of cloud computing and data analytics in order to make greater use of their it infrastructure with its worldclass capabilities in empowering digital technologies epam is well positioned to grab the growing opportunities in the aforementioned it services space acquisitions have been one of the key growth strategies for epam since its stock exchange listing the company has acquired 10 businesses acquisitions have enabled epam to enter new markets diversify and broaden its product portfolio moving ahead such acquisitions are expected to contribute significantly to the companys revenue stream the company expects inorganic revenues mainly th_nk and continuum acquisitions to contribute 1 to fullyear revenue the latest forecast for worldwide it spending by gartner provides optimism to epams growth prospects the research firm expects worldwide it spending will reach 38 trillion in 2019 representing a 32 increase from the figure recorded last year per gartner there are 10 markets driving digital transformation thereby boosting overall it spending these include three cloud segments infrastructureasaservice iaas integrated platformasa service ipaas and communications platformasaservice cpaas range from technologies that enhance the digital workplace such as workstream collaboration workforce analytics and video messageoriented middleware mom to security endpoint detection and response analytics smart data discovery and storage inmemory data grids all are tied to enabling and enhancing an enterprises digital transformation efforts all these encourage us about the companys nearterm prospects epams strategy of enhancing its cloud capabilities through acquisitions and partnerships with the likes of amazon web services and google cloud is a step in the right direction as evident from the recent forecast provided by several independent research firms the research firm gartner predicts that the public cloud services market will witness a compounded annual growth rate cagr of 184 during the 20182021 period reaching 30254 billion by 2021 end exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals compelled several companies to turn to cloud computing vendors therefore considering the rising need for cloudbased applications and software we expect epams investments in this space to propel longterm growth epam has a strong balance sheet with ample liquidity position and meagre debt obligations cash and cash equivalents were 7706 million as of the last reported quarter it should be noted that the company has been able to regularly increase its cash and cash equivalents balance and cash from operations the increasing liquidity and cash flow trend reflect that the company is making investments in the right direction moreover since it carries just 25 million of longterm debt the cash is available for pursuing strategic acquisitions and investment in growth initiatives,buy,"['epam', 'mainly', 'serve', 'fast', 'grow', 'area', 'service', 'include', 'mobile', 'application', 'testing', 'cognitive', 'computing', 'software', 'development', 'advanced', 'analytic', 'benefit', 'operate', 'key', 'service', 'area', 'well', 'understand', 'fact', 'epam', 'revenue', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '25', 'year', 'demand', 'key', 'area', 'likely', 'continue', 'year', 'organization', 'try', 'advantage', 'cloud', 'computing', 'data', 'analytic', 'order', 'great', 'use', 'infrastructure', 'worldclass', 'capability', 'empower', 'digital', 'technology', 'epam', 'positioned', 'grab', 'grow', 'opportunity', 'aforementioned', 'service', 'space', 'acquisition', 'key', 'growth', 'strategy', 'epam', 'stock', 'exchange', 'list', 'company', 'acquire', '10', 'business', 'acquisition', 'enable', 'epam', 'enter', 'new', 'market', 'diversify', 'broaden', 'product', 'portfolio', 'move', 'ahead', 'acquisition', 'expect', 'contribute', 'significantly', 'company', 'revenue', 'stream', 'company', 'expect', 'inorganic', 'revenue', 'mainly', 'th_nk', 'continuum', 'acquisition', 'contribute', '1', 'fullyear', 'revenue', 'late', 'forecast', 'worldwide', 'spend', 'gartner', 'provide', 'optimism', 'epams', 'growth', 'prospect', 'research', 'firm', 'expect', 'worldwide', 'spending', 'reach', '38', 'trillion', '2019', 'represent', '32', 'increase', 'figure', 'record', 'year', 'gartner', '10', 'market', 'drive', 'digital', 'transformation', 'boost', 'overall', 'spend', 'include', 'cloud', 'segment', 'infrastructureasaservice', 'iaas', 'integrate', 'platformasa', 'service', 'ipaas', 'communication', 'platformasaservice', 'cpaas', 'range', 'technology', 'enhance', 'digital', 'workplace', 'workstream', 'collaboration', 'workforce', 'analytic', 'video', 'messageoriente', 'middleware', 'mom', 'security', 'endpoint', 'detection', 'response', 'analytic', 'smart', 'data', 'discovery', 'storage', 'inmemory', 'datum', 'grid', 'tie', 'enable', 'enhance', 'enterprise', 'digital', 'transformation', 'effort', 'encourage', 'company', 'nearterm', 'prospect', 'epam', 'strategy', 'enhance', 'cloud', 'capability', 'acquisition', 'partnership', 'like', 'amazon', 'web', 'service', 'google', 'cloud', 'step', 'right', 'direction', 'evident', 'recent', 'forecast', 'provide', 'independent', 'research', 'firm', 'research', 'firm', 'gartner', 'predict', 'public', 'cloud', 'service', 'market', 'witness', 'compound', 'annual', 'growth', 'rate', 'cagr', '184', '20182021', 'period', 'reach', '30254', 'billion', '2021', 'end', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'compel', 'company', 'turn', 'cloud', 'computing', 'vendor', 'consider', 'rise', 'need', 'cloudbase', 'application', 'software', 'expect', 'epam', 'investment', 'space', 'propel', 'longterm', 'growth', 'epam', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'meagre', 'debt', 'obligation', 'cash', 'cash', 'equivalent', '7706', 'million', 'reported', 'quarter', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'cash', 'equivalent', 'balance', 'cash', 'operation', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'reflect', 'company', 'make', 'investment', 'right', 'direction', 'carry', '25', 'million', 'longterm', 'debt', 'cash', 'available', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative']",epam mainly serve fast grow area service include mobile application testing cognitive computing software development advanced analytic benefit operate key service area well understand fact epam revenue witness compound annual growth rate cagr 25 year demand key area likely continue year organization try advantage cloud computing data analytic order great use infrastructure worldclass capability empower digital technology epam positioned grab grow opportunity aforementioned service space acquisition key growth strategy epam stock exchange list company acquire 10 business acquisition enable epam enter new market diversify broaden product portfolio move ahead acquisition expect contribute significantly company revenue stream company expect inorganic revenue mainly th_nk continuum acquisition contribute 1 fullyear revenue late forecast worldwide spend gartner provide optimism epams growth prospect research firm expect worldwide spending reach 38 trillion 2019 represent 32 increase figure record year gartner 10 market drive digital transformation boost overall spend include cloud segment infrastructureasaservice iaas integrate platformasa service ipaas communication platformasaservice cpaas range technology enhance digital workplace workstream collaboration workforce analytic video messageoriente middleware mom security endpoint detection response analytic smart data discovery storage inmemory datum grid tie enable enhance enterprise digital transformation effort encourage company nearterm prospect epam strategy enhance cloud capability acquisition partnership like amazon web service google cloud step right direction evident recent forecast provide independent research firm research firm gartner predict public cloud service market witness compound annual growth rate cagr 184 20182021 period reach 30254 billion 2021 end exponential growth datum complexity datum format need scale resource regular interval compel company turn cloud computing vendor consider rise need cloudbase application software expect epam investment space propel longterm growth epam strong balance sheet ample liquidity position meagre debt obligation cash cash equivalent 7706 million reported quarter note company able regularly increase cash cash equivalent balance cash operation increase liquidity cash flow trend reflect company make investment right direction carry 25 million longterm debt cash available pursue strategic acquisition investment growth initiative,18,21,-0.075,18,21,-0.075,0.9949
144,EverQuote Inc_Attachment1(2).pdf,EVER,10/15/2020,share performance shares of everquote have gained 1148 against its industry decline of 199 in a years time the companys operational efficiencie and solid capital position,buy,"['share', 'performance', 'share', 'everquote', 'gain', '1148', 'industry', 'decline', '199', 'year', 'time', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position']",share performance share everquote gain 1148 industry decline 199 year time company operational efficiencie solid capital position,1,2,-0.25,1,2,-0.25,0.8126
145,EverQuote Inc_Attachment1(3).pdf,EVER,10/16/2020,share performance shares of everquote have gained 92 against its industry decline of 257 year to date the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '92', 'industry', 'decline', '257', 'year', 'date', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 92 industry decline 257 year date company operational efficiencie solid capital position continue drive share,1,3,-0.4,1,3,-0.4,0.8625
146,EverQuote Inc_Attachment1(4).pdf,EVER,11/9/2020,share performance shares of everquote have gained 158 against its industry decline of 218 year to date the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '158', 'industry', 'decline', '218', 'year', 'date', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 158 industry decline 218 year date company operational efficiencie solid capital position continue drive share,1,3,-0.4,1,3,-0.4,0.8625
147,EverQuote Inc_Attachment1.pdf,EVER,9/28/2020,share performance shares of everquote have gained 894 against its industry decline of 255 in a years time the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '894', 'industry', 'decline', '255', 'year', 'time', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 894 industry decline 255 year time company operational efficiencie solid capital position continue drive share,1,2,-0.25,1,2,-0.25,0.8625
148,EverQuote Inc_Attachment1.pdf,EVER,10/13/2020,share performance shares of everquote have gained 987 against its industry decline of 162 in a years time the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '987', 'industry', 'decline', '162', 'year', 'time', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 987 industry decline 162 year time company operational efficiencie solid capital position continue drive share,1,2,-0.25,1,2,-0.25,0.8625
149,"EverQuote, Inc._Attachment1(2).pdf",EVER,12/8/2020,share performance shares of everquote have gained 61 against its industry decline of 73 in the past year the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '61', 'industry', 'decline', '73', 'past', 'year', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 61 industry decline 73 past year company operational efficiencie solid capital position continue drive share,1,2,-0.25,1,2,-0.25,0.8625
150,"EverQuote, Inc._Attachment1(2).pdf",EVER,12/21/2020,share performance shares of everquote have gained 95 against its industry decline of 114 in the past year the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '95', 'industry', 'decline', '114', 'past', 'year', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 95 industry decline 114 past year company operational efficiencie solid capital position continue drive share,1,2,-0.25,1,2,-0.25,0.8625
151,"EverQuote, Inc._Attachment1(3).pdf",EVER,12/24/2020,share performance shares of everquote have gained 9128 against its industry decline of 101 in the past year the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '9128', 'industry', 'decline', '101', 'past', 'year', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 9128 industry decline 101 past year company operational efficiencie solid capital position continue drive share,1,2,-0.25,1,2,-0.25,0.8625
152,"EverQuote, Inc._Attachment1(4).pdf",EVER,12/29/2020,share performance shares of everquote have gained 104 against its industry decline of 102 in the past year the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '104', 'industry', 'decline', '102', 'past', 'year', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 104 industry decline 102 past year company operational efficiencie solid capital position continue drive share,1,2,-0.25,1,2,-0.25,0.8625
153,"EverQuote, Inc._Attachment1.pdf",EVER,12/1/2020,share performance shares of everquote have gained 08 against its industry decline of 114 in the past year the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '08', 'industry', 'decline', '114', 'past', 'year', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 08 industry decline 114 past year company operational efficiencie solid capital position continue drive share,1,2,-0.25,1,2,-0.25,0.8625
154,"EverQuote, Inc._Attachment1.pdf",EVER,12/16/2020,share performance shares of everquote have gained 45 against its industry decline of 117 in the past year the companys operational efficiencie and solid capital position will continue to drive shares,buy,"['share', 'performance', 'share', 'everquote', 'gain', '45', 'industry', 'decline', '117', 'past', 'year', 'company', 'operational', 'efficiencie', 'solid', 'capital', 'position', 'continue', 'drive', 'share']",share performance share everquote gain 45 industry decline 117 past year company operational efficiencie solid capital position continue drive share,1,2,-0.25,1,2,-0.25,0.8625
155,Facebook Inc_Attachment1.pdf,FB,10/22/2020,facebook continues to witness significant traction in online and mobile advertising spending the company intends to capture the opportunity presented by everincreasing video viewing on social media platforms online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and textbased substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal,buy,"['facebook', 'continue', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spend', 'company', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'textbase', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal']",facebook continue witness significant traction online mobile advertising spend company intend capture opportunity present everincrease video viewing social medium platform online video lucrative component digital advertising video ad generate revenue photo textbase substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal,6,2,0.4444444444444444,6,2,0.4444444444444444,0.765
156,"Facebook, Inc._Attachment1(2).pdf",FB,6/12/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the first quarter of 2017 ad revenues grew 51 year over year to 79 billion while mobile ad revenues were up 58 to 67 billion most importantly average price per ad increased 14 from the yearago quarter moreover ad impressions grew 32 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile moreover facebook is exploring ways to enhance video content ecosystem it has been investing in original content and said that it will keep doing the same this year as well last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more video oriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market over the past one year shares of facebook have grown 3120 compared with the zacks internet services industrys gain of 2285 however ceo mark zuckerberg said that in order to curb the menace of posting of violent videos on facebook live the company is now appointing over 3k people to its community operations team to better handle the review process after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram but facebook had earlier said the platform had over 500000 advertisers the company is now revamping its feed so that stories that users care about are displayed first thereby improving experience it has expanded dynamic ads to instagram while adding features like live and boomerang to stories instagram boasts over 600 million maus and over 400 million daus to bring more advertisers facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram facebook also added that its latest feature stories on instagram has 200 million daily actives in jan 2017 facebook said it will insert ads in stories notably facebook was subjected to severe ridicule when it acquired the snazzy photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions chatbots is the new buzz word in the tech space chatbots could serve as a powerful strategy to monetize the platform the whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 12 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to a recent idc report global revenues of the arvr market will grow to a whopping 1433 billion by 2020 while that for ai would be close to 46 billionrecently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus few days back facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 323 billion and recorded robust cash flow from operations of over 51 billion in the first quarter of 2017 free cash flow amounted to nearly 38 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement but as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at super fast speed along with aquila a solar powered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'quarter', '2017', 'ad', 'revenue', 'grow', '51', 'year', 'year', '79', 'billion', 'mobile', 'ad', 'revenue', '58', '67', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '14', 'yearago', 'quarter', 'ad', 'impression', 'grow', '32', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'facebook', 'explore', 'way', 'enhance', 'video', 'content', 'ecosystem', 'invest', 'original', 'content', 'say', 'year', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'video', 'orient', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'past', 'year', 'share', 'facebook', 'grow', '3120', 'compare', 'zack', 'internet', 'service', 'industry', 'gain', '2285', 'ceo', 'mark', 'zuckerberg', 'say', 'order', 'curb', 'menace', 'posting', 'violent', 'video', 'facebook', 'live', 'company', 'appoint', '3k', 'people', 'community', 'operation', 'team', 'well', 'handle', 'review', 'process', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'facebook', 'early', 'say', 'platform', '500000', 'advertiser', 'company', 'revamp', 'feed', 'story', 'user', 'care', 'display', 'improve', 'experience', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'instagram', 'boast', '600', 'million', 'maus', '400', 'million', 'daus', 'bring', 'advertiser', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'facebook', 'add', 'late', 'feature', 'story', 'instagram', '200', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'facebook', 'subject', 'severe', 'ridicule', 'acquire', 'snazzy', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'chatbot', 'new', 'buzz', 'word', 'tech', 'space', 'chatbot', 'serve', 'powerful', 'strategy', 'monetize', 'platform', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '12', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'grow', 'whopping', '1433', 'billion', '2020', 'ai', 'close', '46', 'billionrecently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'day', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '323', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '51', 'billion', 'quarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '38', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'super', 'fast', 'speed', 'aquila', 'solar', 'powered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work']",facebook witness significant traction online mobile advertising spending short span time quarter 2017 ad revenue grow 51 year year 79 billion mobile ad revenue 58 67 billion importantly average price ad increase 14 yearago quarter ad impression grow 32 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile facebook explore way enhance video content ecosystem invest original content say year year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate video orient content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market past year share facebook grow 3120 compare zack internet service industry gain 2285 ceo mark zuckerberg say order curb menace posting violent video facebook live company appoint 3k people community operation team well handle review process open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram facebook early say platform 500000 advertiser company revamp feed story user care display improve experience expand dynamic ad instagram add feature like live boomerang story instagram boast 600 million maus 400 million daus bring advertiser facebook say unveil new tool promote post evaluate business performance directly instagram facebook add late feature story instagram 200 million daily active jan 2017 facebook say insert ad story notably facebook subject severe ridicule acquire snazzy photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction chatbot new buzz word tech space chatbot serve powerful strategy monetize platform whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 12 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market grow whopping 1433 billion 2020 ai close 46 billionrecently facebook split oculus separate unit division focus develop vr mobile focus vr pc company rope hugo barra spearhead vr effort head oculus plus day facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 323 billion record robust cash flow operation 51 billion quarter 2017 free cash flow amount nearly 38 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum super fast speed aquila solar powered aircraft beam internet sky f8 2017 conference facebook announce work,40,49,-0.1,40,49,-0.1,0.9989
157,"Facebook, Inc._Attachment1(2).pdf",FB,6/26/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier the company had mentioned that video was emerging as a megatrend on the same lines like mobile online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers although no exact numbers with regard to contribution from instagram are shared the growing adoption among advertisers is highly prominent to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 300 million daily actives the company is now working on adding video chat ar camera effects and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4396 billion and recorded robust cash flow from operations of over 786 billion in the firstquarter of 2018 free cash flow amounted to nearly 505 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical cross link technology we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential the number of mobile internet users in the country which has nearly 14 billion people was 456 million in december 2017 per iamai report given the availability of cheaper smartphones faster connectivity and affordable services the figure is estimated to reach 478 million by june 2018 this bodes well for facebook as most developed markets have reached maturity with china off the radar india can prove to be a terrific growth engine a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones will boost facebooks prospects in the country,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'company', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'exact', 'number', 'regard', 'contribution', 'instagram', 'share', 'grow', 'adoption', 'advertiser', 'highly', 'prominent', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '300', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'ar', 'camera', 'effect', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4396', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '786', 'billion', 'firstquarter', '2018', 'free', 'cash', 'flow', 'amount', 'nearly', '505', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'cross', 'link', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'number', 'mobile', 'internet', 'user', 'country', 'nearly', '14', 'billion', 'people', '456', 'million', 'december', '2017', 'iamai', 'report', 'give', 'availability', 'cheap', 'smartphone', 'fast', 'connectivity', 'affordable', 'service', 'figure', 'estimate', 'reach', '478', 'million', 'june', '2018', 'bode', 'facebook', 'develop', 'market', 'reach', 'maturity', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'boost', 'facebook', 'prospect', 'country']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform early company mention video emerge megatrend line like mobile online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser exact number regard contribution instagram share grow adoption advertiser highly prominent bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 300 million daily active company work add video chat ar camera effect new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4396 billion record robust cash flow operation 786 billion firstquarter 2018 free cash flow amount nearly 505 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical cross link technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential number mobile internet user country nearly 14 billion people 456 million december 2017 iamai report give availability cheap smartphone fast connectivity affordable service figure estimate reach 478 million june 2018 bode facebook develop market reach maturity china radar india prove terrific growth engine burgeon welleducate middle class increase spending power rapid adoption smartphone boost facebook prospect country,35,35,0.0,35,35,0.0,0.9988
158,"Facebook, Inc._Attachment1(2).pdf",FB,5/30/2019,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time mobile ad revenues are growing rapidly primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'mobile', 'ad', 'revenue', 'grow', 'rapidly', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift']",facebook witness significant traction online mobile advertising spending short span time mobile ad revenue grow rapidly primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift,4,5,-0.1,4,5,-0.1,0.7783
159,"Facebook, Inc._Attachment1(3).pdf",FB,7/14/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the first quarter of 2017 ad revenues grew 51 year over year to 79 billion while mobile ad revenues were up 58 to 67 billion most importantly average price per ad increased 14 from the yearago quarter moreover ad impressions grew 32 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile moreover facebook is exploring ways to enhance video content ecosystem it has been investing in original content and said that it will keep doing the same this year as well last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more video oriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market over the past one year shares of facebook have grown 358 compared with the zacks internet services industrys gain of 226 however ceo mark zuckerberg said that in order to curb the menace of posting of violent videos on facebook live the company is now appointing over 3k people to its community operations team to better handle the review process after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram but facebook had earlier said the platform had over 500000 advertisers the company is now revamping its feed so that stories that users care about are displayed first thereby improving experience it has expanded dynamic ads to instagram while adding features like live and boomerang to stories instagram boasts over 600 million maus and over 400 million daus to bring more advertisers facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram facebook also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably facebook was subjected to severe ridicule when it acquired the snazzy photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions chatbots is the new buzz word in the tech space chatbots could serve as a powerful strategy to monetize the platform the whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 12 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to a recent idc report global revenues of the arvr market will grow to a whopping 1433 billion by 2020 while that for ai would be close to 46 billionrecently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus few days back facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 323 billion and recorded robust cash flow from operations of over 51 billion in the first quarter of 2017 free cash flow amounted to nearly 38 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement but as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at super fast speed along with aquila a solar powered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'quarter', '2017', 'ad', 'revenue', 'grow', '51', 'year', 'year', '79', 'billion', 'mobile', 'ad', 'revenue', '58', '67', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '14', 'yearago', 'quarter', 'ad', 'impression', 'grow', '32', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'facebook', 'explore', 'way', 'enhance', 'video', 'content', 'ecosystem', 'invest', 'original', 'content', 'say', 'year', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'video', 'orient', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'past', 'year', 'share', 'facebook', 'grow', '358', 'compare', 'zack', 'internet', 'service', 'industry', 'gain', '226', 'ceo', 'mark', 'zuckerberg', 'say', 'order', 'curb', 'menace', 'posting', 'violent', 'video', 'facebook', 'live', 'company', 'appoint', '3k', 'people', 'community', 'operation', 'team', 'well', 'handle', 'review', 'process', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'facebook', 'early', 'say', 'platform', '500000', 'advertiser', 'company', 'revamp', 'feed', 'story', 'user', 'care', 'display', 'improve', 'experience', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'instagram', 'boast', '600', 'million', 'maus', '400', 'million', 'daus', 'bring', 'advertiser', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'facebook', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'facebook', 'subject', 'severe', 'ridicule', 'acquire', 'snazzy', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'chatbot', 'new', 'buzz', 'word', 'tech', 'space', 'chatbot', 'serve', 'powerful', 'strategy', 'monetize', 'platform', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '12', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'grow', 'whopping', '1433', 'billion', '2020', 'ai', 'close', '46', 'billionrecently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'day', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '323', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '51', 'billion', 'quarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '38', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'super', 'fast', 'speed', 'aquila', 'solar', 'powered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work']",facebook witness significant traction online mobile advertising spending short span time quarter 2017 ad revenue grow 51 year year 79 billion mobile ad revenue 58 67 billion importantly average price ad increase 14 yearago quarter ad impression grow 32 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile facebook explore way enhance video content ecosystem invest original content say year year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate video orient content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market past year share facebook grow 358 compare zack internet service industry gain 226 ceo mark zuckerberg say order curb menace posting violent video facebook live company appoint 3k people community operation team well handle review process open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram facebook early say platform 500000 advertiser company revamp feed story user care display improve experience expand dynamic ad instagram add feature like live boomerang story instagram boast 600 million maus 400 million daus bring advertiser facebook say unveil new tool promote post evaluate business performance directly instagram facebook add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably facebook subject severe ridicule acquire snazzy photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction chatbot new buzz word tech space chatbot serve powerful strategy monetize platform whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 12 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market grow whopping 1433 billion 2020 ai close 46 billionrecently facebook split oculus separate unit division focus develop vr mobile focus vr pc company rope hugo barra spearhead vr effort head oculus plus day facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 323 billion record robust cash flow operation 51 billion quarter 2017 free cash flow amount nearly 38 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum super fast speed aquila solar powered aircraft beam internet sky f8 2017 conference facebook announce work,40,49,-0.1,40,49,-0.1,0.9989
160,"Facebook, Inc._Attachment1(3).pdf",FB,3/9/2018,facebook maintains a cautious stance on revenue growth the last reported quarter was no different since the past few quarters the company has maintained that ad revenues will continue to grow but will now face tougher yearoveryear comparisons ad load which so far has been a leading factor driving ad revenues will now cease to be so in the coming quarters and wont be a big factor post 2017 moreover as the company continues to ramp up investments video arvr and ai costs are already on the rise also in the light of the recent russia ads debacle facebook has said it will invest significantly in ramping up security on the platform which will weigh down on the margins facebook planning to go on a hiring spree next year especially engineers and people involved in maintaining safety and security facebook currently faces stiff competition from other big and small social media players although the company has started distributing ads on other websites we believe that google continues to have a significant competitive edge due to its scale and diversified product offering advertising remains facebooks major source of revenues and increasing competition can hurt its topline growth going forward new social media services like snapchat and pinterest offer tough competition as far as user growth especially teenagers is concerned although facebook has significant growth opportunities in the emerging countries of southeast asia and africa low internet penetration in these regions may negatively affect its expansion further while the company can be accessed from hong kong its usage has been restricted in mainland china due to excessive government regulations and censorship this limits its growth opportunities in the asian region facebooks fastest growing user base in terms of geography the company is experiencing better growth in international markets than in the us however average revenue per user arpu is significantly low in these regions compared with the us as facebook hosts a huge amount of personal data it has been under constant scrutiny from privacy groups and federal agencies this huge database is its primary asset for attracting advertisers as a result the company has been criticized for allegedly selling personal data to advertisers in order to boost its top line although the company has denied any wrongdoing we believe that increasing scrutiny by regulators on its data handling practices remains a major concern going forward recently the company ran into trouble with brazilian law enforcement agencies involving its messaging service whatsapp and in germany over antitrust concerns moreover facebook finds itself increasingly at loggerheads with authorities across different countries like israel who accuse the social media giant of repeatedly failing to cooperate with them on extremely sensitive matters facebook will likely be impacted because of the uncertainties relating to brexit given the fact that it will have to redefine everything from tax to data flow and privacy regulations for its operation in the uk moreover the company has its eu headquarters in ireland through which it was getting certain tax benefits now due to brexit facebook will have to chalk out a way to avoid paying higher taxes it might also result in it having to relocate its headquarters and some other facilities as well in order to continue getting the benefits of the eu bloc,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'report', 'quarter', 'different', 'past', 'quarter', 'company', 'maintain', 'ad', 'revenue', 'continue', 'grow', 'face', 'tough', 'yearoveryear', 'comparison', 'ad', 'load', 'far', 'lead', 'factor', 'drive', 'ad', 'revenue', 'cease', 'come', 'quarter', 'will', 'not', 'big', 'factor', 'post', '2017', 'company', 'continue', 'ramp', 'investment', 'video', 'arvr', 'ai', 'cost', 'rise', 'light', 'recent', 'russia', 'ad', 'debacle', 'facebook', 'say', 'invest', 'significantly', 'ramp', 'security', 'platform', 'weigh', 'margin', 'facebook', 'plan', 'hire', 'spree', 'year', 'especially', 'engineer', 'people', 'involve', 'maintain', 'safety', 'security', 'facebook', 'currently', 'face', 'stiff', 'competition', 'big', 'small', 'social', 'medium', 'player', 'company', 'start', 'distribute', 'ad', 'website', 'believe', 'google', 'continue', 'significant', 'competitive', 'edge', 'scale', 'diversified', 'product', 'offer', 'advertising', 'remain', 'facebook', 'major', 'source', 'revenue', 'increase', 'competition', 'hurt', 'topline', 'growth', 'go', 'forward', 'new', 'social', 'medium', 'service', 'like', 'snapchat', 'pinter', 'offer', 'tough', 'competition', 'far', 'user', 'growth', 'especially', 'teenager', 'concern', 'facebook', 'significant', 'growth', 'opportunity', 'emerge', 'country', 'southeast', 'asia', 'africa', 'low', 'internet', 'penetration', 'region', 'negatively', 'affect', 'expansion', 'company', 'access', 'hong', 'kong', 'usage', 'restrict', 'mainland', 'china', 'excessive', 'government', 'regulation', 'censorship', 'limit', 'growth', 'opportunity', 'asian', 'region', 'facebook', 'fast', 'grow', 'user', 'base', 'term', 'geography', 'company', 'experience', 'well', 'growth', 'international', 'market', 'average', 'revenue', 'user', 'arpu', 'significantly', 'low', 'region', 'compare', 'facebook', 'host', 'huge', 'personal', 'datum', 'constant', 'scrutiny', 'privacy', 'group', 'federal', 'agency', 'huge', 'database', 'primary', 'asset', 'attract', 'advertiser', 'result', 'company', 'criticize', 'allegedly', 'sell', 'personal', 'datum', 'advertiser', 'order', 'boost', 'line', 'company', 'deny', 'wrongdoing', 'believe', 'increase', 'scrutiny', 'regulator', 'datum', 'handling', 'practice', 'remain', 'major', 'concern', 'go', 'forward', 'recently', 'company', 'run', 'trouble', 'brazilian', 'law', 'enforcement', 'agency', 'involve', 'message', 'service', 'whatsapp', 'germany', 'antitrust', 'concern', 'facebook', 'find', 'increasingly', 'loggerhead', 'authority', 'different', 'country', 'like', 'israel', 'accuse', 'social', 'medium', 'giant', 'repeatedly', 'fail', 'cooperate', 'extremely', 'sensitive', 'matter', 'facebook', 'likely', 'impact', 'uncertainty', 'relate', 'brexit', 'give', 'fact', 'redefine', 'tax', 'datum', 'flow', 'privacy', 'regulation', 'operation', 'uk', 'company', 'eu', 'headquarters', 'ireland', 'get', 'certain', 'tax', 'benefit', 'brexit', 'facebook', 'chalk', 'way', 'avoid', 'pay', 'high', 'taxis', 'result', 'have', 'relocate', 'headquarters', 'facility', 'order', 'continue', 'get', 'benefit', 'eu', 'bloc']",facebook maintain cautious stance revenue growth report quarter different past quarter company maintain ad revenue continue grow face tough yearoveryear comparison ad load far lead factor drive ad revenue cease come quarter will not big factor post 2017 company continue ramp investment video arvr ai cost rise light recent russia ad debacle facebook say invest significantly ramp security platform weigh margin facebook plan hire spree year especially engineer people involve maintain safety security facebook currently face stiff competition big small social medium player company start distribute ad website believe google continue significant competitive edge scale diversified product offer advertising remain facebook major source revenue increase competition hurt topline growth go forward new social medium service like snapchat pinter offer tough competition far user growth especially teenager concern facebook significant growth opportunity emerge country southeast asia africa low internet penetration region negatively affect expansion company access hong kong usage restrict mainland china excessive government regulation censorship limit growth opportunity asian region facebook fast grow user base term geography company experience well growth international market average revenue user arpu significantly low region compare facebook host huge personal datum constant scrutiny privacy group federal agency huge database primary asset attract advertiser result company criticize allegedly sell personal datum advertiser order boost line company deny wrongdoing believe increase scrutiny regulator datum handling practice remain major concern go forward recently company run trouble brazilian law enforcement agency involve message service whatsapp germany antitrust concern facebook find increasingly loggerhead authority different country like israel accuse social medium giant repeatedly fail cooperate extremely sensitive matter facebook likely impact uncertainty relate brexit give fact redefine tax datum flow privacy regulation operation uk company eu headquarters ireland get certain tax benefit brexit facebook chalk way avoid pay high taxis result have relocate headquarters facility order continue get benefit eu bloc,16,38,-0.4,16,38,-0.4,0.9838
161,"Facebook, Inc._Attachment1(3).pdf",FB,10/17/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 400 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platform with an estimated user base of over 13 billion whatsapp remains one of most important businesses for facebook to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky the company is working on solar powered drones and mmw technologies we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential for the company with china off the radar india can prove to be a terrific growth engine for facebook this is primarily due to a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones in the country facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4231 billion at the end of secondquarter of 2018 free cash flow amounted to nearly 28 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '400', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platform', 'estimate', 'user', 'base', '13', 'billion', 'whatsapp', 'remain', 'important', 'business', 'facebook', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'company', 'work', 'solar', 'powered', 'drone', 'mmw', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'company', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'facebook', 'primarily', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'country', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4231', 'billion', 'end', 'secondquarter', '2018', 'free', 'cash', 'flow', 'amount', 'nearly', '28', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 400 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platform estimate user base 13 billion whatsapp remain important business facebook monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook consider pioneer concept social networking enjoy mover advantage market develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky company work solar powered drone mmw technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential company china radar india prove terrific growth engine facebook primarily burgeon welleducate middle class increase spending power rapid adoption smartphone country facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4231 billion end secondquarter 2018 free cash flow amount nearly 28 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future,30,27,0.05172413793103448,30,27,0.05172413793103448,0.9978
162,"Facebook, Inc._Attachment1(3).pdf",FB,2/4/2019,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time mobile ad revenues are growing rapidly primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 500 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platform with an estimated user base of over 13 billion whatsapp remains one of most important businesses for facebook to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky the company is working on solar powered drones and mmw technologies we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential for the company with china off the radar india can prove to be a terrific growth engine for facebook this is primarily due to a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones in the country facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4111 billion at the end of fourthquarter 2018 free cash flow amounted to 332 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'mobile', 'ad', 'revenue', 'grow', 'rapidly', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '500', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platform', 'estimate', 'user', 'base', '13', 'billion', 'whatsapp', 'remain', 'important', 'business', 'facebook', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'company', 'work', 'solar', 'powered', 'drone', 'mmw', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'company', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'facebook', 'primarily', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'country', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4111', 'billion', 'end', 'fourthquarter', '2018', 'free', 'cash', 'flow', 'amount', '332', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future']",facebook witness significant traction online mobile advertising spending short span time mobile ad revenue grow rapidly primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 500 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platform estimate user base 13 billion whatsapp remain important business facebook monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook consider pioneer concept social networking enjoy mover advantage market develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky company work solar powered drone mmw technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential company china radar india prove terrific growth engine facebook primarily burgeon welleducate middle class increase spending power rapid adoption smartphone country facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4111 billion end fourthquarter 2018 free cash flow amount 332 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future,30,27,0.05172413793103448,30,27,0.05172413793103448,0.9978
163,"Facebook, Inc._Attachment1(3).pdf",FB,2/4/2019,facebook maintains a cautious stance on revenue growth the companys focus on stories which generates lower revenues than news feed is expected to hurt topline growth at least in the near term moreover as the company continues to ramp up investments on products video arvr and ai as well as security costs are already on the rise facebooks is already on a hiring spree especially engineers and people involved in maintaining safety and security this is expected to hurt profitability facebook currently faces stiff competition from other big and small social media players although the company has started distributing ads on other websites we believe that google continues to have a significant competitive edge due to its scale and diversified product offering advertising remains facebooks major source of revenues and increasing competition can hurt its topline growth going forward googles youtube snapchat and pinterest offer tough competition as far as user growth is concerned although facebook has significant growth opportunities in the emerging countries of southeast asia and africa low internet zacks equity research fb wwwzackscom page 3 of 9,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'company', 'focus', 'story', 'generate', 'low', 'revenue', 'news', 'feed', 'expect', 'hurt', 'topline', 'growth', 'near', 'term', 'company', 'continue', 'ramp', 'investment', 'product', 'video', 'arvr', 'ai', 'security', 'cost', 'rise', 'facebook', 'hire', 'spree', 'especially', 'engineer', 'people', 'involve', 'maintain', 'safety', 'security', 'expect', 'hurt', 'profitability', 'facebook', 'currently', 'face', 'stiff', 'competition', 'big', 'small', 'social', 'medium', 'player', 'company', 'start', 'distribute', 'ad', 'website', 'believe', 'google', 'continue', 'significant', 'competitive', 'edge', 'scale', 'diversified', 'product', 'offer', 'advertising', 'remain', 'facebook', 'major', 'source', 'revenue', 'increase', 'competition', 'hurt', 'topline', 'growth', 'go', 'forward', 'google', 'youtube', 'snapchat', 'pinter', 'offer', 'tough', 'competition', 'far', 'user', 'growth', 'concern', 'facebook', 'significant', 'growth', 'opportunity', 'emerge', 'country', 'southeast', 'asia', 'africa', 'low', 'internet', 'zack', 'equity', 'research', 'fb', 'wwwzackscom', 'page', '3', '9']",facebook maintain cautious stance revenue growth company focus story generate low revenue news feed expect hurt topline growth near term company continue ramp investment product video arvr ai security cost rise facebook hire spree especially engineer people involve maintain safety security expect hurt profitability facebook currently face stiff competition big small social medium player company start distribute ad website believe google continue significant competitive edge scale diversified product offer advertising remain facebook major source revenue increase competition hurt topline growth go forward google youtube snapchat pinter offer tough competition far user growth concern facebook significant growth opportunity emerge country southeast asia africa low internet zack equity research fb wwwzackscom page 3 9,5,15,-0.47619047619047616,5,15,-0.47619047619047616,0.9153
164,"Facebook, Inc._Attachment1(4).pdf",FB,7/24/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the first quarter of 2017 ad revenues grew 51 year over year to 79 billion while mobile ad revenues were up 58 to 67 billion most importantly average price per ad increased 14 from the yearago quarter moreover ad impressions grew 32 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile moreover facebook is exploring ways to enhance video content ecosystem it has been investing in original content and said that it will keep doing the same this year as well last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more video oriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market over the past one year shares of facebook have grown 352 compared with the zacks internet services industrys gain of 226 however ceo mark zuckerberg said that in order to curb the menace of posting of violent videos on facebook live the company is now appointing over 3k people to its community operations team to better handle the review process after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram but facebook had earlier said the platform had over 500000 advertisers the company is now revamping its feed so that stories that users care about are displayed first thereby improving experience it has expanded dynamic ads to instagram while adding features like live and boomerang to stories instagram boasts over 700 million maus and over 400 million daus to bring more advertisers facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram facebook also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably facebook was subjected to severe ridicule when it acquired the snazzy photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions chatbots is the new buzz word in the tech space chatbots could serve as a powerful strategy to monetize the platform the whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 12 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to a recent idc report global revenues of the arvr market will grow to a whopping 1433 billion by 2020 while that for ai would be close to 46 billionrecently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus few days back facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 323 billion and recorded robust cash flow from operations of over 51 billion in the first quarter of 2017 free cash flow amounted to nearly 38 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement but as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at super fast speed along with aquila a solar powered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'quarter', '2017', 'ad', 'revenue', 'grow', '51', 'year', 'year', '79', 'billion', 'mobile', 'ad', 'revenue', '58', '67', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '14', 'yearago', 'quarter', 'ad', 'impression', 'grow', '32', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'facebook', 'explore', 'way', 'enhance', 'video', 'content', 'ecosystem', 'invest', 'original', 'content', 'say', 'year', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'video', 'orient', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'past', 'year', 'share', 'facebook', 'grow', '352', 'compare', 'zack', 'internet', 'service', 'industry', 'gain', '226', 'ceo', 'mark', 'zuckerberg', 'say', 'order', 'curb', 'menace', 'posting', 'violent', 'video', 'facebook', 'live', 'company', 'appoint', '3k', 'people', 'community', 'operation', 'team', 'well', 'handle', 'review', 'process', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'facebook', 'early', 'say', 'platform', '500000', 'advertiser', 'company', 'revamp', 'feed', 'story', 'user', 'care', 'display', 'improve', 'experience', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'instagram', 'boast', '700', 'million', 'maus', '400', 'million', 'daus', 'bring', 'advertiser', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'facebook', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'facebook', 'subject', 'severe', 'ridicule', 'acquire', 'snazzy', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'chatbot', 'new', 'buzz', 'word', 'tech', 'space', 'chatbot', 'serve', 'powerful', 'strategy', 'monetize', 'platform', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '12', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'grow', 'whopping', '1433', 'billion', '2020', 'ai', 'close', '46', 'billionrecently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'day', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '323', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '51', 'billion', 'quarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '38', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'super', 'fast', 'speed', 'aquila', 'solar', 'powered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work']",facebook witness significant traction online mobile advertising spending short span time quarter 2017 ad revenue grow 51 year year 79 billion mobile ad revenue 58 67 billion importantly average price ad increase 14 yearago quarter ad impression grow 32 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile facebook explore way enhance video content ecosystem invest original content say year year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate video orient content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market past year share facebook grow 352 compare zack internet service industry gain 226 ceo mark zuckerberg say order curb menace posting violent video facebook live company appoint 3k people community operation team well handle review process open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram facebook early say platform 500000 advertiser company revamp feed story user care display improve experience expand dynamic ad instagram add feature like live boomerang story instagram boast 700 million maus 400 million daus bring advertiser facebook say unveil new tool promote post evaluate business performance directly instagram facebook add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably facebook subject severe ridicule acquire snazzy photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction chatbot new buzz word tech space chatbot serve powerful strategy monetize platform whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 12 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market grow whopping 1433 billion 2020 ai close 46 billionrecently facebook split oculus separate unit division focus develop vr mobile focus vr pc company rope hugo barra spearhead vr effort head oculus plus day facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 323 billion record robust cash flow operation 51 billion quarter 2017 free cash flow amount nearly 38 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum super fast speed aquila solar powered aircraft beam internet sky f8 2017 conference facebook announce work,40,49,-0.1,40,49,-0.1,0.9989
165,"Facebook, Inc._Attachment1(4).pdf",FB,7/24/2017,facebook maintains a cautious stance on revenue growth since the past few quarters the company has maintained that ad revenues will continue to grow but will now face tougher yearoveryear comparisons ad load which so far has been a leading factor driving ad revenues will now cease to be so in the coming quarters and wont be a big factor after mid2017 consequently ad revenue rates will come down meaningfully moreover as facebook continues to ramp up investments costs are already on the rise with facebook planning to go on a hiring spree next year especially engineers it will further add to costs facebook currently faces stiff competition from other big and small social media players although the company has started distributing ads on other websites we believe that google continues to have a significant competitive edge due to its scale and diversified product offering advertising remains facebooks major source of revenues and increasing competition can hurt its topline growth going forward new social media services like snapchat and pinterest offer tough competition as far as user growth especially teenagers is concerned although facebook has significant growth opportunities in the emerging countries of southeast asia and africa low internet penetration in these regions may negatively affect its expansion further while facebook can be accessed from hong kong its usage has been restricted in mainland china due to excessive government regulations and censorship this limits its growth opportunities in the asian region facebooks fastest growing user base in terms of geography moreover the company is experiencing better growth in international markets than in the us however average revenue per user arpu is significantly low in these regions compared to the us arpu in the us and canada was 1500 compared with 500 from europe 100 from asia and 100 from the rest of the world as facebook hosts a huge amount of personal data it has been under constant scrutiny from privacy groups and federal agencies this huge database is its primary asset for attracting advertisers as a result the company has been criticized for allegedly selling personal data to advertisers in order to boost its top line although the company has denied any wrongdoing we believe that increasing scrutiny by regulators on its data handling practices remains a major concern going forward recently the company ran into trouble with brazilian law enforcement agencies involving its messaging service whatsapp and in germany over antitrust concerns moreover facebook finds itself increasingly at loggerheads with authorities across different countries like israel who accuse the social media giant of repeatedly failing to cooperate with them on extremely sensitive matters facebook will likely be impacted because of the uncertainties relating to brexit given the fact that it will have to redefine everything from tax to data flow and privacy regulations for its operation in the uk moreover the company has its eu headquarters in ireland through which it was getting certain tax benefits now as brexit happens facebook will have to chalk out a way to avoid paying higher taxes it might also result in it having to relocate its headquarters and some other facilities as well in order to continue getting the benefits of the eu bloc,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'past', 'quarter', 'company', 'maintain', 'ad', 'revenue', 'continue', 'grow', 'face', 'tough', 'yearoveryear', 'comparison', 'ad', 'load', 'far', 'lead', 'factor', 'drive', 'ad', 'revenue', 'cease', 'come', 'quarter', 'will', 'not', 'big', 'factor', 'mid2017', 'consequently', 'ad', 'revenue', 'rate', 'come', 'meaningfully', 'facebook', 'continue', 'ramp', 'investment', 'cost', 'rise', 'facebook', 'planning', 'hire', 'spree', 'year', 'especially', 'engineer', 'add', 'cost', 'facebook', 'currently', 'face', 'stiff', 'competition', 'big', 'small', 'social', 'medium', 'player', 'company', 'start', 'distribute', 'ad', 'website', 'believe', 'google', 'continue', 'significant', 'competitive', 'edge', 'scale', 'diversified', 'product', 'offer', 'advertising', 'remain', 'facebook', 'major', 'source', 'revenue', 'increase', 'competition', 'hurt', 'topline', 'growth', 'go', 'forward', 'new', 'social', 'medium', 'service', 'like', 'snapchat', 'pinter', 'offer', 'tough', 'competition', 'far', 'user', 'growth', 'especially', 'teenager', 'concern', 'facebook', 'significant', 'growth', 'opportunity', 'emerge', 'country', 'southeast', 'asia', 'africa', 'low', 'internet', 'penetration', 'region', 'negatively', 'affect', 'expansion', 'facebook', 'access', 'hong', 'kong', 'usage', 'restrict', 'mainland', 'china', 'excessive', 'government', 'regulation', 'censorship', 'limit', 'growth', 'opportunity', 'asian', 'region', 'facebook', 'fast', 'grow', 'user', 'base', 'term', 'geography', 'company', 'experience', 'well', 'growth', 'international', 'market', 'average', 'revenue', 'user', 'arpu', 'significantly', 'low', 'region', 'compare', 'arpu', 'canada', '1500', 'compare', '500', 'europe', '100', 'asia', '100', 'rest', 'world', 'facebook', 'host', 'huge', 'personal', 'datum', 'constant', 'scrutiny', 'privacy', 'group', 'federal', 'agency', 'huge', 'database', 'primary', 'asset', 'attract', 'advertiser', 'result', 'company', 'criticize', 'allegedly', 'sell', 'personal', 'datum', 'advertiser', 'order', 'boost', 'line', 'company', 'deny', 'wrongdoing', 'believe', 'increase', 'scrutiny', 'regulator', 'datum', 'handling', 'practice', 'remain', 'major', 'concern', 'go', 'forward', 'recently', 'company', 'run', 'trouble', 'brazilian', 'law', 'enforcement', 'agency', 'involve', 'message', 'service', 'whatsapp', 'germany', 'antitrust', 'concern', 'facebook', 'find', 'increasingly', 'loggerhead', 'authority', 'different', 'country', 'like', 'israel', 'accuse', 'social', 'medium', 'giant', 'repeatedly', 'fail', 'cooperate', 'extremely', 'sensitive', 'matter', 'facebook', 'likely', 'impact', 'uncertainty', 'relate', 'brexit', 'give', 'fact', 'redefine', 'tax', 'datum', 'flow', 'privacy', 'regulation', 'operation', 'uk', 'company', 'eu', 'headquarters', 'ireland', 'get', 'certain', 'tax', 'benefit', 'brexit', 'happen', 'facebook', 'chalk', 'way', 'avoid', 'pay', 'high', 'taxis', 'result', 'have', 'relocate', 'headquarters', 'facility', 'order', 'continue', 'get', 'benefit', 'eu', 'bloc']",facebook maintain cautious stance revenue growth past quarter company maintain ad revenue continue grow face tough yearoveryear comparison ad load far lead factor drive ad revenue cease come quarter will not big factor mid2017 consequently ad revenue rate come meaningfully facebook continue ramp investment cost rise facebook planning hire spree year especially engineer add cost facebook currently face stiff competition big small social medium player company start distribute ad website believe google continue significant competitive edge scale diversified product offer advertising remain facebook major source revenue increase competition hurt topline growth go forward new social medium service like snapchat pinter offer tough competition far user growth especially teenager concern facebook significant growth opportunity emerge country southeast asia africa low internet penetration region negatively affect expansion facebook access hong kong usage restrict mainland china excessive government regulation censorship limit growth opportunity asian region facebook fast grow user base term geography company experience well growth international market average revenue user arpu significantly low region compare arpu canada 1500 compare 500 europe 100 asia 100 rest world facebook host huge personal datum constant scrutiny privacy group federal agency huge database primary asset attract advertiser result company criticize allegedly sell personal datum advertiser order boost line company deny wrongdoing believe increase scrutiny regulator datum handling practice remain major concern go forward recently company run trouble brazilian law enforcement agency involve message service whatsapp germany antitrust concern facebook find increasingly loggerhead authority different country like israel accuse social medium giant repeatedly fail cooperate extremely sensitive matter facebook likely impact uncertainty relate brexit give fact redefine tax datum flow privacy regulation operation uk company eu headquarters ireland get certain tax benefit brexit happen facebook chalk way avoid pay high taxis result have relocate headquarters facility order continue get benefit eu bloc,15,39,-0.43636363636363634,15,39,-0.43636363636363634,0.9741
166,"Facebook, Inc._Attachment1(4).pdf",FB,7/3/2018,facebook maintains a cautious stance on revenue growth the last reported quarter was no different since the past few quarters the company has maintained that ad revenues will continue to grow but will now face tougher yearoveryear comparisons ad load which so far has been a leading factor driving ad revenues will now cease to be so in the coming quarters and wont be a big factor post 2017 moreover as the company continues to ramp up investments video arvr and ai costs zacks equity research fb wwwzackscom page 3 of 9,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'report', 'quarter', 'different', 'past', 'quarter', 'company', 'maintain', 'ad', 'revenue', 'continue', 'grow', 'face', 'tough', 'yearoveryear', 'comparison', 'ad', 'load', 'far', 'lead', 'factor', 'drive', 'ad', 'revenue', 'cease', 'come', 'quarter', 'will', 'not', 'big', 'factor', 'post', '2017', 'company', 'continue', 'ramp', 'investment', 'video', 'arvr', 'ai', 'cost', 'zacks', 'equity', 'research', 'fb', 'wwwzackscom', 'page', '3', '9']",facebook maintain cautious stance revenue growth report quarter different past quarter company maintain ad revenue continue grow face tough yearoveryear comparison ad load far lead factor drive ad revenue cease come quarter will not big factor post 2017 company continue ramp investment video arvr ai cost zacks equity research fb wwwzackscom page 3 9,5,10,-0.3125,5,10,-0.3125,0.1779
167,"Facebook, Inc._Attachment1(4).pdf",FB,11/1/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 400 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platform with an estimated user base of over 13 billion whatsapp remains one of most important businesses for facebook to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky the company is working on solar powered drones and mmw technologies we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential for the company with china off the radar india can prove to be a terrific growth engine for facebook this is primarily due to a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones in the country facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4231 billion at the end of secondquarter of 2018 free cash flow amounted to nearly 42 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '400', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platform', 'estimate', 'user', 'base', '13', 'billion', 'whatsapp', 'remain', 'important', 'business', 'facebook', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'company', 'work', 'solar', 'powered', 'drone', 'mmw', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'company', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'facebook', 'primarily', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'country', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4231', 'billion', 'end', 'secondquarter', '2018', 'free', 'cash', 'flow', 'amount', 'nearly', '42', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 400 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platform estimate user base 13 billion whatsapp remain important business facebook monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook consider pioneer concept social networking enjoy mover advantage market develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky company work solar powered drone mmw technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential company china radar india prove terrific growth engine facebook primarily burgeon welleducate middle class increase spending power rapid adoption smartphone country facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4231 billion end secondquarter 2018 free cash flow amount nearly 42 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future,30,27,0.05172413793103448,30,27,0.05172413793103448,0.9978
168,"Facebook, Inc._Attachment1(4).pdf",FB,2/15/2019,facebook maintains a cautious stance on revenue growth the companys focus on stories which generates lower revenues than news feed is expected to hurt topline growth at least in the near term moreover as the company continues to ramp up investments on products video arvr and ai as well as security costs are already on the rise facebooks is already on a hiring spree especially engineers and people involved in maintaining safety and security this is expected to hurt profitability facebook currently faces stiff competition from other big and small social media players although the company has started distributing ads on other websites we believe that google continues to have a significant competitive edge due to its scale and diversified product offering advertising remains facebooks major source of revenues and increasing competition can hurt its topline growth going forward googles youtube snapchat and pinterest offer tough competition as far as user growth is concerned although facebook has significant growth opportunities in the emerging countries of southeast asia and africa low internet penetration in these regions may negatively affect its expansion further while the company can be accessed from hong kong zacks equity research fb wwwzackscom page 3 of 9,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'company', 'focus', 'story', 'generate', 'low', 'revenue', 'news', 'feed', 'expect', 'hurt', 'topline', 'growth', 'near', 'term', 'company', 'continue', 'ramp', 'investment', 'product', 'video', 'arvr', 'ai', 'security', 'cost', 'rise', 'facebook', 'hire', 'spree', 'especially', 'engineer', 'people', 'involve', 'maintain', 'safety', 'security', 'expect', 'hurt', 'profitability', 'facebook', 'currently', 'face', 'stiff', 'competition', 'big', 'small', 'social', 'medium', 'player', 'company', 'start', 'distribute', 'ad', 'website', 'believe', 'google', 'continue', 'significant', 'competitive', 'edge', 'scale', 'diversified', 'product', 'offer', 'advertising', 'remain', 'facebook', 'major', 'source', 'revenue', 'increase', 'competition', 'hurt', 'topline', 'growth', 'go', 'forward', 'google', 'youtube', 'snapchat', 'pinter', 'offer', 'tough', 'competition', 'far', 'user', 'growth', 'concern', 'facebook', 'significant', 'growth', 'opportunity', 'emerge', 'country', 'southeast', 'asia', 'africa', 'low', 'internet', 'penetration', 'region', 'negatively', 'affect', 'expansion', 'company', 'access', 'hong', 'kong', 'zacks', 'equity', 'research', 'fb', 'wwwzackscom', 'page', '3', '9']",facebook maintain cautious stance revenue growth company focus story generate low revenue news feed expect hurt topline growth near term company continue ramp investment product video arvr ai security cost rise facebook hire spree especially engineer people involve maintain safety security expect hurt profitability facebook currently face stiff competition big small social medium player company start distribute ad website believe google continue significant competitive edge scale diversified product offer advertising remain facebook major source revenue increase competition hurt topline growth go forward google youtube snapchat pinter offer tough competition far user growth concern facebook significant growth opportunity emerge country southeast asia africa low internet penetration region negatively affect expansion company access hong kong zacks equity research fb wwwzackscom page 3 9,5,16,-0.5,5,16,-0.5,0.9153
169,"Facebook, Inc._Attachment1(5).pdf",FB,7/28/2017,facebook maintains a cautious stance on revenue growth the last reported quarter was no different since the past few quarters the company has maintained that ad revenues will continue to grow but will now face tougher yearoveryear comparisons ad load which so far has been a leading factor driving ad revenues will now cease to be so in the coming quarters and wont be a big factor after mid2017 consequently ad revenue rates will come down meaningfully moreover as the company continues to ramp up investments costs are already on the rise with facebook planning to go on a hiring spree next year especially engineers it will further add to costs facebook currently faces stiffcompetition from other big and small social media players although the company has started distributing ads on other websites we believe that google continues to have a significant competitive edge due to its scale and diversified product offering advertising remains facebooks major source of revenues and increasing competition can hurt its topline growth going forward new social media services like snapchat and pinterest offer tough competition as far as user growth especially teenagers is concerned although facebook has significant growth opportunities in the emerging countries of southeast asia and africa low internet penetration in these regions may negatively affect its expansion further while the company can be accessed from hong kong its usage has been restricted in mainland china due to excessive government regulations and censorship this limits its growth opportunities in the asian region facebooks fastest growing user base in terms of geography the company is experiencing better growth in international markets than in the us however average revenue per user arpu is significantly low in these regions compared with the us as facebook hosts a huge amount of personal data it has been under constant scrutiny from privacy groups and federal agencies this huge database is its primary asset for attracting advertisers as a result the company has been criticized for allegedly selling personal data to advertisers in order to boost its top line although the company has denied any wrongdoing we believe that increasing scrutiny by regulators on its data handling practices remains a major concern going forward recently the company ran into trouble with brazilian law enforcement agencies involving its messaging service whatsapp and in germany over antitrust concerns moreover facebook finds itself increasingly at loggerheads with authorities across different countries like israel who accuse the social media giant of repeatedly failing to cooperate with them on extremely sensitive matters facebook will likely be impacted because of the uncertainties relating to brexit given the fact that it will have to redefine everything from tax to data flow and privacy regulations for its operation in the uk moreover the company has its eu headquarters in ireland through which it was getting certain tax benefits now due to brexit facebook will have to chalk out a way to avoid paying higher taxes it might also result in it having to relocate its headquarters and some other facilities as well in order to continue getting the benefits of the eu bloc,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'report', 'quarter', 'different', 'past', 'quarter', 'company', 'maintain', 'ad', 'revenue', 'continue', 'grow', 'face', 'tough', 'yearoveryear', 'comparison', 'ad', 'load', 'far', 'lead', 'factor', 'drive', 'ad', 'revenue', 'cease', 'come', 'quarter', 'will', 'not', 'big', 'factor', 'mid2017', 'consequently', 'ad', 'revenue', 'rate', 'come', 'meaningfully', 'company', 'continue', 'ramp', 'investment', 'cost', 'rise', 'facebook', 'planning', 'hire', 'spree', 'year', 'especially', 'engineer', 'add', 'cost', 'facebook', 'currently', 'face', 'stiffcompetition', 'big', 'small', 'social', 'medium', 'player', 'company', 'start', 'distribute', 'ad', 'website', 'believe', 'google', 'continue', 'significant', 'competitive', 'edge', 'scale', 'diversified', 'product', 'offer', 'advertising', 'remain', 'facebook', 'major', 'source', 'revenue', 'increase', 'competition', 'hurt', 'topline', 'growth', 'go', 'forward', 'new', 'social', 'medium', 'service', 'like', 'snapchat', 'pinter', 'offer', 'tough', 'competition', 'far', 'user', 'growth', 'especially', 'teenager', 'concern', 'facebook', 'significant', 'growth', 'opportunity', 'emerge', 'country', 'southeast', 'asia', 'africa', 'low', 'internet', 'penetration', 'region', 'negatively', 'affect', 'expansion', 'company', 'access', 'hong', 'kong', 'usage', 'restrict', 'mainland', 'china', 'excessive', 'government', 'regulation', 'censorship', 'limit', 'growth', 'opportunity', 'asian', 'region', 'facebook', 'fast', 'grow', 'user', 'base', 'term', 'geography', 'company', 'experience', 'well', 'growth', 'international', 'market', 'average', 'revenue', 'user', 'arpu', 'significantly', 'low', 'region', 'compare', 'facebook', 'host', 'huge', 'personal', 'datum', 'constant', 'scrutiny', 'privacy', 'group', 'federal', 'agency', 'huge', 'database', 'primary', 'asset', 'attract', 'advertiser', 'result', 'company', 'criticize', 'allegedly', 'sell', 'personal', 'datum', 'advertiser', 'order', 'boost', 'line', 'company', 'deny', 'wrongdoing', 'believe', 'increase', 'scrutiny', 'regulator', 'datum', 'handling', 'practice', 'remain', 'major', 'concern', 'go', 'forward', 'recently', 'company', 'run', 'trouble', 'brazilian', 'law', 'enforcement', 'agency', 'involve', 'message', 'service', 'whatsapp', 'germany', 'antitrust', 'concern', 'facebook', 'find', 'increasingly', 'loggerhead', 'authority', 'different', 'country', 'like', 'israel', 'accuse', 'social', 'medium', 'giant', 'repeatedly', 'fail', 'cooperate', 'extremely', 'sensitive', 'matter', 'facebook', 'likely', 'impact', 'uncertainty', 'relate', 'brexit', 'give', 'fact', 'redefine', 'tax', 'datum', 'flow', 'privacy', 'regulation', 'operation', 'uk', 'company', 'eu', 'headquarters', 'ireland', 'get', 'certain', 'tax', 'benefit', 'brexit', 'facebook', 'chalk', 'way', 'avoid', 'pay', 'high', 'taxis', 'result', 'have', 'relocate', 'headquarters', 'facility', 'order', 'continue', 'get', 'benefit', 'eu', 'bloc']",facebook maintain cautious stance revenue growth report quarter different past quarter company maintain ad revenue continue grow face tough yearoveryear comparison ad load far lead factor drive ad revenue cease come quarter will not big factor mid2017 consequently ad revenue rate come meaningfully company continue ramp investment cost rise facebook planning hire spree year especially engineer add cost facebook currently face stiffcompetition big small social medium player company start distribute ad website believe google continue significant competitive edge scale diversified product offer advertising remain facebook major source revenue increase competition hurt topline growth go forward new social medium service like snapchat pinter offer tough competition far user growth especially teenager concern facebook significant growth opportunity emerge country southeast asia africa low internet penetration region negatively affect expansion company access hong kong usage restrict mainland china excessive government regulation censorship limit growth opportunity asian region facebook fast grow user base term geography company experience well growth international market average revenue user arpu significantly low region compare facebook host huge personal datum constant scrutiny privacy group federal agency huge database primary asset attract advertiser result company criticize allegedly sell personal datum advertiser order boost line company deny wrongdoing believe increase scrutiny regulator datum handling practice remain major concern go forward recently company run trouble brazilian law enforcement agency involve message service whatsapp germany antitrust concern facebook find increasingly loggerhead authority different country like israel accuse social medium giant repeatedly fail cooperate extremely sensitive matter facebook likely impact uncertainty relate brexit give fact redefine tax datum flow privacy regulation operation uk company eu headquarters ireland get certain tax benefit brexit facebook chalk way avoid pay high taxis result have relocate headquarters facility order continue get benefit eu bloc,15,38,-0.42592592592592593,15,38,-0.42592592592592593,0.9741
170,"Facebook, Inc._Attachment1(5).pdf",FB,4/11/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 the company stated that mobile conversions are on the rise as data from 17 markets showed that mobile accounted for 69 of online conversions on black friday and 64 on cyber monday it also drove 80 of conversions on singles day a popular day for online shopping in china the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by ever increasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile in august the company had launched watch a dedicated tab for video viewing as cord cutting grows live streaming presents a huge opportunity for growth moreover last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing the audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram it has expanded dynamic ads to instagram while adding features like live and boomerang to stories to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram the company also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably it was subjected to severe ridicule when it acquired the photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on zacks equity research fb wwwzackscom page 3 of 9,sell,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'company', 'state', 'mobile', 'conversion', 'rise', 'datum', '17', 'market', 'show', 'mobile', 'account', '69', 'online', 'conversion', 'black', 'friday', '64', 'cyber', 'monday', 'drive', '80', 'conversion', 'single', 'day', 'popular', 'day', 'online', 'shopping', 'china', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'increase', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'august', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'cord', 'cutting', 'grow', 'live', 'streaming', 'present', 'huge', 'opportunity', 'growth', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'company', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'subject', 'severe', 'ridicule', 'acquire', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'zack', 'equity', 'research', 'fb', 'wwwzackscom', 'page', '3', '9']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 company state mobile conversion rise datum 17 market show mobile account 69 online conversion black friday 64 cyber monday drive 80 conversion single day popular day online shopping china increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present increase video viewing social medium platform early facebook mention video emerge megatrend line like mobile august company launch watch dedicated tab video viewing cord cutting grow live streaming present huge opportunity growth year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram expand dynamic ad instagram add feature like live boomerang story bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram company add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably subject severe ridicule acquire photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work zack equity research fb wwwzackscom page 3 9,20,25,-0.10869565217391304,20,25,-0.10869565217391304,0.9923
171,"Facebook, Inc._Attachment1(5).pdf",FB,7/11/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier the company had mentioned that video was emerging as a megatrend on the same lines like mobile online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers although no exact numbers with regard to contribution from instagram are shared the growing adoption among advertisers is highly prominent to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 400 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4396 billion and recorded robust cash flow from operations of over 786 billion in the firstquarter of 2018 free cash flow amounted to nearly 505 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical cross link technology we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential the number of mobile internet users in the country which has nearly 14 billion people was 456 million in december 2017 per iamai report given the availability of cheaper smartphones faster connectivity and affordable services the figure is estimated to reach 478 million by june 2018 this bodes well for facebook as most developed markets have reached maturity with china off the radar india can prove to be a terrific growth engine a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones will boost facebooks prospects in the country,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'company', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'exact', 'number', 'regard', 'contribution', 'instagram', 'share', 'grow', 'adoption', 'advertiser', 'highly', 'prominent', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '400', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4396', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '786', 'billion', 'firstquarter', '2018', 'free', 'cash', 'flow', 'amount', 'nearly', '505', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'cross', 'link', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'number', 'mobile', 'internet', 'user', 'country', 'nearly', '14', 'billion', 'people', '456', 'million', 'december', '2017', 'iamai', 'report', 'give', 'availability', 'cheap', 'smartphone', 'fast', 'connectivity', 'affordable', 'service', 'figure', 'estimate', 'reach', '478', 'million', 'june', '2018', 'bode', 'facebook', 'develop', 'market', 'reach', 'maturity', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'boost', 'facebook', 'prospect', 'country']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform early company mention video emerge megatrend line like mobile online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser exact number regard contribution instagram share grow adoption advertiser highly prominent bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 400 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4396 billion record robust cash flow operation 786 billion firstquarter 2018 free cash flow amount nearly 505 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical cross link technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential number mobile internet user country nearly 14 billion people 456 million december 2017 iamai report give availability cheap smartphone fast connectivity affordable service figure estimate reach 478 million june 2018 bode facebook develop market reach maturity china radar india prove terrific growth engine burgeon welleducate middle class increase spending power rapid adoption smartphone boost facebook prospect country,35,34,0.014285714285714285,35,34,0.014285714285714285,0.9988
172,"Facebook, Inc._Attachment1(5).pdf",FB,12/3/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 400 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platform with an estimated user base of over 13 billion whatsapp remains one of most important businesses for facebook to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky the company is working on solar powered drones and mmw technologies we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential for the company with china off the radar india can prove to be a terrific growth engine for facebook this is primarily due to a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones in the country facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4121 billion at the end of thirdquarter 2018 free cash flow amounted to nearly 42 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '400', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platform', 'estimate', 'user', 'base', '13', 'billion', 'whatsapp', 'remain', 'important', 'business', 'facebook', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'company', 'work', 'solar', 'powered', 'drone', 'mmw', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'company', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'facebook', 'primarily', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'country', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4121', 'billion', 'end', 'thirdquarter', '2018', 'free', 'cash', 'flow', 'amount', 'nearly', '42', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 400 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platform estimate user base 13 billion whatsapp remain important business facebook monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook consider pioneer concept social networking enjoy mover advantage market develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky company work solar powered drone mmw technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential company china radar india prove terrific growth engine facebook primarily burgeon welleducate middle class increase spending power rapid adoption smartphone country facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4121 billion end thirdquarter 2018 free cash flow amount nearly 42 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future,30,27,0.05172413793103448,30,27,0.05172413793103448,0.9978
173,"Facebook, Inc._Attachment1(5).pdf",FB,3/27/2019,facebook maintains a cautious stance on revenue growth the companys focus on stories which generates lower revenues than news feed is expected to hurt topline growth at least in the near term moreover as the company continues to ramp up investments on products video arvr and ai as well as security costs are already on the rise facebooks is already on a hiring spree especially engineers and people involved in maintaining safety and security this is expected to hurt profitability facebook currently faces stiff competition from other big and small social media players although the company has started distributing ads on other websites we believe that google continues to have a significant competitive edge due to its scale and diversified product offering advertising remains facebooks major source of revenues and increasing competition can hurt its topline growth going forward googles youtube snapchat and pinterest offer tough competition as far as user growth is,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'company', 'focus', 'story', 'generate', 'low', 'revenue', 'news', 'feed', 'expect', 'hurt', 'topline', 'growth', 'near', 'term', 'company', 'continue', 'ramp', 'investment', 'product', 'video', 'arvr', 'ai', 'security', 'cost', 'rise', 'facebook', 'hire', 'spree', 'especially', 'engineer', 'people', 'involve', 'maintain', 'safety', 'security', 'expect', 'hurt', 'profitability', 'facebook', 'currently', 'face', 'stiff', 'competition', 'big', 'small', 'social', 'medium', 'player', 'company', 'start', 'distribute', 'ad', 'website', 'believe', 'google', 'continue', 'significant', 'competitive', 'edge', 'scale', 'diversified', 'product', 'offer', 'advertising', 'remain', 'facebook', 'major', 'source', 'revenue', 'increase', 'competition', 'hurt', 'topline', 'growth', 'go', 'forward', 'google', 'youtube', 'snapchat', 'pinter', 'offer', 'tough', 'competition', 'far', 'user', 'growth']",facebook maintain cautious stance revenue growth company focus story generate low revenue news feed expect hurt topline growth near term company continue ramp investment product video arvr ai security cost rise facebook hire spree especially engineer people involve maintain safety security expect hurt profitability facebook currently face stiff competition big small social medium player company start distribute ad website believe google continue significant competitive edge scale diversified product offer advertising remain facebook major source revenue increase competition hurt topline growth go forward google youtube snapchat pinter offer tough competition far user growth,4,12,-0.47058823529411764,4,12,-0.47058823529411764,0.8271
174,"Facebook, Inc._Attachment1(6).pdf",FB,8/9/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the second quarter of 2017 ad revenues grew 47 year over year to 92 billion while mobile ad revenues were up 53 to 8 billion most importantly average price per ad increased 24 from the yearago quarter moreover ad impressions grew 19 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing the audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market facebook original programming might go live in mid august per reports over the past one year shares of facebook have grown 371 compared with the industrys gain of 146 after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram it has expanded dynamic ads to instagram while adding features like live and boomerang to stories the photosharing app now boasts over 700 million maus and over 400 million daus to bring more advertisers facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram the company also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably it was subjected to severe ridicule when it acquired the snazzy photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to a recent idc report global revenues of the arvr market will grow to a whopping 1433 billion by 2020 while that for ai would be close to 46 billion recently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus few days back facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 355 billion and recorded robust cash flow from operations of over 54 billion in the second quarter of 2017 free cash flow amounted to nearly 39 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in sub saharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical crosslink technology we believe these,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'second', 'quarter', '2017', 'ad', 'revenue', 'grow', '47', 'year', 'year', '92', 'billion', 'mobile', 'ad', 'revenue', '53', '8', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '24', 'yearago', 'quarter', 'ad', 'impression', 'grow', '19', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'facebook', 'original', 'programming', 'live', 'mid', 'august', 'report', 'past', 'year', 'share', 'facebook', 'grow', '371', 'compare', 'industrys', 'gain', '146', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'photoshare', 'app', 'boast', '700', 'million', 'maus', '400', 'million', 'daus', 'bring', 'advertiser', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'company', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'subject', 'severe', 'ridicule', 'acquire', 'snazzy', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'grow', 'whopping', '1433', 'billion', '2020', 'ai', 'close', '46', 'billion', 'recently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'day', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '355', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '54', 'billion', 'second', 'quarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '39', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'sub', 'saharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'crosslink', 'technology', 'believe']",facebook witness significant traction online mobile advertising spending short span time second quarter 2017 ad revenue grow 47 year year 92 billion mobile ad revenue 53 8 billion importantly average price ad increase 24 yearago quarter ad impression grow 19 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market facebook original programming live mid august report past year share facebook grow 371 compare industrys gain 146 open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram expand dynamic ad instagram add feature like live boomerang story photoshare app boast 700 million maus 400 million daus bring advertiser facebook say unveil new tool promote post evaluate business performance directly instagram company add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably subject severe ridicule acquire snazzy photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market grow whopping 1433 billion 2020 ai close 46 billion recently facebook split oculus separate unit division focus develop vr mobile focus vr pc company rope hugo barra spearhead vr effort head oculus plus day facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 355 billion record robust cash flow operation 54 billion second quarter 2017 free cash flow amount nearly 39 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet sub saharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical crosslink technology believe,40,51,-0.11956521739130435,40,51,-0.11956521739130435,0.9989
175,"Facebook, Inc._Attachment1(6).pdf",FB,4/16/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 the company stated that mobile conversions are on the rise as data from 17 markets showed that mobile accounted for 69 of online conversions on black friday and 64 on cyber monday it also drove 80 of conversions on singles day a popular day for online shopping in china the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile in august the company had launched watch a dedicated tab for video viewing as cord cutting grows live streaming presents a huge opportunity for growth moreover last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing the audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram it has expanded dynamic ads to instagram while adding features like live and boomerang to stories to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram the company also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably it was subjected to severe ridicule when it acquired the photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4171 billion and recorded robust cash flow from operations of over 767 billion in the fourthquarter of 2017 free cash flow amounted to nearly 541 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical cross link technology we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention regarding user growth india as the worlds second largest populated country offers tremendous potential it has over 13 billion people of which only a little over 350 million use internet despite low internet penetration india is already one of the largest markets for the company just after the us given its extreme popularity this bodes well for facebook as most developed markets have reached maturity with china off the radar india can prove to be a terrific,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'company', 'state', 'mobile', 'conversion', 'rise', 'datum', '17', 'market', 'show', 'mobile', 'account', '69', 'online', 'conversion', 'black', 'friday', '64', 'cyber', 'monday', 'drive', '80', 'conversion', 'single', 'day', 'popular', 'day', 'online', 'shopping', 'china', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'august', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'cord', 'cutting', 'grow', 'live', 'streaming', 'present', 'huge', 'opportunity', 'growth', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'company', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'subject', 'severe', 'ridicule', 'acquire', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4171', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '767', 'billion', 'fourthquarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '541', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'cross', 'link', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'user', 'growth', 'india', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', '13', 'billion', 'people', 'little', '350', 'million', 'use', 'internet', 'despite', 'low', 'internet', 'penetration', 'india', 'large', 'market', 'company', 'give', 'extreme', 'popularity', 'bode', 'facebook', 'develop', 'market', 'reach', 'maturity', 'china', 'radar', 'india', 'prove', 'terrific']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 company state mobile conversion rise datum 17 market show mobile account 69 online conversion black friday 64 cyber monday drive 80 conversion single day popular day online shopping china increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile august company launch watch dedicated tab video viewing cord cutting grow live streaming present huge opportunity growth year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram expand dynamic ad instagram add feature like live boomerang story bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram company add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably subject severe ridicule acquire photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4171 billion record robust cash flow operation 767 billion fourthquarter 2017 free cash flow amount nearly 541 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical cross link technology believe initiative significantly drive facebook userbase region long run place india deserve special mention user growth india world second large populated country offer tremendous potential 13 billion people little 350 million use internet despite low internet penetration india large market company give extreme popularity bode facebook develop market reach maturity china radar india prove terrific,41,47,-0.06741573033707865,41,47,-0.06741573033707865,0.9989
176,"Facebook, Inc._Attachment1(6).pdf",FB,7/17/2018,facebook maintains a cautious stance on revenue growth the last reported quarter was no different since the past few quarters the company has maintained that ad revenues will continue to grow but will now face tougher yearoveryear comparisons ad load which so far has been a leading factor driving ad revenues will now cease to be so in the coming quarters moreover as the company continues to ramp up investments video arvr and ai costs are already on the rise zacks equity research fb wwwzackscom page 3 of 9,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'report', 'quarter', 'different', 'past', 'quarter', 'company', 'maintain', 'ad', 'revenue', 'continue', 'grow', 'face', 'tough', 'yearoveryear', 'comparison', 'ad', 'load', 'far', 'lead', 'factor', 'drive', 'ad', 'revenue', 'cease', 'come', 'quarter', 'company', 'continue', 'ramp', 'investment', 'video', 'arvr', 'ai', 'cost', 'rise', 'zack', 'equity', 'research', 'fb', 'wwwzackscom', 'page', '3', '9']",facebook maintain cautious stance revenue growth report quarter different past quarter company maintain ad revenue continue grow face tough yearoveryear comparison ad load far lead factor drive ad revenue cease come quarter company continue ramp investment video arvr ai cost rise zack equity research fb wwwzackscom page 3 9,5,10,-0.3125,5,10,-0.3125,0.1779
177,"Facebook, Inc._Attachment1(7).pdf",FB,8/21/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the second quarter of 2017 ad revenues grew 47 year over year to 92 billion while mobile ad revenues were up 53 to 8 billion most importantly average price per ad increased 24 from the yearago quarter moreover ad impressions grew 19 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing the audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market facebook original programming might go live in mid august per reports over the past one year shares of facebook have grown 35 compared with the industrys gain of 13 after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram it has expanded dynamic ads to instagram while adding features like live and boomerang to stories the photosharing app now boasts over 700 million maus and over 400 million daus to bring more advertisers facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram the company also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably it was subjected to severe ridicule when it acquired the snazzy photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to a recent idc report global revenues of the arvr market will grow to a whopping 1433 billion by 2020 while that for ai would be close to 46 billion recently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus few days back facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 355 billion and recorded robust cash flow from operations of over 54 billion in the second quarter of 2017 free cash flow amounted to nearly 39 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in sub saharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical crosslink technology we believe these,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'second', 'quarter', '2017', 'ad', 'revenue', 'grow', '47', 'year', 'year', '92', 'billion', 'mobile', 'ad', 'revenue', '53', '8', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '24', 'yearago', 'quarter', 'ad', 'impression', 'grow', '19', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'facebook', 'original', 'programming', 'live', 'mid', 'august', 'report', 'past', 'year', 'share', 'facebook', 'grow', '35', 'compare', 'industrys', 'gain', '13', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'photoshare', 'app', 'boast', '700', 'million', 'maus', '400', 'million', 'daus', 'bring', 'advertiser', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'company', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'subject', 'severe', 'ridicule', 'acquire', 'snazzy', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'grow', 'whopping', '1433', 'billion', '2020', 'ai', 'close', '46', 'billion', 'recently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'day', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '355', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '54', 'billion', 'second', 'quarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '39', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'sub', 'saharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'crosslink', 'technology', 'believe']",facebook witness significant traction online mobile advertising spending short span time second quarter 2017 ad revenue grow 47 year year 92 billion mobile ad revenue 53 8 billion importantly average price ad increase 24 yearago quarter ad impression grow 19 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market facebook original programming live mid august report past year share facebook grow 35 compare industrys gain 13 open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram expand dynamic ad instagram add feature like live boomerang story photoshare app boast 700 million maus 400 million daus bring advertiser facebook say unveil new tool promote post evaluate business performance directly instagram company add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably subject severe ridicule acquire snazzy photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market grow whopping 1433 billion 2020 ai close 46 billion recently facebook split oculus separate unit division focus develop vr mobile focus vr pc company rope hugo barra spearhead vr effort head oculus plus day facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 355 billion record robust cash flow operation 54 billion second quarter 2017 free cash flow amount nearly 39 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet sub saharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical crosslink technology believe,40,51,-0.11956521739130435,40,51,-0.11956521739130435,0.9989
178,"Facebook, Inc._Attachment1(7).pdf",FB,4/30/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 the company stated that mobile conversions are on the rise as data from 17 markets showed that mobile accounted for 69 of online conversions on black friday and 64 on cyber monday it also drove 80 of conversions on singles day a popular day for online shopping in china the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile in august the company had launched watch a dedicated tab for video viewing as cord cutting grows live streaming presents a huge opportunity for growth moreover last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing the audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram it has expanded dynamic ads to instagram while adding features like live and boomerang to stories to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram the company also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably it was subjected to severe ridicule when it acquired the photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4396 billion and recorded robust cash flow from operations of over 786 billion in the firstquarter of 2018 free cash flow amounted to nearly 505 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical cross link technology we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention regarding user growth india as the worlds second largest populated country offers tremendous potential it has over 13 billion people of which only a little over 350 million use internet despite low internet penetration india is already one of the largest markets for the company just after the us given its extreme popularity this bodes well for facebook as most developed markets have reached maturity with china off the radar india can prove to be a terrific,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'company', 'state', 'mobile', 'conversion', 'rise', 'datum', '17', 'market', 'show', 'mobile', 'account', '69', 'online', 'conversion', 'black', 'friday', '64', 'cyber', 'monday', 'drive', '80', 'conversion', 'single', 'day', 'popular', 'day', 'online', 'shopping', 'china', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'august', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'cord', 'cutting', 'grow', 'live', 'streaming', 'present', 'huge', 'opportunity', 'growth', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'company', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'subject', 'severe', 'ridicule', 'acquire', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4396', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '786', 'billion', 'firstquarter', '2018', 'free', 'cash', 'flow', 'amount', 'nearly', '505', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'cross', 'link', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'user', 'growth', 'india', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', '13', 'billion', 'people', 'little', '350', 'million', 'use', 'internet', 'despite', 'low', 'internet', 'penetration', 'india', 'large', 'market', 'company', 'give', 'extreme', 'popularity', 'bode', 'facebook', 'develop', 'market', 'reach', 'maturity', 'china', 'radar', 'india', 'prove', 'terrific']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 company state mobile conversion rise datum 17 market show mobile account 69 online conversion black friday 64 cyber monday drive 80 conversion single day popular day online shopping china increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile august company launch watch dedicated tab video viewing cord cutting grow live streaming present huge opportunity growth year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram expand dynamic ad instagram add feature like live boomerang story bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram company add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably subject severe ridicule acquire photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4396 billion record robust cash flow operation 786 billion firstquarter 2018 free cash flow amount nearly 505 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical cross link technology believe initiative significantly drive facebook userbase region long run place india deserve special mention user growth india world second large populated country offer tremendous potential 13 billion people little 350 million use internet despite low internet penetration india large market company give extreme popularity bode facebook develop market reach maturity china radar india prove terrific,41,47,-0.06741573033707865,41,47,-0.06741573033707865,0.9989
179,"Facebook, Inc._Attachment1(7).pdf",FB,7/27/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier the company had mentioned that video was emerging as a megatrend on the same lines like mobile online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers although no exact numbers with regard to contribution from instagram are shared the growing adoption among advertisers is highly prominent to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 400 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4231 billion at the end of secondquarter of 2018 free cash flow amounted to nearly 28 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical cross link technology we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential the number of mobile internet users in the country which has nearly 14 billion people was 456 million in december 2017 per iamai report given the availability of cheaper smartphones faster connectivity and affordable services the figure is estimated to reach 478 million by june 2018 this bodes well for facebook as most developed markets have reached maturity with china off the radar india can prove to be a terrific growth engine a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones will boost facebooks prospects in the country,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'company', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'exact', 'number', 'regard', 'contribution', 'instagram', 'share', 'grow', 'adoption', 'advertiser', 'highly', 'prominent', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '400', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4231', 'billion', 'end', 'secondquarter', '2018', 'free', 'cash', 'flow', 'amount', 'nearly', '28', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'cross', 'link', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'number', 'mobile', 'internet', 'user', 'country', 'nearly', '14', 'billion', 'people', '456', 'million', 'december', '2017', 'iamai', 'report', 'give', 'availability', 'cheap', 'smartphone', 'fast', 'connectivity', 'affordable', 'service', 'figure', 'estimate', 'reach', '478', 'million', 'june', '2018', 'bode', 'facebook', 'develop', 'market', 'reach', 'maturity', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'boost', 'facebook', 'prospect', 'country']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform early company mention video emerge megatrend line like mobile online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser exact number regard contribution instagram share grow adoption advertiser highly prominent bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 400 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4231 billion end secondquarter 2018 free cash flow amount nearly 28 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical cross link technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential number mobile internet user country nearly 14 billion people 456 million december 2017 iamai report give availability cheap smartphone fast connectivity affordable service figure estimate reach 478 million june 2018 bode facebook develop market reach maturity china radar india prove terrific growth engine burgeon welleducate middle class increase spending power rapid adoption smartphone boost facebook prospect country,35,35,0.0,35,35,0.0,0.9987
180,"Facebook, Inc._Attachment1(7).pdf",FB,4/4/2019,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time mobile ad revenues are growing rapidly primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 500 million daily actives the company is now,sell,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'mobile', 'ad', 'revenue', 'grow', 'rapidly', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '500', 'million', 'daily', 'active', 'company']",facebook witness significant traction online mobile advertising spending short span time mobile ad revenue grow rapidly primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 500 million daily active company,13,8,0.22727272727272727,13,8,0.22727272727272727,0.9565
181,"Facebook, Inc._Attachment1(8).pdf",FB,9/22/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the second quarter of 2017 ad revenues grew 47 year over year to 92 billion while mobile ad revenues were up 53 to 8 billion most importantly average price per ad increased 24 from the yearago quarter moreover ad impressions grew 19 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing the audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market facebook original programming might go live in mid august per reports over the past one year shares of facebook have grown 315 compared with the industrys gain of 129 after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram it has expanded dynamic ads to instagram while adding features like live and boomerang to stories the photosharing app now boasts over 700 million maus and over 400 million daus to bring more advertisers facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram the company also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably it was subjected to severe ridicule when it acquired the snazzy photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to a recent idc report global revenues of the arvr market will grow to a whopping 1433 billion by 2020 while that for ai would be close to 46 billion recently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus few days back facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 355 billion and recorded robust cash flow from operations of over 54 billion in the second quarter of 2017 free cash flow amounted to nearly 39 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in sub saharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical crosslink technology we believe these,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'second', 'quarter', '2017', 'ad', 'revenue', 'grow', '47', 'year', 'year', '92', 'billion', 'mobile', 'ad', 'revenue', '53', '8', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '24', 'yearago', 'quarter', 'ad', 'impression', 'grow', '19', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'facebook', 'original', 'programming', 'live', 'mid', 'august', 'report', 'past', 'year', 'share', 'facebook', 'grow', '315', 'compare', 'industrys', 'gain', '129', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'photoshare', 'app', 'boast', '700', 'million', 'maus', '400', 'million', 'daus', 'bring', 'advertiser', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'company', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'subject', 'severe', 'ridicule', 'acquire', 'snazzy', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'grow', 'whopping', '1433', 'billion', '2020', 'ai', 'close', '46', 'billion', 'recently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'day', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '355', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '54', 'billion', 'second', 'quarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '39', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'sub', 'saharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'crosslink', 'technology', 'believe']",facebook witness significant traction online mobile advertising spending short span time second quarter 2017 ad revenue grow 47 year year 92 billion mobile ad revenue 53 8 billion importantly average price ad increase 24 yearago quarter ad impression grow 19 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market facebook original programming live mid august report past year share facebook grow 315 compare industrys gain 129 open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram expand dynamic ad instagram add feature like live boomerang story photoshare app boast 700 million maus 400 million daus bring advertiser facebook say unveil new tool promote post evaluate business performance directly instagram company add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably subject severe ridicule acquire snazzy photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market grow whopping 1433 billion 2020 ai close 46 billion recently facebook split oculus separate unit division focus develop vr mobile focus vr pc company rope hugo barra spearhead vr effort head oculus plus day facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 355 billion record robust cash flow operation 54 billion second quarter 2017 free cash flow amount nearly 39 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet sub saharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical crosslink technology believe,40,51,-0.11956521739130435,40,51,-0.11956521739130435,0.9989
182,"Facebook, Inc._Attachment1(8).pdf",FB,7/31/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier the company had mentioned that video was emerging as a megatrend on the same lines like mobile online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers although no exact numbers with regard to contribution from instagram are shared the growing adoption among advertisers is highly prominent to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 400 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an zacks equity research fb wwwzackscom page 3 of 9,sell,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'company', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'exact', 'number', 'regard', 'contribution', 'instagram', 'share', 'grow', 'adoption', 'advertiser', 'highly', 'prominent', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '400', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'zack', 'equity', 'research', 'fb', 'wwwzackscom', 'page', '3', '9']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform early company mention video emerge megatrend line like mobile online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser exact number regard contribution instagram share grow adoption advertiser highly prominent bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 400 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition zack equity research fb wwwzackscom page 3 9,19,16,0.08333333333333333,19,16,0.08333333333333333,0.9909
183,"Facebook, Inc._Attachment1(8).pdf",FB,4/5/2019,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time mobile ad revenues are growing rapidly primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 500 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platform with an estimated user base of over 13 billion whatsapp remains one of most important businesses for facebook to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky the company is working on solar powered drones and mmw technologies we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential for the company with china off the radar india can prove to be a terrific growth engine for facebook this is primarily due to a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones in the country facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4111 billion at the end of fourthquarter 2018 free cash flow amounted to 332 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'mobile', 'ad', 'revenue', 'grow', 'rapidly', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '500', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platform', 'estimate', 'user', 'base', '13', 'billion', 'whatsapp', 'remain', 'important', 'business', 'facebook', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'company', 'work', 'solar', 'powered', 'drone', 'mmw', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'company', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'facebook', 'primarily', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'country', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4111', 'billion', 'end', 'fourthquarter', '2018', 'free', 'cash', 'flow', 'amount', '332', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future']",facebook witness significant traction online mobile advertising spending short span time mobile ad revenue grow rapidly primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 500 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platform estimate user base 13 billion whatsapp remain important business facebook monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook consider pioneer concept social networking enjoy mover advantage market develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky company work solar powered drone mmw technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential company china radar india prove terrific growth engine facebook primarily burgeon welleducate middle class increase spending power rapid adoption smartphone country facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4111 billion end fourthquarter 2018 free cash flow amount 332 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future,30,27,0.05172413793103448,30,27,0.05172413793103448,0.9978
184,"Facebook, Inc._Attachment1(9).pdf",FB,4/10/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the fourth quarter of 2016 ad revenues grew 53 year over year to 86 billion while mobile ad revenues were up 61 to 72 billion most importantly average price per ad increased 3 from the yearago quarter moreover ad impressions grew 49 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums so as marketers move to mobile to target customers facebook is aggressively monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by ever increasing video viewing on social media platforms facebook said that video was emerging as a megatrend on the same lines like mobile moreover facebook is exploring ways to enhance video content ecosystem it has been investing in original content and said that it will keep doing the same this year as well last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more video oriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market over the past one year shares of facebook have grown 2918 compared with the zacks internet services industrys gain of 775 after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram but facebook had earlier said the platform had over 500000 advertisers the company is now revamping its feed so stories users care about are displayed first thereby improving experience it has expanded dynamic ads to instagram while adding features like live and boomerang to stories instagram boasts over 600 million maus and over 400 million daus to bring more advertisers facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram facebook also added that its latest feature stories on instagram has 150 million daily actives in jan 2017 facebook said it will insert ads in stories notably facebook was subject to severe ridicule when it acquired the snazzy photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions chatbots is the new buzz word in the tech space chatbots could serve as a powerful strategy to monetize the platform the whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 12 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to recent idc report global revenues of the arvr market are expected to grow at a cagr of 1813 from 52 billion in 2016 to over 162 billion in 2020 recently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs he has roped in hugo barra to spearhead the companys vr efforts as well as head oculus plus few days back facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 294 billion and recorded robust cash flow from operations of over 161 billion in 2016 free cash flow amounted to nearly 116 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions going forward facebook is considered have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement but as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at super fast speed along with aquila a solar powered aircraft to beam internet from the sky at f8 conference facebook said that it was working on aries antenna radio integration for efficiency in spectrum and terragraph two of its ambitious internet connectivity projects with aries facebook is testing to bring speedier connectivity in rural areas by using antennas to provide faster internet coverage on 2g,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'fourth', 'quarter', '2016', 'ad', 'revenue', 'grow', '53', 'year', 'year', '86', 'billion', 'mobile', 'ad', 'revenue', '61', '72', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '3', 'yearago', 'quarter', 'ad', 'impression', 'grow', '49', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'mobile', 'target', 'customer', 'facebook', 'aggressively', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'increase', 'video', 'viewing', 'social', 'medium', 'platform', 'facebook', 'say', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'facebook', 'explore', 'way', 'enhance', 'video', 'content', 'ecosystem', 'invest', 'original', 'content', 'say', 'year', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'video', 'orient', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'past', 'year', 'share', 'facebook', 'grow', '2918', 'compare', 'zack', 'internet', 'service', 'industry', 'gain', '775', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'facebook', 'early', 'say', 'platform', '500000', 'advertiser', 'company', 'revamp', 'feed', 'story', 'user', 'care', 'display', 'improve', 'experience', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'instagram', 'boast', '600', 'million', 'maus', '400', 'million', 'daus', 'bring', 'advertiser', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'facebook', 'add', 'late', 'feature', 'story', 'instagram', '150', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'facebook', 'subject', 'severe', 'ridicule', 'acquire', 'snazzy', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'chatbot', 'new', 'buzz', 'word', 'tech', 'space', 'chatbot', 'serve', 'powerful', 'strategy', 'monetize', 'platform', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '12', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'expect', 'grow', 'cagr', '1813', '52', 'billion', '2016', '162', 'billion', '2020', 'recently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'rope', 'hugo', 'barra', 'spearhead', 'company', 'vr', 'effort', 'head', 'oculus', 'plus', 'day', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '294', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '161', 'billion', '2016', 'free', 'cash', 'flow', 'amount', 'nearly', '116', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'go', 'forward', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'super', 'fast', 'speed', 'aquila', 'solar', 'powered', 'aircraft', 'beam', 'internet', 'sky', 'f8', 'conference', 'facebook', 'say', 'work', 'arie', 'antenna', 'radio', 'integration', 'efficiency', 'spectrum', 'terragraph', 'ambitious', 'internet', 'connectivity', 'project', 'arie', 'facebook', 'test', 'bring', 'speedy', 'connectivity', 'rural', 'area', 'antenna', 'provide', 'fast', 'internet', 'coverage', '2', 'g']",facebook witness significant traction online mobile advertising spending short span time fourth quarter 2016 ad revenue grow 53 year year 86 billion mobile ad revenue 61 72 billion importantly average price ad increase 3 yearago quarter ad impression grow 49 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer mobile target customer facebook aggressively monetize shift facebook aggressively promote live order boost line intend capture opportunity present increase video viewing social medium platform facebook say video emerge megatrend line like mobile facebook explore way enhance video content ecosystem invest original content say year year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate video orient content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market past year share facebook grow 2918 compare zack internet service industry gain 775 open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram facebook early say platform 500000 advertiser company revamp feed story user care display improve experience expand dynamic ad instagram add feature like live boomerang story instagram boast 600 million maus 400 million daus bring advertiser facebook say unveil new tool promote post evaluate business performance directly instagram facebook add late feature story instagram 150 million daily active jan 2017 facebook say insert ad story notably facebook subject severe ridicule acquire snazzy photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction chatbot new buzz word tech space chatbot serve powerful strategy monetize platform whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 12 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market expect grow cagr 1813 52 billion 2016 162 billion 2020 recently facebook split oculus separate unit division focus develop vr mobile focus vr pc rope hugo barra spearhead company vr effort head oculus plus day facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 294 billion record robust cash flow operation 161 billion 2016 free cash flow amount nearly 116 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition go forward facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum super fast speed aquila solar powered aircraft beam internet sky f8 conference facebook say work arie antenna radio integration efficiency spectrum terragraph ambitious internet connectivity project arie facebook test bring speedy connectivity rural area antenna provide fast internet coverage 2 g,40,49,-0.1,40,49,-0.1,0.999
185,"Facebook, Inc._Attachment1(9).pdf",FB,9/26/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the second quarter of 2017 ad revenues grew 47 year over year to 92 billion while mobile ad revenues were up 53 to 8 billion most importantly average price per ad increased 24 from the yearago quarter moreover ad impressions grew 19 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing the audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market facebook original programming might go live in mid august per reports over the past one year shares of facebook have grown 28 compared with the industrys gain of 145 after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram it has expanded dynamic ads to instagram while adding features like live and boomerang to stories the photosharing app now boasts over 800 million maus and over 500 million daus to bring more advertisers over 2 million nad counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram the company also added that its latest feature stories on instagram has 250 million daily actives in jan 2017 facebook said it will insert ads in stories notably it was subjected to severe ridicule when it acquired the photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to a recent idc report global revenues of the arvr market will grow to a whopping 1433 billion by 2020 while that for ai would be close to 46 billion recently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 355 billion and recorded robust cash flow from operations of over 54 billion in the second quarter of 2017 free cash flow amounted to nearly 39 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in sub saharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical crosslink technology we believe these,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'second', 'quarter', '2017', 'ad', 'revenue', 'grow', '47', 'year', 'year', '92', 'billion', 'mobile', 'ad', 'revenue', '53', '8', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '24', 'yearago', 'quarter', 'ad', 'impression', 'grow', '19', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'facebook', 'original', 'programming', 'live', 'mid', 'august', 'report', 'past', 'year', 'share', 'facebook', 'grow', '28', 'compare', 'industrys', 'gain', '145', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'photoshare', 'app', 'boast', '800', 'million', 'maus', '500', 'million', 'daus', 'bring', 'advertiser', '2', 'million', 'nad', 'counting', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'company', 'add', 'late', 'feature', 'story', 'instagram', '250', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'subject', 'severe', 'ridicule', 'acquire', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'grow', 'whopping', '1433', 'billion', '2020', 'ai', 'close', '46', 'billion', 'recently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '355', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '54', 'billion', 'second', 'quarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '39', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'sub', 'saharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'crosslink', 'technology', 'believe']",facebook witness significant traction online mobile advertising spending short span time second quarter 2017 ad revenue grow 47 year year 92 billion mobile ad revenue 53 8 billion importantly average price ad increase 24 yearago quarter ad impression grow 19 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market facebook original programming live mid august report past year share facebook grow 28 compare industrys gain 145 open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram expand dynamic ad instagram add feature like live boomerang story photoshare app boast 800 million maus 500 million daus bring advertiser 2 million nad counting facebook say unveil new tool promote post evaluate business performance directly instagram company add late feature story instagram 250 million daily active jan 2017 facebook say insert ad story notably subject severe ridicule acquire photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market grow whopping 1433 billion 2020 ai close 46 billion recently facebook split oculus separate unit division focus develop vr mobile focus vr pc company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 355 billion record robust cash flow operation 54 billion second quarter 2017 free cash flow amount nearly 39 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet sub saharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical crosslink technology believe,40,51,-0.11956521739130435,40,51,-0.11956521739130435,0.9989
186,"Facebook, Inc._Attachment1.pdf",FB,5/9/2017,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in the first quarter of 2017 ad revenues grew 51 year over year to 79 billion while mobile ad revenues were up 58 to 67 billion most importantly average price per ad increased 14 from the yearago quarter moreover ad impressions grew 32 due to increases in mobile impressions the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook is aggressively promoting live in order to boost its top line it intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier facebook had mentioned that video was emerging as a megatrend on the same lines like mobile moreover facebook is exploring ways to enhance video content ecosystem it has been investing in original content and said that it will keep doing the same this year as well last year it signed deals with media houses and internet celebrities to churn out more content for its live platform and added a plethora of new features to facebook live these include enabling broadcast for a group or event and at the same time allowing audience to respond to the live broadcast in real time through live reactions online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more video oriented content to bring in more ad dollars given the phenomenal growth in mobile ad business and video efforts facebook has vastly outperformed the broader market over the past one year shares of facebook have grown 2669 compared with the zacks internet services industrys gain of 2088 however ceo mark zuckerberg said that in order to curb the menace of posting of violent videos on facebook live the company is now appointing over 3k people to its community operations team to better handle the review process after opening its ad platform to worldwide advertisers last year instagram has emerged as an important cash cow for facebook again there were no exact numbers with regard to contribution from instagram but facebook had earlier said the platform had over 500000 advertisers the company is now revamping its feed so that stories that users care about are displayed first thereby improving experience it has expanded dynamic ads to instagram while adding features like live and boomerang to stories instagram boasts over 600 million maus and over 400 million daus to bring more advertisers facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram facebook also added that its latest feature stories on instagram has 200 million daily actives in jan 2017 facebook said it will insert ads in stories notably facebook was subjected to severe ridicule when it acquired the snazzy photo sharing app in 2012 for 1 billion messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions chatbots is the new buzz word in the tech space chatbots could serve as a powerful strategy to monetize the platform the whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 12 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities according to a recent idc report global revenues of the arvr market will grow to a whopping 1433 billion by 2020 while that for ai would be close to 46 billionrecently facebook split oculus into two separate units while one division will focus on developing vr for mobile the other one will focus on vr for pcs the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus few days back facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 323 billion and recorded robust cash flow from operations of over 51 billion in the first quarter of 2017 free cash flow amounted to nearly 38 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement but as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so users can get them free or at nominal rates is expanding its presence in these emerging regions africa with a population of over 12 billion has a little over 120 million who use facebook this clearly indicates the immense scope for growth in the region even though it might take a lot of time also the lack of physical infrastructure has propelled the increasing use of mobile internet in the region which is in tune with facebooks growth strategy facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at super fast speed along with aquila a solar powered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'quarter', '2017', 'ad', 'revenue', 'grow', '51', 'year', 'year', '79', 'billion', 'mobile', 'ad', 'revenue', '58', '67', 'billion', 'importantly', 'average', 'price', 'ad', 'increase', '14', 'yearago', 'quarter', 'ad', 'impression', 'grow', '32', 'increase', 'mobile', 'impression', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'aggressively', 'promote', 'live', 'order', 'boost', 'line', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'facebook', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'facebook', 'explore', 'way', 'enhance', 'video', 'content', 'ecosystem', 'invest', 'original', 'content', 'say', 'year', 'year', 'sign', 'deal', 'medium', 'house', 'internet', 'celebrity', 'churn', 'content', 'live', 'platform', 'add', 'plethora', 'new', 'feature', 'facebook', 'live', 'include', 'enable', 'broadcast', 'group', 'event', 'time', 'allow', 'audience', 'respond', 'live', 'broadcast', 'real', 'time', 'live', 'reaction', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'video', 'orient', 'content', 'bring', 'ad', 'dollar', 'give', 'phenomenal', 'growth', 'mobile', 'ad', 'business', 'video', 'effort', 'facebook', 'vastly', 'outperform', 'broad', 'market', 'past', 'year', 'share', 'facebook', 'grow', '2669', 'compare', 'zack', 'internet', 'service', 'industry', 'gain', '2088', 'ceo', 'mark', 'zuckerberg', 'say', 'order', 'curb', 'menace', 'posting', 'violent', 'video', 'facebook', 'live', 'company', 'appoint', '3k', 'people', 'community', 'operation', 'team', 'well', 'handle', 'review', 'process', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'year', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'exact', 'number', 'regard', 'contribution', 'instagram', 'facebook', 'early', 'say', 'platform', '500000', 'advertiser', 'company', 'revamp', 'feed', 'story', 'user', 'care', 'display', 'improve', 'experience', 'expand', 'dynamic', 'ad', 'instagram', 'add', 'feature', 'like', 'live', 'boomerang', 'story', 'instagram', 'boast', '600', 'million', 'maus', '400', 'million', 'daus', 'bring', 'advertiser', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'facebook', 'add', 'late', 'feature', 'story', 'instagram', '200', 'million', 'daily', 'active', 'jan', '2017', 'facebook', 'say', 'insert', 'ad', 'story', 'notably', 'facebook', 'subject', 'severe', 'ridicule', 'acquire', 'snazzy', 'photo', 'share', 'app', '2012', '1', 'billion', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'chatbot', 'new', 'buzz', 'word', 'tech', 'space', 'chatbot', 'serve', 'powerful', 'strategy', 'monetize', 'platform', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '12', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'accord', 'recent', 'idc', 'report', 'global', 'revenue', 'arvr', 'market', 'grow', 'whopping', '1433', 'billion', '2020', 'ai', 'close', '46', 'billionrecently', 'facebook', 'split', 'oculus', 'separate', 'unit', 'division', 'focus', 'develop', 'vr', 'mobile', 'focus', 'vr', 'pc', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'day', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '323', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '51', 'billion', 'quarter', '2017', 'free', 'cash', 'flow', 'amount', 'nearly', '38', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'africa', 'population', '12', 'billion', 'little', '120', 'million', 'use', 'facebook', 'clearly', 'indicate', 'immense', 'scope', 'growth', 'region', 'lot', 'time', 'lack', 'physical', 'infrastructure', 'propel', 'increase', 'use', 'mobile', 'internet', 'region', 'tune', 'facebook', 'growth', 'strategy', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'super', 'fast', 'speed', 'aquila', 'solar', 'powered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work']",facebook witness significant traction online mobile advertising spending short span time quarter 2017 ad revenue grow 51 year year 79 billion mobile ad revenue 58 67 billion importantly average price ad increase 14 yearago quarter ad impression grow 32 increase mobile impression increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook aggressively promote live order boost line intend capture opportunity present everincrease video viewing social medium platform early facebook mention video emerge megatrend line like mobile facebook explore way enhance video content ecosystem invest original content say year year sign deal medium house internet celebrity churn content live platform add plethora new feature facebook live include enable broadcast group event time allow audience respond live broadcast real time live reaction online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate video orient content bring ad dollar give phenomenal growth mobile ad business video effort facebook vastly outperform broad market past year share facebook grow 2669 compare zack internet service industry gain 2088 ceo mark zuckerberg say order curb menace posting violent video facebook live company appoint 3k people community operation team well handle review process open ad platform worldwide advertiser year instagram emerge important cash cow facebook exact number regard contribution instagram facebook early say platform 500000 advertiser company revamp feed story user care display improve experience expand dynamic ad instagram add feature like live boomerang story instagram boast 600 million maus 400 million daus bring advertiser facebook say unveil new tool promote post evaluate business performance directly instagram facebook add late feature story instagram 200 million daily active jan 2017 facebook say insert ad story notably facebook subject severe ridicule acquire snazzy photo share app 2012 1 billion messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction chatbot new buzz word tech space chatbot serve powerful strategy monetize platform whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 12 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity accord recent idc report global revenue arvr market grow whopping 1433 billion 2020 ai close 46 billionrecently facebook split oculus separate unit division focus develop vr mobile focus vr pc company rope hugo barra spearhead vr effort head oculus plus day facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 323 billion record robust cash flow operation 51 billion quarter 2017 free cash flow amount nearly 38 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region africa population 12 billion little 120 million use facebook clearly indicate immense scope growth region lot time lack physical infrastructure propel increase use mobile internet region tune facebook growth strategy facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum super fast speed aquila solar powered aircraft beam internet sky f8 2017 conference facebook announce work,40,49,-0.1,40,49,-0.1,0.9989
187,"Facebook, Inc._Attachment1.pdf",FB,1/2/2018,facebook maintains a cautious stance on revenue growth the last reported quarter was no different since the past few quarters the company has maintained that ad revenues will continue to grow but will now face tougher yearoveryear comparisons ad load which so far has been a leading factor driving ad revenues will now cease to be so in the coming quarters and wont be a big factor after mid2017 moreover as the company continues to ramp up investments video arvr and ai costs are already on the rise also in the light of the recent russia ads debacle facebook has said it will invest significantly in ramping up security on the platform which will weigh down on the margins facebook planning to go on a hiring spree next year especially engineers and people involved in maintaining safety and security facebook currently faces stiff competition from other big and small social media players although the company has started distributing ads on other websites we believe that google continues to have a significant competitive edge due to its scale and diversified product offering advertising remains facebooks major source of revenues and increasing competition can hurt its topline growth going forward new social media services like snapchat and pinterest offer tough competition as far as user growth especially teenagers is concerned although facebook has significant growth opportunities in the emerging countries of southeast asia and africa low internet penetration in these regions may negatively affect its expansion further while the company can be accessed from hong kong its usage has been restricted in mainland china due to excessive government regulations and censorship this limits its growth opportunities in the asian region facebooks fastest growing user base in terms of geography the company is experiencing better growth in international markets than in the us however average revenue per user arpu is significantly low in these regions compared with the us as facebook hosts a huge amount of personal data it has been under constant scrutiny from privacy groups and federal agencies this huge database is its primary asset for attracting advertisers as a result the company has been criticized for allegedly selling personal data to advertisers in order to boost its top line although the company has denied any wrongdoing we believe that increasing scrutiny by regulators on its data handling practices remains a major concern going forward recently the company ran into trouble with brazilian law enforcement agencies involving its messaging service whatsapp and in germany over antitrust concerns moreover facebook finds itself increasingly at loggerheads with authorities across different countries like israel who accuse the social media giant of repeatedly failing to cooperate with them on extremely sensitive matters facebook will likely be impacted because of the uncertainties relating to brexit given the fact that it will have to redefine everything from tax to data flow and privacy regulations for its operation in the uk moreover the company has its eu headquarters in ireland through which it was getting certain tax benefits now due to brexit facebook will have to chalk out a way to avoid paying higher taxes it might also result in it having to relocate its headquarters and some other facilities as well in order to continue getting the benefits of the eu bloc,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'report', 'quarter', 'different', 'past', 'quarter', 'company', 'maintain', 'ad', 'revenue', 'continue', 'grow', 'face', 'tough', 'yearoveryear', 'comparison', 'ad', 'load', 'far', 'lead', 'factor', 'drive', 'ad', 'revenue', 'cease', 'come', 'quarter', 'will', 'not', 'big', 'factor', 'mid2017', 'company', 'continue', 'ramp', 'investment', 'video', 'arvr', 'ai', 'cost', 'rise', 'light', 'recent', 'russia', 'ad', 'debacle', 'facebook', 'say', 'invest', 'significantly', 'ramp', 'security', 'platform', 'weigh', 'margin', 'facebook', 'plan', 'hire', 'spree', 'year', 'especially', 'engineer', 'people', 'involve', 'maintain', 'safety', 'security', 'facebook', 'currently', 'face', 'stiff', 'competition', 'big', 'small', 'social', 'medium', 'player', 'company', 'start', 'distribute', 'ad', 'website', 'believe', 'google', 'continue', 'significant', 'competitive', 'edge', 'scale', 'diversified', 'product', 'offer', 'advertising', 'remain', 'facebook', 'major', 'source', 'revenue', 'increase', 'competition', 'hurt', 'topline', 'growth', 'go', 'forward', 'new', 'social', 'medium', 'service', 'like', 'snapchat', 'pinter', 'offer', 'tough', 'competition', 'far', 'user', 'growth', 'especially', 'teenager', 'concern', 'facebook', 'significant', 'growth', 'opportunity', 'emerge', 'country', 'southeast', 'asia', 'africa', 'low', 'internet', 'penetration', 'region', 'negatively', 'affect', 'expansion', 'company', 'access', 'hong', 'kong', 'usage', 'restrict', 'mainland', 'china', 'excessive', 'government', 'regulation', 'censorship', 'limit', 'growth', 'opportunity', 'asian', 'region', 'facebook', 'fast', 'grow', 'user', 'base', 'term', 'geography', 'company', 'experience', 'well', 'growth', 'international', 'market', 'average', 'revenue', 'user', 'arpu', 'significantly', 'low', 'region', 'compare', 'facebook', 'host', 'huge', 'personal', 'datum', 'constant', 'scrutiny', 'privacy', 'group', 'federal', 'agency', 'huge', 'database', 'primary', 'asset', 'attract', 'advertiser', 'result', 'company', 'criticize', 'allegedly', 'sell', 'personal', 'datum', 'advertiser', 'order', 'boost', 'line', 'company', 'deny', 'wrongdoing', 'believe', 'increase', 'scrutiny', 'regulator', 'datum', 'handling', 'practice', 'remain', 'major', 'concern', 'go', 'forward', 'recently', 'company', 'run', 'trouble', 'brazilian', 'law', 'enforcement', 'agency', 'involve', 'message', 'service', 'whatsapp', 'germany', 'antitrust', 'concern', 'facebook', 'find', 'increasingly', 'loggerhead', 'authority', 'different', 'country', 'like', 'israel', 'accuse', 'social', 'medium', 'giant', 'repeatedly', 'fail', 'cooperate', 'extremely', 'sensitive', 'matter', 'facebook', 'likely', 'impact', 'uncertainty', 'relate', 'brexit', 'give', 'fact', 'redefine', 'tax', 'datum', 'flow', 'privacy', 'regulation', 'operation', 'uk', 'company', 'eu', 'headquarters', 'ireland', 'get', 'certain', 'tax', 'benefit', 'brexit', 'facebook', 'chalk', 'way', 'avoid', 'pay', 'high', 'taxis', 'result', 'have', 'relocate', 'headquarters', 'facility', 'order', 'continue', 'get', 'benefit', 'eu', 'bloc']",facebook maintain cautious stance revenue growth report quarter different past quarter company maintain ad revenue continue grow face tough yearoveryear comparison ad load far lead factor drive ad revenue cease come quarter will not big factor mid2017 company continue ramp investment video arvr ai cost rise light recent russia ad debacle facebook say invest significantly ramp security platform weigh margin facebook plan hire spree year especially engineer people involve maintain safety security facebook currently face stiff competition big small social medium player company start distribute ad website believe google continue significant competitive edge scale diversified product offer advertising remain facebook major source revenue increase competition hurt topline growth go forward new social medium service like snapchat pinter offer tough competition far user growth especially teenager concern facebook significant growth opportunity emerge country southeast asia africa low internet penetration region negatively affect expansion company access hong kong usage restrict mainland china excessive government regulation censorship limit growth opportunity asian region facebook fast grow user base term geography company experience well growth international market average revenue user arpu significantly low region compare facebook host huge personal datum constant scrutiny privacy group federal agency huge database primary asset attract advertiser result company criticize allegedly sell personal datum advertiser order boost line company deny wrongdoing believe increase scrutiny regulator datum handling practice remain major concern go forward recently company run trouble brazilian law enforcement agency involve message service whatsapp germany antitrust concern facebook find increasingly loggerhead authority different country like israel accuse social medium giant repeatedly fail cooperate extremely sensitive matter facebook likely impact uncertainty relate brexit give fact redefine tax datum flow privacy regulation operation uk company eu headquarters ireland get certain tax benefit brexit facebook chalk way avoid pay high taxis result have relocate headquarters facility order continue get benefit eu bloc,16,38,-0.4,16,38,-0.4,0.9838
188,"Facebook, Inc._Attachment1.pdf",FB,6/1/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 the increase in mobile advertisement stems from the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms earlier the company had mentioned that video was emerging as a megatrend on the same lines like mobile online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers although no exact numbers with regard to contribution from instagram are shared the growing adoption among advertisers is highly prominent to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 300 million daily actives the company is now working on adding video chat ar camera effects and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platformthe whatsapp acquisition not only expanded the companys mobile product lineup but also added a user base which is predominantly young at the same time the acquisition eliminated facebooks fastestgrowing competitor in terms of user additions with an estimated user base of over 13 billion it remains one of most important businesses to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to spearhead its vr efforts as well as head oculus plus facebook said it will be spending over 3 billion in the next 10 years on vr facebook has a strong balance sheet and generates significant cash flow which makes it an attractive stock for investors the company has cash and cash equivalents of 4396 billion and recorded robust cash flow from operations of over 786 billion in the firstquarter of 2018 free cash flow amounted to nearly 505 billion the company continues to invest in developing its platform and products we believe that its ability to generate strong cash flows will help it to make further investments in product development and acquisitions in the future facebook is considered to have pioneered the concept of social networking which is why it enjoys a first movers advantage in this market the companys user base continues to grow at a significant pace driven by new features and tools that improve engagement however as developed regions mature facebook has taken measures to drive penetration in emerging markets of south east asia latin america and africa the free basics initiative which involves partnerships with local telecom networks to subsidize some basic internet services including facebook so that users can get them free or at nominal rates is expanding its presence in these emerging regions facebook has collaborated with francebased eutelsat communications to launch a satellite that would beam internet in subsaharan african regions it is also testing express wifi and developing laser technology to move loads of data at superfast speed along with aquila a solarpowered aircraft to beam internet from the sky at f8 2017 conference facebook announced that it is working on solarpowered drones and mmw technologies aquila had a successful second flight as far as connectivity speeds are concerned facebook said that it has broken a few records in case of wireless transfers the company has achieved a pointtopoint data rate of 36 gbps over 13 km with mmw technology and 80 gbps using the optical cross link technology we believe these initiatives will significantly drive facebooks userbase in these regions in the long run of all places india deserves special mention in terms of user growth the worlds second largest populated country offers tremendous potential the number of mobile internet users in the country which has nearly 14 billion people was 456 million in december 2017 per iamai report given the availability of cheaper smartphones faster connectivity and affordable services the figure is estimated to reach 478 million by june 2018 this bodes well for facebook as most developed markets have reached maturity with china off the radar india can prove to be a terrific growth engine a burgeoning welleducated middle class increasing spending power and rapid adoption of smartphones will boost facebooks prospects in the country,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'increase', 'mobile', 'advertisement', 'stem', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'early', 'company', 'mention', 'video', 'emerge', 'megatrend', 'line', 'like', 'mobile', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'exact', 'number', 'regard', 'contribution', 'instagram', 'share', 'grow', 'adoption', 'advertiser', 'highly', 'prominent', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '300', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'ar', 'camera', 'effect', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platformthe', 'whatsapp', 'acquisition', 'expand', 'company', 'mobile', 'product', 'lineup', 'add', 'user', 'base', 'predominantly', 'young', 'time', 'acquisition', 'eliminate', 'facebook', 'fastestgrowe', 'competitor', 'term', 'user', 'addition', 'estimate', 'user', 'base', '13', 'billion', 'remain', 'important', 'business', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'spearhead', 'vr', 'effort', 'head', 'oculus', 'plus', 'facebook', 'say', 'spend', '3', 'billion', '10', 'year', 'vr', 'facebook', 'strong', 'balance', 'sheet', 'generate', 'significant', 'cash', 'flow', 'make', 'attractive', 'stock', 'investor', 'company', 'cash', 'cash', 'equivalent', '4396', 'billion', 'record', 'robust', 'cash', 'flow', 'operation', '786', 'billion', 'firstquarter', '2018', 'free', 'cash', 'flow', 'amount', 'nearly', '505', 'billion', 'company', 'continue', 'invest', 'develop', 'platform', 'product', 'believe', 'ability', 'generate', 'strong', 'cash', 'flow', 'help', 'investment', 'product', 'development', 'acquisition', 'future', 'facebook', 'consider', 'pioneer', 'concept', 'social', 'networking', 'enjoy', 'mover', 'advantage', 'market', 'company', 'user', 'base', 'continue', 'grow', 'significant', 'pace', 'drive', 'new', 'feature', 'tool', 'improve', 'engagement', 'develop', 'region', 'mature', 'facebook', 'take', 'measure', 'drive', 'penetration', 'emerge', 'market', 'south', 'east', 'asia', 'latin', 'america', 'africa', 'free', 'basic', 'initiative', 'involve', 'partnership', 'local', 'telecom', 'network', 'subsidize', 'basic', 'internet', 'service', 'include', 'facebook', 'user', 'free', 'nominal', 'rate', 'expand', 'presence', 'emerge', 'region', 'facebook', 'collaborate', 'francebased', 'eutelsat', 'communication', 'launch', 'satellite', 'beam', 'internet', 'subsaharan', 'african', 'region', 'test', 'express', 'wifi', 'develop', 'laser', 'technology', 'load', 'datum', 'superfast', 'speed', 'aquila', 'solarpowered', 'aircraft', 'beam', 'internet', 'sky', 'f8', '2017', 'conference', 'facebook', 'announce', 'work', 'solarpowere', 'drone', 'mmw', 'technologies', 'aquila', 'successful', 'second', 'flight', 'far', 'connectivity', 'speed', 'concern', 'facebook', 'say', 'break', 'record', 'case', 'wireless', 'transfer', 'company', 'achieve', 'pointtopoint', 'data', 'rate', '36', 'gbps', '13', 'km', 'mmw', 'technology', '80', 'gbps', 'optical', 'cross', 'link', 'technology', 'believe', 'initiative', 'significantly', 'drive', 'facebook', 'userbase', 'region', 'long', 'run', 'place', 'india', 'deserve', 'special', 'mention', 'term', 'user', 'growth', 'world', 'second', 'large', 'populated', 'country', 'offer', 'tremendous', 'potential', 'number', 'mobile', 'internet', 'user', 'country', 'nearly', '14', 'billion', 'people', '456', 'million', 'december', '2017', 'iamai', 'report', 'give', 'availability', 'cheap', 'smartphone', 'fast', 'connectivity', 'affordable', 'service', 'figure', 'estimate', 'reach', '478', 'million', 'june', '2018', 'bode', 'facebook', 'develop', 'market', 'reach', 'maturity', 'china', 'radar', 'india', 'prove', 'terrific', 'growth', 'engine', 'burgeon', 'welleducate', 'middle', 'class', 'increase', 'spending', 'power', 'rapid', 'adoption', 'smartphone', 'boost', 'facebook', 'prospect', 'country']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 increase mobile advertisement stem fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform early company mention video emerge megatrend line like mobile online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser exact number regard contribution instagram share grow adoption advertiser highly prominent bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 300 million daily active company work add video chat ar camera effect new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platformthe whatsapp acquisition expand company mobile product lineup add user base predominantly young time acquisition eliminate facebook fastestgrowe competitor term user addition estimate user base 13 billion remain important business monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra spearhead vr effort head oculus plus facebook say spend 3 billion 10 year vr facebook strong balance sheet generate significant cash flow make attractive stock investor company cash cash equivalent 4396 billion record robust cash flow operation 786 billion firstquarter 2018 free cash flow amount nearly 505 billion company continue invest develop platform product believe ability generate strong cash flow help investment product development acquisition future facebook consider pioneer concept social networking enjoy mover advantage market company user base continue grow significant pace drive new feature tool improve engagement develop region mature facebook take measure drive penetration emerge market south east asia latin america africa free basic initiative involve partnership local telecom network subsidize basic internet service include facebook user free nominal rate expand presence emerge region facebook collaborate francebased eutelsat communication launch satellite beam internet subsaharan african region test express wifi develop laser technology load datum superfast speed aquila solarpowered aircraft beam internet sky f8 2017 conference facebook announce work solarpowere drone mmw technologies aquila successful second flight far connectivity speed concern facebook say break record case wireless transfer company achieve pointtopoint data rate 36 gbps 13 km mmw technology 80 gbps optical cross link technology believe initiative significantly drive facebook userbase region long run place india deserve special mention term user growth world second large populated country offer tremendous potential number mobile internet user country nearly 14 billion people 456 million december 2017 iamai report give availability cheap smartphone fast connectivity affordable service figure estimate reach 478 million june 2018 bode facebook develop market reach maturity china radar india prove terrific growth engine burgeon welleducate middle class increase spending power rapid adoption smartphone boost facebook prospect country,35,35,0.0,35,35,0.0,0.9988
189,"Facebook, Inc._Attachment1.pdf",FB,9/4/2018,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time in 2017 mobile ad revenues grew 56 over 2016 primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift facebook intends to capture the opportunity presented by everincreasing video viewing on social media platforms online video is the most lucrative component of digital advertising as video ads generate more revenues than its photo and text based substitutes facebook is trying to incorporate more and more videooriented content to bring in more ad dollars the company launched watch a dedicated tab for video viewing to achieve its goal instagram has emerged as an important cash cow for facebook after opening its ad platform to worldwide advertisers to bring more advertisers over 2 million and counting facebook said it has unveiled new tools to promote posts and evaluate business performance directly within instagram stories on instagram has surpassed 400 million daily actives the company is now working on adding video chat sound tracks and a new explore tab on instagram soon messenger whatsapp and oculus are the other extremely prized possessions facebook is aggressively working on monetizing the opportunities presented by its subsidiaries chatbots and conversational commerce are likely to be the strategies for messenger and whatsapp the company remains pretty excited as it opened the messenger app which has over 1 billion users to developers for creating chatbots that would enable businesses to extend customer service and other transactions a few weeks back management had announced that it will be opening its subsidiary platform messenger to worldwide advertisers albeit for test run purpose only this underscores the companys efforts to monetize the platform with an estimated user base of over 13 billion whatsapp remains one of most important businesses for facebook to monetize the platform the company has dropped the subscription fees and will eventually bring conversational commerce to the platform whatsapp now boasts 1 billion daily actives oculus will fuel the companys ambitious arvr efforts at its oculus developer conference held in october last year facebook announced another 250 million investment to develop vr content ecosystem it also announced some new products including santa cruz a cheaper standalone vr headset with insideouttracking earlier this year it had launched its vr headset rift ai and arvr technology are fast emerging as lucrative business opportunities the company has roped in hugo barra to zacks equity research fb wwwzackscom page 3 of 9,sell,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', '2017', 'mobile', 'ad', 'revenue', 'grow', '56', '2016', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift', 'facebook', 'intend', 'capture', 'opportunity', 'present', 'everincrease', 'video', 'viewing', 'social', 'medium', 'platform', 'online', 'video', 'lucrative', 'component', 'digital', 'advertising', 'video', 'ad', 'generate', 'revenue', 'photo', 'text', 'base', 'substitute', 'facebook', 'try', 'incorporate', 'videooriented', 'content', 'bring', 'ad', 'dollar', 'company', 'launch', 'watch', 'dedicated', 'tab', 'video', 'viewing', 'achieve', 'goal', 'instagram', 'emerge', 'important', 'cash', 'cow', 'facebook', 'open', 'ad', 'platform', 'worldwide', 'advertiser', 'bring', 'advertiser', '2', 'million', 'count', 'facebook', 'say', 'unveil', 'new', 'tool', 'promote', 'post', 'evaluate', 'business', 'performance', 'directly', 'instagram', 'story', 'instagram', 'surpass', '400', 'million', 'daily', 'active', 'company', 'work', 'add', 'video', 'chat', 'sound', 'track', 'new', 'explore', 'tab', 'instagram', 'soon', 'messenger', 'whatsapp', 'oculus', 'extremely', 'prized', 'possession', 'facebook', 'aggressively', 'work', 'monetize', 'opportunity', 'present', 'subsidiary', 'chatbot', 'conversational', 'commerce', 'likely', 'strategy', 'messenger', 'whatsapp', 'company', 'remain', 'pretty', 'excited', 'open', 'messenger', 'app', '1', 'billion', 'user', 'developer', 'create', 'chatbot', 'enable', 'business', 'extend', 'customer', 'service', 'transaction', 'week', 'management', 'announce', 'open', 'subsidiary', 'platform', 'messenger', 'worldwide', 'advertiser', 'albeit', 'test', 'run', 'purpose', 'underscore', 'company', 'effort', 'monetize', 'platform', 'estimate', 'user', 'base', '13', 'billion', 'whatsapp', 'remain', 'important', 'business', 'facebook', 'monetize', 'platform', 'company', 'drop', 'subscription', 'fee', 'eventually', 'bring', 'conversational', 'commerce', 'platform', 'whatsapp', 'boast', '1', 'billion', 'daily', 'active', 'oculus', 'fuel', 'companys', 'ambitious', 'arvr', 'effort', 'oculus', 'developer', 'conference', 'hold', 'october', 'year', 'facebook', 'announce', '250', 'million', 'investment', 'develop', 'vr', 'content', 'ecosystem', 'announce', 'new', 'product', 'include', 'santa', 'cruz', 'cheap', 'standalone', 'vr', 'headset', 'insideouttracke', 'early', 'year', 'launch', 'vr', 'headset', 'rift', 'ai', 'arvr', 'technology', 'fast', 'emerge', 'lucrative', 'business', 'opportunity', 'company', 'rope', 'hugo', 'barra', 'zacks', 'equity', 'research', 'fb', 'wwwzackscom', 'page', '3', '9']",facebook witness significant traction online mobile advertising spending short span time 2017 mobile ad revenue grow 56 2016 primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift facebook intend capture opportunity present everincrease video viewing social medium platform online video lucrative component digital advertising video ad generate revenue photo text base substitute facebook try incorporate videooriented content bring ad dollar company launch watch dedicated tab video viewing achieve goal instagram emerge important cash cow facebook open ad platform worldwide advertiser bring advertiser 2 million count facebook say unveil new tool promote post evaluate business performance directly instagram story instagram surpass 400 million daily active company work add video chat sound track new explore tab instagram soon messenger whatsapp oculus extremely prized possession facebook aggressively work monetize opportunity present subsidiary chatbot conversational commerce likely strategy messenger whatsapp company remain pretty excited open messenger app 1 billion user developer create chatbot enable business extend customer service transaction week management announce open subsidiary platform messenger worldwide advertiser albeit test run purpose underscore company effort monetize platform estimate user base 13 billion whatsapp remain important business facebook monetize platform company drop subscription fee eventually bring conversational commerce platform whatsapp boast 1 billion daily active oculus fuel companys ambitious arvr effort oculus developer conference hold october year facebook announce 250 million investment develop vr content ecosystem announce new product include santa cruz cheap standalone vr headset insideouttracke early year launch vr headset rift ai arvr technology fast emerge lucrative business opportunity company rope hugo barra zacks equity research fb wwwzackscom page 3 9,22,18,0.0975609756097561,22,18,0.0975609756097561,0.9896
190,"Facebook, Inc._Attachment1.pdf",FB,1/2/2019,facebook maintains a cautious stance on revenue growth the companys focus on stories which generates lower revenues than news feed is expected to hurt topline growth at least in the near term moreover as the company continues to ramp up investments on products video arvr and ai as well as security costs are already on the rise facebooks is already on a hiring spree especially engineers and people involved in maintaining safety and security this is expected to hurt profitability facebook currently faces stiff competition from other big and small social media players although the company has started distributing ads on other websites we believe that google continues to have a significant competitive edge due to its scale and diversified product offering advertising remains facebooks major source of revenues and increasing competition can hurt its topline growth going forward googles youtube snapchat and pinterest offer tough competition as far as user growth is concerned zacks equity research fb wwwzackscom page 3 of 9,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'company', 'focus', 'story', 'generate', 'low', 'revenue', 'news', 'feed', 'expect', 'hurt', 'topline', 'growth', 'near', 'term', 'company', 'continue', 'ramp', 'investment', 'product', 'video', 'arvr', 'ai', 'security', 'cost', 'rise', 'facebook', 'hire', 'spree', 'especially', 'engineer', 'people', 'involve', 'maintain', 'safety', 'security', 'expect', 'hurt', 'profitability', 'facebook', 'currently', 'face', 'stiff', 'competition', 'big', 'small', 'social', 'medium', 'player', 'company', 'start', 'distribute', 'ad', 'website', 'believe', 'google', 'continue', 'significant', 'competitive', 'edge', 'scale', 'diversified', 'product', 'offer', 'advertising', 'remain', 'facebook', 'major', 'source', 'revenue', 'increase', 'competition', 'hurt', 'topline', 'growth', 'go', 'forward', 'google', 'youtube', 'snapchat', 'pinter', 'offer', 'tough', 'competition', 'far', 'user', 'growth', 'concern', 'zack', 'equity', 'research', 'fb', 'wwwzackscom', 'page', '3', '9']",facebook maintain cautious stance revenue growth company focus story generate low revenue news feed expect hurt topline growth near term company continue ramp investment product video arvr ai security cost rise facebook hire spree especially engineer people involve maintain safety security expect hurt profitability facebook currently face stiff competition big small social medium player company start distribute ad website believe google continue significant competitive edge scale diversified product offer advertising remain facebook major source revenue increase competition hurt topline growth go forward google youtube snapchat pinter offer tough competition far user growth concern zack equity research fb wwwzackscom page 3 9,4,14,-0.5263157894736842,4,14,-0.5263157894736842,0.8271
191,"Facebook, Inc._Attachment1.pdf",FB,3/1/2019,facebook has witnessed significant traction in online and mobile advertising spending in a short span of time mobile ad revenues are growing rapidly primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'short', 'span', 'time', 'mobile', 'ad', 'revenue', 'grow', 'rapidly', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift']",facebook witness significant traction online mobile advertising spending short span time mobile ad revenue grow rapidly primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift,4,5,-0.1,4,5,-0.1,0.7783
192,"Facebook, Inc._Attachment1.pdf",FB,3/1/2019,facebook maintains a cautious stance on revenue growth the companys focus on stories which generates lower revenues than news feed is expected to hurt topline growth at least in the near term moreover as the company continues to ramp up investments on products video arvr and ai as well as security costs are already on the rise facebooks is already on a hiring spree especially engineers and people involved in maintaining safety and security this is expected to hurt profitability,sell,"['facebook', 'maintain', 'cautious', 'stance', 'revenue', 'growth', 'company', 'focus', 'story', 'generate', 'low', 'revenue', 'news', 'feed', 'expect', 'hurt', 'topline', 'growth', 'near', 'term', 'company', 'continue', 'ramp', 'investment', 'product', 'video', 'arvr', 'ai', 'security', 'cost', 'rise', 'facebook', 'hire', 'spree', 'especially', 'engineer', 'people', 'involve', 'maintain', 'safety', 'security', 'expect', 'hurt', 'profitability']",facebook maintain cautious stance revenue growth company focus story generate low revenue news feed expect hurt topline growth near term company continue ramp investment product video arvr ai security cost rise facebook hire spree especially engineer people involve maintain safety security expect hurt profitability,2,7,-0.5,2,7,-0.5,0.5574
193,"Facebook, Inc._Attachment1.pdf",FB,3/25/2020,facebook has witnessed significant traction in online and mobile advertising spending mobile ad revenues are growing rapidly primarily due to the fact that mobile ads have far more ad recall value than other mediums since marketers are moving to mobile to target customers facebook is enthusiastically monetizing this shift,buy,"['facebook', 'witness', 'significant', 'traction', 'online', 'mobile', 'advertising', 'spending', 'mobile', 'ad', 'revenue', 'grow', 'rapidly', 'primarily', 'fact', 'mobile', 'ad', 'far', 'ad', 'recall', 'value', 'medium', 'marketer', 'move', 'mobile', 'target', 'customer', 'facebook', 'enthusiastically', 'monetize', 'shift']",facebook witness significant traction online mobile advertising spending mobile ad revenue grow rapidly primarily fact mobile ad far ad recall value medium marketer move mobile target customer facebook enthusiastically monetize shift,4,4,0.0,4,4,0.0,0.7783
194,"FleetCor Technologies, Inc._Attachment1(2).pdf",FLT,4/2/2019,fleetcors top line continues to grow organically driven by increase in both volume and revenues per transaction in certain of its payment programs in 2018 solid organic growth was observed across the companys major product categories its fuel card business was up 9 corporate payments increased 24 toll business grew 13 and lodging business increased 4 organically organic revenue growth was 10 9 and 8 respectively in 2018 2017 and 2016 for 2019 the company expects to register 911 organic growth on the back of continuous solid performance in its fuel card businesses and contributions from trucking business and growing local operations in north america corporate payments toll and lodging businesses are anticipated to grow in midteens and gift and other businesses are predicted to be approximately flat in 2019 acquisitions are contributing significantly to fleetcors top line the company has been continuously acquiring and investing in companies both in the united states as well as internationally to expand customer base headcount and operations and diversify its service offerings across industries on mar 5 2019 fleetcor announced that it has inked a deal to acquire nvoicepay inc the buyout is expected to expand fleetcors corporate payments business with accounts payable cloud platform in 2018 the company made a 212 million worth acquisition in 2017 fleetcor completed three acquisitions creative lodging solutions cls to strengthen its hotel network through increased room nights cambridge global payments cambridge to expand its corporate payments footprint and a fuel card provider in russia since 2002 the company has acquired more than 75 companies and commercial account portfolios in 2018 the company witnessed 97 million of additional revenues from the acquisitions completed in 2017 in 2017 additional revenues of 212 million were generated from acquisitions completed in 2016 and 2017 fleetcor is a cash rich company with a strong balance sheet as of dec 31 2018 the company had cash cash equivalents and restricted cash of approximately 135 billion compared with 119 billion at the end of the prior quarter the company had inked an interest rate swap agreement to clearoff its 2 billion floating rate debt as of jan 31 the significant amount of cash provides fleetcor the flexibility to pursue strategic acquisitions and other related investments cash rich companies not only guarantee protection but are also likely to reward shareholders from their deep cash balances shares of fleetcor have gained 101 in the past six months compared with 34 rise of the industry it belongs to we are impressed with fleetcor technologies endeavors in rewarding its shareholders through share repurchases in 2018 the company repurchased almost 5 million shares for 9587 million further on jan 23 2019 the companys board of directors approved an additional 500 million in share repurchases under its existing share repurchase program thereby taking the total current repurchase authorization to 551 million in 2017 and 2016 fleetcor bought back shares worth 4024 million and 1877 million respectively such moves indicate the companys commitment to create value for shareholders and underline its confidence in its business these shareholderfriendly initiatives not only instill investors confidence but also positively impact earnings per share,buy,"['fleetcor', 'line', 'continue', 'grow', 'organically', 'drive', 'increase', 'volume', 'revenue', 'transaction', 'certain', 'payment', 'program', '2018', 'solid', 'organic', 'growth', 'observe', 'companys', 'major', 'product', 'category', 'fuel', 'card', 'business', '9', 'corporate', 'payment', 'increase', '24', 'toll', 'business', 'grow', '13', 'lodge', 'business', 'increase', '4', 'organically', 'organic', 'revenue', 'growth', '10', '9', '8', 'respectively', '2018', '2017', '2016', '2019', 'company', 'expect', 'register', '911', 'organic', 'growth', 'continuous', 'solid', 'performance', 'fuel', 'card', 'business', 'contribution', 'trucking', 'business', 'grow', 'local', 'operation', 'north', 'america', 'corporate', 'payment', 'toll', 'lodge', 'business', 'anticipate', 'grow', 'midteen', 'gift', 'business', 'predict', 'approximately', 'flat', '2019', 'acquisition', 'contribute', 'significantly', 'fleetcor', 'line', 'company', 'continuously', 'acquire', 'invest', 'company', 'united', 'states', 'internationally', 'expand', 'customer', 'base', 'headcount', 'operation', 'diversify', 'service', 'offering', 'industry', 'mar', '5', '2019', 'fleetcor', 'announce', 'ink', 'deal', 'acquire', 'nvoicepay', 'inc', 'buyout', 'expect', 'expand', 'fleetcor', 'corporate', 'payment', 'business', 'account', 'payable', 'cloud', 'platform', '2018', 'company', '212', 'million', 'worth', 'acquisition', '2017', 'fleetcor', 'complete', 'acquisition', 'creative', 'lodging', 'solution', 'cls', 'strengthen', 'hotel', 'network', 'increase', 'room', 'night', 'cambridge', 'global', 'payment', 'cambridge', 'expand', 'corporate', 'payment', 'footprint', 'fuel', 'card', 'provider', 'russia', '2002', 'company', 'acquire', '75', 'company', 'commercial', 'account', 'portfolio', '2018', 'company', 'witness', '97', 'million', 'additional', 'revenue', 'acquisition', 'complete', '2017', '2017', 'additional', 'revenue', '212', 'million', 'generate', 'acquisition', 'complete', '2016', '2017', 'fleetcor', 'cash', 'rich', 'company', 'strong', 'balance', 'sheet', 'dec', '31', '2018', 'company', 'cash', 'cash', 'equivalent', 'restrict', 'cash', 'approximately', '135', 'billion', 'compare', '119', 'billion', 'end', 'prior', 'quarter', 'company', 'ink', 'interest', 'rate', 'swap', 'agreement', 'clearoff', '2', 'billion', 'float', 'rate', 'debt', 'jan', '31', 'significant', 'cash', 'provide', 'fleetcor', 'flexibility', 'pursue', 'strategic', 'acquisition', 'related', 'investment', 'cash', 'rich', 'company', 'guarantee', 'protection', 'likely', 'reward', 'shareholder', 'deep', 'cash', 'balance', 'share', 'fleetcor', 'gain', '101', 'past', 'month', 'compare', '34', 'rise', 'industry', 'belong', 'impressed', 'fleetcor', 'technology', 'endeavor', 'reward', 'shareholder', 'share', 'repurchase', '2018', 'company', 'repurchase', '5', 'million', 'share', '9587', 'million', 'jan', '23', '2019', 'companys', 'board', 'director', 'approve', 'additional', '500', 'million', 'share', 'repurchase', 'exist', 'share', 'repurchase', 'program', 'take', 'total', 'current', 'repurchase', 'authorization', '551', 'million', '2017', '2016', 'fleetcor', 'buy', 'share', 'worth', '4024', 'million', '1877', 'million', 'respectively', 'move', 'indicate', 'company', 'commitment', 'create', 'value', 'shareholder', 'underline', 'confidence', 'business', 'shareholderfriendly', 'initiative', 'instill', 'investor', 'confidence', 'positively', 'impact', 'earning', 'share']",fleetcor line continue grow organically drive increase volume revenue transaction certain payment program 2018 solid organic growth observe companys major product category fuel card business 9 corporate payment increase 24 toll business grow 13 lodge business increase 4 organically organic revenue growth 10 9 8 respectively 2018 2017 2016 2019 company expect register 911 organic growth continuous solid performance fuel card business contribution trucking business grow local operation north america corporate payment toll lodge business anticipate grow midteen gift business predict approximately flat 2019 acquisition contribute significantly fleetcor line company continuously acquire invest company united states internationally expand customer base headcount operation diversify service offering industry mar 5 2019 fleetcor announce ink deal acquire nvoicepay inc buyout expect expand fleetcor corporate payment business account payable cloud platform 2018 company 212 million worth acquisition 2017 fleetcor complete acquisition creative lodging solution cls strengthen hotel network increase room night cambridge global payment cambridge expand corporate payment footprint fuel card provider russia 2002 company acquire 75 company commercial account portfolio 2018 company witness 97 million additional revenue acquisition complete 2017 2017 additional revenue 212 million generate acquisition complete 2016 2017 fleetcor cash rich company strong balance sheet dec 31 2018 company cash cash equivalent restrict cash approximately 135 billion compare 119 billion end prior quarter company ink interest rate swap agreement clearoff 2 billion float rate debt jan 31 significant cash provide fleetcor flexibility pursue strategic acquisition related investment cash rich company guarantee protection likely reward shareholder deep cash balance share fleetcor gain 101 past month compare 34 rise industry belong impressed fleetcor technology endeavor reward shareholder share repurchase 2018 company repurchase 5 million share 9587 million jan 23 2019 companys board director approve additional 500 million share repurchase exist share repurchase program take total current repurchase authorization 551 million 2017 2016 fleetcor buy share worth 4024 million 1877 million respectively move indicate company commitment create value shareholder underline confidence business shareholderfriendly initiative instill investor confidence positively impact earning share,10,8,0.10526315789473684,10,8,0.10526315789473684,0.9985
195,"FleetCor Technologies, Inc._Attachment1(2).pdf",FLT,4/2/2019,fleetcor is seeing higher interest expense due to increase in libor rate and additional borrowings for shares repurchase and to fund cambridge acquisition completed in in 2018 interest expense of 13849 million increased 293 year over year for 2019 the company expects interest expense to be 160 million which is almost 20 million higher than 2018 it anticipates higher interest expense to negatively impact its bottom line by an estimated 17 cents per share in 2019 fleetcors fuel card workforce payment solutions and gift card businesses are affected by seasonality the companys fuel card and workforce payment solutions businesses are hampered during the first and fourth quarters as a result of the prevailing weather conditions us holidays christmas celebration in russia in january lower business activities in brazil due to summer break and the carnival celebration the gift card business witnesses higher revenues during the third and fourth quarters primarily due to the holiday season and lower revenues in the first and second quarters due to fluctuating consumer spending patterns fleetcors global presence makes it vulnerable to the risks associated with foreign currency exchange rate fluctuations in 2018 almost 39 of revenues were generated from operations outside the united states with business transactions occurring in currencies like british pound brazilian real canadian dollar russian ruble mexican peso czech koruna euro australian dollar and new zealand dollar thus appreciation or depreciation of the dollar versus these foreign currencies could impact the companys financial results fleetcors policy of acquiring a large number of companies results in some integration risk acquisitions can negatively impact its balance sheet in the form of a high level of goodwill and intangible assets which totaled 69 billion or 622 of total assets at the end of 2018 moreover frequent acquisitions are a distraction for management which could impact organic growth,sell,"['fleetcor', 'see', 'high', 'interest', 'expense', 'increase', 'libor', 'rate', 'additional', 'borrowing', 'share', 'repurchase', 'fund', 'cambridge', 'acquisition', 'complete', '2018', 'interest', 'expense', '13849', 'million', 'increase', '293', 'year', 'year', '2019', 'company', 'expect', 'interest', 'expense', '160', 'million', '20', 'million', 'high', '2018', 'anticipate', 'high', 'interest', 'expense', 'negatively', 'impact', 'line', 'estimate', '17', 'cent', 'share', '2019', 'fleetcor', 'fuel', 'card', 'workforce', 'payment', 'solution', 'gift', 'card', 'business', 'affect', 'seasonality', 'company', 'fuel', 'card', 'workforce', 'payment', 'solution', 'business', 'hamper', 'fourth', 'quarter', 'result', 'prevail', 'weather', 'condition', 'holidays', 'christmas', 'celebration', 'russia', 'january', 'low', 'business', 'activity', 'brazil', 'summer', 'break', 'carnival', 'celebration', 'gift', 'card', 'business', 'witness', 'high', 'revenue', 'fourth', 'quarter', 'primarily', 'holiday', 'season', 'low', 'revenue', 'second', 'quarter', 'fluctuate', 'consumer', 'spending', 'pattern', 'fleetcor', 'global', 'presence', 'make', 'vulnerable', 'risk', 'associate', 'foreign', 'currency', 'exchange', 'rate', 'fluctuation', '2018', '39', 'revenue', 'generate', 'operation', 'outside', 'united', 'states', 'business', 'transaction', 'occur', 'currency', 'like', 'british', 'pound', 'brazilian', 'real', 'canadian', 'dollar', 'russian', 'ruble', 'mexican', 'peso', 'czech', 'koruna', 'euro', 'australian', 'dollar', 'new', 'zealand', 'dollar', 'appreciation', 'depreciation', 'dollar', 'versus', 'foreign', 'currency', 'impact', 'company', 'financial', 'result', 'fleetcor', 'policy', 'acquire', 'large', 'number', 'company', 'result', 'integration', 'risk', 'acquisition', 'negatively', 'impact', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'total', '69', 'billion', '622', 'total', 'asset', 'end', '2018', 'frequent', 'acquisition', 'distraction', 'management', 'impact', 'organic', 'growth']",fleetcor see high interest expense increase libor rate additional borrowing share repurchase fund cambridge acquisition complete 2018 interest expense 13849 million increase 293 year year 2019 company expect interest expense 160 million 20 million high 2018 anticipate high interest expense negatively impact line estimate 17 cent share 2019 fleetcor fuel card workforce payment solution gift card business affect seasonality company fuel card workforce payment solution business hamper fourth quarter result prevail weather condition holidays christmas celebration russia january low business activity brazil summer break carnival celebration gift card business witness high revenue fourth quarter primarily holiday season low revenue second quarter fluctuate consumer spending pattern fleetcor global presence make vulnerable risk associate foreign currency exchange rate fluctuation 2018 39 revenue generate operation outside united states business transaction occur currency like british pound brazilian real canadian dollar russian ruble mexican peso czech koruna euro australian dollar new zealand dollar appreciation depreciation dollar versus foreign currency impact company financial result fleetcor policy acquire large number company result integration risk acquisition negatively impact balance sheet form high level goodwill intangible asset total 69 billion 622 total asset end 2018 frequent acquisition distraction management impact organic growth,5,11,-0.35294117647058826,5,11,-0.35294117647058826,0.9893
196,"FleetCor Technologies, Inc._Attachment1(2).pdf",FLT,5/15/2019,fleetcors top line continues to grow organically driven by increase in both volume and revenues per transaction in certain of its payment programs in firstquarter 2019 organic revenue growth was 11 driven by solid doubledigit growth across the companys product categories fuel corporate payments tolls and lodging its fuel card business was up 10 corporate payments increased 18 toll business grew 15 and lodging business increased 6 organically organic revenue growth was 10 9 and 8 respectively in 2018 2017 and 2016 for 2019 the company continues to expect 911 organic growth acquisitions are contributing significantly to fleetcors top line the company has been continuously acquiring and investing in companies both in the united states as well as internationally to expand customer base headcount and operations and diversify its service offerings across industries in firstquarter 2019 fleetcor completed the purchase of nvoicepay the buyout is expected to expand fleetcors corporate payments business with accounts payable cloud platform in 2018 the company made a 212 million worth acquisition in 2017 fleetcor completed three acquisitions creative lodging solutions cls to strengthen its hotel network through increased room nights cambridge global payments cambridge to expand its corporate payments footprint and a fuel card provider in russia since 2002 the company has acquired more than 75 companies and commercial account portfolios in 2018 the company witnessed 97 million of additional revenues from the acquisitions completed in 2017 in 2017 additional revenues of 212 million were generated from acquisitions completed in 2016 and 2017 fleetcor is a cash rich company with a strong balance sheet as of mar 31 2019 the company had cash cash equivalents and restricted cash of 14 billion with no longterm debt to clearoff this significant amount of cash provides fleetcor the flexibility to pursue strategic acquisitions and other related investments cash rich companies not only guarantee protection but are also likely to reward shareholders from their deep cash balances shares of fleetcor have gained 216 in the past six months compared with 89 rise of the industry it belongs to we are impressed with fleetcor technologies endeavors in rewarding its shareholders through share repurchases in first quarter 2019 fleetcor repurchased shares worth 332 million in 2018 2017 and 2016 the company had repurchased shares worth 9587 million 4024 million and 1877 million respectively such moves indicate the companys commitment to create value for shareholders and underline its confidence in its business these shareholderfriendly initiatives not only instill investors confidence but also positively impact earnings per share,buy,"['fleetcor', 'line', 'continue', 'grow', 'organically', 'drive', 'increase', 'volume', 'revenue', 'transaction', 'certain', 'payment', 'program', 'firstquarter', '2019', 'organic', 'revenue', 'growth', '11', 'drive', 'solid', 'doubledigit', 'growth', 'company', 'product', 'category', 'fuel', 'corporate', 'payment', 'toll', 'lodge', 'fuel', 'card', 'business', '10', 'corporate', 'payment', 'increase', '18', 'toll', 'business', 'grow', '15', 'lodge', 'business', 'increase', '6', 'organically', 'organic', 'revenue', 'growth', '10', '9', '8', 'respectively', '2018', '2017', '2016', '2019', 'company', 'continue', 'expect', '911', 'organic', 'growth', 'acquisition', 'contribute', 'significantly', 'fleetcor', 'line', 'company', 'continuously', 'acquire', 'invest', 'company', 'united', 'states', 'internationally', 'expand', 'customer', 'base', 'headcount', 'operation', 'diversify', 'service', 'offering', 'industry', 'firstquarter', '2019', 'fleetcor', 'complete', 'purchase', 'nvoicepay', 'buyout', 'expect', 'expand', 'fleetcor', 'corporate', 'payment', 'business', 'account', 'payable', 'cloud', 'platform', '2018', 'company', '212', 'million', 'worth', 'acquisition', '2017', 'fleetcor', 'complete', 'acquisition', 'creative', 'lodging', 'solution', 'cls', 'strengthen', 'hotel', 'network', 'increase', 'room', 'night', 'cambridge', 'global', 'payment', 'cambridge', 'expand', 'corporate', 'payment', 'footprint', 'fuel', 'card', 'provider', 'russia', '2002', 'company', 'acquire', '75', 'company', 'commercial', 'account', 'portfolio', '2018', 'company', 'witness', '97', 'million', 'additional', 'revenue', 'acquisition', 'complete', '2017', '2017', 'additional', 'revenue', '212', 'million', 'generate', 'acquisition', 'complete', '2016', '2017', 'fleetcor', 'cash', 'rich', 'company', 'strong', 'balance', 'sheet', 'mar', '31', '2019', 'company', 'cash', 'cash', 'equivalent', 'restrict', 'cash', '14', 'billion', 'longterm', 'debt', 'clearoff', 'significant', 'cash', 'provide', 'fleetcor', 'flexibility', 'pursue', 'strategic', 'acquisition', 'related', 'investment', 'cash', 'rich', 'company', 'guarantee', 'protection', 'likely', 'reward', 'shareholder', 'deep', 'cash', 'balance', 'share', 'fleetcor', 'gain', '216', 'past', 'month', 'compare', '89', 'rise', 'industry', 'belong', 'impressed', 'fleetcor', 'technology', 'endeavor', 'reward', 'shareholder', 'share', 'repurchase', 'quarter', '2019', 'fleetcor', 'repurchase', 'share', 'worth', '332', 'million', '2018', '2017', '2016', 'company', 'repurchase', 'share', 'worth', '9587', 'million', '4024', 'million', '1877', 'million', 'respectively', 'move', 'indicate', 'company', 'commitment', 'create', 'value', 'shareholder', 'underline', 'confidence', 'business', 'shareholderfriendly', 'initiative', 'instill', 'investor', 'confidence', 'positively', 'impact', 'earning', 'share']",fleetcor line continue grow organically drive increase volume revenue transaction certain payment program firstquarter 2019 organic revenue growth 11 drive solid doubledigit growth company product category fuel corporate payment toll lodge fuel card business 10 corporate payment increase 18 toll business grow 15 lodge business increase 6 organically organic revenue growth 10 9 8 respectively 2018 2017 2016 2019 company continue expect 911 organic growth acquisition contribute significantly fleetcor line company continuously acquire invest company united states internationally expand customer base headcount operation diversify service offering industry firstquarter 2019 fleetcor complete purchase nvoicepay buyout expect expand fleetcor corporate payment business account payable cloud platform 2018 company 212 million worth acquisition 2017 fleetcor complete acquisition creative lodging solution cls strengthen hotel network increase room night cambridge global payment cambridge expand corporate payment footprint fuel card provider russia 2002 company acquire 75 company commercial account portfolio 2018 company witness 97 million additional revenue acquisition complete 2017 2017 additional revenue 212 million generate acquisition complete 2016 2017 fleetcor cash rich company strong balance sheet mar 31 2019 company cash cash equivalent restrict cash 14 billion longterm debt clearoff significant cash provide fleetcor flexibility pursue strategic acquisition related investment cash rich company guarantee protection likely reward shareholder deep cash balance share fleetcor gain 216 past month compare 89 rise industry belong impressed fleetcor technology endeavor reward shareholder share repurchase quarter 2019 fleetcor repurchase share worth 332 million 2018 2017 2016 company repurchase share worth 9587 million 4024 million 1877 million respectively move indicate company commitment create value shareholder underline confidence business shareholderfriendly initiative instill investor confidence positively impact earning share,11,5,0.35294117647058826,11,5,0.35294117647058826,0.9982
197,"FleetCor Technologies, Inc._Attachment1(2).pdf",FLT,5/15/2019,fleetcor is seeing higher interest expense due to increase in libor rate and additional borrowings for shares repurchase and to fund cambridge acquisition completed in in firstquarter 2019 interest expense of 391 million increased 257 year over year the same rose 293 year over year in 2018 for 2019 the company expects interest expense to be 160 million which is almost 20 million higher than 2018 it anticipates higher interest expense to negatively impact its bottom line by an estimated 17 cents per share in 2019 fleetcors fuel card workforce payment solutions and gift card businesses are affected by seasonality the companys fuel card and workforce payment solutions businesses are hampered during the first and fourth quarters as a result of the prevailing weather conditions us holidays christmas celebration in russia in january lower business activities in brazil due to summer break and the carnival celebration the gift card business witnesses higher revenues during the third and fourth quarters primarily due to the holiday season and lower revenues in the first and second quarters due to fluctuating consumer spending patterns fleetcors global presence makes it vulnerable to the risks associated with foreign currency exchange rate fluctuations in 2018 almost 39 of revenues were generated from operations outside the united states with business transactions occurring in currencies like british pound brazilian real canadian dollar russian ruble mexican peso czech koruna euro australian dollar and new zealand dollar thus appreciation or depreciation of the dollar versus these foreign currencies could impact the companys financial results fleetcors policy of acquiring a large number of companies results in some integration risk acquisitions can negatively impact its balance sheet in the form of a high level of goodwill and intangible assets which totaled 69 billion or 622 of total assets at the end of 2018 moreover frequent acquisitions are a distraction for management which could impact organic growth zacks equity research flt wwwzackscom page 4 of 9,sell,"['fleetcor', 'see', 'high', 'interest', 'expense', 'increase', 'libor', 'rate', 'additional', 'borrowing', 'share', 'repurchase', 'fund', 'cambridge', 'acquisition', 'complete', 'firstquarter', '2019', 'interest', 'expense', '391', 'million', 'increase', '257', 'year', 'year', 'rise', '293', 'year', 'year', '2018', '2019', 'company', 'expect', 'interest', 'expense', '160', 'million', '20', 'million', 'high', '2018', 'anticipate', 'high', 'interest', 'expense', 'negatively', 'impact', 'line', 'estimate', '17', 'cent', 'share', '2019', 'fleetcor', 'fuel', 'card', 'workforce', 'payment', 'solution', 'gift', 'card', 'business', 'affect', 'seasonality', 'company', 'fuel', 'card', 'workforce', 'payment', 'solution', 'business', 'hamper', 'fourth', 'quarter', 'result', 'prevail', 'weather', 'condition', 'holidays', 'christmas', 'celebration', 'russia', 'january', 'low', 'business', 'activity', 'brazil', 'summer', 'break', 'carnival', 'celebration', 'gift', 'card', 'business', 'witness', 'high', 'revenue', 'fourth', 'quarter', 'primarily', 'holiday', 'season', 'low', 'revenue', 'second', 'quarter', 'fluctuate', 'consumer', 'spending', 'pattern', 'fleetcor', 'global', 'presence', 'make', 'vulnerable', 'risk', 'associate', 'foreign', 'currency', 'exchange', 'rate', 'fluctuation', '2018', '39', 'revenue', 'generate', 'operation', 'outside', 'united', 'states', 'business', 'transaction', 'occur', 'currency', 'like', 'british', 'pound', 'brazilian', 'real', 'canadian', 'dollar', 'russian', 'ruble', 'mexican', 'peso', 'czech', 'koruna', 'euro', 'australian', 'dollar', 'new', 'zealand', 'dollar', 'appreciation', 'depreciation', 'dollar', 'versus', 'foreign', 'currency', 'impact', 'company', 'financial', 'result', 'fleetcor', 'policy', 'acquire', 'large', 'number', 'company', 'result', 'integration', 'risk', 'acquisition', 'negatively', 'impact', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'total', '69', 'billion', '622', 'total', 'asset', 'end', '2018', 'frequent', 'acquisition', 'distraction', 'management', 'impact', 'organic', 'growth', 'zack', 'equity', 'research', 'flt', 'wwwzackscom', 'page', '4', '9']",fleetcor see high interest expense increase libor rate additional borrowing share repurchase fund cambridge acquisition complete firstquarter 2019 interest expense 391 million increase 257 year year rise 293 year year 2018 2019 company expect interest expense 160 million 20 million high 2018 anticipate high interest expense negatively impact line estimate 17 cent share 2019 fleetcor fuel card workforce payment solution gift card business affect seasonality company fuel card workforce payment solution business hamper fourth quarter result prevail weather condition holidays christmas celebration russia january low business activity brazil summer break carnival celebration gift card business witness high revenue fourth quarter primarily holiday season low revenue second quarter fluctuate consumer spending pattern fleetcor global presence make vulnerable risk associate foreign currency exchange rate fluctuation 2018 39 revenue generate operation outside united states business transaction occur currency like british pound brazilian real canadian dollar russian ruble mexican peso czech koruna euro australian dollar new zealand dollar appreciation depreciation dollar versus foreign currency impact company financial result fleetcor policy acquire large number company result integration risk acquisition negatively impact balance sheet form high level goodwill intangible asset total 69 billion 622 total asset end 2018 frequent acquisition distraction management impact organic growth zack equity research flt wwwzackscom page 4 9,5,12,-0.3888888888888889,5,12,-0.3888888888888889,0.9893
198,"FleetCor Technologies, Inc._Attachment1(3).pdf",FLT,4/9/2019,fleetcors top line continues to grow organically driven by increase in both volume and revenues per transaction in certain of its payment programs in 2018 solid organic growth was observed across the companys major product categories its fuel card business was up 9 corporate payments increased 24 toll business grew 13 and lodging business increased 4 organically organic revenue growth was 10 9 and 8 respectively in 2018 2017 and 2016 for 2019 the company expects to register 911 organic growth on the back of continuous solid performance in its fuel card businesses and contributions from trucking business and growing local operations in north america corporate payments toll and lodging businesses are anticipated to grow in midteens and gift and other businesses are predicted to be approximately flat in 2019 acquisitions are contributing significantly to fleetcors top line the company has been continuously acquiring and investing in companies both in the united states as well as internationally to expand customer base headcount and operations and diversify its service offerings across industries on mar 5 2019 fleetcor announced that it has inked a deal to acquire nvoicepay inc the buyout is expected to expand fleetcors corporate payments business with accounts payable cloud platform in 2018 the company made a 212 million worth acquisition in 2017 fleetcor completed three acquisitions creative lodging solutions cls to strengthen its hotel network through increased room nights cambridge global payments cambridge to expand its corporate payments footprint and a fuel card provider in russia since 2002 the company has acquired more than 75 companies and commercial account portfolios in 2018 the company witnessed 97 million of additional revenues from the acquisitions completed in 2017 in 2017 additional revenues of 212 million were generated from acquisitions completed in 2016 and 2017 fleetcor is a cash rich company with a strong balance sheet as of dec 31 2018 the company had cash cash equivalents and restricted cash of approximately 135 billion compared with 119 billion at the end of the prior quarter the company had inked an interest rate swap agreement to clearoff its 2 billion floating rate debt as of jan 31 the significant amount of cash provides fleetcor the flexibility to pursue strategic acquisitions and other related investments cash rich companies not only guarantee protection but are also likely to reward shareholders from their deep cash balances shares of fleetcor have gained 222 in the past six months compared with 155 rise of the industry it belongs to we are impressed with fleetcor technologies endeavors in rewarding its shareholders through share repurchases in 2018 the company repurchased almost 5 million shares for 9587 million further on jan 23 2019 the companys board of directors approved an additional 500 million in share repurchases under its existing share repurchase program thereby taking the total current repurchase authorization to 551 million in 2017 and 2016 fleetcor bought back shares worth 4024 million and 1877 million respectively such moves indicate the companys commitment to create value for shareholders and underline its confidence in its business these shareholderfriendly initiatives not only instill investors confidence but also positively impact earnings per share,buy,"['fleetcor', 'line', 'continue', 'grow', 'organically', 'drive', 'increase', 'volume', 'revenue', 'transaction', 'certain', 'payment', 'program', '2018', 'solid', 'organic', 'growth', 'observe', 'companys', 'major', 'product', 'category', 'fuel', 'card', 'business', '9', 'corporate', 'payment', 'increase', '24', 'toll', 'business', 'grow', '13', 'lodge', 'business', 'increase', '4', 'organically', 'organic', 'revenue', 'growth', '10', '9', '8', 'respectively', '2018', '2017', '2016', '2019', 'company', 'expect', 'register', '911', 'organic', 'growth', 'continuous', 'solid', 'performance', 'fuel', 'card', 'business', 'contribution', 'trucking', 'business', 'grow', 'local', 'operation', 'north', 'america', 'corporate', 'payment', 'toll', 'lodge', 'business', 'anticipate', 'grow', 'midteen', 'gift', 'business', 'predict', 'approximately', 'flat', '2019', 'acquisition', 'contribute', 'significantly', 'fleetcor', 'line', 'company', 'continuously', 'acquire', 'invest', 'company', 'united', 'states', 'internationally', 'expand', 'customer', 'base', 'headcount', 'operation', 'diversify', 'service', 'offering', 'industry', 'mar', '5', '2019', 'fleetcor', 'announce', 'ink', 'deal', 'acquire', 'nvoicepay', 'inc', 'buyout', 'expect', 'expand', 'fleetcor', 'corporate', 'payment', 'business', 'account', 'payable', 'cloud', 'platform', '2018', 'company', '212', 'million', 'worth', 'acquisition', '2017', 'fleetcor', 'complete', 'acquisition', 'creative', 'lodging', 'solution', 'cls', 'strengthen', 'hotel', 'network', 'increase', 'room', 'night', 'cambridge', 'global', 'payment', 'cambridge', 'expand', 'corporate', 'payment', 'footprint', 'fuel', 'card', 'provider', 'russia', '2002', 'company', 'acquire', '75', 'company', 'commercial', 'account', 'portfolio', '2018', 'company', 'witness', '97', 'million', 'additional', 'revenue', 'acquisition', 'complete', '2017', '2017', 'additional', 'revenue', '212', 'million', 'generate', 'acquisition', 'complete', '2016', '2017', 'fleetcor', 'cash', 'rich', 'company', 'strong', 'balance', 'sheet', 'dec', '31', '2018', 'company', 'cash', 'cash', 'equivalent', 'restrict', 'cash', 'approximately', '135', 'billion', 'compare', '119', 'billion', 'end', 'prior', 'quarter', 'company', 'ink', 'interest', 'rate', 'swap', 'agreement', 'clearoff', '2', 'billion', 'float', 'rate', 'debt', 'jan', '31', 'significant', 'cash', 'provide', 'fleetcor', 'flexibility', 'pursue', 'strategic', 'acquisition', 'related', 'investment', 'cash', 'rich', 'company', 'guarantee', 'protection', 'likely', 'reward', 'shareholder', 'deep', 'cash', 'balance', 'share', 'fleetcor', 'gain', '222', 'past', 'month', 'compare', '155', 'rise', 'industry', 'belong', 'impressed', 'fleetcor', 'technology', 'endeavor', 'reward', 'shareholder', 'share', 'repurchase', '2018', 'company', 'repurchase', '5', 'million', 'share', '9587', 'million', 'jan', '23', '2019', 'companys', 'board', 'director', 'approve', 'additional', '500', 'million', 'share', 'repurchase', 'exist', 'share', 'repurchase', 'program', 'take', 'total', 'current', 'repurchase', 'authorization', '551', 'million', '2017', '2016', 'fleetcor', 'buy', 'share', 'worth', '4024', 'million', '1877', 'million', 'respectively', 'move', 'indicate', 'company', 'commitment', 'create', 'value', 'shareholder', 'underline', 'confidence', 'business', 'shareholderfriendly', 'initiative', 'instill', 'investor', 'confidence', 'positively', 'impact', 'earning', 'share']",fleetcor line continue grow organically drive increase volume revenue transaction certain payment program 2018 solid organic growth observe companys major product category fuel card business 9 corporate payment increase 24 toll business grow 13 lodge business increase 4 organically organic revenue growth 10 9 8 respectively 2018 2017 2016 2019 company expect register 911 organic growth continuous solid performance fuel card business contribution trucking business grow local operation north america corporate payment toll lodge business anticipate grow midteen gift business predict approximately flat 2019 acquisition contribute significantly fleetcor line company continuously acquire invest company united states internationally expand customer base headcount operation diversify service offering industry mar 5 2019 fleetcor announce ink deal acquire nvoicepay inc buyout expect expand fleetcor corporate payment business account payable cloud platform 2018 company 212 million worth acquisition 2017 fleetcor complete acquisition creative lodging solution cls strengthen hotel network increase room night cambridge global payment cambridge expand corporate payment footprint fuel card provider russia 2002 company acquire 75 company commercial account portfolio 2018 company witness 97 million additional revenue acquisition complete 2017 2017 additional revenue 212 million generate acquisition complete 2016 2017 fleetcor cash rich company strong balance sheet dec 31 2018 company cash cash equivalent restrict cash approximately 135 billion compare 119 billion end prior quarter company ink interest rate swap agreement clearoff 2 billion float rate debt jan 31 significant cash provide fleetcor flexibility pursue strategic acquisition related investment cash rich company guarantee protection likely reward shareholder deep cash balance share fleetcor gain 222 past month compare 155 rise industry belong impressed fleetcor technology endeavor reward shareholder share repurchase 2018 company repurchase 5 million share 9587 million jan 23 2019 companys board director approve additional 500 million share repurchase exist share repurchase program take total current repurchase authorization 551 million 2017 2016 fleetcor buy share worth 4024 million 1877 million respectively move indicate company commitment create value shareholder underline confidence business shareholderfriendly initiative instill investor confidence positively impact earning share,10,8,0.10526315789473684,10,8,0.10526315789473684,0.9985
199,"FleetCor Technologies, Inc._Attachment1(3).pdf",FLT,5/20/2019,fleetcors top line continues to grow organically driven by increase in both volume and revenues per transaction in certain of its payment programs in firstquarter 2019 organic revenue growth was 11 driven by solid doubledigit growth across the companys product categories fuel corporate payments tolls and lodging its fuel card business was up 10 corporate payments increased 18 toll business grew 15 and lodging business increased 6 organically organic revenue growth was 10 9 and 8 respectively in 2018 2017 and 2016 for 2019 the company continues to expect 911 organic growth acquisitions are contributing significantly to fleetcors top line the company has been continuously acquiring and investing in companies both in the united states as well as internationally to expand customer base headcount and operations and diversify its service offerings across industries in firstquarter 2019 fleetcor completed the purchase of nvoicepay the buyout is expected to expand fleetcors corporate payments business with full disbursement accounts payable cloud platform in 2018 the company made a 212 million worth acquisition in 2017 fleetcor completed three acquisitions creative lodging solutions cls to strengthen its hotel network through increased room nights cambridge global payments cambridge to expand its corporate payments footprint and a fuel card provider in russia since 2002 the company has acquired more than 75 companies and commercial account portfolios in 2018 the company witnessed 97 million of additional revenues from the acquisitions completed in 2017 in 2017 additional revenues of 212 million were generated from acquisitions completed in 2016 and 2017 fleetcor is a cash rich company with a strong balance sheet as of mar 31 2019 the company had cash cash equivalents and restricted cash of 14 billion with no longterm debt to clearoff this significant amount of cash provides fleetcor the flexibility to pursue strategic acquisitions and other related investments cash rich companies not only guarantee protection but are also likely to reward shareholders from their deep cash balances shares of fleetcor have gained 431 in the past six months compared with 214 rise of the industry it belongs to we are impressed with fleetcor technologies endeavors in rewarding its shareholders through share repurchases in first quarter 2019 fleetcor repurchased shares worth 332 million in 2018 2017 and 2016 the company had repurchased shares worth 9587 million 4024 million and 1877 million respectively such moves indicate the companys commitment to create value for shareholders and underline its confidence in its business these shareholderfriendly initiatives not only instill investors confidence but also positively impact earnings per share,buy,"['fleetcor', 'line', 'continue', 'grow', 'organically', 'drive', 'increase', 'volume', 'revenue', 'transaction', 'certain', 'payment', 'program', 'firstquarter', '2019', 'organic', 'revenue', 'growth', '11', 'drive', 'solid', 'doubledigit', 'growth', 'company', 'product', 'category', 'fuel', 'corporate', 'payment', 'toll', 'lodge', 'fuel', 'card', 'business', '10', 'corporate', 'payment', 'increase', '18', 'toll', 'business', 'grow', '15', 'lodge', 'business', 'increase', '6', 'organically', 'organic', 'revenue', 'growth', '10', '9', '8', 'respectively', '2018', '2017', '2016', '2019', 'company', 'continue', 'expect', '911', 'organic', 'growth', 'acquisition', 'contribute', 'significantly', 'fleetcor', 'line', 'company', 'continuously', 'acquire', 'invest', 'company', 'united', 'states', 'internationally', 'expand', 'customer', 'base', 'headcount', 'operation', 'diversify', 'service', 'offering', 'industry', 'firstquarter', '2019', 'fleetcor', 'complete', 'purchase', 'nvoicepay', 'buyout', 'expect', 'expand', 'fleetcor', 'corporate', 'payment', 'business', 'disbursement', 'account', 'payable', 'cloud', 'platform', '2018', 'company', '212', 'million', 'worth', 'acquisition', '2017', 'fleetcor', 'complete', 'acquisition', 'creative', 'lodging', 'solution', 'cls', 'strengthen', 'hotel', 'network', 'increase', 'room', 'night', 'cambridge', 'global', 'payment', 'cambridge', 'expand', 'corporate', 'payment', 'footprint', 'fuel', 'card', 'provider', 'russia', '2002', 'company', 'acquire', '75', 'company', 'commercial', 'account', 'portfolio', '2018', 'company', 'witness', '97', 'million', 'additional', 'revenue', 'acquisition', 'complete', '2017', '2017', 'additional', 'revenue', '212', 'million', 'generate', 'acquisition', 'complete', '2016', '2017', 'fleetcor', 'cash', 'rich', 'company', 'strong', 'balance', 'sheet', 'mar', '31', '2019', 'company', 'cash', 'cash', 'equivalent', 'restrict', 'cash', '14', 'billion', 'longterm', 'debt', 'clearoff', 'significant', 'cash', 'provide', 'fleetcor', 'flexibility', 'pursue', 'strategic', 'acquisition', 'related', 'investment', 'cash', 'rich', 'company', 'guarantee', 'protection', 'likely', 'reward', 'shareholder', 'deep', 'cash', 'balance', 'share', 'fleetcor', 'gain', '431', 'past', 'month', 'compare', '214', 'rise', 'industry', 'belong', 'impressed', 'fleetcor', 'technology', 'endeavor', 'reward', 'shareholder', 'share', 'repurchase', 'quarter', '2019', 'fleetcor', 'repurchase', 'share', 'worth', '332', 'million', '2018', '2017', '2016', 'company', 'repurchase', 'share', 'worth', '9587', 'million', '4024', 'million', '1877', 'million', 'respectively', 'move', 'indicate', 'company', 'commitment', 'create', 'value', 'shareholder', 'underline', 'confidence', 'business', 'shareholderfriendly', 'initiative', 'instill', 'investor', 'confidence', 'positively', 'impact', 'earning', 'share']",fleetcor line continue grow organically drive increase volume revenue transaction certain payment program firstquarter 2019 organic revenue growth 11 drive solid doubledigit growth company product category fuel corporate payment toll lodge fuel card business 10 corporate payment increase 18 toll business grow 15 lodge business increase 6 organically organic revenue growth 10 9 8 respectively 2018 2017 2016 2019 company continue expect 911 organic growth acquisition contribute significantly fleetcor line company continuously acquire invest company united states internationally expand customer base headcount operation diversify service offering industry firstquarter 2019 fleetcor complete purchase nvoicepay buyout expect expand fleetcor corporate payment business disbursement account payable cloud platform 2018 company 212 million worth acquisition 2017 fleetcor complete acquisition creative lodging solution cls strengthen hotel network increase room night cambridge global payment cambridge expand corporate payment footprint fuel card provider russia 2002 company acquire 75 company commercial account portfolio 2018 company witness 97 million additional revenue acquisition complete 2017 2017 additional revenue 212 million generate acquisition complete 2016 2017 fleetcor cash rich company strong balance sheet mar 31 2019 company cash cash equivalent restrict cash 14 billion longterm debt clearoff significant cash provide fleetcor flexibility pursue strategic acquisition related investment cash rich company guarantee protection likely reward shareholder deep cash balance share fleetcor gain 431 past month compare 214 rise industry belong impressed fleetcor technology endeavor reward shareholder share repurchase quarter 2019 fleetcor repurchase share worth 332 million 2018 2017 2016 company repurchase share worth 9587 million 4024 million 1877 million respectively move indicate company commitment create value shareholder underline confidence business shareholderfriendly initiative instill investor confidence positively impact earning share,11,5,0.35294117647058826,11,5,0.35294117647058826,0.9982
200,"FleetCor Technologies, Inc._Attachment1(4).pdf",FLT,6/12/2019,fleetcor is seeing higher interest expense due to increase in libor rate and additional borrowings for shares repurchase and to fund cambridge acquisition completed in in firstquarter 2019 interest expense of 391 million increased 257 year over year the same rose 293 year over year in 2018 for 2019 the company expects interest expense to be 160 million which is almost 20 million higher than 2018 it anticipates higher interest expense to negatively impact its bottom line by an estimated 17 cents per share in 2019,sell,"['fleetcor', 'see', 'high', 'interest', 'expense', 'increase', 'libor', 'rate', 'additional', 'borrowing', 'share', 'repurchase', 'fund', 'cambridge', 'acquisition', 'complete', 'firstquarter', '2019', 'interest', 'expense', '391', 'million', 'increase', '257', 'year', 'year', 'rise', '293', 'year', 'year', '2018', '2019', 'company', 'expect', 'interest', 'expense', '160', 'million', '20', 'million', 'high', '2018', 'anticipate', 'high', 'interest', 'expense', 'negatively', 'impact', 'line', 'estimate', '17', 'cent', 'share', '2019']",fleetcor see high interest expense increase libor rate additional borrowing share repurchase fund cambridge acquisition complete firstquarter 2019 interest expense 391 million increase 257 year year rise 293 year year 2018 2019 company expect interest expense 160 million 20 million high 2018 anticipate high interest expense negatively impact line estimate 17 cent share 2019,3,2,0.16666666666666666,3,2,0.16666666666666666,0.9584
201,"FleetCor Technologies, Inc._Attachment1.pdf",FLT,3/28/2019,fleetcors top line continues to grow organically driven by increase in both volume and revenues per transaction in certain of its payment programs in 2018 solid organic growth was observed across the companys major product categories its fuel card business was up 9 corporate payments increased 24 toll business grew 13 and lodging business increased 4 organically organic revenue growth was 10 9 and 8 respectively in 2018 2017 and 2016 for 2019 the company expects to register 911 organic growth on the back of continuous solid performance in its fuel card businesses and contributions from trucking business and growing local operations in north america corporate payments toll and lodging businesses are anticipated to grow in midteens and gift and other businesses are predicted to be approximately flat in 2019 acquisitions are contributing significantly to fleetcors top line the company has been continuously acquiring and investing in companies both in the united states as well as internationally to expand customer base headcount and operations and diversify its service offerings across industries on mar 5 2019 fleetcor announced that it has inked a deal to acquire nvoicepay inc the buyout is expected to expand fleetcors corporate payments business with accounts payable cloud platform in 2018 the company made a 212 million worth acquisition in 2017 fleetcor completed three acquisitions creative lodging solutions cls to strengthen its hotel network through increased room nights cambridge global payments cambridge to expand its corporate payments footprint and a fuel card provider in russia since 2002 the company has acquired more than 75 companies and commercial account portfolios in 2018 the company witnessed 97 million of additional revenues from the acquisitions completed in 2017 in 2017 additional revenues of 212 million were generated from acquisitions completed in 2016 and 2017 fleetcor is a cash rich company with a strong balance sheet as of dec 31 2018 the company had cash cash equivalents and restricted cash of approximately 135 billion compared with 119 billion at the end of the prior quarter the company had inked an interest rate swap agreement to clearoff its 2 billion floating rate debt as of jan 31 the significant amount of cash provides fleetcor the flexibility to pursue strategic acquisitions and other related investments cash rich companies not only guarantee protection but are also likely to reward shareholders from their deep cash balances we are impressed with fleetcor technologies endeavors in rewarding its shareholders through share repurchases in 2018 the company repurchased almost 5 million shares for 9587 million further on jan 23 2019 the companys board of directors approved an additional 500 million in share repurchases under its existing share repurchase program thereby taking the total current repurchase authorization to 551 million in 2017 and 2016 fleetcor bought back shares worth 4024 million and 1877 million respectively such moves indicate the companys commitment to create value for shareholders and underline its confidence in its business these shareholderfriendly initiatives not only instill investors confidence but also positively impact earnings per share,buy,"['fleetcor', 'line', 'continue', 'grow', 'organically', 'drive', 'increase', 'volume', 'revenue', 'transaction', 'certain', 'payment', 'program', '2018', 'solid', 'organic', 'growth', 'observe', 'companys', 'major', 'product', 'category', 'fuel', 'card', 'business', '9', 'corporate', 'payment', 'increase', '24', 'toll', 'business', 'grow', '13', 'lodge', 'business', 'increase', '4', 'organically', 'organic', 'revenue', 'growth', '10', '9', '8', 'respectively', '2018', '2017', '2016', '2019', 'company', 'expect', 'register', '911', 'organic', 'growth', 'continuous', 'solid', 'performance', 'fuel', 'card', 'business', 'contribution', 'trucking', 'business', 'grow', 'local', 'operation', 'north', 'america', 'corporate', 'payment', 'toll', 'lodge', 'business', 'anticipate', 'grow', 'midteen', 'gift', 'business', 'predict', 'approximately', 'flat', '2019', 'acquisition', 'contribute', 'significantly', 'fleetcor', 'line', 'company', 'continuously', 'acquire', 'invest', 'company', 'united', 'states', 'internationally', 'expand', 'customer', 'base', 'headcount', 'operation', 'diversify', 'service', 'offering', 'industry', 'mar', '5', '2019', 'fleetcor', 'announce', 'ink', 'deal', 'acquire', 'nvoicepay', 'inc', 'buyout', 'expect', 'expand', 'fleetcor', 'corporate', 'payment', 'business', 'account', 'payable', 'cloud', 'platform', '2018', 'company', '212', 'million', 'worth', 'acquisition', '2017', 'fleetcor', 'complete', 'acquisition', 'creative', 'lodging', 'solution', 'cls', 'strengthen', 'hotel', 'network', 'increase', 'room', 'night', 'cambridge', 'global', 'payment', 'cambridge', 'expand', 'corporate', 'payment', 'footprint', 'fuel', 'card', 'provider', 'russia', '2002', 'company', 'acquire', '75', 'company', 'commercial', 'account', 'portfolio', '2018', 'company', 'witness', '97', 'million', 'additional', 'revenue', 'acquisition', 'complete', '2017', '2017', 'additional', 'revenue', '212', 'million', 'generate', 'acquisition', 'complete', '2016', '2017', 'fleetcor', 'cash', 'rich', 'company', 'strong', 'balance', 'sheet', 'dec', '31', '2018', 'company', 'cash', 'cash', 'equivalent', 'restrict', 'cash', 'approximately', '135', 'billion', 'compare', '119', 'billion', 'end', 'prior', 'quarter', 'company', 'ink', 'interest', 'rate', 'swap', 'agreement', 'clearoff', '2', 'billion', 'float', 'rate', 'debt', 'jan', '31', 'significant', 'cash', 'provide', 'fleetcor', 'flexibility', 'pursue', 'strategic', 'acquisition', 'related', 'investment', 'cash', 'rich', 'company', 'guarantee', 'protection', 'likely', 'reward', 'shareholder', 'deep', 'cash', 'balance', 'impressed', 'fleetcor', 'technology', 'endeavor', 'reward', 'shareholder', 'share', 'repurchase', '2018', 'company', 'repurchase', '5', 'million', 'share', '9587', 'million', 'jan', '23', '2019', 'companys', 'board', 'director', 'approve', 'additional', '500', 'million', 'share', 'repurchase', 'exist', 'share', 'repurchase', 'program', 'take', 'total', 'current', 'repurchase', 'authorization', '551', 'million', '2017', '2016', 'fleetcor', 'buy', 'share', 'worth', '4024', 'million', '1877', 'million', 'respectively', 'move', 'indicate', 'company', 'commitment', 'create', 'value', 'shareholder', 'underline', 'confidence', 'business', 'shareholderfriendly', 'initiative', 'instill', 'investor', 'confidence', 'positively', 'impact', 'earning', 'share']",fleetcor line continue grow organically drive increase volume revenue transaction certain payment program 2018 solid organic growth observe companys major product category fuel card business 9 corporate payment increase 24 toll business grow 13 lodge business increase 4 organically organic revenue growth 10 9 8 respectively 2018 2017 2016 2019 company expect register 911 organic growth continuous solid performance fuel card business contribution trucking business grow local operation north america corporate payment toll lodge business anticipate grow midteen gift business predict approximately flat 2019 acquisition contribute significantly fleetcor line company continuously acquire invest company united states internationally expand customer base headcount operation diversify service offering industry mar 5 2019 fleetcor announce ink deal acquire nvoicepay inc buyout expect expand fleetcor corporate payment business account payable cloud platform 2018 company 212 million worth acquisition 2017 fleetcor complete acquisition creative lodging solution cls strengthen hotel network increase room night cambridge global payment cambridge expand corporate payment footprint fuel card provider russia 2002 company acquire 75 company commercial account portfolio 2018 company witness 97 million additional revenue acquisition complete 2017 2017 additional revenue 212 million generate acquisition complete 2016 2017 fleetcor cash rich company strong balance sheet dec 31 2018 company cash cash equivalent restrict cash approximately 135 billion compare 119 billion end prior quarter company ink interest rate swap agreement clearoff 2 billion float rate debt jan 31 significant cash provide fleetcor flexibility pursue strategic acquisition related investment cash rich company guarantee protection likely reward shareholder deep cash balance impressed fleetcor technology endeavor reward shareholder share repurchase 2018 company repurchase 5 million share 9587 million jan 23 2019 companys board director approve additional 500 million share repurchase exist share repurchase program take total current repurchase authorization 551 million 2017 2016 fleetcor buy share worth 4024 million 1877 million respectively move indicate company commitment create value shareholder underline confidence business shareholderfriendly initiative instill investor confidence positively impact earning share,9,7,0.11764705882352941,9,7,0.11764705882352941,0.9983
202,"FleetCor Technologies, Inc._Attachment1.pdf",FLT,5/8/2019,fleetcors top line continues to grow organically driven by increase in both volume and revenues per transaction in certain of its payment programs in firstquarter 2019 organic revenue growth was 11 driven by solid doubledigit growth across the companys product categories fuel corporate payments tolls and lodging its fuel card business was up 10 corporate payments increased 18 toll business grew 15 and lodging business increased 6 organically organic revenue growth was 10 9 and 8 respectively in 2018 2017 and 2016 for 2019 the company continues to expect 911 organic growth acquisitions are contributing significantly to fleetcors top line the company has been continuously acquiring and investing in companies both in the united states as well as internationally to expand customer base headcount and operations and diversify its service offerings across industries in firstquarter 2019 fleetcor completed the purchase of nvoicepay the buyout is expected to expand fleetcors corporate payments business with accounts payable cloud platform in 2018 the company made a 212 million worth acquisition in 2017 fleetcor completed three acquisitions creative lodging solutions cls to strengthen its hotel network through increased room nights cambridge global payments cambridge to expand its corporate payments footprint and a fuel card provider in russia since 2002 the company has acquired more than 75 companies and commercial account portfolios in 2018 the company witnessed 97 million of additional revenues from the acquisitions completed in 2017 in 2017 additional revenues of 212 million were generated from acquisitions completed in 2016 and 2017 fleetcor is a cash rich company with a strong balance sheet as of mar 31 2019 the company had cash cash equivalents and restricted cash of approximately 137 billion the company has no longterm debt to clearoff this significant amount of cash provides fleetcor the flexibility to pursue strategic acquisitions and other related investments cash rich companies not only guarantee protection but are also likely to reward shareholders from their deep cash balances shares of fleetcor have gained 216 in the past six months compared with 89 rise of the industry it belongs to we are impressed with fleetcor technologies endeavors in rewarding its shareholders through share repurchases in first quarter 2019 fleetcor repurchased shares worth 332 million in 2018 2017 and 2016 the company had repurchased shares worth 9587 million 4024 million and 1877 million respectively such moves indicate the companys commitment to create value for shareholders and underline its confidence in its business these shareholderfriendly initiatives not only instill investors confidence but also positively impact earnings per share,buy,"['fleetcor', 'line', 'continue', 'grow', 'organically', 'drive', 'increase', 'volume', 'revenue', 'transaction', 'certain', 'payment', 'program', 'firstquarter', '2019', 'organic', 'revenue', 'growth', '11', 'drive', 'solid', 'doubledigit', 'growth', 'company', 'product', 'category', 'fuel', 'corporate', 'payment', 'toll', 'lodge', 'fuel', 'card', 'business', '10', 'corporate', 'payment', 'increase', '18', 'toll', 'business', 'grow', '15', 'lodge', 'business', 'increase', '6', 'organically', 'organic', 'revenue', 'growth', '10', '9', '8', 'respectively', '2018', '2017', '2016', '2019', 'company', 'continue', 'expect', '911', 'organic', 'growth', 'acquisition', 'contribute', 'significantly', 'fleetcor', 'line', 'company', 'continuously', 'acquire', 'invest', 'company', 'united', 'states', 'internationally', 'expand', 'customer', 'base', 'headcount', 'operation', 'diversify', 'service', 'offering', 'industry', 'firstquarter', '2019', 'fleetcor', 'complete', 'purchase', 'nvoicepay', 'buyout', 'expect', 'expand', 'fleetcor', 'corporate', 'payment', 'business', 'account', 'payable', 'cloud', 'platform', '2018', 'company', '212', 'million', 'worth', 'acquisition', '2017', 'fleetcor', 'complete', 'acquisition', 'creative', 'lodging', 'solution', 'cls', 'strengthen', 'hotel', 'network', 'increase', 'room', 'night', 'cambridge', 'global', 'payment', 'cambridge', 'expand', 'corporate', 'payment', 'footprint', 'fuel', 'card', 'provider', 'russia', '2002', 'company', 'acquire', '75', 'company', 'commercial', 'account', 'portfolio', '2018', 'company', 'witness', '97', 'million', 'additional', 'revenue', 'acquisition', 'complete', '2017', '2017', 'additional', 'revenue', '212', 'million', 'generate', 'acquisition', 'complete', '2016', '2017', 'fleetcor', 'cash', 'rich', 'company', 'strong', 'balance', 'sheet', 'mar', '31', '2019', 'company', 'cash', 'cash', 'equivalent', 'restrict', 'cash', 'approximately', '137', 'billion', 'company', 'longterm', 'debt', 'clearoff', 'significant', 'cash', 'provide', 'fleetcor', 'flexibility', 'pursue', 'strategic', 'acquisition', 'related', 'investment', 'cash', 'rich', 'company', 'guarantee', 'protection', 'likely', 'reward', 'shareholder', 'deep', 'cash', 'balance', 'share', 'fleetcor', 'gain', '216', 'past', 'month', 'compare', '89', 'rise', 'industry', 'belong', 'impressed', 'fleetcor', 'technology', 'endeavor', 'reward', 'shareholder', 'share', 'repurchase', 'quarter', '2019', 'fleetcor', 'repurchase', 'share', 'worth', '332', 'million', '2018', '2017', '2016', 'company', 'repurchase', 'share', 'worth', '9587', 'million', '4024', 'million', '1877', 'million', 'respectively', 'move', 'indicate', 'company', 'commitment', 'create', 'value', 'shareholder', 'underline', 'confidence', 'business', 'shareholderfriendly', 'initiative', 'instill', 'investor', 'confidence', 'positively', 'impact', 'earning', 'share']",fleetcor line continue grow organically drive increase volume revenue transaction certain payment program firstquarter 2019 organic revenue growth 11 drive solid doubledigit growth company product category fuel corporate payment toll lodge fuel card business 10 corporate payment increase 18 toll business grow 15 lodge business increase 6 organically organic revenue growth 10 9 8 respectively 2018 2017 2016 2019 company continue expect 911 organic growth acquisition contribute significantly fleetcor line company continuously acquire invest company united states internationally expand customer base headcount operation diversify service offering industry firstquarter 2019 fleetcor complete purchase nvoicepay buyout expect expand fleetcor corporate payment business account payable cloud platform 2018 company 212 million worth acquisition 2017 fleetcor complete acquisition creative lodging solution cls strengthen hotel network increase room night cambridge global payment cambridge expand corporate payment footprint fuel card provider russia 2002 company acquire 75 company commercial account portfolio 2018 company witness 97 million additional revenue acquisition complete 2017 2017 additional revenue 212 million generate acquisition complete 2016 2017 fleetcor cash rich company strong balance sheet mar 31 2019 company cash cash equivalent restrict cash approximately 137 billion company longterm debt clearoff significant cash provide fleetcor flexibility pursue strategic acquisition related investment cash rich company guarantee protection likely reward shareholder deep cash balance share fleetcor gain 216 past month compare 89 rise industry belong impressed fleetcor technology endeavor reward shareholder share repurchase quarter 2019 fleetcor repurchase share worth 332 million 2018 2017 2016 company repurchase share worth 9587 million 4024 million 1877 million respectively move indicate company commitment create value shareholder underline confidence business shareholderfriendly initiative instill investor confidence positively impact earning share,11,5,0.35294117647058826,11,5,0.35294117647058826,0.9982
203,"FleetCor Technologies, Inc._Attachment1.pdf",FLT,5/8/2019,fleetcor is seeing higher interest expense due to increase in libor rate and additional borrowings for shares repurchase and to fund cambridge acquisition completed in in firstquarter 2019 interest expense of 391 million increased 257 year over year the same rose 293 year over year in 2018 for 2019 the company expects interest expense to be 160 million which is almost 20 million higher than 2018 it anticipates higher interest expense to negatively impact its bottom line by an estimated 17 cents per share in 2019 fleetcors fuel card workforce payment solutions and gift card businesses are affected by seasonality the companys fuel card and workforce payment solutions businesses are hampered during the first and fourth quarters as a result of the prevailing weather conditions us holidays christmas celebration in russia in january lower business activities in brazil due to summer break and the carnival celebration the gift card business witnesses higher revenues during the third and fourth quarters primarily due to the holiday season and lower revenues in the first and second quarters due to fluctuating consumer spending patterns fleetcors global presence makes it vulnerable to the risks associated with foreign currency exchange rate fluctuations in 2018 almost 39 of revenues were generated from operations outside the united states with business transactions occurring in currencies like british pound brazilian real canadian dollar russian ruble mexican peso czech koruna euro australian dollar and new zealand dollar thus appreciation or depreciation of the dollar versus these foreign currencies could impact the companys financial results fleetcors policy of acquiring a large number of companies results in some integration risk acquisitions can negatively impact its balance sheet in the form of a high level of goodwill and intangible assets which totaled 69 billion or 622 of total assets at the end of 2018 moreover frequent acquisitions are a distraction for management which could impact organic growth zacks equity research flt wwwzackscom page 4 of 10,sell,"['fleetcor', 'see', 'high', 'interest', 'expense', 'increase', 'libor', 'rate', 'additional', 'borrowing', 'share', 'repurchase', 'fund', 'cambridge', 'acquisition', 'complete', 'firstquarter', '2019', 'interest', 'expense', '391', 'million', 'increase', '257', 'year', 'year', 'rise', '293', 'year', 'year', '2018', '2019', 'company', 'expect', 'interest', 'expense', '160', 'million', '20', 'million', 'high', '2018', 'anticipate', 'high', 'interest', 'expense', 'negatively', 'impact', 'line', 'estimate', '17', 'cent', 'share', '2019', 'fleetcor', 'fuel', 'card', 'workforce', 'payment', 'solution', 'gift', 'card', 'business', 'affect', 'seasonality', 'company', 'fuel', 'card', 'workforce', 'payment', 'solution', 'business', 'hamper', 'fourth', 'quarter', 'result', 'prevail', 'weather', 'condition', 'holidays', 'christmas', 'celebration', 'russia', 'january', 'low', 'business', 'activity', 'brazil', 'summer', 'break', 'carnival', 'celebration', 'gift', 'card', 'business', 'witness', 'high', 'revenue', 'fourth', 'quarter', 'primarily', 'holiday', 'season', 'low', 'revenue', 'second', 'quarter', 'fluctuate', 'consumer', 'spending', 'pattern', 'fleetcor', 'global', 'presence', 'make', 'vulnerable', 'risk', 'associate', 'foreign', 'currency', 'exchange', 'rate', 'fluctuation', '2018', '39', 'revenue', 'generate', 'operation', 'outside', 'united', 'states', 'business', 'transaction', 'occur', 'currency', 'like', 'british', 'pound', 'brazilian', 'real', 'canadian', 'dollar', 'russian', 'ruble', 'mexican', 'peso', 'czech', 'koruna', 'euro', 'australian', 'dollar', 'new', 'zealand', 'dollar', 'appreciation', 'depreciation', 'dollar', 'versus', 'foreign', 'currency', 'impact', 'company', 'financial', 'result', 'fleetcor', 'policy', 'acquire', 'large', 'number', 'company', 'result', 'integration', 'risk', 'acquisition', 'negatively', 'impact', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'intangible', 'asset', 'total', '69', 'billion', '622', 'total', 'asset', 'end', '2018', 'frequent', 'acquisition', 'distraction', 'management', 'impact', 'organic', 'growth', 'zack', 'equity', 'research', 'flt', 'wwwzackscom', 'page', '4', '10']",fleetcor see high interest expense increase libor rate additional borrowing share repurchase fund cambridge acquisition complete firstquarter 2019 interest expense 391 million increase 257 year year rise 293 year year 2018 2019 company expect interest expense 160 million 20 million high 2018 anticipate high interest expense negatively impact line estimate 17 cent share 2019 fleetcor fuel card workforce payment solution gift card business affect seasonality company fuel card workforce payment solution business hamper fourth quarter result prevail weather condition holidays christmas celebration russia january low business activity brazil summer break carnival celebration gift card business witness high revenue fourth quarter primarily holiday season low revenue second quarter fluctuate consumer spending pattern fleetcor global presence make vulnerable risk associate foreign currency exchange rate fluctuation 2018 39 revenue generate operation outside united states business transaction occur currency like british pound brazilian real canadian dollar russian ruble mexican peso czech koruna euro australian dollar new zealand dollar appreciation depreciation dollar versus foreign currency impact company financial result fleetcor policy acquire large number company result integration risk acquisition negatively impact balance sheet form high level goodwill intangible asset total 69 billion 622 total asset end 2018 frequent acquisition distraction management impact organic growth zack equity research flt wwwzackscom page 4 10,5,12,-0.3888888888888889,5,12,-0.3888888888888889,0.9893
204,Groupon Inc_Attachment1(3).pdf,GRPN,7/2/2020,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business the companys partnership with grubhub continues to enable customers to order food delivery from more than 80000 restaurant partners of grubhub via groupon platform further partnerships with parkwhiz coresource american express major league baseball among others are aiding groupon to cater to just about any local need consequently aiding it to rapidly penetrate the market we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to,sell,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'company', 'partnership', 'grubhub', 'continue', 'enable', 'customer', 'order', 'food', 'delivery', '80000', 'restaurant', 'partner', 'grubhub', 'groupon', 'platform', 'partnership', 'parkwhiz', 'coresource', 'american', 'express', 'major', 'league', 'baseball', 'aid', 'groupon', 'cater', 'local', 'need', 'consequently', 'aid', 'rapidly', 'penetrate', 'market', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business company partnership grubhub continue enable customer order food delivery 80000 restaurant partner grubhub groupon platform partnership parkwhiz coresource american express major league baseball aid groupon cater local need consequently aid rapidly penetrate market believe partnership aid company rapidly penetrate local market drive topline growth go ahead groupon policy launch new product regular basis positive company strategy offer special deal prior,10,13,-0.125,10,13,-0.125,0.9872
205,Groupon Inc_Attachment1(3).pdf,GRPN,11/13/2020,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in 2020 the company expects to achieve 140 million in cost savings under its restructuring endeavors and 200 million in 2021 in addition the company is also working to improve its customer service experience groupon has been adding new features to its platform like mapbased search feature along with optimizing relevance and search results to enhance customer experience apart from consumers groupon is working on improving experiences for merchants in the second quarter of 2020 groupon launched selfservice api tool to aid merchants to connect to groupon marketplace platform seamlessly in thirdquarter 2020 groupon rolled out sponsored listings tool to assist merchants in expanding consumer reach we believe that the successful implementation of these initiatives will boost profitability in the long run,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', '2020', 'company', 'expect', 'achieve', '140', 'million', 'cost', 'saving', 'restructure', 'endeavor', '200', 'million', '2021', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'groupon', 'add', 'new', 'feature', 'platform', 'like', 'mapbase', 'search', 'feature', 'optimize', 'relevance', 'search', 'result', 'enhance', 'customer', 'experience', 'apart', 'consumer', 'groupon', 'work', 'improve', 'experience', 'merchant', 'second', 'quarter', '2020', 'groupon', 'launch', 'selfservice', 'api', 'tool', 'aid', 'merchant', 'connect', 'groupon', 'marketplace', 'platform', 'seamlessly', 'thirdquarter', '2020', 'groupon', 'roll', 'sponsor', 'listing', 'tool', 'assist', 'merchant', 'expand', 'consumer', 'reach', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost 2020 company expect achieve 140 million cost saving restructure endeavor 200 million 2021 addition company work improve customer service experience groupon add new feature platform like mapbase search feature optimize relevance search result enhance customer experience apart consumer groupon work improve experience merchant second quarter 2020 groupon launch selfservice api tool aid merchant connect groupon marketplace platform seamlessly thirdquarter 2020 groupon roll sponsor listing tool assist merchant expand consumer reach believe successful implementation initiative boost profitability long run,9,15,-0.24,9,15,-0.24,0.9851
206,Groupon Inc_Attachment1.pdf,GRPN,10/13/2020,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run,7,9,-0.11764705882352941,7,9,-0.11764705882352941,0.969
207,"Groupon, Inc._Attachment1(2).pdf",GRPN,10/8/2018,groupons business model makes it heavily dependent on daily deals which is a major headwind since most of the offerings are consumer discretionary products demand is heavily dependent on macroeconomic conditions as redemptions are high and unused groupons are low revenues recognized upfront in daily deals so an unused groupon boosts the companys revenues the transition is expected to negatively impact the top line in the near term moreover groupon needs to continue spending on generating awareness about its offerings which will drive up costs further the company is likely to incur sizeable expenses owing to the ongoing restructuring activities which can weigh down on its profitability additionally aggressive investments for mobile infrastructure and product development will continue to drive operating expenses higher moreover groupon is investing quite a bit in the transition which is expected to affect its nearterm financials the company is also trying to revive a part of its daily deals business through various offerings for merchants which was not a part of the restructuring program earlier despite growing billings groupon is yet to earn significant profits since its inception moreover revenue growth has slowed down in the last couple of years furthermore the new restructuring plan directly contradicts the companys earlier business model per which itundertook rapid international expansion at the cost of profits as such the increased uncertainties even cast a shadow on the growth prospects from the increase in ecommerce spending on mobile devices intensifying competition remains a major headwind which is also likely to hurt profitability the company expects competition in ecommerce generally and group buying in particular to continue to increase in addition increasing presence of the social media companies in the ecommerce space can also pose serious challenges to groupons recovery as merchants are increasingly adopting these platforms to sell their products growing competition is anticipated to keep groupons pricing under tremendous pressure in the near term moreover it reduces the companys bargaining power with the merchants,sell,"['groupon', 'business', 'model', 'make', 'heavily', 'dependent', 'daily', 'deal', 'major', 'headwind', 'offering', 'consumer', 'discretionary', 'product', 'demand', 'heavily', 'dependent', 'macroeconomic', 'condition', 'redemption', 'high', 'unused', 'groupon', 'low', 'revenue', 'recognize', 'upfront', 'daily', 'deal', 'unused', 'groupon', 'boost', 'companys', 'revenue', 'transition', 'expect', 'negatively', 'impact', 'line', 'near', 'term', 'groupon', 'need', 'continue', 'spend', 'generate', 'awareness', 'offering', 'drive', 'cost', 'company', 'likely', 'incur', 'sizeable', 'expense', 'owe', 'ongoing', 'restructuring', 'activity', 'weigh', 'profitability', 'additionally', 'aggressive', 'investment', 'mobile', 'infrastructure', 'product', 'development', 'continue', 'drive', 'operating', 'expense', 'high', 'groupon', 'invest', 'bit', 'transition', 'expect', 'affect', 'nearterm', 'financial', 'company', 'try', 'revive', 'daily', 'deal', 'business', 'offering', 'merchant', 'restructuring', 'program', 'early', 'despite', 'grow', 'billing', 'groupon', 'earn', 'significant', 'profit', 'inception', 'revenue', 'growth', 'slow', 'couple', 'year', 'furthermore', 'new', 'restructuring', 'plan', 'directly', 'contradict', 'company', 'early', 'business', 'model', 'itundertook', 'rapid', 'international', 'expansion', 'cost', 'profit', 'increase', 'uncertainty', 'cast', 'shadow', 'growth', 'prospect', 'increase', 'ecommerce', 'spend', 'mobile', 'device', 'intensify', 'competition', 'remain', 'major', 'headwind', 'likely', 'hurt', 'profitability', 'company', 'expect', 'competition', 'ecommerce', 'generally', 'group', 'buying', 'particular', 'continue', 'increase', 'addition', 'increase', 'presence', 'social', 'medium', 'company', 'ecommerce', 'space', 'pose', 'challenge', 'groupon', 'recovery', 'merchant', 'increasingly', 'adopt', 'platform', 'sell', 'product', 'grow', 'competition', 'anticipate', 'groupon', 'pricing', 'tremendous', 'pressure', 'near', 'term', 'reduce', 'company', 'bargaining', 'power', 'merchant']",groupon business model make heavily dependent daily deal major headwind offering consumer discretionary product demand heavily dependent macroeconomic condition redemption high unused groupon low revenue recognize upfront daily deal unused groupon boost companys revenue transition expect negatively impact line near term groupon need continue spend generate awareness offering drive cost company likely incur sizeable expense owe ongoing restructuring activity weigh profitability additionally aggressive investment mobile infrastructure product development continue drive operating expense high groupon invest bit transition expect affect nearterm financial company try revive daily deal business offering merchant restructuring program early despite grow billing groupon earn significant profit inception revenue growth slow couple year furthermore new restructuring plan directly contradict company early business model itundertook rapid international expansion cost profit increase uncertainty cast shadow growth prospect increase ecommerce spend mobile device intensify competition remain major headwind likely hurt profitability company expect competition ecommerce generally group buying particular continue increase addition increase presence social medium company ecommerce space pose challenge groupon recovery merchant increasingly adopt platform sell product grow competition anticipate groupon pricing tremendous pressure near term reduce company bargaining power merchant,7,18,-0.4230769230769231,7,18,-0.4230769230769231,0.9517
208,"Groupon, Inc._Attachment1(3).pdf",GRPN,2/12/2018,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead we believe that growth in local billings in north america region will bolster groupons topline growth in the reported quarter local billings improved 08 yearoveryear in north america we believe that strong growth in mobile new user additions continuing investments in pos and payment technologies focus on the pull marketplace and innovation in the push business through introduction of new technology will help groupon to achieve billings growth in future groupon expects smartphone users to grow fivefold over the next five years which will drive mcommerce sales we believe that groupons strong presence in the mobile gives it ample opportunity to benefit from this rapid growth in mobile ecommerce sales in the long run groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract zacks equity research grpn wwwzackscom page 3 of 8,sell,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'believe', 'growth', 'local', 'billing', 'north', 'america', 'region', 'bolster', 'groupon', 'topline', 'growth', 'reported', 'quarter', 'local', 'billing', 'improve', '08', 'yearoveryear', 'north', 'america', 'believe', 'strong', 'growth', 'mobile', 'new', 'user', 'addition', 'continue', 'investment', 'pos', 'payment', 'technology', 'focus', 'pull', 'marketplace', 'innovation', 'push', 'business', 'introduction', 'new', 'technology', 'help', 'groupon', 'achieve', 'billing', 'growth', 'future', 'groupon', 'expect', 'smartphone', 'user', 'grow', 'fivefold', 'year', 'drive', 'mcommerce', 'sale', 'believe', 'groupon', 'strong', 'presence', 'mobile', 'give', 'ample', 'opportunity', 'benefit', 'rapid', 'growth', 'mobile', 'ecommerce', 'sale', 'long', 'run', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'zacks', 'equity', 'research', 'grpn', 'wwwzackscom', 'page', '3', '8']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company believe partnership aid company rapidly penetrate local market drive topline growth go ahead believe growth local billing north america region bolster groupon topline growth reported quarter local billing improve 08 yearoveryear north america believe strong growth mobile new user addition continue investment pos payment technology focus pull marketplace innovation push business introduction new technology help groupon achieve billing growth future groupon expect smartphone user grow fivefold year drive mcommerce sale believe groupon strong presence mobile give ample opportunity benefit rapid growth mobile ecommerce sale long run groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract zacks equity research grpn wwwzackscom page 3 8,25,23,0.04081632653061224,25,23,0.04081632653061224,0.9985
209,"Groupon, Inc._Attachment1(3).pdf",GRPN,2/18/2019,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company the companys partnership with grubhub continues to enable customers to order food delivery from more than 80000 restaurant partners of grubhub via groupon platform further partnerships with coresource american express major league baseball among others are aiding groupon to cater to just about any local need consequently aiding it to rapidly penetrate the market we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well also management noted that its new offering groupon has been well accepted as the company is enhancing customer experience by investing in voucherless initiatives this is expected to be a catalyst going ahead it is currently operating in more than 25 markets the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform the rollout of the companys new cardlinked platform groupon that replaces the voucher system and makes discounting processes easy will be a tailwind in the long haul zacks equity research grpn wwwzackscom page 3 of 8,sell,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'company', 'partnership', 'grubhub', 'continue', 'enable', 'customer', 'order', 'food', 'delivery', '80000', 'restaurant', 'partner', 'grubhub', 'groupon', 'platform', 'partnership', 'coresource', 'american', 'express', 'major', 'league', 'baseball', 'aid', 'groupon', 'cater', 'local', 'need', 'consequently', 'aid', 'rapidly', 'penetrate', 'market', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'management', 'note', 'new', 'offering', 'groupon', 'accept', 'company', 'enhance', 'customer', 'experience', 'invest', 'voucherless', 'initiative', 'expect', 'catalyst', 'go', 'ahead', 'currently', 'operate', '25', 'market', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform', 'rollout', 'company', 'new', 'cardlinke', 'platform', 'groupon', 'replace', 'voucher', 'system', 'make', 'discount', 'process', 'easy', 'tailwind', 'long', 'haul', 'zacks', 'equity', 'research', 'grpn', 'wwwzackscom', 'page', '3', '8']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company company partnership grubhub continue enable customer order food delivery 80000 restaurant partner grubhub groupon platform partnership coresource american express major league baseball aid groupon cater local need consequently aid rapidly penetrate market believe partnership aid company rapidly penetrate local market drive topline growth go ahead groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business management note new offering groupon accept company enhance customer experience invest voucherless initiative expect catalyst go ahead currently operate 25 market company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform rollout company new cardlinke platform groupon replace voucher system make discount process easy tailwind long haul zacks equity research grpn wwwzackscom page 3 8,23,26,-0.06,23,26,-0.06,0.998
210,"Groupon, Inc._Attachment1(4).pdf",GRPN,2/22/2018,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being de emphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead we believe that growth in local billings in north america region will bolster groupons topline growth in the reported quarter local billings improved 25 yearoveryear in north america we believe that strong growth in mobile new user additions continuing investments in pos and payment technologies focus on the pull marketplace and innovation in the push business through introduction of new technology will help groupon to achieve billings growth in future groupon expects smartphone users to grow fivefold over the next five years which will drive mcommerce sales we believe that groupons strong presence in the mobile gives it ample opportunity to benefit from this rapid growth in mobile ecommerce sales in the long run groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform the rollout of the companys new cardlinked platform groupon that replaces the voucher system and makes discounting processes easy will be a tailwind in the long haul,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'de', 'emphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'believe', 'growth', 'local', 'billing', 'north', 'america', 'region', 'bolster', 'groupon', 'topline', 'growth', 'reported', 'quarter', 'local', 'billing', 'improve', '25', 'yearoveryear', 'north', 'america', 'believe', 'strong', 'growth', 'mobile', 'new', 'user', 'addition', 'continue', 'investment', 'pos', 'payment', 'technology', 'focus', 'pull', 'marketplace', 'innovation', 'push', 'business', 'introduction', 'new', 'technology', 'help', 'groupon', 'achieve', 'billing', 'growth', 'future', 'groupon', 'expect', 'smartphone', 'user', 'grow', 'fivefold', 'year', 'drive', 'mcommerce', 'sale', 'believe', 'groupon', 'strong', 'presence', 'mobile', 'give', 'ample', 'opportunity', 'benefit', 'rapid', 'growth', 'mobile', 'ecommerce', 'sale', 'long', 'run', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform', 'rollout', 'company', 'new', 'cardlinke', 'platform', 'groupon', 'replace', 'voucher', 'system', 'make', 'discount', 'process', 'easy', 'tailwind', 'long', 'haul']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product de emphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company believe partnership aid company rapidly penetrate local market drive topline growth go ahead believe growth local billing north america region bolster groupon topline growth reported quarter local billing improve 25 yearoveryear north america believe strong growth mobile new user addition continue investment pos payment technology focus pull marketplace innovation push business introduction new technology help groupon achieve billing growth future groupon expect smartphone user grow fivefold year drive mcommerce sale believe groupon strong presence mobile give ample opportunity benefit rapid growth mobile ecommerce sale long run groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform rollout company new cardlinke platform groupon replace voucher system make discount process easy tailwind long haul,29,25,0.07272727272727272,29,25,0.07272727272727272,0.9989
211,"Groupon, Inc._Attachment1(5).pdf",GRPN,8/21/2017,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 further groupon plans to exit 11 noncore countries going ahead the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead we believe that growth in local billings in north america region will bolster groupons topline growth in the reported quarter local billings improved 08 yearoveryear in north america we believe that strong growth in mobile new user additions continuing investments in pos and payment technologies focus on the pull marketplace and innovation in the push business through introduction of new technology will help groupon to achieve billings growth in future groupon expects smartphone users to grow fivefold over the next five years which will drive mcommerce sales we believe that groupons strong presence in the mobile gives it ample opportunity to benefit from this rapid growth in mobile ecommerce sales in the long run groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform the rollout of the companys new cardlinked platform groupon that replaces the voucher system and makes discounting processes easy will be a tailwind in the long haul,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'groupon', 'plan', 'exit', '11', 'noncore', 'country', 'go', 'ahead', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'believe', 'growth', 'local', 'billing', 'north', 'america', 'region', 'bolster', 'groupon', 'topline', 'growth', 'reported', 'quarter', 'local', 'billing', 'improve', '08', 'yearoveryear', 'north', 'america', 'believe', 'strong', 'growth', 'mobile', 'new', 'user', 'addition', 'continue', 'investment', 'pos', 'payment', 'technology', 'focus', 'pull', 'marketplace', 'innovation', 'push', 'business', 'introduction', 'new', 'technology', 'help', 'groupon', 'achieve', 'billing', 'growth', 'future', 'groupon', 'expect', 'smartphone', 'user', 'grow', 'fivefold', 'year', 'drive', 'mcommerce', 'sale', 'believe', 'groupon', 'strong', 'presence', 'mobile', 'give', 'ample', 'opportunity', 'benefit', 'rapid', 'growth', 'mobile', 'ecommerce', 'sale', 'long', 'run', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform', 'rollout', 'company', 'new', 'cardlinke', 'platform', 'groupon', 'replace', 'voucher', 'system', 'make', 'discount', 'process', 'easy', 'tailwind', 'long', 'haul']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 groupon plan exit 11 noncore country go ahead shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company believe partnership aid company rapidly penetrate local market drive topline growth go ahead believe growth local billing north america region bolster groupon topline growth reported quarter local billing improve 08 yearoveryear north america believe strong growth mobile new user addition continue investment pos payment technology focus pull marketplace innovation push business introduction new technology help groupon achieve billing growth future groupon expect smartphone user grow fivefold year drive mcommerce sale believe groupon strong presence mobile give ample opportunity benefit rapid growth mobile ecommerce sale long run groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform rollout company new cardlinke platform groupon replace voucher system make discount process easy tailwind long haul,29,24,0.09259259259259259,29,24,0.09259259259259259,0.9989
212,"Groupon, Inc._Attachment1(6).pdf",GRPN,4/28/2017,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 26 countries across the globe down from 47 countries that it operated in the beginning of 2015 further groupon plans to exit 11 noncore countries going ahead the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead we believe that growth in local billings in north america region will bolster groupons topline growth in the reported quarter local billings improved 10 in north america we believe that strong growth in mobile new user additions continuing investments in pos and payment technologies focus on the pull marketplace and innovation in the push business through introduction of new technology will help groupon to achieve billings growth in future groupon expects smartphone users to grow fivefold over the next five years which will drive mcommerce sales we believe that groupons strong presence in the mobile gives it ample opportunity to benefit from this rapid growth in mobile ecommerce sales in the long run groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '26', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'groupon', 'plan', 'exit', '11', 'noncore', 'country', 'go', 'ahead', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'believe', 'growth', 'local', 'billing', 'north', 'america', 'region', 'bolster', 'groupon', 'topline', 'growth', 'reported', 'quarter', 'local', 'billing', 'improve', '10', 'north', 'america', 'believe', 'strong', 'growth', 'mobile', 'new', 'user', 'addition', 'continue', 'investment', 'pos', 'payment', 'technology', 'focus', 'pull', 'marketplace', 'innovation', 'push', 'business', 'introduction', 'new', 'technology', 'help', 'groupon', 'achieve', 'billing', 'growth', 'future', 'groupon', 'expect', 'smartphone', 'user', 'grow', 'fivefold', 'year', 'drive', 'mcommerce', 'sale', 'believe', 'groupon', 'strong', 'presence', 'mobile', 'give', 'ample', 'opportunity', 'benefit', 'rapid', 'growth', 'mobile', 'ecommerce', 'sale', 'long', 'run', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 26 country globe 47 country operate beginning 2015 groupon plan exit 11 noncore country go ahead shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company believe partnership aid company rapidly penetrate local market drive topline growth go ahead believe growth local billing north america region bolster groupon topline growth reported quarter local billing improve 10 north america believe strong growth mobile new user addition continue investment pos payment technology focus pull marketplace innovation push business introduction new technology help groupon achieve billing growth future groupon expect smartphone user grow fivefold year drive mcommerce sale believe groupon strong presence mobile give ample opportunity benefit rapid growth mobile ecommerce sale long run groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform,28,23,0.09615384615384616,28,23,0.09615384615384616,0.9988
213,"Groupon, Inc._Attachment1.pdf",GRPN,5/11/2017,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 further groupon plans to exit 11 noncore countries going ahead the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead we believe that growth in local billings in north america region will bolster groupons topline growth in the reported quarter local billings improved 10 in north america we believe that strong growth in mobile new user additions continuing investments in pos and payment technologies focus on the pull marketplace and innovation in the push business through introduction of new technology will help groupon to achieve billings growth in future groupon expects smartphone users to grow fivefold over the next five years which will drive mcommerce sales we believe that groupons strong presence in the mobile gives it ample opportunity to benefit from this rapid growth in mobile ecommerce sales in the long run groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'groupon', 'plan', 'exit', '11', 'noncore', 'country', 'go', 'ahead', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'believe', 'growth', 'local', 'billing', 'north', 'america', 'region', 'bolster', 'groupon', 'topline', 'growth', 'reported', 'quarter', 'local', 'billing', 'improve', '10', 'north', 'america', 'believe', 'strong', 'growth', 'mobile', 'new', 'user', 'addition', 'continue', 'investment', 'pos', 'payment', 'technology', 'focus', 'pull', 'marketplace', 'innovation', 'push', 'business', 'introduction', 'new', 'technology', 'help', 'groupon', 'achieve', 'billing', 'growth', 'future', 'groupon', 'expect', 'smartphone', 'user', 'grow', 'fivefold', 'year', 'drive', 'mcommerce', 'sale', 'believe', 'groupon', 'strong', 'presence', 'mobile', 'give', 'ample', 'opportunity', 'benefit', 'rapid', 'growth', 'mobile', 'ecommerce', 'sale', 'long', 'run', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 groupon plan exit 11 noncore country go ahead shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company believe partnership aid company rapidly penetrate local market drive topline growth go ahead believe growth local billing north america region bolster groupon topline growth reported quarter local billing improve 10 north america believe strong growth mobile new user addition continue investment pos payment technology focus pull marketplace innovation push business introduction new technology help groupon achieve billing growth future groupon expect smartphone user grow fivefold year drive mcommerce sale believe groupon strong presence mobile give ample opportunity benefit rapid growth mobile ecommerce sale long run groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform,28,23,0.09615384615384616,28,23,0.09615384615384616,0.9988
214,"Groupon, Inc._Attachment1.pdf",GRPN,11/6/2017,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 further groupon plans to exit 11 noncore countries going ahead the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead we believe that growth in local billings in north america region will bolster groupons topline growth in the reported quarter local billings improved 08 yearoveryear in north america we believe that strong growth in mobile new user additions continuing investments in pos and payment technologies focus on the pull marketplace and innovation in the push business through introduction of new technology will help groupon to achieve billings growth in future groupon expects smartphone users to grow fivefold over the next five years which will drive mcommerce sales we believe that groupons strong presence in the mobile gives it ample opportunity to benefit from this rapid growth in mobile ecommerce sales in the long run groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform the rollout of the companys new cardlinked platform groupon that replaces the voucher system and makes discounting processes easy will be a tailwind in the long haul,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'groupon', 'plan', 'exit', '11', 'noncore', 'country', 'go', 'ahead', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'believe', 'growth', 'local', 'billing', 'north', 'america', 'region', 'bolster', 'groupon', 'topline', 'growth', 'reported', 'quarter', 'local', 'billing', 'improve', '08', 'yearoveryear', 'north', 'america', 'believe', 'strong', 'growth', 'mobile', 'new', 'user', 'addition', 'continue', 'investment', 'pos', 'payment', 'technology', 'focus', 'pull', 'marketplace', 'innovation', 'push', 'business', 'introduction', 'new', 'technology', 'help', 'groupon', 'achieve', 'billing', 'growth', 'future', 'groupon', 'expect', 'smartphone', 'user', 'grow', 'fivefold', 'year', 'drive', 'mcommerce', 'sale', 'believe', 'groupon', 'strong', 'presence', 'mobile', 'give', 'ample', 'opportunity', 'benefit', 'rapid', 'growth', 'mobile', 'ecommerce', 'sale', 'long', 'run', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform', 'rollout', 'company', 'new', 'cardlinke', 'platform', 'groupon', 'replace', 'voucher', 'system', 'make', 'discount', 'process', 'easy', 'tailwind', 'long', 'haul']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 groupon plan exit 11 noncore country go ahead shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company believe partnership aid company rapidly penetrate local market drive topline growth go ahead believe growth local billing north america region bolster groupon topline growth reported quarter local billing improve 08 yearoveryear north america believe strong growth mobile new user addition continue investment pos payment technology focus pull marketplace innovation push business introduction new technology help groupon achieve billing growth future groupon expect smartphone user grow fivefold year drive mcommerce sale believe groupon strong presence mobile give ample opportunity benefit rapid growth mobile ecommerce sale long run groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform rollout company new cardlinke platform groupon replace voucher system make discount process easy tailwind long haul,29,24,0.09259259259259259,29,24,0.09259259259259259,0.9989
215,"Groupon, Inc._Attachment1.pdf",GRPN,11/6/2017,groupons business model makes it heavily dependent on daily deals which is a major headwind since most of the offerings are consumer discretionary products demand is heavily dependent on macroeconomic conditions as redemptions are high and unused groupons are low revenues recognized upfront in daily deals so an unused groupon boosts the companys revenues the transition is expected to negatively impact the top line in the near term moreover groupon needs to continue spending on generating awareness about its offerings which will drive up costs further the company is likely to incur sizeable expenses owing to the ongoing restructuring activities which can weigh down on its profitability additionally aggressive investments for mobile infrastructure and product development will continue to drive operating expenses higher moreover groupon is investing quite a bit in the transition which is expected to affect its nearterm financials the company is also trying to revive a part of its daily deals business through various offerings for merchants which was not a part of the restructuring program earlier despite growing billings groupon is yet to earn significant profits since its inception moreover revenue growth has slowed down in the last couple of years furthermore the new restructuring plan directly contradicts the companys earlier business model per which it undertook rapid international expansion at the cost of profits as such the increased uncertainties even cast a shadow on the growth prospects from the increase in ecommerce spending on mobile devices intensifying competition remains a major headwind which is also likely to hurt profitability the company expects competition in ecommerce generally and group buying in particular to continue to increase in addition increasing presence of the social media companies in the ecommerce space can also pose serious challenges to groupons recovery as merchants are increasingly adopting these platforms to sell their products growing competition is anticipated to keep groupons pricing under zacks equity research grpn wwwzackscom page 3 of 8,sell,"['groupon', 'business', 'model', 'make', 'heavily', 'dependent', 'daily', 'deal', 'major', 'headwind', 'offering', 'consumer', 'discretionary', 'product', 'demand', 'heavily', 'dependent', 'macroeconomic', 'condition', 'redemption', 'high', 'unused', 'groupon', 'low', 'revenue', 'recognize', 'upfront', 'daily', 'deal', 'unused', 'groupon', 'boost', 'companys', 'revenue', 'transition', 'expect', 'negatively', 'impact', 'line', 'near', 'term', 'groupon', 'need', 'continue', 'spend', 'generate', 'awareness', 'offering', 'drive', 'cost', 'company', 'likely', 'incur', 'sizeable', 'expense', 'owe', 'ongoing', 'restructuring', 'activity', 'weigh', 'profitability', 'additionally', 'aggressive', 'investment', 'mobile', 'infrastructure', 'product', 'development', 'continue', 'drive', 'operating', 'expense', 'high', 'groupon', 'invest', 'bit', 'transition', 'expect', 'affect', 'nearterm', 'financial', 'company', 'try', 'revive', 'daily', 'deal', 'business', 'offering', 'merchant', 'restructuring', 'program', 'early', 'despite', 'grow', 'billing', 'groupon', 'earn', 'significant', 'profit', 'inception', 'revenue', 'growth', 'slow', 'couple', 'year', 'furthermore', 'new', 'restructuring', 'plan', 'directly', 'contradict', 'company', 'early', 'business', 'model', 'undertake', 'rapid', 'international', 'expansion', 'cost', 'profit', 'increase', 'uncertainty', 'cast', 'shadow', 'growth', 'prospect', 'increase', 'ecommerce', 'spend', 'mobile', 'device', 'intensify', 'competition', 'remain', 'major', 'headwind', 'likely', 'hurt', 'profitability', 'company', 'expect', 'competition', 'ecommerce', 'generally', 'group', 'buying', 'particular', 'continue', 'increase', 'addition', 'increase', 'presence', 'social', 'medium', 'company', 'ecommerce', 'space', 'pose', 'challenge', 'groupon', 'recovery', 'merchant', 'increasingly', 'adopt', 'platform', 'sell', 'product', 'grow', 'competition', 'anticipate', 'groupon', 'pricing', 'zack', 'equity', 'research', 'grpn', 'wwwzackscom', 'page', '3', '8']",groupon business model make heavily dependent daily deal major headwind offering consumer discretionary product demand heavily dependent macroeconomic condition redemption high unused groupon low revenue recognize upfront daily deal unused groupon boost companys revenue transition expect negatively impact line near term groupon need continue spend generate awareness offering drive cost company likely incur sizeable expense owe ongoing restructuring activity weigh profitability additionally aggressive investment mobile infrastructure product development continue drive operating expense high groupon invest bit transition expect affect nearterm financial company try revive daily deal business offering merchant restructuring program early despite grow billing groupon earn significant profit inception revenue growth slow couple year furthermore new restructuring plan directly contradict company early business model undertake rapid international expansion cost profit increase uncertainty cast shadow growth prospect increase ecommerce spend mobile device intensify competition remain major headwind likely hurt profitability company expect competition ecommerce generally group buying particular continue increase addition increase presence social medium company ecommerce space pose challenge groupon recovery merchant increasingly adopt platform sell product grow competition anticipate groupon pricing zack equity research grpn wwwzackscom page 3 8,6,18,-0.48,6,18,-0.48,0.9595
216,"Groupon, Inc._Attachment1.pdf",GRPN,1/2/2018,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being de emphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead we believe that growth in local billings in north america region will bolster groupons topline growth in the reported quarter local billings improved 08 yearoveryear in north america we believe that strong growth in mobile new user additions continuing investments in pos and payment technologies focus on the pull marketplace and innovation in the push business through introduction of new technology will help groupon to achieve billings growth in future groupon expects smartphone users to grow fivefold over the next five years which will drive mcommerce sales we believe that groupons strong presence in the mobile gives it ample opportunity to benefit from this rapid growth in mobile ecommerce sales in the long run groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform the rollout of the companys new cardlinked platform groupon that replaces the voucher system and makes discounting processes easy will be a tailwind in the long haul,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'de', 'emphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'believe', 'growth', 'local', 'billing', 'north', 'america', 'region', 'bolster', 'groupon', 'topline', 'growth', 'reported', 'quarter', 'local', 'billing', 'improve', '08', 'yearoveryear', 'north', 'america', 'believe', 'strong', 'growth', 'mobile', 'new', 'user', 'addition', 'continue', 'investment', 'pos', 'payment', 'technology', 'focus', 'pull', 'marketplace', 'innovation', 'push', 'business', 'introduction', 'new', 'technology', 'help', 'groupon', 'achieve', 'billing', 'growth', 'future', 'groupon', 'expect', 'smartphone', 'user', 'grow', 'fivefold', 'year', 'drive', 'mcommerce', 'sale', 'believe', 'groupon', 'strong', 'presence', 'mobile', 'give', 'ample', 'opportunity', 'benefit', 'rapid', 'growth', 'mobile', 'ecommerce', 'sale', 'long', 'run', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform', 'rollout', 'company', 'new', 'cardlinke', 'platform', 'groupon', 'replace', 'voucher', 'system', 'make', 'discount', 'process', 'easy', 'tailwind', 'long', 'haul']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product de emphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company believe partnership aid company rapidly penetrate local market drive topline growth go ahead believe growth local billing north america region bolster groupon topline growth reported quarter local billing improve 08 yearoveryear north america believe strong growth mobile new user addition continue investment pos payment technology focus pull marketplace innovation push business introduction new technology help groupon achieve billing growth future groupon expect smartphone user grow fivefold year drive mcommerce sale believe groupon strong presence mobile give ample opportunity benefit rapid growth mobile ecommerce sale long run groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform rollout company new cardlinke platform groupon replace voucher system make discount process easy tailwind long haul,29,25,0.07272727272727272,29,25,0.07272727272727272,0.9989
217,"Groupon, Inc._Attachment1.pdf",GRPN,5/24/2018,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being de emphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well also management noted that its new offering groupon has been well accepted as the company is enhancing customer experience by investing in voucherless initiatives this is expected to be a catalyst going ahead it is currently operating in more than 25 markets the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform the rollout of the companys new cardlinked platform groupon that replaces the voucher system and makes discounting processes easy will be a tailwind in the long haul,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'de', 'emphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'management', 'note', 'new', 'offering', 'groupon', 'accept', 'company', 'enhance', 'customer', 'experience', 'invest', 'voucherless', 'initiative', 'expect', 'catalyst', 'go', 'ahead', 'currently', 'operate', '25', 'market', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform', 'rollout', 'company', 'new', 'cardlinke', 'platform', 'groupon', 'replace', 'voucher', 'system', 'make', 'discount', 'process', 'easy', 'tailwind', 'long', 'haul']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product de emphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company believe partnership aid company rapidly penetrate local market drive topline growth go ahead groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business management note new offering groupon accept company enhance customer experience invest voucherless initiative expect catalyst go ahead currently operate 25 market company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform rollout company new cardlinke platform groupon replace voucher system make discount process easy tailwind long haul,23,23,0.0,23,23,0.0,0.998
218,"Groupon, Inc._Attachment1.pdf",GRPN,9/10/2018,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being de emphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company the companys partnership with grubhub continues to enable customers to order food delivery from more than 80000 restaurant partners of grubhub via groupon platform further partnerships with coresource american express major league baseball among others are aiding groupon to cater to just about any local need consequently aiding it to rapidly penetrate the market we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well also management noted that its new offering groupon has been well accepted as the company is enhancing customer experience by investing in voucherless initiatives this is expected to be a catalyst going ahead it is currently operating in more than 25 markets the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform the rollout of the companys new cardlinked platform groupon that replaces the voucher system and makes discounting processes easy will be a tailwind in the long haul,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'de', 'emphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'company', 'partnership', 'grubhub', 'continue', 'enable', 'customer', 'order', 'food', 'delivery', '80000', 'restaurant', 'partner', 'grubhub', 'groupon', 'platform', 'partnership', 'coresource', 'american', 'express', 'major', 'league', 'baseball', 'aid', 'groupon', 'cater', 'local', 'need', 'consequently', 'aid', 'rapidly', 'penetrate', 'market', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'management', 'note', 'new', 'offering', 'groupon', 'accept', 'company', 'enhance', 'customer', 'experience', 'invest', 'voucherless', 'initiative', 'expect', 'catalyst', 'go', 'ahead', 'currently', 'operate', '25', 'market', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform', 'rollout', 'company', 'new', 'cardlinke', 'platform', 'groupon', 'replace', 'voucher', 'system', 'make', 'discount', 'process', 'easy', 'tailwind', 'long', 'haul']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product de emphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company company partnership grubhub continue enable customer order food delivery 80000 restaurant partner grubhub groupon platform partnership coresource american express major league baseball aid groupon cater local need consequently aid rapidly penetrate market believe partnership aid company rapidly penetrate local market drive topline growth go ahead groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business management note new offering groupon accept company enhance customer experience invest voucherless initiative expect catalyst go ahead currently operate 25 market company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform rollout company new cardlinke platform groupon replace voucher system make discount process easy tailwind long haul,24,26,-0.0392156862745098,24,26,-0.0392156862745098,0.998
219,"Groupon, Inc._Attachment1.pdf",GRPN,2/27/2019,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run as a part of its growth initiatives groupon is also forming strategic partnerships to expand its business in apr 2016 groupon joined forces with comcast corporation and received a 250 million investment from the cable giant through its private investment firm atairos management this new partnership has opened up avenues for groupon to advance its local business through comcasts impressive subscriber and advertiser network this apart in feb 2016 alibaba also announced that it had taken a 56 stake in the company the companys partnership with grubhub continues to enable customers to order food delivery from more than 80000 restaurant partners of grubhub via groupon platform further partnerships with coresource american express major league baseball among others are aiding groupon to cater to just about any local need consequently aiding it to rapidly penetrate the market we believe that these partnerships will aid the company to rapidly penetrate the local market which will drive topline growth going ahead groupons policy of launching new products on a regular basis is a positive the companys strategy of offering special deals prior to important events like thanksgiving enhances its popularity in aug 2015 groupon launched groupon to go in order to enter the food delivery business we believe that groupon to go service can prove to be of significance for the company as it can act as a bridge to bring its customers to the eateries and open a whole new space for the companys growth freebies include over 30000 digital coupons codes sales giveaways and samples from over 6000 brands spanning 245000 merchant locations the company plans to expand freebies to some key international markets and expects to be added to android devices over the near term freebies is likely help groupon to diversify its business beyond the core daily deals segment in mar 2016 the company launched its food delivery app orderup the service that initially started from pittsburgh is now being expanded to more markets we believe that given the scope for growth in the food delivery business going ahead this initiative can significantly boost groupons local business as well also management noted that its new offering groupon has been well accepted as the company is enhancing customer experience by investing in voucherless initiatives this is expected to be a catalyst going ahead it is currently operating in more than 25 markets the company through its ecommerce platform offers numerous deals that can be accessed by users anywhere and at anytime users who search for these live deals generally tend to spend more the company continues to invest in the platform to attract new merchants which will drive popularity earlier groupon revealed that it intends to reduce the number of discounted deals to attract more merchants groupons longterm prospects rest upon its ability to offer more innovative products and build a broader local ecommerce platform the rollout of the companys new cardlinked platform groupon that replaces the voucher system and makes discounting processes easy will be a tailwind in the long haul,sell,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run', 'growth', 'initiative', 'groupon', 'form', 'strategic', 'partnership', 'expand', 'business', 'apr', '2016', 'groupon', 'join', 'force', 'comcast', 'corporation', 'receive', '250', 'million', 'investment', 'cable', 'giant', 'private', 'investment', 'firm', 'atairo', 'management', 'new', 'partnership', 'open', 'avenue', 'groupon', 'advance', 'local', 'business', 'comcast', 'impressive', 'subscriber', 'advertiser', 'network', 'apart', 'feb', '2016', 'alibaba', 'announce', 'take', '56', 'stake', 'company', 'company', 'partnership', 'grubhub', 'continue', 'enable', 'customer', 'order', 'food', 'delivery', '80000', 'restaurant', 'partner', 'grubhub', 'groupon', 'platform', 'partnership', 'coresource', 'american', 'express', 'major', 'league', 'baseball', 'aid', 'groupon', 'cater', 'local', 'need', 'consequently', 'aid', 'rapidly', 'penetrate', 'market', 'believe', 'partnership', 'aid', 'company', 'rapidly', 'penetrate', 'local', 'market', 'drive', 'topline', 'growth', 'go', 'ahead', 'groupon', 'policy', 'launch', 'new', 'product', 'regular', 'basis', 'positive', 'company', 'strategy', 'offer', 'special', 'deal', 'prior', 'important', 'event', 'like', 'thanksgiving', 'enhance', 'popularity', 'aug', '2015', 'groupon', 'launch', 'groupon', 'order', 'enter', 'food', 'delivery', 'business', 'believe', 'groupon', 'service', 'prove', 'significance', 'company', 'act', 'bridge', 'bring', 'customer', 'eatery', 'open', 'new', 'space', 'company', 'growth', 'freebie', 'include', '30000', 'digital', 'coupon', 'code', 'sale', 'giveaway', 'sample', '6000', 'brand', 'span', '245000', 'merchant', 'location', 'company', 'plan', 'expand', 'freebie', 'key', 'international', 'market', 'expect', 'add', 'android', 'device', 'near', 'term', 'freebie', 'likely', 'help', 'groupon', 'diversify', 'business', 'core', 'daily', 'deal', 'segment', 'mar', '2016', 'company', 'launch', 'food', 'delivery', 'app', 'orderup', 'service', 'initially', 'start', 'pittsburgh', 'expand', 'market', 'believe', 'give', 'scope', 'growth', 'food', 'delivery', 'business', 'go', 'ahead', 'initiative', 'significantly', 'boost', 'groupon', 'local', 'business', 'management', 'note', 'new', 'offering', 'groupon', 'accept', 'company', 'enhance', 'customer', 'experience', 'invest', 'voucherless', 'initiative', 'expect', 'catalyst', 'go', 'ahead', 'currently', 'operate', '25', 'market', 'company', 'ecommerce', 'platform', 'offer', 'numerous', 'deal', 'access', 'user', 'anytime', 'user', 'search', 'live', 'deal', 'generally', 'tend', 'spend', 'company', 'continue', 'invest', 'platform', 'attract', 'new', 'merchant', 'drive', 'popularity', 'early', 'groupon', 'reveal', 'intend', 'reduce', 'number', 'discount', 'deal', 'attract', 'merchant', 'groupon', 'longterm', 'prospect', 'rest', 'ability', 'offer', 'innovative', 'product', 'build', 'broad', 'local', 'ecommerce', 'platform', 'rollout', 'company', 'new', 'cardlinke', 'platform', 'groupon', 'replace', 'voucher', 'system', 'make', 'discount', 'process', 'easy', 'tailwind', 'long', 'haul']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run growth initiative groupon form strategic partnership expand business apr 2016 groupon join force comcast corporation receive 250 million investment cable giant private investment firm atairo management new partnership open avenue groupon advance local business comcast impressive subscriber advertiser network apart feb 2016 alibaba announce take 56 stake company company partnership grubhub continue enable customer order food delivery 80000 restaurant partner grubhub groupon platform partnership coresource american express major league baseball aid groupon cater local need consequently aid rapidly penetrate market believe partnership aid company rapidly penetrate local market drive topline growth go ahead groupon policy launch new product regular basis positive company strategy offer special deal prior important event like thanksgiving enhance popularity aug 2015 groupon launch groupon order enter food delivery business believe groupon service prove significance company act bridge bring customer eatery open new space company growth freebie include 30000 digital coupon code sale giveaway sample 6000 brand span 245000 merchant location company plan expand freebie key international market expect add android device near term freebie likely help groupon diversify business core daily deal segment mar 2016 company launch food delivery app orderup service initially start pittsburgh expand market believe give scope growth food delivery business go ahead initiative significantly boost groupon local business management note new offering groupon accept company enhance customer experience invest voucherless initiative expect catalyst go ahead currently operate 25 market company ecommerce platform offer numerous deal access user anytime user search live deal generally tend spend company continue invest platform attract new merchant drive popularity early groupon reveal intend reduce number discount deal attract merchant groupon longterm prospect rest ability offer innovative product build broad local ecommerce platform rollout company new cardlinke platform groupon replace voucher system make discount process easy tailwind long haul,23,25,-0.04081632653061224,23,25,-0.04081632653061224,0.998
220,"Groupon, Inc._Attachment1.pdf",GRPN,4/22/2020,groupon is trying to change the consumer perception of its brand as it transitions from a deals company to a marketplace company for this the company has outlined a new restructuring plan with focus on three key areas namely marketing international and shopping the company now operates in 15 countries across the globe down from 47 countries that it operated in the beginning of 2015 the shopping business is also being restructured with the lowermargin specifically empty calories products being deemphasized to increase focus on highermargin healthy food offerings most importantly groupon is ramping up its marketing activities especially in north america additionally groupon plans to reorganize its operations over the next couple of years that will improve its overall operating efficiency and reduce sga costs in addition the company is also working to improve its customer service experience while simultaneously enhancing the services it offers to merchants we believe that the successful implementation of these initiatives will boost profitability in the long run,buy,"['groupon', 'try', 'change', 'consumer', 'perception', 'brand', 'transition', 'deal', 'company', 'marketplace', 'company', 'company', 'outline', 'new', 'restructuring', 'plan', 'focus', 'key', 'area', 'market', 'international', 'shop', 'company', 'operate', '15', 'country', 'globe', '47', 'country', 'operate', 'beginning', '2015', 'shopping', 'business', 'restructure', 'lowermargin', 'specifically', 'calorie', 'product', 'deemphasize', 'increase', 'focus', 'highermargin', 'healthy', 'food', 'offering', 'importantly', 'groupon', 'ramp', 'marketing', 'activity', 'especially', 'north', 'america', 'additionally', 'groupon', 'plan', 'reorganize', 'operation', 'couple', 'year', 'improve', 'overall', 'operating', 'efficiency', 'reduce', 'sga', 'cost', 'addition', 'company', 'work', 'improve', 'customer', 'service', 'experience', 'simultaneously', 'enhance', 'service', 'offer', 'merchant', 'believe', 'successful', 'implementation', 'initiative', 'boost', 'profitability', 'long', 'run']",groupon try change consumer perception brand transition deal company marketplace company company outline new restructuring plan focus key area market international shop company operate 15 country globe 47 country operate beginning 2015 shopping business restructure lowermargin specifically calorie product deemphasize increase focus highermargin healthy food offering importantly groupon ramp marketing activity especially north america additionally groupon plan reorganize operation couple year improve overall operating efficiency reduce sga cost addition company work improve customer service experience simultaneously enhance service offer merchant believe successful implementation initiative boost profitability long run,7,9,-0.11764705882352941,7,9,-0.11764705882352941,0.969
221,Guidewire Software Inc_Attachment1(2).pdf,GWRE,9/1/2020,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of 175 of total assets as of apr 30 2020 the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 132x this level compares unfavorably with what the industry witnessed in the last year additionally the ratio is higher than the average level of 1277x and is near the high end of the valuation range in this period consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '175', 'total', 'asset', 'apr', '30', '2020', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '132x', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '1277x', 'near', 'high', 'end', 'valuation', 'range', 'period', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 175 total asset apr 30 2020 company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 132x level compare unfavorably industry witness year additionally ratio high average level 1277x near high end valuation range period consequently valuation looks slightly stretch ps perspective,7,17,-0.4,7,17,-0.4,-0.6486
222,Guidewire Software Inc_Attachment1(4).pdf,GWRE,8/4/2020,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of 175 of total assets as of apr 30 2020 the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 1395x this level compares unfavorably with what the industry witnessed in the last year additionally the ratio is higher than the average level of 1259x and is near the high end of the valuation range in this period consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '175', 'total', 'asset', 'apr', '30', '2020', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '1395x', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '1259x', 'near', 'high', 'end', 'valuation', 'range', 'period', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 175 total asset apr 30 2020 company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 1395x level compare unfavorably industry witness year additionally ratio high average level 1259x near high end valuation range period consequently valuation looks slightly stretch ps perspective,7,17,-0.4,7,17,-0.4,-0.6486
223,Guidewire Software Inc_Attachment1(4).pdf,GWRE,9/10/2020,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2020 revenues were from subscriptionbased products accounting for approximately 65 of new sales it is a considerable improvement over 36 reported in fiscal 2019 backed by strong performance of subscription products management expects new sales from subscription offerings in the lower end of 7080 for fiscal 2021 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to technavio the global softwareasaservice saas market is expected to hit 6036 billion by 2023 witnessing a cagr of 9 between 2019 and 2023 this is expected to favor the companys growth prospects,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2020', 'revenue', 'subscriptionbased', 'product', 'account', 'approximately', '65', 'new', 'sale', 'considerable', 'improvement', '36', 'report', 'fiscal', '2019', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'expect', 'new', 'sale', 'subscription', 'offering', 'low', 'end', '7080', 'fiscal', '2021', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'technavio', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'hit', '6036', 'billion', '2023', 'witness', 'cagr', '9', '2019', '2023', 'expect', 'favor', 'company', 'growth', 'prospect']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2020 revenue subscriptionbased product account approximately 65 new sale considerable improvement 36 report fiscal 2019 back strong performance subscription product management expect new sale subscription offering low end 7080 fiscal 2021 guidewire cloud deployment partner amazon web service gain momentum bode accord technavio global softwareasaservice saas market expect hit 6036 billion 2023 witness cagr 9 2019 2023 expect favor company growth prospect,6,7,-0.07142857142857142,6,7,-0.07142857142857142,0.9612
224,Guidewire Software Inc_Attachment1.pdf,GWRE,8/11/2020,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2019 revenues were from subscriptionbased products accounting for approximately 65 of new sales it is a considerable improvement over 36 reported in fiscal 2018 backed by strong performance of subscription products management continues to expect new sales from subscription offerings in the lower end of 7080 for fiscal 2020 guidewires cloud,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2019', 'revenue', 'subscriptionbased', 'product', 'account', 'approximately', '65', 'new', 'sale', 'considerable', 'improvement', '36', 'report', 'fiscal', '2018', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'continue', 'expect', 'new', 'sale', 'subscription', 'offering', 'low', 'end', '7080', 'fiscal', '2020', 'guidewire', 'cloud']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2019 revenue subscriptionbased product account approximately 65 new sale considerable improvement 36 report fiscal 2018 back strong performance subscription product management continue expect new sale subscription offering low end 7080 fiscal 2020 guidewire cloud,4,5,-0.1,4,5,-0.1,0.836
225,Guidewire Software Inc_Attachment1.pdf,GWRE,8/11/2020,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of 175 of total assets as of apr 30 2020 the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 1267x this level compares unfavorably with what the industry witnessed in the last year additionally the ratio is higher than the average level of 1262x and is near the high end of the valuation range in this period consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '175', 'total', 'asset', 'apr', '30', '2020', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '1267x', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '1262x', 'near', 'high', 'end', 'valuation', 'range', 'period', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 175 total asset apr 30 2020 company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 1267x level compare unfavorably industry witness year additionally ratio high average level 1262x near high end valuation range period consequently valuation looks slightly stretch ps perspective,7,17,-0.4,7,17,-0.4,-0.6486
226,Guidewire Software Inc_Attachment1.pdf,GWRE,10/15/2020,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2020 revenues were from subscriptionbased products accounting for 70 of new sales it is a significant improvement over 65 reported in fiscal 2019 backed by strong performance of subscription products management expects momentum in new sales from subscription offerings to sustain in fiscal 2021 guidewires cloud deployment partner amazon web,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2020', 'revenue', 'subscriptionbased', 'product', 'account', '70', 'new', 'sale', 'significant', 'improvement', '65', 'report', 'fiscal', '2019', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'expect', 'momentum', 'new', 'sale', 'subscription', 'offering', 'sustain', 'fiscal', '2021', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2020 revenue subscriptionbased product account 70 new sale significant improvement 65 report fiscal 2019 back strong performance subscription product management expect momentum new sale subscription offering sustain fiscal 2021 guidewire cloud deployment partner amazon web,4,3,0.125,4,3,0.125,0.91
227,"Guidewire Software, Inc._Attachment1(2).pdf",GWRE,1/8/2018,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward the company expects subscription sales to rise to 20 to 30 in fiscal 2018 from 6 in fiscal 2017 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to increase at a fouryear cagr of 184 over 20162020 time frame this also bodes well for the company guidewire faces less competition due to its unique line of business though there are private players with similar offerings among the listed entities the companys software suite is not common more so because it serves specifically the pc insurance industry this is a major tailwind for the companys top line which will result in impressive earnings per share if the cost structure is stringent guidewires acquisition strategy has aided growth the crossselling of the product suites has increased customer base and revenue generation the companys acquisition of iscs in february 2017 now called insurancenow and one of the highest revenue generating segments added around 162 million in hosting revenues in fiscal 2017 firstbest now called guidewire underwriting management and eagleeye analytics now known as guidewire predictive analytics which were acquired in 2016 and guidewirenow previously alled iscs are a few prominent segments of the company guidewires customer base has expanded consistently as evident from the addition of nine new customers in fourthquarter 2017 including five new customers for the companys core product insurancesuite and one for insurancenow formerly known as iscs guidewire portrays a strong balance sheet with no debt the company exited fiscal 2017 with cash and cash equivalents of 2632 million compared with 2236 million in fiscal 2016 cash from operating activities was 1372 million higher than 999 million in the previous fiscal,sell,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'company', 'expect', 'subscription', 'sale', 'rise', '20', '30', 'fiscal', '2018', '6', 'fiscal', '2017', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'fouryear', 'cagr', '184', '20162020', 'time', 'frame', 'bode', 'company', 'guidewire', 'face', 'competition', 'unique', 'line', 'business', 'private', 'player', 'similar', 'offering', 'list', 'entity', 'companys', 'software', 'suite', 'common', 'serve', 'specifically', 'pc', 'insurance', 'industry', 'major', 'tailwind', 'companys', 'line', 'result', 'impressive', 'earning', 'share', 'cost', 'structure', 'stringent', 'guidewire', 'acquisition', 'strategy', 'aid', 'growth', 'crossselling', 'product', 'suite', 'increase', 'customer', 'base', 'revenue', 'generation', 'company', 'acquisition', 'isc', 'february', '2017', 'call', 'insurancenow', 'high', 'revenue', 'generating', 'segment', 'add', '162', 'million', 'host', 'revenue', 'fiscal', '2017', 'firstb', 'call', 'guidewire', 'underwriting', 'management', 'eagleeye', 'analytic', 'know', 'guidewire', 'predictive', 'analytic', 'acquire', '2016', 'guidewirenow', 'previously', 'alle', 'isc', 'prominent', 'segment', 'company', 'guidewire', 'customer', 'base', 'expand', 'consistently', 'evident', 'addition', 'new', 'customer', 'fourthquarter', '2017', 'include', 'new', 'customer', 'company', 'core', 'product', 'insurancesuite', 'insurancenow', 'know', 'iscs', 'guidewire', 'portray', 'strong', 'balance', 'sheet', 'debt', 'company', 'exit', 'fiscal', '2017', 'cash', 'cash', 'equivalent', '2632', 'million', 'compare', '2236', 'million', 'fiscal', '2016', 'cash', 'operating', 'activity', '1372', 'million', 'high', '999', 'million', 'previous', 'fiscal']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward company expect subscription sale rise 20 30 fiscal 2018 6 fiscal 2017 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect increase fouryear cagr 184 20162020 time frame bode company guidewire face competition unique line business private player similar offering list entity companys software suite common serve specifically pc insurance industry major tailwind companys line result impressive earning share cost structure stringent guidewire acquisition strategy aid growth crossselling product suite increase customer base revenue generation company acquisition isc february 2017 call insurancenow high revenue generating segment add 162 million host revenue fiscal 2017 firstb call guidewire underwriting management eagleeye analytic know guidewire predictive analytic acquire 2016 guidewirenow previously alle isc prominent segment company guidewire customer base expand consistently evident addition new customer fourthquarter 2017 include new customer company core product insurancesuite insurancenow know iscs guidewire portray strong balance sheet debt company exit fiscal 2017 cash cash equivalent 2632 million compare 2236 million fiscal 2016 cash operating activity 1372 million high 999 million previous fiscal,7,20,-0.4642857142857143,7,20,-0.4642857142857143,0.9723
228,"Guidewire Software, Inc._Attachment1(2).pdf",GWRE,6/7/2018,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward the company expects subscription sales to rise to 30 to 40 in fiscal 2018 from 6 in fiscal 2017 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to increase at a four year cagr of 184 over 20162020 time frame this also bodes well for the company guidewire faces less competition due to its unique line of business though there are private players with similar offerings among the listed entities the companys software suite is not common more so because it serves specifically the pc insurance industry this is a major tailwind for the companys top line which will result in impressive earnings per share if the cost structure is stringent guidewires acquisition strategy has aided growth the crossselling of the product suites has increased customer base and revenue generation the company recently completed cyence buyout notably cyence determines the economic impact of a cybercrime via a software platform which is built on cybersecurity related data science the integration of cyence would imply that the company would be able to provide an entire life cycle to the insurance products starting from designing to transaction management the companys acquisition of iscs in february 2017 now called insurancenow and one of the highest revenue generating segments added around 162 million in hosting revenues in fiscal 2017 firstbest now called guidewire underwriting management and eagleeye analytics now known as guidewire predictive analytics which were acquired in 2016 and guidewirenow previously alled iscs are a few prominent segments of the company guidewires customer base has expanded consistently as evident from the addition of nine new customers in fourthquarter 2017 including five new customers for the companys core product insurancesuite and one for insurancenow formerly known as iscs guidewire portrays a strong balance sheet with no debt the company exited fiscal 2017 with cash and cash equivalents of 2632 million compared with 2236 million in fiscal 2016 cash from operating activities was 1372 million higher than 999 million in the previous fiscal further the company had cash and cash equivalents and investments of 9943 on apr 30 2018 as compared with 5695 million in the previous quarter cash flow from operations in the third quarter was 202 million and free cash flow was 19 million,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'company', 'expect', 'subscription', 'sale', 'rise', '30', '40', 'fiscal', '2018', '6', 'fiscal', '2017', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'year', 'cagr', '184', '20162020', 'time', 'frame', 'bode', 'company', 'guidewire', 'face', 'competition', 'unique', 'line', 'business', 'private', 'player', 'similar', 'offering', 'list', 'entity', 'companys', 'software', 'suite', 'common', 'serve', 'specifically', 'pc', 'insurance', 'industry', 'major', 'tailwind', 'companys', 'line', 'result', 'impressive', 'earning', 'share', 'cost', 'structure', 'stringent', 'guidewire', 'acquisition', 'strategy', 'aid', 'growth', 'crossselling', 'product', 'suite', 'increase', 'customer', 'base', 'revenue', 'generation', 'company', 'recently', 'complete', 'cyence', 'buyout', 'notably', 'cyence', 'determine', 'economic', 'impact', 'cybercrime', 'software', 'platform', 'build', 'cybersecurity', 'relate', 'datum', 'science', 'integration', 'cyence', 'imply', 'company', 'able', 'provide', 'entire', 'life', 'cycle', 'insurance', 'product', 'start', 'design', 'transaction', 'management', 'company', 'acquisition', 'isc', 'february', '2017', 'call', 'insurancenow', 'high', 'revenue', 'generating', 'segment', 'add', '162', 'million', 'host', 'revenue', 'fiscal', '2017', 'firstb', 'call', 'guidewire', 'underwriting', 'management', 'eagleeye', 'analytic', 'know', 'guidewire', 'predictive', 'analytic', 'acquire', '2016', 'guidewirenow', 'previously', 'alle', 'isc', 'prominent', 'segment', 'company', 'guidewire', 'customer', 'base', 'expand', 'consistently', 'evident', 'addition', 'new', 'customer', 'fourthquarter', '2017', 'include', 'new', 'customer', 'company', 'core', 'product', 'insurancesuite', 'insurancenow', 'know', 'iscs', 'guidewire', 'portray', 'strong', 'balance', 'sheet', 'debt', 'company', 'exit', 'fiscal', '2017', 'cash', 'cash', 'equivalent', '2632', 'million', 'compare', '2236', 'million', 'fiscal', '2016', 'cash', 'operating', 'activity', '1372', 'million', 'high', '999', 'million', 'previous', 'fiscal', 'company', 'cash', 'cash', 'equivalent', 'investment', '9943', 'apr', '30', '2018', 'compare', '5695', 'million', 'previous', 'quarter', 'cash', 'flow', 'operation', 'quarter', '202', 'million', 'free', 'cash', 'flow', '19', 'million']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward company expect subscription sale rise 30 40 fiscal 2018 6 fiscal 2017 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect increase year cagr 184 20162020 time frame bode company guidewire face competition unique line business private player similar offering list entity companys software suite common serve specifically pc insurance industry major tailwind companys line result impressive earning share cost structure stringent guidewire acquisition strategy aid growth crossselling product suite increase customer base revenue generation company recently complete cyence buyout notably cyence determine economic impact cybercrime software platform build cybersecurity relate datum science integration cyence imply company able provide entire life cycle insurance product start design transaction management company acquisition isc february 2017 call insurancenow high revenue generating segment add 162 million host revenue fiscal 2017 firstb call guidewire underwriting management eagleeye analytic know guidewire predictive analytic acquire 2016 guidewirenow previously alle isc prominent segment company guidewire customer base expand consistently evident addition new customer fourthquarter 2017 include new customer company core product insurancesuite insurancenow know iscs guidewire portray strong balance sheet debt company exit fiscal 2017 cash cash equivalent 2632 million compare 2236 million fiscal 2016 cash operating activity 1372 million high 999 million previous fiscal company cash cash equivalent investment 9943 apr 30 2018 compare 5695 million previous quarter cash flow operation quarter 202 million free cash flow 19 million,8,23,-0.46875,8,23,-0.46875,0.9786
229,"Guidewire Software, Inc._Attachment1(2).pdf",GWRE,10/9/2018,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation in fiscal 2018 management expects the costs related to these payments to drag down margins by around 100 basis points in fiscal 2018 guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company made cyence acquisition in 2018 and two acquisitions in fiscal 2017 namely firstbest in august 2016 and iscs in february 2017 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run guidewire currently has a trailing oneyear ps ratio of 1182 which compares unfavorably to some extent with what the industry saw last year the ratio is higher than the average level of 1152 hence its valuation looks slightly stretched from a ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'fiscal', '2018', 'management', 'expect', 'cost', 'relate', 'payment', 'drag', 'margin', '100', 'basis', 'point', 'fiscal', '2018', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'cyence', 'acquisition', '2018', 'acquisition', 'fiscal', '2017', 'firstbest', 'august', '2016', 'isc', 'february', '2017', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'guidewire', 'currently', 'trail', 'oneyear', 'ps', 'ratio', '1182', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'ratio', 'high', 'average', 'level', '1152', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation fiscal 2018 management expect cost relate payment drag margin 100 basis point fiscal 2018 guidewire frequently acquire company expose integration risk put pressure cash flow notably company cyence acquisition 2018 acquisition fiscal 2017 firstbest august 2016 isc february 2017 believe dependence inorganic growth innovation negative affect company long run guidewire currently trail oneyear ps ratio 1182 compare unfavorably extent industry see year ratio high average level 1152 valuation looks slightly stretch ps perspective,5,16,-0.5,5,16,-0.5,-0.8807
230,"Guidewire Software, Inc._Attachment1(2).pdf",GWRE,12/10/2018,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of almost 218 of total assets as of oct 31 2018 although shares have outperformed the industry in the past year the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 954 this level compares unfavorably with what the industry witnessed in the last year consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '218', 'total', 'asset', 'oct', '31', '2018', 'share', 'outperform', 'industry', 'past', 'year', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '954', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 218 total asset oct 31 2018 share outperform industry past year company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 954 level compare unfavorably industry witness year consequently valuation looks slightly stretch ps perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,-0.4767
231,"Guidewire Software, Inc._Attachment1(2).pdf",GWRE,2/11/2019,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of almost 218 of total assets as of oct 31 2018 although shares have outperformed the industry in the past year the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 1046this level compares unfavorably with what the industry witnessed in the last year consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '218', 'total', 'asset', 'oct', '31', '2018', 'share', 'outperform', 'industry', 'past', 'year', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '1046this', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 218 total asset oct 31 2018 share outperform industry past year company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 1046this level compare unfavorably industry witness year consequently valuation looks slightly stretch ps perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,-0.4767
232,"Guidewire Software, Inc._Attachment1(2).pdf",GWRE,4/15/2019,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of almost 387 of total assets as of jan 31 2019 although shares have outperformed the industry in the past year the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 1148this level compares unfavorably with what the industry witnessed in the last year additionally the ratio is higher than the average level of 1118 and is near the high end of the valuation range in this period consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '387', 'total', 'asset', 'jan', '31', '2019', 'share', 'outperform', 'industry', 'past', 'year', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '1148this', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '1118', 'near', 'high', 'end', 'valuation', 'range', 'period', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 387 total asset jan 31 2019 share outperform industry past year company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 1148this level compare unfavorably industry witness year additionally ratio high average level 1118 near high end valuation range period consequently valuation looks slightly stretch ps perspective,8,17,-0.34615384615384615,8,17,-0.34615384615384615,-0.4767
233,"Guidewire Software, Inc._Attachment1(2).pdf",GWRE,12/23/2020,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of 16 of total assets as of oct 31 2020 the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 1406x this level compares unfavorably with what sp 500 composite witnessed in the last year consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '16', 'total', 'asset', 'oct', '31', '2020', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '1406x', 'level', 'compare', 'unfavorably', 'sp', '500', 'composite', 'witness', 'year', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 16 total asset oct 31 2020 company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 1406x level compare unfavorably sp 500 composite witness year consequently valuation looks slightly stretch ps perspective,5,17,-0.5217391304347826,5,17,-0.5217391304347826,-0.6486
234,"Guidewire Software, Inc._Attachment1(3).pdf",GWRE,10/17/2017,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation in fiscal 2018 management expects the costs related to these payments to drag down margins by around 100 basis points in fiscal 2018 guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company made two acquisitions in fiscal 2017 namely firstbest in august 2016 and iscs in february 2017 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run guidewire currently has a trailing oneyear ps ratio of 1152 which compares unfavorably to some extent with what the industry saw last year the ratio is higher than the average level of 982 and is closer to the high end of the valuation range over this period hence its valuation looks slightly stretched from a ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'fiscal', '2018', 'management', 'expect', 'cost', 'relate', 'payment', 'drag', 'margin', '100', 'basis', 'point', 'fiscal', '2018', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquisition', 'fiscal', '2017', 'firstbest', 'august', '2016', 'isc', 'february', '2017', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'guidewire', 'currently', 'trail', 'oneyear', 'ps', 'ratio', '1152', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'ratio', 'high', 'average', 'level', '982', 'close', 'high', 'end', 'valuation', 'range', 'period', 'valuation', 'look', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation fiscal 2018 management expect cost relate payment drag margin 100 basis point fiscal 2018 guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquisition fiscal 2017 firstbest august 2016 isc february 2017 believe dependence inorganic growth innovation negative affect company long run guidewire currently trail oneyear ps ratio 1152 compare unfavorably extent industry see year ratio high average level 982 close high end valuation range period valuation look slightly stretch ps perspective,6,18,-0.48,6,18,-0.48,-0.8807
235,"Guidewire Software, Inc._Attachment1(3).pdf",GWRE,10/14/2019,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2019 revenues were from subscriptionbased products accounting for approximately 65 of new sales it is a considerable improvement over 36 reported in fiscal 2018 backed by strong performance of subscription products management continues to expect new sales from subscription offerings in the range of 5575 for fiscal 2020 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to witness a cagr of 158 in 20182022 time frame to reach 1437 billion by 2022 which favors the companys growth prospects,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2019', 'revenue', 'subscriptionbased', 'product', 'account', 'approximately', '65', 'new', 'sale', 'considerable', 'improvement', '36', 'report', 'fiscal', '2018', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'continue', 'expect', 'new', 'sale', 'subscription', 'offering', 'range', '5575', 'fiscal', '2020', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'witness', 'cagr', '158', '20182022', 'time', 'frame', 'reach', '1437', 'billion', '2022', 'favor', 'company', 'growth', 'prospect']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2019 revenue subscriptionbased product account approximately 65 new sale considerable improvement 36 report fiscal 2018 back strong performance subscription product management continue expect new sale subscription offering range 5575 fiscal 2020 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect witness cagr 158 20182022 time frame reach 1437 billion 2022 favor company growth prospect,6,6,0.0,6,6,0.0,0.967
236,"Guidewire Software, Inc._Attachment1.pdf",GWRE,9/20/2017,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward the company expects subscription sales to rise to 20 to 30 in fiscal 2018 from 6 in fiscal 2017 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to increase at a four year cagr of 184 over 20162020 time frame this also bodes well for the company guidewire faces less competition due to its unique line of business though there are private players with similar offerings among the listed entities the companys software suite is not common more so because it serves specifically the pc insurance industry this is a major tailwind for the companys top line which will result in impressive earnings per share if the cost structure is stringent guidewires acquisition strategy has aided growth the crossselling of the product suites has increased customer base and revenue generation the companys acquisition of iscs on february 2017 now called insurancenow and one of the highest revenue generating segments added around 162 million in hosting revenues in fiscal 2017 guidewires product suite is largely based on the offerings of the entities acquired by the company firstbest now called guidewire underwriting management and eagleeye analytics now known as guidewire predictive analytics which were acquired in 2016 and guidewirenow previously alled iscs are a few prominent segments of the company guidewires customer base has expanded consistently as evident from the addition of nine new customers in fourthquarter 2017 including five new customers for the companys core product insurancesuite and one for insurancenow formerly known as iscs which the company acquired in february 2017 guidewire portrays a strong balance sheet with no debt the company exited fiscal 2017 with cash and cash equivalents of 2632 million compared with 2236 million in fiscal 2016 cash from operating activities was 1372 million higher than 999 million in the previous fiscal,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'company', 'expect', 'subscription', 'sale', 'rise', '20', '30', 'fiscal', '2018', '6', 'fiscal', '2017', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'year', 'cagr', '184', '20162020', 'time', 'frame', 'bode', 'company', 'guidewire', 'face', 'competition', 'unique', 'line', 'business', 'private', 'player', 'similar', 'offering', 'list', 'entity', 'companys', 'software', 'suite', 'common', 'serve', 'specifically', 'pc', 'insurance', 'industry', 'major', 'tailwind', 'companys', 'line', 'result', 'impressive', 'earning', 'share', 'cost', 'structure', 'stringent', 'guidewire', 'acquisition', 'strategy', 'aid', 'growth', 'crossselling', 'product', 'suite', 'increase', 'customer', 'base', 'revenue', 'generation', 'company', 'acquisition', 'isc', 'february', '2017', 'call', 'insurancenow', 'high', 'revenue', 'generating', 'segment', 'add', '162', 'million', 'host', 'revenue', 'fiscal', '2017', 'guidewire', 'product', 'suite', 'largely', 'base', 'offering', 'entity', 'acquire', 'company', 'firstbest', 'call', 'guidewire', 'underwriting', 'management', 'eagleeye', 'analytic', 'know', 'guidewire', 'predictive', 'analytic', 'acquire', '2016', 'guidewirenow', 'previously', 'alle', 'isc', 'prominent', 'segment', 'company', 'guidewire', 'customer', 'base', 'expand', 'consistently', 'evident', 'addition', 'new', 'customer', 'fourthquarter', '2017', 'include', 'new', 'customer', 'company', 'core', 'product', 'insurancesuite', 'insurancenow', 'know', 'isc', 'company', 'acquire', 'february', '2017', 'guidewire', 'portray', 'strong', 'balance', 'sheet', 'debt', 'company', 'exit', 'fiscal', '2017', 'cash', 'cash', 'equivalent', '2632', 'million', 'compare', '2236', 'million', 'fiscal', '2016', 'cash', 'operating', 'activity', '1372', 'million', 'high', '999', 'million', 'previous', 'fiscal']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward company expect subscription sale rise 20 30 fiscal 2018 6 fiscal 2017 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect increase year cagr 184 20162020 time frame bode company guidewire face competition unique line business private player similar offering list entity companys software suite common serve specifically pc insurance industry major tailwind companys line result impressive earning share cost structure stringent guidewire acquisition strategy aid growth crossselling product suite increase customer base revenue generation company acquisition isc february 2017 call insurancenow high revenue generating segment add 162 million host revenue fiscal 2017 guidewire product suite largely base offering entity acquire company firstbest call guidewire underwriting management eagleeye analytic know guidewire predictive analytic acquire 2016 guidewirenow previously alle isc prominent segment company guidewire customer base expand consistently evident addition new customer fourthquarter 2017 include new customer company core product insurancesuite insurancenow know isc company acquire february 2017 guidewire portray strong balance sheet debt company exit fiscal 2017 cash cash equivalent 2632 million compare 2236 million fiscal 2016 cash operating activity 1372 million high 999 million previous fiscal,7,21,-0.4827586206896552,7,21,-0.4827586206896552,0.9723
237,"Guidewire Software, Inc._Attachment1.pdf",GWRE,9/20/2017,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation in fiscal 2018 management expects the costs related to these payments to drag down margins by around 100 basis points in fiscal 2018 guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company made two acquisitions in fiscal 2017 namely firstbest in august 2016 and iscs in february 2017 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run guidewire currently has a trailing oneyear ps ratio of 1149 which compares unfavorably to some extent with what the industry saw last year the ratio is higher than the average level of 982 and is closer to the high end of the valuation range over this period hence its valuation looks slightly stretched from a ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'fiscal', '2018', 'management', 'expect', 'cost', 'relate', 'payment', 'drag', 'margin', '100', 'basis', 'point', 'fiscal', '2018', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquisition', 'fiscal', '2017', 'firstbest', 'august', '2016', 'isc', 'february', '2017', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'guidewire', 'currently', 'trail', 'oneyear', 'ps', 'ratio', '1149', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'ratio', 'high', 'average', 'level', '982', 'close', 'high', 'end', 'valuation', 'range', 'period', 'valuation', 'look', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation fiscal 2018 management expect cost relate payment drag margin 100 basis point fiscal 2018 guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquisition fiscal 2017 firstbest august 2016 isc february 2017 believe dependence inorganic growth innovation negative affect company long run guidewire currently trail oneyear ps ratio 1149 compare unfavorably extent industry see year ratio high average level 982 close high end valuation range period valuation look slightly stretch ps perspective,6,18,-0.48,6,18,-0.48,-0.8807
238,"Guidewire Software, Inc._Attachment1.pdf",GWRE,11/7/2017,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward the company expects subscription sales to rise to 20 to 30 in fiscal 2018 from 6 in fiscal 2017 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasa service saas market is expected to increase at a fouryear cagr of 184 over 20162020 time frame this also bodes well for the company guidewire faces less competition due to its unique line of business though there are private players with similar offerings among the listed entities the companys software suite is not common more so because it serves specifically the pc insurance industry this is a major tailwind for the companys top line which will result in impressive earnings per share if the cost structure is stringent guidewires acquisition strategy has aided growth the crossselling of the product suites has increased customer base and revenue generation the companys acquisition of iscs in february 2017 now called insurancenow and one of the highest revenue generating segments added around 162 million in hosting revenues in fiscal 2017 firstbest now called guidewire underwriting management and eagleeye analytics now known as guidewire predictive analytics which were acquired in 2016 and guidewirenow previously alled iscs are a few prominent segments of the company guidewires customer base has expanded consistently as evident from the addition of nine new customers in fourthquarter 2017 including five new customers for the companys core product insurancesuite and one for insurancenow formerly known as iscs guidewire portrays a strong balance sheet with no debt the company exited fiscal 2017 with cash and cash equivalents of 2632 million compared with 2236 million in fiscal 2016 cash from operating activities was 1372 million higher than 999 million in the previous fiscal,sell,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'company', 'expect', 'subscription', 'sale', 'rise', '20', '30', 'fiscal', '2018', '6', 'fiscal', '2017', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasa', 'service', 'saas', 'market', 'expect', 'increase', 'fouryear', 'cagr', '184', '20162020', 'time', 'frame', 'bode', 'company', 'guidewire', 'face', 'competition', 'unique', 'line', 'business', 'private', 'player', 'similar', 'offering', 'list', 'entity', 'companys', 'software', 'suite', 'common', 'serve', 'specifically', 'pc', 'insurance', 'industry', 'major', 'tailwind', 'companys', 'line', 'result', 'impressive', 'earning', 'share', 'cost', 'structure', 'stringent', 'guidewire', 'acquisition', 'strategy', 'aid', 'growth', 'crossselling', 'product', 'suite', 'increase', 'customer', 'base', 'revenue', 'generation', 'company', 'acquisition', 'isc', 'february', '2017', 'call', 'insurancenow', 'high', 'revenue', 'generating', 'segment', 'add', '162', 'million', 'host', 'revenue', 'fiscal', '2017', 'firstb', 'call', 'guidewire', 'underwriting', 'management', 'eagleeye', 'analytic', 'know', 'guidewire', 'predictive', 'analytic', 'acquire', '2016', 'guidewirenow', 'previously', 'alle', 'isc', 'prominent', 'segment', 'company', 'guidewire', 'customer', 'base', 'expand', 'consistently', 'evident', 'addition', 'new', 'customer', 'fourthquarter', '2017', 'include', 'new', 'customer', 'company', 'core', 'product', 'insurancesuite', 'insurancenow', 'know', 'iscs', 'guidewire', 'portray', 'strong', 'balance', 'sheet', 'debt', 'company', 'exit', 'fiscal', '2017', 'cash', 'cash', 'equivalent', '2632', 'million', 'compare', '2236', 'million', 'fiscal', '2016', 'cash', 'operating', 'activity', '1372', 'million', 'high', '999', 'million', 'previous', 'fiscal']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward company expect subscription sale rise 20 30 fiscal 2018 6 fiscal 2017 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasa service saas market expect increase fouryear cagr 184 20162020 time frame bode company guidewire face competition unique line business private player similar offering list entity companys software suite common serve specifically pc insurance industry major tailwind companys line result impressive earning share cost structure stringent guidewire acquisition strategy aid growth crossselling product suite increase customer base revenue generation company acquisition isc february 2017 call insurancenow high revenue generating segment add 162 million host revenue fiscal 2017 firstb call guidewire underwriting management eagleeye analytic know guidewire predictive analytic acquire 2016 guidewirenow previously alle isc prominent segment company guidewire customer base expand consistently evident addition new customer fourthquarter 2017 include new customer company core product insurancesuite insurancenow know iscs guidewire portray strong balance sheet debt company exit fiscal 2017 cash cash equivalent 2632 million compare 2236 million fiscal 2016 cash operating activity 1372 million high 999 million previous fiscal,7,20,-0.4642857142857143,7,20,-0.4642857142857143,0.9723
239,"Guidewire Software, Inc._Attachment1.pdf",GWRE,5/11/2018,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward the company expects subscription sales to rise to 20 to 30 in fiscal 2018 from 6 in fiscal 2017 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to increase at a four year cagr of 184 over 20162020 time frame this also bodes well for the company guidewire faces less competition due to its unique line of business though there are private players with similar offerings among the listed entities the companys software suite is not common more so because it serves specifically the pc insurance industry this is a major tailwind for the companys top line which will result in impressive earnings per share if the cost structure is stringent guidewires acquisition strategy has aided growth the crossselling of the product suites has increased customer base and revenue generation the companys acquisition of iscs in february 2017 now called insurancenow and one of the highest revenue generating segments added around 162 million in hosting revenues in fiscal 2017 firstbest now called guidewire underwriting management and eagleeye analytics now known as guidewire predictive analytics which were acquired in 2016 and guidewirenow previously alled iscs are a few prominent segments of the company guidewires customer base has expanded consistently as evident from the addition of nine new customers in fourthquarter 2017 including five new customers for the companys core product insurancesuite and one for insurancenow formerly known as iscs guidewire portrays a strong balance sheet with no debt the company exited fiscal 2017 with cash and cash equivalents of 2632 million compared with 2236 million in fiscal 2016 cash from operating activities was 1372 million higher than 999 million in the previous fiscal,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'company', 'expect', 'subscription', 'sale', 'rise', '20', '30', 'fiscal', '2018', '6', 'fiscal', '2017', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'year', 'cagr', '184', '20162020', 'time', 'frame', 'bode', 'company', 'guidewire', 'face', 'competition', 'unique', 'line', 'business', 'private', 'player', 'similar', 'offering', 'list', 'entity', 'companys', 'software', 'suite', 'common', 'serve', 'specifically', 'pc', 'insurance', 'industry', 'major', 'tailwind', 'companys', 'line', 'result', 'impressive', 'earning', 'share', 'cost', 'structure', 'stringent', 'guidewire', 'acquisition', 'strategy', 'aid', 'growth', 'crossselling', 'product', 'suite', 'increase', 'customer', 'base', 'revenue', 'generation', 'company', 'acquisition', 'isc', 'february', '2017', 'call', 'insurancenow', 'high', 'revenue', 'generating', 'segment', 'add', '162', 'million', 'host', 'revenue', 'fiscal', '2017', 'firstb', 'call', 'guidewire', 'underwriting', 'management', 'eagleeye', 'analytic', 'know', 'guidewire', 'predictive', 'analytic', 'acquire', '2016', 'guidewirenow', 'previously', 'alle', 'isc', 'prominent', 'segment', 'company', 'guidewire', 'customer', 'base', 'expand', 'consistently', 'evident', 'addition', 'new', 'customer', 'fourthquarter', '2017', 'include', 'new', 'customer', 'company', 'core', 'product', 'insurancesuite', 'insurancenow', 'know', 'iscs', 'guidewire', 'portray', 'strong', 'balance', 'sheet', 'debt', 'company', 'exit', 'fiscal', '2017', 'cash', 'cash', 'equivalent', '2632', 'million', 'compare', '2236', 'million', 'fiscal', '2016', 'cash', 'operating', 'activity', '1372', 'million', 'high', '999', 'million', 'previous', 'fiscal']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward company expect subscription sale rise 20 30 fiscal 2018 6 fiscal 2017 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect increase year cagr 184 20162020 time frame bode company guidewire face competition unique line business private player similar offering list entity companys software suite common serve specifically pc insurance industry major tailwind companys line result impressive earning share cost structure stringent guidewire acquisition strategy aid growth crossselling product suite increase customer base revenue generation company acquisition isc february 2017 call insurancenow high revenue generating segment add 162 million host revenue fiscal 2017 firstb call guidewire underwriting management eagleeye analytic know guidewire predictive analytic acquire 2016 guidewirenow previously alle isc prominent segment company guidewire customer base expand consistently evident addition new customer fourthquarter 2017 include new customer company core product insurancesuite insurancenow know iscs guidewire portray strong balance sheet debt company exit fiscal 2017 cash cash equivalent 2632 million compare 2236 million fiscal 2016 cash operating activity 1372 million high 999 million previous fiscal,7,20,-0.4642857142857143,7,20,-0.4642857142857143,0.9723
240,"Guidewire Software, Inc._Attachment1.pdf",GWRE,9/12/2018,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2018 revenues were from subscription based products accounting for approximately 36 of new sales it is a considerable improvement over 6 reported in 2017 backed by strong performance of subscription products management continues to expect subscription sales in the range of 40 60 for 2019 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to increase at a fouryear cagr of 184 over 20162020 time frame this also bodes well for the company guidewire faces less competition due to its unique line of business though there are private players with similar offerings among the listed entities the companys software suite is not common more so because it serves specifically the pc insurance industry this is a major tailwind for the companys top line which will result in impressive earnings per share if the cost structure is stringent guidewires acquisition strategy has aided growth the crossselling of the product suites has increased customer base and revenue generation the company recently completed cyence buyout notably cyence determines the economic impact of a cybercrime via a software platform which is built on cybersecurity related data science the integration of cyence would imply that the company would be able to provide an entire life cycle to the insurance products starting from designing to transaction management the companys acquisition of iscs in february 2017 now called insurancenow and one of the highest revenue generating segments added around 162 million in hosting revenues in fiscal 2017 firstbest now called guidewire underwriting management and eagleeye analytics now known as guidewire predictive analytics which were acquired in 2016 and guidewirenow previously alled iscs are a few prominent segments of the company guidewires customer base has expanded consistently as evident from the addition of nine new customers in fourthquarter 2017 including five new customers for the companys core product insurancesuite and one for insurancenow formerly known as iscs guidewire portrays a strong balance sheet with no debt the company had cash and cash equivalents and shortterm investments of 107 billion as on jul 31 2018 as compared with 9943 million at the end of the previous quarter cash flow from operations in the fourth quarter and fiscal 2018 was 1021 million and 1405 million respectively free cash flow in fiscal 2018 was 984 million and 1284 million,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2018', 'revenue', 'subscription', 'base', 'product', 'account', 'approximately', '36', 'new', 'sale', 'considerable', 'improvement', '6', 'report', '2017', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'continue', 'expect', 'subscription', 'sale', 'range', '40', '60', '2019', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'fouryear', 'cagr', '184', '20162020', 'time', 'frame', 'bode', 'company', 'guidewire', 'face', 'competition', 'unique', 'line', 'business', 'private', 'player', 'similar', 'offering', 'list', 'entity', 'companys', 'software', 'suite', 'common', 'serve', 'specifically', 'pc', 'insurance', 'industry', 'major', 'tailwind', 'companys', 'line', 'result', 'impressive', 'earning', 'share', 'cost', 'structure', 'stringent', 'guidewire', 'acquisition', 'strategy', 'aid', 'growth', 'crossselling', 'product', 'suite', 'increase', 'customer', 'base', 'revenue', 'generation', 'company', 'recently', 'complete', 'cyence', 'buyout', 'notably', 'cyence', 'determine', 'economic', 'impact', 'cybercrime', 'software', 'platform', 'build', 'cybersecurity', 'relate', 'datum', 'science', 'integration', 'cyence', 'imply', 'company', 'able', 'provide', 'entire', 'life', 'cycle', 'insurance', 'product', 'start', 'design', 'transaction', 'management', 'company', 'acquisition', 'isc', 'february', '2017', 'call', 'insurancenow', 'high', 'revenue', 'generating', 'segment', 'add', '162', 'million', 'host', 'revenue', 'fiscal', '2017', 'firstb', 'call', 'guidewire', 'underwriting', 'management', 'eagleeye', 'analytic', 'know', 'guidewire', 'predictive', 'analytic', 'acquire', '2016', 'guidewirenow', 'previously', 'alle', 'isc', 'prominent', 'segment', 'company', 'guidewire', 'customer', 'base', 'expand', 'consistently', 'evident', 'addition', 'new', 'customer', 'fourthquarter', '2017', 'include', 'new', 'customer', 'company', 'core', 'product', 'insurancesuite', 'insurancenow', 'know', 'iscs', 'guidewire', 'portray', 'strong', 'balance', 'sheet', 'debt', 'company', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', '107', 'billion', 'jul', '31', '2018', 'compare', '9943', 'million', 'end', 'previous', 'quarter', 'cash', 'flow', 'operation', 'fourth', 'quarter', 'fiscal', '2018', '1021', 'million', '1405', 'million', 'respectively', 'free', 'cash', 'flow', 'fiscal', '2018', '984', 'million', '1284', 'million']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2018 revenue subscription base product account approximately 36 new sale considerable improvement 6 report 2017 back strong performance subscription product management continue expect subscription sale range 40 60 2019 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect increase fouryear cagr 184 20162020 time frame bode company guidewire face competition unique line business private player similar offering list entity companys software suite common serve specifically pc insurance industry major tailwind companys line result impressive earning share cost structure stringent guidewire acquisition strategy aid growth crossselling product suite increase customer base revenue generation company recently complete cyence buyout notably cyence determine economic impact cybercrime software platform build cybersecurity relate datum science integration cyence imply company able provide entire life cycle insurance product start design transaction management company acquisition isc february 2017 call insurancenow high revenue generating segment add 162 million host revenue fiscal 2017 firstb call guidewire underwriting management eagleeye analytic know guidewire predictive analytic acquire 2016 guidewirenow previously alle isc prominent segment company guidewire customer base expand consistently evident addition new customer fourthquarter 2017 include new customer company core product insurancesuite insurancenow know iscs guidewire portray strong balance sheet debt company cash cash equivalent shortterm investment 107 billion jul 31 2018 compare 9943 million end previous quarter cash flow operation fourth quarter fiscal 2018 1021 million 1405 million respectively free cash flow fiscal 2018 984 million 1284 million,9,25,-0.45714285714285713,9,25,-0.45714285714285713,0.9881
241,"Guidewire Software, Inc._Attachment1.pdf",GWRE,12/7/2018,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2018 revenues were from subscription based products accounting for approximately 36 of new sales it is a considerable improvement over 6 reported in 2017 backed by strong performance of subscription products management continues to expect subscription sales in the range of 4060 for 2019 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 181 over 20172021 time frame to reach 1171 billion by 2021 this also bodes well for the company guidewire faces less competition due to its unique line of business though there are private players with similar offerings among the listed entities the companys software suite is not common more so because it serves specifically the pc insurance industry this is a major tailwind for the companys top line which will result in impressive earnings per share if the cost structure is stringent guidewires acquisition strategy has aided growth the crossselling of the product suites has increased customer base and revenue generation the company recently completed cyence buyout notably cyence determines the economic impact of a cybercrime via a software platform which is built on cybersecurity related data science the integration of cyence would imply that the company would be able to provide an entire life cycle to the insurance products starting from designing to transaction management iscs acquired in february 2017 now called insurancenow and firstbest now called guidewire underwriting management and eagleeye analytics now known as guidewire predictive analytics which were acquired in 2016 form a few prominent segments of the company guidewires customer base has expanded consistently as evident from the addition of four new customers selecting comprehensive guidewire insuranceplatform suite in firstquarter 2019 guidewire portrays a strong balance sheet with no debt the company had cash and cash equivalents and shortterm investments of 108 billion as on oct 31 2018 as compared with 107 billion at the end of the previous quarter,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2018', 'revenue', 'subscription', 'base', 'product', 'account', 'approximately', '36', 'new', 'sale', 'considerable', 'improvement', '6', 'report', '2017', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'continue', 'expect', 'subscription', 'sale', 'range', '4060', '2019', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '181', '20172021', 'time', 'frame', 'reach', '1171', 'billion', '2021', 'bode', 'company', 'guidewire', 'face', 'competition', 'unique', 'line', 'business', 'private', 'player', 'similar', 'offering', 'list', 'entity', 'companys', 'software', 'suite', 'common', 'serve', 'specifically', 'pc', 'insurance', 'industry', 'major', 'tailwind', 'companys', 'line', 'result', 'impressive', 'earning', 'share', 'cost', 'structure', 'stringent', 'guidewire', 'acquisition', 'strategy', 'aid', 'growth', 'crossselling', 'product', 'suite', 'increase', 'customer', 'base', 'revenue', 'generation', 'company', 'recently', 'complete', 'cyence', 'buyout', 'notably', 'cyence', 'determine', 'economic', 'impact', 'cybercrime', 'software', 'platform', 'build', 'cybersecurity', 'relate', 'datum', 'science', 'integration', 'cyence', 'imply', 'company', 'able', 'provide', 'entire', 'life', 'cycle', 'insurance', 'product', 'start', 'design', 'transaction', 'management', 'isc', 'acquire', 'february', '2017', 'call', 'insurancenow', 'firstb', 'call', 'guidewire', 'underwriting', 'management', 'eagleeye', 'analytic', 'know', 'guidewire', 'predictive', 'analytic', 'acquire', '2016', 'form', 'prominent', 'segment', 'company', 'guidewire', 'customer', 'base', 'expand', 'consistently', 'evident', 'addition', 'new', 'customer', 'select', 'comprehensive', 'guidewire', 'insuranceplatform', 'suite', 'firstquarter', '2019', 'guidewire', 'portray', 'strong', 'balance', 'sheet', 'debt', 'company', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', '108', 'billion', 'oct', '31', '2018', 'compare', '107', 'billion', 'end', 'previous', 'quarter']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2018 revenue subscription base product account approximately 36 new sale considerable improvement 6 report 2017 back strong performance subscription product management continue expect subscription sale range 4060 2019 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect increase cagr 181 20172021 time frame reach 1171 billion 2021 bode company guidewire face competition unique line business private player similar offering list entity companys software suite common serve specifically pc insurance industry major tailwind companys line result impressive earning share cost structure stringent guidewire acquisition strategy aid growth crossselling product suite increase customer base revenue generation company recently complete cyence buyout notably cyence determine economic impact cybercrime software platform build cybersecurity relate datum science integration cyence imply company able provide entire life cycle insurance product start design transaction management isc acquire february 2017 call insurancenow firstb call guidewire underwriting management eagleeye analytic know guidewire predictive analytic acquire 2016 form prominent segment company guidewire customer base expand consistently evident addition new customer select comprehensive guidewire insuranceplatform suite firstquarter 2019 guidewire portray strong balance sheet debt company cash cash equivalent shortterm investment 108 billion oct 31 2018 compare 107 billion end previous quarter,8,24,-0.48484848484848486,8,24,-0.48484848484848486,0.9853
242,"Guidewire Software, Inc._Attachment1.pdf",GWRE,1/9/2019,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of almost 218 of total assets as of oct 31 2018 although shares have outperformed the industry in the past year the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 943 this level compares unfavorably with what the industry witnessed in the last year consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '218', 'total', 'asset', 'oct', '31', '2018', 'share', 'outperform', 'industry', 'past', 'year', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '943', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 218 total asset oct 31 2018 share outperform industry past year company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 943 level compare unfavorably industry witness year consequently valuation looks slightly stretch ps perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,-0.4767
243,"Guidewire Software, Inc._Attachment1.pdf",GWRE,3/13/2019,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2018 revenues were from subscription based products accounting for approximately 36 of new sales it is a considerable improvement over 6 reported in 2017 backed by strong performance of subscription products management continues to expect subscription sales in the range of 4060 for 2019 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 181 over 20172021 time frame to reach 1171 billion by 2021 this also bodes well for the company guidewire faces less competition due to its unique line of business though there are private players with similar offerings among the listed entities the companys software suite is not common more so because it serves specifically the pc insurance industry this is a major tailwind for the companys top line which will result in impressive earnings per share if the cost structure is stringent guidewires acquisition strategy has aided growth the crossselling of the product suites has increased customer base and revenue generation the company recently completed cyence buyout notably cyence determines the economic impact of a cybercrime via a software platform which is built on cybersecurity related data science the integration of cyence would imply that the company would be able to provide an entire life cycle to the insurance products starting from designing to transaction management iscs acquired in february 2017 now called insurancenow and firstbest now called guidewire underwriting management and eagleeye analytics now known as guidewire predictive analytics which were acquired in 2016 form a few prominent segments of the company guidewires customer base has expanded consistently as evident from the addition of four new customers selecting comprehensive guidewire insuranceplatform suite in firstquarter 2019 guidewire portrays a strong balance sheet with no debt the company had cash and cash equivalents and shortterm investments of 107 billion as on jan 31 2019 as compared with 108 billion at the end of the previous quarter,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2018', 'revenue', 'subscription', 'base', 'product', 'account', 'approximately', '36', 'new', 'sale', 'considerable', 'improvement', '6', 'report', '2017', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'continue', 'expect', 'subscription', 'sale', 'range', '4060', '2019', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '181', '20172021', 'time', 'frame', 'reach', '1171', 'billion', '2021', 'bode', 'company', 'guidewire', 'face', 'competition', 'unique', 'line', 'business', 'private', 'player', 'similar', 'offering', 'list', 'entity', 'companys', 'software', 'suite', 'common', 'serve', 'specifically', 'pc', 'insurance', 'industry', 'major', 'tailwind', 'companys', 'line', 'result', 'impressive', 'earning', 'share', 'cost', 'structure', 'stringent', 'guidewire', 'acquisition', 'strategy', 'aid', 'growth', 'crossselling', 'product', 'suite', 'increase', 'customer', 'base', 'revenue', 'generation', 'company', 'recently', 'complete', 'cyence', 'buyout', 'notably', 'cyence', 'determine', 'economic', 'impact', 'cybercrime', 'software', 'platform', 'build', 'cybersecurity', 'relate', 'datum', 'science', 'integration', 'cyence', 'imply', 'company', 'able', 'provide', 'entire', 'life', 'cycle', 'insurance', 'product', 'start', 'design', 'transaction', 'management', 'isc', 'acquire', 'february', '2017', 'call', 'insurancenow', 'firstb', 'call', 'guidewire', 'underwriting', 'management', 'eagleeye', 'analytic', 'know', 'guidewire', 'predictive', 'analytic', 'acquire', '2016', 'form', 'prominent', 'segment', 'company', 'guidewire', 'customer', 'base', 'expand', 'consistently', 'evident', 'addition', 'new', 'customer', 'select', 'comprehensive', 'guidewire', 'insuranceplatform', 'suite', 'firstquarter', '2019', 'guidewire', 'portray', 'strong', 'balance', 'sheet', 'debt', 'company', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', '107', 'billion', 'jan', '31', '2019', 'compare', '108', 'billion', 'end', 'previous', 'quarter']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2018 revenue subscription base product account approximately 36 new sale considerable improvement 6 report 2017 back strong performance subscription product management continue expect subscription sale range 4060 2019 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect increase cagr 181 20172021 time frame reach 1171 billion 2021 bode company guidewire face competition unique line business private player similar offering list entity companys software suite common serve specifically pc insurance industry major tailwind companys line result impressive earning share cost structure stringent guidewire acquisition strategy aid growth crossselling product suite increase customer base revenue generation company recently complete cyence buyout notably cyence determine economic impact cybercrime software platform build cybersecurity relate datum science integration cyence imply company able provide entire life cycle insurance product start design transaction management isc acquire february 2017 call insurancenow firstb call guidewire underwriting management eagleeye analytic know guidewire predictive analytic acquire 2016 form prominent segment company guidewire customer base expand consistently evident addition new customer select comprehensive guidewire insuranceplatform suite firstquarter 2019 guidewire portray strong balance sheet debt company cash cash equivalent shortterm investment 107 billion jan 31 2019 compare 108 billion end previous quarter,8,24,-0.48484848484848486,8,24,-0.48484848484848486,0.9853
244,"Guidewire Software, Inc._Attachment1.pdf",GWRE,3/13/2019,guidewires total addressable market tam is limited only to the insurance sector this industryconcentric feature is a headwind for the company in fact the market is limited due to the fact that the companys services are meant for property and casualty pc insurers lack of product diversification is also a major headwind in our view guidewires transition from a term license based to a cloudbased model will negatively impact the top line in the short haul as term license revenues include advance payments whereas subscriptionbased revenues are a bit delayed the transition related investments are also expected to squeeze margins moreover the company received certain advance payments related to term licenses which are anticipated to be headwinds for revenue generation guidewire frequently acquires companies which exposes it to integration risks this puts pressure on cash flow as well notably the company acquired cyence in 2018 iscs in fiscal 2017 and both firstbest and eagleeye analytics in 2016 we believe the dependence on inorganic growth rather than on innovation is also a negative and may affect the company in the long run moreover we note that the buyouts negatively impacted the companys balance sheet in the form of high level of goodwill and net intangible assets which comprised of almost 387 of total assets as of jan 31 2019 although shares have outperformed the industry in the past year the company is trading at premium in terms of pricesales ps guidewire currently has a trailing 12month ps ratio of 1020this level compares unfavorably with what the industry witnessed in the last year consequently the valuation looks slightly stretched from ps perspective,sell,"['guidewire', 'total', 'addressable', 'market', 'tam', 'limit', 'insurance', 'sector', 'industryconcentric', 'feature', 'headwind', 'company', 'fact', 'market', 'limit', 'fact', 'company', 'service', 'mean', 'property', 'casualty', 'pc', 'insurer', 'lack', 'product', 'diversification', 'major', 'headwind', 'view', 'guidewire', 'transition', 'term', 'license', 'base', 'cloudbased', 'model', 'negatively', 'impact', 'line', 'short', 'haul', 'term', 'license', 'revenue', 'include', 'advance', 'payment', 'subscriptionbase', 'revenue', 'bit', 'delay', 'transition', 'relate', 'investment', 'expect', 'squeeze', 'margin', 'company', 'receive', 'certain', 'advance', 'payment', 'relate', 'term', 'license', 'anticipate', 'headwind', 'revenue', 'generation', 'guidewire', 'frequently', 'acquire', 'company', 'expose', 'integration', 'risk', 'put', 'pressure', 'cash', 'flow', 'notably', 'company', 'acquire', 'cyence', '2018', 'isc', 'fiscal', '2017', 'firstb', 'eagleeye', 'analytic', '2016', 'believe', 'dependence', 'inorganic', 'growth', 'innovation', 'negative', 'affect', 'company', 'long', 'run', 'note', 'buyout', 'negatively', 'impact', 'company', 'balance', 'sheet', 'form', 'high', 'level', 'goodwill', 'net', 'intangible', 'asset', 'comprise', '387', 'total', 'asset', 'jan', '31', '2019', 'share', 'outperform', 'industry', 'past', 'year', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'guidewire', 'currently', 'trailing', '12month', 'ps', 'ratio', '1020this', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",guidewire total addressable market tam limit insurance sector industryconcentric feature headwind company fact market limit fact company service mean property casualty pc insurer lack product diversification major headwind view guidewire transition term license base cloudbased model negatively impact line short haul term license revenue include advance payment subscriptionbase revenue bit delay transition relate investment expect squeeze margin company receive certain advance payment relate term license anticipate headwind revenue generation guidewire frequently acquire company expose integration risk put pressure cash flow notably company acquire cyence 2018 isc fiscal 2017 firstb eagleeye analytic 2016 believe dependence inorganic growth innovation negative affect company long run note buyout negatively impact company balance sheet form high level goodwill net intangible asset comprise 387 total asset jan 31 2019 share outperform industry past year company trade premium term pricesale ps guidewire currently trailing 12month ps ratio 1020this level compare unfavorably industry witness year consequently valuation looks slightly stretch ps perspective,6,16,-0.43478260869565216,6,16,-0.43478260869565216,-0.4767
245,"Guidewire Software, Inc._Attachment1.pdf",GWRE,9/5/2019,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2018 revenues were from subscription based products accounting for approximately 36 of new sales it is a considerable improvement over 6 reported in 2017 guidewires cloud,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2018', 'revenue', 'subscription', 'base', 'product', 'account', 'approximately', '36', 'new', 'sale', 'considerable', 'improvement', '6', 'report', '2017', 'guidewire', 'cloud']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2018 revenue subscription base product account approximately 36 new sale considerable improvement 6 report 2017 guidewire cloud,3,2,0.16666666666666666,3,2,0.16666666666666666,0.7717
246,"Guidewire Software, Inc._Attachment1.pdf",GWRE,4/14/2020,guidewire is slowly shifting from the term license based model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2019 revenues were from subscriptionbased products accounting for approximately 65 of new sales it is a considerable improvement over 36 reported in fiscal 2018 backed by strong performance of subscription products management continues to expect new sales from subscription offerings in the range of 5575 for fiscal 2020 guidewires cloud deployment partner amazon web services is also gaining momentum and this bodes well for it according to gartner the global softwareasaservice saas market is expected to hit 1511 billion by 2022 from 857 billion in 2018 witnessing a cagr of 152 this is expected to favor the companys growth prospects,buy,"['guidewire', 'slowly', 'shift', 'term', 'license', 'base', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2019', 'revenue', 'subscriptionbased', 'product', 'account', 'approximately', '65', 'new', 'sale', 'considerable', 'improvement', '36', 'report', 'fiscal', '2018', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'continue', 'expect', 'new', 'sale', 'subscription', 'offering', 'range', '5575', 'fiscal', '2020', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web', 'service', 'gain', 'momentum', 'bode', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'hit', '1511', 'billion', '2022', '857', 'billion', '2018', 'witness', 'cagr', '152', 'expect', 'favor', 'company', 'growth', 'prospect']",guidewire slowly shift term license base model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2019 revenue subscriptionbased product account approximately 65 new sale considerable improvement 36 report fiscal 2018 back strong performance subscription product management continue expect new sale subscription offering range 5575 fiscal 2020 guidewire cloud deployment partner amazon web service gain momentum bode accord gartner global softwareasaservice saas market expect hit 1511 billion 2022 857 billion 2018 witness cagr 152 expect favor company growth prospect,6,5,0.08333333333333333,6,5,0.08333333333333333,0.9666
247,"Guidewire Software, Inc._Attachment1.pdf",GWRE,12/15/2020,guidewire is slowly shifting from the term licensebased model to subscription base this will be beneficial for the company in the long run as majority of the enterprises are expected to lean toward cloud based infrastructure going forward a substantial portion of fiscal 2020 revenues were from subscriptionbased products accounting for 70 of new sales it is a significant improvement over 65 reported in fiscal 2019 backed by strong performance of subscription products management expects momentum in new sales from subscription offerings to sustain in fiscal 2021 guidewires cloud deployment partner amazon web,buy,"['guidewire', 'slowly', 'shift', 'term', 'licensebase', 'model', 'subscription', 'base', 'beneficial', 'company', 'long', 'run', 'majority', 'enterprise', 'expect', 'lean', 'cloud', 'base', 'infrastructure', 'go', 'forward', 'substantial', 'portion', 'fiscal', '2020', 'revenue', 'subscriptionbased', 'product', 'account', '70', 'new', 'sale', 'significant', 'improvement', '65', 'report', 'fiscal', '2019', 'back', 'strong', 'performance', 'subscription', 'product', 'management', 'expect', 'momentum', 'new', 'sale', 'subscription', 'offering', 'sustain', 'fiscal', '2021', 'guidewire', 'cloud', 'deployment', 'partner', 'amazon', 'web']",guidewire slowly shift term licensebase model subscription base beneficial company long run majority enterprise expect lean cloud base infrastructure go forward substantial portion fiscal 2020 revenue subscriptionbased product account 70 new sale significant improvement 65 report fiscal 2019 back strong performance subscription product management expect momentum new sale subscription offering sustain fiscal 2021 guidewire cloud deployment partner amazon web,4,3,0.125,4,3,0.125,0.91
248,Ironwood Pharmaceuticals Inc_Attachment1.pdf,IRWD,10/15/2020,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand,2,0,0.6666666666666666,2,0,0.6666666666666666,0.8481
249,"Ironwood Pharmaceuticals, Inc._Attachment1(2).pdf",IRWD,5/31/2017,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label by expanding the targeted patient population and gaining approval for additional indications the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is expected to boost prescriptions in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing two delayed release formulations of linzess delayed release1 or dr1 and delayed release2 or dr2 a phase iib study for dr1 is currently underway in patients with ibsc this secondgeneration guanylate cyclasec gcc agonist candidate has the potential to provide greater and faster abdominal pain relief in adult ibsc patients expand the ibsc and cic markets and extend patent protection to the mid2030s data announced in dec 2016 showed that the colonic formulation led to improvements in pain relief over linzess phase iii studies are expected to begin in the second half of 2017 dr2 is being developed to improve abdominal pain relief in patients with additional gastrointestinal or gi disorders where lower abdominal pain is a predominant symptom such as nonconstipation subtypes of ibs efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us and promoting canasa ulcerative proctitis and delzicol ulcerative colitis in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including the fixeddose combination of lesinurad and allopurinol zurampic was launched in oct 2016 the fixeddose combination product duzallo is under fda review and is expected to be launched by late 2017 if approved the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing with data expected in mid 2017 ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases zacks equity research irwd wwwzackscom page 3 of 8,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'expand', 'target', 'patient', 'population', 'gain', 'approval', 'additional', 'indication', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'expect', 'boost', 'prescription', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release1', 'dr1', 'delay', 'release2', 'dr2', 'phase', 'iib', 'study', 'dr1', 'currently', 'underway', 'patient', 'ibsc', 'secondgeneration', 'guanylate', 'cyclasec', 'gcc', 'agonist', 'candidate', 'potential', 'provide', 'great', 'fast', 'abdominal', 'pain', 'relief', 'adult', 'ibsc', 'patient', 'expand', 'ibsc', 'cic', 'market', 'extend', 'patent', 'protection', 'mid2030s', 'datum', 'announce', 'dec', '2016', 'show', 'colonic', 'formulation', 'lead', 'improvement', 'pain', 'relief', 'linzess', 'phase', 'iii', 'study', 'expect', 'begin', 'second', 'half', '2017', 'dr2', 'develop', 'improve', 'abdominal', 'pain', 'relief', 'patient', 'additional', 'gastrointestinal', 'gi', 'disorder', 'low', 'abdominal', 'pain', 'predominant', 'symptom', 'nonconstipation', 'subtype', 'ibs', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'oct', '2016', 'fixeddose', 'combination', 'product', 'duzallo', 'fda', 'review', 'expect', 'launch', 'late', '2017', 'approve', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'expect', 'mid', '2017', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'zack', 'equity', 'research', 'irwd', 'wwwzackscom', 'page', '3', '8']",linzess label expansion effort ironwood allergan look broaden linzess label expand target patient population gain approval additional indication company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength expect boost prescription large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release1 dr1 delay release2 dr2 phase iib study dr1 currently underway patient ibsc secondgeneration guanylate cyclasec gcc agonist candidate potential provide great fast abdominal pain relief adult ibsc patient expand ibsc cic market extend patent protection mid2030s datum announce dec 2016 show colonic formulation lead improvement pain relief linzess phase iii study expect begin second half 2017 dr2 develop improve abdominal pain relief patient additional gastrointestinal gi disorder low abdominal pain predominant symptom nonconstipation subtype ibs effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include fixeddose combination lesinurad allopurinol zurampic launch oct 2016 fixeddose combination product duzallo fda review expect launch late 2017 approve company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum expect mid 2017 ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease zack equity research irwd wwwzackscom page 3 8,15,22,-0.18421052631578946,15,22,-0.18421052631578946,0.9929
250,"Ironwood Pharmaceuticals, Inc._Attachment1(2).pdf",IRWD,12/20/2017,linzess approval a milestone the aug 2012 fda approval of linzess was a major milestone for ironwood linzess was launched in dec 2012 ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover cvscaremark has granted linzess an exclusive preferred position on its formulary beginning jan 1 2016 the company commenced a dtc campaign in mar 2016 which is driving both market share as well as overall market growth linzess has been showing rapid sales and prescription growth backed by new patient additions directtoconsumer dtc promotion broad payer access and continued strong demand linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is boosting prescription trends in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the us in mar 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us and promoting canasa ulcerative proctitis and delzicol ulcerative colitis in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including the fixeddose combination of lesinurad and allopurinol zurampic was launched in oct 2016 a fixeddose combination product duzallo was launched in october 2017 duzallo addresses both causes of hyperuricemia in gout over production and underexcretion of serum uric acid in a single pill the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing data from the study presented in jul 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the second half of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules iw1973 diabetic hypertension and iw1701 type ii achalasia commenced in 2016 in dec 2017 ironwood announced positive topline data from the iw1973 diabetic hypertension study meanwhile data from the iw1701 study is expected in 2018 meanwhile iw1973 is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease is expected to be initiated by the end of 2017,buy,"['linzess', 'approval', 'milestone', 'aug', '2012', 'fda', 'approval', 'linzess', 'major', 'milestone', 'ironwood', 'linzess', 'launch', 'dec', '2012', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'beginning', 'jan', '1', '2016', 'company', 'commence', 'dtc', 'campaign', 'mar', '2016', 'drive', 'market', 'share', 'overall', 'market', 'growth', 'linzess', 'show', 'rapid', 'sale', 'prescription', 'growth', 'back', 'new', 'patient', 'addition', 'directtoconsumer', 'dtc', 'promotion', 'broad', 'payer', 'access', 'continue', 'strong', 'demand', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'boost', 'prescription', 'trend', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'mar', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'oct', '2016', 'fixeddose', 'combination', 'product', 'duzallo', 'launch', 'october', '2017', 'duzallo', 'address', 'cause', 'hyperuricemia', 'gout', 'production', 'underexcretion', 'serum', 'uric', 'acid', 'single', 'pill', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'study', 'present', 'jul', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'second', 'half', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'commence', '2016', 'dec', '2017', 'ironwood', 'announce', 'positive', 'topline', 'datum', 'iw1973', 'diabetic', 'hypertension', 'study', 'datum', 'iw1701', 'study', 'expect', '2018', 'iw1973', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'expect', 'initiate', 'end', '2017']",linzess approval milestone aug 2012 fda approval linzess major milestone ironwood linzess launch dec 2012 ironwood work expand manage care access linzess lower ofpocket cost cvscaremark grant linzess exclusive preferred position formulary beginning jan 1 2016 company commence dtc campaign mar 2016 drive market share overall market growth linzess show rapid sale prescription growth back new patient addition directtoconsumer dtc promotion broad payer access continue strong demand linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength boost prescription trend large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product mar 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include fixeddose combination lesinurad allopurinol zurampic launch oct 2016 fixeddose combination product duzallo launch october 2017 duzallo address cause hyperuricemia gout production underexcretion serum uric acid single pill company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum study present jul 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii second half 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule iw1973 diabetic hypertension iw1701 type ii achalasia commence 2016 dec 2017 ironwood announce positive topline datum iw1973 diabetic hypertension study datum iw1701 study expect 2018 iw1973 evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease expect initiate end 2017,19,35,-0.2909090909090909,19,35,-0.2909090909090909,0.9959
251,"Ironwood Pharmaceuticals, Inc._Attachment1(2).pdf",IRWD,1/18/2018,linzess approval a milestone the aug 2012 fda approval of linzess was a major milestone for ironwood linzess was launched in dec 2012 ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover cvscaremark has granted linzess an exclusive preferred position on its formulary beginning jan 1 2016 the company commenced a dtc campaign in mar 2016 which is driving both market share as well as overall market growth linzess has been showing rapid sales and prescription growth backed by new patient additions directtoconsumer dtc promotion broad payer access and continued strong demand linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is boosting prescription trends in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the us in mar 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us and promoting canasa ulcerative proctitis and delzicol ulcerative colitis in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including the fixeddose combination of lesinurad and allopurinol zurampic was launched in oct 2016 a fixeddose combination product duzallo was launched in october 2017 duzallo addresses both causes of hyperuricemia in gout over production and underexcretion of serum uric acid in a single pill the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing data from the study presented in jul 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the second half of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules iw1973 diabetic hypertension and iw1701 type ii achalasia commenced in 2016 in dec 2017 ironwood announced positive topline data from the iw1973 diabetic hypertension study meanwhile data from the iw1701 study is expected in 2018 meanwhile iw1973 is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease was initiated in december 2017,buy,"['linzess', 'approval', 'milestone', 'aug', '2012', 'fda', 'approval', 'linzess', 'major', 'milestone', 'ironwood', 'linzess', 'launch', 'dec', '2012', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'beginning', 'jan', '1', '2016', 'company', 'commence', 'dtc', 'campaign', 'mar', '2016', 'drive', 'market', 'share', 'overall', 'market', 'growth', 'linzess', 'show', 'rapid', 'sale', 'prescription', 'growth', 'back', 'new', 'patient', 'addition', 'directtoconsumer', 'dtc', 'promotion', 'broad', 'payer', 'access', 'continue', 'strong', 'demand', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'boost', 'prescription', 'trend', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'mar', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'oct', '2016', 'fixeddose', 'combination', 'product', 'duzallo', 'launch', 'october', '2017', 'duzallo', 'address', 'cause', 'hyperuricemia', 'gout', 'production', 'underexcretion', 'serum', 'uric', 'acid', 'single', 'pill', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'study', 'present', 'jul', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'second', 'half', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'commence', '2016', 'dec', '2017', 'ironwood', 'announce', 'positive', 'topline', 'datum', 'iw1973', 'diabetic', 'hypertension', 'study', 'datum', 'iw1701', 'study', 'expect', '2018', 'iw1973', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'initiate', 'december', '2017']",linzess approval milestone aug 2012 fda approval linzess major milestone ironwood linzess launch dec 2012 ironwood work expand manage care access linzess lower ofpocket cost cvscaremark grant linzess exclusive preferred position formulary beginning jan 1 2016 company commence dtc campaign mar 2016 drive market share overall market growth linzess show rapid sale prescription growth back new patient addition directtoconsumer dtc promotion broad payer access continue strong demand linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength boost prescription trend large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product mar 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include fixeddose combination lesinurad allopurinol zurampic launch oct 2016 fixeddose combination product duzallo launch october 2017 duzallo address cause hyperuricemia gout production underexcretion serum uric acid single pill company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum study present jul 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii second half 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule iw1973 diabetic hypertension iw1701 type ii achalasia commence 2016 dec 2017 ironwood announce positive topline datum iw1973 diabetic hypertension study datum iw1701 study expect 2018 iw1973 evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease initiate december 2017,19,34,-0.2777777777777778,19,34,-0.2777777777777778,0.9959
252,"Ironwood Pharmaceuticals, Inc._Attachment1(2).pdf",IRWD,5/4/2018,linzess approval a milestone the august 2012 fda approval of linzess was a major milestone for ironwood linzess was launched in december 2012 ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 while a regulatory filing has been submitted in china for the indication decision expected in second quarter of another regulatory application seeking label expansion of linzess in chronic constipation is under review in japan linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including duzallo fixeddose combination of lesinurad and allopurinol zurampic was launched in october 2016 while duzallo was launched in october 2017 duzallo addresses both causes of hyperuricemia in gout overproduction and under excretion of serum uric acid in a single pill the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with the company planning to advance it in phase iii studies in the third quarter of 2018 data from a phase iib doseranging refractory gastroesophageal reflux disease gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the second half of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw1973 diabetic hypertension and iw1701 type ii achalasia phase iia commenced in 2016 in december 2017 ironwood announced positive topline data from the praliciguat diabetic hypertension study which showed blood pressure reduction and improvement in metabolic parameters in patient treated with the candidate meanwhile data from the iw1701 study is expected in 2018 meanwhile praliciguat is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease was initiated in december 2017 meanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,buy,"['linzess', 'approval', 'milestone', 'august', '2012', 'fda', 'approval', 'linzess', 'major', 'milestone', 'ironwood', 'linzess', 'launch', 'december', '2012', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'second', 'quarter', 'regulatory', 'application', 'seek', 'label', 'expansion', 'linzess', 'chronic', 'constipation', 'review', 'japan', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'duzallo', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'october', '2016', 'duzallo', 'launch', 'october', '2017', 'duzallo', 'address', 'cause', 'hyperuricemia', 'gout', 'overproduction', 'excretion', 'serum', 'uric', 'acid', 'single', 'pill', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'company', 'plan', 'advance', 'phase', 'iii', 'study', 'quarter', '2018', 'datum', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'second', 'half', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'phase', 'iia', 'commence', '2016', 'december', '2017', 'ironwood', 'announce', 'positive', 'topline', 'datum', 'praliciguat', 'diabetic', 'hypertension', 'study', 'show', 'blood', 'pressure', 'reduction', 'improvement', 'metabolic', 'parameter', 'patient', 'treat', 'candidate', 'datum', 'iw1701', 'study', 'expect', '2018', 'praliciguat', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'initiate', 'december', '2017', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess approval milestone august 2012 fda approval linzess major milestone ironwood linzess launch december 2012 ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan march 2017 regulatory filing submit china indication decision expect second quarter regulatory application seek label expansion linzess chronic constipation review japan linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include duzallo fixeddose combination lesinurad allopurinol zurampic launch october 2016 duzallo launch october 2017 duzallo address cause hyperuricemia gout overproduction excretion serum uric acid single pill company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting company plan advance phase iii study quarter 2018 datum phase iib doserange refractory gastroesophageal reflux disease gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii second half 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw1973 diabetic hypertension iw1701 type ii achalasia phase iia commence 2016 december 2017 ironwood announce positive topline datum praliciguat diabetic hypertension study show blood pressure reduction improvement metabolic parameter patient treat candidate datum iw1701 study expect 2018 praliciguat evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease initiate december 2017 quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,20,35,-0.26785714285714285,20,35,-0.26785714285714285,0.9963
253,"Ironwood Pharmaceuticals, Inc._Attachment1(2).pdf",IRWD,10/10/2018,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients in july 2018 a phase iii study was initiated to expand linzess label in two new symptoms associated with ibsc bloating and discomfort moreover the company is currently designing a phase iib study to evaluate linzess delayed release formulation for treating all subtypes of ibs including ibsc ibs with diarrhea and ibsmixed efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expnaded to include chronic constipation in august 2018 while a regulatory filing has been submitted in china for the indication decision expected by the end of pipeline progress to capture the lucrative gi market ironwood is developing several candidates in june 2018 the company initiated two phase iii studies to evaluate iw3718 in patients with persistent refractory gastroesophageal reflux disease gerd data from a phase iib doseranging gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw and olinciguat iw the company is progressingpraliciguat in two phase ii studies to evaluate it in diabetic nephropathy and heart failure with preserved ejection fraction hfpef topline from both the studies is expected in the second half of 2019 meanwhile two phase ii studies will evaluate olinciguat for treating sickle cell disease and achalasia data from the achalasia study is expected in the second half of 2018 the candidate enjoys orphan drug designation in the united states for sickle cell diseasemeanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'july', '2018', 'phase', 'iii', 'study', 'initiate', 'expand', 'linzess', 'label', 'new', 'symptom', 'associate', 'ibsc', 'bloat', 'discomfort', 'company', 'currently', 'design', 'phase', 'iib', 'study', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'subtype', 'ibs', 'include', 'ibsc', 'ib', 'diarrhea', 'ibsmixed', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expnade', 'include', 'chronic', 'constipation', 'august', '2018', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'end', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'june', '2018', 'company', 'initiate', 'phase', 'iii', 'study', 'evaluate', 'iw3718', 'patient', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'datum', 'phase', 'iib', 'doserange', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw', 'olinciguat', 'iw', 'company', 'progressingpraliciguat', 'phase', 'ii', 'study', 'evaluate', 'diabetic', 'nephropathy', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'topline', 'study', 'expect', 'second', 'half', '2019', 'phase', 'ii', 'study', 'evaluate', 'olinciguat', 'treat', 'sickle', 'cell', 'disease', 'achalasia', 'datum', 'achalasia', 'study', 'expect', 'second', 'half', '2018', 'candidate', 'enjoy', 'orphan', 'drug', 'designation', 'united', 'states', 'sickle', 'cell', 'diseasemeanwhile', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient july 2018 phase iii study initiate expand linzess label new symptom associate ibsc bloat discomfort company currently design phase iib study evaluate linzess delay release formulation treat subtype ibs include ibsc ib diarrhea ibsmixed effort expand exus territory linzess launch ibsc japan march 2017 label expnade include chronic constipation august 2018 regulatory filing submit china indication decision expect end pipeline progress capture lucrative gi market ironwood develop candidate june 2018 company initiate phase iii study evaluate iw3718 patient persistent refractory gastroesophageal reflux disease gerd datum phase iib doserange gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw olinciguat iw company progressingpraliciguat phase ii study evaluate diabetic nephropathy heart failure preserve ejection fraction hfpef topline study expect second half 2019 phase ii study evaluate olinciguat treat sickle cell disease achalasia datum achalasia study expect second half 2018 candidate enjoy orphan drug designation united states sickle cell diseasemeanwhile quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,7,28,-0.5833333333333334,7,28,-0.5833333333333334,0.5574
254,"Ironwood Pharmaceuticals, Inc._Attachment1(2).pdf",IRWD,4/4/2019,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space these initiatives have supported the drugs growth linzess has the potential to be a blockbuster product with global sales crossing 750 million in 2018 by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is also progressing well with development of the drug in japan and china per iqvia data linzess is the leading prescribed drug for adult patients in the united states with ibsc or cic ironwood estimates that its ibsccic franchise including linzess and the delayed release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies are conducting a phase iii study to expand linzess label in additional abdominal symptoms associated with ibsc including bloating and discomfort a label expansion in pediatric patients is also being plannedironwood and allergan are developing a delayed release formulation of linzess delayed release2 md to address patient populations suffering from all forms of ibs the company is planning to initiate a phase ii study in the second quarter of 2019 to evaluate linzess delayed release formulation for treating ibsd linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patientsefforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expanded to include chronic constipation in august 2018 in january 2019 the drug was approved for ibsc in china meanwhile to capture the lucrative gi market ironwood is developing several candidates the most advanced pipeline candidate is iw3718 which is being evaluated in phase iii studies for treating persistent refractory gastroesophageal reflux disease gerd strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenues for ironwood additional partnerships in other territories will be a positive for the company spinoff of cyclerion encouraging ironwoods separation of its sgc pipeline into a separate entity cyclerion is expected to be a positive the transaction is likely to bring down research and development costs significantly the company will also be able to put more efforts in building its gi products especially linzess moreover the spinoff along with some restructuring initiatives will also reduce the workforce lowering operating expenses further,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'initiative', 'support', 'drug', 'growth', 'linzess', 'potential', 'blockbuster', 'product', 'global', 'sale', 'cross', '750', 'million', '2018', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'progress', 'development', 'drug', 'japan', 'china', 'iqvia', 'datum', 'linzess', 'lead', 'prescribe', 'drug', 'adult', 'patient', 'united', 'states', 'ibsc', 'cic', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'delay', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'conduct', 'phase', 'iii', 'study', 'expand', 'linzess', 'label', 'additional', 'abdominal', 'symptom', 'associate', 'ibsc', 'include', 'bloat', 'discomfort', 'label', 'expansion', 'pediatric', 'patient', 'plannedironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'md', 'address', 'patient', 'population', 'suffer', 'form', 'ibs', 'company', 'plan', 'initiate', 'phase', 'ii', 'study', 'second', 'quarter', '2019', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'ibsd', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patientseffort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expand', 'include', 'chronic', 'constipation', 'august', '2018', 'january', '2019', 'drug', 'approve', 'ibsc', 'china', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'advanced', 'pipeline', 'candidate', 'iw3718', 'evaluate', 'phase', 'iii', 'study', 'treat', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'spinoff', 'cyclerion', 'encourage', 'ironwood', 'separation', 'sgc', 'pipeline', 'separate', 'entity', 'cyclerion', 'expect', 'positive', 'transaction', 'likely', 'bring', 'research', 'development', 'cost', 'significantly', 'company', 'able', 'effort', 'build', 'gi', 'product', 'especially', 'linzess', 'spinoff', 'restructuring', 'initiative', 'reduce', 'workforce', 'lower', 'operating', 'expense']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space initiative support drug growth linzess potential blockbuster product global sale cross 750 million 2018 end 2020 ironwood expect annual sale linzess cross 1 billion company progress development drug japan china iqvia datum linzess lead prescribe drug adult patient united states ibsc cic ironwood estimate ibsccic franchise include linzess delay release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company conduct phase iii study expand linzess label additional abdominal symptom associate ibsc include bloat discomfort label expansion pediatric patient plannedironwood allergan develop delay release formulation linzess delay release2 md address patient population suffer form ibs company plan initiate phase ii study second quarter 2019 evaluate linzess delay release formulation treat ibsd linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patientseffort expand exus territory linzess launch ibsc japan march 2017 label expand include chronic constipation august 2018 january 2019 drug approve ibsc china capture lucrative gi market ironwood develop candidate advanced pipeline candidate iw3718 evaluate phase iii study treat persistent refractory gastroesophageal reflux disease gerd strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company spinoff cyclerion encourage ironwood separation sgc pipeline separate entity cyclerion expect positive transaction likely bring research development cost significantly company able effort build gi product especially linzess spinoff restructuring initiative reduce workforce lower operating expense,17,30,-0.2708333333333333,17,30,-0.2708333333333333,0.9969
255,"Ironwood Pharmaceuticals, Inc._Attachment1(3).pdf",IRWD,6/6/2018,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 while a regulatory filing has been submitted in china for the indication decision expected in second quarter of another regulatory application seeking label expansion of linzess in chronic constipation is under review in japan linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including duzallo fixeddose combination of lesinurad and allopurinol zurampic was launched in october 2016 while duzallo was launched in october 2017 duzallo addresses both causes of hyperuricemia in gout overproduction and under excretion of serum uric acid in a single pill the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with the company planning to advance it in phase iii studies in the third quarter of 2018 data from a phase iib doseranging refractory gastroesophageal reflux disease gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the third quarter of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw1973 diabetic hypertension and iw1701 type ii achalasia phase iia commenced in 2016 in december 2017 ironwood announced positive topline data from the praliciguat diabetic hypertension study which showed blood pressure reduction and improvement in metabolic parameters in patient treated with the candidate meanwhile data from the iw1701 study is expected in 2018 meanwhile praliciguat is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease was initiated in december 2017 meanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'second', 'quarter', 'regulatory', 'application', 'seek', 'label', 'expansion', 'linzess', 'chronic', 'constipation', 'review', 'japan', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'duzallo', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'october', '2016', 'duzallo', 'launch', 'october', '2017', 'duzallo', 'address', 'cause', 'hyperuricemia', 'gout', 'overproduction', 'excretion', 'serum', 'uric', 'acid', 'single', 'pill', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'company', 'plan', 'advance', 'phase', 'iii', 'study', 'quarter', '2018', 'datum', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'quarter', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'phase', 'iia', 'commence', '2016', 'december', '2017', 'ironwood', 'announce', 'positive', 'topline', 'datum', 'praliciguat', 'diabetic', 'hypertension', 'study', 'show', 'blood', 'pressure', 'reduction', 'improvement', 'metabolic', 'parameter', 'patient', 'treat', 'candidate', 'datum', 'iw1701', 'study', 'expect', '2018', 'praliciguat', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'initiate', 'december', '2017', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan march 2017 regulatory filing submit china indication decision expect second quarter regulatory application seek label expansion linzess chronic constipation review japan linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include duzallo fixeddose combination lesinurad allopurinol zurampic launch october 2016 duzallo launch october 2017 duzallo address cause hyperuricemia gout overproduction excretion serum uric acid single pill company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting company plan advance phase iii study quarter 2018 datum phase iib doserange refractory gastroesophageal reflux disease gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii quarter 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw1973 diabetic hypertension iw1701 type ii achalasia phase iia commence 2016 december 2017 ironwood announce positive topline datum praliciguat diabetic hypertension study show blood pressure reduction improvement metabolic parameter patient treat candidate datum iw1701 study expect 2018 praliciguat evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease initiate december 2017 quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,22,35,-0.22413793103448276,22,35,-0.22413793103448276,0.9966
256,"Ironwood Pharmaceuticals, Inc._Attachment1(3).pdf",IRWD,2/5/2019,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 including the lower dose 72 mcg of the product which was launched in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations ironwood and allergan are developing a delayed release formulation of linzess delayed release2 md to address new patient populations beyond ibsc and chronic constipation in july 2018 a phase iii study was initiated to expand linzess label in two new symptoms associated with ibsc bloating and discomfort moreover the company is planning to initiate a phase iib study in the first quarter of 2019 to evaluate linzess delayed release formulation for treating all subtypes of ibs including ibsc ibs with diarrhea and ibsmixed linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patientsefforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expanded to include chronic constipation in august 2018 in january 2019 the drug was approved for ibsc in china strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company pipeline progress to capture the lucrative gi market ironwood is developing several candidates in june 2018 the company initiated two phase iii studies to evaluate iw3718 in patients with persistent refractory gastroesophageal reflux disease gerd data from a phase iib doseranging gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies are evaluating two lead molecules praliciguat iw and olinciguat iw the company is progressing praliciguat in two phase ii studies to evaluate it in diabetic nephropathy and heart failure with preserved ejection fraction hfpef topline from both the studies is expected in the second half of 2019 meanwhile a phase ii study is enrolling patients which will evaluate olinciguat for treating sickle cell disease although data from the achalasia study was positive the company will stop further development it has decided to focus on developing olinciguat for sickle cell disease as its represents significant opportunity the candidate enjoys orphan drug designation in the united states for sickle cell disease meanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'include', 'lower', 'dose', '72', 'mcg', 'product', 'launch', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'md', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'july', '2018', 'phase', 'iii', 'study', 'initiate', 'expand', 'linzess', 'label', 'new', 'symptom', 'associate', 'ibsc', 'bloat', 'discomfort', 'company', 'plan', 'initiate', 'phase', 'iib', 'study', 'quarter', '2019', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'subtype', 'ibs', 'include', 'ibsc', 'ib', 'diarrhea', 'ibsmixed', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patientseffort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expand', 'include', 'chronic', 'constipation', 'august', '2018', 'january', '2019', 'drug', 'approve', 'ibsc', 'china', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'june', '2018', 'company', 'initiate', 'phase', 'iii', 'study', 'evaluate', 'iw3718', 'patient', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'datum', 'phase', 'iib', 'doserange', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'evaluate', 'lead', 'molecule', 'praliciguat', 'iw', 'olinciguat', 'iw', 'company', 'progress', 'praliciguat', 'phase', 'ii', 'study', 'evaluate', 'diabetic', 'nephropathy', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'topline', 'study', 'expect', 'second', 'half', '2019', 'phase', 'ii', 'study', 'enrol', 'patient', 'evaluate', 'olinciguat', 'treat', 'sickle', 'cell', 'disease', 'datum', 'achalasia', 'study', 'positive', 'company', 'stop', 'development', 'decide', 'focus', 'develop', 'olinciguat', 'sickle', 'cell', 'disease', 'represent', 'significant', 'opportunity', 'candidate', 'enjoy', 'orphan', 'drug', 'designation', 'united', 'states', 'sickle', 'cell', 'disease', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 include lower dose 72 mcg product launch united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 md address new patient population ibsc chronic constipation july 2018 phase iii study initiate expand linzess label new symptom associate ibsc bloat discomfort company plan initiate phase iib study quarter 2019 evaluate linzess delay release formulation treat subtype ibs include ibsc ib diarrhea ibsmixed linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patientseffort expand exus territory linzess launch ibsc japan march 2017 label expand include chronic constipation august 2018 january 2019 drug approve ibsc china strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company pipeline progress capture lucrative gi market ironwood develop candidate june 2018 company initiate phase iii study evaluate iw3718 patient persistent refractory gastroesophageal reflux disease gerd datum phase iib doserange gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study evaluate lead molecule praliciguat iw olinciguat iw company progress praliciguat phase ii study evaluate diabetic nephropathy heart failure preserve ejection fraction hfpef topline study expect second half 2019 phase ii study enrol patient evaluate olinciguat treat sickle cell disease datum achalasia study positive company stop development decide focus develop olinciguat sickle cell disease represent significant opportunity candidate enjoy orphan drug designation united states sickle cell disease quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,20,37,-0.29310344827586204,20,37,-0.29310344827586204,0.9975
257,"Ironwood Pharmaceuticals, Inc._Attachment1(3).pdf",IRWD,4/16/2019,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space these initiatives have supported the drugs growth linzess has the potential to be a blockbuster product with global sales crossing 750 million in 2018 by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is also progressing well with development of the drug in japan and china per iqvia data linzess is the leading prescribed drug for adult patients in the united states with ibsc or cic ironwood estimates that its ibsccic franchise including linzess and the delayed release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies are conducting a phase iii study to expand linzess label in additional abdominal symptoms associated with ibsc including bloating and discomfort a label expansion in pediatric patients is also being plannedironwood and allergan are developing a delayed release formulation of linzess delayed release2 md to address patient populations suffering from all forms of ibs the company is planning to initiate a phase ii study in the second quarter of 2019 to evaluate linzess delayed release formulation for treating ibsd linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patientsefforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expanded to include chronic constipation in august 2018 in january 2019 the drug was approved for ibsc in china meanwhile to capture the lucrative gi market ironwood is developing several candidates the most advanced pipeline candidate is iw3718 which is being evaluated in phase iii studies for treating persistent refractory gastroesophageal reflux disease gerd strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenues for ironwood additional partnerships in other territories will be a positive for the company spinoff of cyclerion encouraging ironwoods separation of its sgc pipeline into a separate entity cyclerion is expected to be a positive the transaction is likely to bring down research and development costs significantly the company will also be able to put more efforts in building its gi products especially linzess moreover the spinoff along with some restructuring initiatives will also reduce the workforce lowering operating expenses further,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'initiative', 'support', 'drug', 'growth', 'linzess', 'potential', 'blockbuster', 'product', 'global', 'sale', 'cross', '750', 'million', '2018', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'progress', 'development', 'drug', 'japan', 'china', 'iqvia', 'datum', 'linzess', 'lead', 'prescribe', 'drug', 'adult', 'patient', 'united', 'states', 'ibsc', 'cic', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'delay', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'conduct', 'phase', 'iii', 'study', 'expand', 'linzess', 'label', 'additional', 'abdominal', 'symptom', 'associate', 'ibsc', 'include', 'bloat', 'discomfort', 'label', 'expansion', 'pediatric', 'patient', 'plannedironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'md', 'address', 'patient', 'population', 'suffer', 'form', 'ibs', 'company', 'plan', 'initiate', 'phase', 'ii', 'study', 'second', 'quarter', '2019', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'ibsd', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patientseffort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expand', 'include', 'chronic', 'constipation', 'august', '2018', 'january', '2019', 'drug', 'approve', 'ibsc', 'china', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'advanced', 'pipeline', 'candidate', 'iw3718', 'evaluate', 'phase', 'iii', 'study', 'treat', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'spinoff', 'cyclerion', 'encourage', 'ironwood', 'separation', 'sgc', 'pipeline', 'separate', 'entity', 'cyclerion', 'expect', 'positive', 'transaction', 'likely', 'bring', 'research', 'development', 'cost', 'significantly', 'company', 'able', 'effort', 'build', 'gi', 'product', 'especially', 'linzess', 'spinoff', 'restructuring', 'initiative', 'reduce', 'workforce', 'lower', 'operating', 'expense']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space initiative support drug growth linzess potential blockbuster product global sale cross 750 million 2018 end 2020 ironwood expect annual sale linzess cross 1 billion company progress development drug japan china iqvia datum linzess lead prescribe drug adult patient united states ibsc cic ironwood estimate ibsccic franchise include linzess delay release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company conduct phase iii study expand linzess label additional abdominal symptom associate ibsc include bloat discomfort label expansion pediatric patient plannedironwood allergan develop delay release formulation linzess delay release2 md address patient population suffer form ibs company plan initiate phase ii study second quarter 2019 evaluate linzess delay release formulation treat ibsd linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patientseffort expand exus territory linzess launch ibsc japan march 2017 label expand include chronic constipation august 2018 january 2019 drug approve ibsc china capture lucrative gi market ironwood develop candidate advanced pipeline candidate iw3718 evaluate phase iii study treat persistent refractory gastroesophageal reflux disease gerd strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company spinoff cyclerion encourage ironwood separation sgc pipeline separate entity cyclerion expect positive transaction likely bring research development cost significantly company able effort build gi product especially linzess spinoff restructuring initiative reduce workforce lower operating expense,17,30,-0.2708333333333333,17,30,-0.2708333333333333,0.9969
258,"Ironwood Pharmaceuticals, Inc._Attachment1(3).pdf",IRWD,4/16/2019,overdependence on linzess while we are pleased with the approval of linzess we remain concerned about the companys dependence on the product for growth any negative news related to linzess would adversely impact the company and its growth prospects although the performance of linzess improved in 2018 customer buying patterns can have unfavorable impact as seen earlier moreover the product is couple of years away from achieving blockbuster status meanwhile in august 2018 ironwood terminated its licensing agreement with astrazeneca related to zurampic and all products containing lesinurad including duzallo fixeddose combination of lesinurad and allopurinol the termination was based on unfavorable data from a study exploring a path for value creation of lesinuradbased products this has impacted the top line unfavorably as expected moreover upon completion of the termination of lenisurad franchise the company solely depends on linzess for the majority of its revenues pipeline candidates still a few years from commercialization pipeline candidates still a few years from commercialization ironwoods midlatestage nature of the pipeline runs its own risk although the company has multiple few midlatestage candidates in its pipeline it will be several years before any of these candidates are close to commercialization moreover we note that clinical development involves a high degree of risk gaining approval for pipeline candidates has become more difficult given the tough regulatory environment development and regulatory setbacks for pipeline candidates would be a major disappointment for the company and have an adverse impact on the shares zacks equity research irwd wwwzackscom page 3 of 7,sell,"['overdependence', 'linzess', 'pleased', 'approval', 'linzess', 'remain', 'concerned', 'company', 'dependence', 'product', 'growth', 'negative', 'news', 'relate', 'linzess', 'adversely', 'impact', 'company', 'growth', 'prospect', 'performance', 'linzess', 'improve', '2018', 'customer', 'buying', 'pattern', 'unfavorable', 'impact', 'see', 'early', 'product', 'couple', 'year', 'away', 'achieve', 'blockbuster', 'status', 'august', '2018', 'ironwood', 'terminate', 'licensing', 'agreement', 'astrazeneca', 'relate', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'duzallo', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'termination', 'base', 'unfavorable', 'datum', 'study', 'explore', 'path', 'value', 'creation', 'lesinuradbase', 'product', 'impact', 'line', 'unfavorably', 'expect', 'completion', 'termination', 'lenisurad', 'franchise', 'company', 'solely', 'depend', 'linzess', 'majority', 'revenue', 'pipeline', 'candidate', 'year', 'commercialization', 'pipeline', 'candidate', 'year', 'commercialization', 'ironwood', 'midlatestage', 'nature', 'pipeline', 'run', 'risk', 'company', 'multiple', 'midlatestage', 'candidate', 'pipeline', 'year', 'candidate', 'close', 'commercialization', 'note', 'clinical', 'development', 'involve', 'high', 'degree', 'risk', 'gain', 'approval', 'pipeline', 'candidate', 'difficult', 'give', 'tough', 'regulatory', 'environment', 'development', 'regulatory', 'setback', 'pipeline', 'candidate', 'major', 'disappointment', 'company', 'adverse', 'impact', 'share', 'zack', 'equity', 'research', 'irwd', 'wwwzackscom', 'page', '3', '7']",overdependence linzess pleased approval linzess remain concerned company dependence product growth negative news relate linzess adversely impact company growth prospect performance linzess improve 2018 customer buying pattern unfavorable impact see early product couple year away achieve blockbuster status august 2018 ironwood terminate licensing agreement astrazeneca relate zurampic product contain lesinurad include duzallo fixeddose combination lesinurad allopurinol termination base unfavorable datum study explore path value creation lesinuradbase product impact line unfavorably expect completion termination lenisurad franchise company solely depend linzess majority revenue pipeline candidate year commercialization pipeline candidate year commercialization ironwood midlatestage nature pipeline run risk company multiple midlatestage candidate pipeline year candidate close commercialization note clinical development involve high degree risk gain approval pipeline candidate difficult give tough regulatory environment development regulatory setback pipeline candidate major disappointment company adverse impact share zack equity research irwd wwwzackscom page 3 7,8,17,-0.34615384615384615,8,17,-0.34615384615384615,0.9524
259,"Ironwood Pharmaceuticals, Inc._Attachment1(4).pdf",IRWD,7/17/2017,strong share price performance in 2017 so far the companys shares are up 246 compared to a 57 gain for the zacks classified drugs industry linzess approval a milestone the aug 2012 fda approval of linzess was a major milestone for ironwood linzess was launched in dec 2012 the company is focusing on promoting linzess to gastroenterologists and primary care physicians ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover cvscaremark has granted linzess an exclusive preferred position on its formulary beginning jan 1 2016 and the company commenced a new dtc campaign in mar 2016 linzess has been showing rapid sales and prescription growth backed by new patient additions directtoconsumer dtc promotion broad payer access and continued strong demand in 2016 27 million prescriptions of linzess were filled representing growth of 27 year over year the trend is expected to continue in 2017 linzess label expansion efforts ironwood and allergan are looking to broaden linzess label by expanding the targeted patient population and gaining approval for additional indications the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is expected to boost prescriptions in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing two delayed release formulations of linzess delayed release1 or dr1 and delayed release2 or dr2 a phase iib study for dr1 is currently underway in patients with ibsc this secondgeneration guanylate cyclasec gcc agonist candidate has the potential to provide greater and faster abdominal pain relief in adult ibsc patients expand the ibsc and cic markets and extend patent protection to the mid2030s data announced in dec 2016 showed that the colonic formulation led to improvements in pain relief over linzess phase iii studies are expected to begin in the second half of 2017 dr2 is being developed to improve abdominal pain relief in patients with additional gastrointestinal or gi disorders where lower abdominal pain is a predominant symptom such as nonconstipation subtypes of ibs efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the us in mar 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us and promoting canasa ulcerative proctitis and delzicol ulcerative colitis in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including the fixeddose combination of lesinurad and allopurinol zurampic was launched in oct 2016 the fixeddose combination product duzallo is under fda review and is expected to be launched by late 2017 if approved the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing with data expected in mid2017 ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules iw1973 diabetic hypertension and iw1701 type ii achalasia commenced in 2016 data from the studies are expected in the second half of 2017 in the second half of 2017 ironwood expects to initiate phase ii clinical trials evaluating iw1973 in three indications resistant hypertension rhtn heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn,buy,"['strong', 'share', 'price', 'performance', '2017', 'far', 'company', 'share', '246', 'compare', '57', 'gain', 'zack', 'classify', 'drug', 'industry', 'linzess', 'approval', 'milestone', 'aug', '2012', 'fda', 'approval', 'linzess', 'major', 'milestone', 'ironwood', 'linzess', 'launch', 'dec', '2012', 'company', 'focus', 'promote', 'linzess', 'gastroenterologist', 'primary', 'care', 'physician', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'beginning', 'jan', '1', '2016', 'company', 'commence', 'new', 'dtc', 'campaign', 'mar', '2016', 'linzess', 'show', 'rapid', 'sale', 'prescription', 'growth', 'back', 'new', 'patient', 'addition', 'directtoconsumer', 'dtc', 'promotion', 'broad', 'payer', 'access', 'continue', 'strong', 'demand', '2016', '27', 'million', 'prescription', 'linzess', 'fill', 'represent', 'growth', '27', 'year', 'year', 'trend', 'expect', 'continue', '2017', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'expand', 'target', 'patient', 'population', 'gain', 'approval', 'additional', 'indication', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'expect', 'boost', 'prescription', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release1', 'dr1', 'delay', 'release2', 'dr2', 'phase', 'iib', 'study', 'dr1', 'currently', 'underway', 'patient', 'ibsc', 'secondgeneration', 'guanylate', 'cyclasec', 'gcc', 'agonist', 'candidate', 'potential', 'provide', 'great', 'fast', 'abdominal', 'pain', 'relief', 'adult', 'ibsc', 'patient', 'expand', 'ibsc', 'cic', 'market', 'extend', 'patent', 'protection', 'mid2030s', 'datum', 'announce', 'dec', '2016', 'show', 'colonic', 'formulation', 'lead', 'improvement', 'pain', 'relief', 'linzess', 'phase', 'iii', 'study', 'expect', 'begin', 'second', 'half', '2017', 'dr2', 'develop', 'improve', 'abdominal', 'pain', 'relief', 'patient', 'additional', 'gastrointestinal', 'gi', 'disorder', 'low', 'abdominal', 'pain', 'predominant', 'symptom', 'nonconstipation', 'subtype', 'ibs', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'mar', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'oct', '2016', 'fixeddose', 'combination', 'product', 'duzallo', 'fda', 'review', 'expect', 'launch', 'late', '2017', 'approve', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'expect', 'mid2017', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'commence', '2016', 'datum', 'study', 'expect', 'second', 'half', '2017', 'second', 'half', '2017', 'ironwood', 'expect', 'initiate', 'phase', 'ii', 'clinical', 'trial', 'evaluate', 'iw1973', 'indication', 'resistant', 'hypertension', 'rhtn', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn']",strong share price performance 2017 far company share 246 compare 57 gain zack classify drug industry linzess approval milestone aug 2012 fda approval linzess major milestone ironwood linzess launch dec 2012 company focus promote linzess gastroenterologist primary care physician ironwood work expand manage care access linzess lower ofpocket cost cvscaremark grant linzess exclusive preferred position formulary beginning jan 1 2016 company commence new dtc campaign mar 2016 linzess show rapid sale prescription growth back new patient addition directtoconsumer dtc promotion broad payer access continue strong demand 2016 27 million prescription linzess fill represent growth 27 year year trend expect continue 2017 linzess label expansion effort ironwood allergan look broaden linzess label expand target patient population gain approval additional indication company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength expect boost prescription large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release1 dr1 delay release2 dr2 phase iib study dr1 currently underway patient ibsc secondgeneration guanylate cyclasec gcc agonist candidate potential provide great fast abdominal pain relief adult ibsc patient expand ibsc cic market extend patent protection mid2030s datum announce dec 2016 show colonic formulation lead improvement pain relief linzess phase iii study expect begin second half 2017 dr2 develop improve abdominal pain relief patient additional gastrointestinal gi disorder low abdominal pain predominant symptom nonconstipation subtype ibs effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product mar 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include fixeddose combination lesinurad allopurinol zurampic launch oct 2016 fixeddose combination product duzallo fda review expect launch late 2017 approve company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum expect mid2017 ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule iw1973 diabetic hypertension iw1701 type ii achalasia commence 2016 datum study expect second half 2017 second half 2017 ironwood expect initiate phase ii clinical trial evaluate iw1973 indication resistant hypertension rhtn heart failure preserve ejection fraction hfpef diabetic nephropathy dn,22,37,-0.25,22,37,-0.25,0.9981
260,"Ironwood Pharmaceuticals, Inc._Attachment1(4).pdf",IRWD,2/21/2018,linzess approval a milestone the august 2012 fda approval of linzess was a major milestone for ironwood linzess was launched in december 2012 ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover cvscaremark has granted linzess an exclusive preferred position on its formulary beginning jan 1 2016 the company commenced a directto consumer dtc campaign in march 2016 which is driving both market share as well as overall market growth linzess has been showing rapid sales and prescription growth backed by new patient additions dtc promotion broad payer access and continued strong demand linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies received fda approval for a 72 mcg dose for cic in january 2017 the new dose was launched in march 2017 the launch of this lower dose strength is boosting prescription trends in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 while a regulatory filing has been submitted in china for the indication decision expected in 1h another regulatory application seeking label expansion of linzess in chronic constipation is under review in japan linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including recently launched duzallo fixeddose combination of lesinurad and allopurinol zurampic was launched in october 2016 while duzallo was launched in october 2017 duzallo addresses both causes of hyperuricemia in gout over production and underexcretion of serum uric acid in a single pill the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing data from the study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the second half of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw1973 diabetic hypertension and iw1701 type ii achalasia phase iia commenced in 2016 in december 2017 ironwood announced positive topline data from the praliciguat diabetic hypertension study which showed blood pressure reduction and improvement in metabolic parameters meanwhile data,buy,"['linzess', 'approval', 'milestone', 'august', '2012', 'fda', 'approval', 'linzess', 'major', 'milestone', 'ironwood', 'linzess', 'launch', 'december', '2012', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'beginning', 'jan', '1', '2016', 'company', 'commence', 'directto', 'consumer', 'dtc', 'campaign', 'march', '2016', 'drive', 'market', 'share', 'overall', 'market', 'growth', 'linzess', 'show', 'rapid', 'sale', 'prescription', 'growth', 'back', 'new', 'patient', 'addition', 'dtc', 'promotion', 'broad', 'payer', 'access', 'continue', 'strong', 'demand', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'january', '2017', 'new', 'dose', 'launch', 'march', '2017', 'launch', 'low', 'dose', 'strength', 'boost', 'prescription', 'trend', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', '1h', 'regulatory', 'application', 'seek', 'label', 'expansion', 'linzess', 'chronic', 'constipation', 'review', 'japan', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'recently', 'launch', 'duzallo', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'october', '2016', 'duzallo', 'launch', 'october', '2017', 'duzallo', 'address', 'cause', 'hyperuricemia', 'gout', 'production', 'underexcretion', 'serum', 'uric', 'acid', 'single', 'pill', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'second', 'half', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'phase', 'iia', 'commence', '2016', 'december', '2017', 'ironwood', 'announce', 'positive', 'topline', 'datum', 'praliciguat', 'diabetic', 'hypertension', 'study', 'show', 'blood', 'pressure', 'reduction', 'improvement', 'metabolic', 'parameter', 'data']",linzess approval milestone august 2012 fda approval linzess major milestone ironwood linzess launch december 2012 ironwood work expand manage care access linzess lower ofpocket cost cvscaremark grant linzess exclusive preferred position formulary beginning jan 1 2016 company commence directto consumer dtc campaign march 2016 drive market share overall market growth linzess show rapid sale prescription growth back new patient addition dtc promotion broad payer access continue strong demand linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company receive fda approval 72 mcg dose cic january 2017 new dose launch march 2017 launch low dose strength boost prescription trend large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan march 2017 regulatory filing submit china indication decision expect 1h regulatory application seek label expansion linzess chronic constipation review japan linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include recently launch duzallo fixeddose combination lesinurad allopurinol zurampic launch october 2016 duzallo launch october 2017 duzallo address cause hyperuricemia gout production underexcretion serum uric acid single pill company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii second half 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw1973 diabetic hypertension iw1701 type ii achalasia phase iia commence 2016 december 2017 ironwood announce positive topline datum praliciguat diabetic hypertension study show blood pressure reduction improvement metabolic parameter data,19,30,-0.22,19,30,-0.22,0.9972
261,"Ironwood Pharmaceuticals, Inc._Attachment1(4).pdf",IRWD,7/9/2018,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 while a regulatory filing has been submitted in china for the indication decision expected in second quarter of another regulatory application seeking label expansion of linzess in chronic constipation is under review in japan linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including duzallo fixeddose combination of lesinurad and allopurinol zurampic was launched in october 2016 while duzallo was launched in october 2017 duzallo addresses both causes of hyperuricemia in gout overproduction and under excretion of serum uric acid in a single pill the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with the company advancing it in phase iii studies in july 2018 data from a phase iib doseranging refractory gastroesophageal reflux disease gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw1973 diabetic hypertension and olinciguat iw1701 type ii achalasia phase iia commenced in 2016 in december 2017 ironwood announced positive topline data from the praliciguat diabetic hypertension study which showed blood pressure reduction and improvement in metabolic parameters in patient treated with the candidate meanwhile data from the olinciguat study is expected in 2018 the candidate enjoys oprhan drug designation in the united states meanwhile praliciguat is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease was initiated in december 2017 meanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'second', 'quarter', 'regulatory', 'application', 'seek', 'label', 'expansion', 'linzess', 'chronic', 'constipation', 'review', 'japan', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'duzallo', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'october', '2016', 'duzallo', 'launch', 'october', '2017', 'duzallo', 'address', 'cause', 'hyperuricemia', 'gout', 'overproduction', 'excretion', 'serum', 'uric', 'acid', 'single', 'pill', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'company', 'advance', 'phase', 'iii', 'study', 'july', '2018', 'datum', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw1973', 'diabetic', 'hypertension', 'olinciguat', 'iw1701', 'type', 'ii', 'achalasia', 'phase', 'iia', 'commence', '2016', 'december', '2017', 'ironwood', 'announce', 'positive', 'topline', 'datum', 'praliciguat', 'diabetic', 'hypertension', 'study', 'show', 'blood', 'pressure', 'reduction', 'improvement', 'metabolic', 'parameter', 'patient', 'treat', 'candidate', 'datum', 'olinciguat', 'study', 'expect', '2018', 'candidate', 'enjoy', 'oprhan', 'drug', 'designation', 'united', 'states', 'praliciguat', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'initiate', 'december', '2017', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan march 2017 regulatory filing submit china indication decision expect second quarter regulatory application seek label expansion linzess chronic constipation review japan linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include duzallo fixeddose combination lesinurad allopurinol zurampic launch october 2016 duzallo launch october 2017 duzallo address cause hyperuricemia gout overproduction excretion serum uric acid single pill company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting company advance phase iii study july 2018 datum phase iib doserange refractory gastroesophageal reflux disease gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw1973 diabetic hypertension olinciguat iw1701 type ii achalasia phase iia commence 2016 december 2017 ironwood announce positive topline datum praliciguat diabetic hypertension study show blood pressure reduction improvement metabolic parameter patient treat candidate datum olinciguat study expect 2018 candidate enjoy oprhan drug designation united states praliciguat evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease initiate december 2017 quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,22,36,-0.23728813559322035,22,36,-0.23728813559322035,0.9971
262,"Ironwood Pharmaceuticals, Inc._Attachment1(4).pdf",IRWD,11/19/2018,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 including the lower dose 72 mcg of the product which was launched in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations ironwood and allergan are developing a delayed release formulation of linzess delayed release2 md to address new patient populations beyond ibsc and chronic constipation in july 2018 a phase iii study was initiated to expand linzess label in two new symptoms associated with ibsc bloating and discomfort moreover the company is planning to initiate a phase iib study in the first quarter of 2019 to evaluate linzess delayed release formulation for treating all subtypes of ibs including ibsc ibs with diarrhea and ibsmixed linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patientsefforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expanded to include chronic constipation in august 2018 while a regulatory filing has been submitted in china for the indication decision expected in early strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company pipeline progress to capture the lucrative gi market ironwood is developing several candidates in june 2018 the company initiated two phase iii studies to evaluate iw3718 in patients with persistent refractory gastroesophageal reflux disease gerd data from a phase iib doseranging gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies are evaluating two lead molecules praliciguat iw and olinciguat iw the company is progressing praliciguat in two phase ii studies to evaluate it in diabetic nephropathy and heart failure with preserved ejection fraction hfpef topline from both the studies is expected in the second half of 2019 meanwhile a phase ii study is enrolling patients which will evaluate olinciguat for treating sickle cell disease although data from the achalasia study was positive the company will stop further development it has decided to focus on developing olinciguat for sickle cell disease as its represents significant opportunity the candidate enjoys orphan drug designation in the united states for sickle cell disease meanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'include', 'lower', 'dose', '72', 'mcg', 'product', 'launch', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'md', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'july', '2018', 'phase', 'iii', 'study', 'initiate', 'expand', 'linzess', 'label', 'new', 'symptom', 'associate', 'ibsc', 'bloat', 'discomfort', 'company', 'plan', 'initiate', 'phase', 'iib', 'study', 'quarter', '2019', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'subtype', 'ibs', 'include', 'ibsc', 'ib', 'diarrhea', 'ibsmixed', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patientseffort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expand', 'include', 'chronic', 'constipation', 'august', '2018', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'early', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'june', '2018', 'company', 'initiate', 'phase', 'iii', 'study', 'evaluate', 'iw3718', 'patient', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'datum', 'phase', 'iib', 'doserange', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'evaluate', 'lead', 'molecule', 'praliciguat', 'iw', 'olinciguat', 'iw', 'company', 'progress', 'praliciguat', 'phase', 'ii', 'study', 'evaluate', 'diabetic', 'nephropathy', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'topline', 'study', 'expect', 'second', 'half', '2019', 'phase', 'ii', 'study', 'enrol', 'patient', 'evaluate', 'olinciguat', 'treat', 'sickle', 'cell', 'disease', 'datum', 'achalasia', 'study', 'positive', 'company', 'stop', 'development', 'decide', 'focus', 'develop', 'olinciguat', 'sickle', 'cell', 'disease', 'represent', 'significant', 'opportunity', 'candidate', 'enjoy', 'orphan', 'drug', 'designation', 'united', 'states', 'sickle', 'cell', 'disease', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 include lower dose 72 mcg product launch united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 md address new patient population ibsc chronic constipation july 2018 phase iii study initiate expand linzess label new symptom associate ibsc bloat discomfort company plan initiate phase iib study quarter 2019 evaluate linzess delay release formulation treat subtype ibs include ibsc ib diarrhea ibsmixed linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patientseffort expand exus territory linzess launch ibsc japan march 2017 label expand include chronic constipation august 2018 regulatory filing submit china indication decision expect early strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company pipeline progress capture lucrative gi market ironwood develop candidate june 2018 company initiate phase iii study evaluate iw3718 patient persistent refractory gastroesophageal reflux disease gerd datum phase iib doserange gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study evaluate lead molecule praliciguat iw olinciguat iw company progress praliciguat phase ii study evaluate diabetic nephropathy heart failure preserve ejection fraction hfpef topline study expect second half 2019 phase ii study enrol patient evaluate olinciguat treat sickle cell disease datum achalasia study positive company stop development decide focus develop olinciguat sickle cell disease represent significant opportunity candidate enjoy orphan drug designation united states sickle cell disease quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,20,38,-0.3050847457627119,20,38,-0.3050847457627119,0.9975
263,"Ironwood Pharmaceuticals, Inc._Attachment1(4).pdf",IRWD,2/22/2019,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space these initiatives have supported the drugs growth linzess has the potential to be a blockbuster product with global sales crossing 750 million in 2018 by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is also progressing well with development of the drug in japan and china per iqvia data linzess is the leading prescribed drug for adult patients in the united states with ibsc or cic ironwood estimates that its ibsccic franchise including linzess and the delayed release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the company is conducting a phase iii study to expand linzess label in two new symptoms associated with ibsc bloating and discomfort ironwood and allergan are developing a delayed release formulation of linzess delayed release2 md to address patient populations suffering from all forms of ibs the company is planning to initiate a phase ii study in the second quarter of 2019 to evaluate linzess delayed release formulation for treating ibsd linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patientsefforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expanded to include chronic constipation in august 2018 in january 2019 the drug was approved for ibsc in china strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company pipeline progress to capture the lucrative gi market ironwood is developing several candidates in june 2018 the company initiated two phase iii studies to evaluate iw3718 in patients with persistent refractory gastroesophageal reflux disease gerd data from a phase iib doseranging gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring five soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases however it is on track to transfer these candidates to cyclerion after separation the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies are evaluating two lead molecules praliciguat iw and olinciguat iw the company is progressing praliciguat in two phase ii studies to evaluate it in diabetic nephropathy and heart failure with preserved ejection fraction hfpef topline data from both the studies is expected in the second half of 2019 meanwhile a phase ii study is enrolling patients which will evaluate olinciguat for treating sickle cell disease data from the study is expected in the second half of 2019 the candidate enjoys orphan drug designation in the united states for sickle cell disease apart from these two the company has one earlystage candidate iw6463 which is being developed for central nervous system cns disorders and two latestage candidates targeting serious liver and lung diseases spinoff of cyclerion encouraging ironwoods plan to separate its sgc pipeline into a separate entity cyclerion is expected to be a positive the transaction is likely to bring down research and development costs significantly the company will also be able to put more efforts in building its gi products especially linzess moreover the spinoff along with some restructuring initiatives will also reduce the workforce lowering operating expenses further,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'initiative', 'support', 'drug', 'growth', 'linzess', 'potential', 'blockbuster', 'product', 'global', 'sale', 'cross', '750', 'million', '2018', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'progress', 'development', 'drug', 'japan', 'china', 'iqvia', 'datum', 'linzess', 'lead', 'prescribe', 'drug', 'adult', 'patient', 'united', 'states', 'ibsc', 'cic', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'delay', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'conduct', 'phase', 'iii', 'study', 'expand', 'linzess', 'label', 'new', 'symptom', 'associate', 'ibsc', 'bloat', 'discomfort', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'md', 'address', 'patient', 'population', 'suffer', 'form', 'ibs', 'company', 'plan', 'initiate', 'phase', 'ii', 'study', 'second', 'quarter', '2019', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'ibsd', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patientseffort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expand', 'include', 'chronic', 'constipation', 'august', '2018', 'january', '2019', 'drug', 'approve', 'ibsc', 'china', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'june', '2018', 'company', 'initiate', 'phase', 'iii', 'study', 'evaluate', 'iw3718', 'patient', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'datum', 'phase', 'iib', 'doserange', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'track', 'transfer', 'candidate', 'cyclerion', 'separation', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'evaluate', 'lead', 'molecule', 'praliciguat', 'iw', 'olinciguat', 'iw', 'company', 'progress', 'praliciguat', 'phase', 'ii', 'study', 'evaluate', 'diabetic', 'nephropathy', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'topline', 'datum', 'study', 'expect', 'second', 'half', '2019', 'phase', 'ii', 'study', 'enrol', 'patient', 'evaluate', 'olinciguat', 'treat', 'sickle', 'cell', 'disease', 'datum', 'study', 'expect', 'second', 'half', '2019', 'candidate', 'enjoy', 'orphan', 'drug', 'designation', 'united', 'states', 'sickle', 'cell', 'disease', 'apart', 'company', 'earlystage', 'candidate', 'iw6463', 'develop', 'central', 'nervous', 'system', 'cns', 'disorder', 'latestage', 'candidate', 'target', 'liver', 'lung', 'disease', 'spinoff', 'cyclerion', 'encourage', 'ironwood', 'plan', 'separate', 'sgc', 'pipeline', 'separate', 'entity', 'cyclerion', 'expect', 'positive', 'transaction', 'likely', 'bring', 'research', 'development', 'cost', 'significantly', 'company', 'able', 'effort', 'build', 'gi', 'product', 'especially', 'linzess', 'spinoff', 'restructuring', 'initiative', 'reduce', 'workforce', 'lower', 'operating', 'expense']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space initiative support drug growth linzess potential blockbuster product global sale cross 750 million 2018 end 2020 ironwood expect annual sale linzess cross 1 billion company progress development drug japan china iqvia datum linzess lead prescribe drug adult patient united states ibsc cic ironwood estimate ibsccic franchise include linzess delay release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company conduct phase iii study expand linzess label new symptom associate ibsc bloat discomfort ironwood allergan develop delay release formulation linzess delay release2 md address patient population suffer form ibs company plan initiate phase ii study second quarter 2019 evaluate linzess delay release formulation treat ibsd linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patientseffort expand exus territory linzess launch ibsc japan march 2017 label expand include chronic constipation august 2018 january 2019 drug approve ibsc china strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company pipeline progress capture lucrative gi market ironwood develop candidate june 2018 company initiate phase iii study evaluate iw3718 patient persistent refractory gastroesophageal reflux disease gerd datum phase iib doserange gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease track transfer candidate cyclerion separation company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study evaluate lead molecule praliciguat iw olinciguat iw company progress praliciguat phase ii study evaluate diabetic nephropathy heart failure preserve ejection fraction hfpef topline datum study expect second half 2019 phase ii study enrol patient evaluate olinciguat treat sickle cell disease datum study expect second half 2019 candidate enjoy orphan drug designation united states sickle cell disease apart company earlystage candidate iw6463 develop central nervous system cns disorder latestage candidate target liver lung disease spinoff cyclerion encourage ironwood plan separate sgc pipeline separate entity cyclerion expect positive transaction likely bring research development cost significantly company able effort build gi product especially linzess spinoff restructuring initiative reduce workforce lower operating expense,21,40,-0.3064516129032258,21,40,-0.3064516129032258,0.9971
264,"Ironwood Pharmaceuticals, Inc._Attachment1(5).pdf",IRWD,8/18/2017,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label by expanding the targeted patient population and gaining approval for additional indications the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is expected to boost prescriptions in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing two delayed release formulations of linzess delayed release1 or dr1 and delayed release2 or dr2 a phase iib study for dr1 is currently underway in patients with ibsc this secondgeneration guanylate cyclasec gcc agonist candidate has the potential to provide greater and faster abdominal pain relief in adult ibsc patients expand the ibsc and cic markets and extend patent protection to the mid2030s data announced in dec 2016 showed that the colonic formulation led to improvements in pain relief over linzess phase iii studies are expected to begin in the second half of 2017 dr2 is being developed to improve abdominal pain relief in patients with additional gastrointestinal or gi disorders where lower abdominal pain is a predominant symptom such as nonconstipation subtypes of ibs phase iib dose ranging studies are expected to begin next year efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the us in mar 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us and promoting canasa ulcerative proctitis and delzicol ulcerative colitis in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the zacks equity research irwd wwwzackscom page 3 of 8,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'expand', 'target', 'patient', 'population', 'gain', 'approval', 'additional', 'indication', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'expect', 'boost', 'prescription', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release1', 'dr1', 'delay', 'release2', 'dr2', 'phase', 'iib', 'study', 'dr1', 'currently', 'underway', 'patient', 'ibsc', 'secondgeneration', 'guanylate', 'cyclasec', 'gcc', 'agonist', 'candidate', 'potential', 'provide', 'great', 'fast', 'abdominal', 'pain', 'relief', 'adult', 'ibsc', 'patient', 'expand', 'ibsc', 'cic', 'market', 'extend', 'patent', 'protection', 'mid2030s', 'datum', 'announce', 'dec', '2016', 'show', 'colonic', 'formulation', 'lead', 'improvement', 'pain', 'relief', 'linzess', 'phase', 'iii', 'study', 'expect', 'begin', 'second', 'half', '2017', 'dr2', 'develop', 'improve', 'abdominal', 'pain', 'relief', 'patient', 'additional', 'gastrointestinal', 'gi', 'disorder', 'low', 'abdominal', 'pain', 'predominant', 'symptom', 'nonconstipation', 'subtype', 'ibs', 'phase', 'iib', 'dose', 'range', 'study', 'expect', 'begin', 'year', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'mar', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'zack', 'equity', 'research', 'irwd', 'wwwzackscom', 'page', '3', '8']",linzess label expansion effort ironwood allergan look broaden linzess label expand target patient population gain approval additional indication company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength expect boost prescription large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release1 dr1 delay release2 dr2 phase iib study dr1 currently underway patient ibsc secondgeneration guanylate cyclasec gcc agonist candidate potential provide great fast abdominal pain relief adult ibsc patient expand ibsc cic market extend patent protection mid2030s datum announce dec 2016 show colonic formulation lead improvement pain relief linzess phase iii study expect begin second half 2017 dr2 develop improve abdominal pain relief patient additional gastrointestinal gi disorder low abdominal pain predominant symptom nonconstipation subtype ibs phase iib dose range study expect begin year effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product mar 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive zack equity research irwd wwwzackscom page 3 8,14,24,-0.2564102564102564,14,24,-0.2564102564102564,0.9942
265,"Ironwood Pharmaceuticals, Inc._Attachment1(5).pdf",IRWD,8/13/2018,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients in july 2018 a phase iii study was initiated to expand linzess label in two new symptoms associated with ibsc bloating and discomfort moreover the company is currently designing a phase iib study to evaluate linzess delayed release formulation for treating all subtypes of ibs including ibsc ibs with diarrhea and ibsmixed efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 while a regulatory filing has been submitted in china for the indication decision expected by the end of another regulatory application seeking label expansion of linzess in chronic constipation is under review in japan strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company pipeline progress to capture the lucrative gi market ironwood is developing several candidates in june 2018 the company initiated two phase iii studies to evaluate iw3718 in patients with persistent refractory gastroesophageal reflux disease gerd data from a phase iib doseranging gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw and olinciguat iw the company is progressing praliciguat in two phase ii studies to evaluate it in diabetic nephropathy and heart failure with preserved ejection fraction hfpef topline from both the studies is expected in the second half of 2019 meanwhile two phase ii studies will evaluate olinciguat for treating sickle cell disease and achalasia data from the achalasia study is expected in the second half of 2018 the candidate enjoys orphan drug designation in the united states for sickle cell diseasemeanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'july', '2018', 'phase', 'iii', 'study', 'initiate', 'expand', 'linzess', 'label', 'new', 'symptom', 'associate', 'ibsc', 'bloat', 'discomfort', 'company', 'currently', 'design', 'phase', 'iib', 'study', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'subtype', 'ibs', 'include', 'ibsc', 'ib', 'diarrhea', 'ibsmixed', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'end', 'regulatory', 'application', 'seek', 'label', 'expansion', 'linzess', 'chronic', 'constipation', 'review', 'japan', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'june', '2018', 'company', 'initiate', 'phase', 'iii', 'study', 'evaluate', 'iw3718', 'patient', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'datum', 'phase', 'iib', 'doserange', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw', 'olinciguat', 'iw', 'company', 'progress', 'praliciguat', 'phase', 'ii', 'study', 'evaluate', 'diabetic', 'nephropathy', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'topline', 'study', 'expect', 'second', 'half', '2019', 'phase', 'ii', 'study', 'evaluate', 'olinciguat', 'treat', 'sickle', 'cell', 'disease', 'achalasia', 'datum', 'achalasia', 'study', 'expect', 'second', 'half', '2018', 'candidate', 'enjoy', 'orphan', 'drug', 'designation', 'united', 'states', 'sickle', 'cell', 'diseasemeanwhile', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient july 2018 phase iii study initiate expand linzess label new symptom associate ibsc bloat discomfort company currently design phase iib study evaluate linzess delay release formulation treat subtype ibs include ibsc ib diarrhea ibsmixed effort expand exus territory linzess launch ibsc japan march 2017 regulatory filing submit china indication decision expect end regulatory application seek label expansion linzess chronic constipation review japan strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company pipeline progress capture lucrative gi market ironwood develop candidate june 2018 company initiate phase iii study evaluate iw3718 patient persistent refractory gastroesophageal reflux disease gerd datum phase iib doserange gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw olinciguat iw company progress praliciguat phase ii study evaluate diabetic nephropathy heart failure preserve ejection fraction hfpef topline study expect second half 2019 phase ii study evaluate olinciguat treat sickle cell disease achalasia datum achalasia study expect second half 2018 candidate enjoy orphan drug designation united states sickle cell diseasemeanwhile quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,18,38,-0.3508771929824561,18,38,-0.3508771929824561,0.9965
266,"Ironwood Pharmaceuticals, Inc._Attachment1(6).pdf",IRWD,4/28/2017,strong share price performance ironwoods shares rose 319 in 2016 even when the zacks classified drugs industry declined 260 backed by regular positive news flow and regulatory updates in 2017 so far the company continued its rise outperforming the industry with shares up 71 compared to a 38 gain for the industry linzess approval a milestone the aug 2012 fda approval of linzess was a major milestone for ironwood linzess was launched in dec 2012 the company is focusing on promoting linzess to gastroenterologists and primary care physicians ironwood is working on expanding managed care access to linzess and lowering outofpocket costs moreover cvscaremark has granted linzess an exclusive preferred position on its formulary beginning jan 1 2016 and the company commenced a new dtc campaign in mar 2016 linzess has been showing rapid sales and prescription growth backed by new patient additions direct toconsumer dtc promotion broad payer access and continued strong demand in 2016 27 million prescriptions of linzess were filled representing growth of 27 year over year the trend is expected to continue in 2017 linzess label expansion efforts ironwood and allergan are looking to broaden linzess label by expanding the targeted patient population and gaining approval for additional indications the companies received fda approval for a 72 mcg dose for cic in jan 2017 with the launch expected in early 2017 approval for this lower dose strength would boost prescriptions in the large heterogeneous adult cic patient population meanwhile a phase iib study for a colonic formulation of linzess is currently underway in patients with ibsc this second generation guanylate cyclasec gcc agonist candidate has the potential to provide greater and faster abdominal pain relief in adult ibsc patients expand the ibsc and cic markets and extend patent protection to the mid2030s data announced in dec 2016 showed that the colonic formulation led to improvements in pain relief over linzess supporting the advancement of the colonic formulation to phase iii development in 2017 ironwood and allergan are also developing linaclotide colonic release2 or cr2 to improve abdominal pain relief in patients with additional gastrointestinal or gi disorders where lower abdominal pain is a predominant symptom such as nonconstipation subtypes of ibs efforts are on to expand in exus territories as well linzess was approved for ibsc in japan in dec 2016 while a regulatory filing has been submitted in china for the indication linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the us in early 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including the fixeddose combination of lesinurad and allopurinol zurampic was launched in oct 2016 the fixeddose combination product duzallo is under fda review and is expected to be launched by late 2017 if approved the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing with data expected in mid2017 ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules iw1973 diabetic hypertension and iw1701 type ii achalasia commenced in 2016 data from the studies are expected in 2017 in the second half of 2017 ironwood expects to initiate phase ii clinical trials evaluating iw1973 in three indications resistant hypertension rhtn heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn,buy,"['strong', 'share', 'price', 'performance', 'ironwood', 'share', 'rise', '319', '2016', 'zack', 'classify', 'drug', 'industry', 'decline', '260', 'back', 'regular', 'positive', 'news', 'flow', 'regulatory', 'update', '2017', 'far', 'company', 'continue', 'rise', 'outperform', 'industry', 'share', '71', 'compare', '38', 'gain', 'industry', 'linzess', 'approval', 'milestone', 'aug', '2012', 'fda', 'approval', 'linzess', 'major', 'milestone', 'ironwood', 'linzess', 'launch', 'dec', '2012', 'company', 'focus', 'promote', 'linzess', 'gastroenterologist', 'primary', 'care', 'physician', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'outofpocket', 'cost', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'beginning', 'jan', '1', '2016', 'company', 'commence', 'new', 'dtc', 'campaign', 'mar', '2016', 'linzess', 'show', 'rapid', 'sale', 'prescription', 'growth', 'back', 'new', 'patient', 'addition', 'direct', 'toconsumer', 'dtc', 'promotion', 'broad', 'payer', 'access', 'continue', 'strong', 'demand', '2016', '27', 'million', 'prescription', 'linzess', 'fill', 'represent', 'growth', '27', 'year', 'year', 'trend', 'expect', 'continue', '2017', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'expand', 'target', 'patient', 'population', 'gain', 'approval', 'additional', 'indication', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'launch', 'expect', 'early', '2017', 'approval', 'low', 'dose', 'strength', 'boost', 'prescription', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'phase', 'iib', 'study', 'colonic', 'formulation', 'linzess', 'currently', 'underway', 'patient', 'ibsc', 'second', 'generation', 'guanylate', 'cyclasec', 'gcc', 'agonist', 'candidate', 'potential', 'provide', 'great', 'fast', 'abdominal', 'pain', 'relief', 'adult', 'ibsc', 'patient', 'expand', 'ibsc', 'cic', 'market', 'extend', 'patent', 'protection', 'mid2030s', 'datum', 'announce', 'dec', '2016', 'show', 'colonic', 'formulation', 'lead', 'improvement', 'pain', 'relief', 'linzess', 'support', 'advancement', 'colonic', 'formulation', 'phase', 'iii', 'development', '2017', 'ironwood', 'allergan', 'develop', 'linaclotide', 'colonic', 'release2', 'cr2', 'improve', 'abdominal', 'pain', 'relief', 'patient', 'additional', 'gastrointestinal', 'gi', 'disorder', 'low', 'abdominal', 'pain', 'predominant', 'symptom', 'nonconstipation', 'subtype', 'ibs', 'effort', 'expand', 'exus', 'territory', 'linzess', 'approve', 'ibsc', 'japan', 'dec', '2016', 'regulatory', 'filing', 'submit', 'china', 'indication', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'early', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'oct', '2016', 'fixeddose', 'combination', 'product', 'duzallo', 'fda', 'review', 'expect', 'launch', 'late', '2017', 'approve', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'expect', 'mid2017', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'commence', '2016', 'datum', 'study', 'expect', '2017', 'second', 'half', '2017', 'ironwood', 'expect', 'initiate', 'phase', 'ii', 'clinical', 'trial', 'evaluate', 'iw1973', 'indication', 'resistant', 'hypertension', 'rhtn', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn']",strong share price performance ironwood share rise 319 2016 zack classify drug industry decline 260 back regular positive news flow regulatory update 2017 far company continue rise outperform industry share 71 compare 38 gain industry linzess approval milestone aug 2012 fda approval linzess major milestone ironwood linzess launch dec 2012 company focus promote linzess gastroenterologist primary care physician ironwood work expand manage care access linzess lower outofpocket cost cvscaremark grant linzess exclusive preferred position formulary beginning jan 1 2016 company commence new dtc campaign mar 2016 linzess show rapid sale prescription growth back new patient addition direct toconsumer dtc promotion broad payer access continue strong demand 2016 27 million prescription linzess fill represent growth 27 year year trend expect continue 2017 linzess label expansion effort ironwood allergan look broaden linzess label expand target patient population gain approval additional indication company receive fda approval 72 mcg dose cic jan 2017 launch expect early 2017 approval low dose strength boost prescription large heterogeneous adult cic patient population phase iib study colonic formulation linzess currently underway patient ibsc second generation guanylate cyclasec gcc agonist candidate potential provide great fast abdominal pain relief adult ibsc patient expand ibsc cic market extend patent protection mid2030s datum announce dec 2016 show colonic formulation lead improvement pain relief linzess support advancement colonic formulation phase iii development 2017 ironwood allergan develop linaclotide colonic release2 cr2 improve abdominal pain relief patient additional gastrointestinal gi disorder low abdominal pain predominant symptom nonconstipation subtype ibs effort expand exus territory linzess approve ibsc japan dec 2016 regulatory filing submit china indication linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product early 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include fixeddose combination lesinurad allopurinol zurampic launch oct 2016 fixeddose combination product duzallo fda review expect launch late 2017 approve company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum expect mid2017 ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule iw1973 diabetic hypertension iw1701 type ii achalasia commence 2016 datum study expect 2017 second half 2017 ironwood expect initiate phase ii clinical trial evaluate iw1973 indication resistant hypertension rhtn heart failure preserve ejection fraction hfpef diabetic nephropathy dn,25,37,-0.19047619047619047,25,37,-0.19047619047619047,0.9986
267,"Ironwood Pharmaceuticals, Inc._Attachment1(6).pdf",IRWD,9/19/2017,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label by expanding the targeted patient population and gaining approval for additional indications the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is expected to boost prescriptions in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing two delayed release formulations of linzess delayed release1 or dr1 and delayed release2 or dr2 a phase iib study for dr1 is currently underway in patients with ibsc this secondgeneration guanylate cyclasec gcc agonist candidate has the potential to provide greater and faster abdominal pain relief in adult ibsc patients expand the ibsc and cic markets and extend patent protection to the mid2030s data announced in dec 2016 showed that the colonic formulation led to improvements in pain relief over linzess phase iii studies are expected to begin in the second half of 2017 dr2 is being developed to improve abdominal pain relief in patients with additional gastrointestinal or gi disorders where lower abdominal pain is a predominant symptom such as nonconstipation subtypes of ibs phase iib dose ranging studies are expected to begin next year efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the us in mar 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us and promoting canasa ulcerative proctitis and delzicol ulcerative colitis in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including the fixeddose combination of lesinurad and allopurinol zurampic was launched in oct 2016 the fixeddose combination product duzallo is under fda review and is expected to be launched by late 2017 if approved the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million zacks equity research irwd wwwzackscom page 3 of 8,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'expand', 'target', 'patient', 'population', 'gain', 'approval', 'additional', 'indication', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'expect', 'boost', 'prescription', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release1', 'dr1', 'delay', 'release2', 'dr2', 'phase', 'iib', 'study', 'dr1', 'currently', 'underway', 'patient', 'ibsc', 'secondgeneration', 'guanylate', 'cyclasec', 'gcc', 'agonist', 'candidate', 'potential', 'provide', 'great', 'fast', 'abdominal', 'pain', 'relief', 'adult', 'ibsc', 'patient', 'expand', 'ibsc', 'cic', 'market', 'extend', 'patent', 'protection', 'mid2030s', 'datum', 'announce', 'dec', '2016', 'show', 'colonic', 'formulation', 'lead', 'improvement', 'pain', 'relief', 'linzess', 'phase', 'iii', 'study', 'expect', 'begin', 'second', 'half', '2017', 'dr2', 'develop', 'improve', 'abdominal', 'pain', 'relief', 'patient', 'additional', 'gastrointestinal', 'gi', 'disorder', 'low', 'abdominal', 'pain', 'predominant', 'symptom', 'nonconstipation', 'subtype', 'ibs', 'phase', 'iib', 'dose', 'range', 'study', 'expect', 'begin', 'year', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'mar', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'oct', '2016', 'fixeddose', 'combination', 'product', 'duzallo', 'fda', 'review', 'expect', 'launch', 'late', '2017', 'approve', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'zack', 'equity', 'research', 'irwd', 'wwwzackscom', 'page', '3', '8']",linzess label expansion effort ironwood allergan look broaden linzess label expand target patient population gain approval additional indication company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength expect boost prescription large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release1 dr1 delay release2 dr2 phase iib study dr1 currently underway patient ibsc secondgeneration guanylate cyclasec gcc agonist candidate potential provide great fast abdominal pain relief adult ibsc patient expand ibsc cic market extend patent protection mid2030s datum announce dec 2016 show colonic formulation lead improvement pain relief linzess phase iii study expect begin second half 2017 dr2 develop improve abdominal pain relief patient additional gastrointestinal gi disorder low abdominal pain predominant symptom nonconstipation subtype ibs phase iib dose range study expect begin year effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product mar 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include fixeddose combination lesinurad allopurinol zurampic launch oct 2016 fixeddose combination product duzallo fda review expect launch late 2017 approve company estimate uncontrolled gout market represent peak sale potential 300 million zack equity research irwd wwwzackscom page 3 8,15,26,-0.2619047619047619,15,26,-0.2619047619047619,0.9947
268,"Ironwood Pharmaceuticals, Inc._Attachment1(6).pdf",IRWD,4/18/2018,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies received fda approval for a 72 mcg dose for cic in january 2017 the new dose was launched in march 2017 the launch of this lower dose strength is boosting prescription trends in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 while a regulatory filing has been submitted in china for the indication decision expected in 1h another regulatory application seeking label expansion of linzess in chronic constipation is under review in japan linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing data from the study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the second half of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw1973 diabetic hypertension and iw1701 type ii achalasia phase iia commenced in 2016 in december 2017 ironwood announced positive topline data from the praliciguat diabetic hypertension study which showed blood pressure reduction and improvement in metabolic parameters meanwhile data from the iw1701 study is expected in 2018 meanwhile praliciguat is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease was initiated in december 2017,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'january', '2017', 'new', 'dose', 'launch', 'march', '2017', 'launch', 'low', 'dose', 'strength', 'boost', 'prescription', 'trend', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', '1h', 'regulatory', 'application', 'seek', 'label', 'expansion', 'linzess', 'chronic', 'constipation', 'review', 'japan', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'second', 'half', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'phase', 'iia', 'commence', '2016', 'december', '2017', 'ironwood', 'announce', 'positive', 'topline', 'datum', 'praliciguat', 'diabetic', 'hypertension', 'study', 'show', 'blood', 'pressure', 'reduction', 'improvement', 'metabolic', 'parameter', 'data', 'iw1701', 'study', 'expect', '2018', 'praliciguat', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'initiate', 'december', '2017']",linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company receive fda approval 72 mcg dose cic january 2017 new dose launch march 2017 launch low dose strength boost prescription trend large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan march 2017 regulatory filing submit china indication decision expect 1h regulatory application seek label expansion linzess chronic constipation review japan linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii second half 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw1973 diabetic hypertension iw1701 type ii achalasia phase iia commence 2016 december 2017 ironwood announce positive topline datum praliciguat diabetic hypertension study show blood pressure reduction improvement metabolic parameter data iw1701 study expect 2018 praliciguat evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease initiate december 2017,12,28,-0.3902439024390244,12,28,-0.3902439024390244,0.9584
269,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,5/18/2017,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label by expanding the targeted patient population and gaining approval for additional indications the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is expected to boost prescriptions in the large heterogeneous adult cic patient population meanwhile a phase iib study for a colonic formulation of linzess is currently underway in patients with ibsc this second generation guanylate cyclasec gcc agonist candidate has the potential to provide greater and faster abdominal pain relief in adult ibsc patients expand the ibsc and cic markets and extend patent protection to the mid2030s data announced in dec 2016 showed that the colonic formulation led to improvements in pain relief over linzess phase iii studies are expected to begin in the second half of 2017 ironwood and allergan are also developing linaclotide colonic release2 or cr2 to improve abdominal pain relief in patients with additional gastrointestinal or gi disorders where lower abdominal pain is a predominant symptom such as nonconstipation subtypes of ibs efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including the fixeddose combination of lesinurad and allopurinol zurampic was launched in oct 2016 the fixeddose combination product duzallo is under fda review and is expected to be launched by late 2017 if approved the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing with data expected in mid 2017 ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules iw1973 diabetic hypertension and iw1701 type ii zacks equity research irwd wwwzackscom page 3 of 8,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'expand', 'target', 'patient', 'population', 'gain', 'approval', 'additional', 'indication', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'expect', 'boost', 'prescription', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'phase', 'iib', 'study', 'colonic', 'formulation', 'linzess', 'currently', 'underway', 'patient', 'ibsc', 'second', 'generation', 'guanylate', 'cyclasec', 'gcc', 'agonist', 'candidate', 'potential', 'provide', 'great', 'fast', 'abdominal', 'pain', 'relief', 'adult', 'ibsc', 'patient', 'expand', 'ibsc', 'cic', 'market', 'extend', 'patent', 'protection', 'mid2030s', 'datum', 'announce', 'dec', '2016', 'show', 'colonic', 'formulation', 'lead', 'improvement', 'pain', 'relief', 'linzess', 'phase', 'iii', 'study', 'expect', 'begin', 'second', 'half', '2017', 'ironwood', 'allergan', 'develop', 'linaclotide', 'colonic', 'release2', 'cr2', 'improve', 'abdominal', 'pain', 'relief', 'patient', 'additional', 'gastrointestinal', 'gi', 'disorder', 'low', 'abdominal', 'pain', 'predominant', 'symptom', 'nonconstipation', 'subtype', 'ibs', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'oct', '2016', 'fixeddose', 'combination', 'product', 'duzallo', 'fda', 'review', 'expect', 'launch', 'late', '2017', 'approve', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'expect', 'mid', '2017', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'zacks', 'equity', 'research', 'irwd', 'wwwzackscom', 'page', '3', '8']",linzess label expansion effort ironwood allergan look broaden linzess label expand target patient population gain approval additional indication company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength expect boost prescription large heterogeneous adult cic patient population phase iib study colonic formulation linzess currently underway patient ibsc second generation guanylate cyclasec gcc agonist candidate potential provide great fast abdominal pain relief adult ibsc patient expand ibsc cic market extend patent protection mid2030s datum announce dec 2016 show colonic formulation lead improvement pain relief linzess phase iii study expect begin second half 2017 ironwood allergan develop linaclotide colonic release2 cr2 improve abdominal pain relief patient additional gastrointestinal gi disorder low abdominal pain predominant symptom nonconstipation subtype ibs effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include fixeddose combination lesinurad allopurinol zurampic launch oct 2016 fixeddose combination product duzallo fda review expect launch late 2017 approve company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum expect mid 2017 ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule iw1973 diabetic hypertension iw1701 type ii zacks equity research irwd wwwzackscom page 3 8,16,19,-0.08333333333333333,16,19,-0.08333333333333333,0.9939
270,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,11/21/2017,linzess approval a milestone the aug 2012 fda approval of linzess was a major milestone for ironwood linzess was launched in dec 2012 ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover cvscaremark has granted linzess an exclusive preferred position on its formulary beginning jan 1 2016 the company commenced a dtc campaign in mar 2016 which is driving both market share as well as overall market growth linzess has been showing rapid sales and prescription growth backed by new patient additions directtoconsumer dtc promotion broad payer access and continued strong demand linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is boosting prescription trends in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the us in mar 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the us and europe given allergans expertise and strong presence both in the us and eu markets we believe it is a suitable partner for ironwood ironwood is also copromoting viberzi ibsd with allergan in the us and promoting canasa ulcerative proctitis and delzicol ulcerative colitis in the us the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company meanwhile ironwood has a licensing agreement with astrazeneca for exclusive us rights to zurampic and all products containing lesinurad including the fixeddose combination of lesinurad and allopurinol zurampic was launched in oct 2016 a fixeddose combination product duzallo was launched in october 2017 duzallo addresses both causes of hyperuricemia in gout over production and underexcretion of serum uric acid in a single pill the company estimates that the uncontrolled gout market represents peak us sales potential of more than 300 million pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing data from the study presented in jul 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the second half of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules iw1973 diabetic hypertension and iw1701 type ii achalasia commenced in 2016 while data from the iw1973 study is expected by the end of 2017 that from the iw1701 study is expected in 2018 meanwhile iw1973 is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease is expected to be initiated by the end of 2017,buy,"['linzess', 'approval', 'milestone', 'aug', '2012', 'fda', 'approval', 'linzess', 'major', 'milestone', 'ironwood', 'linzess', 'launch', 'dec', '2012', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'beginning', 'jan', '1', '2016', 'company', 'commence', 'dtc', 'campaign', 'mar', '2016', 'drive', 'market', 'share', 'overall', 'market', 'growth', 'linzess', 'show', 'rapid', 'sale', 'prescription', 'growth', 'back', 'new', 'patient', 'addition', 'directtoconsumer', 'dtc', 'promotion', 'broad', 'payer', 'access', 'continue', 'strong', 'demand', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'boost', 'prescription', 'trend', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'mar', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'ironwood', 'copromote', 'viberzi', 'ibsd', 'allergan', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'ironwood', 'licensing', 'agreement', 'astrazeneca', 'exclusive', 'right', 'zurampic', 'product', 'contain', 'lesinurad', 'include', 'fixeddose', 'combination', 'lesinurad', 'allopurinol', 'zurampic', 'launch', 'oct', '2016', 'fixeddose', 'combination', 'product', 'duzallo', 'launch', 'october', '2017', 'duzallo', 'address', 'cause', 'hyperuricemia', 'gout', 'production', 'underexcretion', 'serum', 'uric', 'acid', 'single', 'pill', 'company', 'estimate', 'uncontrolled', 'gout', 'market', 'represent', 'peak', 'sale', 'potential', '300', 'million', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'study', 'present', 'jul', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'second', 'half', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'commence', '2016', 'datum', 'iw1973', 'study', 'expect', 'end', '2017', 'iw1701', 'study', 'expect', '2018', 'iw1973', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'expect', 'initiate', 'end', '2017']",linzess approval milestone aug 2012 fda approval linzess major milestone ironwood linzess launch dec 2012 ironwood work expand manage care access linzess lower ofpocket cost cvscaremark grant linzess exclusive preferred position formulary beginning jan 1 2016 company commence dtc campaign mar 2016 drive market share overall market growth linzess show rapid sale prescription growth back new patient addition directtoconsumer dtc promotion broad payer access continue strong demand linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength boost prescription trend large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product mar 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent strong partnership positive ironwood agreement allergan development commercialization linzess europe give allergan expertise strong presence eu market believe suitable partner ironwood ironwood copromote viberzi ibsd allergan promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company ironwood licensing agreement astrazeneca exclusive right zurampic product contain lesinurad include fixeddose combination lesinurad allopurinol zurampic launch oct 2016 fixeddose combination product duzallo launch october 2017 duzallo address cause hyperuricemia gout production underexcretion serum uric acid single pill company estimate uncontrolled gout market represent peak sale potential 300 million pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum study present jul 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii second half 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule iw1973 diabetic hypertension iw1701 type ii achalasia commence 2016 datum iw1973 study expect end 2017 iw1701 study expect 2018 iw1973 evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease expect initiate end 2017,18,35,-0.3148148148148148,18,35,-0.3148148148148148,0.9953
271,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,1/9/2018,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies received fda approval for a 72 mcg dose for cic in jan 2017 the new dose was launched in mar 2017 the launch of this lower dose strength is boosting prescription trends in the large heterogeneous adult cic patient population meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in mar 2017 while a regulatory filing has been submitted in china for the indication linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the us in mar 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with a phase iib doseranging refractory gastroesophageal reflux disease gerd study currently ongoing data from the study presented in jul 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the second half of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules iw1973 diabetic hypertension and iw1701 type ii achalasia commenced in 2016 while data from the iw1973 study is expected by the end of 2017 that from the iw1701 study is expected in 2018 meanwhile iw1973 is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease was initiated in december 2017,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'receive', 'fda', 'approval', '72', 'mcg', 'dose', 'cic', 'jan', '2017', 'new', 'dose', 'launch', 'mar', '2017', 'launch', 'low', 'dose', 'strength', 'boost', 'prescription', 'trend', 'large', 'heterogeneous', 'adult', 'cic', 'patient', 'population', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'mar', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'mar', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'currently', 'ongoing', 'datum', 'study', 'present', 'jul', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'second', 'half', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'commence', '2016', 'datum', 'iw1973', 'study', 'expect', 'end', '2017', 'iw1701', 'study', 'expect', '2018', 'iw1973', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'initiate', 'december', '2017']",linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company receive fda approval 72 mcg dose cic jan 2017 new dose launch mar 2017 launch low dose strength boost prescription trend large heterogeneous adult cic patient population ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan mar 2017 regulatory filing submit china indication linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product mar 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting phase iib doserange refractory gastroesophageal reflux disease gerd study currently ongoing datum study present jul 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii second half 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule iw1973 diabetic hypertension iw1701 type ii achalasia commence 2016 datum iw1973 study expect end 2017 iw1701 study expect 2018 iw1973 evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease initiate december 2017,10,27,-0.4473684210526316,10,27,-0.4473684210526316,0.8957
272,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,5/3/2018,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations meanwhile ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients meanwhile a phase iii study is expected to begin in 2018 which is looking to add two new symptoms associated with ibsc to linzess label bloating and discomfort efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 while a regulatory filing has been submitted in china for the indication decision expected in second quarter of another regulatory application seeking label expansion of linzess in chronic constipation is under review in japan pipeline progress to capture the lucrative gi market ironwood is developing several candidates iw3718 looks interesting with the company planning to advance it in phase iii studies in the third quarter of 2018 data from a phase iib doseranging refractory gastroesophageal reflux disease gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion and expects to advance iw3718 into phase iii in the second half of 2018 meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw1973 diabetic hypertension and iw1701 type ii achalasia phase iia commenced in 2016 meanwhile praliciguat is also being evaluated in phase ii studies in two indications heart failure with preserved ejection fraction hfpef and diabetic nephropathy dn a form of chronic kidney disease also a phase ii study of iw1701 in stable sickle cell disease was initiated in december 2017 meanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'phase', 'iii', 'study', 'expect', 'begin', '2018', 'look', 'add', 'new', 'symptom', 'associate', 'ibsc', 'linzess', 'label', 'bloat', 'discomfort', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'second', 'quarter', 'regulatory', 'application', 'seek', 'label', 'expansion', 'linzess', 'chronic', 'constipation', 'review', 'japan', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'iw3718', 'look', 'interesting', 'company', 'plan', 'advance', 'phase', 'iii', 'study', 'quarter', '2018', 'datum', 'phase', 'iib', 'doserange', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'expect', 'advance', 'iw3718', 'phase', 'iii', 'second', 'half', '2018', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw1973', 'diabetic', 'hypertension', 'iw1701', 'type', 'ii', 'achalasia', 'phase', 'iia', 'commence', '2016', 'praliciguat', 'evaluate', 'phase', 'ii', 'study', 'indication', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'diabetic', 'nephropathy', 'dn', 'form', 'chronic', 'kidney', 'disease', 'phase', 'ii', 'study', 'iw1701', 'stable', 'sickle', 'cell', 'disease', 'initiate', 'december', '2017', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient phase iii study expect begin 2018 look add new symptom associate ibsc linzess label bloat discomfort effort expand exus territory linzess launch ibsc japan march 2017 regulatory filing submit china indication decision expect second quarter regulatory application seek label expansion linzess chronic constipation review japan pipeline progress capture lucrative gi market ironwood develop candidate iw3718 look interesting company plan advance phase iii study quarter 2018 datum phase iib doserange refractory gastroesophageal reflux disease gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion expect advance iw3718 phase iii second half 2018 ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw1973 diabetic hypertension iw1701 type ii achalasia phase iia commence 2016 praliciguat evaluate phase ii study indication heart failure preserve ejection fraction hfpef diabetic nephropathy dn form chronic kidney disease phase ii study iw1701 stable sickle cell disease initiate december 2017 quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,9,21,-0.3870967741935484,9,21,-0.3870967741935484,-0.4404
273,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,9/14/2018,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space linzess has the potential to be a blockbuster product by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is targeting at least three additional launches of linzess by the end of 2018 starting with the lower dose 72 mcg of the product in the united states in march 2017 ironwood estimates that its ibsccic franchise including linzess and the colonic release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations ironwood and allergan are developing a delayed release formulation of linzess delayed release2 or dr2 to address new patient populations beyond ibsc and chronic constipation dr2 is being developed as a visceral nonopioid pain relieving agent for patients suffering from all ibs subtypes linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patients in july 2018 a phase iii study was initiated to expand linzess label in two new symptoms associated with ibsc bloating and discomfort moreover the company is currently designing a phase iib study to evaluate linzess delayed release formulation for treating all subtypes of ibs including ibsc ibs with diarrhea and ibsmixed efforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 while a regulatory filing has been submitted in china for the indication decision expected by the end of another regulatory application seeking label expansion of linzess in chronic constipation is under review in japan strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis and delzicol ulcerative colitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company pipeline progress to capture the lucrative gi market ironwood is developing several candidates in june 2018 the company initiated two phase iii studies to evaluate iw3718 in patients with persistent refractory gastroesophageal reflux disease gerd data from a phase iib doseranging gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies with the two lead molecules praliciguat iw and olinciguat iw the company is progressing praliciguat in two phase ii studies to evaluate it in diabetic nephropathy and heart failure with preserved ejection fraction hfpef topline from both the studies is expected in the second half of 2019 meanwhile two phase ii studies will evaluate olinciguat for treating sickle cell disease and achalasia data from the achalasia study is expected in the second half of 2018 the candidate enjoys orphan drug designation in the united states for sickle cell diseasemeanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'linzess', 'potential', 'blockbuster', 'product', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'target', 'additional', 'launch', 'linzess', 'end', '2018', 'start', 'low', 'dose', '72', 'mcg', 'product', 'united', 'states', 'march', '2017', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'colonic', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'dr2', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'dr2', 'develop', 'visceral', 'nonopioid', 'pain', 'relieve', 'agent', 'patient', 'suffer', 'ibs', 'subtype', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patient', 'july', '2018', 'phase', 'iii', 'study', 'initiate', 'expand', 'linzess', 'label', 'new', 'symptom', 'associate', 'ibsc', 'bloat', 'discomfort', 'company', 'currently', 'design', 'phase', 'iib', 'study', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'subtype', 'ibs', 'include', 'ibsc', 'ib', 'diarrhea', 'ibsmixed', 'effort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'end', 'regulatory', 'application', 'seek', 'label', 'expansion', 'linzess', 'chronic', 'constipation', 'review', 'japan', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'delzicol', 'ulcerative', 'colitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'june', '2018', 'company', 'initiate', 'phase', 'iii', 'study', 'evaluate', 'iw3718', 'patient', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'datum', 'phase', 'iib', 'doserange', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'lead', 'molecule', 'praliciguat', 'iw', 'olinciguat', 'iw', 'company', 'progress', 'praliciguat', 'phase', 'ii', 'study', 'evaluate', 'diabetic', 'nephropathy', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'topline', 'study', 'expect', 'second', 'half', '2019', 'phase', 'ii', 'study', 'evaluate', 'olinciguat', 'treat', 'sickle', 'cell', 'disease', 'achalasia', 'datum', 'achalasia', 'study', 'expect', 'second', 'half', '2018', 'candidate', 'enjoy', 'orphan', 'drug', 'designation', 'united', 'states', 'sickle', 'cell', 'diseasemeanwhile', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space linzess potential blockbuster product end 2020 ironwood expect annual sale linzess cross 1 billion company target additional launch linzess end 2018 start low dose 72 mcg product united states march 2017 ironwood estimate ibsccic franchise include linzess colonic release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 dr2 address new patient population ibsc chronic constipation dr2 develop visceral nonopioid pain relieve agent patient suffer ibs subtype linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patient july 2018 phase iii study initiate expand linzess label new symptom associate ibsc bloat discomfort company currently design phase iib study evaluate linzess delay release formulation treat subtype ibs include ibsc ib diarrhea ibsmixed effort expand exus territory linzess launch ibsc japan march 2017 regulatory filing submit china indication decision expect end regulatory application seek label expansion linzess chronic constipation review japan strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis delzicol ulcerative colitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company pipeline progress capture lucrative gi market ironwood develop candidate june 2018 company initiate phase iii study evaluate iw3718 patient persistent refractory gastroesophageal reflux disease gerd datum phase iib doserange gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study lead molecule praliciguat iw olinciguat iw company progress praliciguat phase ii study evaluate diabetic nephropathy heart failure preserve ejection fraction hfpef topline study expect second half 2019 phase ii study evaluate olinciguat treat sickle cell disease achalasia datum achalasia study expect second half 2018 candidate enjoy orphan drug designation united states sickle cell diseasemeanwhile quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,18,38,-0.3508771929824561,18,38,-0.3508771929824561,0.9965
274,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,1/8/2019,linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations ironwood and allergan are developing a delayed release formulation of linzess delayed release2 md to address new patient populations beyond ibsc and chronic constipation in july 2018 a phase iii study was initiated to expand linzess label in two new symptoms associated with ibsc bloating and discomfort moreover the company is planning to initiate a phase iib study in the first quarter of 2019 to evaluate linzess delayed release formulation for treating all subtypes of ibs including ibs c ibs with diarrhea and ibsmixed linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patientsefforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expanded to include chronic constipation in august 2018 while a regulatory filing has been submitted in china for the indication decision expected in early pipeline progress to capture the lucrative gi market ironwood is developing several candidates in june 2018 the company initiated two phase iii studies to evaluate iw3718 in patients with persistent refractory gastroesophageal reflux disease gerd data from a phase iib doseranging gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies are evaluating two lead molecules praliciguat iw and olinciguat iw the company is progressing praliciguat in two phase ii studies to evaluate it in diabetic nephropathy and heart failure with preserved ejection fraction hfpef topline from both the studies is expected in the second half of 2019 meanwhile a phase ii study is enrolling patients which will evaluate olinciguat for treating sickle cell disease although data from the achalasia study was positive the company will stop further development it has decided to focus on developing olinciguat for sickle cell disease as its represents significant opportunity the candidate enjoys orphan drug designation in the united states for sickle cell disease meanwhile in its first quarter earnings call ironwood announced that it will transfer its sgc pipeline to a separate entity which will allow the company to have better focus on development and strategic opportunity in future,sell,"['linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'md', 'address', 'new', 'patient', 'population', 'ibsc', 'chronic', 'constipation', 'july', '2018', 'phase', 'iii', 'study', 'initiate', 'expand', 'linzess', 'label', 'new', 'symptom', 'associate', 'ibsc', 'bloat', 'discomfort', 'company', 'plan', 'initiate', 'phase', 'iib', 'study', 'quarter', '2019', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'subtype', 'ibs', 'include', 'ibs', 'c', 'ibs', 'diarrhea', 'ibsmixed', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patientseffort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expand', 'include', 'chronic', 'constipation', 'august', '2018', 'regulatory', 'filing', 'submit', 'china', 'indication', 'decision', 'expect', 'early', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'june', '2018', 'company', 'initiate', 'phase', 'iii', 'study', 'evaluate', 'iw3718', 'patient', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'datum', 'phase', 'iib', 'doserange', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'evaluate', 'lead', 'molecule', 'praliciguat', 'iw', 'olinciguat', 'iw', 'company', 'progress', 'praliciguat', 'phase', 'ii', 'study', 'evaluate', 'diabetic', 'nephropathy', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'topline', 'study', 'expect', 'second', 'half', '2019', 'phase', 'ii', 'study', 'enrol', 'patient', 'evaluate', 'olinciguat', 'treat', 'sickle', 'cell', 'disease', 'datum', 'achalasia', 'study', 'positive', 'company', 'stop', 'development', 'decide', 'focus', 'develop', 'olinciguat', 'sickle', 'cell', 'disease', 'represent', 'significant', 'opportunity', 'candidate', 'enjoy', 'orphan', 'drug', 'designation', 'united', 'states', 'sickle', 'cell', 'disease', 'quarter', 'earning', 'ironwood', 'announce', 'transfer', 'sgc', 'pipeline', 'separate', 'entity', 'allow', 'company', 'well', 'focus', 'development', 'strategic', 'opportunity', 'future']",linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation ironwood allergan develop delay release formulation linzess delay release2 md address new patient population ibsc chronic constipation july 2018 phase iii study initiate expand linzess label new symptom associate ibsc bloat discomfort company plan initiate phase iib study quarter 2019 evaluate linzess delay release formulation treat subtype ibs include ibs c ibs diarrhea ibsmixed linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patientseffort expand exus territory linzess launch ibsc japan march 2017 label expand include chronic constipation august 2018 regulatory filing submit china indication decision expect early pipeline progress capture lucrative gi market ironwood develop candidate june 2018 company initiate phase iii study evaluate iw3718 patient persistent refractory gastroesophageal reflux disease gerd datum phase iib doserange gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study evaluate lead molecule praliciguat iw olinciguat iw company progress praliciguat phase ii study evaluate diabetic nephropathy heart failure preserve ejection fraction hfpef topline study expect second half 2019 phase ii study enrol patient evaluate olinciguat treat sickle cell disease datum achalasia study positive company stop development decide focus develop olinciguat sickle cell disease represent significant opportunity candidate enjoy orphan drug designation united states sickle cell disease quarter earning ironwood announce transfer sgc pipeline separate entity allow company well focus development strategic opportunity future,10,29,-0.475,10,29,-0.475,0.9584
275,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,3/25/2019,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space these initiatives have supported the drugs growth linzess has the potential to be a blockbuster product with global sales crossing 750 million in 2018 by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is also progressing well with development of the drug in japan and china per iqvia data linzess is the leading prescribed drug for adult patients in the united states with ibsc or cic ironwood estimates that its ibsccic franchise including linzess and the delayed release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies are conducting a phase iii study to expand linzess label in additional abdominal symptoms associated with ibsc including bloating and discomfort a label expansion in pediatric patients is also being plannedironwood and allergan are developing a delayed release formulation of linzess delayed release2 md to address patient populations suffering from all forms of ibs the company is planning to initiate a phase ii study in the second quarter of 2019 to evaluate linzess delayed release formulation for treating ibsd linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patientsefforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expanded to include chronic constipation in august 2018 in january 2019 the drug was approved for ibsc in china strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states and promoting canasa ulcerative proctitis the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenue for ironwood additional partnerships in other territories will be a positive for the company pipeline progress to capture the lucrative gi market ironwood is developing several candidates in june 2018 the company initiated two phase iii studies to evaluate iw3718 in patients with persistent refractory gastroesophageal reflux disease gerd data from a phase iib doseranging gerd study presented in july 2017 showed that iw3718 led to a significant reduction in heartburn severity in patients with uncontrolled gerd ironwood believes that iw3718 represents peak sales potential of more than 2 billion meanwhile ironwood is exploring five soluble guanylate cyclase sgc stimulators for the treatment of vascular and fibrotic diseases however it is on track to transfer these candidates to cyclerion after separation the company expects this platform to deliver multiple products a number of which could generate peak sales exceeding 1 billion phase ii proof of concept studies are evaluating two lead molecules praliciguat iw and olinciguat iw the company is progressing praliciguat in two phase ii studies to evaluate it in diabetic nephropathy and heart failure with preserved ejection fraction hfpef topline data from both the studies is expected in the second half of 2019 meanwhile a phase ii study is enrolling patients which will evaluate olinciguat for treating sickle cell disease data from the study is expected in the second half of 2019 the candidate enjoys orphan drug designation in the united states for sickle cell disease apart from these two the company has one earlystage candidate iw6463 which is being developed for central nervous system cns disorders and two latestage candidates targeting serious liver and lung diseases spinoff of cyclerion encouraging ironwoods plan to separate its sgc pipeline into a separate entity cyclerion is expected to be a positive the transaction is likely to bring down research and development costs significantly the company will also be able to put more efforts in building its gi products especially linzess moreover the spinoff along with some restructuring initiatives will also reduce the workforce lowering operating expenses further,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'initiative', 'support', 'drug', 'growth', 'linzess', 'potential', 'blockbuster', 'product', 'global', 'sale', 'cross', '750', 'million', '2018', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'progress', 'development', 'drug', 'japan', 'china', 'iqvia', 'datum', 'linzess', 'lead', 'prescribe', 'drug', 'adult', 'patient', 'united', 'states', 'ibsc', 'cic', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'delay', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'conduct', 'phase', 'iii', 'study', 'expand', 'linzess', 'label', 'additional', 'abdominal', 'symptom', 'associate', 'ibsc', 'include', 'bloat', 'discomfort', 'label', 'expansion', 'pediatric', 'patient', 'plannedironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'md', 'address', 'patient', 'population', 'suffer', 'form', 'ibs', 'company', 'plan', 'initiate', 'phase', 'ii', 'study', 'second', 'quarter', '2019', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'ibsd', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patientseffort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expand', 'include', 'chronic', 'constipation', 'august', '2018', 'january', '2019', 'drug', 'approve', 'ibsc', 'china', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'promote', 'canasa', 'ulcerative', 'proctitis', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'pipeline', 'progress', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'june', '2018', 'company', 'initiate', 'phase', 'iii', 'study', 'evaluate', 'iw3718', 'patient', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'datum', 'phase', 'iib', 'doserange', 'gerd', 'study', 'present', 'july', '2017', 'show', 'iw3718', 'lead', 'significant', 'reduction', 'heartburn', 'severity', 'patient', 'uncontrolled', 'gerd', 'ironwood', 'believe', 'iw3718', 'represent', 'peak', 'sale', 'potential', '2', 'billion', 'ironwood', 'explore', 'soluble', 'guanylate', 'cyclase', 'sgc', 'stimulator', 'treatment', 'vascular', 'fibrotic', 'disease', 'track', 'transfer', 'candidate', 'cyclerion', 'separation', 'company', 'expect', 'platform', 'deliver', 'multiple', 'product', 'number', 'generate', 'peak', 'sale', 'exceed', '1', 'billion', 'phase', 'ii', 'proof', 'concept', 'study', 'evaluate', 'lead', 'molecule', 'praliciguat', 'iw', 'olinciguat', 'iw', 'company', 'progress', 'praliciguat', 'phase', 'ii', 'study', 'evaluate', 'diabetic', 'nephropathy', 'heart', 'failure', 'preserve', 'ejection', 'fraction', 'hfpef', 'topline', 'datum', 'study', 'expect', 'second', 'half', '2019', 'phase', 'ii', 'study', 'enrol', 'patient', 'evaluate', 'olinciguat', 'treat', 'sickle', 'cell', 'disease', 'datum', 'study', 'expect', 'second', 'half', '2019', 'candidate', 'enjoy', 'orphan', 'drug', 'designation', 'united', 'states', 'sickle', 'cell', 'disease', 'apart', 'company', 'earlystage', 'candidate', 'iw6463', 'develop', 'central', 'nervous', 'system', 'cns', 'disorder', 'latestage', 'candidate', 'target', 'liver', 'lung', 'disease', 'spinoff', 'cyclerion', 'encourage', 'ironwood', 'plan', 'separate', 'sgc', 'pipeline', 'separate', 'entity', 'cyclerion', 'expect', 'positive', 'transaction', 'likely', 'bring', 'research', 'development', 'cost', 'significantly', 'company', 'able', 'effort', 'build', 'gi', 'product', 'especially', 'linzess', 'spinoff', 'restructuring', 'initiative', 'reduce', 'workforce', 'lower', 'operating', 'expense']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space initiative support drug growth linzess potential blockbuster product global sale cross 750 million 2018 end 2020 ironwood expect annual sale linzess cross 1 billion company progress development drug japan china iqvia datum linzess lead prescribe drug adult patient united states ibsc cic ironwood estimate ibsccic franchise include linzess delay release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company conduct phase iii study expand linzess label additional abdominal symptom associate ibsc include bloat discomfort label expansion pediatric patient plannedironwood allergan develop delay release formulation linzess delay release2 md address patient population suffer form ibs company plan initiate phase ii study second quarter 2019 evaluate linzess delay release formulation treat ibsd linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patientseffort expand exus territory linzess launch ibsc japan march 2017 label expand include chronic constipation august 2018 january 2019 drug approve ibsc china strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states promote canasa ulcerative proctitis company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company pipeline progress capture lucrative gi market ironwood develop candidate june 2018 company initiate phase iii study evaluate iw3718 patient persistent refractory gastroesophageal reflux disease gerd datum phase iib doserange gerd study present july 2017 show iw3718 lead significant reduction heartburn severity patient uncontrolled gerd ironwood believe iw3718 represent peak sale potential 2 billion ironwood explore soluble guanylate cyclase sgc stimulator treatment vascular fibrotic disease track transfer candidate cyclerion separation company expect platform deliver multiple product number generate peak sale exceed 1 billion phase ii proof concept study evaluate lead molecule praliciguat iw olinciguat iw company progress praliciguat phase ii study evaluate diabetic nephropathy heart failure preserve ejection fraction hfpef topline datum study expect second half 2019 phase ii study enrol patient evaluate olinciguat treat sickle cell disease datum study expect second half 2019 candidate enjoy orphan drug designation united states sickle cell disease apart company earlystage candidate iw6463 develop central nervous system cns disorder latestage candidate target liver lung disease spinoff cyclerion encourage ironwood plan separate sgc pipeline separate entity cyclerion expect positive transaction likely bring research development cost significantly company able effort build gi product especially linzess spinoff restructuring initiative reduce workforce lower operating expense,21,41,-0.31746031746031744,21,41,-0.31746031746031744,0.9971
276,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,5/20/2019,linzess performance encouraging following the approval of linzess in 2012 the sales of the drug has grown significantly on back of strong demand ironwood is working on expanding managed care access to linzess and lowering out ofpocket costs moreover since 2016 cvscaremark has granted linzess an exclusive preferred position on its formulary the company commenced a new directto consumer dtc campaign in april 2018 focusing on digital space as well as the social media space these initiatives have supported the drugs growth linzess has the potential to be a blockbuster product with global sales crossing 750 million in 2018 by the end of 2020 ironwood expects annual sales of linzess to cross 1 billion the company is also progressing well with development of the drug in japan and china per iqvia data linzess is the leading prescribed drug for adult patients in the united states with ibsc or cic ironwood estimates that its ibsccic franchise including linzess and the delayed release formulation upon approval may represent a peak us sales opportunity of over 2 billion with additional global potential moreover linzess is well protected by patents and is unlikely to face generic competition before 2031 ironwood and allergan are working to strengthen the patent further linzess label expansion efforts ironwood and allergan are looking to broaden linzess label to include new indications populations and formulations the companies are conducting a phase iii study to expand linzess label in additional abdominal symptoms associated with ibsc including bloating and discomfort topline data from the study is expected by mid2019 a label expansion in pediatric patients is also being planned ironwood and allergan are developing a delayed release formulation of linzess delayed release2 md to address patient populations suffering from all forms of ibs the company is planning to initiate a phase ii study in the second quarter of 2019 to evaluate linzess delayed release formulation for treating ibsd linzess is also being evaluated as a potential treatment of the gi dysfunction associated with opioidinduced constipation or oic and in pediatric studies in ibsc patientsefforts are on to expand in exus territories as well linzess was launched for ibsc in japan in march 2017 and its label was expanded to include chronic constipation in august 2018 in january 2019 the drug was approved for ibsc in china meanwhile to capture the lucrative gi market ironwood is developing several candidates the most advanced pipeline candidate is iw3718 which is being evaluated in phase iii studies for treating persistent refractory gastroesophageal reflux disease gerd strong partnerships we are positive on ironwoods agreement with allergan for the development and commercialization of linzess both in the united states and europe given allergans expertise and strong presence both in the united states and eu markets we believe it is a suitable partner for ironwood the company is copromoting viberzi ibsd with allergan in the united states the company also has a deal with astellas for the development of linzess in japan ironwood has an agreement with astrazeneca for linzess in china hong kong and macau the collaborations have not only reduced the cost of developing the drug these also act as a source of revenues for ironwood additional partnerships in other territories will be a positive for the company spinoff of cyclerion encouraging ironwoods separation of its sgc pipeline into a separate entity cyclerion should be a positive the transaction is likely to bring down research and development costs significantly the company will also be able to put more efforts in building its gi products especially linzess moreover the spinoff along with some restructuring initiatives will also reduce the workforce lowering operating expenses further,buy,"['linzess', 'performance', 'encourage', 'follow', 'approval', 'linzess', '2012', 'sale', 'drug', 'grow', 'significantly', 'strong', 'demand', 'ironwood', 'work', 'expand', 'manage', 'care', 'access', 'linzess', 'lower', 'ofpocket', 'cost', '2016', 'cvscaremark', 'grant', 'linzess', 'exclusive', 'preferred', 'position', 'formulary', 'company', 'commence', 'new', 'directto', 'consumer', 'dtc', 'campaign', 'april', '2018', 'focus', 'digital', 'space', 'social', 'medium', 'space', 'initiative', 'support', 'drug', 'growth', 'linzess', 'potential', 'blockbuster', 'product', 'global', 'sale', 'cross', '750', 'million', '2018', 'end', '2020', 'ironwood', 'expect', 'annual', 'sale', 'linzess', 'cross', '1', 'billion', 'company', 'progress', 'development', 'drug', 'japan', 'china', 'iqvia', 'datum', 'linzess', 'lead', 'prescribe', 'drug', 'adult', 'patient', 'united', 'states', 'ibsc', 'cic', 'ironwood', 'estimate', 'ibsccic', 'franchise', 'include', 'linzess', 'delay', 'release', 'formulation', 'approval', 'represent', 'peak', 'sale', 'opportunity', '2', 'billion', 'additional', 'global', 'potential', 'linzess', 'protect', 'patent', 'unlikely', 'face', 'generic', 'competition', '2031', 'ironwood', 'allergan', 'work', 'strengthen', 'patent', 'linzess', 'label', 'expansion', 'effort', 'ironwood', 'allergan', 'look', 'broaden', 'linzess', 'label', 'include', 'new', 'indication', 'population', 'formulation', 'company', 'conduct', 'phase', 'iii', 'study', 'expand', 'linzess', 'label', 'additional', 'abdominal', 'symptom', 'associate', 'ibsc', 'include', 'bloat', 'discomfort', 'topline', 'datum', 'study', 'expect', 'mid2019', 'label', 'expansion', 'pediatric', 'patient', 'plan', 'ironwood', 'allergan', 'develop', 'delay', 'release', 'formulation', 'linzess', 'delay', 'release2', 'md', 'address', 'patient', 'population', 'suffer', 'form', 'ibs', 'company', 'plan', 'initiate', 'phase', 'ii', 'study', 'second', 'quarter', '2019', 'evaluate', 'linzess', 'delay', 'release', 'formulation', 'treat', 'ibsd', 'linzess', 'evaluate', 'potential', 'treatment', 'gi', 'dysfunction', 'associate', 'opioidinduce', 'constipation', 'oic', 'pediatric', 'study', 'ibsc', 'patientseffort', 'expand', 'exus', 'territory', 'linzess', 'launch', 'ibsc', 'japan', 'march', '2017', 'label', 'expand', 'include', 'chronic', 'constipation', 'august', '2018', 'january', '2019', 'drug', 'approve', 'ibsc', 'china', 'capture', 'lucrative', 'gi', 'market', 'ironwood', 'develop', 'candidate', 'advanced', 'pipeline', 'candidate', 'iw3718', 'evaluate', 'phase', 'iii', 'study', 'treat', 'persistent', 'refractory', 'gastroesophageal', 'reflux', 'disease', 'gerd', 'strong', 'partnership', 'positive', 'ironwood', 'agreement', 'allergan', 'development', 'commercialization', 'linzess', 'united', 'states', 'europe', 'give', 'allergan', 'expertise', 'strong', 'presence', 'united', 'states', 'eu', 'market', 'believe', 'suitable', 'partner', 'ironwood', 'company', 'copromote', 'viberzi', 'ibsd', 'allergan', 'united', 'states', 'company', 'deal', 'astella', 'development', 'linzess', 'japan', 'ironwood', 'agreement', 'astrazeneca', 'linzess', 'china', 'hong', 'kong', 'macau', 'collaboration', 'reduce', 'cost', 'develop', 'drug', 'act', 'source', 'revenue', 'ironwood', 'additional', 'partnership', 'territory', 'positive', 'company', 'spinoff', 'cyclerion', 'encourage', 'ironwood', 'separation', 'sgc', 'pipeline', 'separate', 'entity', 'cyclerion', 'positive', 'transaction', 'likely', 'bring', 'research', 'development', 'cost', 'significantly', 'company', 'able', 'effort', 'build', 'gi', 'product', 'especially', 'linzess', 'spinoff', 'restructuring', 'initiative', 'reduce', 'workforce', 'lower', 'operating', 'expense']",linzess performance encourage follow approval linzess 2012 sale drug grow significantly strong demand ironwood work expand manage care access linzess lower ofpocket cost 2016 cvscaremark grant linzess exclusive preferred position formulary company commence new directto consumer dtc campaign april 2018 focus digital space social medium space initiative support drug growth linzess potential blockbuster product global sale cross 750 million 2018 end 2020 ironwood expect annual sale linzess cross 1 billion company progress development drug japan china iqvia datum linzess lead prescribe drug adult patient united states ibsc cic ironwood estimate ibsccic franchise include linzess delay release formulation approval represent peak sale opportunity 2 billion additional global potential linzess protect patent unlikely face generic competition 2031 ironwood allergan work strengthen patent linzess label expansion effort ironwood allergan look broaden linzess label include new indication population formulation company conduct phase iii study expand linzess label additional abdominal symptom associate ibsc include bloat discomfort topline datum study expect mid2019 label expansion pediatric patient plan ironwood allergan develop delay release formulation linzess delay release2 md address patient population suffer form ibs company plan initiate phase ii study second quarter 2019 evaluate linzess delay release formulation treat ibsd linzess evaluate potential treatment gi dysfunction associate opioidinduce constipation oic pediatric study ibsc patientseffort expand exus territory linzess launch ibsc japan march 2017 label expand include chronic constipation august 2018 january 2019 drug approve ibsc china capture lucrative gi market ironwood develop candidate advanced pipeline candidate iw3718 evaluate phase iii study treat persistent refractory gastroesophageal reflux disease gerd strong partnership positive ironwood agreement allergan development commercialization linzess united states europe give allergan expertise strong presence united states eu market believe suitable partner ironwood company copromote viberzi ibsd allergan united states company deal astella development linzess japan ironwood agreement astrazeneca linzess china hong kong macau collaboration reduce cost develop drug act source revenue ironwood additional partnership territory positive company spinoff cyclerion encourage ironwood separation sgc pipeline separate entity cyclerion positive transaction likely bring research development cost significantly company able effort build gi product especially linzess spinoff restructuring initiative reduce workforce lower operating expense,17,30,-0.2708333333333333,17,30,-0.2708333333333333,0.9967
277,"Ironwood Pharmaceuticals, Inc._Attachment1.pdf",IRWD,12/9/2019,overdependence on linzess while we are pleased with the performance of linzess we are concerned about the companys dependence on the product for growth any negative news related to linzess would adversely impact the company and its growth prospects although the performance of linzess improved in 2018 customer buying patterns can have unfavorable impact in future years as seen earlier moreover the product is more than a year away from achieving blockbuster status,sell,"['overdependence', 'linzess', 'pleased', 'performance', 'linzess', 'concerned', 'company', 'dependence', 'product', 'growth', 'negative', 'news', 'relate', 'linzess', 'adversely', 'impact', 'company', 'growth', 'prospect', 'performance', 'linzess', 'improve', '2018', 'customer', 'buying', 'pattern', 'unfavorable', 'impact', 'future', 'year', 'see', 'early', 'product', 'year', 'away', 'achieve', 'blockbuster', 'status']",overdependence linzess pleased performance linzess concerned company dependence product growth negative news relate linzess adversely impact company growth prospect performance linzess improve 2018 customer buying pattern unfavorable impact future year see early product year away achieve blockbuster status,4,4,0.0,4,4,0.0,0.891
278,"Merrimack Pharmaceuticals, Inc._Attachment1(2).pdf",MACK,5/15/2017,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack expects 575 million upfront cash payment from ipsen upon the closing of the asset sale and up to 450 million as milestone payments the company intends to use these proceeds to declare and pay a special cash dividend of at least 200 million to stockholders and use an additional 1951 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 the company plans to invest 175 million from the proceeds of the sale to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its three pipeline candidates mm121 mm141 and mm 310 mm121 is being evaluated for the treatment of nonsmall cell lung cancer trial in an ongoing trial the candidate will also be evaluated in a more focused proofofconcept study with topline data expected by the end of 2018 the company also plans to evaluate the candidate in a phase ii clinical study in her2 negative hormone receptor and heregulin positive breast cancer patients in 2017 mm141 a monoclonal antibody targets both the her3 and the igf1 receptors the company is evaluating the drug in pancreatic cancer patients with increased levels of the igf1 biomarker and has retooled the ongoing phase ii study into a proofof concept trial and anticipates topline data in 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study and the company expects to report the recommended phase to dose in 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'expect', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', '450', 'million', 'milestone', 'payment', 'company', 'intend', 'use', 'proceed', 'declare', 'pay', 'special', 'cash', 'dividend', '200', 'million', 'stockholder', 'use', 'additional', '1951', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'plan', 'invest', '175', 'million', 'proceed', 'sale', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm141', 'mm', '310', 'mm121', 'evaluate', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'candidate', 'evaluate', 'focused', 'proofofconcept', 'study', 'topline', 'datum', 'expect', 'end', '2018', 'company', 'plan', 'evaluate', 'candidate', 'phase', 'ii', 'clinical', 'study', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'breast', 'cancer', 'patient', '2017', 'mm141', 'monoclonal', 'antibody', 'target', 'her3', 'igf1', 'receptor', 'company', 'evaluate', 'drug', 'pancreatic', 'cancer', 'patient', 'increase', 'level', 'igf1', 'biomarker', 'retool', 'ongoing', 'phase', 'ii', 'study', 'proofof', 'concept', 'trial', 'anticipate', 'topline', 'datum', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'company', 'expect', 'report', 'recommend', 'phase', 'dose', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack expect 575 million upfront cash payment ipsen closing asset sale 450 million milestone payment company intend use proceed declare pay special cash dividend 200 million stockholder use additional 1951 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company plan invest 175 million proceed sale develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm141 mm 310 mm121 evaluate treatment nonsmall cell lung cancer trial ongoing trial candidate evaluate focused proofofconcept study topline datum expect end 2018 company plan evaluate candidate phase ii clinical study her2 negative hormone receptor heregulin positive breast cancer patient 2017 mm141 monoclonal antibody target her3 igf1 receptor company evaluate drug pancreatic cancer patient increase level igf1 biomarker retool ongoing phase ii study proofof concept trial anticipate topline datum 2018 mm310 antibody direct nanoliposome currently phase study company expect report recommend phase dose 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility,7,17,-0.4,7,17,-0.4,0.9485
279,"Merrimack Pharmaceuticals, Inc._Attachment1(2).pdf",MACK,10/10/2018,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its two pipeline candidates mm121 and mm310 mm 121 in combination with sanofis taxotere is being evaluated in a phase ii study sherloc for the treatment of nonsmall cell lung cancer trial in an ongoing trial and completed enrollment in the ongoing phase ii study the fda granted mm121 orphan drug designation for this indication the study was amended to be a more focused proofofconcept study and increased patient population with topline data expected in the second half of 2018 the company is also evaluating the candidate in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients the company expects to report topline results from the sherloc clinical trial during the second half of 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm310', 'mm', '121', 'combination', 'sanofis', 'taxotere', 'evaluate', 'phase', 'ii', 'study', 'sherloc', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'complete', 'enrollment', 'ongoing', 'phase', 'ii', 'study', 'fda', 'grant', 'mm121', 'orphan', 'drug', 'designation', 'indication', 'study', 'amend', 'focused', 'proofofconcept', 'study', 'increase', 'patient', 'population', 'topline', 'datum', 'expect', 'second', 'half', '2018', 'company', 'evaluate', 'candidate', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', 'company', 'expect', 'report', 'topline', 'result', 'sherloc', 'clinical', 'trial', 'second', 'half', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm310 mm 121 combination sanofis taxotere evaluate phase ii study sherloc treatment nonsmall cell lung cancer trial ongoing trial complete enrollment ongoing phase ii study fda grant mm121 orphan drug designation indication study amend focused proofofconcept study increase patient population topline datum expect second half 2018 company evaluate candidate combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient company expect report topline result sherloc clinical trial second half 2018 mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,7,17,-0.4,7,17,-0.4,0.9732
280,"Merrimack Pharmaceuticals, Inc._Attachment1(3).pdf",MACK,10/24/2018,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its two pipeline candidates mm121 and mm310 the company is evaluating mm121 in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm310', 'company', 'evaluate', 'mm121', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm310 company evaluate mm121 combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,7,13,-0.2857142857142857,7,13,-0.2857142857142857,0.9698
281,"Merrimack Pharmaceuticals, Inc._Attachment1(3).pdf",MACK,10/24/2018,no approved products merrimack undertook divestment strategies in order to repay debt and focus on the development of pipeline candidates further the company sold its only marketed drug onivyde the sale included commercialization rights in the united states and its licensing agreement with shire ipsen also purchased merrimacks generic version of doxil merrimack is back to being a developmentstage biopharmaceutical company the revenue generation is anticipated to fluctuate forthcoming quarters pipeline candidates still in mid or early stages of development although onivydes launch was disappointing it was the only marketed drug in merrimacks portfolio the companys pipeline currently comprises early and midstage candidates and an unfavorable outcome of any of the development programs would adversely impact shares in december 2016 the company discontinued its phase ii trial on its breast cancer candidate mm302 based on an independent data and safety monitoring board dsmb recommendation that the continuation of the trial is unlikely to demonstrate benefit over the comparator treatments which was confirmed by a subsequent futility analysis notably merrimack faced a major pipeline setback in june 2018 when it stopped developing mm141 post disappointing results from a phase ii analysis carrie for the treatment of frontline metastatic pancreatic cancer in october 2018 merrimack faced another pipeline setback when it decided to terminate the phase ii sherloc study on mm121 due to futility the study did not improve progression free survival in patients with heregulin positive nsclc,sell,"['approve', 'product', 'merrimack', 'undertake', 'divestment', 'strategy', 'order', 'repay', 'debt', 'focus', 'development', 'pipeline', 'candidate', 'company', 'sell', 'market', 'drug', 'onivyde', 'sale', 'include', 'commercialization', 'right', 'united', 'states', 'licensing', 'agreement', 'shire', 'ipsen', 'purchase', 'merrimack', 'generic', 'version', 'doxil', 'merrimack', 'developmentstage', 'biopharmaceutical', 'company', 'revenue', 'generation', 'anticipate', 'fluctuate', 'forthcoming', 'quarter', 'pipeline', 'candidate', 'mid', 'early', 'stage', 'development', 'onivyde', 'launch', 'disappointing', 'market', 'drug', 'merrimack', 'portfolio', 'companys', 'pipeline', 'currently', 'comprise', 'early', 'midstage', 'candidate', 'unfavorable', 'outcome', 'development', 'program', 'adversely', 'impact', 'share', 'december', '2016', 'company', 'discontinue', 'phase', 'ii', 'trial', 'breast', 'cancer', 'candidate', 'mm302', 'base', 'independent', 'datum', 'safety', 'monitoring', 'board', 'dsmb', 'recommendation', 'continuation', 'trial', 'unlikely', 'demonstrate', 'benefit', 'comparator', 'treatment', 'confirm', 'subsequent', 'futility', 'analysis', 'notably', 'merrimack', 'face', 'major', 'pipeline', 'setback', 'june', '2018', 'stop', 'develop', 'mm141', 'post', 'disappointing', 'result', 'phase', 'ii', 'analysis', 'carrie', 'treatment', 'frontline', 'metastatic', 'pancreatic', 'cancer', 'october', '2018', 'merrimack', 'face', 'pipeline', 'setback', 'decide', 'terminate', 'phase', 'ii', 'sherloc', 'study', 'mm121', 'futility', 'study', 'improve', 'progression', 'free', 'survival', 'patient', 'heregulin', 'positive', 'nsclc']",approve product merrimack undertake divestment strategy order repay debt focus development pipeline candidate company sell market drug onivyde sale include commercialization right united states licensing agreement shire ipsen purchase merrimack generic version doxil merrimack developmentstage biopharmaceutical company revenue generation anticipate fluctuate forthcoming quarter pipeline candidate mid early stage development onivyde launch disappointing market drug merrimack portfolio companys pipeline currently comprise early midstage candidate unfavorable outcome development program adversely impact share december 2016 company discontinue phase ii trial breast cancer candidate mm302 base independent datum safety monitoring board dsmb recommendation continuation trial unlikely demonstrate benefit comparator treatment confirm subsequent futility analysis notably merrimack face major pipeline setback june 2018 stop develop mm141 post disappointing result phase ii analysis carrie treatment frontline metastatic pancreatic cancer october 2018 merrimack face pipeline setback decide terminate phase ii sherloc study mm121 futility study improve progression free survival patient heregulin positive nsclc,4,14,-0.5263157894736842,4,14,-0.5263157894736842,0.2732
282,"Merrimack Pharmaceuticals, Inc._Attachment1(4).pdf",MACK,7/11/2017,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company intends to use these proceeds to declare and pay a special cash dividend of at least 200 million to stockholders and use an additional 1951 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 the company plans to invest 175 million from the proceeds of the sale to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its three pipeline candidates mm121 mm141 and mm310 mm121 is being evaluated for the treatment of nonsmall cell lung cancer trial in an ongoing trial the candidate will also be evaluated in a more focused proofofconcept study with topline data expected by the end of 2018 the company also plans to evaluate the candidate in her2 negative hormone receptor and heregulin positive breast cancer patients in 2017 mm 141 a monoclonal antibody targets both the her3 and the igf1 receptors the company is evaluating the drug in pancreatic cancer patients with increased levels of the igf1 biomarker and anticipates topline data in first half of 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study and the company expects to report the recommended phase to dose in 2018,sell,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'intend', 'use', 'proceed', 'declare', 'pay', 'special', 'cash', 'dividend', '200', 'million', 'stockholder', 'use', 'additional', '1951', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'plan', 'invest', '175', 'million', 'proceed', 'sale', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm141', 'mm310', 'mm121', 'evaluate', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'candidate', 'evaluate', 'focused', 'proofofconcept', 'study', 'topline', 'datum', 'expect', 'end', '2018', 'company', 'plan', 'evaluate', 'candidate', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'breast', 'cancer', 'patient', '2017', 'mm', '141', 'monoclonal', 'antibody', 'target', 'her3', 'igf1', 'receptor', 'company', 'evaluate', 'drug', 'pancreatic', 'cancer', 'patient', 'increase', 'level', 'igf1', 'biomarker', 'anticipate', 'topline', 'datum', 'half', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'company', 'expect', 'report', 'recommend', 'phase', 'dose', '2018']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company intend use proceed declare pay special cash dividend 200 million stockholder use additional 1951 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company plan invest 175 million proceed sale develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm141 mm310 mm121 evaluate treatment nonsmall cell lung cancer trial ongoing trial candidate evaluate focused proofofconcept study topline datum expect end 2018 company plan evaluate candidate her2 negative hormone receptor heregulin positive breast cancer patient 2017 mm 141 monoclonal antibody target her3 igf1 receptor company evaluate drug pancreatic cancer patient increase level igf1 biomarker anticipate topline datum half 2018 mm310 antibody direct nanoliposome currently phase study company expect report recommend phase dose 2018,3,11,-0.5333333333333333,3,11,-0.5333333333333333,0.0258
283,"Merrimack Pharmaceuticals, Inc._Attachment1(4).pdf",MACK,7/20/2018,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its two pipeline candidates mm121 and mm310 mm 121 in combination with sanofis taxotere is being evaluated in a phase ii study sherloc for the treatment of nonsmall cell lung cancer trial in an ongoing trial the fda granted mm121 orphan drug designation for this indication the study was amended to be a more focused proofofconcept study and increased patient population with topline data expected in the second half of 2018 the company is also evaluating the candidate in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm310', 'mm', '121', 'combination', 'sanofis', 'taxotere', 'evaluate', 'phase', 'ii', 'study', 'sherloc', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'fda', 'grant', 'mm121', 'orphan', 'drug', 'designation', 'indication', 'study', 'amend', 'focused', 'proofofconcept', 'study', 'increase', 'patient', 'population', 'topline', 'datum', 'expect', 'second', 'half', '2018', 'company', 'evaluate', 'candidate', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm310 mm 121 combination sanofis taxotere evaluate phase ii study sherloc treatment nonsmall cell lung cancer trial ongoing trial fda grant mm121 orphan drug designation indication study amend focused proofofconcept study increase patient population topline datum expect second half 2018 company evaluate candidate combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,7,16,-0.375,7,16,-0.375,0.9732
284,"Merrimack Pharmaceuticals, Inc._Attachment1(4).pdf",MACK,11/26/2018,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline in september 2018 merrimack secured a 5million milestone from shire following the sale of onivyde in the first major noneuropean and nonasian country promising candidates in pipeline merrimack is currently working on developing its only earlystage pipeline candidate mm310 for the treatment of solid tumors a phase i study on mm310 is under way to evaluate the candidates safety in patients with solid tumors and also identify its maximum tolerated dose however after treating the first 14 patients in the dose escalation program the study was amended to test an alternative dosing schedule the company plans to report safety data from the study during the first quarter of 2019 merrimack intends to advance its two preclinical candidates an immunooncology program mm401 an agonistic antibody targeting a novel immunooncology target tnfr and mm201 a highly stabilized agonistfc fusion protein targeting death receptors 4 and prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility merrimack is planning to lay off workforce by 60 as part of its corporate restructuring planpost which the company expects to have approximately 27 employeesthis reduction in headcount is expected to be completed by february 2019 promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'september', '2018', 'merrimack', 'secure', '5million', 'milestone', 'shire', 'follow', 'sale', 'onivyde', 'major', 'noneuropean', 'nonasian', 'country', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'earlystage', 'pipeline', 'candidate', 'mm310', 'treatment', 'solid', 'tumor', 'phase', 'study', 'mm310', 'way', 'evaluate', 'candidate', 'safety', 'patient', 'solid', 'tumor', 'identify', 'maximum', 'tolerate', 'dose', 'treat', '14', 'patient', 'dose', 'escalation', 'program', 'study', 'amend', 'test', 'alternative', 'dose', 'schedule', 'company', 'plan', 'report', 'safety', 'datum', 'study', 'quarter', '2019', 'merrimack', 'intend', 'advance', 'preclinical', 'candidate', 'immunooncology', 'program', 'mm401', 'agonistic', 'antibody', 'target', 'novel', 'immunooncology', 'target', 'tnfr', 'mm201', 'highly', 'stabilize', 'agonistfc', 'fusion', 'protein', 'target', 'death', 'receptor', '4', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'merrimack', 'plan', 'lay', 'workforce', '60', 'corporate', 'restructuring', 'planpost', 'company', 'expect', 'approximately', '27', 'employeesthis', 'reduction', 'headcount', 'expect', 'complete', 'february', '2019', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline september 2018 merrimack secure 5million milestone shire follow sale onivyde major noneuropean nonasian country promise candidate pipeline merrimack currently work develop earlystage pipeline candidate mm310 treatment solid tumor phase study mm310 way evaluate candidate safety patient solid tumor identify maximum tolerate dose treat 14 patient dose escalation program study amend test alternative dose schedule company plan report safety datum study quarter 2019 merrimack intend advance preclinical candidate immunooncology program mm401 agonistic antibody target novel immunooncology target tnfr mm201 highly stabilize agonistfc fusion protein target death receptor 4 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility merrimack plan lay workforce 60 corporate restructuring planpost company expect approximately 27 employeesthis reduction headcount expect complete february 2019 promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,9,18,-0.32142857142857145,9,18,-0.32142857142857145,0.9881
285,"Merrimack Pharmaceuticals, Inc._Attachment1(5).pdf",MACK,3/31/2017,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that the company was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given the companys cashcrunched position and huge debt the cash received from ipsen will be used to pay down the huge debt and return value to shareholders in the form of dividends merrimack expects 575 million upfront cash payment from ipsen upon the closing of the asset sale and up to 450 million as milestone payments the company intends to use these proceeds to declare and pay a special cash dividend of at least 200million to stockholders and use an additional 1951 million to redeem its senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund its operations into the second half of 2019 the company plans to invest 175 million from the proceeds of the sale to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its three pipeline candidates mm121 mm141 and mm 310 mm121 is being evaluated for the treatment of nonsmall cell lung cancer trial in an ongoing trial the candidate will also be evaluated in a more focused proofofconcept study with topline data expected by the end of 2018 the company also plans to evaluate the candidate in a phase ii clinical study in her2 negative hormone receptor and heregulin positive breast cancer patients in 2017 mm141 a monoclonal antibody targets both the her3 and the igf1 receptors the company is evaluating the drug in pancreatic cancer patients with increased levels of the igf1 biomarker and has retooled the ongoing phase ii study into a proofof concept trial and anticipates topline data in 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study and the company expects to report the recommended phase to dose in 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'company', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'company', 'cashcrunche', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'expect', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', '450', 'million', 'milestone', 'payment', 'company', 'intend', 'use', 'proceed', 'declare', 'pay', 'special', 'cash', 'dividend', '200million', 'stockholder', 'use', 'additional', '1951', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'plan', 'invest', '175', 'million', 'proceed', 'sale', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm141', 'mm', '310', 'mm121', 'evaluate', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'candidate', 'evaluate', 'focused', 'proofofconcept', 'study', 'topline', 'datum', 'expect', 'end', '2018', 'company', 'plan', 'evaluate', 'candidate', 'phase', 'ii', 'clinical', 'study', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'breast', 'cancer', 'patient', '2017', 'mm141', 'monoclonal', 'antibody', 'target', 'her3', 'igf1', 'receptor', 'company', 'evaluate', 'drug', 'pancreatic', 'cancer', 'patient', 'increase', 'level', 'igf1', 'biomarker', 'retool', 'ongoing', 'phase', 'ii', 'study', 'proofof', 'concept', 'trial', 'anticipate', 'topline', 'datum', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'company', 'expect', 'report', 'recommend', 'phase', 'dose', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility']",onivyde sale positive view sale onivyde positive company give fact company struggle market drug properly sale provide company need capital influx cash sale definite positive give company cashcrunche position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack expect 575 million upfront cash payment ipsen closing asset sale 450 million milestone payment company intend use proceed declare pay special cash dividend 200million stockholder use additional 1951 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company plan invest 175 million proceed sale develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm141 mm 310 mm121 evaluate treatment nonsmall cell lung cancer trial ongoing trial candidate evaluate focused proofofconcept study topline datum expect end 2018 company plan evaluate candidate phase ii clinical study her2 negative hormone receptor heregulin positive breast cancer patient 2017 mm141 monoclonal antibody target her3 igf1 receptor company evaluate drug pancreatic cancer patient increase level igf1 biomarker retool ongoing phase ii study proofof concept trial anticipate topline datum 2018 mm310 antibody direct nanoliposome currently phase study company expect report recommend phase dose 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility,7,17,-0.4,7,17,-0.4,0.9485
286,"Merrimack Pharmaceuticals, Inc._Attachment1(6).pdf",MACK,8/14/2017,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its three pipeline candidates mm121 mm141 and mm310 mm121 in combination with sanofis taxotere is being evaluated in a phase ii study sherloc for the treatment of nonsmall cell lung cancer trial in an ongoing trial the candidate will also be evaluated in a more focused proofofconcept study with topline data expected by the end of 2018 the company also plans to evaluate the candidate in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients in 2017 mm141 a monoclonal antibody targets both the her3 and the igf 1 receptors the company is evaluating the drug in combination with current standard of care gemzar abraxane in pancreatic cancer patients with increased levels of the igf1 biomarker and has retooled the ongoing phase ii study carrie into a proofofconcept trial and anticipates topline data in 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018,sell,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm141', 'mm310', 'mm121', 'combination', 'sanofis', 'taxotere', 'evaluate', 'phase', 'ii', 'study', 'sherloc', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'candidate', 'evaluate', 'focused', 'proofofconcept', 'study', 'topline', 'datum', 'expect', 'end', '2018', 'company', 'plan', 'evaluate', 'candidate', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', '2017', 'mm141', 'monoclonal', 'antibody', 'target', 'her3', 'igf', '1', 'receptor', 'company', 'evaluate', 'drug', 'combination', 'current', 'standard', 'care', 'gemzar', 'abraxane', 'pancreatic', 'cancer', 'patient', 'increase', 'level', 'igf1', 'biomarker', 'retool', 'ongoing', 'phase', 'ii', 'study', 'carrie', 'proofofconcept', 'trial', 'anticipate', 'topline', 'datum', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm141 mm310 mm121 combination sanofis taxotere evaluate phase ii study sherloc treatment nonsmall cell lung cancer trial ongoing trial candidate evaluate focused proofofconcept study topline datum expect end 2018 company plan evaluate candidate combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient 2017 mm141 monoclonal antibody target her3 igf 1 receptor company evaluate drug combination current standard care gemzar abraxane pancreatic cancer patient increase level igf1 biomarker retool ongoing phase ii study carrie proofofconcept trial anticipate topline datum 2018 mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018,4,10,-0.4,4,10,-0.4,0.802
287,"Merrimack Pharmaceuticals, Inc._Attachment1(6).pdf",MACK,8/22/2018,share price outperformance merrimack has outperformed the industry in the past month the stock has gained 27 against the industrys decrease of 22 onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its two pipeline candidates mm121 and mm310 mm 121 in combination with sanofis taxotere is being evaluated in a phase ii study sherloc for the treatment of nonsmall cell lung cancer trial in an ongoing trial the fda granted mm121 orphan drug designation for this indication the study was amended to be a more focused proofofconcept study and increased patient population with topline data expected in the second half of 2018 the company is also evaluating the candidate in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients the company expects to report topline results from the sherloc clinical trial during the second half of 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['share', 'price', 'outperformance', 'merrimack', 'outperform', 'industry', 'past', 'month', 'stock', 'gain', '27', 'industrys', 'decrease', '22', 'onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm310', 'mm', '121', 'combination', 'sanofis', 'taxotere', 'evaluate', 'phase', 'ii', 'study', 'sherloc', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'fda', 'grant', 'mm121', 'orphan', 'drug', 'designation', 'indication', 'study', 'amend', 'focused', 'proofofconcept', 'study', 'increase', 'patient', 'population', 'topline', 'datum', 'expect', 'second', 'half', '2018', 'company', 'evaluate', 'candidate', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', 'company', 'expect', 'report', 'topline', 'result', 'sherloc', 'clinical', 'trial', 'second', 'half', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",share price outperformance merrimack outperform industry past month stock gain 27 industrys decrease 22 onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm310 mm 121 combination sanofis taxotere evaluate phase ii study sherloc treatment nonsmall cell lung cancer trial ongoing trial fda grant mm121 orphan drug designation indication study amend focused proofofconcept study increase patient population topline datum expect second half 2018 company evaluate candidate combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient company expect report topline result sherloc clinical trial second half 2018 mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,9,19,-0.3448275862068966,9,19,-0.3448275862068966,0.9818
288,"Merrimack Pharmaceuticals, Inc._Attachment1(6).pdf",MACK,8/22/2018,no approved products merrimack undertook divestment strategies in order to repay debt and focus on the development of pipeline candidates further the company sold its only marketed drug onivyde the sale included commercialization rights in the united states and its licensing agreement with shire ipsen also purchased merrimacks generic version of doxil merrimack is back to being a developmentstage biopharmaceutical company the revenue generation is anticipated to fluctuate forthcoming quarters pipeline candidates still in mid or early stages of development although onivydes launch was disappointing it was the only marketed drug in merrimacks portfolio the companys pipeline currently comprises early and midstage candidates and an unfavorable outcome of any of the development programs would adversely impact shares in december 2016 the company discontinued its phase ii trial on its breast cancer candidate mm302 based on an independent data and safety monitoring board dsmb recommendation that the continuation of the trial is unlikely to demonstrate benefit over the comparator treatments which was confirmed by a subsequent futility analysis notably merrimack faced a major pipeline setback in june 2018 when it stopped developing mm141 post disappointing results from a phase ii analysis carrie for the treatment of frontline metastatic pancreatic cancer,sell,"['approve', 'product', 'merrimack', 'undertake', 'divestment', 'strategy', 'order', 'repay', 'debt', 'focus', 'development', 'pipeline', 'candidate', 'company', 'sell', 'market', 'drug', 'onivyde', 'sale', 'include', 'commercialization', 'right', 'united', 'states', 'licensing', 'agreement', 'shire', 'ipsen', 'purchase', 'merrimack', 'generic', 'version', 'doxil', 'merrimack', 'developmentstage', 'biopharmaceutical', 'company', 'revenue', 'generation', 'anticipate', 'fluctuate', 'forthcoming', 'quarter', 'pipeline', 'candidate', 'mid', 'early', 'stage', 'development', 'onivyde', 'launch', 'disappointing', 'market', 'drug', 'merrimack', 'portfolio', 'companys', 'pipeline', 'currently', 'comprise', 'early', 'midstage', 'candidate', 'unfavorable', 'outcome', 'development', 'program', 'adversely', 'impact', 'share', 'december', '2016', 'company', 'discontinue', 'phase', 'ii', 'trial', 'breast', 'cancer', 'candidate', 'mm302', 'base', 'independent', 'datum', 'safety', 'monitoring', 'board', 'dsmb', 'recommendation', 'continuation', 'trial', 'unlikely', 'demonstrate', 'benefit', 'comparator', 'treatment', 'confirm', 'subsequent', 'futility', 'analysis', 'notably', 'merrimack', 'face', 'major', 'pipeline', 'setback', 'june', '2018', 'stop', 'develop', 'mm141', 'post', 'disappointing', 'result', 'phase', 'ii', 'analysis', 'carrie', 'treatment', 'frontline', 'metastatic', 'pancreatic', 'cancer']",approve product merrimack undertake divestment strategy order repay debt focus development pipeline candidate company sell market drug onivyde sale include commercialization right united states licensing agreement shire ipsen purchase merrimack generic version doxil merrimack developmentstage biopharmaceutical company revenue generation anticipate fluctuate forthcoming quarter pipeline candidate mid early stage development onivyde launch disappointing market drug merrimack portfolio companys pipeline currently comprise early midstage candidate unfavorable outcome development program adversely impact share december 2016 company discontinue phase ii trial breast cancer candidate mm302 base independent datum safety monitoring board dsmb recommendation continuation trial unlikely demonstrate benefit comparator treatment confirm subsequent futility analysis notably merrimack face major pipeline setback june 2018 stop develop mm141 post disappointing result phase ii analysis carrie treatment frontline metastatic pancreatic cancer,2,11,-0.6428571428571429,2,11,-0.6428571428571429,-0.8271
289,"Merrimack Pharmaceuticals, Inc._Attachment1(7).pdf",MACK,9/15/2017,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its three pipeline candidates mm121 mm141 and mm 310 mm121 in combination with sanofis taxotere is being evaluated in a phase ii study sherloc for the treatment of non small cell lung cancer trial in an ongoing trial the candidate will also be evaluated in a more focused proofofconcept study with topline data expected by the end of 2018 the company also plans to evaluate the candidate in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients in 2017 mm141 a monoclonal antibody targets both the her3 and the igf1 receptors the company is evaluating the drug in combination with current standard of care gemzar abraxane in pancreatic cancer patients with increased levels of the igf1 biomarker and has retooled the ongoing phase ii study carrie into a proofofconcept trial and anticipates topline data in 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm141', 'mm', '310', 'mm121', 'combination', 'sanofis', 'taxotere', 'evaluate', 'phase', 'ii', 'study', 'sherloc', 'treatment', 'non', 'small', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'candidate', 'evaluate', 'focused', 'proofofconcept', 'study', 'topline', 'datum', 'expect', 'end', '2018', 'company', 'plan', 'evaluate', 'candidate', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', '2017', 'mm141', 'monoclonal', 'antibody', 'target', 'her3', 'igf1', 'receptor', 'company', 'evaluate', 'drug', 'combination', 'current', 'standard', 'care', 'gemzar', 'abraxane', 'pancreatic', 'cancer', 'patient', 'increase', 'level', 'igf1', 'biomarker', 'retool', 'ongoing', 'phase', 'ii', 'study', 'carrie', 'proofofconcept', 'trial', 'anticipate', 'topline', 'datum', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm141 mm 310 mm121 combination sanofis taxotere evaluate phase ii study sherloc treatment non small cell lung cancer trial ongoing trial candidate evaluate focused proofofconcept study topline datum expect end 2018 company plan evaluate candidate combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient 2017 mm141 monoclonal antibody target her3 igf1 receptor company evaluate drug combination current standard care gemzar abraxane pancreatic cancer patient increase level igf1 biomarker retool ongoing phase ii study carrie proofofconcept trial anticipate topline datum 2018 mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility,7,16,-0.375,7,16,-0.375,0.9545
290,"Merrimack Pharmaceuticals, Inc._Attachment1(7).pdf",MACK,5/2/2018,no approved products merrimack undertook divestment strategies in order to repay debt and focus on the development of pipeline candidates further the company sold its only marketed drug onivyde the sale included commercialization rights in the united states and its licensing agreement with shire ipsen also purchased merrimacks generic version of doxil merrimack is back to being a developmentstage biopharmaceutical company the revenue generation is anticipated to fluctuate forthcoming quarters pipeline candidates still in mid or early stages of development although onivydes launch was disappointing it was the only marketed drug in merrimacks portfolio the companys pipeline currently comprises early and midstage candidates and an unfavorable outcome of any of the development programs would adversely impact shares in december 2016 the company discontinued its phase ii trial on its breast cancer candidate mm302 based on an independent data and safety monitoring board dsmb recommendation that the continuation of the trial is unlikely to demonstrate benefit over the comparator treatments which was confirmed by a subsequent futility analysis,sell,"['approve', 'product', 'merrimack', 'undertake', 'divestment', 'strategy', 'order', 'repay', 'debt', 'focus', 'development', 'pipeline', 'candidate', 'company', 'sell', 'market', 'drug', 'onivyde', 'sale', 'include', 'commercialization', 'right', 'united', 'states', 'licensing', 'agreement', 'shire', 'ipsen', 'purchase', 'merrimack', 'generic', 'version', 'doxil', 'merrimack', 'developmentstage', 'biopharmaceutical', 'company', 'revenue', 'generation', 'anticipate', 'fluctuate', 'forthcoming', 'quarter', 'pipeline', 'candidate', 'mid', 'early', 'stage', 'development', 'onivyde', 'launch', 'disappointing', 'market', 'drug', 'merrimack', 'portfolio', 'companys', 'pipeline', 'currently', 'comprise', 'early', 'midstage', 'candidate', 'unfavorable', 'outcome', 'development', 'program', 'adversely', 'impact', 'share', 'december', '2016', 'company', 'discontinue', 'phase', 'ii', 'trial', 'breast', 'cancer', 'candidate', 'mm302', 'base', 'independent', 'datum', 'safety', 'monitoring', 'board', 'dsmb', 'recommendation', 'continuation', 'trial', 'unlikely', 'demonstrate', 'benefit', 'comparator', 'treatment', 'confirm', 'subsequent', 'futility', 'analysis']",approve product merrimack undertake divestment strategy order repay debt focus development pipeline candidate company sell market drug onivyde sale include commercialization right united states licensing agreement shire ipsen purchase merrimack generic version doxil merrimack developmentstage biopharmaceutical company revenue generation anticipate fluctuate forthcoming quarter pipeline candidate mid early stage development onivyde launch disappointing market drug merrimack portfolio companys pipeline currently comprise early midstage candidate unfavorable outcome development program adversely impact share december 2016 company discontinue phase ii trial breast cancer candidate mm302 base independent datum safety monitoring board dsmb recommendation continuation trial unlikely demonstrate benefit comparator treatment confirm subsequent futility analysis,2,7,-0.5,2,7,-0.5,0.2732
291,"Merrimack Pharmaceuticals, Inc._Attachment1.pdf",MACK,5/2/2017,promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its three pipeline candidates mm121 mm141 and mm310 mm121 is being evaluated for the treatment of nonsmall cell lung cancer trial in an ongoing trial the candidate will also be evaluated in a more focused proofofconcept study with topline data expected by the end of 2018 the company also plans to evaluate the candidate in a phase ii clinical study in her2 negative hormone receptor and heregulin positive breast cancer patients in 2017 mm141 a monoclonal antibody targets both the her3 and the igf1 receptors the company is evaluating the drug in pancreatic cancer patients with increased levels of the igf1 biomarker and has retooled the ongoing phase ii study into a proofofconcept trial and anticipates topline data in 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study and the company expects to report the recommended phase to dose in 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility,sell,"['promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm141', 'mm310', 'mm121', 'evaluate', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'candidate', 'evaluate', 'focused', 'proofofconcept', 'study', 'topline', 'datum', 'expect', 'end', '2018', 'company', 'plan', 'evaluate', 'candidate', 'phase', 'ii', 'clinical', 'study', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'breast', 'cancer', 'patient', '2017', 'mm141', 'monoclonal', 'antibody', 'target', 'her3', 'igf1', 'receptor', 'company', 'evaluate', 'drug', 'pancreatic', 'cancer', 'patient', 'increase', 'level', 'igf1', 'biomarker', 'retool', 'ongoing', 'phase', 'ii', 'study', 'proofofconcept', 'trial', 'anticipate', 'topline', 'datum', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'company', 'expect', 'report', 'recommend', 'phase', 'dose', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility']",promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm141 mm310 mm121 evaluate treatment nonsmall cell lung cancer trial ongoing trial candidate evaluate focused proofofconcept study topline datum expect end 2018 company plan evaluate candidate phase ii clinical study her2 negative hormone receptor heregulin positive breast cancer patient 2017 mm141 monoclonal antibody target her3 igf1 receptor company evaluate drug pancreatic cancer patient increase level igf1 biomarker retool ongoing phase ii study proofofconcept trial anticipate topline datum 2018 mm310 antibody direct nanoliposome currently phase study company expect report recommend phase dose 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility,4,11,-0.4375,4,11,-0.4375,-0.2023
292,"Merrimack Pharmaceuticals, Inc._Attachment1.pdf",MACK,1/19/2018,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its three pipeline candidates mm121 mm141 and mm 310 mm121 in combination with sanofis taxotere is being evaluated in a phase ii study sherloc for the treatment of non small cell lung cancer trial in an ongoing trial the fda granted mm121 orphan drug designation for this indication the candidate will also be evaluated in a more focused proofofconcept study with topline data expected by the end of 2018 the company is also evaluating the candidate in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients topline data is expected in the second half of 2018 mm141 a monoclonal antibody targets both the her3 and the igf1 receptors the company is evaluating the drug in combination with current standard of care gemzar abraxane in pancreatic cancer patients with increased levels of the igf1 biomarker and has retooled the ongoing phase ii study carrie into a proofofconcept trial and anticipates topline data in the first half of 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm141', 'mm', '310', 'mm121', 'combination', 'sanofis', 'taxotere', 'evaluate', 'phase', 'ii', 'study', 'sherloc', 'treatment', 'non', 'small', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'fda', 'grant', 'mm121', 'orphan', 'drug', 'designation', 'indication', 'candidate', 'evaluate', 'focused', 'proofofconcept', 'study', 'topline', 'datum', 'expect', 'end', '2018', 'company', 'evaluate', 'candidate', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', 'topline', 'datum', 'expect', 'second', 'half', '2018', 'mm141', 'monoclonal', 'antibody', 'target', 'her3', 'igf1', 'receptor', 'company', 'evaluate', 'drug', 'combination', 'current', 'standard', 'care', 'gemzar', 'abraxane', 'pancreatic', 'cancer', 'patient', 'increase', 'level', 'igf1', 'biomarker', 'retool', 'ongoing', 'phase', 'ii', 'study', 'carrie', 'proofofconcept', 'trial', 'anticipate', 'topline', 'datum', 'half', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm141 mm 310 mm121 combination sanofis taxotere evaluate phase ii study sherloc treatment non small cell lung cancer trial ongoing trial fda grant mm121 orphan drug designation indication candidate evaluate focused proofofconcept study topline datum expect end 2018 company evaluate candidate combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient topline datum expect second half 2018 mm141 monoclonal antibody target her3 igf1 receptor company evaluate drug combination current standard care gemzar abraxane pancreatic cancer patient increase level igf1 biomarker retool ongoing phase ii study carrie proofofconcept trial anticipate topline datum half 2018 mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,7,19,-0.4444444444444444,7,19,-0.4444444444444444,0.969
293,"Merrimack Pharmaceuticals, Inc._Attachment1.pdf",MACK,5/3/2018,onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its three pipeline candidates mm121 mm141 and mm 310 mm121 in combination with sanofis taxotere is being evaluated in a phase ii study sherloc for the treatment of non small cell lung cancer trial in an ongoing trial the fda granted mm121 orphan drug designation for this indication the study was amended to be a more focused proofofconcept study and increased patient population with topline data expected in the second half of 2018 the company is also evaluating the candidate in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients mm 141 a monoclonal antibody targets both the her3 and the igf1 receptors the company is evaluating the drug in combination with current standard of care gemzar abraxane in pancreatic cancer patients with increased levels of the igf1 biomarker and has retooled the ongoing phase ii study carrie into a proofofconcept trial and anticipates topline data in the first half of 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm141', 'mm', '310', 'mm121', 'combination', 'sanofis', 'taxotere', 'evaluate', 'phase', 'ii', 'study', 'sherloc', 'treatment', 'non', 'small', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'fda', 'grant', 'mm121', 'orphan', 'drug', 'designation', 'indication', 'study', 'amend', 'focused', 'proofofconcept', 'study', 'increase', 'patient', 'population', 'topline', 'datum', 'expect', 'second', 'half', '2018', 'company', 'evaluate', 'candidate', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', 'mm', '141', 'monoclonal', 'antibody', 'target', 'her3', 'igf1', 'receptor', 'company', 'evaluate', 'drug', 'combination', 'current', 'standard', 'care', 'gemzar', 'abraxane', 'pancreatic', 'cancer', 'patient', 'increase', 'level', 'igf1', 'biomarker', 'retool', 'ongoing', 'phase', 'ii', 'study', 'carrie', 'proofofconcept', 'trial', 'anticipate', 'topline', 'datum', 'half', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm141 mm 310 mm121 combination sanofis taxotere evaluate phase ii study sherloc treatment non small cell lung cancer trial ongoing trial fda grant mm121 orphan drug designation indication study amend focused proofofconcept study increase patient population topline datum expect second half 2018 company evaluate candidate combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient mm 141 monoclonal antibody target her3 igf1 receptor company evaluate drug combination current standard care gemzar abraxane pancreatic cancer patient increase level igf1 biomarker retool ongoing phase ii study carrie proofofconcept trial anticipate topline datum half 2018 mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,7,18,-0.4230769230769231,7,18,-0.4230769230769231,0.9735
294,"Merrimack Pharmaceuticals, Inc._Attachment1.pdf",MACK,9/24/2018,share price outperformance shares of merrimack has outperformed the industry in the past three months the stock has gained 83 against the industrys increase of 38 onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline promising candidates in pipeline merrimack is currently working on developing candidates for the treatment of different types of cancer the company now focuses its resources on the development of its two pipeline candidates mm121 and mm310 mm 121 in combination with sanofis taxotere is being evaluated in a phase ii study sherloc for the treatment of nonsmall cell lung cancer trial in an ongoing trial and completed enrollment in the ongoing phase ii study the fda granted mm121 orphan drug designation for this indication the study was amended to be a more focused proofofconcept study and increased patient population with topline data expected in the second half of 2018 the company is also evaluating the candidate in combination with astrazenecas faslodex in a phase ii clinical study sherboc in her2 negative hormone receptor and heregulin positive postmenopausal metastatic breast cancer patients the company expects to report topline results from the sherloc clinical trial during the second half of 2018 mm310 an antibody directed nanoliposome and is currently in a phase i study on solid tumors and the company expects to report the recommended phase ii dose in the second half of 2018 prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['share', 'price', 'outperformance', 'share', 'merrimack', 'outperform', 'industry', 'past', 'month', 'stock', 'gain', '83', 'industrys', 'increase', '38', 'onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'candidate', 'treatment', 'different', 'type', 'cancer', 'company', 'focus', 'resource', 'development', 'pipeline', 'candidate', 'mm121', 'mm310', 'mm', '121', 'combination', 'sanofis', 'taxotere', 'evaluate', 'phase', 'ii', 'study', 'sherloc', 'treatment', 'nonsmall', 'cell', 'lung', 'cancer', 'trial', 'ongoing', 'trial', 'complete', 'enrollment', 'ongoing', 'phase', 'ii', 'study', 'fda', 'grant', 'mm121', 'orphan', 'drug', 'designation', 'indication', 'study', 'amend', 'focused', 'proofofconcept', 'study', 'increase', 'patient', 'population', 'topline', 'datum', 'expect', 'second', 'half', '2018', 'company', 'evaluate', 'candidate', 'combination', 'astrazenecas', 'faslodex', 'phase', 'ii', 'clinical', 'study', 'sherboc', 'her2', 'negative', 'hormone', 'receptor', 'heregulin', 'positive', 'postmenopausal', 'metastatic', 'breast', 'cancer', 'patient', 'company', 'expect', 'report', 'topline', 'result', 'sherloc', 'clinical', 'trial', 'second', 'half', '2018', 'mm310', 'antibody', 'direct', 'nanoliposome', 'currently', 'phase', 'study', 'solid', 'tumor', 'company', 'expect', 'report', 'recommend', 'phase', 'ii', 'dose', 'second', 'half', '2018', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",share price outperformance share merrimack outperform industry past month stock gain 83 industrys increase 38 onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline promise candidate pipeline merrimack currently work develop candidate treatment different type cancer company focus resource development pipeline candidate mm121 mm310 mm 121 combination sanofis taxotere evaluate phase ii study sherloc treatment nonsmall cell lung cancer trial ongoing trial complete enrollment ongoing phase ii study fda grant mm121 orphan drug designation indication study amend focused proofofconcept study increase patient population topline datum expect second half 2018 company evaluate candidate combination astrazenecas faslodex phase ii clinical study sherboc her2 negative hormone receptor heregulin positive postmenopausal metastatic breast cancer patient company expect report topline result sherloc clinical trial second half 2018 mm310 antibody direct nanoliposome currently phase study solid tumor company expect report recommend phase ii dose second half 2018 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,9,19,-0.3448275862068966,9,19,-0.3448275862068966,0.9855
295,"Merrimack Pharmaceuticals, Inc._Attachment1.pdf",MACK,9/24/2018,no approved products merrimack undertook divestment strategies in order to repay debt and focus on the development of pipeline candidates further the company sold its only marketed drug onivyde the sale included commercialization rights in the united states and its licensing agreement with shire ipsen also purchased merrimacks generic version of doxil merrimack is back to being a developmentstage biopharmaceutical company the revenue generation is anticipated to fluctuate forthcoming quarters pipeline candidates still in mid or early stages of development although onivydes launch was disappointing it was the only marketed drug in merrimacks portfolio the companys pipeline currently comprises early and midstage candidates and an unfavorable outcome of any of the development programs would adversely impact shares in december 2016 the company discontinued its phase ii trial on its breast cancer candidate mm302 based on an independent data and safety monitoring board dsmb recommendation that the continuation of the trial is unlikely to demonstrate benefit over the comparator treatments which was confirmed by a subsequent futility analysis notably merrimack faced a major pipeline setback in june 2018 when it stopped developing mm141 post disappointing results from a phase ii analysis carrie for the treatment of frontline metastatic pancreatic cancer,sell,"['approve', 'product', 'merrimack', 'undertake', 'divestment', 'strategy', 'order', 'repay', 'debt', 'focus', 'development', 'pipeline', 'candidate', 'company', 'sell', 'market', 'drug', 'onivyde', 'sale', 'include', 'commercialization', 'right', 'united', 'states', 'licensing', 'agreement', 'shire', 'ipsen', 'purchase', 'merrimack', 'generic', 'version', 'doxil', 'merrimack', 'developmentstage', 'biopharmaceutical', 'company', 'revenue', 'generation', 'anticipate', 'fluctuate', 'forthcoming', 'quarter', 'pipeline', 'candidate', 'mid', 'early', 'stage', 'development', 'onivyde', 'launch', 'disappointing', 'market', 'drug', 'merrimack', 'portfolio', 'companys', 'pipeline', 'currently', 'comprise', 'early', 'midstage', 'candidate', 'unfavorable', 'outcome', 'development', 'program', 'adversely', 'impact', 'share', 'december', '2016', 'company', 'discontinue', 'phase', 'ii', 'trial', 'breast', 'cancer', 'candidate', 'mm302', 'base', 'independent', 'datum', 'safety', 'monitoring', 'board', 'dsmb', 'recommendation', 'continuation', 'trial', 'unlikely', 'demonstrate', 'benefit', 'comparator', 'treatment', 'confirm', 'subsequent', 'futility', 'analysis', 'notably', 'merrimack', 'face', 'major', 'pipeline', 'setback', 'june', '2018', 'stop', 'develop', 'mm141', 'post', 'disappointing', 'result', 'phase', 'ii', 'analysis', 'carrie', 'treatment', 'frontline', 'metastatic', 'pancreatic', 'cancer']",approve product merrimack undertake divestment strategy order repay debt focus development pipeline candidate company sell market drug onivyde sale include commercialization right united states licensing agreement shire ipsen purchase merrimack generic version doxil merrimack developmentstage biopharmaceutical company revenue generation anticipate fluctuate forthcoming quarter pipeline candidate mid early stage development onivyde launch disappointing market drug merrimack portfolio companys pipeline currently comprise early midstage candidate unfavorable outcome development program adversely impact share december 2016 company discontinue phase ii trial breast cancer candidate mm302 base independent datum safety monitoring board dsmb recommendation continuation trial unlikely demonstrate benefit comparator treatment confirm subsequent futility analysis notably merrimack face major pipeline setback june 2018 stop develop mm141 post disappointing result phase ii analysis carrie treatment frontline metastatic pancreatic cancer,2,11,-0.6428571428571429,2,11,-0.6428571428571429,-0.8271
296,"Merrimack Pharmaceuticals, Inc._Attachment1.pdf",MACK,3/4/2019,share price outperformance shares of merrimack have outperformed the industry so far this year the stock has rallied 549 compared with the industrys increase of 16 onivyde sale a positive we view that the sale of onivyde is a positive for the company given the fact that it was struggling to market the drug properly the sale also provides the company with much needed capital the influx of cash from the sale is a definite positive given its cashstarved position and huge debt the cash received from ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends merrimack received 575 million upfront cash payment from ipsen upon the closing of the asset sale and expects up to 450 million as milestone payments the company used these proceeds to pay a special cash dividend of at least 140 million to stockholders and paid 175 million to redeem senior secured notes due in 2022 the cash infusion from these steps along with potential cash inflows arising from the restructuring plan undertaken in jan 2017 should be sufficient to fund operations into the second half of 2019 further the company invested 175 million from the sales proceeds to develop its streamlined oncology pipeline in september 2018 merrimack secured a 5million milestone from shire following the sale of onivyde in the first major noneuropean and nonasian country promising candidates in pipeline merrimack is currently working on developing its only earlystage pipeline candidate mm310 for the treatment of solid tumors a phase i study on mm310 is under way to evaluate the candidates safety in patients with solid tumors and also identify its maximum tolerated dose however after treating the first 14 patients in the dose escalation program the study was amended to test an alternative dosing schedule the company plans to report safety data from the study during the first quarter of 2019 merrimack intends to advance its two preclinical candidates an immunooncology program mm401 an agonistic antibody targeting a novel immunooncology target tnfr and mm201 a highly stabilized agonistfc fusion protein targeting death receptors 4 and prioritizing rd efforts merrimack undertook a restructuring move to prioritize its rd focused on a set of oncology products and to strengthen its cash runway over the next two years as part of this move the company has reduced its headcount by 22 this will lead to the elimination of over 200 million in expected costs over the next two years the company will also invest 175 million to develop its streamlined oncology pipeline this move will allow the company to strategically align its pipeline with core capabilities and prioritize the ongoing clinical development efforts it will also help to improve its financial flexibility merrimack is planning to lay off workforce by 60 as part of its corporate restructuring planpost which the company expects to have approximately 27 employeesthis reduction in headcount is expected to be completed by february 2019 promising cash position merrimack expects its current financial resources along with anticipated milestone payments from shire to be sufficient to fund its operations at the estimated spending rates through the second half of 2019,buy,"['share', 'price', 'outperformance', 'share', 'merrimack', 'outperform', 'industry', 'far', 'year', 'stock', 'rally', '549', 'compare', 'industrys', 'increase', '16', 'onivyde', 'sale', 'positive', 'view', 'sale', 'onivyde', 'positive', 'company', 'give', 'fact', 'struggle', 'market', 'drug', 'properly', 'sale', 'provide', 'company', 'need', 'capital', 'influx', 'cash', 'sale', 'definite', 'positive', 'give', 'cashstarve', 'position', 'huge', 'debt', 'cash', 'receive', 'ipsen', 'pay', 'huge', 'debt', 'return', 'value', 'shareholder', 'form', 'dividend', 'merrimack', 'receive', '575', 'million', 'upfront', 'cash', 'payment', 'ipsen', 'closing', 'asset', 'sale', 'expect', '450', 'million', 'milestone', 'payment', 'company', 'proceed', 'pay', 'special', 'cash', 'dividend', '140', 'million', 'stockholder', 'pay', '175', 'million', 'redeem', 'senior', 'secure', 'note', '2022', 'cash', 'infusion', 'step', 'potential', 'cash', 'inflow', 'arise', 'restructure', 'plan', 'undertake', 'jan', '2017', 'sufficient', 'fund', 'operation', 'second', 'half', '2019', 'company', 'invest', '175', 'million', 'sale', 'proceed', 'develop', 'streamlined', 'oncology', 'pipeline', 'september', '2018', 'merrimack', 'secure', '5million', 'milestone', 'shire', 'follow', 'sale', 'onivyde', 'major', 'noneuropean', 'nonasian', 'country', 'promise', 'candidate', 'pipeline', 'merrimack', 'currently', 'work', 'develop', 'earlystage', 'pipeline', 'candidate', 'mm310', 'treatment', 'solid', 'tumor', 'phase', 'study', 'mm310', 'way', 'evaluate', 'candidate', 'safety', 'patient', 'solid', 'tumor', 'identify', 'maximum', 'tolerate', 'dose', 'treat', '14', 'patient', 'dose', 'escalation', 'program', 'study', 'amend', 'test', 'alternative', 'dose', 'schedule', 'company', 'plan', 'report', 'safety', 'datum', 'study', 'quarter', '2019', 'merrimack', 'intend', 'advance', 'preclinical', 'candidate', 'immunooncology', 'program', 'mm401', 'agonistic', 'antibody', 'target', 'novel', 'immunooncology', 'target', 'tnfr', 'mm201', 'highly', 'stabilize', 'agonistfc', 'fusion', 'protein', 'target', 'death', 'receptor', '4', 'prioritize', 'rd', 'effort', 'merrimack', 'undertake', 'restructure', 'prioritize', 'rd', 'focus', 'set', 'oncology', 'product', 'strengthen', 'cash', 'runway', 'year', 'company', 'reduce', 'headcount', '22', 'lead', 'elimination', '200', 'million', 'expect', 'cost', 'year', 'company', 'invest', '175', 'million', 'develop', 'streamlined', 'oncology', 'pipeline', 'allow', 'company', 'strategically', 'align', 'pipeline', 'core', 'capability', 'prioritize', 'ongoing', 'clinical', 'development', 'effort', 'help', 'improve', 'financial', 'flexibility', 'merrimack', 'plan', 'lay', 'workforce', '60', 'corporate', 'restructuring', 'planpost', 'company', 'expect', 'approximately', '27', 'employeesthis', 'reduction', 'headcount', 'expect', 'complete', 'february', '2019', 'promise', 'cash', 'position', 'merrimack', 'expect', 'current', 'financial', 'resource', 'anticipated', 'milestone', 'payment', 'shire', 'sufficient', 'fund', 'operation', 'estimate', 'spending', 'rate', 'second', 'half', '2019']",share price outperformance share merrimack outperform industry far year stock rally 549 compare industrys increase 16 onivyde sale positive view sale onivyde positive company give fact struggle market drug properly sale provide company need capital influx cash sale definite positive give cashstarve position huge debt cash receive ipsen pay huge debt return value shareholder form dividend merrimack receive 575 million upfront cash payment ipsen closing asset sale expect 450 million milestone payment company proceed pay special cash dividend 140 million stockholder pay 175 million redeem senior secure note 2022 cash infusion step potential cash inflow arise restructure plan undertake jan 2017 sufficient fund operation second half 2019 company invest 175 million sale proceed develop streamlined oncology pipeline september 2018 merrimack secure 5million milestone shire follow sale onivyde major noneuropean nonasian country promise candidate pipeline merrimack currently work develop earlystage pipeline candidate mm310 treatment solid tumor phase study mm310 way evaluate candidate safety patient solid tumor identify maximum tolerate dose treat 14 patient dose escalation program study amend test alternative dose schedule company plan report safety datum study quarter 2019 merrimack intend advance preclinical candidate immunooncology program mm401 agonistic antibody target novel immunooncology target tnfr mm201 highly stabilize agonistfc fusion protein target death receptor 4 prioritize rd effort merrimack undertake restructure prioritize rd focus set oncology product strengthen cash runway year company reduce headcount 22 lead elimination 200 million expect cost year company invest 175 million develop streamlined oncology pipeline allow company strategically align pipeline core capability prioritize ongoing clinical development effort help improve financial flexibility merrimack plan lay workforce 60 corporate restructuring planpost company expect approximately 27 employeesthis reduction headcount expect complete february 2019 promise cash position merrimack expect current financial resource anticipated milestone payment shire sufficient fund operation estimate spending rate second half 2019,10,19,-0.3,10,19,-0.3,0.991
297,NXP Semiconductors NV_Attachment1.pdf,NXPI,10/13/2020,nxps automotive business has a strategic importance and high growth opportunities it accounts for nearly half the companys revenues the company designs and develops products for the adas,buy,"['nxps', 'automotive', 'business', 'strategic', 'importance', 'high', 'growth', 'opportunity', 'account', 'nearly', 'half', 'company', 'revenue', 'company', 'design', 'develop', 'product', 'adas']",nxps automotive business strategic importance high growth opportunity account nearly half company revenue company design develop product adas,2,0,0.6666666666666666,2,0,0.6666666666666666,0.7845
298,NXP Semiconductors NV_Attachment1.pdf,NXPI,10/13/2020,customer concentration remains an overhang the majority of nxps sales depends on top customers including distributors in 2019 sales to two of its customers each accounted for 10 or more of the companys revenues no other distributor accounted for greater than 10 of revenues in 2019 therefore any loss in orders from a major customer could impact its sales figure exposure to the consumer endmarket could result in pricing pressure nxp has exposure to the consumer end market through the mobile segment given the exposure to this end market nxp potentially faces significant pricing pressure for products sold for mobile phones and other consumer applications nxp is subject to changing laws and regulations as it based in the netherlands the geopolitical environment makes it quite uncertain how the regulatory bodies will handle companies operating in different countries thus any change in tax laws or tariffs could impact its financial results the companys balance sheet is highly leveraged it has always had a good amount of debt on the balance sheet as of jun 30 2020 its net debt was 61 billion compared with 63 billion reported in the first quarter the debt to total capital was 508 versus the industry average of 463 as of jun 30 2020 thus the company has to constantly generate adequate amount of operating cash flow to service its debt,sell,"['customer', 'concentration', 'remain', 'overhang', 'majority', 'nxps', 'sale', 'depend', 'customer', 'include', 'distributor', '2019', 'sale', 'customer', 'account', '10', 'company', 'revenue', 'distributor', 'account', 'great', '10', 'revenue', '2019', 'loss', 'order', 'major', 'customer', 'impact', 'sale', 'figure', 'exposure', 'consumer', 'endmarket', 'result', 'pricing', 'pressure', 'nxp', 'exposure', 'consumer', 'end', 'market', 'mobile', 'segment', 'give', 'exposure', 'end', 'market', 'nxp', 'potentially', 'face', 'significant', 'pricing', 'pressure', 'product', 'sell', 'mobile', 'phone', 'consumer', 'application', 'nxp', 'subject', 'change', 'law', 'regulation', 'base', 'netherlands', 'geopolitical', 'environment', 'make', 'uncertain', 'regulatory', 'body', 'handle', 'company', 'operate', 'different', 'country', 'change', 'tax', 'law', 'tariff', 'impact', 'financial', 'result', 'company', 'balance', 'sheet', 'highly', 'leveraged', 'good', 'debt', 'balance', 'sheet', 'jun', '30', '2020', 'net', 'debt', '61', 'billion', 'compare', '63', 'billion', 'report', 'quarter', 'debt', 'total', 'capital', '508', 'versus', 'industry', 'average', '463', 'jun', '30', '2020', 'company', 'constantly', 'generate', 'adequate', 'operate', 'cash', 'flow', 'service', 'debt']",customer concentration remain overhang majority nxps sale depend customer include distributor 2019 sale customer account 10 company revenue distributor account great 10 revenue 2019 loss order major customer impact sale figure exposure consumer endmarket result pricing pressure nxp exposure consumer end market mobile segment give exposure end market nxp potentially face significant pricing pressure product sell mobile phone consumer application nxp subject change law regulation base netherlands geopolitical environment make uncertain regulatory body handle company operate different country change tax law tariff impact financial result company balance sheet highly leveraged good debt balance sheet jun 30 2020 net debt 61 billion compare 63 billion report quarter debt total capital 508 versus industry average 463 jun 30 2020 company constantly generate adequate operate cash flow service debt,3,10,-0.5,3,10,-0.5,-0.7892
299,Palo Alto Networks Inc_Attachment1.pdf,PANW,10/22/2020,cyber security has become a missioncritical highprofile requirement as financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by,sell,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic']",cyber security missioncritical highprofile requirement financial brand reputation enterprise expose sophisticated cyber threat palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic,2,3,-0.16666666666666666,2,3,-0.16666666666666666,0.9231
300,"Palo Alto Networks, Inc._Attachment1(10).pdf",PANW,2/8/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 167 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '167', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 167 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break zack equity research panw wwwzackscom page 3 8,1,3,-0.4,1,3,-0.4,0.8074
301,"Palo Alto Networks, Inc._Attachment1(2).pdf",PANW,5/23/2017,the decelerating revenue growth trend makes us slightly cautious about palo altos nearterm performance notably the company has witnessed over 50 growth in quarterly revenues for nearly two years except in the past two quarters during the first quarter of fiscal 2017 and second quarter of fiscal 2017 the yearoveryear growth rates were 34 and 263 respectively moreover palo altos revenue growth guidance range of 17 to 20 for the third quarter of fiscal 2017 has increased our concerns furthermore the companys billings growth rate of 22 during the second quarter were also much lower than the previous two quarters growth rates of 33 and 45 nearterm prospects for palo alto are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment this makes us slightly cautious about the companys nearterm performance the recent forecast for worldwide it spending by gartner raises concerns about palo altos nearterm performance the research firm has lowered its forecast on it spending for 2017 the recent forecast 27 year over year growth in it spending is 02 lower than its previous projection of 29 growth gartner now expects it spending in 2017 will be approximately 346 trillion this was the third time in 2016 that the firm has lowered its global it spending forecast for 2017 although the research firm has not mentioned any cut in it security spending we believe that soft it spending trend could have a negative impact on this segment as well palo alto faces stiff competition from several big and small players in the security application market further over the past few years the demand for it security has been on the rise driven by increasing awareness and cyber attacks making the market more attractive for new players also there are some established players in the adjacent markets like cisco and juniper that can cross sell security products and include security into their existing product lines further intensifying competition in the space therefore companies must deliver prompt and advanced technologies to suit customer requirements and expedite product launch to stay afloat to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years palo alto has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this has negatively impacted its operating margins furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period,sell,"['decelerate', 'revenue', 'growth', 'trend', 'make', 'slightly', 'cautious', 'palo', 'altos', 'nearterm', 'performance', 'notably', 'company', 'witness', '50', 'growth', 'quarterly', 'revenue', 'nearly', 'year', 'past', 'quarter', 'quarter', 'fiscal', '2017', 'second', 'quarter', 'fiscal', '2017', 'yearoveryear', 'growth', 'rate', '34', '263', 'respectively', 'palo', 'altos', 'revenue', 'growth', 'guidance', 'range', '17', '20', 'quarter', 'fiscal', '2017', 'increase', 'concern', 'furthermore', 'company', 'billing', 'growth', 'rate', '22', 'second', 'quarter', 'low', 'previous', 'quarter', 'growth', 'rate', '33', '45', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'make', 'slightly', 'cautious', 'company', 'nearterm', 'performance', 'recent', 'forecast', 'worldwide', 'spend', 'gartner', 'raise', 'concern', 'palo', 'altos', 'nearterm', 'performance', 'research', 'firm', 'lower', 'forecast', 'spend', '2017', 'recent', 'forecast', '27', 'year', 'year', 'growth', 'spending', '02', 'low', 'previous', 'projection', '29', 'growth', 'gartner', 'expect', 'spend', '2017', 'approximately', '346', 'trillion', 'time', '2016', 'firm', 'lower', 'global', 'spending', 'forecast', '2017', 'research', 'firm', 'mention', 'cut', 'security', 'spending', 'believe', 'soft', 'spend', 'trend', 'negative', 'impact', 'segment', 'palo', 'alto', 'face', 'stiff', 'competition', 'big', 'small', 'player', 'security', 'application', 'market', 'past', 'year', 'demand', 'security', 'rise', 'drive', 'increase', 'awareness', 'cyber', 'attack', 'make', 'market', 'attractive', 'new', 'player', 'establish', 'player', 'adjacent', 'market', 'like', 'cisco', 'juniper', 'cross', 'sell', 'security', 'product', 'include', 'security', 'exist', 'product', 'line', 'intensify', 'competition', 'space', 'company', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'launch', 'stay', 'afloat', 'survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'palo', 'alto', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'negatively', 'impact', 'operating', 'margin', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period']",decelerate revenue growth trend make slightly cautious palo altos nearterm performance notably company witness 50 growth quarterly revenue nearly year past quarter quarter fiscal 2017 second quarter fiscal 2017 yearoveryear growth rate 34 263 respectively palo altos revenue growth guidance range 17 20 quarter fiscal 2017 increase concern furthermore company billing growth rate 22 second quarter low previous quarter growth rate 33 45 nearterm prospect palo alto promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment make slightly cautious company nearterm performance recent forecast worldwide spend gartner raise concern palo altos nearterm performance research firm lower forecast spend 2017 recent forecast 27 year year growth spending 02 low previous projection 29 growth gartner expect spend 2017 approximately 346 trillion time 2016 firm lower global spending forecast 2017 research firm mention cut security spending believe soft spend trend negative impact segment palo alto face stiff competition big small player security application market past year demand security rise drive increase awareness cyber attack make market attractive new player establish player adjacent market like cisco juniper cross sell security product include security exist product line intensify competition space company deliver prompt advanced technology suit customer requirement expedite product launch stay afloat survive highly competitive cyber security market player continually invest broaden capability past year palo alto invest heavily enhance sale marketing capability particularly increase sale force negatively impact operating margin furthermore company foresee investment garner benefit long run note uncertainty payback period,5,19,-0.56,5,19,-0.56,0.9884
302,"Palo Alto Networks, Inc._Attachment1(2).pdf",PANW,11/17/2017,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth in feb 2017 palo alto completed the buyout of lightcyber for 105 million the acquisition has expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach in 2014 the company took over morta security and israelbased cyvera which expanded its product portfolio as well as the customer base the company in may 2015 acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched two more subscriptionbased services autofocus and aperture which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the fourth quarter the company added nearly 3000 customers bringing the total to over 42500 worldwide it is to be noted that in each of the last 22 quarters palo alto has added at least 1000 customers this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model notably the company garners nearly 23 of the total revenue from these services which has helped it to retain its gross margin above 70 over the last few quarters we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscription based services like wildfire and trap the wildfire customer base reached over 19000 at the end of fourthquarter fiscal 2017 compared with 17000 at the end of thirdquarter further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations cash and shortterm investments were 1375 billion as of jul 31 2017 which translates to approximately 40 of the total assets moreover during fiscal 2017 the company generated 8685 million of cash flow from operational activities notably the company has been able to regularly increase its cash and marketable securities which reached 1375 billion at the end of fiscal 2017 from 3226 million at the end of fiscal 2012,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'feb', '2017', 'palo', 'alto', 'complete', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', '2014', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'company', '2015', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'subscriptionbased', 'service', 'autofocus', 'aperture', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'fourth', 'quarter', 'company', 'add', 'nearly', '3000', 'customer', 'bring', 'total', '42500', 'worldwide', 'note', '22', 'quarter', 'palo', 'alto', 'add', '1000', 'customer', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '23', 'total', 'revenue', 'service', 'help', 'retain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscription', 'base', 'service', 'like', 'wildfire', 'trap', 'wildfire', 'customer', 'base', 'reach', '19000', 'end', 'fourthquarter', 'fiscal', '2017', 'compare', '17000', 'end', 'thirdquarter', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '1375', 'billion', 'jul', '31', '2017', 'translate', 'approximately', '40', 'total', 'asset', 'fiscal', '2017', 'company', 'generate', '8685', 'million', 'cash', 'flow', 'operational', 'activity', 'notably', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '1375', 'billion', 'end', 'fiscal', '2017', '3226', 'million', 'end', 'fiscal', '2012']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth feb 2017 palo alto complete buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach 2014 company take morta security israelbase cyvera expand product portfolio customer base company 2015 acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch subscriptionbased service autofocus aperture expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth fourth quarter company add nearly 3000 customer bring total 42500 worldwide note 22 quarter palo alto add 1000 customer vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model notably company garner nearly 23 total revenue service help retain gross margin 70 quarter believe strategy continue improve company line line palo alto witness tremendous customer growth subscription base service like wildfire trap wildfire customer base reach 19000 end fourthquarter fiscal 2017 compare 17000 end thirdquarter company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation cash shortterm investment 1375 billion jul 31 2017 translate approximately 40 total asset fiscal 2017 company generate 8685 million cash flow operational activity notably company able regularly increase cash marketable security reach 1375 billion end fiscal 2017 3226 million end fiscal 2012,24,40,-0.24615384615384617,24,40,-0.24615384615384617,0.999
303,"Palo Alto Networks, Inc._Attachment1(2).pdf",PANW,1/22/2018,changing customer spending behavior may negatively impact palo alto networks nearterm financial performance for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment this makes us slightly cautious about the companys nearterm performance palo alto faces stiff competition from several big and small players in the security application market further over the past few years the demand for it security has been on the rise driven by increasing awareness and cyber attacks making the market more attractive for new players also there are some established players in the adjacent markets like cisco and juniper that can cross sell security products and include security into their existing product lines further intensifying competition in the space therefore companies must deliver prompt and advanced technologies to suit customer requirements and expedite product launch to stay afloat to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years palo alto has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this has negatively impacted its operating margins furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period,sell,"['change', 'customer', 'spend', 'behavior', 'negatively', 'impact', 'palo', 'alto', 'networks', 'nearterm', 'financial', 'performance', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'make', 'slightly', 'cautious', 'company', 'nearterm', 'performance', 'palo', 'alto', 'face', 'stiff', 'competition', 'big', 'small', 'player', 'security', 'application', 'market', 'past', 'year', 'demand', 'security', 'rise', 'drive', 'increase', 'awareness', 'cyber', 'attack', 'make', 'market', 'attractive', 'new', 'player', 'establish', 'player', 'adjacent', 'market', 'like', 'cisco', 'juniper', 'cross', 'sell', 'security', 'product', 'include', 'security', 'exist', 'product', 'line', 'intensify', 'competition', 'space', 'company', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'launch', 'stay', 'afloat', 'survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'palo', 'alto', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'negatively', 'impact', 'operating', 'margin', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period']",change customer spend behavior negatively impact palo alto networks nearterm financial performance past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment make slightly cautious company nearterm performance palo alto face stiff competition big small player security application market past year demand security rise drive increase awareness cyber attack make market attractive new player establish player adjacent market like cisco juniper cross sell security product include security exist product line intensify competition space company deliver prompt advanced technology suit customer requirement expedite product launch stay afloat survive highly competitive cyber security market player continually invest broaden capability past year palo alto invest heavily enhance sale marketing capability particularly increase sale force negatively impact operating margin furthermore company foresee investment garner benefit long run note uncertainty payback period,5,14,-0.45,5,14,-0.45,0.9652
304,"Palo Alto Networks, Inc._Attachment1(2).pdf",PANW,1/18/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 1539 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as changing customer spending behavior has recently hit several other zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '1539', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 1539 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise change customer spending behavior recently hit zack equity research panw wwwzackscom page 3 8,1,2,-0.25,1,2,-0.25,0.7096
305,"Palo Alto Networks, Inc._Attachment1(2).pdf",PANW,3/20/2019,cyber security has become a missioncritical highprofile requirement as financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth the buyout of lightcyber expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach buyouts of morta security and cyvera expanded its product portfolio as well as the customer base another acquired company cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better moreover the company expects to expand its endpoint detection and response edr capabilities with the latest acquisition of secdo moreover the redlock buyout is expected to extend its leadership in cloud security with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth the vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscriptionbased services like wildfire and trap further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity palo alto exited the last reported quarter with cash cash equivalents and shortterm investments of approximately 36 billion it generated cash flow from operations of 2754 million in the quarter free cash flow came in at 2519million the increasing liquidity and cash flow trend confirms that the company is investing in the right areas going ahead the company plans to significantly step up investment in building infrastructure cloud services and facilities to support business growth,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'buyout', 'lightcyber', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', 'buyout', 'morta', 'security', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'acquire', 'company', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'company', 'expect', 'expand', 'endpoint', 'detection', 'response', 'edr', 'capability', 'late', 'acquisition', 'secdo', 'redlock', 'buyout', 'expect', 'extend', 'leadership', 'cloud', 'security', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'like', 'wildfire', 'trap', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'palo', 'alto', 'exit', 'reported', 'quarter', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '36', 'billion', 'generate', 'cash', 'flow', 'operation', '2754', 'million', 'quarter', 'free', 'cash', 'flow', 'come', '2519million', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'confirm', 'company', 'invest', 'right', 'area', 'go', 'ahead', 'company', 'plan', 'significantly', 'step', 'investment', 'build', 'infrastructure', 'cloud', 'service', 'facility', 'support', 'business', 'growth']",cyber security missioncritical highprofile requirement financial brand reputation enterprise expose sophisticated cyber threat palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth buyout lightcyber expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach buyout morta security cyvera expand product portfolio customer base acquire company cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well company expect expand endpoint detection response edr capability late acquisition secdo redlock buyout expect extend leadership cloud security advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model believe strategy continue improve company line line palo alto witness tremendous customer growth subscriptionbase service like wildfire trap company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity palo alto exit reported quarter cash cash equivalent shortterm investment approximately 36 billion generate cash flow operation 2754 million quarter free cash flow come 2519million increase liquidity cash flow trend confirm company invest right area go ahead company plan significantly step investment build infrastructure cloud service facility support business growth,24,31,-0.125,24,31,-0.125,0.9991
306,"Palo Alto Networks, Inc._Attachment1(2).pdf",PANW,4/7/2020,cyber security has become a missioncritical highprofile requirement as financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have in depth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'depth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge']",cyber security missioncritical highprofile requirement financial brand reputation enterprise expose sophisticated cyber threat palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization depth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge,2,6,-0.4444444444444444,2,6,-0.4444444444444444,0.9545
307,"Palo Alto Networks, Inc._Attachment1(3).pdf",PANW,11/28/2017,the decelerating revenue growth trend makes us slightly cautious about palo altos nearterm performance notably the company has witnessed over 50 growth in quarterly revenues for nearly two years except in the fiscal 2017 during fiscal 2017 and firstquarter of fiscal 2018 the yearoveryear growth rates were 28 and 27 respectively moreover palo altos revenue growth guidance range of 22 to 24 for fiscal 2018 has increased our concerns furthermore the companys reducing billings growth rate remain a major concern nearterm prospects for palo alto are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment this makes us slightly cautious about the companys nearterm performance palo alto faces stiff competition from several big and small players in the security application market further over the past few years the demand for it security has been on the rise driven by increasing awareness and cyber attacks making the market more attractive for new players also there are some established players in the adjacent markets like cisco and juniper that can cross sell security products and include security into their existing product lines further intensifying competition in the space therefore companies must deliver prompt and advanced technologies to suit customer requirements and expedite product launch to stay afloat to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years palo alto has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this has negatively impacted its operating margins furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period,sell,"['decelerate', 'revenue', 'growth', 'trend', 'make', 'slightly', 'cautious', 'palo', 'altos', 'nearterm', 'performance', 'notably', 'company', 'witness', '50', 'growth', 'quarterly', 'revenue', 'nearly', 'year', 'fiscal', '2017', 'fiscal', '2017', 'firstquarter', 'fiscal', '2018', 'yearoveryear', 'growth', 'rate', '28', '27', 'respectively', 'palo', 'altos', 'revenue', 'growth', 'guidance', 'range', '22', '24', 'fiscal', '2018', 'increase', 'concern', 'furthermore', 'company', 'reduce', 'billing', 'growth', 'rate', 'remain', 'major', 'concern', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'make', 'slightly', 'cautious', 'company', 'nearterm', 'performance', 'palo', 'alto', 'face', 'stiff', 'competition', 'big', 'small', 'player', 'security', 'application', 'market', 'past', 'year', 'demand', 'security', 'rise', 'drive', 'increase', 'awareness', 'cyber', 'attack', 'make', 'market', 'attractive', 'new', 'player', 'establish', 'player', 'adjacent', 'market', 'like', 'cisco', 'juniper', 'cross', 'sell', 'security', 'product', 'include', 'security', 'exist', 'product', 'line', 'intensify', 'competition', 'space', 'company', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'launch', 'stay', 'afloat', 'survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'palo', 'alto', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'negatively', 'impact', 'operating', 'margin', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period']",decelerate revenue growth trend make slightly cautious palo altos nearterm performance notably company witness 50 growth quarterly revenue nearly year fiscal 2017 fiscal 2017 firstquarter fiscal 2018 yearoveryear growth rate 28 27 respectively palo altos revenue growth guidance range 22 24 fiscal 2018 increase concern furthermore company reduce billing growth rate remain major concern nearterm prospect palo alto promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment make slightly cautious company nearterm performance palo alto face stiff competition big small player security application market past year demand security rise drive increase awareness cyber attack make market attractive new player establish player adjacent market like cisco juniper cross sell security product include security exist product line intensify competition space company deliver prompt advanced technology suit customer requirement expedite product launch stay afloat survive highly competitive cyber security market player continually invest broaden capability past year palo alto invest heavily enhance sale marketing capability particularly increase sale force negatively impact operating margin furthermore company foresee investment garner benefit long run note uncertainty payback period,5,15,-0.47619047619047616,5,15,-0.47619047619047616,0.9901
308,"Palo Alto Networks, Inc._Attachment1(3).pdf",PANW,1/23/2018,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth in feb 2017 palo alto completed the buyout of lightcyber for 105 million the acquisition has expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach in 2014 the company took over morta security and israelbased cyvera which expanded its product portfolio as well as the customer base the company in may 2015 acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the first quarter the company added nearly 2500 customers bringing the total to over 45000 worldwide it is to be noted that in each of the last 23 quarters palo alto has added at least 1000 customers this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model notably the company garners nearly 23 of the total revenue from these services which has helped it to retain its gross margin above 70 over the last few quarters we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscription based services like wildfire and trap the wildfire customer base reached over 19000 at the end of fourthquarter fiscal 2017 compared with 17000 at the end of thirdquarter further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations cash and shortterm investments were 1375 billion as of jul 31 2017 which translates to approximately 40 of the total assets moreover during fiscal 2017 the company generated 8685 million of cash flow from operational activities notably the company has been able to regularly increase its cash and marketable securities which reached 1375 billion at the end of fiscal 2017 from 3226 million at the end of fiscal 2012,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'feb', '2017', 'palo', 'alto', 'complete', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', '2014', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'company', '2015', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'quarter', 'company', 'add', 'nearly', '2500', 'customer', 'bring', 'total', '45000', 'worldwide', 'note', '23', 'quarter', 'palo', 'alto', 'add', '1000', 'customer', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '23', 'total', 'revenue', 'service', 'help', 'retain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscription', 'base', 'service', 'like', 'wildfire', 'trap', 'wildfire', 'customer', 'base', 'reach', '19000', 'end', 'fourthquarter', 'fiscal', '2017', 'compare', '17000', 'end', 'thirdquarter', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '1375', 'billion', 'jul', '31', '2017', 'translate', 'approximately', '40', 'total', 'asset', 'fiscal', '2017', 'company', 'generate', '8685', 'million', 'cash', 'flow', 'operational', 'activity', 'notably', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '1375', 'billion', 'end', 'fiscal', '2017', '3226', 'million', 'end', 'fiscal', '2012']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth feb 2017 palo alto complete buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach 2014 company take morta security israelbase cyvera expand product portfolio customer base company 2015 acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth quarter company add nearly 2500 customer bring total 45000 worldwide note 23 quarter palo alto add 1000 customer vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model notably company garner nearly 23 total revenue service help retain gross margin 70 quarter believe strategy continue improve company line line palo alto witness tremendous customer growth subscription base service like wildfire trap wildfire customer base reach 19000 end fourthquarter fiscal 2017 compare 17000 end thirdquarter company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation cash shortterm investment 1375 billion jul 31 2017 translate approximately 40 total asset fiscal 2017 company generate 8685 million cash flow operational activity notably company able regularly increase cash marketable security reach 1375 billion end fiscal 2017 3226 million end fiscal 2012,24,40,-0.24615384615384617,24,40,-0.24615384615384617,0.999
309,"Palo Alto Networks, Inc._Attachment1(3).pdf",PANW,7/16/2018,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth in feb 2017 palo alto completed the buyout of lightcyber for 105 million the acquisition has expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach in 2014 the company took over morta security and israelbased cyvera which expanded its product portfolio as well as the customer base the company in may 2015 acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the first quarter the company added over 3000 customers bringing the total to over 51000 worldwide it is to be noted that in each of the last 24 quarters palo alto has added at least 1000 customers this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model notably the company garners nearly 23 of the total revenue from these services which has helped it to retain its gross margin above 70 over the last few quarters we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscription based services like wildfire and trap the wildfire customer base reached over 19000 at the end of fourthquarter fiscal 2017 compared with 17000 at the end of thirdquarter further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations cash and shortterm investments were 1375 billion as of jul 31 2017 which translates to approximately 40 of the total assets moreover during fiscal 2017 the company generated 8685 million of cash flow from operational activities notably the company has been able to regularly increase its cash and marketable securities which reached 1375 billion at the end of fiscal 2017 from 3226 million at the end of fiscal 2012,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'feb', '2017', 'palo', 'alto', 'complete', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', '2014', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'company', '2015', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'quarter', 'company', 'add', '3000', 'customer', 'bring', 'total', '51000', 'worldwide', 'note', '24', 'quarter', 'palo', 'alto', 'add', '1000', 'customer', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '23', 'total', 'revenue', 'service', 'help', 'retain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscription', 'base', 'service', 'like', 'wildfire', 'trap', 'wildfire', 'customer', 'base', 'reach', '19000', 'end', 'fourthquarter', 'fiscal', '2017', 'compare', '17000', 'end', 'thirdquarter', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '1375', 'billion', 'jul', '31', '2017', 'translate', 'approximately', '40', 'total', 'asset', 'fiscal', '2017', 'company', 'generate', '8685', 'million', 'cash', 'flow', 'operational', 'activity', 'notably', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '1375', 'billion', 'end', 'fiscal', '2017', '3226', 'million', 'end', 'fiscal', '2012']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth feb 2017 palo alto complete buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach 2014 company take morta security israelbase cyvera expand product portfolio customer base company 2015 acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth quarter company add 3000 customer bring total 51000 worldwide note 24 quarter palo alto add 1000 customer vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model notably company garner nearly 23 total revenue service help retain gross margin 70 quarter believe strategy continue improve company line line palo alto witness tremendous customer growth subscription base service like wildfire trap wildfire customer base reach 19000 end fourthquarter fiscal 2017 compare 17000 end thirdquarter company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation cash shortterm investment 1375 billion jul 31 2017 translate approximately 40 total asset fiscal 2017 company generate 8685 million cash flow operational activity notably company able regularly increase cash marketable security reach 1375 billion end fiscal 2017 3226 million end fiscal 2012,24,40,-0.24615384615384617,24,40,-0.24615384615384617,0.999
310,"Palo Alto Networks, Inc._Attachment1(3).pdf",PANW,9/12/2018,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth in feb 2017 palo alto completed the buyout of lightcyber for 105 million the acquisition has expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach in 2014 the company took over morta security and israelbased cyvera which expanded its product portfolio as well as the customer base the company in may 2015 acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better moreover the company expects to expand its endpoint detection and response edr capabilities with the latest acquisition of secdo with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the first quarter the company added over 3000 customers bringing the total to over 54000 worldwide this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated with traps the company now caters to more than 3000 customers and protects over 5 million endpoints these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscriptionbased services like wildfire and trap further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations palo alto exited the last reported quarter with cash cash equivalents and shortterm investments of approximately 34 billion it generated cash flow from operations of 2779 million in the quarter free cash flow came in at 2525 million the increasing liquidity and cash flow trend confirms that the company is investing in the right areas going ahead the company plans to significantly step up investment in building infrastructure cloud services and facilities to support business growth,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'feb', '2017', 'palo', 'alto', 'complete', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', '2014', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'company', '2015', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'company', 'expect', 'expand', 'endpoint', 'detection', 'response', 'edr', 'capability', 'late', 'acquisition', 'secdo', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'quarter', 'company', 'add', '3000', 'customer', 'bring', 'total', '54000', 'worldwide', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'trap', 'company', 'cater', '3000', 'customer', 'protect', '5', 'million', 'endpoint', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'like', 'wildfire', 'trap', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'palo', 'alto', 'exit', 'reported', 'quarter', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '34', 'billion', 'generate', 'cash', 'flow', 'operation', '2779', 'million', 'quarter', 'free', 'cash', 'flow', 'come', '2525', 'million', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'confirm', 'company', 'invest', 'right', 'area', 'go', 'ahead', 'company', 'plan', 'significantly', 'step', 'investment', 'build', 'infrastructure', 'cloud', 'service', 'facility', 'support', 'business', 'growth']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth feb 2017 palo alto complete buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach 2014 company take morta security israelbase cyvera expand product portfolio customer base company 2015 acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well company expect expand endpoint detection response edr capability late acquisition secdo advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth quarter company add 3000 customer bring total 54000 worldwide vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update trap company cater 3000 customer protect 5 million endpoint factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model believe strategy continue improve company line line palo alto witness tremendous customer growth subscriptionbase service like wildfire trap company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation palo alto exit reported quarter cash cash equivalent shortterm investment approximately 34 billion generate cash flow operation 2779 million quarter free cash flow come 2525 million increase liquidity cash flow trend confirm company invest right area go ahead company plan significantly step investment build infrastructure cloud service facility support business growth,24,35,-0.18333333333333332,24,35,-0.18333333333333332,0.9991
311,"Palo Alto Networks, Inc._Attachment1(3).pdf",PANW,4/10/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 2106 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '2106', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 2106 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break zack equity research panw wwwzackscom page 3 8,1,3,-0.4,1,3,-0.4,0.8074
312,"Palo Alto Networks, Inc._Attachment1(3).pdf",PANW,4/29/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 215 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment this makes us slightly cautious about the companys nearterm performance palo alto faces stiff competition from several big and small players in the security application market further over the past few years the demand for it security has been on the rise driven by increasing awareness and cyber attacks making the market more attractive for new players also there are some established players in the adjacent markets like cisco and juniper that can cross sell security products and include security into their existing product lines further intensifying competition in the space therefore companies must deliver prompt and advanced technologies to suit customer requirements and expedite product launch to stay afloat to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years palo alto has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this has negatively impacted its operating margins furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period zacks equity research panw wwwzackscom page 4 of 10,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '215', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'make', 'slightly', 'cautious', 'company', 'nearterm', 'performance', 'palo', 'alto', 'face', 'stiff', 'competition', 'big', 'small', 'player', 'security', 'application', 'market', 'past', 'year', 'demand', 'security', 'rise', 'drive', 'increase', 'awareness', 'cyber', 'attack', 'make', 'market', 'attractive', 'new', 'player', 'establish', 'player', 'adjacent', 'market', 'like', 'cisco', 'juniper', 'cross', 'sell', 'security', 'product', 'include', 'security', 'exist', 'product', 'line', 'intensify', 'competition', 'space', 'company', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'launch', 'stay', 'afloat', 'survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'palo', 'alto', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'negatively', 'impact', 'operating', 'margin', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '4', '10']",note palo alto currently trailing 12month pricebook value pb ratio 215 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment make slightly cautious company nearterm performance palo alto face stiff competition big small player security application market past year demand security rise drive increase awareness cyber attack make market attractive new player establish player adjacent market like cisco juniper cross sell security product include security exist product line intensify competition space company deliver prompt advanced technology suit customer requirement expedite product launch stay afloat survive highly competitive cyber security market player continually invest broaden capability past year palo alto invest heavily enhance sale marketing capability particularly increase sale force negatively impact operating margin furthermore company foresee investment garner benefit long run note uncertainty payback period zack equity research panw wwwzackscom page 4 10,6,15,-0.4090909090909091,6,15,-0.4090909090909091,0.9781
313,"Palo Alto Networks, Inc._Attachment1(4).pdf",PANW,7/4/2017,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth palo alto recently announced the buyout of lightcyber for 105 million the acquisition will expand the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach most recently the company acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise will help palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better we believe that this acquisition will not only expand its capabilities but the customer base as well additionally last year the company took over morta security and israelbased cyvera which further expanded its product portfolio as well as the customer base with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company will mainly focus on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative last year it expanded its strategic partnership with vmware to address mobile security needs as more and more organizations are adopting byod policy per the deal both the companies have integrated their enterprise security and mobile management technologies to provide a unique combination of mobile device management mdm with advanced threat prevention solution to secure enterprise byod support apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has recently launched two more subscriptionbased services autofocus and aperture which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the third quarter the company added over 2000 customers bringing the total to approximately 39500 worldwide which also includes over 86 of the fortune 100 and more than 60 of the global 2000 it is to be noted that in each of the last 21 quarters palo alto has added at least 1000 customers this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model notably the company garners nearly 23 of the total revenue from these services which has helped it to retain its gross margin above 70 over the last few quarters we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscription based services like wildfire and trap the wildfire customer base reached over 17000 in the thirdquarter fiscal 2017 compared with 15500 at the end of secondquarter further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations cash and shortterm investments were 1372,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'palo', 'alto', 'recently', 'announce', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', 'recently', 'company', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'believe', 'acquisition', 'expand', 'capability', 'customer', 'base', 'additionally', 'year', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'mobile', 'security', 'need', 'organization', 'adopt', 'byod', 'policy', 'deal', 'company', 'integrate', 'enterprise', 'security', 'mobile', 'management', 'technology', 'provide', 'unique', 'combination', 'mobile', 'device', 'management', 'mdm', 'advanced', 'threat', 'prevention', 'solution', 'secure', 'enterprise', 'byod', 'support', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'recently', 'launch', 'subscriptionbased', 'service', 'autofocus', 'aperture', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'quarter', 'company', 'add', '2000', 'customer', 'bring', 'total', 'approximately', '39500', 'worldwide', 'include', '86', 'fortune', '100', '60', 'global', '2000', 'note', '21', 'quarter', 'palo', 'alto', 'add', '1000', 'customer', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '23', 'total', 'revenue', 'service', 'help', 'retain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscription', 'base', 'service', 'like', 'wildfire', 'trap', 'wildfire', 'customer', 'base', 'reach', '17000', 'thirdquarter', 'fiscal', '2017', 'compare', '15500', 'end', 'secondquarter', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '1372']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth palo alto recently announce buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach recently company acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well believe acquisition expand capability customer base additionally year company take morta security israelbase cyvera expand product portfolio customer base advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address mobile security need organization adopt byod policy deal company integrate enterprise security mobile management technology provide unique combination mobile device management mdm advanced threat prevention solution secure enterprise byod support apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto recently launch subscriptionbased service autofocus aperture expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth quarter company add 2000 customer bring total approximately 39500 worldwide include 86 fortune 100 60 global 2000 note 21 quarter palo alto add 1000 customer vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model notably company garner nearly 23 total revenue service help retain gross margin 70 quarter believe strategy continue improve company line line palo alto witness tremendous customer growth subscription base service like wildfire trap wildfire customer base reach 17000 thirdquarter fiscal 2017 compare 15500 end secondquarter company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation cash shortterm investment 1372,24,35,-0.18333333333333332,24,35,-0.18333333333333332,0.999
314,"Palo Alto Networks, Inc._Attachment1(4).pdf",PANW,11/29/2017,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth in feb 2017 palo alto completed the buyout of lightcyber for 105 million the acquisition has expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach in 2014 the company took over morta security and israelbased cyvera which expanded its product portfolio as well as the customer base the company in may 2015 acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the first quarter the company added nearly 2500 customers bringing the total to over 45000 worldwide it is to be noted that in each of the last 23 quarters palo alto has added at least 1000 customers this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model notably the company garners nearly 23 of the total revenue from these services which has helped it to retain its gross margin above 70 over the last few quarters we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscription based services like wildfire and trap the wildfire customer base reached over 19000 at the end of fourthquarter fiscal 2017 compared with 17000 at the end of thirdquarter further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations cash and shortterm investments were 1375 billion as of jul 31 2017 which translates to approximately 40 of the total assets moreover during fiscal 2017 the company generated 8685 million of cash flow from operational activities notably the company has been able to regularly increase its cash and marketable securities which reached 1375 billion at the end of fiscal 2017 from 3226 million at the end of fiscal 2012 similarly palo altos cash flow from operations reached approximately 8685 million at the end of fiscal 2017 from roughly 774,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'feb', '2017', 'palo', 'alto', 'complete', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', '2014', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'company', '2015', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'quarter', 'company', 'add', 'nearly', '2500', 'customer', 'bring', 'total', '45000', 'worldwide', 'note', '23', 'quarter', 'palo', 'alto', 'add', '1000', 'customer', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '23', 'total', 'revenue', 'service', 'help', 'retain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscription', 'base', 'service', 'like', 'wildfire', 'trap', 'wildfire', 'customer', 'base', 'reach', '19000', 'end', 'fourthquarter', 'fiscal', '2017', 'compare', '17000', 'end', 'thirdquarter', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '1375', 'billion', 'jul', '31', '2017', 'translate', 'approximately', '40', 'total', 'asset', 'fiscal', '2017', 'company', 'generate', '8685', 'million', 'cash', 'flow', 'operational', 'activity', 'notably', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '1375', 'billion', 'end', 'fiscal', '2017', '3226', 'million', 'end', 'fiscal', '2012', 'similarly', 'palo', 'alto', 'cash', 'flow', 'operation', 'reach', 'approximately', '8685', 'million', 'end', 'fiscal', '2017', 'roughly', '774']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth feb 2017 palo alto complete buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach 2014 company take morta security israelbase cyvera expand product portfolio customer base company 2015 acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth quarter company add nearly 2500 customer bring total 45000 worldwide note 23 quarter palo alto add 1000 customer vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model notably company garner nearly 23 total revenue service help retain gross margin 70 quarter believe strategy continue improve company line line palo alto witness tremendous customer growth subscription base service like wildfire trap wildfire customer base reach 19000 end fourthquarter fiscal 2017 compare 17000 end thirdquarter company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation cash shortterm investment 1375 billion jul 31 2017 translate approximately 40 total asset fiscal 2017 company generate 8685 million cash flow operational activity notably company able regularly increase cash marketable security reach 1375 billion end fiscal 2017 3226 million end fiscal 2012 similarly palo alto cash flow operation reach approximately 8685 million end fiscal 2017 roughly 774,24,42,-0.26865671641791045,24,42,-0.26865671641791045,0.999
315,"Palo Alto Networks, Inc._Attachment1(4).pdf",PANW,8/7/2018,palo alto has made strategic acquisitions to boost growth in feb 2017 palo alto completed the buyout of lightcyber for 105 million the acquisition has expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach in 2014 the company took over morta security and israelbased cyvera which expanded its product portfolio as well as the customer base the company in may 2015 acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities,sell,"['palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'feb', '2017', 'palo', 'alto', 'complete', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', '2014', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'company', '2015', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'better', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capability']",palo alto strategic acquisition boost growth feb 2017 palo alto complete buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach 2014 company take morta security israelbase cyvera expand product portfolio customer base company 2015 acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox better palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capability,8,14,-0.2608695652173913,8,14,-0.2608695652173913,0.996
316,"Palo Alto Networks, Inc._Attachment1(4).pdf",PANW,1/23/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 1539 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '1539', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 1539 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player zack equity research panw wwwzackscom page 3 8,1,2,-0.25,1,2,-0.25,0.7096
317,"Palo Alto Networks, Inc._Attachment1(4).pdf",PANW,4/16/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 217 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '217', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 217 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break zack equity research panw wwwzackscom page 3 8,1,3,-0.4,1,3,-0.4,0.8074
318,"Palo Alto Networks, Inc._Attachment1(5).pdf",PANW,11/6/2018,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth the buyout of lightcyber expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach buyouts of morta security and cyvera expanded its product portfolio as well as the customer base another acquired company cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better moreover the company expects to expand its endpoint detection and response edr capabilities with the latest acquisition of secdo with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the first quarter the company added over 3000 customers bringing the total to over 54000 worldwide this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated with traps the company now caters to more than 3000 customers and protects over 5 million endpoints these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscriptionbased services like wildfire and trap further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations palo alto exited the last reported quarter with cash cash equivalents and shortterm investments of approximately 34 billion it generated cash flow from operations of 2779 million in the quarter free cash flow came in at 2525 million the increasing liquidity and cash flow trend confirms that the company is investing in the right areas going ahead the company plans to significantly step up investment in building infrastructure cloud services and facilities to support business growth,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'buyout', 'lightcyber', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', 'buyout', 'morta', 'security', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'acquire', 'company', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'company', 'expect', 'expand', 'endpoint', 'detection', 'response', 'edr', 'capability', 'late', 'acquisition', 'secdo', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'quarter', 'company', 'add', '3000', 'customer', 'bring', 'total', '54000', 'worldwide', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'trap', 'company', 'cater', '3000', 'customer', 'protect', '5', 'million', 'endpoint', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'like', 'wildfire', 'trap', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'palo', 'alto', 'exit', 'reported', 'quarter', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '34', 'billion', 'generate', 'cash', 'flow', 'operation', '2779', 'million', 'quarter', 'free', 'cash', 'flow', 'come', '2525', 'million', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'confirm', 'company', 'invest', 'right', 'area', 'go', 'ahead', 'company', 'plan', 'significantly', 'step', 'investment', 'build', 'infrastructure', 'cloud', 'service', 'facility', 'support', 'business', 'growth']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth buyout lightcyber expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach buyout morta security cyvera expand product portfolio customer base acquire company cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well company expect expand endpoint detection response edr capability late acquisition secdo advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth quarter company add 3000 customer bring total 54000 worldwide vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update trap company cater 3000 customer protect 5 million endpoint factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model believe strategy continue improve company line line palo alto witness tremendous customer growth subscriptionbase service like wildfire trap company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation palo alto exit reported quarter cash cash equivalent shortterm investment approximately 34 billion generate cash flow operation 2779 million quarter free cash flow come 2525 million increase liquidity cash flow trend confirm company invest right area go ahead company plan significantly step investment build infrastructure cloud service facility support business growth,23,32,-0.16071428571428573,23,32,-0.16071428571428573,0.999
319,"Palo Alto Networks, Inc._Attachment1(5).pdf",PANW,1/25/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 1594 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '1594', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 1594 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player zack equity research panw wwwzackscom page 3 8,1,2,-0.25,1,2,-0.25,0.7096
320,"Palo Alto Networks, Inc._Attachment1(5).pdf",PANW,5/2/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 216 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment this makes us slightly cautious about the companys nearterm performance palo alto faces stiff competition from several big and small players in the security application market further over the past few years the demand for it security has been on the rise driven by increasing awareness and cyber attacks making the market more attractive for new players also there are some established players in the adjacent markets like cisco and juniper that can cross sell security products and include security into their existing product lines further intensifying competition in the space therefore companies must deliver prompt and advanced technologies to suit customer requirements and expedite product launch to stay afloat to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years palo alto has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this has negatively impacted its operating margins furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period zacks equity research panw wwwzackscom page 4 of 10,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '216', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'make', 'slightly', 'cautious', 'company', 'nearterm', 'performance', 'palo', 'alto', 'face', 'stiff', 'competition', 'big', 'small', 'player', 'security', 'application', 'market', 'past', 'year', 'demand', 'security', 'rise', 'drive', 'increase', 'awareness', 'cyber', 'attack', 'make', 'market', 'attractive', 'new', 'player', 'establish', 'player', 'adjacent', 'market', 'like', 'cisco', 'juniper', 'cross', 'sell', 'security', 'product', 'include', 'security', 'exist', 'product', 'line', 'intensify', 'competition', 'space', 'company', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'launch', 'stay', 'afloat', 'survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'palo', 'alto', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'negatively', 'impact', 'operating', 'margin', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '4', '10']",note palo alto currently trailing 12month pricebook value pb ratio 216 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment make slightly cautious company nearterm performance palo alto face stiff competition big small player security application market past year demand security rise drive increase awareness cyber attack make market attractive new player establish player adjacent market like cisco juniper cross sell security product include security exist product line intensify competition space company deliver prompt advanced technology suit customer requirement expedite product launch stay afloat survive highly competitive cyber security market player continually invest broaden capability past year palo alto invest heavily enhance sale marketing capability particularly increase sale force negatively impact operating margin furthermore company foresee investment garner benefit long run note uncertainty payback period zack equity research panw wwwzackscom page 4 10,6,15,-0.4090909090909091,6,15,-0.4090909090909091,0.9781
321,"Palo Alto Networks, Inc._Attachment1(6).pdf",PANW,4/7/2017,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth palo alto recently announced the buyout of lightcyber for 105 million the acquisition will expand the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach most recently the company acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise will help palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better we believe that this acquisition will not only expand its capabilities but the customer base as well additionally last year the company took over morta security and israelbased cyvera which further expanded its product portfolio as well as the customer base with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company will mainly focus on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative last year it expanded its strategic partnership with vmware to address mobile security needs as more and more organizations are adopting byod policy per the deal both the companies have integrated their enterprise security and mobile management technologies to provide a unique combination of mobile device management mdm with advanced threat prevention solution to secure enterprise byod support apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has recently launched two more subscriptionbased services autofocus and aperture which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the first quarter the company added over 1500 customers bringing the total to approximately 35500 worldwide which also includes over 85 of the fortune 100 more than 70 of the fortune 500 and higher than 55 of the global 2000 companies it is to be noted that in each of the last 19 quarters palo alto has added at least 1000 customers this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model notably the company garners nearly 23 of the total revenue from these services which has helped it to retain its gross margin above 70 over the last few quarters we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscription based services like wildfire and trap the wildfire customer base reached over 14000 in the firstquarter fiscal 2017 compared with 12500 at the end of fourthquarter fiscal 2016 further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'palo', 'alto', 'recently', 'announce', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', 'recently', 'company', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'believe', 'acquisition', 'expand', 'capability', 'customer', 'base', 'additionally', 'year', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'mobile', 'security', 'need', 'organization', 'adopt', 'byod', 'policy', 'deal', 'company', 'integrate', 'enterprise', 'security', 'mobile', 'management', 'technology', 'provide', 'unique', 'combination', 'mobile', 'device', 'management', 'mdm', 'advanced', 'threat', 'prevention', 'solution', 'secure', 'enterprise', 'byod', 'support', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'recently', 'launch', 'subscriptionbased', 'service', 'autofocus', 'aperture', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'quarter', 'company', 'add', '1500', 'customer', 'bring', 'total', 'approximately', '35500', 'worldwide', 'include', '85', 'fortune', '100', '70', 'fortune', '500', 'high', '55', 'global', '2000', 'company', 'note', '19', 'quarter', 'palo', 'alto', 'add', '1000', 'customer', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '23', 'total', 'revenue', 'service', 'help', 'retain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscription', 'base', 'service', 'like', 'wildfire', 'trap', 'wildfire', 'customer', 'base', 'reach', '14000', 'firstquarter', 'fiscal', '2017', 'compare', '12500', 'end', 'fourthquarter', 'fiscal', '2016', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth palo alto recently announce buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach recently company acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well believe acquisition expand capability customer base additionally year company take morta security israelbase cyvera expand product portfolio customer base advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address mobile security need organization adopt byod policy deal company integrate enterprise security mobile management technology provide unique combination mobile device management mdm advanced threat prevention solution secure enterprise byod support apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto recently launch subscriptionbased service autofocus aperture expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth quarter company add 1500 customer bring total approximately 35500 worldwide include 85 fortune 100 70 fortune 500 high 55 global 2000 company note 19 quarter palo alto add 1000 customer vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model notably company garner nearly 23 total revenue service help retain gross margin 70 quarter believe strategy continue improve company line line palo alto witness tremendous customer growth subscription base service like wildfire trap wildfire customer base reach 14000 firstquarter fiscal 2017 compare 12500 end fourthquarter fiscal 2016 company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line,24,33,-0.15517241379310345,24,33,-0.15517241379310345,0.999
322,"Palo Alto Networks, Inc._Attachment1(6).pdf",PANW,11/8/2018,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 1848 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '1848', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 1848 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise change customer spending behavior recently hit player space past month competitor cyber security space notice company zack equity research panw wwwzackscom page 3 8,1,2,-0.25,1,2,-0.25,0.8074
323,"Palo Alto Networks, Inc._Attachment1(6).pdf",PANW,1/28/2019,cyber security has become a missioncritical highprofile requirement as financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth the buyout of lightcyber expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach buyouts of morta security and cyvera expanded its product portfolio as well as the customer base another acquired company cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better moreover the company expects to expand its endpoint detection and response edr capabilities with the latest acquisition of secdo moreover the redlock buyout is expected to extend its leadership in cloud security with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth the vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscriptionbased services like wildfire and trap further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations palo alto exited the last reported quarter with cash cash equivalents and shortterm investments of approximately 34 billion it generated cash flow from operations of 2523 million in the quarter free cash flow came in at 218 million the increasing liquidity and cash flow trend confirms that the company is investing in the right areas going ahead the company plans to significantly step up investment in building infrastructure cloud services and facilities to support business growth,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'buyout', 'lightcyber', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', 'buyout', 'morta', 'security', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'acquire', 'company', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'company', 'expect', 'expand', 'endpoint', 'detection', 'response', 'edr', 'capability', 'late', 'acquisition', 'secdo', 'redlock', 'buyout', 'expect', 'extend', 'leadership', 'cloud', 'security', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'like', 'wildfire', 'trap', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'palo', 'alto', 'exit', 'reported', 'quarter', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '34', 'billion', 'generate', 'cash', 'flow', 'operation', '2523', 'million', 'quarter', 'free', 'cash', 'flow', 'come', '218', 'million', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'confirm', 'company', 'invest', 'right', 'area', 'go', 'ahead', 'company', 'plan', 'significantly', 'step', 'investment', 'build', 'infrastructure', 'cloud', 'service', 'facility', 'support', 'business', 'growth']",cyber security missioncritical highprofile requirement financial brand reputation enterprise expose sophisticated cyber threat palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth buyout lightcyber expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach buyout morta security cyvera expand product portfolio customer base acquire company cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well company expect expand endpoint detection response edr capability late acquisition secdo redlock buyout expect extend leadership cloud security advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model believe strategy continue improve company line line palo alto witness tremendous customer growth subscriptionbase service like wildfire trap company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation palo alto exit reported quarter cash cash equivalent shortterm investment approximately 34 billion generate cash flow operation 2523 million quarter free cash flow come 218 million increase liquidity cash flow trend confirm company invest right area go ahead company plan significantly step investment build infrastructure cloud service facility support business growth,24,31,-0.125,24,31,-0.125,0.9991
324,"Palo Alto Networks, Inc._Attachment1(7).pdf",PANW,1/30/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 1566 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '1566', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 1566 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break zack equity research panw wwwzackscom page 3 8,1,3,-0.4,1,3,-0.4,0.8074
325,"Palo Alto Networks, Inc._Attachment1(9).pdf",PANW,10/10/2017,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 1770 this level compares unfavorably with what the industry witnessed in the last year the ratio is higher than the average level of 1505 hence valuation looks slightly stretched from a pb perspective the decelerating revenue growth trend makes us slightly cautious about palo altos nearterm performance notably the company has witnessed over 50 growth in quarterly revenues for nearly two years except in the past four quarters during the first second third and fourth quarters of fiscal 2017 the yearoveryear growth rates were 34 263 249 and 27 respectively moreover palo altos revenue growth guidance range of 21 to 24 for the first quarter of fiscal 2018 has increased our concerns furthermore although the companys billings growth rate of 17 during the fourth quarter was higher than the third quarters growth rate of 12 it is still lower than the first and second quarters growth rates of 33 and 22 respectively nearterm prospects for palo alto are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment this makes us slightly cautious about the companys nearterm performance palo alto faces stiff competition from several big and small players in the security application market further over the past few years the demand for it security has been on the rise driven by increasing awareness and cyber attacks making the market more attractive for new players also there are some established players in the adjacent markets like cisco and juniper that can cross sell security products and include security into their existing product lines further intensifying competition in the space therefore companies must deliver prompt and advanced technologies to suit customer requirements and expedite product launch to stay afloat to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years palo alto has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this has negatively impacted its operating margins furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '1770', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'ratio', 'high', 'average', 'level', '1505', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'decelerate', 'revenue', 'growth', 'trend', 'make', 'slightly', 'cautious', 'palo', 'altos', 'nearterm', 'performance', 'notably', 'company', 'witness', '50', 'growth', 'quarterly', 'revenue', 'nearly', 'year', 'past', 'quarter', 'second', 'fourth', 'quarter', 'fiscal', '2017', 'yearoveryear', 'growth', 'rate', '34', '263', '249', '27', 'respectively', 'palo', 'altos', 'revenue', 'growth', 'guidance', 'range', '21', '24', 'quarter', 'fiscal', '2018', 'increase', 'concern', 'furthermore', 'company', 'billing', 'growth', 'rate', '17', 'fourth', 'quarter', 'high', 'quarter', 'growth', 'rate', '12', 'low', 'second', 'quarter', 'growth', 'rate', '33', '22', 'respectively', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'make', 'slightly', 'cautious', 'company', 'nearterm', 'performance', 'palo', 'alto', 'face', 'stiff', 'competition', 'big', 'small', 'player', 'security', 'application', 'market', 'past', 'year', 'demand', 'security', 'rise', 'drive', 'increase', 'awareness', 'cyber', 'attack', 'make', 'market', 'attractive', 'new', 'player', 'establish', 'player', 'adjacent', 'market', 'like', 'cisco', 'juniper', 'cross', 'sell', 'security', 'product', 'include', 'security', 'exist', 'product', 'line', 'intensify', 'competition', 'space', 'company', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'launch', 'stay', 'afloat', 'survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'palo', 'alto', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'negatively', 'impact', 'operating', 'margin', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period']",note palo alto currently trailing 12month pricebook value pb ratio 1770 level compare unfavorably industry witness year ratio high average level 1505 valuation look slightly stretch pb perspective decelerate revenue growth trend make slightly cautious palo altos nearterm performance notably company witness 50 growth quarterly revenue nearly year past quarter second fourth quarter fiscal 2017 yearoveryear growth rate 34 263 249 27 respectively palo altos revenue growth guidance range 21 24 quarter fiscal 2018 increase concern furthermore company billing growth rate 17 fourth quarter high quarter growth rate 12 low second quarter growth rate 33 22 respectively nearterm prospect palo alto promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment make slightly cautious company nearterm performance palo alto face stiff competition big small player security application market past year demand security rise drive increase awareness cyber attack make market attractive new player establish player adjacent market like cisco juniper cross sell security product include security exist product line intensify competition space company deliver prompt advanced technology suit customer requirement expedite product launch stay afloat survive highly competitive cyber security market player continually invest broaden capability past year palo alto invest heavily enhance sale marketing capability particularly increase sale force negatively impact operating margin furthermore company foresee investment garner benefit long run note uncertainty payback period,8,16,-0.32,8,16,-0.32,0.9929
326,"Palo Alto Networks, Inc._Attachment1(9).pdf",PANW,12/4/2018,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by application user and content as a result organizations have indepth visibility into all traffic and applications which help them to control usage content risks and cyber threats at the user level therefore palo altos security platforms simplify security infrastructure for organizations by eliminating the need for multiple standalone security appliances and software products this reduces the total cost of ownership thereby giving the organization a competitive edge palo alto has made strategic acquisitions to boost growth the buyout of lightcyber expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach buyouts of morta security and cyvera expanded its product portfolio as well as the customer base another acquired company cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better moreover the company expects to expand its endpoint detection and response edr capabilities with the latest acquisition of secdo moreover with the completion of redlock buyout in the quarter under consideration the company expects to extend its leadership in cloud security with the advancement in technology more organizations are adopting the bringyourowndevice byod policy which has enhanced employee productivity with anytime anywhere access on the flipside however it has become all the more necessary for organizations to enforce data security measures to capitalize on this particular emerging opportunity palo alto launched globalprotect a nextgeneration network firewall security product which helps enterprises protect ios and androidbased mobile devices with this the company mainly focuses on organizations that follow predetermined byod policies as the product detects device application and innetwork threats apart from this the company provides realtime mobile security and intelligence to any organizations existing security and mobility infrastructure palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line the exponential growth in the amount of data complexity of data formats and the need to scale resources at regular intervals has led to a tremendous surge in demand for cloud computing software and applications this trend on the other hand has made it necessary for companies to enforce stricter data security measures therefore looking at the industrys trends palo alto is currently focusing on cloudbased protection services the company currently offers a subscriptionbased cloud protection service wildfire which helps endcustomers in identifying malware on any network and takes preventive measures automatically moreover palo alto has launched several new subscriptionbased services in the last few months autofocus aperture globalprotect cloud service and logging service which have expanded its cloud protection capabilities palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth the vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line palo alto is currently focusing on selling more subscriptionbased services this unique business model is helping it to generate stable revenues while expanding margins subscriptionbased service is a high grossmargin business approximately 80 compared with the hardwarecentric model we believe that the strategy will continue to improve the companys top line and bottom line palo alto has been witnessing tremendous customer growth for its subscriptionbased services like wildfire and trap further the companys subscriptionbased services autofocus aperture traps and virtual continue to witness solid growth we believe that continued focus on subscriptionbased products and services and product upgrades will boost the companys top line palo alto has a strong balance sheet with ample liquidity and no debt obligations palo alto exited the last reported quarter with cash cash equivalents and shortterm investments of approximately 34 billion it generated cash flow from operations of 2523 million in the quarter free cash flow came in at 218 million the increasing liquidity and cash flow trend confirms that the company is investing in the right areas going ahead the company plans to significantly step up investment in building infrastructure cloud services and facilities to support business growth,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic', 'application', 'user', 'content', 'result', 'organization', 'indepth', 'visibility', 'traffic', 'application', 'help', 'control', 'usage', 'content', 'risk', 'cyber', 'threat', 'user', 'level', 'palo', 'altos', 'security', 'platform', 'simplify', 'security', 'infrastructure', 'organization', 'eliminate', 'need', 'multiple', 'standalone', 'security', 'appliance', 'software', 'product', 'reduce', 'total', 'cost', 'ownership', 'give', 'organization', 'competitive', 'edge', 'palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'buyout', 'lightcyber', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', 'buyout', 'morta', 'security', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'acquire', 'company', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'well', 'company', 'expect', 'expand', 'endpoint', 'detection', 'response', 'edr', 'capability', 'late', 'acquisition', 'secdo', 'completion', 'redlock', 'buyout', 'quarter', 'consideration', 'company', 'expect', 'extend', 'leadership', 'cloud', 'security', 'advancement', 'technology', 'organization', 'adopt', 'bringyourowndevice', 'byod', 'policy', 'enhance', 'employee', 'productivity', 'anytime', 'access', 'flipside', 'necessary', 'organization', 'enforce', 'data', 'security', 'measure', 'capitalize', 'particular', 'emerge', 'opportunity', 'palo', 'alto', 'launch', 'globalprotect', 'nextgeneration', 'network', 'firewall', 'security', 'product', 'help', 'enterprise', 'protect', 'io', 'androidbased', 'mobile', 'device', 'company', 'mainly', 'focus', 'organization', 'follow', 'predetermine', 'byod', 'policy', 'product', 'detect', 'device', 'application', 'innetwork', 'threat', 'apart', 'company', 'provide', 'realtime', 'mobile', 'security', 'intelligence', 'organization', 'exist', 'security', 'mobility', 'infrastructure', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'exponential', 'growth', 'datum', 'complexity', 'datum', 'format', 'need', 'scale', 'resource', 'regular', 'interval', 'lead', 'tremendous', 'surge', 'demand', 'cloud', 'computing', 'software', 'application', 'trend', 'hand', 'necessary', 'company', 'enforce', 'strict', 'datum', 'security', 'measure', 'look', 'industrys', 'trends', 'palo', 'alto', 'currently', 'focus', 'cloudbase', 'protection', 'service', 'company', 'currently', 'offer', 'subscriptionbased', 'cloud', 'protection', 'service', 'wildfire', 'help', 'endcustomer', 'identify', 'malware', 'network', 'take', 'preventive', 'measure', 'automatically', 'palo', 'alto', 'launch', 'new', 'subscriptionbased', 'service', 'month', 'autofocus', 'aperture', 'globalprotect', 'cloud', 'service', 'log', 'service', 'expand', 'cloud', 'protection', 'capabilities', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line', 'palo', 'alto', 'currently', 'focus', 'sell', 'subscriptionbased', 'service', 'unique', 'business', 'model', 'help', 'generate', 'stable', 'revenue', 'expand', 'margin', 'subscriptionbase', 'service', 'high', 'grossmargin', 'business', 'approximately', '80', 'compare', 'hardwarecentric', 'model', 'believe', 'strategy', 'continue', 'improve', 'company', 'line', 'line', 'palo', 'alto', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'like', 'wildfire', 'trap', 'company', 'subscriptionbase', 'service', 'autofocus', 'aperture', 'trap', 'virtual', 'continue', 'witness', 'solid', 'growth', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'company', 'line', 'palo', 'alto', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'debt', 'obligation', 'palo', 'alto', 'exit', 'reported', 'quarter', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '34', 'billion', 'generate', 'cash', 'flow', 'operation', '2523', 'million', 'quarter', 'free', 'cash', 'flow', 'come', '218', 'million', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'confirm', 'company', 'invest', 'right', 'area', 'go', 'ahead', 'company', 'plan', 'significantly', 'step', 'investment', 'build', 'infrastructure', 'cloud', 'service', 'facility', 'support', 'business', 'growth']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic application user content result organization indepth visibility traffic application help control usage content risk cyber threat user level palo altos security platform simplify security infrastructure organization eliminate need multiple standalone security appliance software product reduce total cost ownership give organization competitive edge palo alto strategic acquisition boost growth buyout lightcyber expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach buyout morta security cyvera expand product portfolio customer base acquire company cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox well company expect expand endpoint detection response edr capability late acquisition secdo completion redlock buyout quarter consideration company expect extend leadership cloud security advancement technology organization adopt bringyourowndevice byod policy enhance employee productivity anytime access flipside necessary organization enforce data security measure capitalize particular emerge opportunity palo alto launch globalprotect nextgeneration network firewall security product help enterprise protect io androidbased mobile device company mainly focus organization follow predetermine byod policy product detect device application innetwork threat apart company provide realtime mobile security intelligence organization exist security mobility infrastructure palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line exponential growth datum complexity datum format need scale resource regular interval lead tremendous surge demand cloud computing software application trend hand necessary company enforce strict datum security measure look industrys trends palo alto currently focus cloudbase protection service company currently offer subscriptionbased cloud protection service wildfire help endcustomer identify malware network take preventive measure automatically palo alto launch new subscriptionbased service month autofocus aperture globalprotect cloud service log service expand cloud protection capabilities palo alto gain customer account increase penetration exist customer drive revenue growth vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line palo alto currently focus sell subscriptionbased service unique business model help generate stable revenue expand margin subscriptionbase service high grossmargin business approximately 80 compare hardwarecentric model believe strategy continue improve company line line palo alto witness tremendous customer growth subscriptionbase service like wildfire trap company subscriptionbase service autofocus aperture trap virtual continue witness solid growth believe continue focus subscriptionbase product service product upgrade boost company line palo alto strong balance sheet ample liquidity debt obligation palo alto exit reported quarter cash cash equivalent shortterm investment approximately 34 billion generate cash flow operation 2523 million quarter free cash flow come 218 million increase liquidity cash flow trend confirm company invest right area go ahead company plan significantly step investment build infrastructure cloud service facility support business growth,24,32,-0.14035087719298245,24,32,-0.14035087719298245,0.999
327,"Palo Alto Networks, Inc._Attachment1(9).pdf",PANW,12/4/2018,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 172 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as changing customer spending behavior has recently hit several other zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '172', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 172 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise change customer spending behavior recently hit zack equity research panw wwwzackscom page 3 8,1,2,-0.25,1,2,-0.25,0.7096
328,"Palo Alto Networks, Inc._Attachment1(9).pdf",PANW,2/6/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 166 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '166', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 166 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break zack equity research panw wwwzackscom page 3 8,1,3,-0.4,1,3,-0.4,0.8074
329,"Palo Alto Networks, Inc._Attachment1.pdf",PANW,11/13/2017,palo alto has made strategic acquisitions to boost growth in feb 2017 palo alto completed the buyout of lightcyber for 105 million the acquisition has expanded the companys nextgeneration security platform over the last few years the company also completed three important buyouts to broaden its portfolio and global reach in 2014 the company took over morta security and israelbased cyvera which expanded its product portfolio as well as the customer base the company in may 2015 acquired cirrosecure a startup which specializes in guarding softwareasaservice saas applications cirrosecures resources and expertise has helped palo alto in expanding the functionality of its enterprise security platform and guard the saas collaboration products of salesforcecom google drive box and dropbox better palo alto has made strategic partnerships to expedite growth the company formed the nextwave technology partner program under which an organization can join as strategic or integration partner under this program palo alto integrates its solutions with its partners and ensures that the combined products are working seamlessly thereby allowing organizations to be more mobile nimble and collaborative over the last one year it has expanded its strategic partnership with vmware to address cloud and mobile security needs of organizations apart from this palo alto has made strategic alliance with aruba networks to offer security solutions tailored for mobile users furthermore with another partnership with splunk palo alto is offering solutions to effectively coordinate detection incident investigation and response for advanced threats moreover by integrating its solutions with citrix the company offers security solutions to cloud networking platforms these strategic partnerships bring in customers for palo alto thereby boosting the top line palo alto is gaining customer accounts and increasing penetration of existing customers thereby driving revenue growth during the fourth quarter the company added nearly 3000 customers bringing the total to over 42500 worldwide it is to be noted that in each of the last 22 quarters palo alto has added at least 1000 customers this vast customer base presents the company an opportunity to upsell products within its installed user base moreover any product refresh brings in additional dollars as every enterprise attempts to keep their threat management infrastructure updated these factors in turn support palo altos top line,sell,"['palo', 'alto', 'strategic', 'acquisition', 'boost', 'growth', 'feb', '2017', 'palo', 'alto', 'complete', 'buyout', 'lightcyber', '105', 'million', 'acquisition', 'expand', 'company', 'nextgeneration', 'security', 'platform', 'year', 'company', 'complete', 'important', 'buyout', 'broaden', 'portfolio', 'global', 'reach', '2014', 'company', 'take', 'morta', 'security', 'israelbase', 'cyvera', 'expand', 'product', 'portfolio', 'customer', 'base', 'company', '2015', 'acquire', 'cirrosecure', 'startup', 'specialize', 'guard', 'softwareasaservice', 'saas', 'application', 'cirrosecure', 'resource', 'expertise', 'help', 'palo', 'alto', 'expand', 'functionality', 'enterprise', 'security', 'platform', 'guard', 'saas', 'collaboration', 'product', 'salesforcecom', 'google', 'drive', 'box', 'dropbox', 'better', 'palo', 'alto', 'strategic', 'partnership', 'expedite', 'growth', 'company', 'form', 'nextwave', 'technology', 'partner', 'program', 'organization', 'join', 'strategic', 'integration', 'partner', 'program', 'palo', 'alto', 'integrate', 'solution', 'partner', 'ensure', 'combine', 'product', 'work', 'seamlessly', 'allow', 'organization', 'mobile', 'nimble', 'collaborative', 'year', 'expand', 'strategic', 'partnership', 'vmware', 'address', 'cloud', 'mobile', 'security', 'need', 'organization', 'apart', 'palo', 'alto', 'strategic', 'alliance', 'aruba', 'network', 'offer', 'security', 'solution', 'tailor', 'mobile', 'user', 'furthermore', 'partnership', 'splunk', 'palo', 'alto', 'offer', 'solution', 'effectively', 'coordinate', 'detection', 'incident', 'investigation', 'response', 'advanced', 'threat', 'integrate', 'solution', 'citrix', 'company', 'offer', 'security', 'solution', 'cloud', 'networking', 'platform', 'strategic', 'partnership', 'bring', 'customer', 'palo', 'alto', 'boost', 'line', 'palo', 'alto', 'gain', 'customer', 'account', 'increase', 'penetration', 'exist', 'customer', 'drive', 'revenue', 'growth', 'fourth', 'quarter', 'company', 'add', 'nearly', '3000', 'customer', 'bring', 'total', '42500', 'worldwide', 'note', '22', 'quarter', 'palo', 'alto', 'add', '1000', 'customer', 'vast', 'customer', 'base', 'present', 'company', 'opportunity', 'upsell', 'product', 'instal', 'user', 'base', 'product', 'refresh', 'bring', 'additional', 'dollar', 'enterprise', 'attempt', 'threat', 'management', 'infrastructure', 'update', 'factor', 'turn', 'support', 'palo', 'altos', 'line']",palo alto strategic acquisition boost growth feb 2017 palo alto complete buyout lightcyber 105 million acquisition expand company nextgeneration security platform year company complete important buyout broaden portfolio global reach 2014 company take morta security israelbase cyvera expand product portfolio customer base company 2015 acquire cirrosecure startup specialize guard softwareasaservice saas application cirrosecure resource expertise help palo alto expand functionality enterprise security platform guard saas collaboration product salesforcecom google drive box dropbox better palo alto strategic partnership expedite growth company form nextwave technology partner program organization join strategic integration partner program palo alto integrate solution partner ensure combine product work seamlessly allow organization mobile nimble collaborative year expand strategic partnership vmware address cloud mobile security need organization apart palo alto strategic alliance aruba network offer security solution tailor mobile user furthermore partnership splunk palo alto offer solution effectively coordinate detection incident investigation response advanced threat integrate solution citrix company offer security solution cloud networking platform strategic partnership bring customer palo alto boost line palo alto gain customer account increase penetration exist customer drive revenue growth fourth quarter company add nearly 3000 customer bring total 42500 worldwide note 22 quarter palo alto add 1000 customer vast customer base present company opportunity upsell product instal user base product refresh bring additional dollar enterprise attempt threat management infrastructure update factor turn support palo altos line,9,14,-0.20833333333333334,9,14,-0.20833333333333334,0.9957
330,"Palo Alto Networks, Inc._Attachment1.pdf",PANW,5/15/2018,the financial well being brands and reputation of enterprises are exposed to sophisticated cyber threats consequently cyber security has become a mission critical highprofile requirement palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security,buy,"['financial', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'consequently', 'cyber', 'security', 'mission', 'critical', 'highprofile', 'requirement', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security']",financial brand reputation enterprise expose sophisticated cyber threat consequently cyber security mission critical highprofile requirement palo alto grow rapidly space innovative nextgeneration security platform company security,1,3,-0.4,1,3,-0.4,0.7506
331,"Palo Alto Networks, Inc._Attachment1.pdf",PANW,3/6/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 1775 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking zacks equity research panw wwwzackscom page 3 of 7,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '1775', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '7']",note palo alto currently trailing 12month pricebook value pb ratio 1775 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break zack equity research panw wwwzackscom page 3 7,1,3,-0.4,1,3,-0.4,0.8074
332,"Palo Alto Networks, Inc._Attachment1.pdf",PANW,4/22/2019,we note that palo alto currently has a trailing 12month pricebook value pb ratio of 206 this level compares unfavorably with what the industry witnessed in the last year hence valuation looks slightly stretched from a pb perspective nearterm prospects for palo alto are not promising as customer changing behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking zacks equity research panw wwwzackscom page 3 of 8,sell,"['note', 'palo', 'alto', 'currently', 'trailing', '12month', 'pricebook', 'value', 'pb', 'ratio', '206', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'nearterm', 'prospect', 'palo', 'alto', 'promise', 'customer', 'change', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'zack', 'equity', 'research', 'panw', 'wwwzackscom', 'page', '3', '8']",note palo alto currently trailing 12month pricebook value pb ratio 206 level compare unfavorably industry witness year valuation look slightly stretch pb perspective nearterm prospect palo alto promise customer change behavior recently hit player space past month competitor cyber security space notice company break zack equity research panw wwwzackscom page 3 8,1,3,-0.4,1,3,-0.4,0.8074
333,"Palo Alto Networks, Inc._Attachment1.pdf",PANW,12/16/2020,cyber security has become a missioncritical highprofile requirement as financial wellbeing brands and reputation of enterprises are exposed to sophisticated cyber threats palo alto is growing rapidly in this space on the back of its innovative nextgeneration security platforms the companys security platforms have innovative traffic classification engine that helps it in identifying network traffic by,sell,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'financial', 'wellbeing', 'brand', 'reputation', 'enterprise', 'expose', 'sophisticated', 'cyber', 'threat', 'palo', 'alto', 'grow', 'rapidly', 'space', 'innovative', 'nextgeneration', 'security', 'platform', 'company', 'security', 'platform', 'innovative', 'traffic', 'classification', 'engine', 'help', 'identify', 'network', 'traffic']",cyber security missioncritical highprofile requirement financial wellbeing brand reputation enterprise expose sophisticated cyber threat palo alto grow rapidly space innovative nextgeneration security platform company security platform innovative traffic classification engine help identify network traffic,2,3,-0.16666666666666666,2,3,-0.16666666666666666,0.9231
334,Proofpoint Inc_Attachment1.pdf,PFPT,10/15/2020,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand,0,3,-0.75,0,3,-0.75,0.34
335,"Proofpoint, Inc._Attachment1(2).pdf",PFPT,5/10/2018,the demand for cyber security is on the rise the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products consequently cyber security is becoming a missioncritical highprofile requirement as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 96 billion in 2018 from 89 billion in 2017 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 11 in the 20172022 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to defend protect archive and govern their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth most recently in february 2018 the company signed a definitive agreement to buy wombat security technologies inc in 2017 the company made two important buyouts cloudmark which is specialized in providing security protection for messaging services and weblifeio a leader in browser isolation solutions in 2016 the company acquired firelayers an innovator in cloud security the acquisition has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path the integration of return paths efp business has helped proofpoint to further enhance its business email compromise bec capabilities in 2015 the company made two important acquisitions emerging threats a leading provider of advanced threat intelligence and socialware a leading provider of social media compliance solutions apart from this last year proofpoint also purchased certain assets from marble security inc and emerging threats pro llc in 2014 the company acquired two businesses nexgate inc and netcitadel inc while in 2013 it purchased four companies sendmail armorize technologies abaca technology and mail distiller we believe that the aforementioned acquisitions have not only expanded proofpoints product portfolio but also its customer and revenue base social media networks have made the world a smaller place and though it has been here since a decade only its difficult to imagine life without it as social media is now being used for various personal professional and business purposes it is increasingly becoming the prime target of cyber attacks according to proofpoint on an average companies have over 300 brandowned social media accounts on different platforms such as facebook twitter linkedin google youtube instagram pinterest and others while each of these accounts provides an opportunity to strengthen the connection of the brand with its audience there is also a downside the accounts are vulnerable to security breaches also heightened regulatory requirements for brandowned accounts pose the risk of violations and fines therefore in an effort to tap the growing opportunity in this space proofpoint acquired nexgate a pioneer in security and compliance solutions for social media communication channels in 2014 with this acquisition the company forayed into the social media security and compliance space proofpoint further enhanced its capabilities in this space by acquiring socialware a leading provider of social media compliance solutions in 2015 we believe that proofpoint is well positioned to grab the opportunities from growing cyber attacks on social networks proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a strong balance sheet with ample liquidity position and low debt obligations cash and shortterm investments were 3316 million as of dec 31 2017 which translates to over 34 of the total assets moreover the company generated about 1537 million of cash flow from operational activities in 2017 it is to be noted that the company has been able to regularly increase its cash and marketable securities which reached 3316 million at the end of 2017 from 127 million at the end of 2011 similarly proofpoints cash flow from operations increased to approximately 154 million at 2017end from about 13 million at 2013end the increasing liquidity and cash flow trend ensures that the company is making investments in right directions in 2017 the company incurred capital expenditure capex of 47 million include purchase of property equipment but excludes acquisitions compared with 344 million in 2016 258 million in 2015 15 million in 2014 and 77 million in 2013 for 2018 the company expects to incur capex of around 45 million which reflects its strategy of continuously investing in growth areas,buy,"['demand', 'cyber', 'security', 'rise', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'consequently', 'cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '96', 'billion', '2018', '89', 'billion', '2017', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '11', '20172022', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'defend', 'protect', 'archive', 'govern', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'recently', 'february', '2018', 'company', 'sign', 'definitive', 'agreement', 'buy', 'wombat', 'security', 'technologies', 'inc', '2017', 'company', 'important', 'buyout', 'cloudmark', 'specialize', 'provide', 'security', 'protection', 'message', 'service', 'weblifeio', 'leader', 'browser', 'isolation', 'solution', '2016', 'company', 'acquire', 'firelayer', 'innovator', 'cloud', 'security', 'acquisition', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'integration', 'return', 'path', 'efp', 'business', 'help', 'proofpoint', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', '2015', 'company', 'important', 'acquisition', 'emerge', 'threat', 'lead', 'provider', 'advanced', 'threat', 'intelligence', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', 'apart', 'year', 'proofpoint', 'purchase', 'certain', 'asset', 'marble', 'security', 'inc', 'emerge', 'threat', 'pro', 'llc', '2014', 'company', 'acquire', 'business', 'nexgate', 'inc', 'netcitadel', 'inc', '2013', 'purchase', 'company', 'sendmail', 'armorize', 'technologies', 'abaca', 'technology', 'mail', 'distiller', 'believe', 'aforementioned', 'acquisition', 'expand', 'proofpoint', 'product', 'portfolio', 'customer', 'revenue', 'base', 'social', 'medium', 'network', 'world', 'small', 'place', 'decade', 'difficult', 'imagine', 'life', 'social', 'medium', 'personal', 'professional', 'business', 'purpose', 'increasingly', 'prime', 'target', 'cyber', 'attack', 'accord', 'proofpoint', 'average', 'company', '300', 'brandowne', 'social', 'medium', 'account', 'different', 'platform', 'facebook', 'twitter', 'linkedin', 'google', 'youtube', 'instagram', 'pinterest', 'account', 'provide', 'opportunity', 'strengthen', 'connection', 'brand', 'audience', 'downside', 'account', 'vulnerable', 'security', 'breach', 'heighten', 'regulatory', 'requirement', 'brandowne', 'account', 'pose', 'risk', 'violation', 'fine', 'effort', 'tap', 'grow', 'opportunity', 'space', 'proofpoint', 'acquire', 'nexgate', 'pioneer', 'security', 'compliance', 'solution', 'social', 'medium', 'communication', 'channel', '2014', 'acquisition', 'company', 'foray', 'social', 'medium', 'security', 'compliance', 'space', 'proofpoint', 'enhance', 'capability', 'space', 'acquire', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', '2015', 'believe', 'proofpoint', 'positioned', 'grab', 'opportunity', 'grow', 'cyber', 'attack', 'social', 'network', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'low', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '3316', 'million', 'dec', '31', '2017', 'translate', '34', 'total', 'asset', 'company', 'generate', '1537', 'million', 'cash', 'flow', 'operational', 'activity', '2017', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '3316', 'million', 'end', '2017', '127', 'million', 'end', '2011', 'similarly', 'proofpoint', 'cash', 'flow', 'operation', 'increase', 'approximately', '154', 'million', '2017end', '13', 'million', '2013end', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'ensure', 'company', 'make', 'investment', 'right', 'direction', '2017', 'company', 'incur', 'capital', 'expenditure', 'capex', '47', 'million', 'include', 'purchase', 'property', 'equipment', 'exclude', 'acquisition', 'compare', '344', 'million', '2016', '258', 'million', '2015', '15', 'million', '2014', '77', 'million', '2013', '2018', 'company', 'expect', 'incur', 'capex', '45', 'million', 'reflect', 'strategy', 'continuously', 'invest', 'growth', 'area']",demand cyber security rise long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product consequently cyber security missioncritical highprofile requirement result company allot increase portion budget security solution gartner new report worldwide spending security reach 96 billion 2018 89 billion 2017 report market market suggest cyber security market expect grow cagr 11 20172022 period prediction bode proofpoint diversified product portfolio large midsized organization defend protect archive govern sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth recently february 2018 company sign definitive agreement buy wombat security technologies inc 2017 company important buyout cloudmark specialize provide security protection message service weblifeio leader browser isolation solution 2016 company acquire firelayer innovator cloud security acquisition help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path integration return path efp business help proofpoint enhance business email compromise bec capability 2015 company important acquisition emerge threat lead provider advanced threat intelligence socialware lead provider social medium compliance solution apart year proofpoint purchase certain asset marble security inc emerge threat pro llc 2014 company acquire business nexgate inc netcitadel inc 2013 purchase company sendmail armorize technologies abaca technology mail distiller believe aforementioned acquisition expand proofpoint product portfolio customer revenue base social medium network world small place decade difficult imagine life social medium personal professional business purpose increasingly prime target cyber attack accord proofpoint average company 300 brandowne social medium account different platform facebook twitter linkedin google youtube instagram pinterest account provide opportunity strengthen connection brand audience downside account vulnerable security breach heighten regulatory requirement brandowne account pose risk violation fine effort tap grow opportunity space proofpoint acquire nexgate pioneer security compliance solution social medium communication channel 2014 acquisition company foray social medium security compliance space proofpoint enhance capability space acquire socialware lead provider social medium compliance solution 2015 believe proofpoint positioned grab opportunity grow cyber attack social network proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint strong balance sheet ample liquidity position low debt obligation cash shortterm investment 3316 million dec 31 2017 translate 34 total asset company generate 1537 million cash flow operational activity 2017 note company able regularly increase cash marketable security reach 3316 million end 2017 127 million end 2011 similarly proofpoint cash flow operation increase approximately 154 million 2017end 13 million 2013end increase liquidity cash flow trend ensure company make investment right direction 2017 company incur capital expenditure capex 47 million include purchase property equipment exclude acquisition compare 344 million 2016 258 million 2015 15 million 2014 77 million 2013 2018 company expect incur capex 45 million reflect strategy continuously invest growth area,19,45,-0.4,19,45,-0.4,0.9976
336,"Proofpoint, Inc._Attachment1(2).pdf",PFPT,9/25/2018,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 96 billion in 2018 from 89 billion in 2017 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 11 in the 20172022 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark in 2017 the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition in 2017 the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers an innovator in cloud security in 2016 has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 1341 million as of jun 30 2018 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '96', 'billion', '2018', '89', 'billion', '2017', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '11', '20172022', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', '2017', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', '2017', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'innovator', 'cloud', 'security', '2016', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '1341', 'million', 'jun', '30', '2018', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner new report worldwide spending security reach 96 billion 2018 89 billion 2017 report market market suggest cyber security market expect grow cagr 11 20172022 period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark 2017 company earn opportunity continue grow footprint carrier community result weblife acquisition 2017 company bring market new personal email defense new browser isolation solution acquisition firelayer innovator cloud security 2016 help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 1341 million jun 30 2018 enhance liquidity fund product development pursue growth strategy like acquisition,10,16,-0.2222222222222222,10,16,-0.2222222222222222,0.9962
337,"Proofpoint, Inc._Attachment1(2).pdf",PFPT,1/28/2019,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security is expected to exceed 124 billion in 2019 marking an approximately 87 growth from 2018 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 102 in the 20182023 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark in 2017 the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition in 2017 the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers an innovator in cloud security in 2016 has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 1904 million as of sep 30 2018 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,sell,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'expect', 'exceed', '124', 'billion', '2019', 'mark', 'approximately', '87', 'growth', '2018', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '102', '20182023', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', '2017', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', '2017', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'innovator', 'cloud', 'security', '2016', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '1904', 'million', 'sep', '30', '2018', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner new report worldwide spending security expect exceed 124 billion 2019 mark approximately 87 growth 2018 report market market suggest cyber security market expect grow cagr 102 20182023 period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark 2017 company earn opportunity continue grow footprint carrier community result weblife acquisition 2017 company bring market new personal email defense new browser isolation solution acquisition firelayer innovator cloud security 2016 help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 1904 million sep 30 2018 enhance liquidity fund product development pursue growth strategy like acquisition,10,15,-0.19230769230769232,10,15,-0.19230769230769232,0.9964
338,"Proofpoint, Inc._Attachment1(2).pdf",PFPT,2/27/2019,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners report worldwide spending on it security will grow 87 to reach 124 billion in 2019 going by marketsandmarkets the global cybersecurity market size was valued at 13763 billion in 2017 and is projected to attain 24826 billion by 2023 witnessing a cagr of 102 during the forecast period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark in 2017 the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition in 2017 the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers an innovator in cloud security in 2016 has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 2317 million as of dec 31 2018 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'report', 'worldwide', 'spending', 'security', 'grow', '87', 'reach', '124', 'billion', '2019', 'go', 'marketsandmarket', 'global', 'cybersecurity', 'market', 'size', 'value', '13763', 'billion', '2017', 'project', 'attain', '24826', 'billion', '2023', 'witness', 'cagr', '102', 'forecast', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', '2017', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', '2017', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'innovator', 'cloud', 'security', '2016', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '2317', 'million', 'dec', '31', '2018', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner report worldwide spending security grow 87 reach 124 billion 2019 go marketsandmarket global cybersecurity market size value 13763 billion 2017 project attain 24826 billion 2023 witness cagr 102 forecast period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark 2017 company earn opportunity continue grow footprint carrier community result weblife acquisition 2017 company bring market new personal email defense new browser isolation solution acquisition firelayer innovator cloud security 2016 help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 2317 million dec 31 2018 enhance liquidity fund product development pursue growth strategy like acquisition,12,17,-0.16666666666666666,12,17,-0.16666666666666666,0.9962
339,"Proofpoint, Inc._Attachment1(2).pdf",PFPT,2/27/2019,to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years proofpoint has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this remains a drag on the companys bottomline results furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period nearterm prospects for proofpoint are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment therefore we are slightly cautious about the companys nearterm prospects proofpoint faces competition from numerous big and small companies in the security application market as internet threats and attacks increase stiff competition will follow suit competing firms must deliver prompt and advanced technologies to suit customer requirements and expedite product introduction in order to survive moreover we believe that proofpoints dominance could be challenged by new entrants this could lead the company to resort to competitive pricing to maintain and capture market share proofpoint expects the inorganic revenue contributions in 2018 to lead to challenging yearoveryear comparison in 2019 the company anticipates additional headwinds in the coming year due to adoption of asc 606 and no contribution from cloudmark business moreover the company anticipates the first quarter of 2019 to witness a relatively low yearoveryear growth rate which makes us anxious,sell,"['survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'proofpoint', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'remain', 'drag', 'company', 'bottomline', 'result', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period', 'nearterm', 'prospect', 'proofpoint', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'slightly', 'cautious', 'company', 'nearterm', 'prospect', 'proofpoint', 'face', 'competition', 'numerous', 'big', 'small', 'company', 'security', 'application', 'market', 'internet', 'threat', 'attack', 'increase', 'stiff', 'competition', 'follow', 'suit', 'compete', 'firm', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'introduction', 'order', 'survive', 'believe', 'proofpoint', 'dominance', 'challenge', 'new', 'entrant', 'lead', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'proofpoint', 'expect', 'inorganic', 'revenue', 'contribution', '2018', 'lead', 'challenge', 'yearoveryear', 'comparison', '2019', 'company', 'anticipate', 'additional', 'headwind', 'come', 'year', 'adoption', 'asc', '606', 'contribution', 'cloudmark', 'business', 'company', 'anticipate', 'quarter', '2019', 'witness', 'relatively', 'low', 'yearoveryear', 'growth', 'rate', 'make', 'anxious']",survive highly competitive cyber security market player continually invest broaden capability past year proofpoint invest heavily enhance sale marketing capability particularly increase sale force remain drag company bottomline result furthermore company foresee investment garner benefit long run note uncertainty payback period nearterm prospect proofpoint promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment slightly cautious company nearterm prospect proofpoint face competition numerous big small company security application market internet threat attack increase stiff competition follow suit compete firm deliver prompt advanced technology suit customer requirement expedite product introduction order survive believe proofpoint dominance challenge new entrant lead company resort competitive pricing maintain capture market share proofpoint expect inorganic revenue contribution 2018 lead challenge yearoveryear comparison 2019 company anticipate additional headwind come year adoption asc 606 contribution cloudmark business company anticipate quarter 2019 witness relatively low yearoveryear growth rate make anxious,7,18,-0.4230769230769231,7,18,-0.4230769230769231,0.9521
340,"Proofpoint, Inc._Attachment1(3).pdf",PFPT,9/26/2018,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 96 billion in 2018 from 89 billion in 2017 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 11 in the 20172022 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark in 2017 the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition in 2017 the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers an innovator in cloud security in 2016 has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 1341 million as of jun 30 2018 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,sell,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '96', 'billion', '2018', '89', 'billion', '2017', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '11', '20172022', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', '2017', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', '2017', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'innovator', 'cloud', 'security', '2016', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '1341', 'million', 'jun', '30', '2018', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner new report worldwide spending security reach 96 billion 2018 89 billion 2017 report market market suggest cyber security market expect grow cagr 11 20172022 period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark 2017 company earn opportunity continue grow footprint carrier community result weblife acquisition 2017 company bring market new personal email defense new browser isolation solution acquisition firelayer innovator cloud security 2016 help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 1341 million jun 30 2018 enhance liquidity fund product development pursue growth strategy like acquisition,10,16,-0.2222222222222222,10,16,-0.2222222222222222,0.9962
341,"Proofpoint, Inc._Attachment1(4).pdf",PFPT,8/1/2017,we note that proofpoint currently has a trailing 12 month pricebook value pb ratio of 10292 this level compares unfavorably with what the industry saw over the last year the ratio is way higher than the average level of 7556 and is in line with its high end of the valuation range over this period hence valuation looks slightly stretched from a pb perspective although proofpoints topline growth has been remarkable as a result of sustained focus on launching new products acquisitions and partnerships the company has failed to deliver on the bottom line since apr 2012 when it was listed on nasdaq the company has not been able to report profits on an adjusted basis in even a single quarter as the company is yet to achieve profitability we are slightly cautious about the stocks future performance nearterm prospects for proofpoint are not promising as changing customer spending behavior has recently hit several other zacks equity research pfpt wwwzackscom page 3 of 8,sell,"['note', 'proofpoint', 'currently', 'trail', '12', 'month', 'pricebook', 'value', 'pb', 'ratio', '10292', 'level', 'compare', 'unfavorably', 'industry', 'see', 'year', 'ratio', 'way', 'high', 'average', 'level', '7556', 'line', 'high', 'end', 'valuation', 'range', 'period', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'proofpoint', 'topline', 'growth', 'remarkable', 'result', 'sustained', 'focus', 'launch', 'new', 'product', 'acquisition', 'partnership', 'company', 'fail', 'deliver', 'line', 'apr', '2012', 'list', 'nasdaq', 'company', 'able', 'report', 'profit', 'adjust', 'basis', 'single', 'quarter', 'company', 'achieve', 'profitability', 'slightly', 'cautious', 'stock', 'future', 'performance', 'nearterm', 'prospect', 'proofpoint', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'zack', 'equity', 'research', 'pfpt', 'wwwzackscom', 'page', '3', '8']",note proofpoint currently trail 12 month pricebook value pb ratio 10292 level compare unfavorably industry see year ratio way high average level 7556 line high end valuation range period valuation look slightly stretch pb perspective proofpoint topline growth remarkable result sustained focus launch new product acquisition partnership company fail deliver line apr 2012 list nasdaq company able report profit adjust basis single quarter company achieve profitability slightly cautious stock future performance nearterm prospect proofpoint promise change customer spending behavior recently hit zack equity research pfpt wwwzackscom page 3 8,6,9,-0.1875,6,9,-0.1875,0.9099
342,"Proofpoint, Inc._Attachment1(4).pdf",PFPT,12/22/2017,nearterm prospects for proofpoint are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead zacks equity research pfpt wwwzackscom page 3 of 8,sell,"['nearterm', 'prospect', 'proofpoint', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'zack', 'equity', 'research', 'pfpt', 'wwwzackscom', 'page', '3', '8']",nearterm prospect proofpoint promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead zack equity research pfpt wwwzackscom page 3 8,0,4,-0.8,0,4,-0.8,0.7096
343,"Proofpoint, Inc._Attachment1(4).pdf",PFPT,4/10/2018,the demand for cyber security is on the rise the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products consequently cyber security is becoming a missioncritical highprofile requirement as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 96 billion in 2018 from 89 billion in 2017 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 11 in the 20172022 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to defend protect archive and govern their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth most recently in february 2018 the company signed a definitive agreement to buy wombat security technologies inc in 2017 the company made two important buyouts cloudmark which is specialized in providing security protection for messaging services and weblifeio a leader in browser isolation solutions in 2016 the company acquired firelayers an innovator in cloud security the acquisition has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path the integration of return paths efp business has helped proofpoint to further enhance its business email compromise bec capabilities in 2015 the company made two important acquisitions emerging threats a leading provider of advanced threat intelligence and socialware a leading provider of social media compliance solutions apart from this last year proofpoint also purchased certain assets from marble security inc and emerging threats pro llc in 2014 the company acquired two businesses nexgate inc and netcitadel inc while in 2013 it purchased four companies sendmail armorize technologies abaca technology and mail distiller we believe that the aforementioned acquisitions have not only expanded proofpoints product portfolio but also its customer and revenue base social media networks have made the world a smaller place and though it has been here since a decade only its difficult to imagine life without it as social media is now being used for various personal professional and business purposes it is increasingly becoming the prime target of cyber attacks according to proofpoint on an average companies have over 300 brandowned social media accounts on different platforms such as facebook twitter linkedin google youtube instagram pinterest and others while each of these accounts provides an opportunity to strengthen the connection of the brand with its audience there is also a downside the accounts are vulnerable to security breaches also heightened regulatory requirements for brandowned accounts pose the risk of violations and fines therefore in an effort to tap the growing opportunity in this space proofpoint acquired nexgate a pioneer in security and compliance solutions for social media communication channels in 2014 with this acquisition the company forayed into the social media security and compliance space proofpoint further enhanced its capabilities in this space by acquiring socialware a leading provider of social media compliance solutions in 2015 we believe that proofpoint is well positioned to grab the opportunities from growing cyber attacks on social networks proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a strong balance sheet with ample liquidity position and low debt obligations cash and shortterm investments were 3316 million as of dec 31 2017 which translates to over 34 of the total assets moreover the company zacks equity research pfpt wwwzackscom page 3 of 8,sell,"['demand', 'cyber', 'security', 'rise', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'consequently', 'cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '96', 'billion', '2018', '89', 'billion', '2017', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '11', '20172022', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'defend', 'protect', 'archive', 'govern', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'recently', 'february', '2018', 'company', 'sign', 'definitive', 'agreement', 'buy', 'wombat', 'security', 'technologies', 'inc', '2017', 'company', 'important', 'buyout', 'cloudmark', 'specialize', 'provide', 'security', 'protection', 'message', 'service', 'weblifeio', 'leader', 'browser', 'isolation', 'solution', '2016', 'company', 'acquire', 'firelayer', 'innovator', 'cloud', 'security', 'acquisition', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'integration', 'return', 'path', 'efp', 'business', 'help', 'proofpoint', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', '2015', 'company', 'important', 'acquisition', 'emerge', 'threat', 'lead', 'provider', 'advanced', 'threat', 'intelligence', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', 'apart', 'year', 'proofpoint', 'purchase', 'certain', 'asset', 'marble', 'security', 'inc', 'emerge', 'threat', 'pro', 'llc', '2014', 'company', 'acquire', 'business', 'nexgate', 'inc', 'netcitadel', 'inc', '2013', 'purchase', 'company', 'sendmail', 'armorize', 'technologies', 'abaca', 'technology', 'mail', 'distiller', 'believe', 'aforementioned', 'acquisition', 'expand', 'proofpoint', 'product', 'portfolio', 'customer', 'revenue', 'base', 'social', 'medium', 'network', 'world', 'small', 'place', 'decade', 'difficult', 'imagine', 'life', 'social', 'medium', 'personal', 'professional', 'business', 'purpose', 'increasingly', 'prime', 'target', 'cyber', 'attack', 'accord', 'proofpoint', 'average', 'company', '300', 'brandowne', 'social', 'medium', 'account', 'different', 'platform', 'facebook', 'twitter', 'linkedin', 'google', 'youtube', 'instagram', 'pinterest', 'account', 'provide', 'opportunity', 'strengthen', 'connection', 'brand', 'audience', 'downside', 'account', 'vulnerable', 'security', 'breach', 'heighten', 'regulatory', 'requirement', 'brandowne', 'account', 'pose', 'risk', 'violation', 'fine', 'effort', 'tap', 'grow', 'opportunity', 'space', 'proofpoint', 'acquire', 'nexgate', 'pioneer', 'security', 'compliance', 'solution', 'social', 'medium', 'communication', 'channel', '2014', 'acquisition', 'company', 'foray', 'social', 'medium', 'security', 'compliance', 'space', 'proofpoint', 'enhance', 'capability', 'space', 'acquire', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', '2015', 'believe', 'proofpoint', 'positioned', 'grab', 'opportunity', 'grow', 'cyber', 'attack', 'social', 'network', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'low', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '3316', 'million', 'dec', '31', '2017', 'translate', '34', 'total', 'asset', 'company', 'zack', 'equity', 'research', 'pfpt', 'wwwzackscom', 'page', '3', '8']",demand cyber security rise long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product consequently cyber security missioncritical highprofile requirement result company allot increase portion budget security solution gartner new report worldwide spending security reach 96 billion 2018 89 billion 2017 report market market suggest cyber security market expect grow cagr 11 20172022 period prediction bode proofpoint diversified product portfolio large midsized organization defend protect archive govern sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth recently february 2018 company sign definitive agreement buy wombat security technologies inc 2017 company important buyout cloudmark specialize provide security protection message service weblifeio leader browser isolation solution 2016 company acquire firelayer innovator cloud security acquisition help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path integration return path efp business help proofpoint enhance business email compromise bec capability 2015 company important acquisition emerge threat lead provider advanced threat intelligence socialware lead provider social medium compliance solution apart year proofpoint purchase certain asset marble security inc emerge threat pro llc 2014 company acquire business nexgate inc netcitadel inc 2013 purchase company sendmail armorize technologies abaca technology mail distiller believe aforementioned acquisition expand proofpoint product portfolio customer revenue base social medium network world small place decade difficult imagine life social medium personal professional business purpose increasingly prime target cyber attack accord proofpoint average company 300 brandowne social medium account different platform facebook twitter linkedin google youtube instagram pinterest account provide opportunity strengthen connection brand audience downside account vulnerable security breach heighten regulatory requirement brandowne account pose risk violation fine effort tap grow opportunity space proofpoint acquire nexgate pioneer security compliance solution social medium communication channel 2014 acquisition company foray social medium security compliance space proofpoint enhance capability space acquire socialware lead provider social medium compliance solution 2015 believe proofpoint positioned grab opportunity grow cyber attack social network proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint strong balance sheet ample liquidity position low debt obligation cash shortterm investment 3316 million dec 31 2017 translate 34 total asset company zack equity research pfpt wwwzackscom page 3 8,18,37,-0.3392857142857143,18,37,-0.3392857142857143,0.9968
344,"Proofpoint, Inc._Attachment1(4).pdf",PFPT,10/29/2018,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 96 billion in 2018 from 89 billion in 2017 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 11 in the 20172022 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark in 2017 the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition in 2017 the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers an innovator in cloud security in 2016 has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 1904 million as of sep 30 2018 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,sell,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '96', 'billion', '2018', '89', 'billion', '2017', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '11', '20172022', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', '2017', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', '2017', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'innovator', 'cloud', 'security', '2016', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '1904', 'million', 'sep', '30', '2018', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner new report worldwide spending security reach 96 billion 2018 89 billion 2017 report market market suggest cyber security market expect grow cagr 11 20172022 period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark 2017 company earn opportunity continue grow footprint carrier community result weblife acquisition 2017 company bring market new personal email defense new browser isolation solution acquisition firelayer innovator cloud security 2016 help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 1904 million sep 30 2018 enhance liquidity fund product development pursue growth strategy like acquisition,10,16,-0.2222222222222222,10,16,-0.2222222222222222,0.9962
345,"Proofpoint, Inc._Attachment1(5).pdf",PFPT,10/31/2018,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 96 billion in 2018 from 89 billion in 2017 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 11 in the 20172022 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark in 2017 the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition in 2017 the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers an innovator in cloud security in 2016 has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 1904 million as of sep 30 2018 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '96', 'billion', '2018', '89', 'billion', '2017', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '11', '20172022', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', '2017', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', '2017', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'innovator', 'cloud', 'security', '2016', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '1904', 'million', 'sep', '30', '2018', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner new report worldwide spending security reach 96 billion 2018 89 billion 2017 report market market suggest cyber security market expect grow cagr 11 20172022 period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark 2017 company earn opportunity continue grow footprint carrier community result weblife acquisition 2017 company bring market new personal email defense new browser isolation solution acquisition firelayer innovator cloud security 2016 help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 1904 million sep 30 2018 enhance liquidity fund product development pursue growth strategy like acquisition,10,16,-0.2222222222222222,10,16,-0.2222222222222222,0.9962
346,"Proofpoint, Inc._Attachment1(5).pdf",PFPT,5/16/2019,to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years proofpoint has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this remains a drag on the companys bottomline results furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period nearterm prospects for proofpoint are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment therefore we are slightly cautious about the companys nearterm prospects proofpoint faces competition from numerous big and small companies in the security application market as internet threats and attacks increase stiff competition will follow suit competing firms must deliver prompt and advanced technologies to suit customer requirements and expedite product introduction in order to survive moreover we believe that proofpoints dominance could be challenged by new entrants this could lead the company to resort to competitive pricing to maintain and capture market share proofpoint expects the inorganic revenue contributions in 2018 to lead to challenging yearoveryear comparison in 2019 the company anticipates additional headwinds in the coming year due to adoption of asc 606 and no contribution from cloudmarks oem business zacks equity research pfpt wwwzackscom page 4 of 10,sell,"['survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'proofpoint', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'remain', 'drag', 'company', 'bottomline', 'result', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period', 'nearterm', 'prospect', 'proofpoint', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'slightly', 'cautious', 'company', 'nearterm', 'prospect', 'proofpoint', 'face', 'competition', 'numerous', 'big', 'small', 'company', 'security', 'application', 'market', 'internet', 'threat', 'attack', 'increase', 'stiff', 'competition', 'follow', 'suit', 'compete', 'firm', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'introduction', 'order', 'survive', 'believe', 'proofpoint', 'dominance', 'challenge', 'new', 'entrant', 'lead', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'proofpoint', 'expect', 'inorganic', 'revenue', 'contribution', '2018', 'lead', 'challenge', 'yearoveryear', 'comparison', '2019', 'company', 'anticipate', 'additional', 'headwind', 'come', 'year', 'adoption', 'asc', '606', 'contribution', 'cloudmarks', 'oem', 'business', 'zack', 'equity', 'research', 'pfpt', 'wwwzackscom', 'page', '4', '10']",survive highly competitive cyber security market player continually invest broaden capability past year proofpoint invest heavily enhance sale marketing capability particularly increase sale force remain drag company bottomline result furthermore company foresee investment garner benefit long run note uncertainty payback period nearterm prospect proofpoint promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment slightly cautious company nearterm prospect proofpoint face competition numerous big small company security application market internet threat attack increase stiff competition follow suit compete firm deliver prompt advanced technology suit customer requirement expedite product introduction order survive believe proofpoint dominance challenge new entrant lead company resort competitive pricing maintain capture market share proofpoint expect inorganic revenue contribution 2018 lead challenge yearoveryear comparison 2019 company anticipate additional headwind come year adoption asc 606 contribution cloudmarks oem business zack equity research pfpt wwwzackscom page 4 10,6,18,-0.48,6,18,-0.48,0.9556
347,"Proofpoint, Inc._Attachment1(7).pdf",PFPT,9/22/2017,the demand for cyber security is on the rise the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products consequently cyber security is becoming a missioncritical highprofile requirement as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 101 billion in 2018 from 75 billion in 2015 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 98 through 2015 2020 these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to defend protect archive and govern their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth in oct 2016 the company signed a definite agreement to acquire firelayers an innovator in cloud security the acquisition is anticipated to help proofpoint in extending its targeted attack protection tap solution to saas applications and protect these from advanced malware prior to that in aug 2016 it acquired the email fraud protection efp business unit from return path the integration of return paths efp business has helped proofpoint to further enhance its business email compromise bec capabilities in 2015 the company made two important acquisitions emerging threats a leading provider of advanced threat intelligence and socialware a leading provider of social media compliance solutions apart from this last year proofpoint also purchased certain assets from marble security inc and emerging threats pro llc in 2014 the company acquired two businesses nexgate inc and netcitadel inc while in 2013 it purchased four companies sendmail armorize technologies abaca technology and mail distiller we believe that the aforementioned acquisitions have not only expanded proofpoints product portfolio but also its customer and revenue base social media networks have made the world a smaller place and though it has been here since a decade only its difficult to imagine life without it as social media is now being used for various personal professional and business purposes it is increasingly becoming the prime target of cyber attacks according to proofpoint on an average companies have over 300 brandowned social media accounts on different platforms such as facebook twitter linkedin google youtube instagram pinterest and others while each of these accounts provides an opportunity to strengthen the connection of the brand with its audience there is also a downside the accounts are vulnerable to security breaches also heightened regulatory requirements for brandowned accounts pose the risk of violations and fines therefore in an effort to tap the growing opportunity in this space proofpoint acquired nexgate a pioneer in security and compliance solutions for social media communication channels in 2014 with this acquisition the company forayed into the social media security and compliance space proofpoint further enhanced its capabilities in this space by acquiring socialware a leading provider of social media compliance solutions in 2015 we believe that proofpoint is well positioned to grab the opportunities from growing cyber attacks on social networks proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 97 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a strong balance sheet with ample liquidity position and low debt obligations cash and shortterm investments were 4295 million as of jun 30 2017 which translates to over 51 of the total assets moreover the company generated about 67 million of cash flow from operational activities in first half of 2017 it is to be noted that the company has been able to regularly increase its cash and marketable securities which reached 397 million at the end of 2016 from 127 million at the end of 2011 similarly proofpoints cash flow from operations increased to approximately 94 million at 2016end from about 13 million at 2013end the increasing liquidity and cash flow trend ensures that the company is making investments in right directions in 2016 the company incurred capital expenditure capex of 344 million include purchase of property equipment but excludes acquisitions compared with 258 million in 2015 15 million in 2014 and 77 million in 2013 for 2017 the company expects to incur capex in a range of 40 million to 42 million which reflects its strategy of continuously investing in growth areas,buy,"['demand', 'cyber', 'security', 'rise', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'consequently', 'cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '101', 'billion', '2018', '75', 'billion', '2015', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '98', '2015', '2020', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'defend', 'protect', 'archive', 'govern', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'oct', '2016', 'company', 'sign', 'definite', 'agreement', 'acquire', 'firelayer', 'innovator', 'cloud', 'security', 'acquisition', 'anticipate', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'prior', 'aug', '2016', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'integration', 'return', 'path', 'efp', 'business', 'help', 'proofpoint', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', '2015', 'company', 'important', 'acquisition', 'emerge', 'threat', 'lead', 'provider', 'advanced', 'threat', 'intelligence', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', 'apart', 'year', 'proofpoint', 'purchase', 'certain', 'asset', 'marble', 'security', 'inc', 'emerge', 'threat', 'pro', 'llc', '2014', 'company', 'acquire', 'business', 'nexgate', 'inc', 'netcitadel', 'inc', '2013', 'purchase', 'company', 'sendmail', 'armorize', 'technologies', 'abaca', 'technology', 'mail', 'distiller', 'believe', 'aforementioned', 'acquisition', 'expand', 'proofpoint', 'product', 'portfolio', 'customer', 'revenue', 'base', 'social', 'medium', 'network', 'world', 'small', 'place', 'decade', 'difficult', 'imagine', 'life', 'social', 'medium', 'personal', 'professional', 'business', 'purpose', 'increasingly', 'prime', 'target', 'cyber', 'attack', 'accord', 'proofpoint', 'average', 'company', '300', 'brandowne', 'social', 'medium', 'account', 'different', 'platform', 'facebook', 'twitter', 'linkedin', 'google', 'youtube', 'instagram', 'pinterest', 'account', 'provide', 'opportunity', 'strengthen', 'connection', 'brand', 'audience', 'downside', 'account', 'vulnerable', 'security', 'breach', 'heighten', 'regulatory', 'requirement', 'brandowne', 'account', 'pose', 'risk', 'violation', 'fine', 'effort', 'tap', 'grow', 'opportunity', 'space', 'proofpoint', 'acquire', 'nexgate', 'pioneer', 'security', 'compliance', 'solution', 'social', 'medium', 'communication', 'channel', '2014', 'acquisition', 'company', 'foray', 'social', 'medium', 'security', 'compliance', 'space', 'proofpoint', 'enhance', 'capability', 'space', 'acquire', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', '2015', 'believe', 'proofpoint', 'positioned', 'grab', 'opportunity', 'grow', 'cyber', 'attack', 'social', 'network', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '97', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'low', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '4295', 'million', 'jun', '30', '2017', 'translate', '51', 'total', 'asset', 'company', 'generate', '67', 'million', 'cash', 'flow', 'operational', 'activity', 'half', '2017', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '397', 'million', 'end', '2016', '127', 'million', 'end', '2011', 'similarly', 'proofpoint', 'cash', 'flow', 'operation', 'increase', 'approximately', '94', 'million', '2016end', '13', 'million', '2013end', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'ensure', 'company', 'make', 'investment', 'right', 'direction', '2016', 'company', 'incur', 'capital', 'expenditure', 'capex', '344', 'million', 'include', 'purchase', 'property', 'equipment', 'exclude', 'acquisition', 'compare', '258', 'million', '2015', '15', 'million', '2014', '77', 'million', '2013', '2017', 'company', 'expect', 'incur', 'capex', 'range', '40', 'million', '42', 'million', 'reflect', 'strategy', 'continuously', 'invest', 'growth', 'area']",demand cyber security rise long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product consequently cyber security missioncritical highprofile requirement result company allot increase portion budget security solution gartner new report worldwide spending security reach 101 billion 2018 75 billion 2015 report market market suggest cyber security market expect grow cagr 98 2015 2020 prediction bode proofpoint diversified product portfolio large midsized organization defend protect archive govern sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth oct 2016 company sign definite agreement acquire firelayer innovator cloud security acquisition anticipate help proofpoint extend target attack protection tap solution saas application protect advanced malware prior aug 2016 acquire email fraud protection efp business unit return path integration return path efp business help proofpoint enhance business email compromise bec capability 2015 company important acquisition emerge threat lead provider advanced threat intelligence socialware lead provider social medium compliance solution apart year proofpoint purchase certain asset marble security inc emerge threat pro llc 2014 company acquire business nexgate inc netcitadel inc 2013 purchase company sendmail armorize technologies abaca technology mail distiller believe aforementioned acquisition expand proofpoint product portfolio customer revenue base social medium network world small place decade difficult imagine life social medium personal professional business purpose increasingly prime target cyber attack accord proofpoint average company 300 brandowne social medium account different platform facebook twitter linkedin google youtube instagram pinterest account provide opportunity strengthen connection brand audience downside account vulnerable security breach heighten regulatory requirement brandowne account pose risk violation fine effort tap grow opportunity space proofpoint acquire nexgate pioneer security compliance solution social medium communication channel 2014 acquisition company foray social medium security compliance space proofpoint enhance capability space acquire socialware lead provider social medium compliance solution 2015 believe proofpoint positioned grab opportunity grow cyber attack social network proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 97 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint strong balance sheet ample liquidity position low debt obligation cash shortterm investment 4295 million jun 30 2017 translate 51 total asset company generate 67 million cash flow operational activity half 2017 note company able regularly increase cash marketable security reach 397 million end 2016 127 million end 2011 similarly proofpoint cash flow operation increase approximately 94 million 2016end 13 million 2013end increase liquidity cash flow trend ensure company make investment right direction 2016 company incur capital expenditure capex 344 million include purchase property equipment exclude acquisition compare 258 million 2015 15 million 2014 77 million 2013 2017 company expect incur capex range 40 million 42 million reflect strategy continuously invest growth area,18,44,-0.4126984126984127,18,44,-0.4126984126984127,0.9974
348,"Proofpoint, Inc._Attachment1(9).pdf",PFPT,4/26/2017,the demand for cyber security is on the rise the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products consequently cyber security is becoming a missioncritical highprofile requirement as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 101 billion in 2018 from 75 billion in 2015 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 98 through 2015 2020 these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to defend protect archive and govern their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth in oct 2016 the company signed a definite agreement to acquire firelayers an innovator in cloud security the acquisition is anticipated to help proofpoint in extending its targeted attack protection tap solution to saas applications and protect these from advanced malware prior to that in aug 2016 it acquired the email fraud protection efp business unit from return path the integration of return paths efp business has helped proofpoint to further enhance its business email compromise bec capabilities in 2015 the company made two important acquisitions emerging threats a leading provider of advanced threat intelligence and socialware a leading provider of social media compliance solutions apart from this last year proofpoint also purchased certain assets from marble security inc and emerging threats pro llc in 2014 the company acquired two businesses nexgate inc and netcitadel inc while in 2013 it purchased four companies sendmail armorize technologies abaca technology and mail distiller we believe that the aforementioned acquisitions have not only expanded proofpoints product portfolio but also its customer and revenue base social media networks have made the world a smaller place and though it has been here since a decade only its difficult to imagine life without it as social media is now being used for various personal professional and business purposes it is increasingly becoming the prime target of cyber attacks according to proofpoint on an average companies have over 300 brandowned social media accounts on different platforms such as facebook twitter linkedin google youtube instagram pinterest and others while each of these accounts provides an opportunity to strengthen the connection of the brand with its audience there is also a downside the accounts are vulnerable to security breaches also heightened regulatory requirements for brandowned accounts pose the risk of violations and fines therefore in an effort to tap the growing opportunity in this space proofpoint acquired nexgate a pioneer in security and compliance solutions for social media communication channels in 2014 with this acquisition the company forayed into the social media security and compliance space proofpoint further enhanced its capabilities in this space by acquiring socialware a leading provider of social media compliance solutions in 2015 we believe that proofpoint is well positioned to grab the opportunities from growing cyber attacks on social networks proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 97 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a strong balance sheet with ample liquidity position and low debt obligations cash and shortterm investments were 4129 million as of mar 31 2017 which translates to approximately 511 of the total assets moreover the company generated about 405 million of cash flow from operational activities in firstquarter 2017 it is to be noted that the company has been able to regularly increase its cash and marketable securities which reached 397 million at the end of 2016 from 127 million at the end of 2011 similarly proofpoints cash flow from operations increased to approximately 94 million at 2016end from about 13 million at 2013end the increasing liquidity and cash flow trend ensures that the company is making investments in right directions in 2016 the company incurred capital expenditure capex of 344 million include purchase of property equipment but excludes acquisitions compared with 258 million in 2015 15 million in 2014 and 77 million in 2013 for 2017 the company expects to incur capex in a range of 40 million to 42 million which reflects its strategy of continuously investing in growth areas,buy,"['demand', 'cyber', 'security', 'rise', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'consequently', 'cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '101', 'billion', '2018', '75', 'billion', '2015', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '98', '2015', '2020', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'defend', 'protect', 'archive', 'govern', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'oct', '2016', 'company', 'sign', 'definite', 'agreement', 'acquire', 'firelayer', 'innovator', 'cloud', 'security', 'acquisition', 'anticipate', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'prior', 'aug', '2016', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'integration', 'return', 'path', 'efp', 'business', 'help', 'proofpoint', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', '2015', 'company', 'important', 'acquisition', 'emerge', 'threat', 'lead', 'provider', 'advanced', 'threat', 'intelligence', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', 'apart', 'year', 'proofpoint', 'purchase', 'certain', 'asset', 'marble', 'security', 'inc', 'emerge', 'threat', 'pro', 'llc', '2014', 'company', 'acquire', 'business', 'nexgate', 'inc', 'netcitadel', 'inc', '2013', 'purchase', 'company', 'sendmail', 'armorize', 'technologies', 'abaca', 'technology', 'mail', 'distiller', 'believe', 'aforementioned', 'acquisition', 'expand', 'proofpoint', 'product', 'portfolio', 'customer', 'revenue', 'base', 'social', 'medium', 'network', 'world', 'small', 'place', 'decade', 'difficult', 'imagine', 'life', 'social', 'medium', 'personal', 'professional', 'business', 'purpose', 'increasingly', 'prime', 'target', 'cyber', 'attack', 'accord', 'proofpoint', 'average', 'company', '300', 'brandowne', 'social', 'medium', 'account', 'different', 'platform', 'facebook', 'twitter', 'linkedin', 'google', 'youtube', 'instagram', 'pinterest', 'account', 'provide', 'opportunity', 'strengthen', 'connection', 'brand', 'audience', 'downside', 'account', 'vulnerable', 'security', 'breach', 'heighten', 'regulatory', 'requirement', 'brandowne', 'account', 'pose', 'risk', 'violation', 'fine', 'effort', 'tap', 'grow', 'opportunity', 'space', 'proofpoint', 'acquire', 'nexgate', 'pioneer', 'security', 'compliance', 'solution', 'social', 'medium', 'communication', 'channel', '2014', 'acquisition', 'company', 'foray', 'social', 'medium', 'security', 'compliance', 'space', 'proofpoint', 'enhance', 'capability', 'space', 'acquire', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', '2015', 'believe', 'proofpoint', 'positioned', 'grab', 'opportunity', 'grow', 'cyber', 'attack', 'social', 'network', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '97', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'low', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '4129', 'million', 'mar', '31', '2017', 'translate', 'approximately', '511', 'total', 'asset', 'company', 'generate', '405', 'million', 'cash', 'flow', 'operational', 'activity', 'firstquarter', '2017', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '397', 'million', 'end', '2016', '127', 'million', 'end', '2011', 'similarly', 'proofpoint', 'cash', 'flow', 'operation', 'increase', 'approximately', '94', 'million', '2016end', '13', 'million', '2013end', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'ensure', 'company', 'make', 'investment', 'right', 'direction', '2016', 'company', 'incur', 'capital', 'expenditure', 'capex', '344', 'million', 'include', 'purchase', 'property', 'equipment', 'exclude', 'acquisition', 'compare', '258', 'million', '2015', '15', 'million', '2014', '77', 'million', '2013', '2017', 'company', 'expect', 'incur', 'capex', 'range', '40', 'million', '42', 'million', 'reflect', 'strategy', 'continuously', 'invest', 'growth', 'area']",demand cyber security rise long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product consequently cyber security missioncritical highprofile requirement result company allot increase portion budget security solution gartner new report worldwide spending security reach 101 billion 2018 75 billion 2015 report market market suggest cyber security market expect grow cagr 98 2015 2020 prediction bode proofpoint diversified product portfolio large midsized organization defend protect archive govern sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth oct 2016 company sign definite agreement acquire firelayer innovator cloud security acquisition anticipate help proofpoint extend target attack protection tap solution saas application protect advanced malware prior aug 2016 acquire email fraud protection efp business unit return path integration return path efp business help proofpoint enhance business email compromise bec capability 2015 company important acquisition emerge threat lead provider advanced threat intelligence socialware lead provider social medium compliance solution apart year proofpoint purchase certain asset marble security inc emerge threat pro llc 2014 company acquire business nexgate inc netcitadel inc 2013 purchase company sendmail armorize technologies abaca technology mail distiller believe aforementioned acquisition expand proofpoint product portfolio customer revenue base social medium network world small place decade difficult imagine life social medium personal professional business purpose increasingly prime target cyber attack accord proofpoint average company 300 brandowne social medium account different platform facebook twitter linkedin google youtube instagram pinterest account provide opportunity strengthen connection brand audience downside account vulnerable security breach heighten regulatory requirement brandowne account pose risk violation fine effort tap grow opportunity space proofpoint acquire nexgate pioneer security compliance solution social medium communication channel 2014 acquisition company foray social medium security compliance space proofpoint enhance capability space acquire socialware lead provider social medium compliance solution 2015 believe proofpoint positioned grab opportunity grow cyber attack social network proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 97 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint strong balance sheet ample liquidity position low debt obligation cash shortterm investment 4129 million mar 31 2017 translate approximately 511 total asset company generate 405 million cash flow operational activity firstquarter 2017 note company able regularly increase cash marketable security reach 397 million end 2016 127 million end 2011 similarly proofpoint cash flow operation increase approximately 94 million 2016end 13 million 2013end increase liquidity cash flow trend ensure company make investment right direction 2016 company incur capital expenditure capex 344 million include purchase property equipment exclude acquisition compare 258 million 2015 15 million 2014 77 million 2013 2017 company expect incur capex range 40 million 42 million reflect strategy continuously invest growth area,18,44,-0.4126984126984127,18,44,-0.4126984126984127,0.9974
349,"Proofpoint, Inc._Attachment1.pdf",PFPT,11/27/2017,the demand for cyber security is on the rise the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products consequently cyber security is becoming a missioncritical highprofile requirement as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 101 billion in 2018 from 75 billion in 2015 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 98 through 2015 2020 these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to defend protect archive and govern their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth in oct 2016 the company signed a definite agreement to acquire firelayers an innovator in cloud security the acquisition is anticipated to help proofpoint in extending its targeted attack protection tap solution to saas applications and protect these from advanced malware prior to that in aug 2016 it acquired the email fraud protection efp business unit from return path the integration of return paths efp business has helped proofpoint to further enhance its business email compromise bec capabilities in 2015 the company made two important acquisitions emerging threats a leading provider of advanced threat intelligence and socialware a leading provider of social media compliance solutions apart from this last year proofpoint also purchased certain assets from marble security inc and emerging threats pro llc in 2014 the company acquired two businesses nexgate inc and netcitadel inc while in 2013 it purchased four companies sendmail armorize technologies abaca technology and mail distiller we believe that the aforementioned acquisitions have not only expanded proofpoints product portfolio but also its customer and revenue base social media networks have made the world a smaller place and though it has been here since a decade only its difficult to imagine life without it as social media is now being used for various personal professional and business purposes it is increasingly becoming the prime target of cyber attacks according to proofpoint on an average companies have over 300 brandowned social media accounts on different platforms such as facebook twitter linkedin google youtube instagram pinterest and others while each of these accounts provides an opportunity to strengthen the connection of the brand with its audience there is also a downside the accounts are vulnerable to security breaches also heightened regulatory requirements for brandowned accounts pose the risk of violations and fines therefore in an effort to tap the growing opportunity in this space proofpoint acquired nexgate a pioneer in security and compliance solutions for social media communication channels in 2014 with this acquisition the company forayed into the social media security and compliance space proofpoint further enhanced its capabilities in this space by acquiring socialware a leading provider of social media compliance solutions in 2015 we believe that proofpoint is well positioned to grab the opportunities from growing cyber attacks on social networks proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 97 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a strong balance sheet with ample liquidity position and low debt obligations cash and shortterm investments were 4596 million as of sep 30 2017 which translates to over 51 of the total assets moreover the company generated about 1112 million of cash flow from operational activities in first three quarters of 2017 it is to be noted that the company has been able to regularly increase its cash and marketable securities which reached 397 million at the end of 2016 from 127 million at the end of 2011 similarly proofpoints cash flow from operations increased to approximately 94 million at 2016end from about 13 million at 2013end the increasing liquidity and cash flow trend ensures that the company is making investments in right directions in 2016 the company incurred capital expenditure capex of 344 million include purchase of property equipment but excludes acquisitions compared with 258 million in 2015 15 million in 2014 and 77 million in 2013 for 2017 the company expects to incur capex in a range of 40 million to 42 million which reflects its strategy of continuously investing in growth areas,buy,"['demand', 'cyber', 'security', 'rise', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'consequently', 'cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '101', 'billion', '2018', '75', 'billion', '2015', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '98', '2015', '2020', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'defend', 'protect', 'archive', 'govern', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'oct', '2016', 'company', 'sign', 'definite', 'agreement', 'acquire', 'firelayer', 'innovator', 'cloud', 'security', 'acquisition', 'anticipate', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'prior', 'aug', '2016', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'integration', 'return', 'path', 'efp', 'business', 'help', 'proofpoint', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', '2015', 'company', 'important', 'acquisition', 'emerge', 'threat', 'lead', 'provider', 'advanced', 'threat', 'intelligence', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', 'apart', 'year', 'proofpoint', 'purchase', 'certain', 'asset', 'marble', 'security', 'inc', 'emerge', 'threat', 'pro', 'llc', '2014', 'company', 'acquire', 'business', 'nexgate', 'inc', 'netcitadel', 'inc', '2013', 'purchase', 'company', 'sendmail', 'armorize', 'technologies', 'abaca', 'technology', 'mail', 'distiller', 'believe', 'aforementioned', 'acquisition', 'expand', 'proofpoint', 'product', 'portfolio', 'customer', 'revenue', 'base', 'social', 'medium', 'network', 'world', 'small', 'place', 'decade', 'difficult', 'imagine', 'life', 'social', 'medium', 'personal', 'professional', 'business', 'purpose', 'increasingly', 'prime', 'target', 'cyber', 'attack', 'accord', 'proofpoint', 'average', 'company', '300', 'brandowne', 'social', 'medium', 'account', 'different', 'platform', 'facebook', 'twitter', 'linkedin', 'google', 'youtube', 'instagram', 'pinterest', 'account', 'provide', 'opportunity', 'strengthen', 'connection', 'brand', 'audience', 'downside', 'account', 'vulnerable', 'security', 'breach', 'heighten', 'regulatory', 'requirement', 'brandowne', 'account', 'pose', 'risk', 'violation', 'fine', 'effort', 'tap', 'grow', 'opportunity', 'space', 'proofpoint', 'acquire', 'nexgate', 'pioneer', 'security', 'compliance', 'solution', 'social', 'medium', 'communication', 'channel', '2014', 'acquisition', 'company', 'foray', 'social', 'medium', 'security', 'compliance', 'space', 'proofpoint', 'enhance', 'capability', 'space', 'acquire', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', '2015', 'believe', 'proofpoint', 'positioned', 'grab', 'opportunity', 'grow', 'cyber', 'attack', 'social', 'network', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '97', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'low', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '4596', 'million', 'sep', '30', '2017', 'translate', '51', 'total', 'asset', 'company', 'generate', '1112', 'million', 'cash', 'flow', 'operational', 'activity', 'quarter', '2017', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '397', 'million', 'end', '2016', '127', 'million', 'end', '2011', 'similarly', 'proofpoint', 'cash', 'flow', 'operation', 'increase', 'approximately', '94', 'million', '2016end', '13', 'million', '2013end', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'ensure', 'company', 'make', 'investment', 'right', 'direction', '2016', 'company', 'incur', 'capital', 'expenditure', 'capex', '344', 'million', 'include', 'purchase', 'property', 'equipment', 'exclude', 'acquisition', 'compare', '258', 'million', '2015', '15', 'million', '2014', '77', 'million', '2013', '2017', 'company', 'expect', 'incur', 'capex', 'range', '40', 'million', '42', 'million', 'reflect', 'strategy', 'continuously', 'invest', 'growth', 'area']",demand cyber security rise long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product consequently cyber security missioncritical highprofile requirement result company allot increase portion budget security solution gartner new report worldwide spending security reach 101 billion 2018 75 billion 2015 report market market suggest cyber security market expect grow cagr 98 2015 2020 prediction bode proofpoint diversified product portfolio large midsized organization defend protect archive govern sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth oct 2016 company sign definite agreement acquire firelayer innovator cloud security acquisition anticipate help proofpoint extend target attack protection tap solution saas application protect advanced malware prior aug 2016 acquire email fraud protection efp business unit return path integration return path efp business help proofpoint enhance business email compromise bec capability 2015 company important acquisition emerge threat lead provider advanced threat intelligence socialware lead provider social medium compliance solution apart year proofpoint purchase certain asset marble security inc emerge threat pro llc 2014 company acquire business nexgate inc netcitadel inc 2013 purchase company sendmail armorize technologies abaca technology mail distiller believe aforementioned acquisition expand proofpoint product portfolio customer revenue base social medium network world small place decade difficult imagine life social medium personal professional business purpose increasingly prime target cyber attack accord proofpoint average company 300 brandowne social medium account different platform facebook twitter linkedin google youtube instagram pinterest account provide opportunity strengthen connection brand audience downside account vulnerable security breach heighten regulatory requirement brandowne account pose risk violation fine effort tap grow opportunity space proofpoint acquire nexgate pioneer security compliance solution social medium communication channel 2014 acquisition company foray social medium security compliance space proofpoint enhance capability space acquire socialware lead provider social medium compliance solution 2015 believe proofpoint positioned grab opportunity grow cyber attack social network proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 97 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint strong balance sheet ample liquidity position low debt obligation cash shortterm investment 4596 million sep 30 2017 translate 51 total asset company generate 1112 million cash flow operational activity quarter 2017 note company able regularly increase cash marketable security reach 397 million end 2016 127 million end 2011 similarly proofpoint cash flow operation increase approximately 94 million 2016end 13 million 2013end increase liquidity cash flow trend ensure company make investment right direction 2016 company incur capital expenditure capex 344 million include purchase property equipment exclude acquisition compare 258 million 2015 15 million 2014 77 million 2013 2017 company expect incur capex range 40 million 42 million reflect strategy continuously invest growth area,18,44,-0.4126984126984127,18,44,-0.4126984126984127,0.9974
350,"Proofpoint, Inc._Attachment1.pdf",PFPT,1/29/2018,the demand for cyber security is on the rise the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products consequently cyber security is becoming a missioncritical highprofile requirement as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 101 billion in 2018 from 75 billion in 2015 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 98 through 2015 2020 these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to defend protect archive and govern their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth in 2017 the company made two important buyouts cloudmark which is specialized in providing security protection for messaging services and weblifeio a leader in browser isolation solutions in 2016 the company acquired firelayers an innovator in cloud security the acquisition has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path the integration of return paths efp business has helped proofpoint to further enhance its business email compromise bec capabilities in 2015 the company made two important acquisitions emerging threats a leading provider of advanced threat intelligence and socialware a leading provider of social media compliance solutions apart from this last year proofpoint also purchased certain assets from marble security inc and emerging threats pro llc in 2014 the company acquired two businesses nexgate inc and netcitadel inc while in 2013 it purchased four companies sendmail armorize technologies abaca technology and mail distiller we believe that the aforementioned acquisitions have not only expanded proofpoints product portfolio but also its customer and revenue base social media networks have made the world a smaller place and though it has been here since a decade only its difficult to imagine life without it as social media is now being used for various personal professional and business purposes it is increasingly becoming the prime target of cyber attacks according to proofpoint on an average companies have over 300 brandowned social media accounts on different platforms such as facebook twitter linkedin google youtube instagram pinterest and others while each of these accounts provides an opportunity to strengthen the connection of the brand with its audience there is also a downside the accounts are vulnerable to security breaches also heightened regulatory requirements for brandowned accounts pose the risk of violations and fines therefore in an effort to tap the growing opportunity in this space proofpoint acquired nexgate a pioneer in security and compliance solutions for social media communication channels in 2014 with this acquisition the company forayed into the social media security and compliance space proofpoint further enhanced its capabilities in this space by acquiring socialware a leading provider of social media compliance solutions in 2015 we believe that proofpoint is well positioned to grab the opportunities from growing cyber attacks on social networks proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 97 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a strong balance sheet with ample liquidity position and low debt obligations cash and shortterm investments were 4596 million as of sep 30 2017 which translates to over 51 of the total assets moreover the company generated about 1112 million of cash flow from operational activities in first three quarters of 2017 it is to be noted that the company has been able to regularly increase its cash and marketable securities which reached 397 million at the end of 2016 from 127 million at the end of 2011 similarly proofpoints cash flow from operations increased to approximately 94 million at 2016end from about 13 million at 2013end the increasing liquidity and cash flow trend ensures that the company is making investments in right directions in 2016 the company incurred capital expenditure capex of 344 million include purchase of property equipment but excludes acquisitions compared with 258 million in 2015 15 million in 2014 and 77 million in 2013 for 2017 the company expects to incur capex in a range of 40 million to 42 million which reflects its strategy of continuously investing in growth areas,buy,"['demand', 'cyber', 'security', 'rise', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'consequently', 'cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '101', 'billion', '2018', '75', 'billion', '2015', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '98', '2015', '2020', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'defend', 'protect', 'archive', 'govern', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', '2017', 'company', 'important', 'buyout', 'cloudmark', 'specialize', 'provide', 'security', 'protection', 'message', 'service', 'weblifeio', 'leader', 'browser', 'isolation', 'solution', '2016', 'company', 'acquire', 'firelayer', 'innovator', 'cloud', 'security', 'acquisition', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'integration', 'return', 'path', 'efp', 'business', 'help', 'proofpoint', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', '2015', 'company', 'important', 'acquisition', 'emerge', 'threat', 'lead', 'provider', 'advanced', 'threat', 'intelligence', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', 'apart', 'year', 'proofpoint', 'purchase', 'certain', 'asset', 'marble', 'security', 'inc', 'emerge', 'threat', 'pro', 'llc', '2014', 'company', 'acquire', 'business', 'nexgate', 'inc', 'netcitadel', 'inc', '2013', 'purchase', 'company', 'sendmail', 'armorize', 'technologies', 'abaca', 'technology', 'mail', 'distiller', 'believe', 'aforementioned', 'acquisition', 'expand', 'proofpoint', 'product', 'portfolio', 'customer', 'revenue', 'base', 'social', 'medium', 'network', 'world', 'small', 'place', 'decade', 'difficult', 'imagine', 'life', 'social', 'medium', 'personal', 'professional', 'business', 'purpose', 'increasingly', 'prime', 'target', 'cyber', 'attack', 'accord', 'proofpoint', 'average', 'company', '300', 'brandowne', 'social', 'medium', 'account', 'different', 'platform', 'facebook', 'twitter', 'linkedin', 'google', 'youtube', 'instagram', 'pinterest', 'account', 'provide', 'opportunity', 'strengthen', 'connection', 'brand', 'audience', 'downside', 'account', 'vulnerable', 'security', 'breach', 'heighten', 'regulatory', 'requirement', 'brandowne', 'account', 'pose', 'risk', 'violation', 'fine', 'effort', 'tap', 'grow', 'opportunity', 'space', 'proofpoint', 'acquire', 'nexgate', 'pioneer', 'security', 'compliance', 'solution', 'social', 'medium', 'communication', 'channel', '2014', 'acquisition', 'company', 'foray', 'social', 'medium', 'security', 'compliance', 'space', 'proofpoint', 'enhance', 'capability', 'space', 'acquire', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', '2015', 'believe', 'proofpoint', 'positioned', 'grab', 'opportunity', 'grow', 'cyber', 'attack', 'social', 'network', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '97', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'low', 'debt', 'obligation', 'cash', 'shortterm', 'investment', '4596', 'million', 'sep', '30', '2017', 'translate', '51', 'total', 'asset', 'company', 'generate', '1112', 'million', 'cash', 'flow', 'operational', 'activity', 'quarter', '2017', 'note', 'company', 'able', 'regularly', 'increase', 'cash', 'marketable', 'security', 'reach', '397', 'million', 'end', '2016', '127', 'million', 'end', '2011', 'similarly', 'proofpoint', 'cash', 'flow', 'operation', 'increase', 'approximately', '94', 'million', '2016end', '13', 'million', '2013end', 'increase', 'liquidity', 'cash', 'flow', 'trend', 'ensure', 'company', 'make', 'investment', 'right', 'direction', '2016', 'company', 'incur', 'capital', 'expenditure', 'capex', '344', 'million', 'include', 'purchase', 'property', 'equipment', 'exclude', 'acquisition', 'compare', '258', 'million', '2015', '15', 'million', '2014', '77', 'million', '2013', '2017', 'company', 'expect', 'incur', 'capex', 'range', '40', 'million', '42', 'million', 'reflect', 'strategy', 'continuously', 'invest', 'growth', 'area']",demand cyber security rise long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product consequently cyber security missioncritical highprofile requirement result company allot increase portion budget security solution gartner new report worldwide spending security reach 101 billion 2018 75 billion 2015 report market market suggest cyber security market expect grow cagr 98 2015 2020 prediction bode proofpoint diversified product portfolio large midsized organization defend protect archive govern sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth 2017 company important buyout cloudmark specialize provide security protection message service weblifeio leader browser isolation solution 2016 company acquire firelayer innovator cloud security acquisition help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path integration return path efp business help proofpoint enhance business email compromise bec capability 2015 company important acquisition emerge threat lead provider advanced threat intelligence socialware lead provider social medium compliance solution apart year proofpoint purchase certain asset marble security inc emerge threat pro llc 2014 company acquire business nexgate inc netcitadel inc 2013 purchase company sendmail armorize technologies abaca technology mail distiller believe aforementioned acquisition expand proofpoint product portfolio customer revenue base social medium network world small place decade difficult imagine life social medium personal professional business purpose increasingly prime target cyber attack accord proofpoint average company 300 brandowne social medium account different platform facebook twitter linkedin google youtube instagram pinterest account provide opportunity strengthen connection brand audience downside account vulnerable security breach heighten regulatory requirement brandowne account pose risk violation fine effort tap grow opportunity space proofpoint acquire nexgate pioneer security compliance solution social medium communication channel 2014 acquisition company foray social medium security compliance space proofpoint enhance capability space acquire socialware lead provider social medium compliance solution 2015 believe proofpoint positioned grab opportunity grow cyber attack social network proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 97 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint strong balance sheet ample liquidity position low debt obligation cash shortterm investment 4596 million sep 30 2017 translate 51 total asset company generate 1112 million cash flow operational activity quarter 2017 note company able regularly increase cash marketable security reach 397 million end 2016 127 million end 2011 similarly proofpoint cash flow operation increase approximately 94 million 2016end 13 million 2013end increase liquidity cash flow trend ensure company make investment right direction 2016 company incur capital expenditure capex 344 million include purchase property equipment exclude acquisition compare 258 million 2015 15 million 2014 77 million 2013 2017 company expect incur capex range 40 million 42 million reflect strategy continuously invest growth area,19,43,-0.38095238095238093,19,43,-0.38095238095238093,0.9973
351,"Proofpoint, Inc._Attachment1.pdf",PFPT,5/8/2018,proofpoint has made strategic acquisitions to expedite growth most recently in february 2018 the company signed a definitive agreement to buy wombat security technologies inc in 2017 the company made two important buyouts cloudmark which is specialized in providing security protection for messaging services and weblifeio a leader in browser isolation solutions in 2016 the company acquired firelayers an innovator in cloud security the acquisition has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path the integration of return paths efp business has helped proofpoint to further enhance its business email compromise bec capabilities in 2015 the company made two important acquisitions emerging threats a leading provider of advanced threat intelligence and socialware a leading provider of social media compliance solutions apart from this last year proofpoint also purchased certain assets from marble security inc and emerging threats pro llc in 2014 the company acquired two businesses nexgate inc and netcitadel inc while in 2013 it purchased four companies sendmail armorize technologies abaca technology and mail distiller we believe that the aforementioned acquisitions have not only expanded proofpoints product portfolio but also its customer and revenue base social media networks have made the world a smaller place and though it has been here since a decade only its difficult to imagine life without it as social media is now being used for various personal professional and business purposes it is increasingly becoming the prime target of cyber attacks according to proofpoint on an average companies have over 300 brandowned social media accounts on different platforms such as facebook twitter linkedin google youtube instagram pinterest and others while each of these accounts provides an opportunity to strengthen the connection of the brand with its audience there is also a downside the accounts are vulnerable to security breaches also heightened regulatory requirements for brandowned accounts pose the risk of violations and fines therefore in an effort to tap the growing opportunity in this space proofpoint acquired nexgate a pioneer in security and compliance solutions for social media communication channels in 2014 with this acquisition the company forayed into the social media security and compliance space proofpoint further enhanced its capabilities in this space by acquiring socialware a leading provider of social media compliance solutions in 2015 we believe that proofpoint is well positioned to grab the opportunities from growing cyber attacks on social networks proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line,sell,"['proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'recently', 'february', '2018', 'company', 'sign', 'definitive', 'agreement', 'buy', 'wombat', 'security', 'technologies', 'inc', '2017', 'company', 'important', 'buyout', 'cloudmark', 'specialize', 'provide', 'security', 'protection', 'message', 'service', 'weblifeio', 'leader', 'browser', 'isolation', 'solution', '2016', 'company', 'acquire', 'firelayer', 'innovator', 'cloud', 'security', 'acquisition', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'integration', 'return', 'path', 'efp', 'business', 'help', 'proofpoint', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', '2015', 'company', 'important', 'acquisition', 'emerge', 'threat', 'lead', 'provider', 'advanced', 'threat', 'intelligence', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', 'apart', 'year', 'proofpoint', 'purchase', 'certain', 'asset', 'marble', 'security', 'inc', 'emerge', 'threat', 'pro', 'llc', '2014', 'company', 'acquire', 'business', 'nexgate', 'inc', 'netcitadel', 'inc', '2013', 'purchase', 'company', 'sendmail', 'armorize', 'technologies', 'abaca', 'technology', 'mail', 'distiller', 'believe', 'aforementioned', 'acquisition', 'expand', 'proofpoint', 'product', 'portfolio', 'customer', 'revenue', 'base', 'social', 'medium', 'network', 'world', 'small', 'place', 'decade', 'difficult', 'imagine', 'life', 'social', 'medium', 'personal', 'professional', 'business', 'purpose', 'increasingly', 'prime', 'target', 'cyber', 'attack', 'accord', 'proofpoint', 'average', 'company', '300', 'brandowne', 'social', 'medium', 'account', 'different', 'platform', 'facebook', 'twitter', 'linkedin', 'google', 'youtube', 'instagram', 'pinterest', 'account', 'provide', 'opportunity', 'strengthen', 'connection', 'brand', 'audience', 'downside', 'account', 'vulnerable', 'security', 'breach', 'heighten', 'regulatory', 'requirement', 'brandowne', 'account', 'pose', 'risk', 'violation', 'fine', 'effort', 'tap', 'grow', 'opportunity', 'space', 'proofpoint', 'acquire', 'nexgate', 'pioneer', 'security', 'compliance', 'solution', 'social', 'medium', 'communication', 'channel', '2014', 'acquisition', 'company', 'foray', 'social', 'medium', 'security', 'compliance', 'space', 'proofpoint', 'enhance', 'capability', 'space', 'acquire', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', '2015', 'believe', 'proofpoint', 'positioned', 'grab', 'opportunity', 'grow', 'cyber', 'attack', 'social', 'network', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line']",proofpoint strategic acquisition expedite growth recently february 2018 company sign definitive agreement buy wombat security technologies inc 2017 company important buyout cloudmark specialize provide security protection message service weblifeio leader browser isolation solution 2016 company acquire firelayer innovator cloud security acquisition help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path integration return path efp business help proofpoint enhance business email compromise bec capability 2015 company important acquisition emerge threat lead provider advanced threat intelligence socialware lead provider social medium compliance solution apart year proofpoint purchase certain asset marble security inc emerge threat pro llc 2014 company acquire business nexgate inc netcitadel inc 2013 purchase company sendmail armorize technologies abaca technology mail distiller believe aforementioned acquisition expand proofpoint product portfolio customer revenue base social medium network world small place decade difficult imagine life social medium personal professional business purpose increasingly prime target cyber attack accord proofpoint average company 300 brandowne social medium account different platform facebook twitter linkedin google youtube instagram pinterest account provide opportunity strengthen connection brand audience downside account vulnerable security breach heighten regulatory requirement brandowne account pose risk violation fine effort tap grow opportunity space proofpoint acquire nexgate pioneer security compliance solution social medium communication channel 2014 acquisition company foray social medium security compliance space proofpoint enhance capability space acquire socialware lead provider social medium compliance solution 2015 believe proofpoint positioned grab opportunity grow cyber attack social network proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line,17,21,-0.10256410256410256,17,21,-0.10256410256410256,0.9859
352,"Proofpoint, Inc._Attachment1.pdf",PFPT,9/4/2018,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 96 billion in 2018 from 89 billion in 2017 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 11 in the 20172022 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark in 2017 the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition in 2017 the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers an innovator in cloud security in 2016 has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities moreover in an effort to tap the growing opportunity in the social media security and compliance space proofpoint acquired nexgate in 2014 proofpoint further enhanced its capabilities in this space by acquiring socialware a leading provider of social media compliance solutions in 2015 apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 1341 million as of jun 30 2018 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '96', 'billion', '2018', '89', 'billion', '2017', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '11', '20172022', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', '2017', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', '2017', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'innovator', 'cloud', 'security', '2016', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'effort', 'tap', 'grow', 'opportunity', 'social', 'medium', 'security', 'compliance', 'space', 'proofpoint', 'acquire', 'nexgate', '2014', 'proofpoint', 'enhance', 'capability', 'space', 'acquire', 'socialware', 'lead', 'provider', 'social', 'medium', 'compliance', 'solution', '2015', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '1341', 'million', 'jun', '30', '2018', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner new report worldwide spending security reach 96 billion 2018 89 billion 2017 report market market suggest cyber security market expect grow cagr 11 20172022 period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark 2017 company earn opportunity continue grow footprint carrier community result weblife acquisition 2017 company bring market new personal email defense new browser isolation solution acquisition firelayer innovator cloud security 2016 help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability effort tap grow opportunity social medium security compliance space proofpoint acquire nexgate 2014 proofpoint enhance capability space acquire socialware lead provider social medium compliance solution 2015 apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 1341 million jun 30 2018 enhance liquidity fund product development pursue growth strategy like acquisition,13,17,-0.12903225806451613,13,17,-0.12903225806451613,0.9968
353,"Proofpoint, Inc._Attachment1.pdf",PFPT,9/4/2018,to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years proofpoint has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force notably the companys sales and marketing expenses have increased over fivefold to 2588 million in 2017 from 427 million in 2011 this remains a drag on the companys bottomline results furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period nearterm prospects for proofpoint are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment therefore we are slightly cautious about the companys nearterm prospects proofpoint faces competition from numerous big and small companies in the security application market as internet threats and attacks increase stiff competition will follow suit competing firms must deliver prompt and advanced technologies to suit customer requirements and expedite product introduction in order to survive moreover we believe that proofpoints dominance could be challenged by new entrants this could lead the company to resort to competitive pricing to maintain and capture market share,sell,"['survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'proofpoint', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'notably', 'company', 'sale', 'marketing', 'expense', 'increase', 'fivefold', '2588', 'million', '2017', '427', 'million', '2011', 'remain', 'drag', 'company', 'bottomline', 'result', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period', 'nearterm', 'prospect', 'proofpoint', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'slightly', 'cautious', 'company', 'nearterm', 'prospect', 'proofpoint', 'face', 'competition', 'numerous', 'big', 'small', 'company', 'security', 'application', 'market', 'internet', 'threat', 'attack', 'increase', 'stiff', 'competition', 'follow', 'suit', 'compete', 'firm', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'introduction', 'order', 'survive', 'believe', 'proofpoint', 'dominance', 'challenge', 'new', 'entrant', 'lead', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share']",survive highly competitive cyber security market player continually invest broaden capability past year proofpoint invest heavily enhance sale marketing capability particularly increase sale force notably company sale marketing expense increase fivefold 2588 million 2017 427 million 2011 remain drag company bottomline result furthermore company foresee investment garner benefit long run note uncertainty payback period nearterm prospect proofpoint promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment slightly cautious company nearterm prospect proofpoint face competition numerous big small company security application market internet threat attack increase stiff competition follow suit compete firm deliver prompt advanced technology suit customer requirement expedite product introduction order survive believe proofpoint dominance challenge new entrant lead company resort competitive pricing maintain capture market share,5,15,-0.47619047619047616,5,15,-0.47619047619047616,0.963
354,"Proofpoint, Inc._Attachment1.pdf",PFPT,12/26/2018,to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years proofpoint has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force notably the companys sales and marketing expenses have increased over fivefold to 2588 million in 2017 from 427 million in 2011 this remains a drag on the companys bottomline results furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period nearterm prospects for proofpoint are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment therefore we are slightly cautious about the companys nearterm prospects proofpoint faces competition from numerous big and small companies in the security application market as internet threats and attacks increase stiff competition will follow suit competing firms must deliver prompt and advanced technologies to suit customer requirements and expedite product introduction in order to survive moreover we believe that proofpoints dominance could be challenged by new entrants this could lead the company to resort to competitive pricing to maintain and capture market share proofpoint expects the inorganic revenue contributions in 2018 to lead to challenging yearoveryear comparison in 2019 the company anticipates additional headwinds in the coming year due to adoption of asc 606 and no contribution from cloudmark business moreover the company anticipates the first quarter of 2019 to witness a relatively low yearoveryear growth rate which makes us anxious,sell,"['survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'proofpoint', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'notably', 'company', 'sale', 'marketing', 'expense', 'increase', 'fivefold', '2588', 'million', '2017', '427', 'million', '2011', 'remain', 'drag', 'company', 'bottomline', 'result', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period', 'nearterm', 'prospect', 'proofpoint', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'slightly', 'cautious', 'company', 'nearterm', 'prospect', 'proofpoint', 'face', 'competition', 'numerous', 'big', 'small', 'company', 'security', 'application', 'market', 'internet', 'threat', 'attack', 'increase', 'stiff', 'competition', 'follow', 'suit', 'compete', 'firm', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'introduction', 'order', 'survive', 'believe', 'proofpoint', 'dominance', 'challenge', 'new', 'entrant', 'lead', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'proofpoint', 'expect', 'inorganic', 'revenue', 'contribution', '2018', 'lead', 'challenge', 'yearoveryear', 'comparison', '2019', 'company', 'anticipate', 'additional', 'headwind', 'come', 'year', 'adoption', 'asc', '606', 'contribution', 'cloudmark', 'business', 'company', 'anticipate', 'quarter', '2019', 'witness', 'relatively', 'low', 'yearoveryear', 'growth', 'rate', 'make', 'anxious']",survive highly competitive cyber security market player continually invest broaden capability past year proofpoint invest heavily enhance sale marketing capability particularly increase sale force notably company sale marketing expense increase fivefold 2588 million 2017 427 million 2011 remain drag company bottomline result furthermore company foresee investment garner benefit long run note uncertainty payback period nearterm prospect proofpoint promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment slightly cautious company nearterm prospect proofpoint face competition numerous big small company security application market internet threat attack increase stiff competition follow suit compete firm deliver prompt advanced technology suit customer requirement expedite product introduction order survive believe proofpoint dominance challenge new entrant lead company resort competitive pricing maintain capture market share proofpoint expect inorganic revenue contribution 2018 lead challenge yearoveryear comparison 2019 company anticipate additional headwind come year adoption asc 606 contribution cloudmark business company anticipate quarter 2019 witness relatively low yearoveryear growth rate make anxious,7,18,-0.4230769230769231,7,18,-0.4230769230769231,0.962
355,"Proofpoint, Inc._Attachment1.pdf",PFPT,1/10/2019,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners new report worldwide spending on it security will reach 96 billion in 2018 from 89 billion in 2017 another report from markets and markets suggests that cyber security market is expected to grow at a cagr of 102 in the 20182023 period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark in 2017 the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition in 2017 the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers an innovator in cloud security in 2016 has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 1904 million as of sep 30 2018 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,sell,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'new', 'report', 'worldwide', 'spending', 'security', 'reach', '96', 'billion', '2018', '89', 'billion', '2017', 'report', 'market', 'market', 'suggest', 'cyber', 'security', 'market', 'expect', 'grow', 'cagr', '102', '20182023', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', '2017', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', '2017', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'innovator', 'cloud', 'security', '2016', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '1904', 'million', 'sep', '30', '2018', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner new report worldwide spending security reach 96 billion 2018 89 billion 2017 report market market suggest cyber security market expect grow cagr 102 20182023 period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark 2017 company earn opportunity continue grow footprint carrier community result weblife acquisition 2017 company bring market new personal email defense new browser isolation solution acquisition firelayer innovator cloud security 2016 help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 1904 million sep 30 2018 enhance liquidity fund product development pursue growth strategy like acquisition,10,16,-0.2222222222222222,10,16,-0.2222222222222222,0.9962
356,"Proofpoint, Inc._Attachment1.pdf",PFPT,4/30/2019,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost has further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners report worldwide spending on it security will grow 87 to reach 124 billion in 2019 going by marketsandmarkets the global cybersecurity market size was valued at 13763 billion in 2017 and is projected to attain 24826 billion by 2023 witnessing a cagr of 102 during the forecast period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers proofpoints rich experience in the security space and continued delivery of missioncritical solutions will help it to grow its market share proofpoint has made strategic acquisitions to expedite growth with the acquisition of cloudmark the company earned the opportunity to continue to grow footprint within the carrier community as a result of its weblife acquisition the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions which have not only expanded its product portfolio but also its customer and revenue base likewise management remains optimistic about its most recently acquisition of wombat security technologies in february proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues as well as higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenue fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost the companys top and the bottom line proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will boost its top line proofpoint has a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 2166 million as of mar 31 2019 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'report', 'worldwide', 'spending', 'security', 'grow', '87', 'reach', '124', 'billion', '2019', 'go', 'marketsandmarket', 'global', 'cybersecurity', 'market', 'size', 'value', '13763', 'billion', '2017', 'project', 'attain', '24826', 'billion', '2023', 'witness', 'cagr', '102', 'forecast', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'proofpoint', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'acquisition', 'cloudmark', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'likewise', 'management', 'remain', 'optimistic', 'recently', 'acquisition', 'wombat', 'security', 'technology', 'february', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'company', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'boost', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '2166', 'million', 'mar', '31', '2019', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner report worldwide spending security grow 87 reach 124 billion 2019 go marketsandmarket global cybersecurity market size value 13763 billion 2017 project attain 24826 billion 2023 witness cagr 102 forecast period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer proofpoint rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth acquisition cloudmark company earn opportunity continue grow footprint carrier community result weblife acquisition company bring market new personal email defense new browser isolation solution acquisition firelayer help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base likewise management remain optimistic recently acquisition wombat security technology february proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost company line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade boost line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 2166 million mar 31 2019 enhance liquidity fund product development pursue growth strategy like acquisition,11,16,-0.17857142857142858,11,16,-0.17857142857142858,0.9959
357,"Proofpoint, Inc._Attachment1.pdf",PFPT,4/30/2019,to survive in the highly competitive cyber security market each player must continually invest in broadening its capabilities over the past few years proofpoint has invested heavily to enhance its sales and marketing capabilities particularly by increasing the sales force this remains a drag on the companys bottomline results furthermore though the company foresees these investments to garner benefit over the long run we note that there is uncertainty about the payback period nearterm prospects for proofpoint are not promising as changing customer spending behavior has recently hit several other players in this space for the past few months various competitors in the cyber security space noticed that the companies have been breaking their cybersecurity investment plans into phases and implementing the same over longer periods of time instead of making a single large investment therefore we are slightly cautious about the companys nearterm prospects proofpoint faces competition from numerous big and small companies in the security application market as internet threats and attacks increase stiff competition will follow suit competing firms must deliver prompt and advanced technologies to suit customer requirements and expedite product introduction in order to survive moreover we believe that proofpoints dominance could be challenged by new entrants this could lead the company to resort to competitive pricing to maintain and capture market share proofpoint expects the inorganic revenue contributions in 2018 to lead to challenging yearoveryear comparison in 2019 the company anticipates additional headwinds in the coming year due to adoption of asc 606 and no contribution from cloudmarks oem business moreover the company anticipates the first quarter of 2019 to witness a relatively low yearoveryear growth rate which makes us anxious zacks equity research pfpt wwwzackscom page 4 of 10,sell,"['survive', 'highly', 'competitive', 'cyber', 'security', 'market', 'player', 'continually', 'invest', 'broaden', 'capability', 'past', 'year', 'proofpoint', 'invest', 'heavily', 'enhance', 'sale', 'marketing', 'capability', 'particularly', 'increase', 'sale', 'force', 'remain', 'drag', 'company', 'bottomline', 'result', 'furthermore', 'company', 'foresee', 'investment', 'garner', 'benefit', 'long', 'run', 'note', 'uncertainty', 'payback', 'period', 'nearterm', 'prospect', 'proofpoint', 'promise', 'change', 'customer', 'spending', 'behavior', 'recently', 'hit', 'player', 'space', 'past', 'month', 'competitor', 'cyber', 'security', 'space', 'notice', 'company', 'break', 'cybersecurity', 'investment', 'plan', 'phase', 'implement', 'long', 'period', 'time', 'instead', 'make', 'single', 'large', 'investment', 'slightly', 'cautious', 'company', 'nearterm', 'prospect', 'proofpoint', 'face', 'competition', 'numerous', 'big', 'small', 'company', 'security', 'application', 'market', 'internet', 'threat', 'attack', 'increase', 'stiff', 'competition', 'follow', 'suit', 'compete', 'firm', 'deliver', 'prompt', 'advanced', 'technology', 'suit', 'customer', 'requirement', 'expedite', 'product', 'introduction', 'order', 'survive', 'believe', 'proofpoint', 'dominance', 'challenge', 'new', 'entrant', 'lead', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'proofpoint', 'expect', 'inorganic', 'revenue', 'contribution', '2018', 'lead', 'challenge', 'yearoveryear', 'comparison', '2019', 'company', 'anticipate', 'additional', 'headwind', 'come', 'year', 'adoption', 'asc', '606', 'contribution', 'cloudmarks', 'oem', 'business', 'company', 'anticipate', 'quarter', '2019', 'witness', 'relatively', 'low', 'yearoveryear', 'growth', 'rate', 'make', 'anxious', 'zack', 'equity', 'research', 'pfpt', 'wwwzackscom', 'page', '4', '10']",survive highly competitive cyber security market player continually invest broaden capability past year proofpoint invest heavily enhance sale marketing capability particularly increase sale force remain drag company bottomline result furthermore company foresee investment garner benefit long run note uncertainty payback period nearterm prospect proofpoint promise change customer spending behavior recently hit player space past month competitor cyber security space notice company break cybersecurity investment plan phase implement long period time instead make single large investment slightly cautious company nearterm prospect proofpoint face competition numerous big small company security application market internet threat attack increase stiff competition follow suit compete firm deliver prompt advanced technology suit customer requirement expedite product introduction order survive believe proofpoint dominance challenge new entrant lead company resort competitive pricing maintain capture market share proofpoint expect inorganic revenue contribution 2018 lead challenge yearoveryear comparison 2019 company anticipate additional headwind come year adoption asc 606 contribution cloudmarks oem business company anticipate quarter 2019 witness relatively low yearoveryear growth rate make anxious zack equity research pfpt wwwzackscom page 4 10,7,19,-0.4444444444444444,7,19,-0.4444444444444444,0.9521
358,"Proofpoint, Inc._Attachment1.pdf",PFPT,12/23/2019,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost have further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners report worldwide spending on it security will grow 87 to 124,buy,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'report', 'worldwide', 'spending', 'security', 'grow', '87', '124']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner report worldwide spending security grow 87 124,0,7,-0.875,0,7,-0.875,0.9274
359,"Proofpoint, Inc._Attachment1.pdf",PFPT,3/30/2020,cyber security is becoming a missioncritical highprofile requirement the long list of data breaches has brought to light the fact that a companys financial wellbeing brands and reputation are today increasingly exposed to sophisticated cyber threats the advent of cloud computing and the idea of sharing resources to lower cost have further increased demand for adequate security policies protocols and products as a result companies are allotting increasing portions of their it budgets for security solutions per gartners report worldwide spending on it security will grow 87 to 124 billion in 2019 going by marketsandmarkets the global cybersecurity market size was valued at 13763 billion in 2017 and is projected to reach 24826 billion by 2023 witnessing a cagr of 102 during the period these predictions bode well for proofpoint which has a diversified product portfolio for large and midsized organizations to protect their sensitive data furthermore proofpoint has partnered with palo alto networks cyberark ibm imperva and intel to provide bestinclass cyber security solutions to customers its rich experience in the security space and continued delivery of missioncritical solutions will help it to grow market share proofpoint has made strategic acquisitions to expedite growth with the buyout of cloudmark the company earned the opportunity to continue growing its footprint within the carrier community as a result of its weblife acquisition the company brought to market a new personal email defense which is its new browser isolation solution the acquisition of firelayers has helped proofpoint in extending its targeted attack protection tap solution to saas applications and protects these from advanced malware same year it acquired the email fraud protection efp business unit from return path which helped it further enhance its business email compromise bec capabilities apart from these the company made various other acquisitions that have not only expanded its product portfolio but also its customer and revenue base proofpoint mainly focuses on selling subscriptionbased services this business model generates recurring revenues and higher margins for the company approximately 70 than the hardwarecentric model notably the company garners nearly 98 of total revenues fy from these services which has helped it to maintain gross margin above 70 over the last few quarters we believe that the strategy will continue to boost its top and the bottom lines proofpoint has been witnessing tremendous customer growth for its subscriptionbased services we believe that continued focus on subscriptionbased products and services and product upgrades will enhance its top line proofpoint had a debt free balance sheet with cash and cash equivalents and shortterm investments of approximately 8901 million as of dec 31 2019 this enhances liquidity and can be used for funding product development and to pursue growth strategies like acquisitions,sell,"['cyber', 'security', 'missioncritical', 'highprofile', 'requirement', 'long', 'list', 'data', 'breach', 'bring', 'light', 'fact', 'companys', 'financial', 'wellbeing', 'brand', 'reputation', 'today', 'increasingly', 'expose', 'sophisticated', 'cyber', 'threat', 'advent', 'cloud', 'computing', 'idea', 'share', 'resource', 'low', 'cost', 'increase', 'demand', 'adequate', 'security', 'policy', 'protocol', 'product', 'result', 'company', 'allot', 'increase', 'portion', 'budget', 'security', 'solution', 'gartner', 'report', 'worldwide', 'spending', 'security', 'grow', '87', '124', 'billion', '2019', 'go', 'marketsandmarket', 'global', 'cybersecurity', 'market', 'size', 'value', '13763', 'billion', '2017', 'project', 'reach', '24826', 'billion', '2023', 'witness', 'cagr', '102', 'period', 'prediction', 'bode', 'proofpoint', 'diversified', 'product', 'portfolio', 'large', 'midsized', 'organization', 'protect', 'sensitive', 'datum', 'furthermore', 'proofpoint', 'partner', 'palo', 'alto', 'networks', 'cyberark', 'ibm', 'imperva', 'intel', 'provide', 'bestinclass', 'cyber', 'security', 'solution', 'customer', 'rich', 'experience', 'security', 'space', 'continue', 'delivery', 'missioncritical', 'solution', 'help', 'grow', 'market', 'share', 'proofpoint', 'strategic', 'acquisition', 'expedite', 'growth', 'buyout', 'cloudmark', 'company', 'earn', 'opportunity', 'continue', 'grow', 'footprint', 'carrier', 'community', 'result', 'weblife', 'acquisition', 'company', 'bring', 'market', 'new', 'personal', 'email', 'defense', 'new', 'browser', 'isolation', 'solution', 'acquisition', 'firelayer', 'help', 'proofpoint', 'extend', 'target', 'attack', 'protection', 'tap', 'solution', 'saas', 'application', 'protect', 'advanced', 'malware', 'year', 'acquire', 'email', 'fraud', 'protection', 'efp', 'business', 'unit', 'return', 'path', 'help', 'enhance', 'business', 'email', 'compromise', 'bec', 'capability', 'apart', 'company', 'acquisition', 'expand', 'product', 'portfolio', 'customer', 'revenue', 'base', 'proofpoint', 'mainly', 'focus', 'sell', 'subscriptionbase', 'service', 'business', 'model', 'generate', 'recur', 'revenue', 'high', 'margin', 'company', 'approximately', '70', 'hardwarecentric', 'model', 'notably', 'company', 'garner', 'nearly', '98', 'total', 'revenue', 'fy', 'service', 'help', 'maintain', 'gross', 'margin', '70', 'quarter', 'believe', 'strategy', 'continue', 'boost', 'line', 'proofpoint', 'witness', 'tremendous', 'customer', 'growth', 'subscriptionbase', 'service', 'believe', 'continue', 'focus', 'subscriptionbase', 'product', 'service', 'product', 'upgrade', 'enhance', 'line', 'proofpoint', 'debt', 'free', 'balance', 'sheet', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '8901', 'million', 'dec', '31', '2019', 'enhance', 'liquidity', 'fund', 'product', 'development', 'pursue', 'growth', 'strategy', 'like', 'acquisition']",cyber security missioncritical highprofile requirement long list data breach bring light fact companys financial wellbeing brand reputation today increasingly expose sophisticated cyber threat advent cloud computing idea share resource low cost increase demand adequate security policy protocol product result company allot increase portion budget security solution gartner report worldwide spending security grow 87 124 billion 2019 go marketsandmarket global cybersecurity market size value 13763 billion 2017 project reach 24826 billion 2023 witness cagr 102 period prediction bode proofpoint diversified product portfolio large midsized organization protect sensitive datum furthermore proofpoint partner palo alto networks cyberark ibm imperva intel provide bestinclass cyber security solution customer rich experience security space continue delivery missioncritical solution help grow market share proofpoint strategic acquisition expedite growth buyout cloudmark company earn opportunity continue grow footprint carrier community result weblife acquisition company bring market new personal email defense new browser isolation solution acquisition firelayer help proofpoint extend target attack protection tap solution saas application protect advanced malware year acquire email fraud protection efp business unit return path help enhance business email compromise bec capability apart company acquisition expand product portfolio customer revenue base proofpoint mainly focus sell subscriptionbase service business model generate recur revenue high margin company approximately 70 hardwarecentric model notably company garner nearly 98 total revenue fy service help maintain gross margin 70 quarter believe strategy continue boost line proofpoint witness tremendous customer growth subscriptionbase service believe continue focus subscriptionbase product service product upgrade enhance line proofpoint debt free balance sheet cash cash equivalent shortterm investment approximately 8901 million dec 31 2019 enhance liquidity fund product development pursue growth strategy like acquisition,9,17,-0.2962962962962963,9,17,-0.2962962962962963,0.9949
360,ServiceNow Inc_Attachment1(2).pdf,NOW,7/1/2020,servicenow faces stiff competition in the nonitsm markets from the likes of oracle and salesforcecom which are wellestablished players although the company has an edge in the security response market the customer service and hr solutions faces significant competition from these players as nonitsm markets become a larger contributor to the companys total revenue increasing competition can weigh on growth moreover cutthroat competition can hurt pricing power as well as lengthen the sales cycle which will negatively impact topline servicenow has been incurring losses over the last five years and has an accumulated deficit of 304 million as of mar 31 2020 the company anticipates reporting loss in the near term due to increased costs such as noncash charges associated with equity awards business combinations and other expenses despite the improving top line mounting losses doesnt bode well for investor confidence servicenow generates a significant portion 35 in firstquarter of revenues from the international market adverse foreign currency exchange rates are likely to impede revenue growth in the near term owing to the strengthening of the us dollar compared with the euro and other foreign currencies which is a significant concern the company is trading at premium in terms of pricesales ps servicenow currently has a trailing 12month ps ratio of 2178x this level compares unfavorably with what the industry witnessed in the prior year additionally the ratio is higher than the average level of 1702x and is near the high end of the valuation range in this period consequently the valuation looks slightly stretched from ps perspective,sell,"['servicenow', 'face', 'stiff', 'competition', 'nonitsm', 'market', 'like', 'oracle', 'salesforcecom', 'wellestablished', 'player', 'company', 'edge', 'security', 'response', 'market', 'customer', 'service', 'hr', 'solution', 'face', 'significant', 'competition', 'player', 'nonitsm', 'market', 'large', 'contributor', 'companys', 'total', 'revenue', 'increase', 'competition', 'weigh', 'growth', 'cutthroat', 'competition', 'hurt', 'pricing', 'power', 'lengthen', 'sale', 'cycle', 'negatively', 'impact', 'topline', 'servicenow', 'incur', 'loss', 'year', 'accumulate', 'deficit', '304', 'million', 'mar', '31', '2020', 'company', 'anticipate', 'report', 'loss', 'near', 'term', 'increase', 'cost', 'noncash', 'charge', 'associate', 'equity', 'award', 'business', 'combination', 'expense', 'despite', 'improve', 'line', 'mount', 'loss', 'not', 'bode', 'investor', 'confidence', 'servicenow', 'generate', 'significant', 'portion', '35', 'firstquarter', 'revenue', 'international', 'market', 'adverse', 'foreign', 'currency', 'exchange', 'rate', 'likely', 'impede', 'revenue', 'growth', 'near', 'term', 'owe', 'strengthening', 'dollar', 'compare', 'euro', 'foreign', 'currency', 'significant', 'concern', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'servicenow', 'currently', 'trailing', '12month', 'ps', 'ratio', '2178x', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'prior', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '1702x', 'near', 'high', 'end', 'valuation', 'range', 'period', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",servicenow face stiff competition nonitsm market like oracle salesforcecom wellestablished player company edge security response market customer service hr solution face significant competition player nonitsm market large contributor companys total revenue increase competition weigh growth cutthroat competition hurt pricing power lengthen sale cycle negatively impact topline servicenow incur loss year accumulate deficit 304 million mar 31 2020 company anticipate report loss near term increase cost noncash charge associate equity award business combination expense despite improve line mount loss not bode investor confidence servicenow generate significant portion 35 firstquarter revenue international market adverse foreign currency exchange rate likely impede revenue growth near term owe strengthening dollar compare euro foreign currency significant concern company trade premium term pricesale ps servicenow currently trailing 12month ps ratio 2178x level compare unfavorably industry witness prior year additionally ratio high average level 1702x near high end valuation range period consequently valuation looks slightly stretch ps perspective,5,21,-0.5925925925925926,5,21,-0.5925925925925926,0.7574
361,ServiceNow Inc_Attachment1(3).pdf,NOW,7/22/2020,servicenow faces stiff competition in the nonitsm markets from the likes of oracle and salesforcecom which are wellestablished players although the company has an edge in the security response market the customer service and hr solutions faces significant competition from these players as nonitsm markets become a larger contributor to the companys total revenue increasing competition can weigh on growth moreover cutthroat competition can hurt pricing power as well as lengthen the sales cycle which will negatively impact topline servicenow has been incurring losses over the last five years and has an accumulated deficit of 304 million as of mar 31 2020 the company anticipates reporting loss in the near term due to increased costs such as noncash charges associated with equity awards business combinations and other expenses despite the improving top line mounting losses doesnt bode well for investor confidence servicenow generates a significant portion 35 in firstquarter of revenues from the international market adverse foreign currency exchange rates are likely to impede revenue growth in the near term owing to the strengthening of the us dollar compared with the euro and other foreign currencies which is a significant concern the company is trading at premium in terms of pricesales ps servicenow currently has a trailing 12month ps ratio of 2351x this level compares unfavorably with what the industry witnessed in the prior year additionally the ratio is higher than the average level of 1703x and is near the high end of the valuation range in this period consequently the valuation looks slightly stretched from ps perspective,sell,"['servicenow', 'face', 'stiff', 'competition', 'nonitsm', 'market', 'like', 'oracle', 'salesforcecom', 'wellestablished', 'player', 'company', 'edge', 'security', 'response', 'market', 'customer', 'service', 'hr', 'solution', 'face', 'significant', 'competition', 'player', 'nonitsm', 'market', 'large', 'contributor', 'companys', 'total', 'revenue', 'increase', 'competition', 'weigh', 'growth', 'cutthroat', 'competition', 'hurt', 'pricing', 'power', 'lengthen', 'sale', 'cycle', 'negatively', 'impact', 'topline', 'servicenow', 'incur', 'loss', 'year', 'accumulate', 'deficit', '304', 'million', 'mar', '31', '2020', 'company', 'anticipate', 'report', 'loss', 'near', 'term', 'increase', 'cost', 'noncash', 'charge', 'associate', 'equity', 'award', 'business', 'combination', 'expense', 'despite', 'improve', 'line', 'mount', 'loss', 'not', 'bode', 'investor', 'confidence', 'servicenow', 'generate', 'significant', 'portion', '35', 'firstquarter', 'revenue', 'international', 'market', 'adverse', 'foreign', 'currency', 'exchange', 'rate', 'likely', 'impede', 'revenue', 'growth', 'near', 'term', 'owe', 'strengthening', 'dollar', 'compare', 'euro', 'foreign', 'currency', 'significant', 'concern', 'company', 'trade', 'premium', 'term', 'pricesale', 'ps', 'servicenow', 'currently', 'trailing', '12month', 'ps', 'ratio', '2351x', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'prior', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '1703x', 'near', 'high', 'end', 'valuation', 'range', 'period', 'consequently', 'valuation', 'looks', 'slightly', 'stretch', 'ps', 'perspective']",servicenow face stiff competition nonitsm market like oracle salesforcecom wellestablished player company edge security response market customer service hr solution face significant competition player nonitsm market large contributor companys total revenue increase competition weigh growth cutthroat competition hurt pricing power lengthen sale cycle negatively impact topline servicenow incur loss year accumulate deficit 304 million mar 31 2020 company anticipate report loss near term increase cost noncash charge associate equity award business combination expense despite improve line mount loss not bode investor confidence servicenow generate significant portion 35 firstquarter revenue international market adverse foreign currency exchange rate likely impede revenue growth near term owe strengthening dollar compare euro foreign currency significant concern company trade premium term pricesale ps servicenow currently trailing 12month ps ratio 2351x level compare unfavorably industry witness prior year additionally ratio high average level 1703x near high end valuation range period consequently valuation looks slightly stretch ps perspective,5,21,-0.5925925925925926,5,21,-0.5925925925925926,0.7574
362,ServiceNow Inc_Attachment1.pdf,NOW,11/2/2020,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes g2k customers contribute approximately 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at fortune 500 clientele 80 has been driving servicenows topline growth further it is focusing primarily on public and big private entities rapidly which will further drive topline growth in the long run moreover servicenow has been named a leader in the 2020 gartner magic quadrant for it risk management the company was evaluated for its governance risk and compliance grc platform,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'g2k', 'customer', 'contribute', 'approximately', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'fortune', '500', 'clientele', '80', 'drive', 'servicenow', 'topline', 'growth', 'focus', 'primarily', 'public', 'big', 'private', 'entity', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'name', 'leader', '2020', 'gartner', 'magic', 'quadrant', 'risk', 'management', 'company', 'evaluate', 'governance', 'risk', 'compliance', 'grc', 'platform']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process g2k customer contribute approximately 50 topline company expect mix remain steady long haul grow penetration fortune 500 clientele 80 drive servicenow topline growth focus primarily public big private entity rapidly drive topline growth long run servicenow name leader 2020 gartner magic quadrant risk management company evaluate governance risk compliance grc platform,2,2,0.0,2,2,0.0,0.7906
363,"ServiceNow, Inc._Attachment1(2).pdf",NOW,10/31/2018,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloud based processes g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows topline growth the strong backlog of approximately 26 billion at the end of 2017 up 368 over is a key catalyst in this regard further it is penetrating the nong2k customer base focusing primarily on public and big private entities rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 840 at the end of 2017 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 500 at the end of 2017 given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also in 2017 the company had acquiredqlue a developer of virtual messaging agents the buyout is expected to enhance its customer experiencethe acquisitions of telepathy and skygiraffeboth concluded in are expected to enhance the companys enterprise mobile experience further in a bid to add natural language query nlq technology capabilities to make now platform user friendly the company recently inked a deal to buy friendlydata,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloud', 'base', 'process', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'topline', 'growth', 'strong', 'backlog', 'approximately', '26', 'billion', 'end', '2017', '368', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', 'focus', 'primarily', 'public', 'big', 'private', 'entity', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '840', 'end', '2017', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '500', 'end', '2017', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', '2017', 'company', 'acquiredqlue', 'developer', 'virtual', 'messaging', 'agent', 'buyout', 'expect', 'enhance', 'customer', 'experiencethe', 'acquisition', 'telepathy', 'skygiraffeboth', 'conclude', 'expect', 'enhance', 'company', 'enterprise', 'mobile', 'experience', 'bid', 'add', 'natural', 'language', 'query', 'nlq', 'technology', 'capability', 'platform', 'user', 'friendly', 'company', 'recently', 'ink', 'deal', 'buy', 'friendlydata']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloud base process g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow topline growth strong backlog approximately 26 billion end 2017 368 key catalyst regard penetrate nong2k customer base focus primarily public big private entity rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 840 end 2017 number customer annualize contract value acv great 1 million increase 157 end 2014 500 end 2017 give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead 2017 company acquiredqlue developer virtual messaging agent buyout expect enhance customer experiencethe acquisition telepathy skygiraffeboth conclude expect enhance company enterprise mobile experience bid add natural language query nlq technology capability platform user friendly company recently ink deal buy friendlydata,15,12,0.10714285714285714,15,12,0.10714285714285714,0.9978
364,"ServiceNow, Inc._Attachment1(2).pdf",NOW,5/31/2019,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes g2k customers contribute approximately 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base 44 has been driving servicenows topline growth the strong backlog of approximately 51 billion at the end of 2018 up 35 over is a key catalyst in this regard further it is penetrating the nong2k customer base focusing primarily on public and big private entities rapidly which will further drive topline growth in the long run,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'g2k', 'customer', 'contribute', 'approximately', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', '44', 'drive', 'servicenow', 'topline', 'growth', 'strong', 'backlog', 'approximately', '51', 'billion', 'end', '2018', '35', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', 'focus', 'primarily', 'public', 'big', 'private', 'entity', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process g2k customer contribute approximately 50 topline company expect mix remain steady long haul grow penetration g2k customer base 44 drive servicenow topline growth strong backlog approximately 51 billion end 2018 35 key catalyst regard penetrate nong2k customer base focus primarily public big private entity rapidly drive topline growth long run,2,4,-0.2857142857142857,2,4,-0.2857142857142857,0.926
365,"ServiceNow, Inc._Attachment1(2).pdf",NOW,12/26/2019,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes g2k customers contribute approximately 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at global 2000 or g2k customer base 44 and fortune 500 clientele 75 has been driving servicenows topline growth the strong backlog of approximately 51 billion at the end of 2018 up 35 over is a key catalyst in this regard further it is penetrating the nong2k customer base focusing primarily on public and big private entities rapidly which will further drive topline growth in the long run,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'g2k', 'customer', 'contribute', 'approximately', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'global', '2000', 'g2k', 'customer', 'base', '44', 'fortune', '500', 'clientele', '75', 'drive', 'servicenow', 'topline', 'growth', 'strong', 'backlog', 'approximately', '51', 'billion', 'end', '2018', '35', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', 'focus', 'primarily', 'public', 'big', 'private', 'entity', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process g2k customer contribute approximately 50 topline company expect mix remain steady long haul grow penetration global 2000 g2k customer base 44 fortune 500 clientele 75 drive servicenow topline growth strong backlog approximately 51 billion end 2018 35 key catalyst regard penetrate nong2k customer base focus primarily public big private entity rapidly drive topline growth long run,2,4,-0.2857142857142857,2,4,-0.2857142857142857,0.926
366,"ServiceNow, Inc._Attachment1(2).pdf",NOW,12/26/2019,servicenow faces stiff competition in the nonitsm markets from the likes of oracle and salesforcecom which are wellestablished players although the company has an edge in the security response market the customer service and hr solutions faces significant competition from these players as nonitsm markets become a larger contributor to the companys total revenue increasing competition can weigh on growth moreover cutthroat competition can hurt pricing power as well as lengthen the sales cycle which will negatively impact topline servicenow has been incurring losses over the last five years and has an accumulated deficit of 95097 million as of sep 30 2019 the company anticipates reporting loss in the near term due to increased costs such as noncash charges associated with equity awards business combinations and other expenses despite the improving top line mounting losses doesnt bode well for investor confidence servicenow generates a significant portion 34 in of revenues from the international market adverse foreign currency exchange rates are likely to impede revenue growth in the near term owing to the strengthening of the us dollar compared with the euro and other foreign currencies which is a significant concern,sell,"['servicenow', 'face', 'stiff', 'competition', 'nonitsm', 'market', 'like', 'oracle', 'salesforcecom', 'wellestablished', 'player', 'company', 'edge', 'security', 'response', 'market', 'customer', 'service', 'hr', 'solution', 'face', 'significant', 'competition', 'player', 'nonitsm', 'market', 'large', 'contributor', 'companys', 'total', 'revenue', 'increase', 'competition', 'weigh', 'growth', 'cutthroat', 'competition', 'hurt', 'pricing', 'power', 'lengthen', 'sale', 'cycle', 'negatively', 'impact', 'topline', 'servicenow', 'incur', 'loss', 'year', 'accumulate', 'deficit', '95097', 'million', 'sep', '30', '2019', 'company', 'anticipate', 'report', 'loss', 'near', 'term', 'increase', 'cost', 'noncash', 'charge', 'associate', 'equity', 'award', 'business', 'combination', 'expense', 'despite', 'improve', 'line', 'mount', 'loss', 'not', 'bode', 'investor', 'confidence', 'servicenow', 'generate', 'significant', 'portion', '34', 'revenue', 'international', 'market', 'adverse', 'foreign', 'currency', 'exchange', 'rate', 'likely', 'impede', 'revenue', 'growth', 'near', 'term', 'owe', 'strengthening', 'dollar', 'compare', 'euro', 'foreign', 'currency', 'significant', 'concern']",servicenow face stiff competition nonitsm market like oracle salesforcecom wellestablished player company edge security response market customer service hr solution face significant competition player nonitsm market large contributor companys total revenue increase competition weigh growth cutthroat competition hurt pricing power lengthen sale cycle negatively impact topline servicenow incur loss year accumulate deficit 95097 million sep 30 2019 company anticipate report loss near term increase cost noncash charge associate equity award business combination expense despite improve line mount loss not bode investor confidence servicenow generate significant portion 34 revenue international market adverse foreign currency exchange rate likely impede revenue growth near term owe strengthening dollar compare euro foreign currency significant concern,2,16,-0.7368421052631579,2,16,-0.7368421052631579,0.7574
367,"ServiceNow, Inc._Attachment1(3).pdf",NOW,6/27/2017,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes addition of well known companies such as general mills dnb bank and renault in fourthquarter 2016 reflects the companys growing clout in the g2k customer base g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows topline growth which has been exemplary increasing at a cagr of more than 70 over 20092016 time frame revenues are now projected to grow in the 3133 range for fullyear 2017 the strong backlog of approximately 19 billion at the end of 2016 up 462 over is a key catalyst in this regard further it is penetrating the nong2k customer base 20 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 735 at the end of 2016 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 341 at the end of 2016 servicenow projects g2k customer base to increase to 1000 by 2020 which means approximately 17 customers per quarter given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also the companys recently announced acquisition of qlue a developer of virtual messaging agents is expected to enhance its customer experience,sell,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'addition', 'know', 'company', 'general', 'mill', 'dnb', 'bank', 'renault', 'fourthquarter', '2016', 'reflect', 'company', 'grow', 'clout', 'g2k', 'customer', 'base', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'topline', 'growth', 'exemplary', 'increase', 'cagr', '70', '20092016', 'time', 'frame', 'revenue', 'project', 'grow', '3133', 'range', 'fullyear', '2017', 'strong', 'backlog', 'approximately', '19', 'billion', 'end', '2016', '462', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', '20', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '735', 'end', '2016', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '341', 'end', '2016', 'servicenow', 'project', 'g2k', 'customer', 'base', 'increase', '1000', '2020', 'mean', 'approximately', '17', 'customer', 'quarter', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', 'company', 'recently', 'announce', 'acquisition', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'expect', 'enhance', 'customer', 'experience']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process addition know company general mill dnb bank renault fourthquarter 2016 reflect company grow clout g2k customer base g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow topline growth exemplary increase cagr 70 20092016 time frame revenue project grow 3133 range fullyear 2017 strong backlog approximately 19 billion end 2016 462 key catalyst regard penetrate nong2k customer base 20 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 735 end 2016 number customer annualize contract value acv great 1 million increase 157 end 2014 341 end 2016 servicenow project g2k customer base increase 1000 2020 mean approximately 17 customer quarter give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead company recently announce acquisition qlue developer virtual messaging agent expect enhance customer experience,14,13,0.03571428571428571,14,13,0.03571428571428571,0.9977
368,"ServiceNow, Inc._Attachment1(3).pdf",NOW,2/1/2018,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows top line growth the strong backlog of approximately 39 billion at the end of 2017 up 39 over is a key catalyst in this regard further it is penetrating the nong2k customer base 20 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 735 at the end of 2016 to 840 at the end of 2017 number of customers with annualized contract value acv greater than 1 million has also increased from 341 at the end of 2016 to 500 at the end of 2017 given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also the companys acquisition of qlue a developer of virtual messaging agents is expected to enhance its customer experience further the announced acquisitions of telepathy and skygiraffe are expected to enhance the companys enterprise mobile experience,sell,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'line', 'growth', 'strong', 'backlog', 'approximately', '39', 'billion', 'end', '2017', '39', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', '20', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '735', 'end', '2016', '840', 'end', '2017', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '341', 'end', '2016', '500', 'end', '2017', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', 'company', 'acquisition', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'expect', 'enhance', 'customer', 'experience', 'announce', 'acquisition', 'telepathy', 'skygiraffe', 'expect', 'enhance', 'company', 'enterprise', 'mobile', 'experience']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow line growth strong backlog approximately 39 billion end 2017 39 key catalyst regard penetrate nong2k customer base 20 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 735 end 2016 840 end 2017 number customer annualize contract value acv great 1 million increase 341 end 2016 500 end 2017 give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead company acquisition qlue developer virtual messaging agent expect enhance customer experience announce acquisition telepathy skygiraffe expect enhance company enterprise mobile experience,14,14,0.0,14,14,0.0,0.9975
369,"ServiceNow, Inc._Attachment1(3).pdf",NOW,7/30/2018,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows top line growth the strong backlog of approximately 26 billion at the end of 2017 up 368 over is a key catalyst in this regard further it is penetrating the nong2k customer base focusing primarily on public and big private entities 38 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 840 at the end of 2017 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 500 at the end of 2017 given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also the companys recently announced acquisition of qlue a developer of virtual messaging agents is expected to enhance its customer experience further the announced acquisitions of telepathy and skygiraffe are expected to enhance the companys enterprise mobile experience,sell,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'line', 'growth', 'strong', 'backlog', 'approximately', '26', 'billion', 'end', '2017', '368', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', 'focus', 'primarily', 'public', 'big', 'private', 'entity', '38', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '840', 'end', '2017', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '500', 'end', '2017', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', 'company', 'recently', 'announce', 'acquisition', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'expect', 'enhance', 'customer', 'experience', 'announce', 'acquisition', 'telepathy', 'skygiraffe', 'expect', 'enhance', 'company', 'enterprise', 'mobile', 'experience']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow line growth strong backlog approximately 26 billion end 2017 368 key catalyst regard penetrate nong2k customer base focus primarily public big private entity 38 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 840 end 2017 number customer annualize contract value acv great 1 million increase 157 end 2014 500 end 2017 give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead company recently announce acquisition qlue developer virtual messaging agent expect enhance customer experience announce acquisition telepathy skygiraffe expect enhance company enterprise mobile experience,14,14,0.0,14,14,0.0,0.9975
370,"ServiceNow, Inc._Attachment1(4).pdf",NOW,4/28/2017,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes addition of well known companies such as general mills dnb bank and renault in fourth quarter 2016 reflects the companys growing clout in the g2k customer base g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows top line growth which has been exemplary increasing at a cagr of more than 70 over 20092016 time frame revenues are now projected to grow in the 3133 range for fullyear 2017 the strong backlog of approximately 19 billion at the end of 2016 up 462 over is a key catalyst in this regard further it is penetrating the nong2k customer base 20 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 735 at the end of 2016 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 341 at the end of 2016 servicenow projects g2k customer base to increase to 1000 by 2020 which means approximately 17 customers per quarter given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'addition', 'know', 'company', 'general', 'mill', 'dnb', 'bank', 'renault', 'fourth', 'quarter', '2016', 'reflect', 'company', 'grow', 'clout', 'g2k', 'customer', 'base', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'line', 'growth', 'exemplary', 'increase', 'cagr', '70', '20092016', 'time', 'frame', 'revenue', 'project', 'grow', '3133', 'range', 'fullyear', '2017', 'strong', 'backlog', 'approximately', '19', 'billion', 'end', '2016', '462', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', '20', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '735', 'end', '2016', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '341', 'end', '2016', 'servicenow', 'project', 'g2k', 'customer', 'base', 'increase', '1000', '2020', 'mean', 'approximately', '17', 'customer', 'quarter', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process addition know company general mill dnb bank renault fourth quarter 2016 reflect company grow clout g2k customer base g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow line growth exemplary increase cagr 70 20092016 time frame revenue project grow 3133 range fullyear 2017 strong backlog approximately 19 billion end 2016 462 key catalyst regard penetrate nong2k customer base 20 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 735 end 2016 number customer annualize contract value acv great 1 million increase 157 end 2014 341 end 2016 servicenow project g2k customer base increase 1000 2020 mean approximately 17 customer quarter give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead,13,13,0.0,13,13,0.0,0.9977
371,"ServiceNow, Inc._Attachment1(4).pdf",NOW,4/28/2017,servicenow faces stiff competition in the nonitsm markets from the likes of oracle and salesforcecom which are well established players although the company has an edge in the security response market the customer service and hr solutions faces significant competition from these players as nonitsm markets become a larger contributor to the companys total revenue increasing competition can weigh on growth moreover cutthroat competition can hurt pricing power as well as lengthen the sales cycle which will negatively impact topline although servicenows subscription business remains strong the professional service business is expected to remain a drag on overall topline growth the business grew a modest 74 in 2016 over 2015 which was a decline from 36 growth reported in 2015 over 2014 figure management projects this business to grow at a less than 10 rate in the long run servicenow has been incurring losses over the last five years and has an accumulated deficit of 9974 million as of dec 31 2016 the company anticipates reporting loss in the near term due to increased costs such as noncash charges associated with equity awards business combinations and other expenses despite the improving top line mounting losses doesnt bode well for investor confidence moreover the company is trading at premium in terms of enterprise valuesales servicenow currently has a trailing 12 month evsales ratio of 1062 which compares unfavorably to some extent with what the industry saw in the last year additionally the ratio is nearly close to its high end of the valuation range in this period hence valuation looks slightly stretched from an evsales perspective,sell,"['servicenow', 'face', 'stiff', 'competition', 'nonitsm', 'market', 'like', 'oracle', 'salesforcecom', 'establish', 'player', 'company', 'edge', 'security', 'response', 'market', 'customer', 'service', 'hr', 'solution', 'face', 'significant', 'competition', 'player', 'nonitsm', 'market', 'large', 'contributor', 'companys', 'total', 'revenue', 'increase', 'competition', 'weigh', 'growth', 'cutthroat', 'competition', 'hurt', 'pricing', 'power', 'lengthen', 'sale', 'cycle', 'negatively', 'impact', 'topline', 'servicenow', 'subscription', 'business', 'remain', 'strong', 'professional', 'service', 'business', 'expect', 'remain', 'drag', 'overall', 'topline', 'growth', 'business', 'grow', 'modest', '74', '2016', '2015', 'decline', '36', 'growth', 'report', '2015', '2014', 'figure', 'management', 'project', 'business', 'grow', '10', 'rate', 'long', 'run', 'servicenow', 'incur', 'loss', 'year', 'accumulate', 'deficit', '9974', 'million', 'dec', '31', '2016', 'company', 'anticipate', 'report', 'loss', 'near', 'term', 'increase', 'cost', 'noncash', 'charge', 'associate', 'equity', 'award', 'business', 'combination', 'expense', 'despite', 'improve', 'line', 'mount', 'loss', 'not', 'bode', 'investor', 'confidence', 'company', 'trade', 'premium', 'term', 'enterprise', 'valuesale', 'servicenow', 'currently', 'trail', '12', 'month', 'evsale', 'ratio', '1062', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'additionally', 'ratio', 'nearly', 'close', 'high', 'end', 'valuation', 'range', 'period', 'valuation', 'look', 'slightly', 'stretch', 'evsale', 'perspective']",servicenow face stiff competition nonitsm market like oracle salesforcecom establish player company edge security response market customer service hr solution face significant competition player nonitsm market large contributor companys total revenue increase competition weigh growth cutthroat competition hurt pricing power lengthen sale cycle negatively impact topline servicenow subscription business remain strong professional service business expect remain drag overall topline growth business grow modest 74 2016 2015 decline 36 growth report 2015 2014 figure management project business grow 10 rate long run servicenow incur loss year accumulate deficit 9974 million dec 31 2016 company anticipate report loss near term increase cost noncash charge associate equity award business combination expense despite improve line mount loss not bode investor confidence company trade premium term enterprise valuesale servicenow currently trail 12 month evsale ratio 1062 compare unfavorably extent industry see year additionally ratio nearly close high end valuation range period valuation look slightly stretch evsale perspective,5,19,-0.56,5,19,-0.56,0.8016
372,"ServiceNow, Inc._Attachment1(4).pdf",NOW,7/11/2017,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes addition of well known companies such as general mills dnb bank and renault in fourth quarter 2016 reflects the companys growing clout in the g2k customer base g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows top line growth which has been exemplary increasing at a cagr of more than 70 over 20092016 time frame revenues are now projected to grow in the 3133 range for fullyear 2017 the strong backlog of approximately 19 billion at the end of 2016 up 462 over is a key catalyst in this regard further it is penetrating the nong2k customer base 20 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 735 at the end of 2016 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 341 at the end of 2016 servicenow projects g2k customer base to increase to 1000 by 2020 which means approximately 17 customers per quarter given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also the companys recently announced acquisition of qlue a developer of virtual messaging agents is expected to enhance its customer experience,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'addition', 'know', 'company', 'general', 'mill', 'dnb', 'bank', 'renault', 'fourth', 'quarter', '2016', 'reflect', 'company', 'grow', 'clout', 'g2k', 'customer', 'base', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'line', 'growth', 'exemplary', 'increase', 'cagr', '70', '20092016', 'time', 'frame', 'revenue', 'project', 'grow', '3133', 'range', 'fullyear', '2017', 'strong', 'backlog', 'approximately', '19', 'billion', 'end', '2016', '462', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', '20', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '735', 'end', '2016', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '341', 'end', '2016', 'servicenow', 'project', 'g2k', 'customer', 'base', 'increase', '1000', '2020', 'mean', 'approximately', '17', 'customer', 'quarter', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', 'company', 'recently', 'announce', 'acquisition', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'expect', 'enhance', 'customer', 'experience']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process addition know company general mill dnb bank renault fourth quarter 2016 reflect company grow clout g2k customer base g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow line growth exemplary increase cagr 70 20092016 time frame revenue project grow 3133 range fullyear 2017 strong backlog approximately 19 billion end 2016 462 key catalyst regard penetrate nong2k customer base 20 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 735 end 2016 number customer annualize contract value acv great 1 million increase 157 end 2014 341 end 2016 servicenow project g2k customer base increase 1000 2020 mean approximately 17 customer quarter give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead company recently announce acquisition qlue developer virtual messaging agent expect enhance customer experience,14,14,0.0,14,14,0.0,0.9977
373,"ServiceNow, Inc._Attachment1(5).pdf",NOW,7/28/2017,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes addition of well known companies such as general mills dnb bank and renault in fourth quarter 2016 reflects the companys growing clout in the g2k customer base g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows top line growth which has been exemplary increasing at a cagr of more than 70 over 20092016 time frame revenues are now projected to grow in the 3738 range for fullyear 2017 the strong backlog of approximately 19 billion at the end of 2016 up 462 over is a key catalyst in this regard further it is penetrating the nong2k customer base 20 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 735 at the end of 2016 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 341 at the end of 2016 servicenow projects g2k customer base to increase to 1000 by 2020 which means approximately 17 customers per quarter given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also the companys recently announced acquisition of qlue a developer of virtual messaging agents is expected to enhance its customer experience,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'addition', 'know', 'company', 'general', 'mill', 'dnb', 'bank', 'renault', 'fourth', 'quarter', '2016', 'reflect', 'company', 'grow', 'clout', 'g2k', 'customer', 'base', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'line', 'growth', 'exemplary', 'increase', 'cagr', '70', '20092016', 'time', 'frame', 'revenue', 'project', 'grow', '3738', 'range', 'fullyear', '2017', 'strong', 'backlog', 'approximately', '19', 'billion', 'end', '2016', '462', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', '20', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '735', 'end', '2016', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '341', 'end', '2016', 'servicenow', 'project', 'g2k', 'customer', 'base', 'increase', '1000', '2020', 'mean', 'approximately', '17', 'customer', 'quarter', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', 'company', 'recently', 'announce', 'acquisition', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'expect', 'enhance', 'customer', 'experience']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process addition know company general mill dnb bank renault fourth quarter 2016 reflect company grow clout g2k customer base g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow line growth exemplary increase cagr 70 20092016 time frame revenue project grow 3738 range fullyear 2017 strong backlog approximately 19 billion end 2016 462 key catalyst regard penetrate nong2k customer base 20 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 735 end 2016 number customer annualize contract value acv great 1 million increase 157 end 2014 341 end 2016 servicenow project g2k customer base increase 1000 2020 mean approximately 17 customer quarter give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead company recently announce acquisition qlue developer virtual messaging agent expect enhance customer experience,14,14,0.0,14,14,0.0,0.9977
374,"ServiceNow, Inc._Attachment1(5).pdf",NOW,7/30/2019,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloud based processes g2k customers contribute approximately 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at global 2000 or g2k customer base 44 and fortune 500 clientele 75 has been driving servicenows topline growth the strong backlog of approximately 51 billion at the end of 2018 up 35 over is a key catalyst in this regard further it is penetrating the nong2k customer base focusing primarily on public and big private entities rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 883 at the end of 2018 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 678 at the end of 2018 given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions also in 2017 the company had acquired qlue a developer of virtual messaging agents the buyout is expected to enhance its customer experience the acquisitions of telepathy and skygiraffe both concluded in are expected to enhance the companys enterprise mobile experience the acquisitions of dxcontinuum parlo friendlydata and appsee are expected to boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloud', 'base', 'process', 'g2k', 'customer', 'contribute', 'approximately', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'global', '2000', 'g2k', 'customer', 'base', '44', 'fortune', '500', 'clientele', '75', 'drive', 'servicenow', 'topline', 'growth', 'strong', 'backlog', 'approximately', '51', 'billion', 'end', '2018', '35', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', 'focus', 'primarily', 'public', 'big', 'private', 'entity', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '883', 'end', '2018', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '678', 'end', '2018', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', '2017', 'company', 'acquire', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'buyout', 'expect', 'enhance', 'customer', 'experience', 'acquisition', 'telepathy', 'skygiraffe', 'conclude', 'expect', 'enhance', 'company', 'enterprise', 'mobile', 'experience', 'acquisition', 'dxcontinuum', 'parlo', 'friendlydata', 'appsee', 'expect', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloud base process g2k customer contribute approximately 50 topline company expect mix remain steady long haul grow penetration global 2000 g2k customer base 44 fortune 500 clientele 75 drive servicenow topline growth strong backlog approximately 51 billion end 2018 35 key catalyst regard penetrate nong2k customer base focus primarily public big private entity rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 883 end 2018 number customer annualize contract value acv great 1 million increase 157 end 2014 678 end 2018 give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution 2017 company acquire qlue developer virtual messaging agent buyout expect enhance customer experience acquisition telepathy skygiraffe conclude expect enhance company enterprise mobile experience acquisition dxcontinuum parlo friendlydata appsee expect boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead,14,12,0.07407407407407407,14,12,0.07407407407407407,0.9975
375,"ServiceNow, Inc._Attachment1.pdf",NOW,1/5/2018,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows topline growth which has been exemplary increasing at a cagr of more than 70 over 20092016 time frame the strong backlog of approximately 19 billion at the end of 2016 up 462 over is a key catalyst in this regard further it is penetrating the non g2k customer base 20 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shorter sales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 735 at the end of 2016 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 341 at the end of 2016 given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also the companys recently announced acquisition of qlue a developer of virtual messaging agents is expected to enhance its customer experience further the announced acquisitions of telepathy and skygiraffe are expected to enhance the companys enterprise mobile experience,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'topline', 'growth', 'exemplary', 'increase', 'cagr', '70', '20092016', 'time', 'frame', 'strong', 'backlog', 'approximately', '19', 'billion', 'end', '2016', '462', 'key', 'catalyst', 'regard', 'penetrate', 'non', 'g2k', 'customer', 'base', '20', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'short', 'sale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '735', 'end', '2016', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '341', 'end', '2016', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', 'company', 'recently', 'announce', 'acquisition', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'expect', 'enhance', 'customer', 'experience', 'announce', 'acquisition', 'telepathy', 'skygiraffe', 'expect', 'enhance', 'company', 'enterprise', 'mobile', 'experience']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow topline growth exemplary increase cagr 70 20092016 time frame strong backlog approximately 19 billion end 2016 462 key catalyst regard penetrate non g2k customer base 20 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 short sale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 735 end 2016 number customer annualize contract value acv great 1 million increase 157 end 2014 341 end 2016 give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead company recently announce acquisition qlue developer virtual messaging agent expect enhance customer experience announce acquisition telepathy skygiraffe expect enhance company enterprise mobile experience,15,14,0.03333333333333333,15,14,0.03333333333333333,0.9976
376,"ServiceNow, Inc._Attachment1.pdf",NOW,5/29/2018,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows topline growth the strong backlog of approximately 26 billion at the end of 2017 up 368 over is a key catalyst in this regard further it is penetrating the non g2k customer base focusing primarily on public and big private entities 38 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shorter sales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 840 at the end of 2017 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 500 at the end of 2017 given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also the companys recently announced acquisition of qlue a developer of virtual messaging agents is expected to enhance its customer experience further the announced acquisitions of telepathy and skygiraffe are expected to enhance the companys enterprise mobile experience,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'topline', 'growth', 'strong', 'backlog', 'approximately', '26', 'billion', 'end', '2017', '368', 'key', 'catalyst', 'regard', 'penetrate', 'non', 'g2k', 'customer', 'base', 'focus', 'primarily', 'public', 'big', 'private', 'entity', '38', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'short', 'sale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '840', 'end', '2017', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '500', 'end', '2017', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', 'company', 'recently', 'announce', 'acquisition', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'expect', 'enhance', 'customer', 'experience', 'announce', 'acquisition', 'telepathy', 'skygiraffe', 'expect', 'enhance', 'company', 'enterprise', 'mobile', 'experience']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow topline growth strong backlog approximately 26 billion end 2017 368 key catalyst regard penetrate non g2k customer base focus primarily public big private entity 38 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 short sale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 840 end 2017 number customer annualize contract value acv great 1 million increase 157 end 2014 500 end 2017 give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead company recently announce acquisition qlue developer virtual messaging agent expect enhance customer experience announce acquisition telepathy skygiraffe expect enhance company enterprise mobile experience,14,14,0.0,14,14,0.0,0.9975
377,"ServiceNow, Inc._Attachment1.pdf",NOW,10/5/2018,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloud based processes g2k customers contribute almost 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base has been driving servicenows topline growth the strong backlog of approximately 26 billion at the end of 2017 up 368 over is a key catalyst in this regard further it is penetrating the nong2k customer base focusing primarily on public and big private entities 38 of the business rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services the company noted that 72 of its customers now use multiple products beyond itsm as compared with 49 in 2014 shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 840 at the end of 2017 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 500 at the end of 2017 given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions the recent acquisition of dxcontinuum will boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead also the companys recently announced acquisition of qlue a developer of virtual messaging agents is expected to enhance its customer experience further the announced acquisitions of telepathy and skygiraffe are expected to enhance the companys enterprise mobile experience,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloud', 'base', 'process', 'g2k', 'customer', 'contribute', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', 'drive', 'servicenow', 'topline', 'growth', 'strong', 'backlog', 'approximately', '26', 'billion', 'end', '2017', '368', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', 'focus', 'primarily', 'public', 'big', 'private', 'entity', '38', 'business', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'company', 'note', '72', 'customer', 'use', 'multiple', 'product', 'itsm', 'compare', '49', '2014', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '840', 'end', '2017', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '500', 'end', '2017', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', 'recent', 'acquisition', 'dxcontinuum', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead', 'company', 'recently', 'announce', 'acquisition', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'expect', 'enhance', 'customer', 'experience', 'announce', 'acquisition', 'telepathy', 'skygiraffe', 'expect', 'enhance', 'company', 'enterprise', 'mobile', 'experience']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloud base process g2k customer contribute 50 topline company expect mix remain steady long haul grow penetration g2k customer base drive servicenow topline growth strong backlog approximately 26 billion end 2017 368 key catalyst regard penetrate nong2k customer base focus primarily public big private entity 38 business rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service company note 72 customer use multiple product itsm compare 49 2014 shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 840 end 2017 number customer annualize contract value acv great 1 million increase 157 end 2014 500 end 2017 give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution recent acquisition dxcontinuum boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead company recently announce acquisition qlue developer virtual messaging agent expect enhance customer experience announce acquisition telepathy skygiraffe expect enhance company enterprise mobile experience,14,13,0.03571428571428571,14,13,0.03571428571428571,0.9975
378,"ServiceNow, Inc._Attachment1.pdf",NOW,3/8/2019,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloud based processes g2k customers contribute approximately 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at g2k customer base 44 has been driving servicenows topline growth the strong backlog of approximately 51 billion at the end of 2018 up 35 over is a key catalyst in this regard further it is penetrating the nong2k customer base focusing primarily on public and big private entities rapidly which will further drive topline growth in the long run servicenow is rapidly expanding into nonitsm markets like human resource and security solutions by launching new products and services shortersales cycle of these new products particularly security solutions as compared with the traditional itsm business is driving topline growth the company is also focused on strengthening sales team across the different nonitsm markets which will expand customer base going ahead servicenow has a diversified customer base which is evident from the fact that none of the customers exceeded 10 of revenues in the last couple of years the companys customer base has increased steadily during the period with global 2000 as defined by forbes customers increasing from 533 at the end of 2014 to 883 at the end of 2018 number of customers with annualized contract value acv greater than 1 million has also increased from 157 at the end of 2014 to 678 at the end of 2018 given the companys expanding product portfolio including emerging products increasing multiproduct customer base and strong renewal rate almost 98 we expect the company to achieve this target much earlier acv is also expected to improve from 1 million in 2016 to 2 million by 2020 which will help the company easily achieve the topline target of 4 billion acquisitions have played an important part in servicenows growth trajectory over the years the acquisitions of neebula systems brightpoint security and itapp both in has aided the company to expand product portfolio particularly security and itom solutions also in 2017 the company had acquired qlue a developer of virtual messaging agents the buyout is expected to enhance its customer experience the acquisitions of telepathy and skygiraffe both concluded in are expected to enhance the companys enterprise mobile experience the acquisitions of dxcontinuum parlo and friendlydata are expected to boost its predictive modelling capabilities consequently expanding servicenows intelligent automation product portfolio going ahead,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloud', 'base', 'process', 'g2k', 'customer', 'contribute', 'approximately', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'g2k', 'customer', 'base', '44', 'drive', 'servicenow', 'topline', 'growth', 'strong', 'backlog', 'approximately', '51', 'billion', 'end', '2018', '35', 'key', 'catalyst', 'regard', 'penetrate', 'nong2k', 'customer', 'base', 'focus', 'primarily', 'public', 'big', 'private', 'entity', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run', 'servicenow', 'rapidly', 'expand', 'nonitsm', 'market', 'like', 'human', 'resource', 'security', 'solution', 'launch', 'new', 'product', 'service', 'shortersale', 'cycle', 'new', 'product', 'particularly', 'security', 'solution', 'compare', 'traditional', 'itsm', 'business', 'drive', 'topline', 'growth', 'company', 'focus', 'strengthen', 'sale', 'team', 'different', 'nonitsm', 'market', 'expand', 'customer', 'base', 'go', 'ahead', 'servicenow', 'diversified', 'customer', 'base', 'evident', 'fact', 'customer', 'exceed', '10', 'revenue', 'couple', 'year', 'companys', 'customer', 'base', 'increase', 'steadily', 'period', 'global', '2000', 'define', 'forbes', 'customer', 'increase', '533', 'end', '2014', '883', 'end', '2018', 'number', 'customer', 'annualize', 'contract', 'value', 'acv', 'great', '1', 'million', 'increase', '157', 'end', '2014', '678', 'end', '2018', 'give', 'company', 'expand', 'product', 'portfolio', 'include', 'emerge', 'product', 'increase', 'multiproduct', 'customer', 'base', 'strong', 'renewal', 'rate', '98', 'expect', 'company', 'achieve', 'target', 'early', 'acv', 'expect', 'improve', '1', 'million', '2016', '2', 'million', '2020', 'help', 'company', 'easily', 'achieve', 'topline', 'target', '4', 'billion', 'acquisition', 'play', 'important', 'servicenow', 'growth', 'trajectory', 'year', 'acquisition', 'neebula', 'systems', 'brightpoint', 'security', 'itapp', 'aid', 'company', 'expand', 'product', 'portfolio', 'particularly', 'security', 'itom', 'solution', '2017', 'company', 'acquire', 'qlue', 'developer', 'virtual', 'messaging', 'agent', 'buyout', 'expect', 'enhance', 'customer', 'experience', 'acquisition', 'telepathy', 'skygiraffe', 'conclude', 'expect', 'enhance', 'company', 'enterprise', 'mobile', 'experience', 'acquisition', 'dxcontinuum', 'parlo', 'friendlydata', 'expect', 'boost', 'predictive', 'modelling', 'capability', 'consequently', 'expand', 'servicenow', 'intelligent', 'automation', 'product', 'portfolio', 'go', 'ahead']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloud base process g2k customer contribute approximately 50 topline company expect mix remain steady long haul grow penetration g2k customer base 44 drive servicenow topline growth strong backlog approximately 51 billion end 2018 35 key catalyst regard penetrate nong2k customer base focus primarily public big private entity rapidly drive topline growth long run servicenow rapidly expand nonitsm market like human resource security solution launch new product service shortersale cycle new product particularly security solution compare traditional itsm business drive topline growth company focus strengthen sale team different nonitsm market expand customer base go ahead servicenow diversified customer base evident fact customer exceed 10 revenue couple year companys customer base increase steadily period global 2000 define forbes customer increase 533 end 2014 883 end 2018 number customer annualize contract value acv great 1 million increase 157 end 2014 678 end 2018 give company expand product portfolio include emerge product increase multiproduct customer base strong renewal rate 98 expect company achieve target early acv expect improve 1 million 2016 2 million 2020 help company easily achieve topline target 4 billion acquisition play important servicenow growth trajectory year acquisition neebula systems brightpoint security itapp aid company expand product portfolio particularly security itom solution 2017 company acquire qlue developer virtual messaging agent buyout expect enhance customer experience acquisition telepathy skygiraffe conclude expect enhance company enterprise mobile experience acquisition dxcontinuum parlo friendlydata expect boost predictive modelling capability consequently expand servicenow intelligent automation product portfolio go ahead,14,12,0.07407407407407407,14,12,0.07407407407407407,0.9975
379,"ServiceNow, Inc._Attachment1.pdf",NOW,4/30/2019,servicenow faces stiff competition in the nonitsm markets from the likes of oracle and salesforcecom which are well established players although the company has an edge in the security response market the customer service and hr solutions faces significant competition from these players as nonitsm markets become a larger contributor to the companys total revenue increasing competition can weigh on growth moreover cutthroat competition can hurt pricing power as well as lengthen the sales cycle which will negatively impact topline servicenow has been incurring losses over the last five years and has an accumulated deficit of 9788 million as of dec 31 2018 the company anticipates reporting loss in the near term due to increased costs such as noncash charges associated with equity awards business combinations and other expenses despite the improving top line mounting losses doesnt bode well for investor confidence moreover the company is trading at premium in terms of pricebook pb servicenow currently has a trailing 12 month pb ratio of 4410 which compares unfavorably to some extent with what the industry saw in the last year additionally the ratio is higher than the average level of 3635 hence valuation looks slightly stretched from pb perspective zacks equity research now wwwzackscom page 4 of 10,sell,"['servicenow', 'face', 'stiff', 'competition', 'nonitsm', 'market', 'like', 'oracle', 'salesforcecom', 'establish', 'player', 'company', 'edge', 'security', 'response', 'market', 'customer', 'service', 'hr', 'solution', 'face', 'significant', 'competition', 'player', 'nonitsm', 'market', 'large', 'contributor', 'companys', 'total', 'revenue', 'increase', 'competition', 'weigh', 'growth', 'cutthroat', 'competition', 'hurt', 'pricing', 'power', 'lengthen', 'sale', 'cycle', 'negatively', 'impact', 'topline', 'servicenow', 'incur', 'loss', 'year', 'accumulate', 'deficit', '9788', 'million', 'dec', '31', '2018', 'company', 'anticipate', 'report', 'loss', 'near', 'term', 'increase', 'cost', 'noncash', 'charge', 'associate', 'equity', 'award', 'business', 'combination', 'expense', 'despite', 'improve', 'line', 'mount', 'loss', 'not', 'bode', 'investor', 'confidence', 'company', 'trade', 'premium', 'term', 'pricebook', 'pb', 'servicenow', 'currently', 'trail', '12', 'month', 'pb', 'ratio', '4410', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '3635', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective', 'zack', 'equity', 'research', 'wwwzackscom', 'page', '4', '10']",servicenow face stiff competition nonitsm market like oracle salesforcecom establish player company edge security response market customer service hr solution face significant competition player nonitsm market large contributor companys total revenue increase competition weigh growth cutthroat competition hurt pricing power lengthen sale cycle negatively impact topline servicenow incur loss year accumulate deficit 9788 million dec 31 2018 company anticipate report loss near term increase cost noncash charge associate equity award business combination expense despite improve line mount loss not bode investor confidence company trade premium term pricebook pb servicenow currently trail 12 month pb ratio 4410 compare unfavorably extent industry see year additionally ratio high average level 3635 valuation look slightly stretch pb perspective zack equity research wwwzackscom page 4 10,4,15,-0.55,4,15,-0.55,0.1511
380,"ServiceNow, Inc._Attachment1.pdf",NOW,3/30/2020,servicenow is a dominant name in the it service market itsm the company continues to win market share by replacing legacy onpremise systems with cloudbased processes g2k customers contribute approximately 50 of the topline and the company expects the mix to remain steady in the long haul the growing penetration at fortune 500 clientele 80 has been driving servicenows topline growth further it is focusing primarily on public and big private entities rapidly which will further drive topline growth in the long run,buy,"['servicenow', 'dominant', 'service', 'market', 'itsm', 'company', 'continue', 'win', 'market', 'share', 'replace', 'legacy', 'onpremise', 'system', 'cloudbase', 'process', 'g2k', 'customer', 'contribute', 'approximately', '50', 'topline', 'company', 'expect', 'mix', 'remain', 'steady', 'long', 'haul', 'grow', 'penetration', 'fortune', '500', 'clientele', '80', 'drive', 'servicenow', 'topline', 'growth', 'focus', 'primarily', 'public', 'big', 'private', 'entity', 'rapidly', 'drive', 'topline', 'growth', 'long', 'run']",servicenow dominant service market itsm company continue win market share replace legacy onpremise system cloudbase process g2k customer contribute approximately 50 topline company expect mix remain steady long haul grow penetration fortune 500 clientele 80 drive servicenow topline growth focus primarily public big private entity rapidly drive topline growth long run,1,2,-0.25,1,2,-0.25,0.8807
381,Splunk Inc._Attachment1(2).pdf,SPLK,12/4/2020,splunks software offerings enables users to have deep insight of their data on a realtime basis thereby making the operational decision making process faster the companys software has a broad range of applications including security analytics business analytics and it operations the valuable insight into machine and big data is allowing usersenterprises to improve service levels reduce operational costs mitigate security risks and maintain compliance splunks customer base is expanding rapidly due to these factors notably the company had 19400 customers in more than 130 countries at the end of fiscal 2020 splunks software can be deployed in a wide variety of computing environments from a single laptop to large globally distributed data centers as well as public private and hybrid cloud environments the companys top line is benefiting from high demand for its cloud solutions splunks es solutions also hold promise users leverage es to centralize security management on a single platform and better handle the big data scale of their security operations center splunk also benefits from the ongoing siem replacement cycle further the companys integration with amazon web services aws security hub to help customers accelerate detection investigation and response to potential threats within their aws security environment is a key catalyst for the long haul the companys business transition from perpetual licenses to subscription or renewable model is expected to benefit it in the long run splunk has been witnessing an increase in the number of renewable terms contracts which is a tailwind the company booked 35 orders greater than 10 million in 2020 compared with 24 in the prior year additionally cloud annual recurring revenues arr were 630 million up 712 in thirdquarter fiscal 2021 the company ended fiscal third quarter with 444 customers with arr greater than 1 million splunks aggressive acquisition strategy has played a pivotal part in developing its business over the last couple of years the signalfx acquisition makes the company a leader in cloud monitoring and apm for organizations transitioning to cloud the victorops buyout helps it in addressing the needs of devops which is a rapidly growing domain of software engineering the acquisition of phantom cyber aided in the addition of security orchestration automation and response to splunks portfolio the buyout of rocana has strengthened the companys machine data platform some of the other acquisitions include signalsense drastin and caspida among others these,sell,"['splunk', 'software', 'offering', 'enable', 'user', 'deep', 'insight', 'datum', 'realtime', 'basis', 'make', 'operational', 'decision', 'make', 'process', 'fast', 'company', 'software', 'broad', 'range', 'application', 'include', 'security', 'analytic', 'business', 'analytic', 'operation', 'valuable', 'insight', 'machine', 'big', 'datum', 'allow', 'usersenterprise', 'improve', 'service', 'level', 'reduce', 'operational', 'cost', 'mitigate', 'security', 'risk', 'maintain', 'compliance', 'splunk', 'customer', 'base', 'expand', 'rapidly', 'factor', 'notably', 'company', '19400', 'customer', '130', 'country', 'end', 'fiscal', '2020', 'splunk', 'software', 'deploy', 'wide', 'variety', 'compute', 'environment', 'single', 'laptop', 'large', 'globally', 'distribute', 'data', 'center', 'public', 'private', 'hybrid', 'cloud', 'environment', 'company', 'line', 'benefit', 'high', 'demand', 'cloud', 'solution', 'splunk', 'es', 'solution', 'hold', 'promise', 'user', 'leverage', 'es', 'centralize', 'security', 'management', 'single', 'platform', 'well', 'handle', 'big', 'data', 'scale', 'security', 'operation', 'center', 'splunk', 'benefit', 'ongoing', 'siem', 'replacement', 'cycle', 'companys', 'integration', 'amazon', 'web', 'services', 'aw', 'security', 'hub', 'help', 'customer', 'accelerate', 'detection', 'investigation', 'response', 'potential', 'threat', 'aw', 'security', 'environment', 'key', 'catalyst', 'long', 'haul', 'company', 'business', 'transition', 'perpetual', 'license', 'subscription', 'renewable', 'model', 'expect', 'benefit', 'long', 'run', 'splunk', 'witness', 'increase', 'number', 'renewable', 'term', 'contract', 'tailwind', 'company', 'book', '35', 'order', 'great', '10', 'million', '2020', 'compare', '24', 'prior', 'year', 'additionally', 'cloud', 'annual', 'recur', 'revenue', 'arr', '630', 'million', '712', 'thirdquarter', 'fiscal', '2021', 'company', 'end', 'fiscal', 'quarter', '444', 'customer', 'arr', 'great', '1', 'million', 'splunk', 'aggressive', 'acquisition', 'strategy', 'play', 'pivotal', 'develop', 'business', 'couple', 'year', 'signalfx', 'acquisition', 'make', 'company', 'leader', 'cloud', 'monitoring', 'apm', 'organization', 'transition', 'cloud', 'victorop', 'buyout', 'help', 'address', 'need', 'devop', 'rapidly', 'grow', 'domain', 'software', 'engineer', 'acquisition', 'phantom', 'cyber', 'aid', 'addition', 'security', 'orchestration', 'automation', 'response', 'splunk', 'portfolio', 'buyout', 'rocana', 'strengthen', 'company', 'machine', 'datum', 'platform', 'acquisition', 'include', 'signalsense', 'drastin', 'caspida']",splunk software offering enable user deep insight datum realtime basis make operational decision make process fast company software broad range application include security analytic business analytic operation valuable insight machine big datum allow usersenterprise improve service level reduce operational cost mitigate security risk maintain compliance splunk customer base expand rapidly factor notably company 19400 customer 130 country end fiscal 2020 splunk software deploy wide variety compute environment single laptop large globally distribute data center public private hybrid cloud environment company line benefit high demand cloud solution splunk es solution hold promise user leverage es centralize security management single platform well handle big data scale security operation center splunk benefit ongoing siem replacement cycle companys integration amazon web services aw security hub help customer accelerate detection investigation response potential threat aw security environment key catalyst long haul company business transition perpetual license subscription renewable model expect benefit long run splunk witness increase number renewable term contract tailwind company book 35 order great 10 million 2020 compare 24 prior year additionally cloud annual recur revenue arr 630 million 712 thirdquarter fiscal 2021 company end fiscal quarter 444 customer arr great 1 million splunk aggressive acquisition strategy play pivotal develop business couple year signalfx acquisition make company leader cloud monitoring apm organization transition cloud victorop buyout help address need devop rapidly grow domain software engineer acquisition phantom cyber aid addition security orchestration automation response splunk portfolio buyout rocana strengthen company machine datum platform acquisition include signalsense drastin caspida,12,19,-0.21875,12,19,-0.21875,0.9946
382,Splunk Inc._Attachment1(4).pdf,SPLK,10/25/2019,splunks top line over the last couple of years has been negatively impacted by the ongoing business model transition moreover the transition from perpetual licenses to subscription or renewablebased model has severely hurt the companys cash flow generation ability due to lower upfront payment although longterm cash yield is expected to return to the mid20 level the company is unsure about the time frame moreover the maintenance services segment revenues are slowing down due to the ongoing transition to the cloud splunk relies on partners to provide maintenance and professional services since its a lowmargin business which is another reason behind the,sell,"['splunk', 'line', 'couple', 'year', 'negatively', 'impact', 'ongoing', 'business', 'model', 'transition', 'transition', 'perpetual', 'license', 'subscription', 'renewablebased', 'model', 'severely', 'hurt', 'company', 'cash', 'flow', 'generation', 'ability', 'lower', 'upfront', 'payment', 'longterm', 'cash', 'yield', 'expect', 'return', 'mid20', 'level', 'company', 'unsure', 'time', 'frame', 'maintenance', 'service', 'segment', 'revenue', 'slow', 'ongoing', 'transition', 'cloud', 'splunk', 'rely', 'partner', 'provide', 'maintenance', 'professional', 'service', 'lowmargin', 'business', 'reason']",splunk line couple year negatively impact ongoing business model transition transition perpetual license subscription renewablebased model severely hurt company cash flow generation ability lower upfront payment longterm cash yield expect return mid20 level company unsure time frame maintenance service segment revenue slow ongoing transition cloud splunk rely partner provide maintenance professional service lowmargin business reason,0,6,-0.8571428571428571,0,6,-0.8571428571428571,-0.8074
383,Splunk Inc_Attachment1.pdf,SPLK,10/27/2020,splunks software offerings enables users to have deep insight of their data on a realtime basis thereby making the operational decision making process faster the companys software has a broad range of applications including security analytics business analytics and it operations the valuable insight into machine and big data is allowing usersenterprises to improve service levels reduce operational costs mitigate security risks and maintain compliance splunks customer base is expanding rapidly due to these factors notably the company had 19400 customers in more than 130 countries at the end of fiscal 2020 splunks software can be deployed in a wide variety of computing environments from a single laptop to large globally distributed data centers as well as public private and hybrid cloud environments the companys top line is benefiting from high demand for its cloud solutions splunks es solutions also hold promise users leverage es to centralize security management on a single platform and better handle the big data scale of their security operations center splunk also benefits from the ongoing siem replacement cycle further the companys integration with amazon web services aws security hub to help customers accelerate detection investigation and response to potential threats within their aws security environment is a key catalyst for the long haul the companys business transition from perpetual licenses to subscription or renewable model is expected to benefit it in the long run splunk has been witnessing an increase in the number of renewable terms contracts which is a tailwind the company booked 35 orders greater than 10 million in 2020 compared with 24 in the prior year additionally cloud arr was 442 million in fourthquarter fiscal 2020 these indicate strong subscription revenue growth for the rest of fiscal 2021 splunks aggressive acquisition strategy has played a pivotal part in developing its business over the last couple of years the signalfx acquisition makes the company a leader in cloud monitoring and apm for organizations transitioning to cloud the victorops buyout helps it in addressing the needs of devops which is a rapidly growing domain of software engineering the acquisition of phantom cyber aided in the addition of security orchestration automation and response to splunks portfolio the buyout of rocana has strengthened the companys machine data platform some of the other acquisitions include signalsense drastin and caspida among others these,sell,"['splunk', 'software', 'offering', 'enable', 'user', 'deep', 'insight', 'datum', 'realtime', 'basis', 'make', 'operational', 'decision', 'make', 'process', 'fast', 'company', 'software', 'broad', 'range', 'application', 'include', 'security', 'analytic', 'business', 'analytic', 'operation', 'valuable', 'insight', 'machine', 'big', 'datum', 'allow', 'usersenterprise', 'improve', 'service', 'level', 'reduce', 'operational', 'cost', 'mitigate', 'security', 'risk', 'maintain', 'compliance', 'splunk', 'customer', 'base', 'expand', 'rapidly', 'factor', 'notably', 'company', '19400', 'customer', '130', 'country', 'end', 'fiscal', '2020', 'splunk', 'software', 'deploy', 'wide', 'variety', 'compute', 'environment', 'single', 'laptop', 'large', 'globally', 'distribute', 'data', 'center', 'public', 'private', 'hybrid', 'cloud', 'environment', 'company', 'line', 'benefit', 'high', 'demand', 'cloud', 'solution', 'splunk', 'es', 'solution', 'hold', 'promise', 'user', 'leverage', 'es', 'centralize', 'security', 'management', 'single', 'platform', 'well', 'handle', 'big', 'data', 'scale', 'security', 'operation', 'center', 'splunk', 'benefit', 'ongoing', 'siem', 'replacement', 'cycle', 'companys', 'integration', 'amazon', 'web', 'services', 'aw', 'security', 'hub', 'help', 'customer', 'accelerate', 'detection', 'investigation', 'response', 'potential', 'threat', 'aw', 'security', 'environment', 'key', 'catalyst', 'long', 'haul', 'company', 'business', 'transition', 'perpetual', 'license', 'subscription', 'renewable', 'model', 'expect', 'benefit', 'long', 'run', 'splunk', 'witness', 'increase', 'number', 'renewable', 'term', 'contract', 'tailwind', 'company', 'book', '35', 'order', 'great', '10', 'million', '2020', 'compare', '24', 'prior', 'year', 'additionally', 'cloud', 'arr', '442', 'million', 'fourthquarter', 'fiscal', '2020', 'indicate', 'strong', 'subscription', 'revenue', 'growth', 'rest', 'fiscal', '2021', 'splunk', 'aggressive', 'acquisition', 'strategy', 'play', 'pivotal', 'develop', 'business', 'couple', 'year', 'signalfx', 'acquisition', 'make', 'company', 'leader', 'cloud', 'monitoring', 'apm', 'organization', 'transition', 'cloud', 'victorop', 'buyout', 'help', 'address', 'need', 'devop', 'rapidly', 'grow', 'domain', 'software', 'engineer', 'acquisition', 'phantom', 'cyber', 'aid', 'addition', 'security', 'orchestration', 'automation', 'response', 'splunk', 'portfolio', 'buyout', 'rocana', 'strengthen', 'company', 'machine', 'datum', 'platform', 'acquisition', 'include', 'signalsense', 'drastin', 'caspida']",splunk software offering enable user deep insight datum realtime basis make operational decision make process fast company software broad range application include security analytic business analytic operation valuable insight machine big datum allow usersenterprise improve service level reduce operational cost mitigate security risk maintain compliance splunk customer base expand rapidly factor notably company 19400 customer 130 country end fiscal 2020 splunk software deploy wide variety compute environment single laptop large globally distribute data center public private hybrid cloud environment company line benefit high demand cloud solution splunk es solution hold promise user leverage es centralize security management single platform well handle big data scale security operation center splunk benefit ongoing siem replacement cycle companys integration amazon web services aw security hub help customer accelerate detection investigation response potential threat aw security environment key catalyst long haul company business transition perpetual license subscription renewable model expect benefit long run splunk witness increase number renewable term contract tailwind company book 35 order great 10 million 2020 compare 24 prior year additionally cloud arr 442 million fourthquarter fiscal 2020 indicate strong subscription revenue growth rest fiscal 2021 splunk aggressive acquisition strategy play pivotal develop business couple year signalfx acquisition make company leader cloud monitoring apm organization transition cloud victorop buyout help address need devop rapidly grow domain software engineer acquisition phantom cyber aid addition security orchestration automation response splunk portfolio buyout rocana strengthen company machine datum platform acquisition include signalsense drastin caspida,12,17,-0.16666666666666666,12,17,-0.16666666666666666,0.9948
384,"TESARO, Inc._Attachment1(2).pdf",TSRO,7/3/2018,zejula approval a boost with the approval of zejula in march 2017 tesaros revenues got a major boost driven by strong demand for the drug the drug was approved in europe in november 2017 the drug has bright prospects given the immense commercial potential in the target market and tremendous demand for parp inhibitors zejula holds greater than 50 us ovarian cancer market share in the parp inhibitor segment meanwhile the drug is included in the nccn clinical practice guidelines in oncology ovarian cancer which increases awareness of zejulas benefits and can aid treatment decisions for patients collaborations boosts revenues tesaros earns a significant amount of its revenues in the form of license and collaboration revenues related to zejulas development the company has granted janssen a subsidiary of jj global rights except japan for developing niraparib in prostate cancer the company received 350 million upfront fees and is eligible to receive more than 400 million in regulatory and sales based milestone payments in july 2017 tesaro inkedexclusive license agreement with japanbased takeda granting rights to develop niraparib in all tumor types in japan and all tumor types excluding prostate cancer in south korea taiwan russia and australia the company also has a collaboration agreement with chinabased zai lab for the development of niraparib in china hong kong and macao or the china territories tesaro received 100 million and 15 million in upfront fees from takeda and zai lab respectively the company is also eligible to receive additional regulatory and sales milestones and royalties a collaboration agreement with merck reimburses part of the costs related to clinical studies evaluating the zejulakeytruda combination regime in june 2018 tesaro collaborated with genentech a subsidiary of roche to develop zejula in combination with the latters pdl1 antibody drug tecentriq and mek inhibitor cotellic in ovarian cancer patients who are sensitive to platinumbased chemotherapy the companies are also planning to develop zejula in combination with tecentriq for the treatment of metastatic bladder cancer a phase ibii study is expected to be initiated by the end of 2018,sell,"['zejula', 'approval', 'boost', 'approval', 'zejula', 'march', '2017', 'tesaros', 'revenue', 'get', 'major', 'boost', 'drive', 'strong', 'demand', 'drug', 'drug', 'approve', 'europe', 'november', '2017', 'drug', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'zejula', 'hold', 'great', '50', 'ovarian', 'cancer', 'market', 'share', 'parp', 'inhibitor', 'segment', 'drug', 'include', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'ovarian', 'cancer', 'increase', 'awareness', 'zejula', 'benefit', 'aid', 'treatment', 'decision', 'patient', 'collaboration', 'boost', 'revenue', 'tesaros', 'earn', 'significant', 'revenue', 'form', 'license', 'collaboration', 'revenue', 'relate', 'zejula', 'development', 'company', 'grant', 'janssen', 'subsidiary', 'jj', 'global', 'right', 'japan', 'develop', 'niraparib', 'prostate', 'cancer', 'company', 'receive', '350', 'million', 'upfront', 'fee', 'eligible', 'receive', '400', 'million', 'regulatory', 'sale', 'base', 'milestone', 'payment', 'july', '2017', 'tesaro', 'inkedexclusive', 'license', 'agreement', 'japanbase', 'takeda', 'grant', 'right', 'develop', 'niraparib', 'tumor', 'type', 'japan', 'tumor', 'type', 'exclude', 'prostate', 'cancer', 'south', 'korea', 'taiwan', 'russia', 'australia', 'company', 'collaboration', 'agreement', 'chinabase', 'zai', 'lab', 'development', 'niraparib', 'china', 'hong', 'kong', 'macao', 'china', 'territories', 'tesaro', 'receive', '100', 'million', '15', 'million', 'upfront', 'fee', 'takeda', 'zai', 'lab', 'respectively', 'company', 'eligible', 'receive', 'additional', 'regulatory', 'sale', 'milestone', 'royalty', 'collaboration', 'agreement', 'merck', 'reimburse', 'cost', 'relate', 'clinical', 'study', 'evaluate', 'zejulakeytruda', 'combination', 'regime', 'june', '2018', 'tesaro', 'collaborate', 'genentech', 'subsidiary', 'roche', 'develop', 'zejula', 'combination', 'latter', 'pdl1', 'antibody', 'drug', 'tecentriq', 'mek', 'inhibitor', 'cotellic', 'ovarian', 'cancer', 'patient', 'sensitive', 'platinumbase', 'chemotherapy', 'company', 'plan', 'develop', 'zejula', 'combination', 'tecentriq', 'treatment', 'metastatic', 'bladder', 'cancer', 'phase', 'ibii', 'study', 'expect', 'initiate', 'end', '2018']",zejula approval boost approval zejula march 2017 tesaros revenue get major boost drive strong demand drug drug approve europe november 2017 drug bright prospect give immense commercial potential target market tremendous demand parp inhibitor zejula hold great 50 ovarian cancer market share parp inhibitor segment drug include nccn clinical practice guideline oncology ovarian cancer increase awareness zejula benefit aid treatment decision patient collaboration boost revenue tesaros earn significant revenue form license collaboration revenue relate zejula development company grant janssen subsidiary jj global right japan develop niraparib prostate cancer company receive 350 million upfront fee eligible receive 400 million regulatory sale base milestone payment july 2017 tesaro inkedexclusive license agreement japanbase takeda grant right develop niraparib tumor type japan tumor type exclude prostate cancer south korea taiwan russia australia company collaboration agreement chinabase zai lab development niraparib china hong kong macao china territories tesaro receive 100 million 15 million upfront fee takeda zai lab respectively company eligible receive additional regulatory sale milestone royalty collaboration agreement merck reimburse cost relate clinical study evaluate zejulakeytruda combination regime june 2018 tesaro collaborate genentech subsidiary roche develop zejula combination latter pdl1 antibody drug tecentriq mek inhibitor cotellic ovarian cancer patient sensitive platinumbase chemotherapy company plan develop zejula combination tecentriq treatment metastatic bladder cancer phase ibii study expect initiate end 2018,12,4,0.47058823529411764,12,4,0.47058823529411764,0.9136
385,"TESARO, Inc._Attachment1(3).pdf",TSRO,10/23/2018,zejula approval a boost with the approval of zejula in march 2017 tesaros revenues got a major boost driven by strong demand for the drug the drug was approved in europe in november 2017 the drug has bright prospects given the immense commercial potential in the target market and tremendous demand for parp inhibitors zejula holds a lead position in the us ovarian cancer market share in the parp inhibitor segment meanwhile the drug is included in the nccn clinical practice guidelines in oncology ovarian cancer which increases awareness of zejulas benefits and boost prospect of the drug additional indications being evaluated tesaro is looking to expand zejulas label into other treatment settings for ovarian cancer and additional cancer types like prostrate and breast a phase iii prima study is evaluating zejula in the firstline maintenance setting in ovarian cancer patients who have responded to firstline platinum chemotherapy topline data is expected in late 2019 two separate phase ii studies are evaluating zejula in patients with firstline ovarian cancer and recurrent ovarian cancer in combination with roches avastin based on successful completion of a phase ii quadra study monotherapy the company is planning to file a regulatory application seeking label expansion in patients with ovarian cancer who have received three or four regimens of therapy a snda is expected to be filed by year end an investigatorsponsored phase iii avanova study is comparing the combination regimen against avastin alone in ovarian cancer patients a third phase ii topacio study is evaluating zejula and mercks anti pd1 therapy keytruda combination regimen in patients with triple negative breast cancer and patients with ovarian cancer the company is also planning to initiate a registration phase iii study first in september 2018 to evaluate zejula in combination with its own anti pd1 therapy tsr042 in firstline ovarian cancer two phase ii studies are evaluating the combination in ovarian cancer and in nonsmall cell lung cancer nsclc tesaro also has several collaborations with other pharma companies for development of zejula in other tumor types collaborations boosts revenues tesaros earns a significant amount of its revenues in the form of license and collaboration revenues related to zejulas development the company has granted janssen a subsidiary of jj global rights except japan for developing niraparib in prostate cancer the company received 350 million upfront fees and is eligible to receive more than 400 million in regulatory and sales based milestone payments in july 2017 tesaro inked exclusive license agreement with japan based takeda granting rights to develop niraparib in all tumor types in japan and all tumor types excluding prostate cancer in south korea taiwan russia and australia the company also has a collaboration agreement with chinabased zai lab for the development of niraparib in china hong kong and macao or the china territories tesaro received 100 million and 15 million in upfront fees from takeda and zai lab respectively the company is also eligible to receive additional regulatory and sales milestones and royalties a collaboration agreement with merck reimburses part of the costs related to clinical studies evaluating the zejulakeytruda combination regime in june 2018 tesaro collaborated with genentech a subsidiary of roche to develop zejula in combination with the latters pdl1 antibody drug tecentriq and mek inhibitor cotellic in ovarian cancer patients who are sensitive to platinumbased chemotherapy the companies are also planning to develop zejula in combination with tecentriq for the treatment of metastatic bladder cancer a phase ibii study is expected to be initiated by the end of 2018 potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer will be diagnosed in the united states in 2018 and more than 45000 in europe with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is a huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore zejula has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 164000 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society,buy,"['zejula', 'approval', 'boost', 'approval', 'zejula', 'march', '2017', 'tesaros', 'revenue', 'get', 'major', 'boost', 'drive', 'strong', 'demand', 'drug', 'drug', 'approve', 'europe', 'november', '2017', 'drug', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'zejula', 'hold', 'lead', 'position', 'ovarian', 'cancer', 'market', 'share', 'parp', 'inhibitor', 'segment', 'drug', 'include', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'ovarian', 'cancer', 'increase', 'awareness', 'zejula', 'benefit', 'boost', 'prospect', 'drug', 'additional', 'indication', 'evaluate', 'tesaro', 'look', 'expand', 'zejulas', 'label', 'treatment', 'setting', 'ovarian', 'cancer', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'phase', 'iii', 'prima', 'study', 'evaluate', 'zejula', 'firstline', 'maintenance', 'setting', 'ovarian', 'cancer', 'patient', 'respond', 'firstline', 'platinum', 'chemotherapy', 'topline', 'datum', 'expect', 'late', '2019', 'separate', 'phase', 'ii', 'study', 'evaluate', 'zejula', 'patient', 'firstline', 'ovarian', 'cancer', 'recurrent', 'ovarian', 'cancer', 'combination', 'roche', 'avastin', 'base', 'successful', 'completion', 'phase', 'ii', 'quadra', 'study', 'monotherapy', 'company', 'plan', 'file', 'regulatory', 'application', 'seek', 'label', 'expansion', 'patient', 'ovarian', 'cancer', 'receive', 'regimen', 'therapy', 'snda', 'expect', 'file', 'year', 'end', 'investigatorsponsored', 'phase', 'iii', 'avanova', 'study', 'compare', 'combination', 'regiman', 'avastin', 'ovarian', 'cancer', 'patient', 'phase', 'ii', 'topacio', 'study', 'evaluate', 'zejula', 'merck', 'anti', 'pd1', 'therapy', 'keytruda', 'combination', 'regiman', 'patient', 'triple', 'negative', 'breast', 'cancer', 'patient', 'ovarian', 'cancer', 'company', 'plan', 'initiate', 'registration', 'phase', 'iii', 'study', 'september', '2018', 'evaluate', 'zejula', 'combination', 'anti', 'pd1', 'therapy', 'tsr042', 'firstline', 'ovarian', 'cancer', 'phase', 'ii', 'study', 'evaluate', 'combination', 'ovarian', 'cancer', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'tesaro', 'collaboration', 'pharma', 'company', 'development', 'zejula', 'tumor', 'type', 'collaboration', 'boost', 'revenue', 'tesaros', 'earn', 'significant', 'revenue', 'form', 'license', 'collaboration', 'revenue', 'relate', 'zejula', 'development', 'company', 'grant', 'janssen', 'subsidiary', 'jj', 'global', 'right', 'japan', 'develop', 'niraparib', 'prostate', 'cancer', 'company', 'receive', '350', 'million', 'upfront', 'fee', 'eligible', 'receive', '400', 'million', 'regulatory', 'sale', 'base', 'milestone', 'payment', 'july', '2017', 'tesaro', 'ink', 'exclusive', 'license', 'agreement', 'japan', 'base', 'takeda', 'grant', 'right', 'develop', 'niraparib', 'tumor', 'type', 'japan', 'tumor', 'type', 'exclude', 'prostate', 'cancer', 'south', 'korea', 'taiwan', 'russia', 'australia', 'company', 'collaboration', 'agreement', 'chinabase', 'zai', 'lab', 'development', 'niraparib', 'china', 'hong', 'kong', 'macao', 'china', 'territories', 'tesaro', 'receive', '100', 'million', '15', 'million', 'upfront', 'fee', 'takeda', 'zai', 'lab', 'respectively', 'company', 'eligible', 'receive', 'additional', 'regulatory', 'sale', 'milestone', 'royalty', 'collaboration', 'agreement', 'merck', 'reimburse', 'cost', 'relate', 'clinical', 'study', 'evaluate', 'zejulakeytruda', 'combination', 'regime', 'june', '2018', 'tesaro', 'collaborate', 'genentech', 'subsidiary', 'roche', 'develop', 'zejula', 'combination', 'latter', 'pdl1', 'antibody', 'drug', 'tecentriq', 'mek', 'inhibitor', 'cotellic', 'ovarian', 'cancer', 'patient', 'sensitive', 'platinumbase', 'chemotherapy', 'company', 'plan', 'develop', 'zejula', 'combination', 'tecentriq', 'treatment', 'metastatic', 'bladder', 'cancer', 'phase', 'ibii', 'study', 'expect', 'initiate', 'end', '2018', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', '45000', 'europe', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'zejula', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '164000', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society']",zejula approval boost approval zejula march 2017 tesaros revenue get major boost drive strong demand drug drug approve europe november 2017 drug bright prospect give immense commercial potential target market tremendous demand parp inhibitor zejula hold lead position ovarian cancer market share parp inhibitor segment drug include nccn clinical practice guideline oncology ovarian cancer increase awareness zejula benefit boost prospect drug additional indication evaluate tesaro look expand zejulas label treatment setting ovarian cancer additional cancer type like prostrate breast phase iii prima study evaluate zejula firstline maintenance setting ovarian cancer patient respond firstline platinum chemotherapy topline datum expect late 2019 separate phase ii study evaluate zejula patient firstline ovarian cancer recurrent ovarian cancer combination roche avastin base successful completion phase ii quadra study monotherapy company plan file regulatory application seek label expansion patient ovarian cancer receive regimen therapy snda expect file year end investigatorsponsored phase iii avanova study compare combination regiman avastin ovarian cancer patient phase ii topacio study evaluate zejula merck anti pd1 therapy keytruda combination regiman patient triple negative breast cancer patient ovarian cancer company plan initiate registration phase iii study september 2018 evaluate zejula combination anti pd1 therapy tsr042 firstline ovarian cancer phase ii study evaluate combination ovarian cancer nonsmall cell lung cancer nsclc tesaro collaboration pharma company development zejula tumor type collaboration boost revenue tesaros earn significant revenue form license collaboration revenue relate zejula development company grant janssen subsidiary jj global right japan develop niraparib prostate cancer company receive 350 million upfront fee eligible receive 400 million regulatory sale base milestone payment july 2017 tesaro ink exclusive license agreement japan base takeda grant right develop niraparib tumor type japan tumor type exclude prostate cancer south korea taiwan russia australia company collaboration agreement chinabase zai lab development niraparib china hong kong macao china territories tesaro receive 100 million 15 million upfront fee takeda zai lab respectively company eligible receive additional regulatory sale milestone royalty collaboration agreement merck reimburse cost relate clinical study evaluate zejulakeytruda combination regime june 2018 tesaro collaborate genentech subsidiary roche develop zejula combination latter pdl1 antibody drug tecentriq mek inhibitor cotellic ovarian cancer patient sensitive platinumbase chemotherapy company plan develop zejula combination tecentriq treatment metastatic bladder cancer phase ibii study expect initiate end 2018 potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states 2018 45000 europe standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation zejula bright prospect give immense commercial potential target market tremendous demand parp inhibitor 164000 newly diagnose prostate cancer patient united state 2018 american cancer society,17,12,0.16666666666666666,17,12,0.16666666666666666,-0.9983
386,"TESARO, Inc._Attachment1(4).pdf",TSRO,8/8/2018,zejula approval a boost with the approval of zejula in march 2017 tesaros revenues got a major boost driven by strong demand for the drug the drug was approved in europe in november 2017 the drug has bright prospects given the immense commercial potential in the target market and tremendous demand for parp inhibitors zejula holds a lead position in the us ovarian cancer market share in the parp inhibitor segment meanwhile the drug is included in the nccn clinical practice guidelines in oncology ovarian cancer which increases awareness of zejulas benefits and boost prospect of the drug collaborations boosts revenues tesaros earns a significant amount of its revenues in the form of license and collaboration revenues related to zejulas development the company has granted janssen a subsidiary of jj global rights except japan for developing niraparib in prostate cancer the company received 350 million upfront fees and is eligible to receive more than 400 million in regulatory and sales based milestone payments in july 2017 tesaro inked exclusive license agreement with japanbased takeda granting rights to develop niraparib in all tumor types in japan and all tumor types excluding prostate cancer in south korea taiwan russia and australia the company also has a collaboration agreement with chinabased zai lab for the development of niraparib in china hong kong and macao or the china territories tesaro received 100 million and 15 million in upfront fees from takeda and zai lab respectively the company is also eligible to receive additional regulatory and sales milestones and royalties a collaboration agreement with merck reimburses part of the costs related to clinical studies evaluating the zejulakeytruda combination regime in june 2018 tesaro collaborated with genentech a subsidiary of roche to develop zejula in combination with the latters pdl1 antibody drug tecentriq and mek inhibitor cotellic in ovarian cancer patients who are sensitive to platinumbased chemotherapy the companies are also planning to develop zejula in combination with tecentriq for the treatment of metastatic bladder cancer a phase ibii study is expected to be initiated by the end of 2018,sell,"['zejula', 'approval', 'boost', 'approval', 'zejula', 'march', '2017', 'tesaros', 'revenue', 'get', 'major', 'boost', 'drive', 'strong', 'demand', 'drug', 'drug', 'approve', 'europe', 'november', '2017', 'drug', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'zejula', 'hold', 'lead', 'position', 'ovarian', 'cancer', 'market', 'share', 'parp', 'inhibitor', 'segment', 'drug', 'include', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'ovarian', 'cancer', 'increase', 'awareness', 'zejula', 'benefit', 'boost', 'prospect', 'drug', 'collaboration', 'boost', 'revenue', 'tesaros', 'earn', 'significant', 'revenue', 'form', 'license', 'collaboration', 'revenue', 'relate', 'zejula', 'development', 'company', 'grant', 'janssen', 'subsidiary', 'jj', 'global', 'right', 'japan', 'develop', 'niraparib', 'prostate', 'cancer', 'company', 'receive', '350', 'million', 'upfront', 'fee', 'eligible', 'receive', '400', 'million', 'regulatory', 'sale', 'base', 'milestone', 'payment', 'july', '2017', 'tesaro', 'ink', 'exclusive', 'license', 'agreement', 'japanbase', 'takeda', 'grant', 'right', 'develop', 'niraparib', 'tumor', 'type', 'japan', 'tumor', 'type', 'exclude', 'prostate', 'cancer', 'south', 'korea', 'taiwan', 'russia', 'australia', 'company', 'collaboration', 'agreement', 'chinabase', 'zai', 'lab', 'development', 'niraparib', 'china', 'hong', 'kong', 'macao', 'china', 'territories', 'tesaro', 'receive', '100', 'million', '15', 'million', 'upfront', 'fee', 'takeda', 'zai', 'lab', 'respectively', 'company', 'eligible', 'receive', 'additional', 'regulatory', 'sale', 'milestone', 'royalty', 'collaboration', 'agreement', 'merck', 'reimburse', 'cost', 'relate', 'clinical', 'study', 'evaluate', 'zejulakeytruda', 'combination', 'regime', 'june', '2018', 'tesaro', 'collaborate', 'genentech', 'subsidiary', 'roche', 'develop', 'zejula', 'combination', 'latter', 'pdl1', 'antibody', 'drug', 'tecentriq', 'mek', 'inhibitor', 'cotellic', 'ovarian', 'cancer', 'patient', 'sensitive', 'platinumbase', 'chemotherapy', 'company', 'plan', 'develop', 'zejula', 'combination', 'tecentriq', 'treatment', 'metastatic', 'bladder', 'cancer', 'phase', 'ibii', 'study', 'expect', 'initiate', 'end', '2018']",zejula approval boost approval zejula march 2017 tesaros revenue get major boost drive strong demand drug drug approve europe november 2017 drug bright prospect give immense commercial potential target market tremendous demand parp inhibitor zejula hold lead position ovarian cancer market share parp inhibitor segment drug include nccn clinical practice guideline oncology ovarian cancer increase awareness zejula benefit boost prospect drug collaboration boost revenue tesaros earn significant revenue form license collaboration revenue relate zejula development company grant janssen subsidiary jj global right japan develop niraparib prostate cancer company receive 350 million upfront fee eligible receive 400 million regulatory sale base milestone payment july 2017 tesaro ink exclusive license agreement japanbase takeda grant right develop niraparib tumor type japan tumor type exclude prostate cancer south korea taiwan russia australia company collaboration agreement chinabase zai lab development niraparib china hong kong macao china territories tesaro receive 100 million 15 million upfront fee takeda zai lab respectively company eligible receive additional regulatory sale milestone royalty collaboration agreement merck reimburse cost relate clinical study evaluate zejulakeytruda combination regime june 2018 tesaro collaborate genentech subsidiary roche develop zejula combination latter pdl1 antibody drug tecentriq mek inhibitor cotellic ovarian cancer patient sensitive platinumbase chemotherapy company plan develop zejula combination tecentriq treatment metastatic bladder cancer phase ibii study expect initiate end 2018,14,4,0.5263157894736842,14,4,0.5263157894736842,0.9186
387,"TESARO, Inc._Attachment1(4).pdf",TSRO,11/22/2018,zejula has commercial potential with the approval of zejula in march 2017 tesaros revenues got a major boost driven by strong demand for the drug the drug was approved in europe in november 2017 the drug has bright prospects given the immense commercial potential in the target market zejula holds significant us ovarian cancer market share in the parp inhibitor segment the drug is also capturing the european market fast meanwhile the drug is included in the nccn clinical practice guidelines in oncology ovarian cancer which increases awareness of zejulas benefits and boost prospect of the drug additional indications being evaluated tesaro is looking to expand zejulas label into other treatment settings for ovarian cancer and additional cancer types like prostrate and breast a phase iii prima study is evaluating zejula in the firstline maintenance setting in ovarian cancer patients who have responded to firstline platinum chemotherapy topline data is expected in late 2019 two separate phase ii studies are evaluating zejula in patients with firstline ovarian cancer and recurrent ovarian cancer in combination with roches avastin based on successful completion of a phase ii quadra study monotherapy the company is planning to file a regulatory application seeking label expansion in patients with ovarian cancer who have received three or four regimens of therapy a snda is expected to be filed by year end an investigatorsponsored phase iii avanova study is comparing the combination regimen against avastin alone in ovarian cancer patients a third phase ii topacio study is evaluating zejula and mercks anti pd1 therapy keytruda combination regimen in patients with triple negative breast cancer and patients with ovarian cancer a registration phase iii study first is evaluating zejula in combination with tesaros own anti pd1 therapy tsr042 in firstline ovarian cancer two phase ii studies are evaluating the combination in ovarian cancer and in nonsmall cell lung cancer nsclc tesaro also has several collaborations with other pharma companies for development of zejula in other tumor types collaborations boosts revenues tesaro earns a significant amount of its revenues in the form of license and collaboration revenues related to zejulas development the company has granted janssen a subsidiary of jj global rights except japan for developing niraparib in prostate cancer the company received 350 million upfront fees and is eligible to receive more than 400 million in regulatory and sales based milestone payments in july 2017 tesaro inked exclusive license agreement with japan based takeda granting rights to develop niraparib in all tumor types in japan and all tumor types excluding prostate cancer in south korea taiwan russia and australia the company also has a collaboration agreement with chinabased zai lab for the development of niraparib in china hong kong and macao or the china territories tesaro received 100 million and 15 million in upfront fees from takeda and zai lab respectively the company is also eligible to receive additional regulatory and sales milestones and royalties arena gets reimbursement of costs related to clinical studies evaluating the zejulakeytruda combination regime from merck as a part of a collaboration agreement in june 2018 tesaro collaborated with genentech a subsidiary of roche to develop zejula in combination with the latters pdl1 antibody drug tecentriq and mek inhibitor cotellic in ovarian cancer patients who are sensitive to platinumbased chemotherapy the companies are also planning to develop zejula in combination with tecentriq for the treatment of metastatic bladder cancer a phase ibii study is expected to be initiated by the end of 2018 potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer will be diagnosed in the united states in 2018 and more than 45000 in europe with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 therefore zejula has bright prospects given the immense commercial potential of the target market moreover there will be 164000 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society,buy,"['zejula', 'commercial', 'potential', 'approval', 'zejula', 'march', '2017', 'tesaros', 'revenue', 'get', 'major', 'boost', 'drive', 'strong', 'demand', 'drug', 'drug', 'approve', 'europe', 'november', '2017', 'drug', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'zejula', 'hold', 'significant', 'ovarian', 'cancer', 'market', 'share', 'parp', 'inhibitor', 'segment', 'drug', 'capture', 'european', 'market', 'fast', 'drug', 'include', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'ovarian', 'cancer', 'increase', 'awareness', 'zejula', 'benefit', 'boost', 'prospect', 'drug', 'additional', 'indication', 'evaluate', 'tesaro', 'look', 'expand', 'zejulas', 'label', 'treatment', 'setting', 'ovarian', 'cancer', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'phase', 'iii', 'prima', 'study', 'evaluate', 'zejula', 'firstline', 'maintenance', 'setting', 'ovarian', 'cancer', 'patient', 'respond', 'firstline', 'platinum', 'chemotherapy', 'topline', 'datum', 'expect', 'late', '2019', 'separate', 'phase', 'ii', 'study', 'evaluate', 'zejula', 'patient', 'firstline', 'ovarian', 'cancer', 'recurrent', 'ovarian', 'cancer', 'combination', 'roche', 'avastin', 'base', 'successful', 'completion', 'phase', 'ii', 'quadra', 'study', 'monotherapy', 'company', 'plan', 'file', 'regulatory', 'application', 'seek', 'label', 'expansion', 'patient', 'ovarian', 'cancer', 'receive', 'regimen', 'therapy', 'snda', 'expect', 'file', 'year', 'end', 'investigatorsponsored', 'phase', 'iii', 'avanova', 'study', 'compare', 'combination', 'regiman', 'avastin', 'ovarian', 'cancer', 'patient', 'phase', 'ii', 'topacio', 'study', 'evaluate', 'zejula', 'merck', 'anti', 'pd1', 'therapy', 'keytruda', 'combination', 'regiman', 'patient', 'triple', 'negative', 'breast', 'cancer', 'patient', 'ovarian', 'cancer', 'registration', 'phase', 'iii', 'study', 'evaluate', 'zejula', 'combination', 'tesaros', 'anti', 'pd1', 'therapy', 'tsr042', 'firstline', 'ovarian', 'cancer', 'phase', 'ii', 'study', 'evaluate', 'combination', 'ovarian', 'cancer', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'tesaro', 'collaboration', 'pharma', 'company', 'development', 'zejula', 'tumor', 'type', 'collaboration', 'boost', 'revenue', 'tesaro', 'earn', 'significant', 'revenue', 'form', 'license', 'collaboration', 'revenue', 'relate', 'zejula', 'development', 'company', 'grant', 'janssen', 'subsidiary', 'jj', 'global', 'right', 'japan', 'develop', 'niraparib', 'prostate', 'cancer', 'company', 'receive', '350', 'million', 'upfront', 'fee', 'eligible', 'receive', '400', 'million', 'regulatory', 'sale', 'base', 'milestone', 'payment', 'july', '2017', 'tesaro', 'ink', 'exclusive', 'license', 'agreement', 'japan', 'base', 'takeda', 'grant', 'right', 'develop', 'niraparib', 'tumor', 'type', 'japan', 'tumor', 'type', 'exclude', 'prostate', 'cancer', 'south', 'korea', 'taiwan', 'russia', 'australia', 'company', 'collaboration', 'agreement', 'chinabase', 'zai', 'lab', 'development', 'niraparib', 'china', 'hong', 'kong', 'macao', 'china', 'territories', 'tesaro', 'receive', '100', 'million', '15', 'million', 'upfront', 'fee', 'takeda', 'zai', 'lab', 'respectively', 'company', 'eligible', 'receive', 'additional', 'regulatory', 'sale', 'milestone', 'royalty', 'arena', 'get', 'reimbursement', 'cost', 'relate', 'clinical', 'study', 'evaluate', 'zejulakeytruda', 'combination', 'regime', 'merck', 'collaboration', 'agreement', 'june', '2018', 'tesaro', 'collaborate', 'genentech', 'subsidiary', 'roche', 'develop', 'zejula', 'combination', 'latter', 'pdl1', 'antibody', 'drug', 'tecentriq', 'mek', 'inhibitor', 'cotellic', 'ovarian', 'cancer', 'patient', 'sensitive', 'platinumbase', 'chemotherapy', 'company', 'plan', 'develop', 'zejula', 'combination', 'tecentriq', 'treatment', 'metastatic', 'bladder', 'cancer', 'phase', 'ibii', 'study', 'expect', 'initiate', 'end', '2018', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', '45000', 'europe', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'zejula', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', '164000', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society']",zejula commercial potential approval zejula march 2017 tesaros revenue get major boost drive strong demand drug drug approve europe november 2017 drug bright prospect give immense commercial potential target market zejula hold significant ovarian cancer market share parp inhibitor segment drug capture european market fast drug include nccn clinical practice guideline oncology ovarian cancer increase awareness zejula benefit boost prospect drug additional indication evaluate tesaro look expand zejulas label treatment setting ovarian cancer additional cancer type like prostrate breast phase iii prima study evaluate zejula firstline maintenance setting ovarian cancer patient respond firstline platinum chemotherapy topline datum expect late 2019 separate phase ii study evaluate zejula patient firstline ovarian cancer recurrent ovarian cancer combination roche avastin base successful completion phase ii quadra study monotherapy company plan file regulatory application seek label expansion patient ovarian cancer receive regimen therapy snda expect file year end investigatorsponsored phase iii avanova study compare combination regiman avastin ovarian cancer patient phase ii topacio study evaluate zejula merck anti pd1 therapy keytruda combination regiman patient triple negative breast cancer patient ovarian cancer registration phase iii study evaluate zejula combination tesaros anti pd1 therapy tsr042 firstline ovarian cancer phase ii study evaluate combination ovarian cancer nonsmall cell lung cancer nsclc tesaro collaboration pharma company development zejula tumor type collaboration boost revenue tesaro earn significant revenue form license collaboration revenue relate zejula development company grant janssen subsidiary jj global right japan develop niraparib prostate cancer company receive 350 million upfront fee eligible receive 400 million regulatory sale base milestone payment july 2017 tesaro ink exclusive license agreement japan base takeda grant right develop niraparib tumor type japan tumor type exclude prostate cancer south korea taiwan russia australia company collaboration agreement chinabase zai lab development niraparib china hong kong macao china territories tesaro receive 100 million 15 million upfront fee takeda zai lab respectively company eligible receive additional regulatory sale milestone royalty arena get reimbursement cost relate clinical study evaluate zejulakeytruda combination regime merck collaboration agreement june 2018 tesaro collaborate genentech subsidiary roche develop zejula combination latter pdl1 antibody drug tecentriq mek inhibitor cotellic ovarian cancer patient sensitive platinumbase chemotherapy company plan develop zejula combination tecentriq treatment metastatic bladder cancer phase ibii study expect initiate end 2018 potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states 2018 45000 europe standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 zejula bright prospect give immense commercial potential target market 164000 newly diagnose prostate cancer patient united state 2018 american cancer society,13,11,0.08,13,11,0.08,-0.9982
388,"TESARO, Inc._Attachment1.pdf",TSRO,6/22/2018,zejula approval a boost with the approval of zejula in march 2017 tesaros revenues got a major boost driven by strong demand for the drug the drug was approved in europe in november 2017 the drug has bright prospects given the immense commercial potential in the target market and tremendous demand for parp inhibitors zejula holds greater than 50 us ovarian cancer market share in the parp inhibitor segment meanwhile the drug is included in the nccn clinical practice guidelines in oncology ovarian cancer which increases awareness of zejulas benefits and can aid treatment decisions for patients additional indications being evaluated tesaro is looking to expand zejulas label into other treatment settings for ovarian cancer and additional cancer types like prostrate and breast a phase iii prima study is evaluating zejula in the firstline maintenance setting in ovarian cancer patients who have responded to firstline platinum chemotherapy top line data is expected in late 2019 another phase ii study is evaluating zejula in combination with roches avastin in patients with firstline ovarian cancer based on successful completion of a phase ii quadra study the company is planning to file a regulatory application seeking label expansion in patients with ovarian cancer who have received three or four regimens of therapy an investigatorsponsored phase iii avanova study is comparing the combination regimen against avastin alone in ovarian cancer patients a third phase ii topacio study is evaluating zejula and mercks anti pd1 therapy keytruda combination regimen in patients with triple negative breast cancer and patients with ovarian cancer the company is also planning to initiate a registration phase iii study first in the second quarter of 2018 to evaluate zejula in combination with its own anti pd1 therapy tsr042 in firstline ovarian cancer two phase ii studies are evaluating the combination in ovarian cancer and in nonsmall cell lung cancer nsclc tesaro also has several collaborations with other pharma companies for development of zejula in other tumor types collaborations boosts revenues tesaros earns a significant amount of its revenues in the form of license and collaboration revenues related to zejulas development the company has granted janssen a subsidiary of jj global rights except japan for developing niraparib in prostate cancer the company received 350 million upfront fees and is eligible to receive more than 400 million in regulatory and sales based milestone payments in july 2017 tesaro inkedexclusive license agreement with japan based takeda granting rights to develop niraparib in all tumor types in japan and all tumor types excluding prostate cancer in south korea taiwan russia and australia the company also has a collaboration agreement with chinabased zai lab for the development of niraparib in china hong kong and macao or the china territories tesaro received 100 million and 15 million in upfront fees from takeda and zai lab respectively the company is also eligible to receive additional regulatory and sales milestones and royalties a collaboration agreement with merck reimburses part of the costs related to clinical studies evaluating the zejulakeytruda combination regime in june 2018 tesaro collaborated with genentech a subsidiary of roche to develop zejula in combination with the latters pdl1 antibody drug tecentriq and mek inhibitor cotellic in ovarian cancer patients who are sensitive to platinumbased chemotherapy the companies are also planning to develop zejula in combination with tecentriq for the treatment of metastatic bladder cancer a phase ibii study is expected to be initiated by the end of 2018 potential in the target market according to the american cancer society ovarian cancer ranks fifth in cancer deaths among women accounting for more deaths than any other cancer of the female reproductive system it is estimated that more than 22440 cases of ovarian cancer will be diagnosed in the united states in 2018 and more than 45000 in europe with standardofcare treatments for ovarian cancer including surgery radiation chemotherapy targeted and hormone therapies the fiveyear relative survival rate for all types of ovarian cancer is 45 there is a huge unmet need for new treatment options given that one in four women with ovarian cancer have a germline or somatic brca mutation therefore zejula has bright prospects given the immense commercial potential of the target market and the tremendous demand for parp inhibitors moreover there will be 164000 newly diagnosed prostate cancer patients in the united stated in 2018 per the american cancer society,buy,"['zejula', 'approval', 'boost', 'approval', 'zejula', 'march', '2017', 'tesaros', 'revenue', 'get', 'major', 'boost', 'drive', 'strong', 'demand', 'drug', 'drug', 'approve', 'europe', 'november', '2017', 'drug', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'zejula', 'hold', 'great', '50', 'ovarian', 'cancer', 'market', 'share', 'parp', 'inhibitor', 'segment', 'drug', 'include', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'ovarian', 'cancer', 'increase', 'awareness', 'zejula', 'benefit', 'aid', 'treatment', 'decision', 'patient', 'additional', 'indication', 'evaluate', 'tesaro', 'look', 'expand', 'zejulas', 'label', 'treatment', 'setting', 'ovarian', 'cancer', 'additional', 'cancer', 'type', 'like', 'prostrate', 'breast', 'phase', 'iii', 'prima', 'study', 'evaluate', 'zejula', 'firstline', 'maintenance', 'setting', 'ovarian', 'cancer', 'patient', 'respond', 'firstline', 'platinum', 'chemotherapy', 'line', 'datum', 'expect', 'late', '2019', 'phase', 'ii', 'study', 'evaluate', 'zejula', 'combination', 'roche', 'avastin', 'patient', 'firstline', 'ovarian', 'cancer', 'base', 'successful', 'completion', 'phase', 'ii', 'quadra', 'study', 'company', 'plan', 'file', 'regulatory', 'application', 'seek', 'label', 'expansion', 'patient', 'ovarian', 'cancer', 'receive', 'regimen', 'therapy', 'investigatorsponsored', 'phase', 'iii', 'avanova', 'study', 'compare', 'combination', 'regiman', 'avastin', 'ovarian', 'cancer', 'patient', 'phase', 'ii', 'topacio', 'study', 'evaluate', 'zejula', 'merck', 'anti', 'pd1', 'therapy', 'keytruda', 'combination', 'regiman', 'patient', 'triple', 'negative', 'breast', 'cancer', 'patient', 'ovarian', 'cancer', 'company', 'plan', 'initiate', 'registration', 'phase', 'iii', 'study', 'second', 'quarter', '2018', 'evaluate', 'zejula', 'combination', 'anti', 'pd1', 'therapy', 'tsr042', 'firstline', 'ovarian', 'cancer', 'phase', 'ii', 'study', 'evaluate', 'combination', 'ovarian', 'cancer', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'tesaro', 'collaboration', 'pharma', 'company', 'development', 'zejula', 'tumor', 'type', 'collaboration', 'boost', 'revenue', 'tesaros', 'earn', 'significant', 'revenue', 'form', 'license', 'collaboration', 'revenue', 'relate', 'zejula', 'development', 'company', 'grant', 'janssen', 'subsidiary', 'jj', 'global', 'right', 'japan', 'develop', 'niraparib', 'prostate', 'cancer', 'company', 'receive', '350', 'million', 'upfront', 'fee', 'eligible', 'receive', '400', 'million', 'regulatory', 'sale', 'base', 'milestone', 'payment', 'july', '2017', 'tesaro', 'inkedexclusive', 'license', 'agreement', 'japan', 'base', 'takeda', 'grant', 'right', 'develop', 'niraparib', 'tumor', 'type', 'japan', 'tumor', 'type', 'exclude', 'prostate', 'cancer', 'south', 'korea', 'taiwan', 'russia', 'australia', 'company', 'collaboration', 'agreement', 'chinabase', 'zai', 'lab', 'development', 'niraparib', 'china', 'hong', 'kong', 'macao', 'china', 'territories', 'tesaro', 'receive', '100', 'million', '15', 'million', 'upfront', 'fee', 'takeda', 'zai', 'lab', 'respectively', 'company', 'eligible', 'receive', 'additional', 'regulatory', 'sale', 'milestone', 'royalty', 'collaboration', 'agreement', 'merck', 'reimburse', 'cost', 'relate', 'clinical', 'study', 'evaluate', 'zejulakeytruda', 'combination', 'regime', 'june', '2018', 'tesaro', 'collaborate', 'genentech', 'subsidiary', 'roche', 'develop', 'zejula', 'combination', 'latter', 'pdl1', 'antibody', 'drug', 'tecentriq', 'mek', 'inhibitor', 'cotellic', 'ovarian', 'cancer', 'patient', 'sensitive', 'platinumbase', 'chemotherapy', 'company', 'plan', 'develop', 'zejula', 'combination', 'tecentriq', 'treatment', 'metastatic', 'bladder', 'cancer', 'phase', 'ibii', 'study', 'expect', 'initiate', 'end', '2018', 'potential', 'target', 'market', 'accord', 'american', 'cancer', 'society', 'ovarian', 'cancer', 'rank', 'fifth', 'cancer', 'death', 'woman', 'account', 'death', 'cancer', 'female', 'reproductive', 'system', 'estimate', '22440', 'case', 'ovarian', 'cancer', 'diagnose', 'united', 'states', '2018', '45000', 'europe', 'standardofcare', 'treatment', 'ovarian', 'cancer', 'include', 'surgery', 'radiation', 'chemotherapy', 'target', 'hormone', 'therapie', 'fiveyear', 'relative', 'survival', 'rate', 'type', 'ovarian', 'cancer', '45', 'huge', 'unmet', 'need', 'new', 'treatment', 'option', 'give', 'woman', 'ovarian', 'cancer', 'germline', 'somatic', 'brca', 'mutation', 'zejula', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', '164000', 'newly', 'diagnose', 'prostate', 'cancer', 'patient', 'united', 'state', '2018', 'american', 'cancer', 'society']",zejula approval boost approval zejula march 2017 tesaros revenue get major boost drive strong demand drug drug approve europe november 2017 drug bright prospect give immense commercial potential target market tremendous demand parp inhibitor zejula hold great 50 ovarian cancer market share parp inhibitor segment drug include nccn clinical practice guideline oncology ovarian cancer increase awareness zejula benefit aid treatment decision patient additional indication evaluate tesaro look expand zejulas label treatment setting ovarian cancer additional cancer type like prostrate breast phase iii prima study evaluate zejula firstline maintenance setting ovarian cancer patient respond firstline platinum chemotherapy line datum expect late 2019 phase ii study evaluate zejula combination roche avastin patient firstline ovarian cancer base successful completion phase ii quadra study company plan file regulatory application seek label expansion patient ovarian cancer receive regimen therapy investigatorsponsored phase iii avanova study compare combination regiman avastin ovarian cancer patient phase ii topacio study evaluate zejula merck anti pd1 therapy keytruda combination regiman patient triple negative breast cancer patient ovarian cancer company plan initiate registration phase iii study second quarter 2018 evaluate zejula combination anti pd1 therapy tsr042 firstline ovarian cancer phase ii study evaluate combination ovarian cancer nonsmall cell lung cancer nsclc tesaro collaboration pharma company development zejula tumor type collaboration boost revenue tesaros earn significant revenue form license collaboration revenue relate zejula development company grant janssen subsidiary jj global right japan develop niraparib prostate cancer company receive 350 million upfront fee eligible receive 400 million regulatory sale base milestone payment july 2017 tesaro inkedexclusive license agreement japan base takeda grant right develop niraparib tumor type japan tumor type exclude prostate cancer south korea taiwan russia australia company collaboration agreement chinabase zai lab development niraparib china hong kong macao china territories tesaro receive 100 million 15 million upfront fee takeda zai lab respectively company eligible receive additional regulatory sale milestone royalty collaboration agreement merck reimburse cost relate clinical study evaluate zejulakeytruda combination regime june 2018 tesaro collaborate genentech subsidiary roche develop zejula combination latter pdl1 antibody drug tecentriq mek inhibitor cotellic ovarian cancer patient sensitive platinumbase chemotherapy company plan develop zejula combination tecentriq treatment metastatic bladder cancer phase ibii study expect initiate end 2018 potential target market accord american cancer society ovarian cancer rank fifth cancer death woman account death cancer female reproductive system estimate 22440 case ovarian cancer diagnose united states 2018 45000 europe standardofcare treatment ovarian cancer include surgery radiation chemotherapy target hormone therapie fiveyear relative survival rate type ovarian cancer 45 huge unmet need new treatment option give woman ovarian cancer germline somatic brca mutation zejula bright prospect give immense commercial potential target market tremendous demand parp inhibitor 164000 newly diagnose prostate cancer patient united state 2018 american cancer society,15,12,0.10714285714285714,15,12,0.10714285714285714,-0.9981
389,"TESARO, Inc._Attachment1.pdf",TSRO,9/10/2018,zejula approval a boost with the approval of zejula in march 2017 tesaros revenues got a major boost driven by strong demand for the drug the drug was approved in europe in november 2017 the drug has bright prospects given the immense commercial potential in the target market and tremendous demand for parp inhibitors zejula holds a lead position in the us ovarian cancer market share in the parp inhibitor segment meanwhile the drug is included in the nccn clinical practice guidelines in oncology ovarian cancer which increases awareness of zejulas benefits and boost prospect of the drug collaborations boosts revenues tesaros earns a significant amount of its revenues in the form of license and collaboration revenues related to zejulas development the company has granted janssen a subsidiary of jj global rights except japan for developing niraparib in prostate cancer the company received 350 million upfront fees and is eligible to receive more than 400 million in regulatory and sales based milestone payments in july 2017 tesaro inked exclusive license agreement with japanbased takeda granting rights to develop niraparib in all tumor types in japan and all tumor types excluding prostate cancer in south korea taiwan russia and australia the company also has a collaboration agreement with chinabased zai lab for the development of niraparib in china hong kong and macao or the china territories tesaro received 100 million and 15 million in upfront fees from takeda and zai lab respectively the company is also eligible to receive additional regulatory and sales milestones and royalties a collaboration agreement with merck reimburses part of the costs related to clinical studies evaluating the zejulakeytruda combination regime in june 2018 tesaro collaborated with genentech a subsidiary of roche to develop zejula in combination with the latters pdl1 antibody drug tecentriq and mek inhibitor cotellic in ovarian cancer patients who are sensitive to platinumbased chemotherapy the companies are also planning to develop zejula in combination with tecentriq for the treatment of metastatic bladder cancer a phase ibii study is expected to be initiated by the end of 2018,sell,"['zejula', 'approval', 'boost', 'approval', 'zejula', 'march', '2017', 'tesaros', 'revenue', 'get', 'major', 'boost', 'drive', 'strong', 'demand', 'drug', 'drug', 'approve', 'europe', 'november', '2017', 'drug', 'bright', 'prospect', 'give', 'immense', 'commercial', 'potential', 'target', 'market', 'tremendous', 'demand', 'parp', 'inhibitor', 'zejula', 'hold', 'lead', 'position', 'ovarian', 'cancer', 'market', 'share', 'parp', 'inhibitor', 'segment', 'drug', 'include', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'ovarian', 'cancer', 'increase', 'awareness', 'zejula', 'benefit', 'boost', 'prospect', 'drug', 'collaboration', 'boost', 'revenue', 'tesaros', 'earn', 'significant', 'revenue', 'form', 'license', 'collaboration', 'revenue', 'relate', 'zejula', 'development', 'company', 'grant', 'janssen', 'subsidiary', 'jj', 'global', 'right', 'japan', 'develop', 'niraparib', 'prostate', 'cancer', 'company', 'receive', '350', 'million', 'upfront', 'fee', 'eligible', 'receive', '400', 'million', 'regulatory', 'sale', 'base', 'milestone', 'payment', 'july', '2017', 'tesaro', 'ink', 'exclusive', 'license', 'agreement', 'japanbase', 'takeda', 'grant', 'right', 'develop', 'niraparib', 'tumor', 'type', 'japan', 'tumor', 'type', 'exclude', 'prostate', 'cancer', 'south', 'korea', 'taiwan', 'russia', 'australia', 'company', 'collaboration', 'agreement', 'chinabase', 'zai', 'lab', 'development', 'niraparib', 'china', 'hong', 'kong', 'macao', 'china', 'territories', 'tesaro', 'receive', '100', 'million', '15', 'million', 'upfront', 'fee', 'takeda', 'zai', 'lab', 'respectively', 'company', 'eligible', 'receive', 'additional', 'regulatory', 'sale', 'milestone', 'royalty', 'collaboration', 'agreement', 'merck', 'reimburse', 'cost', 'relate', 'clinical', 'study', 'evaluate', 'zejulakeytruda', 'combination', 'regime', 'june', '2018', 'tesaro', 'collaborate', 'genentech', 'subsidiary', 'roche', 'develop', 'zejula', 'combination', 'latter', 'pdl1', 'antibody', 'drug', 'tecentriq', 'mek', 'inhibitor', 'cotellic', 'ovarian', 'cancer', 'patient', 'sensitive', 'platinumbase', 'chemotherapy', 'company', 'plan', 'develop', 'zejula', 'combination', 'tecentriq', 'treatment', 'metastatic', 'bladder', 'cancer', 'phase', 'ibii', 'study', 'expect', 'initiate', 'end', '2018']",zejula approval boost approval zejula march 2017 tesaros revenue get major boost drive strong demand drug drug approve europe november 2017 drug bright prospect give immense commercial potential target market tremendous demand parp inhibitor zejula hold lead position ovarian cancer market share parp inhibitor segment drug include nccn clinical practice guideline oncology ovarian cancer increase awareness zejula benefit boost prospect drug collaboration boost revenue tesaros earn significant revenue form license collaboration revenue relate zejula development company grant janssen subsidiary jj global right japan develop niraparib prostate cancer company receive 350 million upfront fee eligible receive 400 million regulatory sale base milestone payment july 2017 tesaro ink exclusive license agreement japanbase takeda grant right develop niraparib tumor type japan tumor type exclude prostate cancer south korea taiwan russia australia company collaboration agreement chinabase zai lab development niraparib china hong kong macao china territories tesaro receive 100 million 15 million upfront fee takeda zai lab respectively company eligible receive additional regulatory sale milestone royalty collaboration agreement merck reimburse cost relate clinical study evaluate zejulakeytruda combination regime june 2018 tesaro collaborate genentech subsidiary roche develop zejula combination latter pdl1 antibody drug tecentriq mek inhibitor cotellic ovarian cancer patient sensitive platinumbase chemotherapy company plan develop zejula combination tecentriq treatment metastatic bladder cancer phase ibii study expect initiate end 2018,14,4,0.5263157894736842,14,4,0.5263157894736842,0.9186
390,Workday Inc_Attachment1(4).pdf,WDAY,6/1/2020,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers moreover growing clout of workday prism analytics and adaptive insights business planning cloud offerings holds promise according to gartner the global softwareasaservice saas revenues are expected to touch 1511 billion in 2022 from 857 billion in 2018 witnessing a cagr of 1201 based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'grow', 'clout', 'workday', 'prism', 'analytic', 'adaptive', 'insight', 'business', 'planning', 'cloud', 'offering', 'hold', 'promise', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'revenue', 'expect', 'touch', '1511', 'billion', '2022', '857', 'billion', '2018', 'witness', 'cagr', '1201', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver grow clout workday prism analytic adaptive insight business planning cloud offering hold promise accord gartner global softwareasaservice saas revenue expect touch 1511 billion 2022 857 billion 2018 witness cagr 1201 base expand product portfolio believe workday positioned gain strong growth prospect go forward,4,1,0.5,4,1,0.5,0.9698
391,Workday Inc_Attachment1.pdf,WDAY,10/22/2020,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers moreover growing clout of workday prism analytics and adaptive insights business planning cloud offerings holds promise according to technavio the global softwareasaservice saas market is expected to grow by 742 billion between 2020 and 2024 based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'grow', 'clout', 'workday', 'prism', 'analytic', 'adaptive', 'insight', 'business', 'planning', 'cloud', 'offering', 'hold', 'promise', 'accord', 'technavio', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'grow', '742', 'billion', '2020', '2024', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver grow clout workday prism analytic adaptive insight business planning cloud offering hold promise accord technavio global softwareasaservice saas market expect grow 742 billion 2020 2024 base expand product portfolio believe workday positioned gain strong growth prospect go forward,4,1,0.5,4,1,0.5,0.9698
392,"Workday, Inc._Attachment1(2).pdf",WDAY,10/10/2017,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 184 over 20162020 time frame based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud per management the companys application has been selected for core hr by more than 30 of fortune 500 companies we therefore see much room for expansion here the companys growing clout in the hcm market is evident from market research firm gartners august 2017 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the companys clientele includes enterprises like citigroup management corporation nordstrom qualcomm and humana per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys dominance in the financial management sector is also increasing which is evident from gartners june 2017 magic quadrant for cloud core financial management suites for midsize large and global enterprises report where workday was again placed in the leaders quadrant customers of its financial management application include the likes of ohio health corporation the childrens hospital of philadelphia giant tiger stores and carlyle moreover workday planning application is also doing well with more than 170 customers including qualcomm and bank of america workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in 2016 the company achieved industryleading 97 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from the 59 yearoveryear increase in revenues in the last reported quarter reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 3487 million cash from operating activities in fiscal 2017 which increased from 112 million in 2013 workday exited fiscal 2017 with cash and cash equivalents of 5399 million compared with 3001 million in fiscal 2016 workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '184', '20162020', 'time', 'frame', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'management', 'company', 'application', 'select', 'core', 'hr', '30', 'fortune', '500', 'company', 'room', 'expansion', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'august', '2017', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'clientele', 'include', 'enterprise', 'like', 'citigroup', 'management', 'corporation', 'nordstrom', 'qualcomm', 'humana', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2017', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'workday', 'place', 'leader', 'quadrant', 'customer', 'financial', 'management', 'application', 'include', 'like', 'ohio', 'health', 'corporation', 'childrens', 'hospital', 'philadelphia', 'giant', 'tiger', 'store', 'carlyle', 'workday', 'planning', 'application', '170', 'customer', 'include', 'qualcomm', 'bank', 'america', 'workdays', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', '2016', 'company', 'achieve', 'industryleade', '97', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', '59', 'yearoveryear', 'increase', 'revenue', 'reported', 'quarter', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '3487', 'million', 'cash', 'operate', 'activity', 'fiscal', '2017', 'increase', '112', 'million', '2013', 'workday', 'exit', 'fiscal', '2017', 'cash', 'cash', 'equivalent', '5399', 'million', 'compare', '3001', 'million', 'fiscal', '2016', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver accord gartner global softwareasaservice saas market expect increase cagr 184 20162020 time frame base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud management company application select core hr 30 fortune 500 company room expansion company grow clout hcm market evident market research firm gartner august 2017 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company clientele include enterprise like citigroup management corporation nordstrom qualcomm humana research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company dominance financial management sector increase evident gartner june 2017 magic quadrant cloud core financial management suite midsize large global enterprise report workday place leader quadrant customer financial management application include like ohio health corporation childrens hospital philadelphia giant tiger store carlyle workday planning application 170 customer include qualcomm bank america workdays diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model 2016 company achieve industryleade 97 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident 59 yearoveryear increase revenue reported quarter reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 3487 million cash operate activity fiscal 2017 increase 112 million 2013 workday exit fiscal 2017 cash cash equivalent 5399 million compare 3001 million fiscal 2016 workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,16,9,0.2692307692307692,16,9,0.2692307692307692,0.9952
393,"Workday, Inc._Attachment1(2).pdf",WDAY,10/10/2017,competition in the hcm and financial management software market is increasing which could lead to pricing pressure and affect workdays margins oracles strong momentum in the cloud is a headwind for the company moreover we believe that workdays dominance could be challenged by new entrants this could make the company take resort to competitive pricing to maintain and capture further market share this apart the ongoing trend to invest more in cloud solutions exposes workday to the risk of losing existing onpremise customers which can adversely impact its topline performance especially in the near term the companys margin continues to be affected by higher operating expense primarily due to an increase in headcount and marketing spending as of jul 31 2017 workday had about 7400 employees compared with about 1500 employees as of its listing date in october 2012 notably sales and marketing expenses in fiscal 2017 increased 345 year over year to 5839 million we believe workdays continuous investments in order to achieve longterm growth will hurt its margins in the short haul workday has a trailing 12 month pb ratio of 1650 this level compares unfavorably to some extent with what the industry saw over the last year the ratio is higher than the average level of 1507 and is toward its higher end of the valuation range over this period hence valuation looks slightly stretched from a pb perspective,sell,"['competition', 'hcm', 'financial', 'management', 'software', 'market', 'increase', 'lead', 'pricing', 'pressure', 'affect', 'workday', 'margin', 'oracle', 'strong', 'momentum', 'cloud', 'headwind', 'company', 'believe', 'workdays', 'dominance', 'challenge', 'new', 'entrant', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'apart', 'ongoing', 'trend', 'invest', 'cloud', 'solution', 'expose', 'workday', 'risk', 'lose', 'exist', 'onpremise', 'customer', 'adversely', 'impact', 'topline', 'performance', 'especially', 'near', 'term', 'company', 'margin', 'continue', 'affect', 'high', 'operating', 'expense', 'primarily', 'increase', 'headcount', 'marketing', 'spending', 'jul', '31', '2017', 'workday', '7400', 'employee', 'compare', '1500', 'employee', 'listing', 'date', 'october', '2012', 'notably', 'sale', 'marketing', 'expense', 'fiscal', '2017', 'increase', '345', 'year', 'year', '5839', 'million', 'believe', 'workdays', 'continuous', 'investment', 'order', 'achieve', 'longterm', 'growth', 'hurt', 'margin', 'short', 'haul', 'workday', 'trail', '12', 'month', 'pb', 'ratio', '1650', 'level', 'compare', 'unfavorably', 'extent', 'industry', 'see', 'year', 'ratio', 'high', 'average', 'level', '1507', 'high', 'end', 'valuation', 'range', 'period', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective']",competition hcm financial management software market increase lead pricing pressure affect workday margin oracle strong momentum cloud headwind company believe workdays dominance challenge new entrant company resort competitive pricing maintain capture market share apart ongoing trend invest cloud solution expose workday risk lose exist onpremise customer adversely impact topline performance especially near term company margin continue affect high operating expense primarily increase headcount marketing spending jul 31 2017 workday 7400 employee compare 1500 employee listing date october 2012 notably sale marketing expense fiscal 2017 increase 345 year year 5839 million believe workdays continuous investment order achieve longterm growth hurt margin short haul workday trail 12 month pb ratio 1650 level compare unfavorably extent industry see year ratio high average level 1507 high end valuation range period valuation look slightly stretch pb perspective,7,13,-0.2857142857142857,7,13,-0.2857142857142857,0.743
394,"Workday, Inc._Attachment1(2).pdf",WDAY,6/6/2018,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 184 over 20162020 time frame based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud per management the companys application has been selected for core hr by more than 30 of fortune 500 companies we therefore see much room for expansion here the companys growing clout in the hcm market is evident from market research firm gartners august 2017 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the companys clientele includes enterprises like citigroup management corporation nordstrom qualcomm and humana per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys dominance in the financial management sector is also increasing which is evident from gartners june 2017 magic quadrant for cloud core financial management suites for midsize large and global enterprises report where workday was again placed in the leaders quadrant customers of its financial management application include the likes of ohio health corporation the childrens hospital of philadelphia giant tiger stores and carlyle moreover workday planning application is also doing well with more than 170 customers including qualcomm and bank of america workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in the fourthquarter the company achieved industryleading 98 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from approximately 29 yearoveryear increase in revenues in the last reported quarter reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 4657 million cash from operating activities in fiscal 2018 which increased from 112 million in 2013 workday exited fiscal 2018 with cash and cash equivalents of 1134 billion compared with 5399 million in fiscal 2017 workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '184', '20162020', 'time', 'frame', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'management', 'company', 'application', 'select', 'core', 'hr', '30', 'fortune', '500', 'company', 'room', 'expansion', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'august', '2017', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'clientele', 'include', 'enterprise', 'like', 'citigroup', 'management', 'corporation', 'nordstrom', 'qualcomm', 'humana', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2017', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'workday', 'place', 'leader', 'quadrant', 'customer', 'financial', 'management', 'application', 'include', 'like', 'ohio', 'health', 'corporation', 'childrens', 'hospital', 'philadelphia', 'giant', 'tiger', 'store', 'carlyle', 'workday', 'planning', 'application', '170', 'customer', 'include', 'qualcomm', 'bank', 'america', 'workdays', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', 'fourthquarter', 'company', 'achieve', 'industryleade', '98', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', 'approximately', '29', 'yearoveryear', 'increase', 'revenue', 'reported', 'quarter', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '4657', 'million', 'cash', 'operate', 'activity', 'fiscal', '2018', 'increase', '112', 'million', '2013', 'workday', 'exit', 'fiscal', '2018', 'cash', 'cash', 'equivalent', '1134', 'billion', 'compare', '5399', 'million', 'fiscal', '2017', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver accord gartner global softwareasaservice saas market expect increase cagr 184 20162020 time frame base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud management company application select core hr 30 fortune 500 company room expansion company grow clout hcm market evident market research firm gartner august 2017 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company clientele include enterprise like citigroup management corporation nordstrom qualcomm humana research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company dominance financial management sector increase evident gartner june 2017 magic quadrant cloud core financial management suite midsize large global enterprise report workday place leader quadrant customer financial management application include like ohio health corporation childrens hospital philadelphia giant tiger store carlyle workday planning application 170 customer include qualcomm bank america workdays diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model fourthquarter company achieve industryleade 98 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident approximately 29 yearoveryear increase revenue reported quarter reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 4657 million cash operate activity fiscal 2018 increase 112 million 2013 workday exit fiscal 2018 cash cash equivalent 1134 billion compare 5399 million fiscal 2017 workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,16,9,0.2692307692307692,16,9,0.2692307692307692,0.9952
395,"Workday, Inc._Attachment1(2).pdf",WDAY,6/6/2018,competition in the hcm and financial management software market is increasing which could lead to pricing pressure and affect workdays margins oracles strong momentum in the cloud is a headwind for the company moreover we believe that workdays dominance could be challenged by new entrants this could make the company take resort to competitive pricing to maintain and capture further market share this apart the ongoing trend to invest more in cloud solutions exposes workday to the risk of losing existing onpremise customers which can adversely impact its topline performance especially in the near term the companys margin continues to be affected by higher operating expense primarily due to an increase in headcount and marketing spending as of jan 31 2017 workday had about 8200 employees compared with about 1500 employees as of its listing date in october 2012 notably sales and marketing expenses in fiscal 2018 increased 209 year over year to 6834 million we believe workdays continuous investments in order to achieve longterm growth will hurt its margins in the short haul we note that workday currently has a trailing 12month pricebook pb ratio of 1727 this level compares unfavorably with what the industry witnessed in the last year the ratio is higher than the average level of 1600 hence valuation looks slightly stretched from a pb perspective,sell,"['competition', 'hcm', 'financial', 'management', 'software', 'market', 'increase', 'lead', 'pricing', 'pressure', 'affect', 'workday', 'margin', 'oracle', 'strong', 'momentum', 'cloud', 'headwind', 'company', 'believe', 'workdays', 'dominance', 'challenge', 'new', 'entrant', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'apart', 'ongoing', 'trend', 'invest', 'cloud', 'solution', 'expose', 'workday', 'risk', 'lose', 'exist', 'onpremise', 'customer', 'adversely', 'impact', 'topline', 'performance', 'especially', 'near', 'term', 'company', 'margin', 'continue', 'affect', 'high', 'operating', 'expense', 'primarily', 'increase', 'headcount', 'marketing', 'spending', 'jan', '31', '2017', 'workday', '8200', 'employee', 'compare', '1500', 'employee', 'listing', 'date', 'october', '2012', 'notably', 'sale', 'marketing', 'expense', 'fiscal', '2018', 'increase', '209', 'year', 'year', '6834', 'million', 'believe', 'workdays', 'continuous', 'investment', 'order', 'achieve', 'longterm', 'growth', 'hurt', 'margin', 'short', 'haul', 'note', 'workday', 'currently', 'trailing', '12month', 'pricebook', 'pb', 'ratio', '1727', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'ratio', 'high', 'average', 'level', '1600', 'valuation', 'looks', 'slightly', 'stretch', 'pb', 'perspective']",competition hcm financial management software market increase lead pricing pressure affect workday margin oracle strong momentum cloud headwind company believe workdays dominance challenge new entrant company resort competitive pricing maintain capture market share apart ongoing trend invest cloud solution expose workday risk lose exist onpremise customer adversely impact topline performance especially near term company margin continue affect high operating expense primarily increase headcount marketing spending jan 31 2017 workday 8200 employee compare 1500 employee listing date october 2012 notably sale marketing expense fiscal 2018 increase 209 year year 6834 million believe workdays continuous investment order achieve longterm growth hurt margin short haul note workday currently trailing 12month pricebook pb ratio 1727 level compare unfavorably industry witness year ratio high average level 1600 valuation looks slightly stretch pb perspective,6,12,-0.3157894736842105,6,12,-0.3157894736842105,0.743
396,"Workday, Inc._Attachment1(2).pdf",WDAY,9/7/2018,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 184 over 20162020 time frame based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud per management the companys application has been selected for core hr by more than 30 of fortune 500 companies we therefore see much room for expansion here the companys growing clout in the hcm market is evident from market research firm gartners august 2017 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the company was ranked 4 on the list of the 100 best workplaces for millennial by fortune and great place to work institute additionally the company was ranked 6 on the list of the best large workplaces in europe by great place to work institute workday has more than 2200 customers during the second quarter the company added eli lilly and company bridgestone americas siemens healthineers and dbs bank as its new hcm customers the companys clientele includes enterprises like citigroup management corporation nordstrom qualcomm and humana per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys dominance in the financial management sector is also increasing which is evident from gartners june 2017 magic quadrant for cloud core financial management suites for midsize large and global enterprises report where workday was again placed in the leaders quadrant customers of its financial management application include the likes of ohio health corporation the childrens hospital of philadelphia giant tiger stores and carlyle moreover workday planning application is also doing well with more than 170 customers including qualcomm and bank of america workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in the fourthquarter the company achieved industryleading 98 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from approximately 28 yearoveryear increase in revenues in the last reported quarter reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 4657 million cash from operating activities in fiscal 2018 which increased from 112 million in 2013 workday exited fiscal 2018 with cash and cash equivalents of 1134 billion compared with 5399 million in fiscal 2017 workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '184', '20162020', 'time', 'frame', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'management', 'company', 'application', 'select', 'core', 'hr', '30', 'fortune', '500', 'company', 'room', 'expansion', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'august', '2017', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'rank', '4', 'list', '100', 'good', 'workplace', 'millennial', 'fortune', 'great', 'place', 'work', 'institute', 'additionally', 'company', 'rank', '6', 'list', 'good', 'large', 'workplace', 'europe', 'great', 'place', 'work', 'institute', 'workday', '2200', 'customer', 'second', 'quarter', 'company', 'add', 'eli', 'lilly', 'company', 'bridgestone', 'americas', 'siemens', 'healthineer', 'dbs', 'bank', 'new', 'hcm', 'customer', 'company', 'clientele', 'include', 'enterprise', 'like', 'citigroup', 'management', 'corporation', 'nordstrom', 'qualcomm', 'humana', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2017', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'workday', 'place', 'leader', 'quadrant', 'customer', 'financial', 'management', 'application', 'include', 'like', 'ohio', 'health', 'corporation', 'childrens', 'hospital', 'philadelphia', 'giant', 'tiger', 'store', 'carlyle', 'workday', 'planning', 'application', '170', 'customer', 'include', 'qualcomm', 'bank', 'america', 'workdays', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', 'fourthquarter', 'company', 'achieve', 'industryleade', '98', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', 'approximately', '28', 'yearoveryear', 'increase', 'revenue', 'reported', 'quarter', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '4657', 'million', 'cash', 'operate', 'activity', 'fiscal', '2018', 'increase', '112', 'million', '2013', 'workday', 'exit', 'fiscal', '2018', 'cash', 'cash', 'equivalent', '1134', 'billion', 'compare', '5399', 'million', 'fiscal', '2017', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver accord gartner global softwareasaservice saas market expect increase cagr 184 20162020 time frame base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud management company application select core hr 30 fortune 500 company room expansion company grow clout hcm market evident market research firm gartner august 2017 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company rank 4 list 100 good workplace millennial fortune great place work institute additionally company rank 6 list good large workplace europe great place work institute workday 2200 customer second quarter company add eli lilly company bridgestone americas siemens healthineer dbs bank new hcm customer company clientele include enterprise like citigroup management corporation nordstrom qualcomm humana research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company dominance financial management sector increase evident gartner june 2017 magic quadrant cloud core financial management suite midsize large global enterprise report workday place leader quadrant customer financial management application include like ohio health corporation childrens hospital philadelphia giant tiger store carlyle workday planning application 170 customer include qualcomm bank america workdays diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model fourthquarter company achieve industryleade 98 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident approximately 28 yearoveryear increase revenue reported quarter reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 4657 million cash operate activity fiscal 2018 increase 112 million 2013 workday exit fiscal 2018 cash cash equivalent 1134 billion compare 5399 million fiscal 2017 workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,20,15,0.1388888888888889,20,15,0.1388888888888889,0.9969
397,"Workday, Inc._Attachment1(2).pdf",WDAY,3/7/2019,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers moreover growing clout of workday prism analytics and adaptive insights business planning cloud offerings holds promise according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 178 from 588 billion in 2017 to reach 1131 billion in 2021 based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud in fact per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys growing clout in the hcm market is evident from market research firm gartners june 2018 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the company was ranked 4 on the list of the 100 best workplaces for millennial by fortune and great place to work institute additionally the company was ranked 6 on the list of the best large workplaces in europe by great place to work institute workday has more than 2600 customers the clientele now includes approximately 40 fortune 500 and half of the fortune 50 customers we therefore see much room for expansion here during the fourth quarter the company added bank of caterpillar ap mollermaersk wyndham worldwide operations and sumitomo chemical as new hcm customers notably siemens ag mckesson corporation and lloyds bank plc were a few companies to recently deploy hcm solution the companys dominance in the financial management sector is also increasing which is evident from gartners june 2018 magic quadrant for cloud core financial management suites for midsize large and global enterprises report revised where workday was again placed in the leaders quadrant in the fourth quarter the adoption of workday financial management solution by allina health ryder truck ameriprise and banner health among others is notable recent prominent deal wins include quicken loans and alight solutions furthermore workday prism analytics witnessed tripledigit growth in acv in the fourth quarter workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in the fourthquarter the company achieved industryleading 98 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from approximately 41 yearoveryear increase in revenues to 184 million approximately 233 of total fourthquarter fiscal 2019 revenues reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 6067 million cash from operating activities in fiscal 2019 which increased from 112 million in 2013 cash cash equivalents and marketable securities were 178 billion as of jan 31 2018 compared with 158 billion in the previous quarter workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'grow', 'clout', 'workday', 'prism', 'analytic', 'adaptive', 'insight', 'business', 'planning', 'cloud', 'offering', 'hold', 'promise', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '178', '588', 'billion', '2017', 'reach', '1131', 'billion', '2021', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'fact', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'june', '2018', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'rank', '4', 'list', '100', 'good', 'workplace', 'millennial', 'fortune', 'great', 'place', 'work', 'institute', 'additionally', 'company', 'rank', '6', 'list', 'good', 'large', 'workplace', 'europe', 'great', 'place', 'work', 'institute', 'workday', '2600', 'customer', 'clientele', 'include', 'approximately', '40', 'fortune', '500', 'half', 'fortune', '50', 'customer', 'room', 'expansion', 'fourth', 'quarter', 'company', 'add', 'bank', 'caterpillar', 'ap', 'mollermaersk', 'wyndham', 'worldwide', 'operation', 'sumitomo', 'chemical', 'new', 'hcm', 'customer', 'notably', 'siemens', 'ag', 'mckesson', 'corporation', 'lloyds', 'bank', 'plc', 'company', 'recently', 'deploy', 'hcm', 'solution', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2018', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'revise', 'workday', 'place', 'leader', 'quadrant', 'fourth', 'quarter', 'adoption', 'workday', 'financial', 'management', 'solution', 'allina', 'health', 'ryder', 'truck', 'ameriprise', 'banner', 'health', 'notable', 'recent', 'prominent', 'deal', 'win', 'include', 'quicken', 'loan', 'alight', 'solution', 'furthermore', 'workday', 'prism', 'analytic', 'witness', 'tripledigit', 'growth', 'acv', 'fourth', 'quarter', 'workday', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', 'fourthquarter', 'company', 'achieve', 'industryleade', '98', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', 'approximately', '41', 'yearoveryear', 'increase', 'revenue', '184', 'million', 'approximately', '233', 'total', 'fourthquarter', 'fiscal', '2019', 'revenue', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '6067', 'million', 'cash', 'operate', 'activity', 'fiscal', '2019', 'increase', '112', 'million', '2013', 'cash', 'cash', 'equivalent', 'marketable', 'security', '178', 'billion', 'jan', '31', '2018', 'compare', '158', 'billion', 'previous', 'quarter', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver grow clout workday prism analytic adaptive insight business planning cloud offering hold promise accord gartner global softwareasaservice saas market expect increase cagr 178 588 billion 2017 reach 1131 billion 2021 base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud fact research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company grow clout hcm market evident market research firm gartner june 2018 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company rank 4 list 100 good workplace millennial fortune great place work institute additionally company rank 6 list good large workplace europe great place work institute workday 2600 customer clientele include approximately 40 fortune 500 half fortune 50 customer room expansion fourth quarter company add bank caterpillar ap mollermaersk wyndham worldwide operation sumitomo chemical new hcm customer notably siemens ag mckesson corporation lloyds bank plc company recently deploy hcm solution company dominance financial management sector increase evident gartner june 2018 magic quadrant cloud core financial management suite midsize large global enterprise report revise workday place leader quadrant fourth quarter adoption workday financial management solution allina health ryder truck ameriprise banner health notable recent prominent deal win include quicken loan alight solution furthermore workday prism analytic witness tripledigit growth acv fourth quarter workday diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model fourthquarter company achieve industryleade 98 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident approximately 41 yearoveryear increase revenue 184 million approximately 233 total fourthquarter fiscal 2019 revenue reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 6067 million cash operate activity fiscal 2019 increase 112 million 2013 cash cash equivalent marketable security 178 billion jan 31 2018 compare 158 billion previous quarter workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,22,18,0.0975609756097561,22,18,0.0975609756097561,0.9978
398,"Workday, Inc._Attachment1(3).pdf",WDAY,7/9/2018,competition in the hcm and financial management software market is increasing which could lead to pricing pressure and affect workdays margins oracles strong momentum in the cloud is a headwind for the company moreover we believe that workdays dominance could be challenged by new entrants this could make the company take resort to competitive pricing to maintain and capture further market share this apart the ongoing trend to invest more in cloud solutions exposes workday to the risk of losing existing onpremise customers which can adversely impact its topline performance especially in the near term the companys margin continues to be affected by higher operating expense primarily due to an increase in headcount and marketing spending as of jan 31 2017 workday had about 8200 employees compared with about 1500 employees as of its listing date in october 2012 notably sales and marketing expenses in fiscal 2018 increased 209 year over year to 6834 million we believe workdays continuous investments in order to achieve longterm growth will hurt its margins in the short haul we note that workday currently has a trailing 12month pricebook pb ratio of 1647 this level compares unfavorably with what the industry witnessed in the last year the ratio is higher than the average level of 1606 hence valuation looks slightly stretched from a pb perspective,sell,"['competition', 'hcm', 'financial', 'management', 'software', 'market', 'increase', 'lead', 'pricing', 'pressure', 'affect', 'workday', 'margin', 'oracle', 'strong', 'momentum', 'cloud', 'headwind', 'company', 'believe', 'workdays', 'dominance', 'challenge', 'new', 'entrant', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'apart', 'ongoing', 'trend', 'invest', 'cloud', 'solution', 'expose', 'workday', 'risk', 'lose', 'exist', 'onpremise', 'customer', 'adversely', 'impact', 'topline', 'performance', 'especially', 'near', 'term', 'company', 'margin', 'continue', 'affect', 'high', 'operating', 'expense', 'primarily', 'increase', 'headcount', 'marketing', 'spending', 'jan', '31', '2017', 'workday', '8200', 'employee', 'compare', '1500', 'employee', 'listing', 'date', 'october', '2012', 'notably', 'sale', 'marketing', 'expense', 'fiscal', '2018', 'increase', '209', 'year', 'year', '6834', 'million', 'believe', 'workdays', 'continuous', 'investment', 'order', 'achieve', 'longterm', 'growth', 'hurt', 'margin', 'short', 'haul', 'note', 'workday', 'currently', 'trailing', '12month', 'pricebook', 'pb', 'ratio', '1647', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'ratio', 'high', 'average', 'level', '1606', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective']",competition hcm financial management software market increase lead pricing pressure affect workday margin oracle strong momentum cloud headwind company believe workdays dominance challenge new entrant company resort competitive pricing maintain capture market share apart ongoing trend invest cloud solution expose workday risk lose exist onpremise customer adversely impact topline performance especially near term company margin continue affect high operating expense primarily increase headcount marketing spending jan 31 2017 workday 8200 employee compare 1500 employee listing date october 2012 notably sale marketing expense fiscal 2018 increase 209 year year 6834 million believe workdays continuous investment order achieve longterm growth hurt margin short haul note workday currently trailing 12month pricebook pb ratio 1647 level compare unfavorably industry witness year ratio high average level 1606 valuation look slightly stretch pb perspective,6,12,-0.3157894736842105,6,12,-0.3157894736842105,0.743
399,"Workday, Inc._Attachment1(3).pdf",WDAY,2/13/2019,competition in the hcm and financial management software market is increasing which could lead to pricing pressure and affect workdays margins oracles strong momentum in the cloud is a headwind for the company moreover we believe that workdays dominance could be challenged by new entrants this could make the company take resort to competitive pricing to maintain and capture further market share this apart the ongoing trend to invest more in cloud solutions exposes workday to the risk of losing existing onpremise customers which can adversely impact its topline performance especially in the near term the companys margin continues to be affected by higher operating expense primarily due to an increase in headcount and marketing spending as of jul 31 2018 workday had about 9100 employees compared with about 1500 employees as of its listing date in october 2012 notably sales and marketing expenses in fiscal 2018 increased 209 year over year to 6834 million we believe workdays continuous investments in order to achieve longterm growth will hurt its margins in the short haul we note that workday currently has a trailing 12month pricebook pb ratio of 2275 this level compares unfavorably with what the industry witnessed in the last year additionally the ratio is higher than the average level of 1704 and matches the high end of the valuation range in this period hence valuation looks slightly stretched from a pb perspective,sell,"['competition', 'hcm', 'financial', 'management', 'software', 'market', 'increase', 'lead', 'pricing', 'pressure', 'affect', 'workday', 'margin', 'oracle', 'strong', 'momentum', 'cloud', 'headwind', 'company', 'believe', 'workdays', 'dominance', 'challenge', 'new', 'entrant', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'apart', 'ongoing', 'trend', 'invest', 'cloud', 'solution', 'expose', 'workday', 'risk', 'lose', 'exist', 'onpremise', 'customer', 'adversely', 'impact', 'topline', 'performance', 'especially', 'near', 'term', 'company', 'margin', 'continue', 'affect', 'high', 'operating', 'expense', 'primarily', 'increase', 'headcount', 'marketing', 'spending', 'jul', '31', '2018', 'workday', '9100', 'employee', 'compare', '1500', 'employee', 'listing', 'date', 'october', '2012', 'notably', 'sale', 'marketing', 'expense', 'fiscal', '2018', 'increase', '209', 'year', 'year', '6834', 'million', 'believe', 'workdays', 'continuous', 'investment', 'order', 'achieve', 'longterm', 'growth', 'hurt', 'margin', 'short', 'haul', 'note', 'workday', 'currently', 'trailing', '12month', 'pricebook', 'pb', 'ratio', '2275', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '1704', 'match', 'high', 'end', 'valuation', 'range', 'period', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective']",competition hcm financial management software market increase lead pricing pressure affect workday margin oracle strong momentum cloud headwind company believe workdays dominance challenge new entrant company resort competitive pricing maintain capture market share apart ongoing trend invest cloud solution expose workday risk lose exist onpremise customer adversely impact topline performance especially near term company margin continue affect high operating expense primarily increase headcount marketing spending jul 31 2018 workday 9100 employee compare 1500 employee listing date october 2012 notably sale marketing expense fiscal 2018 increase 209 year year 6834 million believe workdays continuous investment order achieve longterm growth hurt margin short haul note workday currently trailing 12month pricebook pb ratio 2275 level compare unfavorably industry witness year additionally ratio high average level 1704 match high end valuation range period valuation look slightly stretch pb perspective,7,14,-0.3181818181818182,7,14,-0.3181818181818182,0.743
400,"Workday, Inc._Attachment1(4).pdf",WDAY,8/1/2018,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 184 over 20162020 time frame based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud per management the companys application has been selected for core hr by more than 30 of fortune 500 companies we therefore see much room for expansion here the companys growing clout in the hcm market is evident from market research firm gartners august 2017 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the companys clientele includes enterprises like citigroup management corporation nordstrom qualcomm and humana per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys dominance in the financial management sector is also increasing which is evident from gartners june 2017 magic quadrant for cloud core financial management suites for midsize large and global enterprises report where workday was again placed in the leaders quadrant customers of its financial management application include the likes of ohio health corporation the childrens hospital of philadelphia giant tiger stores and carlyle moreover workday planning application is also doing well with more than 170 customers including qualcomm and bank of america workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in the fourthquarter the company achieved industry leading 98 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from approximately 29 yearoveryear increase in revenues in the last reported quarter reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 4657 million cash from operating activities in fiscal 2018 which increased from 112 million in 2013 workday exited fiscal 2018 with cash and cash equivalents of 1134 billion compared with 5399 million in fiscal 2017 workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,sell,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '184', '20162020', 'time', 'frame', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'management', 'company', 'application', 'select', 'core', 'hr', '30', 'fortune', '500', 'company', 'room', 'expansion', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'august', '2017', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'clientele', 'include', 'enterprise', 'like', 'citigroup', 'management', 'corporation', 'nordstrom', 'qualcomm', 'humana', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2017', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'workday', 'place', 'leader', 'quadrant', 'customer', 'financial', 'management', 'application', 'include', 'like', 'ohio', 'health', 'corporation', 'childrens', 'hospital', 'philadelphia', 'giant', 'tiger', 'store', 'carlyle', 'workday', 'planning', 'application', '170', 'customer', 'include', 'qualcomm', 'bank', 'america', 'workdays', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', 'fourthquarter', 'company', 'achieve', 'industry', 'lead', '98', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', 'approximately', '29', 'yearoveryear', 'increase', 'revenue', 'reported', 'quarter', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '4657', 'million', 'cash', 'operate', 'activity', 'fiscal', '2018', 'increase', '112', 'million', '2013', 'workday', 'exit', 'fiscal', '2018', 'cash', 'cash', 'equivalent', '1134', 'billion', 'compare', '5399', 'million', 'fiscal', '2017', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver accord gartner global softwareasaservice saas market expect increase cagr 184 20162020 time frame base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud management company application select core hr 30 fortune 500 company room expansion company grow clout hcm market evident market research firm gartner august 2017 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company clientele include enterprise like citigroup management corporation nordstrom qualcomm humana research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company dominance financial management sector increase evident gartner june 2017 magic quadrant cloud core financial management suite midsize large global enterprise report workday place leader quadrant customer financial management application include like ohio health corporation childrens hospital philadelphia giant tiger store carlyle workday planning application 170 customer include qualcomm bank america workdays diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model fourthquarter company achieve industry lead 98 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident approximately 29 yearoveryear increase revenue reported quarter reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 4657 million cash operate activity fiscal 2018 increase 112 million 2013 workday exit fiscal 2018 cash cash equivalent 1134 billion compare 5399 million fiscal 2017 workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,17,10,0.25,17,10,0.25,0.9952
401,"Workday, Inc._Attachment1(5).pdf",WDAY,12/4/2018,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 184 over 20162020 time frame based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud per management the companys application has been selected for core hr by more than 30 of fortune 500 companies we therefore see much room for expansion here the companys growing clout in the hcm market is evident from market research firm gartners august 2017 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the company was ranked 4 on the list of the 100 best workplaces for millennial by fortune and great place to work institute additionally the company was ranked 6 on the list of the best large workplaces in europe by great place to work institute workday has more than 2200 customers during the second quarter the company added eli lilly and company bridgestone americas siemens healthineers and dbs bank as its new hcm customers the companys clientele includes enterprises like citigroup management corporation nordstrom qualcomm and humana per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys dominance in the financial management sector is also increasing which is evident from gartners june 2017 magic quadrant for cloud core financial management suites for midsize large and global enterprises report where workday was again placed in the leaders quadrant customers of its financial management application include the likes of ohio health corporation the childrens hospital of philadelphia giant tiger stores and carlyle moreover workday planning application is also doing well with more than 170 customers including qualcomm and bank of america workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in the fourthquarter the company achieved industryleading 98 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from approximately 338 yearoveryear increase in revenues in the last reported quarter reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 4657 million cash from operating activities in fiscal 2018 which increased from 112 million in 2013 workday exited fiscal 2018 with cash and cash equivalents of 1134 billion compared with 5399 million in fiscal 2017 workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '184', '20162020', 'time', 'frame', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'management', 'company', 'application', 'select', 'core', 'hr', '30', 'fortune', '500', 'company', 'room', 'expansion', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'august', '2017', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'rank', '4', 'list', '100', 'good', 'workplace', 'millennial', 'fortune', 'great', 'place', 'work', 'institute', 'additionally', 'company', 'rank', '6', 'list', 'good', 'large', 'workplace', 'europe', 'great', 'place', 'work', 'institute', 'workday', '2200', 'customer', 'second', 'quarter', 'company', 'add', 'eli', 'lilly', 'company', 'bridgestone', 'americas', 'siemens', 'healthineer', 'dbs', 'bank', 'new', 'hcm', 'customer', 'company', 'clientele', 'include', 'enterprise', 'like', 'citigroup', 'management', 'corporation', 'nordstrom', 'qualcomm', 'humana', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2017', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'workday', 'place', 'leader', 'quadrant', 'customer', 'financial', 'management', 'application', 'include', 'like', 'ohio', 'health', 'corporation', 'childrens', 'hospital', 'philadelphia', 'giant', 'tiger', 'store', 'carlyle', 'workday', 'planning', 'application', '170', 'customer', 'include', 'qualcomm', 'bank', 'america', 'workdays', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', 'fourthquarter', 'company', 'achieve', 'industryleade', '98', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', 'approximately', '338', 'yearoveryear', 'increase', 'revenue', 'reported', 'quarter', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '4657', 'million', 'cash', 'operate', 'activity', 'fiscal', '2018', 'increase', '112', 'million', '2013', 'workday', 'exit', 'fiscal', '2018', 'cash', 'cash', 'equivalent', '1134', 'billion', 'compare', '5399', 'million', 'fiscal', '2017', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver accord gartner global softwareasaservice saas market expect increase cagr 184 20162020 time frame base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud management company application select core hr 30 fortune 500 company room expansion company grow clout hcm market evident market research firm gartner august 2017 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company rank 4 list 100 good workplace millennial fortune great place work institute additionally company rank 6 list good large workplace europe great place work institute workday 2200 customer second quarter company add eli lilly company bridgestone americas siemens healthineer dbs bank new hcm customer company clientele include enterprise like citigroup management corporation nordstrom qualcomm humana research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company dominance financial management sector increase evident gartner june 2017 magic quadrant cloud core financial management suite midsize large global enterprise report workday place leader quadrant customer financial management application include like ohio health corporation childrens hospital philadelphia giant tiger store carlyle workday planning application 170 customer include qualcomm bank america workdays diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model fourthquarter company achieve industryleade 98 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident approximately 338 yearoveryear increase revenue reported quarter reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 4657 million cash operate activity fiscal 2018 increase 112 million 2013 workday exit fiscal 2018 cash cash equivalent 1134 billion compare 5399 million fiscal 2017 workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,20,15,0.1388888888888889,20,15,0.1388888888888889,0.9969
402,"Workday, Inc._Attachment1.pdf",WDAY,9/20/2017,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers according to gartner the global softwareasa service saas market is expected to increase at a cagr of 184 over 20162020 time frame based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud per management the companys application has been selected for core hr by more than 30 of fortune 500 companies we therefore see much room for expansion here the companys growing clout in the hcm market is evident from market research firm gartners august 2017 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the companys clientele includes enterprises like citigroup management corporation nordstrom qualcomm and humana per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys dominance in the financial management sector is also increasing which is evident from gartners june 2017 magic quadrant for cloud core financial management suites for midsize large and global enterprises report where workday was again placed in the leaders quadrant customers of its financial management application include the likes of ohio health corporation the childrens hospital of philadelphia giant tiger stores and carlyle moreover workday planning application is also doing well with more than 170 customers including qualcomm and bank of america workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in 2016 the company achieved industryleading 97 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from the 59 yearoveryear increase in revenues in the last reported quarter reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 3487 million cash from operating activities in fiscal 2017 which increased from 112 million in 2013 workday exited fiscal 2017 with cash and cash equivalents of 5399 million compared with 3001 million in fiscal 2016 workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'accord', 'gartner', 'global', 'softwareasa', 'service', 'saas', 'market', 'expect', 'increase', 'cagr', '184', '20162020', 'time', 'frame', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'management', 'company', 'application', 'select', 'core', 'hr', '30', 'fortune', '500', 'company', 'room', 'expansion', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'august', '2017', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'clientele', 'include', 'enterprise', 'like', 'citigroup', 'management', 'corporation', 'nordstrom', 'qualcomm', 'humana', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2017', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'workday', 'place', 'leader', 'quadrant', 'customer', 'financial', 'management', 'application', 'include', 'like', 'ohio', 'health', 'corporation', 'childrens', 'hospital', 'philadelphia', 'giant', 'tiger', 'store', 'carlyle', 'workday', 'planning', 'application', '170', 'customer', 'include', 'qualcomm', 'bank', 'america', 'workdays', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', '2016', 'company', 'achieve', 'industryleade', '97', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', '59', 'yearoveryear', 'increase', 'revenue', 'reported', 'quarter', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '3487', 'million', 'cash', 'operate', 'activity', 'fiscal', '2017', 'increase', '112', 'million', '2013', 'workday', 'exit', 'fiscal', '2017', 'cash', 'cash', 'equivalent', '5399', 'million', 'compare', '3001', 'million', 'fiscal', '2016', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver accord gartner global softwareasa service saas market expect increase cagr 184 20162020 time frame base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud management company application select core hr 30 fortune 500 company room expansion company grow clout hcm market evident market research firm gartner august 2017 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company clientele include enterprise like citigroup management corporation nordstrom qualcomm humana research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company dominance financial management sector increase evident gartner june 2017 magic quadrant cloud core financial management suite midsize large global enterprise report workday place leader quadrant customer financial management application include like ohio health corporation childrens hospital philadelphia giant tiger store carlyle workday planning application 170 customer include qualcomm bank america workdays diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model 2016 company achieve industryleade 97 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident 59 yearoveryear increase revenue reported quarter reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 3487 million cash operate activity fiscal 2017 increase 112 million 2013 workday exit fiscal 2017 cash cash equivalent 5399 million compare 3001 million fiscal 2016 workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,16,9,0.2692307692307692,16,9,0.2692307692307692,0.9952
403,"Workday, Inc._Attachment1.pdf",WDAY,1/2/2018,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 184 over 20162020 time frame based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud per management the companys application has been selected for core hr by more than 30 of fortune 500 companies we therefore see much room for expansion here the companys growing clout in the hcm market is evident from market research firm gartners august 2017 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the companys clientele includes enterprises like citigroup management corporation nordstrom qualcomm and humana per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys dominance in the financial management sector is also increasing which is evident from gartners june 2017 magic quadrant for cloud core financial management suites for midsize large and global enterprises report where workday was again placed in the leaders quadrant customers of its financial management application include the likes of ohio health corporation the childrens hospital of philadelphia giant tiger stores and carlyle moreover workday planning application is also doing well with more than 170 customers including qualcomm and bank of america workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in the thirdquarter the company achieved industryleading 98 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from the 59 yearoveryear increase in revenues in the last reported quarter reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 3487 million cash from operating activities in fiscal 2017 which increased from 112 million in 2013 workday exited fiscal 2017 with cash and cash equivalents of 5399 million compared with 3001 million in fiscal 2016 workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '184', '20162020', 'time', 'frame', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'management', 'company', 'application', 'select', 'core', 'hr', '30', 'fortune', '500', 'company', 'room', 'expansion', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'august', '2017', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'clientele', 'include', 'enterprise', 'like', 'citigroup', 'management', 'corporation', 'nordstrom', 'qualcomm', 'humana', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2017', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'workday', 'place', 'leader', 'quadrant', 'customer', 'financial', 'management', 'application', 'include', 'like', 'ohio', 'health', 'corporation', 'childrens', 'hospital', 'philadelphia', 'giant', 'tiger', 'store', 'carlyle', 'workday', 'planning', 'application', '170', 'customer', 'include', 'qualcomm', 'bank', 'america', 'workdays', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', 'thirdquarter', 'company', 'achieve', 'industryleade', '98', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', '59', 'yearoveryear', 'increase', 'revenue', 'reported', 'quarter', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '3487', 'million', 'cash', 'operate', 'activity', 'fiscal', '2017', 'increase', '112', 'million', '2013', 'workday', 'exit', 'fiscal', '2017', 'cash', 'cash', 'equivalent', '5399', 'million', 'compare', '3001', 'million', 'fiscal', '2016', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver accord gartner global softwareasaservice saas market expect increase cagr 184 20162020 time frame base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud management company application select core hr 30 fortune 500 company room expansion company grow clout hcm market evident market research firm gartner august 2017 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company clientele include enterprise like citigroup management corporation nordstrom qualcomm humana research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company dominance financial management sector increase evident gartner june 2017 magic quadrant cloud core financial management suite midsize large global enterprise report workday place leader quadrant customer financial management application include like ohio health corporation childrens hospital philadelphia giant tiger store carlyle workday planning application 170 customer include qualcomm bank america workdays diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model thirdquarter company achieve industryleade 98 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident 59 yearoveryear increase revenue reported quarter reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 3487 million cash operate activity fiscal 2017 increase 112 million 2013 workday exit fiscal 2017 cash cash equivalent 5399 million compare 3001 million fiscal 2016 workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,16,9,0.2692307692307692,16,9,0.2692307692307692,0.9952
404,"Workday, Inc._Attachment1.pdf",WDAY,5/7/2018,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 184 over 20162020 time frame based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward workdays hcm suite of applications demonstrates strong growth momentum driven by the transition of organizations to the cloud per management the companys application has been selected for core hr by more than 30 of fortune 500 companies we therefore see much room for expansion here the companys growing clout in the hcm market is evident from market research firm gartners august 2017 magic quadrant for cloud hcm suites for midmarket and large enterprises report where it put workday in the leaders quadrant the companys clientele includes enterprises like citigroup management corporation nordstrom qualcomm and humana per research firm marketsandmarkets the hcm market size is anticipated to grow from 145 billion in 2017 to 225 billion by 2022 at a cagr of 92 the companys dominance in the financial management sector is also increasing which is evident from gartners june 2017 magic quadrant for cloud core financial management suites for midsize large and global enterprises report where workday was again placed in the leaders quadrant customers of its financial management application include the likes of ohio health corporation the childrens hospital of philadelphia giant tiger stores and carlyle moreover workday planning application is also doing well with more than 170 customers including qualcomm and bank of america workdays diversified product portfolio continues to yield a steady flow of customers we believe that the companys high customer satisfaction rate bodes well for its longterm business model in the fourthquarter the company achieved industryleading 98 customer satisfaction rating which even surpassed its target of 95 it plans to achieve similar levels every year workday is also gaining traction in the international market which is evident from the 33 yearoveryear increase in revenues in the last reported quarter reportedly munich germanybased manufacturing giant siemens replaced its current hr system with workday hcm additionally in europe and asia pacifics japan region the company added shell and johnson electric respectively as customers in recent times workday is a cashrich company with a strong balance sheet the company generated approximately 4657 million cash from operating activities in fiscal 2018 which increased from 112 million in 2013 workday exited fiscal 2018 with cash and cash equivalents of 1134 billion compared with 5399 million in fiscal 2017 workday has no longterm debt the strong cash balance can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '184', '20162020', 'time', 'frame', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward', 'workdays', 'hcm', 'suite', 'application', 'demonstrate', 'strong', 'growth', 'momentum', 'drive', 'transition', 'organization', 'cloud', 'management', 'company', 'application', 'select', 'core', 'hr', '30', 'fortune', '500', 'company', 'room', 'expansion', 'company', 'grow', 'clout', 'hcm', 'market', 'evident', 'market', 'research', 'firm', 'gartner', 'august', '2017', 'magic', 'quadrant', 'cloud', 'hcm', 'suite', 'midmarket', 'large', 'enterprise', 'report', 'workday', 'leader', 'quadrant', 'company', 'clientele', 'include', 'enterprise', 'like', 'citigroup', 'management', 'corporation', 'nordstrom', 'qualcomm', 'humana', 'research', 'firm', 'marketsandmarket', 'hcm', 'market', 'size', 'anticipate', 'grow', '145', 'billion', '2017', '225', 'billion', '2022', 'cagr', '92', 'company', 'dominance', 'financial', 'management', 'sector', 'increase', 'evident', 'gartner', 'june', '2017', 'magic', 'quadrant', 'cloud', 'core', 'financial', 'management', 'suite', 'midsize', 'large', 'global', 'enterprise', 'report', 'workday', 'place', 'leader', 'quadrant', 'customer', 'financial', 'management', 'application', 'include', 'like', 'ohio', 'health', 'corporation', 'childrens', 'hospital', 'philadelphia', 'giant', 'tiger', 'store', 'carlyle', 'workday', 'planning', 'application', '170', 'customer', 'include', 'qualcomm', 'bank', 'america', 'workdays', 'diversified', 'product', 'portfolio', 'continue', 'yield', 'steady', 'flow', 'customer', 'believe', 'companys', 'high', 'customer', 'satisfaction', 'rate', 'bode', 'longterm', 'business', 'model', 'fourthquarter', 'company', 'achieve', 'industryleade', '98', 'customer', 'satisfaction', 'rating', 'surpass', 'target', '95', 'plan', 'achieve', 'similar', 'level', 'year', 'workday', 'gain', 'traction', 'international', 'market', 'evident', '33', 'yearoveryear', 'increase', 'revenue', 'reported', 'quarter', 'reportedly', 'munich', 'germanybase', 'manufacturing', 'giant', 'siemen', 'replace', 'current', 'hr', 'system', 'workday', 'hcm', 'additionally', 'europe', 'asia', 'pacifics', 'japan', 'region', 'company', 'add', 'shell', 'johnson', 'electric', 'respectively', 'customer', 'recent', 'time', 'workday', 'cashrich', 'company', 'strong', 'balance', 'sheet', 'company', 'generate', 'approximately', '4657', 'million', 'cash', 'operate', 'activity', 'fiscal', '2018', 'increase', '112', 'million', '2013', 'workday', 'exit', 'fiscal', '2018', 'cash', 'cash', 'equivalent', '1134', 'billion', 'compare', '5399', 'million', 'fiscal', '2017', 'workday', 'longterm', 'debt', 'strong', 'cash', 'balance', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver accord gartner global softwareasaservice saas market expect increase cagr 184 20162020 time frame base expand product portfolio believe workday positioned gain strong growth prospect go forward workdays hcm suite application demonstrate strong growth momentum drive transition organization cloud management company application select core hr 30 fortune 500 company room expansion company grow clout hcm market evident market research firm gartner august 2017 magic quadrant cloud hcm suite midmarket large enterprise report workday leader quadrant company clientele include enterprise like citigroup management corporation nordstrom qualcomm humana research firm marketsandmarket hcm market size anticipate grow 145 billion 2017 225 billion 2022 cagr 92 company dominance financial management sector increase evident gartner june 2017 magic quadrant cloud core financial management suite midsize large global enterprise report workday place leader quadrant customer financial management application include like ohio health corporation childrens hospital philadelphia giant tiger store carlyle workday planning application 170 customer include qualcomm bank america workdays diversified product portfolio continue yield steady flow customer believe companys high customer satisfaction rate bode longterm business model fourthquarter company achieve industryleade 98 customer satisfaction rating surpass target 95 plan achieve similar level year workday gain traction international market evident 33 yearoveryear increase revenue reported quarter reportedly munich germanybase manufacturing giant siemen replace current hr system workday hcm additionally europe asia pacifics japan region company add shell johnson electric respectively customer recent time workday cashrich company strong balance sheet company generate approximately 4657 million cash operate activity fiscal 2018 increase 112 million 2013 workday exit fiscal 2018 cash cash equivalent 1134 billion compare 5399 million fiscal 2017 workday longterm debt strong cash balance pursue strategic acquisition investment growth initiative distribution shareholder,16,9,0.2692307692307692,16,9,0.2692307692307692,0.9952
405,"Workday, Inc._Attachment1.pdf",WDAY,5/7/2018,competition in the hcm and financial management software market is increasing which could lead to pricing pressure and affect workdays margins oracles strong momentum in the cloud is a headwind for the company moreover we believe that workdays dominance could be challenged by new entrants this could make the company take resort to competitive pricing to maintain and capture further market share this apart the ongoing trend to invest more in cloud solutions exposes workday to the risk of losing existing onpremise customers which can adversely impact its topline performance especially in the near term the companys margin continues to be affected by higher operating expense primarily due to an increase in headcount and marketing spending as of jan 31 2017 workday had about 8200 employees compared with about 1500 employees as of its listing date in october 2012 notably sales and marketing expenses in fiscal 2018 increased 209 year over year to 6834 million we believe workdays continuous investments in order to achieve longterm growth will hurt its margins in the short haul we note that workday currently has a trailing 12month pricebook pb ratio of 1745 this level compares unfavorably with what the industry witnessed in the last year the ratio is higher than the average level of 1580 hence valuation looks slightly stretched from a pb perspective,sell,"['competition', 'hcm', 'financial', 'management', 'software', 'market', 'increase', 'lead', 'pricing', 'pressure', 'affect', 'workday', 'margin', 'oracle', 'strong', 'momentum', 'cloud', 'headwind', 'company', 'believe', 'workdays', 'dominance', 'challenge', 'new', 'entrant', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'apart', 'ongoing', 'trend', 'invest', 'cloud', 'solution', 'expose', 'workday', 'risk', 'lose', 'exist', 'onpremise', 'customer', 'adversely', 'impact', 'topline', 'performance', 'especially', 'near', 'term', 'company', 'margin', 'continue', 'affect', 'high', 'operating', 'expense', 'primarily', 'increase', 'headcount', 'marketing', 'spending', 'jan', '31', '2017', 'workday', '8200', 'employee', 'compare', '1500', 'employee', 'listing', 'date', 'october', '2012', 'notably', 'sale', 'marketing', 'expense', 'fiscal', '2018', 'increase', '209', 'year', 'year', '6834', 'million', 'believe', 'workdays', 'continuous', 'investment', 'order', 'achieve', 'longterm', 'growth', 'hurt', 'margin', 'short', 'haul', 'note', 'workday', 'currently', 'trailing', '12month', 'pricebook', 'pb', 'ratio', '1745', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'ratio', 'high', 'average', 'level', '1580', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective']",competition hcm financial management software market increase lead pricing pressure affect workday margin oracle strong momentum cloud headwind company believe workdays dominance challenge new entrant company resort competitive pricing maintain capture market share apart ongoing trend invest cloud solution expose workday risk lose exist onpremise customer adversely impact topline performance especially near term company margin continue affect high operating expense primarily increase headcount marketing spending jan 31 2017 workday 8200 employee compare 1500 employee listing date october 2012 notably sale marketing expense fiscal 2018 increase 209 year year 6834 million believe workdays continuous investment order achieve longterm growth hurt margin short haul note workday currently trailing 12month pricebook pb ratio 1745 level compare unfavorably industry witness year ratio high average level 1580 valuation look slightly stretch pb perspective,6,12,-0.3157894736842105,6,12,-0.3157894736842105,0.743
406,"Workday, Inc._Attachment1.pdf",WDAY,9/6/2018,competition in the hcm and financial management software market is increasing which could lead to pricing pressure and affect workdays margins oracles strong momentum in the cloud is a headwind for the company moreover we believe that workdays dominance could be challenged by new entrants this could make the company take resort to competitive pricing to maintain and capture further market share this apart the ongoing trend to invest more in cloud solutions exposes workday to the risk of losing existing onpremise customers which can adversely impact its topline performance especially in the near term the companys margin continues to be affected by higher operating expense primarily due to an increase in headcount and marketing spending as of jul 31 2018 workday had about 9100 employees compared with about 1500 employees as of its listing date in october 2012 notably sales and marketing expenses in fiscal 2018 increased 209 year over year to 6834 million we believe workdays continuous investments in order to achieve longterm growth will hurt its margins in the short haul we note that workday currently has a trailing 12month pricebook pb ratio of 1854 this level compares unfavorably with what the industry witnessed in the last year additionally the ratio is higher than the average level of 1641 and matches the high end of the valuation range in this period hence valuation looks slightly stretched from a pb perspective,sell,"['competition', 'hcm', 'financial', 'management', 'software', 'market', 'increase', 'lead', 'pricing', 'pressure', 'affect', 'workday', 'margin', 'oracle', 'strong', 'momentum', 'cloud', 'headwind', 'company', 'believe', 'workdays', 'dominance', 'challenge', 'new', 'entrant', 'company', 'resort', 'competitive', 'pricing', 'maintain', 'capture', 'market', 'share', 'apart', 'ongoing', 'trend', 'invest', 'cloud', 'solution', 'expose', 'workday', 'risk', 'lose', 'exist', 'onpremise', 'customer', 'adversely', 'impact', 'topline', 'performance', 'especially', 'near', 'term', 'company', 'margin', 'continue', 'affect', 'high', 'operating', 'expense', 'primarily', 'increase', 'headcount', 'marketing', 'spending', 'jul', '31', '2018', 'workday', '9100', 'employee', 'compare', '1500', 'employee', 'listing', 'date', 'october', '2012', 'notably', 'sale', 'marketing', 'expense', 'fiscal', '2018', 'increase', '209', 'year', 'year', '6834', 'million', 'believe', 'workdays', 'continuous', 'investment', 'order', 'achieve', 'longterm', 'growth', 'hurt', 'margin', 'short', 'haul', 'note', 'workday', 'currently', 'trailing', '12month', 'pricebook', 'pb', 'ratio', '1854', 'level', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'additionally', 'ratio', 'high', 'average', 'level', '1641', 'match', 'high', 'end', 'valuation', 'range', 'period', 'valuation', 'look', 'slightly', 'stretch', 'pb', 'perspective']",competition hcm financial management software market increase lead pricing pressure affect workday margin oracle strong momentum cloud headwind company believe workdays dominance challenge new entrant company resort competitive pricing maintain capture market share apart ongoing trend invest cloud solution expose workday risk lose exist onpremise customer adversely impact topline performance especially near term company margin continue affect high operating expense primarily increase headcount marketing spending jul 31 2018 workday 9100 employee compare 1500 employee listing date october 2012 notably sale marketing expense fiscal 2018 increase 209 year year 6834 million believe workdays continuous investment order achieve longterm growth hurt margin short haul note workday currently trailing 12month pricebook pb ratio 1854 level compare unfavorably industry witness year additionally ratio high average level 1641 match high end valuation range period valuation look slightly stretch pb perspective,7,14,-0.3181818181818182,7,14,-0.3181818181818182,0.743
407,"Workday, Inc._Attachment1.pdf",WDAY,11/29/2019,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers moreover growing clout of workday prism analytics and adaptive insights business planning cloud offerings holds promise according to gartner the global softwareasaservice saas market is expected to increase at a cagr of 178 from 588 billion in 2017 to reach 1131 billion in 2021 based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'grow', 'clout', 'workday', 'prism', 'analytic', 'adaptive', 'insight', 'business', 'planning', 'cloud', 'offering', 'hold', 'promise', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'market', 'expect', 'increase', 'cagr', '178', '588', 'billion', '2017', 'reach', '1131', 'billion', '2021', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver grow clout workday prism analytic adaptive insight business planning cloud offering hold promise accord gartner global softwareasaservice saas market expect increase cagr 178 588 billion 2017 reach 1131 billion 2021 base expand product portfolio believe workday positioned gain strong growth prospect go forward,4,2,0.2857142857142857,4,2,0.2857142857142857,0.9744
408,"Workday, Inc._Attachment1.pdf",WDAY,3/26/2020,workdays revenue growth continues to be driven by high demand for its hcm and financial management solutions the companys cloudbased business model and expanding product portfolio have been the primary growth drivers moreover growing clout of workday prism analytics and adaptive insights business planning cloud offerings holds promise according to gartner the global softwareasaservice saas revenues are expected to touch 1437 billion in 2022 from 80 billion in 2018 witnessing a cagr of 158 based on its expanding product portfolio we believe that workday is well positioned to gain from this strong growth prospect going forward,buy,"['workday', 'revenue', 'growth', 'continue', 'drive', 'high', 'demand', 'hcm', 'financial', 'management', 'solution', 'company', 'cloudbase', 'business', 'model', 'expand', 'product', 'portfolio', 'primary', 'growth', 'driver', 'grow', 'clout', 'workday', 'prism', 'analytic', 'adaptive', 'insight', 'business', 'planning', 'cloud', 'offering', 'hold', 'promise', 'accord', 'gartner', 'global', 'softwareasaservice', 'saas', 'revenue', 'expect', 'touch', '1437', 'billion', '2022', '80', 'billion', '2018', 'witness', 'cagr', '158', 'base', 'expand', 'product', 'portfolio', 'believe', 'workday', 'positioned', 'gain', 'strong', 'growth', 'prospect', 'go', 'forward']",workday revenue growth continue drive high demand hcm financial management solution company cloudbase business model expand product portfolio primary growth driver grow clout workday prism analytic adaptive insight business planning cloud offering hold promise accord gartner global softwareasaservice saas revenue expect touch 1437 billion 2022 80 billion 2018 witness cagr 158 base expand product portfolio believe workday positioned gain strong growth prospect go forward,4,1,0.5,4,1,0.5,0.9698
409,Yandex N.V._Attachment1(2).pdf,YNDX,9/17/2018,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2017 the company accounted for 551 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 562 in the secondquarter 2018 moreover the companys search share on android in russia was 478 in the second quarter which was up from 382 in the yearago quarter the company is well poised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2017 it accounted for 93 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2017 total revenues of the company improved 304 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company operates in the ecommerce market and has entered ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector,sell,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2017', 'company', 'account', '551', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '562', 'secondquarter', '2018', 'company', 'search', 'share', 'android', 'russia', '478', 'second', 'quarter', '382', 'yearago', 'quarter', 'company', 'poise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2017', 'account', '93', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2017', 'total', 'revenue', 'company', 'improve', '304', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'operate', 'ecommerce', 'market', 'enter', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2017 company account 551 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 562 secondquarter 2018 company search share android russia 478 second quarter 382 yearago quarter company poise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2017 account 93 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2017 total revenue company improve 304 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company operate ecommerce market enter ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector,17,18,-0.027777777777777776,17,18,-0.027777777777777776,0.9979
410,Yandex N.V._Attachment1(2).pdf,YNDX,3/22/2019,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2017 the company accounted for 551 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 565 in the fourthquarter 2018 moreover the companys search share on android in russia was 495 in the fourth quarter the company is wellpoised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2018 it accounted for 805 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2018 total revenues of the company improved 36 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company operates in the ecommerce market and has entered ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector,sell,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2017', 'company', 'account', '551', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '565', 'fourthquarter', '2018', 'company', 'search', 'share', 'android', 'russia', '495', 'fourth', 'quarter', 'company', 'wellpoise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2018', 'account', '805', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2018', 'total', 'revenue', 'company', 'improve', '36', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'operate', 'ecommerce', 'market', 'enter', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2017 company account 551 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 565 fourthquarter 2018 company search share android russia 495 fourth quarter company wellpoise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2018 account 805 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2018 total revenue company improve 36 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company operate ecommerce market enter ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector,17,18,-0.027777777777777776,17,18,-0.027777777777777776,0.9979
411,Yandex N.V._Attachment1(2).pdf,YNDX,5/17/2019,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2018 the company accounted for 563 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 57 in the firstquarter 2019 moreover the companys search share on android in russia was 512 in the first quarter the company is wellpoised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2018 it accounted for 805 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2018 total revenues of the company improved 36 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company operates in the ecommerce market and has entered ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2018', 'company', 'account', '563', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '57', 'firstquarter', '2019', 'company', 'search', 'share', 'android', 'russia', '512', 'quarter', 'company', 'wellpoise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2018', 'account', '805', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2018', 'total', 'revenue', 'company', 'improve', '36', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'operate', 'ecommerce', 'market', 'enter', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2018 company account 563 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 57 firstquarter 2019 company search share android russia 512 quarter company wellpoise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2018 account 805 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2018 total revenue company improve 36 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company operate ecommerce market enter ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector,17,18,-0.027777777777777776,17,18,-0.027777777777777776,0.9979
412,Yandex N.V._Attachment1(2).pdf,YNDX,3/26/2020,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2018 the company accounted for 563 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further reached 575 in the fourthquarter 2019,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2018', 'company', 'account', '563', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'reach', '575', 'fourthquarter', '2019']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2018 company account 563 share overall russian search traffic google mailru 396 34 respectively yandexs share reach 575 fourthquarter 2019,1,2,-0.25,1,2,-0.25,0.9325
413,Yandex N.V._Attachment1(3).pdf,YNDX,4/9/2019,yandexs mounting investments across all segments pose a serious threat to profitability deconsolidation of yandexmarket remains an overhang nevertheless the company continues to benefit from increasing online advertising revenues on the back of robust yandex properties its solid momentum across the russian search market remained a key growth driver increasing desktop and mobile search shares are boosting search revenues additionally the companys strong performing taxi classifieds and experiments segments drove the results and are expected to contribute well in the upcoming quarters as well increasing number of rides will continue to aid growth in the taxi segment also robust yandexdrive and cloud platform remain major positives,buy,"['yandexs', 'mount', 'investment', 'segment', 'pose', 'threat', 'profitability', 'deconsolidation', 'yandexmarket', 'remain', 'overhang', 'company', 'continue', 'benefit', 'increase', 'online', 'advertising', 'revenue', 'robust', 'yandex', 'propertie', 'solid', 'momentum', 'russian', 'search', 'market', 'remain', 'key', 'growth', 'driver', 'increase', 'desktop', 'mobile', 'search', 'share', 'boost', 'search', 'revenue', 'additionally', 'company', 'strong', 'perform', 'taxi', 'classified', 'experiment', 'segment', 'drive', 'result', 'expect', 'contribute', 'upcoming', 'quarter', 'increase', 'number', 'ride', 'continue', 'aid', 'growth', 'taxi', 'segment', 'robust', 'yandexdrive', 'cloud', 'platform', 'remain', 'major', 'positive']",yandexs mount investment segment pose threat profitability deconsolidation yandexmarket remain overhang company continue benefit increase online advertising revenue robust yandex propertie solid momentum russian search market remain key growth driver increase desktop mobile search share boost search revenue additionally company strong perform taxi classified experiment segment drive result expect contribute upcoming quarter increase number ride continue aid growth taxi segment robust yandexdrive cloud platform remain major positive,5,5,0.0,5,5,0.0,0.9805
414,Yandex N.V._Attachment1(3).pdf,YNDX,6/13/2019,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2018 the company accounted for 563 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 57 in the firstquarter 2019,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2018', 'company', 'account', '563', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '57', 'firstquarter', '2019']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2018 company account 563 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 57 firstquarter 2019,1,1,0.0,1,1,0.0,0.9451
415,Yandex N.V._Attachment1(3).pdf,YNDX,3/27/2020,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2018 the company accounted for 563 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further,sell,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2018', 'company', 'account', '563', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2018 company account 563 share overall russian search traffic google mailru 396 34 respectively yandexs share,1,1,0.0,1,1,0.0,0.9313
416,Yandex N.V._Attachment1(4).pdf,YNDX,10/15/2018,the company derives revenues majorly from online advertising which reflects the concentration of its revenues the company operates primarily in emerging markets where overall online advertising spending and internet use penetration is comparatively lower than the developed countries moreover traditional modes of advertising such as television and radio are still preferable than the online internet advertising in most of the developing countries this remains a headwind notably any customer or group of customers of the company have not even accounted for more than 10 of its revenues since 2015 yandex operates primarily in russia consequently its financial and operating activities are exposed to economic conditions of the country hence any unfavorable economic situation is bound to impact the companys fundamentals significantly russias high dependency on oil and gas exports makes its economy prone to the fluctuations in the world oil and gas prices the economy witnessed a severe downturn in 2014 and 2015 due to a sharp fall in oil prices and this led to a substantial decline in the countrys stock market and depreciation of ruble additionally strict tax laws in russia remain major concerns as the company has recorded 5 million of unrecognized tax benefits as liabilities now if the company plans to enter the global market it will face a tough competition from google which already poses a stiff challenge in russia notably the company is trading at premium in terms of pricesales currently yandex has a trailing 12month ps ratio of 602 which compares unfavorably with what the industry witnessed over the last year consequently valuation looks slightly stretched from ps perspective,sell,"['company', 'derive', 'revenue', 'majorly', 'online', 'advertising', 'reflect', 'concentration', 'revenue', 'company', 'operate', 'primarily', 'emerge', 'market', 'overall', 'online', 'advertising', 'spending', 'internet', 'use', 'penetration', 'comparatively', 'low', 'develop', 'country', 'traditional', 'mode', 'advertising', 'television', 'radio', 'preferable', 'online', 'internet', 'advertising', 'develop', 'country', 'remain', 'headwind', 'notably', 'customer', 'group', 'customer', 'company', 'account', '10', 'revenue', '2015', 'yandex', 'operate', 'primarily', 'russia', 'consequently', 'financial', 'operating', 'activity', 'expose', 'economic', 'condition', 'country', 'unfavorable', 'economic', 'situation', 'bind', 'impact', 'company', 'fundamental', 'significantly', 'russia', 'high', 'dependency', 'oil', 'gas', 'export', 'make', 'economy', 'prone', 'fluctuation', 'world', 'oil', 'gas', 'price', 'economy', 'witness', 'severe', 'downturn', '2014', '2015', 'sharp', 'fall', 'oil', 'price', 'lead', 'substantial', 'decline', 'countrys', 'stock', 'market', 'depreciation', 'ruble', 'additionally', 'strict', 'tax', 'law', 'russia', 'remain', 'major', 'concern', 'company', 'record', '5', 'million', 'unrecognized', 'tax', 'benefit', 'liability', 'company', 'plan', 'enter', 'global', 'market', 'face', 'tough', 'competition', 'google', 'pose', 'stiff', 'challenge', 'russia', 'notably', 'company', 'trade', 'premium', 'term', 'pricesale', 'currently', 'yandex', 'trailing', '12month', 'ps', 'ratio', '602', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'consequently', 'valuation', 'look', 'slightly', 'stretch', 'ps', 'perspective']",company derive revenue majorly online advertising reflect concentration revenue company operate primarily emerge market overall online advertising spending internet use penetration comparatively low develop country traditional mode advertising television radio preferable online internet advertising develop country remain headwind notably customer group customer company account 10 revenue 2015 yandex operate primarily russia consequently financial operating activity expose economic condition country unfavorable economic situation bind impact company fundamental significantly russia high dependency oil gas export make economy prone fluctuation world oil gas price economy witness severe downturn 2014 2015 sharp fall oil price lead substantial decline countrys stock market depreciation ruble additionally strict tax law russia remain major concern company record 5 million unrecognized tax benefit liability company plan enter global market face tough competition google pose stiff challenge russia notably company trade premium term pricesale currently yandex trailing 12month ps ratio 602 compare unfavorably industry witness year consequently valuation look slightly stretch ps perspective,5,22,-0.6071428571428571,5,22,-0.6071428571428571,-0.3612
417,Yandex N.V._Attachment1(5).pdf,YNDX,4/30/2020,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2019 the company accounted for 563 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further,sell,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2019', 'company', 'account', '563', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2019 company account 563 share overall russian search traffic google mailru 396 34 respectively yandexs share,1,1,0.0,1,1,0.0,0.9313
418,Yandex N.V._Attachment1(6).pdf,YNDX,7/22/2019,the company derives revenues majorly from online advertising which reflects the concentration of its revenues the company operates primarily in emerging markets where overall online advertising spending and internet use penetration is comparatively lower than the developed countries moreover traditional modes of advertising such as television and radio are still preferable than the online internet advertising in most of the developing countries this remains a headwind notably any customer or group of customers of the company have not even accounted for more than 10 of its revenues since 2015 yandex operates primarily in russia consequently its financial and operating activities are exposed to economic conditions of the country hence any unfavorable economic situation is bound to impact the companys fundamentals significantly russias high dependency on oil and gas exports makes its economy prone to the fluctuations in the world oil and gas prices the economy witnessed a severe downturn in 2014 and 2015 due to a sharp fall in oil prices and this led to a substantial decline in the countrys stock market and depreciation of ruble additionally strict tax laws in russia remain major concerns as the company has recorded 5 million of unrecognized tax benefits as liabilities now if the company plans to enter the global market it will face a tough competition from google which already poses a stiff challenge in russia notably the company is trading at premium in terms of priceearnings currently yandex has a trailing 12month pe ratio of 3667 which compares unfavorably with what the industry witnessed over the last year consequently valuation looks stretched from pe perspective,sell,"['company', 'derive', 'revenue', 'majorly', 'online', 'advertising', 'reflect', 'concentration', 'revenue', 'company', 'operate', 'primarily', 'emerge', 'market', 'overall', 'online', 'advertising', 'spending', 'internet', 'use', 'penetration', 'comparatively', 'low', 'develop', 'country', 'traditional', 'mode', 'advertising', 'television', 'radio', 'preferable', 'online', 'internet', 'advertising', 'develop', 'country', 'remain', 'headwind', 'notably', 'customer', 'group', 'customer', 'company', 'account', '10', 'revenue', '2015', 'yandex', 'operate', 'primarily', 'russia', 'consequently', 'financial', 'operating', 'activity', 'expose', 'economic', 'condition', 'country', 'unfavorable', 'economic', 'situation', 'bind', 'impact', 'company', 'fundamental', 'significantly', 'russia', 'high', 'dependency', 'oil', 'gas', 'export', 'make', 'economy', 'prone', 'fluctuation', 'world', 'oil', 'gas', 'price', 'economy', 'witness', 'severe', 'downturn', '2014', '2015', 'sharp', 'fall', 'oil', 'price', 'lead', 'substantial', 'decline', 'countrys', 'stock', 'market', 'depreciation', 'ruble', 'additionally', 'strict', 'tax', 'law', 'russia', 'remain', 'major', 'concern', 'company', 'record', '5', 'million', 'unrecognized', 'tax', 'benefit', 'liability', 'company', 'plan', 'enter', 'global', 'market', 'face', 'tough', 'competition', 'google', 'pose', 'stiff', 'challenge', 'russia', 'notably', 'company', 'trade', 'premium', 'term', 'priceearning', 'currently', 'yandex', 'trailing', '12month', 'pe', 'ratio', '3667', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'consequently', 'valuation', 'look', 'stretch', 'pe', 'perspective']",company derive revenue majorly online advertising reflect concentration revenue company operate primarily emerge market overall online advertising spending internet use penetration comparatively low develop country traditional mode advertising television radio preferable online internet advertising develop country remain headwind notably customer group customer company account 10 revenue 2015 yandex operate primarily russia consequently financial operating activity expose economic condition country unfavorable economic situation bind impact company fundamental significantly russia high dependency oil gas export make economy prone fluctuation world oil gas price economy witness severe downturn 2014 2015 sharp fall oil price lead substantial decline countrys stock market depreciation ruble additionally strict tax law russia remain major concern company record 5 million unrecognized tax benefit liability company plan enter global market face tough competition google pose stiff challenge russia notably company trade premium term priceearning currently yandex trailing 12month pe ratio 3667 compare unfavorably industry witness year consequently valuation look stretch pe perspective,5,22,-0.6071428571428571,5,22,-0.6071428571428571,-0.3612
419,Yandex N.V._Attachment1(7).pdf,YNDX,11/21/2018,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2017 the company accounted for 551 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 559 in the thirdquarter 2018 moreover the companys search share on android in russia was 491 in the third quarter which was up from 412 in the yearago quarter the company is wellpoised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2017 it accounted for 93 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2017 total revenues of the company improved 304 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company operates in the ecommerce market and has entered ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2017', 'company', 'account', '551', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '559', 'thirdquarter', '2018', 'company', 'search', 'share', 'android', 'russia', '491', 'quarter', '412', 'yearago', 'quarter', 'company', 'wellpoise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2017', 'account', '93', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2017', 'total', 'revenue', 'company', 'improve', '304', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'operate', 'ecommerce', 'market', 'enter', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2017 company account 551 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 559 thirdquarter 2018 company search share android russia 491 quarter 412 yearago quarter company wellpoise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2017 account 93 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2017 total revenue company improve 304 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company operate ecommerce market enter ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector,17,18,-0.027777777777777776,17,18,-0.027777777777777776,0.9979
420,Yandex N.V._Attachment1.pdf,YNDX,6/29/2018,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2017 the company accounted for 551 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 565 in the firstquarter 2018 moreover the companys search share on android in russia was 463 in the first quarter which was up from 38 in the yearago quarter the company is wellpoised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2017 it accounted for 93 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2017 total revenues of the company improved 304 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company entered the ecommerce market with yandexmarket ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2017', 'company', 'account', '551', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '565', 'firstquarter', '2018', 'company', 'search', 'share', 'android', 'russia', '463', 'quarter', '38', 'yearago', 'quarter', 'company', 'wellpoise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2017', 'account', '93', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2017', 'total', 'revenue', 'company', 'improve', '304', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'enter', 'ecommerce', 'market', 'yandexmarket', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2017 company account 551 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 565 firstquarter 2018 company search share android russia 463 quarter 38 yearago quarter company wellpoise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2017 account 93 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2017 total revenue company improve 304 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company enter ecommerce market yandexmarket ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector,17,18,-0.027777777777777776,17,18,-0.027777777777777776,0.9979
421,Yandex N.V._Attachment1.pdf,YNDX,6/29/2018,the company derives revenues majorly from online advertising which reflects the concentration of its revenues the company operates primarily in emerging markets where overall online advertising spending and internet use penetration is comparatively lower than the developed countries moreover traditional modes of advertising such as television and radio are still preferable than the online internet advertising in most of the developing countries this remains a headwind notably any customer or group of customers of the company have not even accounted for more than 10 of its revenues since 2015 yandex operates primarily in russia consequently its financial and operating activities are exposed to economic conditions of the country hence any unfavorable economic situation is bound to impact the companys fundamentals significantly russias high dependency on oil and gas exports makes its economy prone to the fluctuations in the world oil and gas prices the economy witnessed a severe downturn in 2014 and 2015 due to a sharp fall in oil prices and this led to a substantial decline in the countrys stock market and depreciation of ruble additionally strict tax laws in russia remain major concerns as the company has recorded 5 million of unrecognized tax benefits as liabilities now if the company plans to enter the global market it will face a tough competition from google which already poses a stiff challenge in russia notably the company is trading at premium in terms of pricesales currently yandex has a trailing 12month ps ratio of 684 which compares unfavorably with what the industry witnessed over the last year additionally the ratio is is toward the high end of the valuation range in this period consequently valuation looks slightly stretched from ps perspective,sell,"['company', 'derive', 'revenue', 'majorly', 'online', 'advertising', 'reflect', 'concentration', 'revenue', 'company', 'operate', 'primarily', 'emerge', 'market', 'overall', 'online', 'advertising', 'spending', 'internet', 'use', 'penetration', 'comparatively', 'low', 'develop', 'country', 'traditional', 'mode', 'advertising', 'television', 'radio', 'preferable', 'online', 'internet', 'advertising', 'develop', 'country', 'remain', 'headwind', 'notably', 'customer', 'group', 'customer', 'company', 'account', '10', 'revenue', '2015', 'yandex', 'operate', 'primarily', 'russia', 'consequently', 'financial', 'operating', 'activity', 'expose', 'economic', 'condition', 'country', 'unfavorable', 'economic', 'situation', 'bind', 'impact', 'company', 'fundamental', 'significantly', 'russia', 'high', 'dependency', 'oil', 'gas', 'export', 'make', 'economy', 'prone', 'fluctuation', 'world', 'oil', 'gas', 'price', 'economy', 'witness', 'severe', 'downturn', '2014', '2015', 'sharp', 'fall', 'oil', 'price', 'lead', 'substantial', 'decline', 'countrys', 'stock', 'market', 'depreciation', 'ruble', 'additionally', 'strict', 'tax', 'law', 'russia', 'remain', 'major', 'concern', 'company', 'record', '5', 'million', 'unrecognized', 'tax', 'benefit', 'liability', 'company', 'plan', 'enter', 'global', 'market', 'face', 'tough', 'competition', 'google', 'pose', 'stiff', 'challenge', 'russia', 'notably', 'company', 'trade', 'premium', 'term', 'pricesale', 'currently', 'yandex', 'trailing', '12month', 'ps', 'ratio', '684', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'additionally', 'ratio', 'high', 'end', 'valuation', 'range', 'period', 'consequently', 'valuation', 'look', 'slightly', 'stretch', 'ps', 'perspective']",company derive revenue majorly online advertising reflect concentration revenue company operate primarily emerge market overall online advertising spending internet use penetration comparatively low develop country traditional mode advertising television radio preferable online internet advertising develop country remain headwind notably customer group customer company account 10 revenue 2015 yandex operate primarily russia consequently financial operating activity expose economic condition country unfavorable economic situation bind impact company fundamental significantly russia high dependency oil gas export make economy prone fluctuation world oil gas price economy witness severe downturn 2014 2015 sharp fall oil price lead substantial decline countrys stock market depreciation ruble additionally strict tax law russia remain major concern company record 5 million unrecognized tax benefit liability company plan enter global market face tough competition google pose stiff challenge russia notably company trade premium term pricesale currently yandex trailing 12month ps ratio 684 compare unfavorably industry witness year additionally ratio high end valuation range period consequently valuation look slightly stretch ps perspective,6,23,-0.5666666666666667,6,23,-0.5666666666666667,-0.3612
422,Yandex N.V._Attachment1.pdf,YNDX,9/4/2018,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2017 the company accounted for 551 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 562 in the secondquarter 2018 moreover the companys search share on android in russia was 478 in the second quarter which was up from 382 in the yearago quarter the company is wellpoised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2017 it accounted for 93 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2017 total revenues of the company improved 304 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company operates in the ecommerce market and has entered ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2017', 'company', 'account', '551', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '562', 'secondquarter', '2018', 'company', 'search', 'share', 'android', 'russia', '478', 'second', 'quarter', '382', 'yearago', 'quarter', 'company', 'wellpoise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2017', 'account', '93', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2017', 'total', 'revenue', 'company', 'improve', '304', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'operate', 'ecommerce', 'market', 'enter', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2017 company account 551 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 562 secondquarter 2018 company search share android russia 478 second quarter 382 yearago quarter company wellpoise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2017 account 93 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2017 total revenue company improve 304 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company operate ecommerce market enter ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector,17,18,-0.027777777777777776,17,18,-0.027777777777777776,0.9979
423,Yandex N.V._Attachment1.pdf,YNDX,1/7/2019,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2017 the company accounted for 551 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 559 in the thirdquarter 2018 moreover the companys search share on android in russia was 491 in the third quarter which was up from 412 in the yearago quarter the company is wellpoised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2017 it accounted for 93 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2017 total revenues of the company improved 304 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company operates in the ecommerce market and has entered ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector,sell,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2017', 'company', 'account', '551', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '559', 'thirdquarter', '2018', 'company', 'search', 'share', 'android', 'russia', '491', 'quarter', '412', 'yearago', 'quarter', 'company', 'wellpoise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2017', 'account', '93', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2017', 'total', 'revenue', 'company', 'improve', '304', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'operate', 'ecommerce', 'market', 'enter', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2017 company account 551 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 559 thirdquarter 2018 company search share android russia 491 quarter 412 yearago quarter company wellpoise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2017 account 93 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2017 total revenue company improve 304 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company operate ecommerce market enter ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector,17,18,-0.027777777777777776,17,18,-0.027777777777777776,0.9979
424,Yandex N.V._Attachment1.pdf,YNDX,3/5/2019,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2017 the company accounted for 551 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 565 in the fourthquarter 2018 moreover the companys search share on android in russia was 495 in the fourth quarter the company is wellpoised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2018 it accounted for 805 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2018 total revenues of the company improved 36 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company operates in the ecommerce market and has entered ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2017', 'company', 'account', '551', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '565', 'fourthquarter', '2018', 'company', 'search', 'share', 'android', 'russia', '495', 'fourth', 'quarter', 'company', 'wellpoise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2018', 'account', '805', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2018', 'total', 'revenue', 'company', 'improve', '36', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'operate', 'ecommerce', 'market', 'enter', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2017 company account 551 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 565 fourthquarter 2018 company search share android russia 495 fourth quarter company wellpoise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2018 account 805 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2018 total revenue company improve 36 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company operate ecommerce market enter ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector,17,18,-0.027777777777777776,17,18,-0.027777777777777776,0.9979
425,Yandex N.V._Attachment1.pdf,YNDX,4/23/2019,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2017 the company accounted for 551 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 565 in the fourthquarter 2018 moreover the companys search share on android in russia was 495 in the fourth quarter the company is wellpoised to capitalize on benefits from an increased penetration in the russian search engine market with the introduction of new apps such as turbo pages and alice which are aimed at enhancing its search results the online advertising services remain the key driver of yandexs topline growth in 2018 it accounted for 805 of total revenues the digital advertising market holds immense potential as the global spending on advertisement is increasing at a rapid pace per the reports from a media agency magna the global digital ad spending is expected to reach 291 billion and account for 50 of the total ad spending in 2020 for the past few years mobile advertising has been playing an important role driving the overall growth of online advertising market per zeniths report mobile advertising spend is expected to hit 180 billion by 2020 further mobile is anticipated to generate 35 of total revenues in this particular market of russia by 2022 consequently yandex is well poised to reap benefits from this high growth market on the back of its vast ad network various kinds of ad formats and robust yandexdirect an advertising placement platform yandexs strong efforts toward expansion of its product portfolio continue to aid its market share growth moreover the company has been successful in exhibiting strong doubledigit topline growth which indicates good management execution in 2018 total revenues of the company improved 36 from the previous year moreover both revenues and gross profit of the company have grown at a cagr of 8 over a period of last five years this can be attributed to strengthening search business as well as its new business units named taxi classifieds and media services the companys efforts toward expanding business beyond the search engine world are major positives the company has made significant amount of investments to diversify business the company operates in the ecommerce market and has entered ride sharing business with yandextaxi auto dealer market with autoru real estate sector with yandexrealty job search market with yandexjobs travel sector with yandextravel and video streaming market with its robust media services it also recently launched a car rental service called yandexdrive apart from these the company also managed to foray into the cloud industry with the launch of yandexcloud the company has rolled out its voice assistant alice and smart speaker yandexstation these have reinforced its competitive position against other players especially google in russia consequently we note that yandexs business is well diversified which will help it to overcome the loss from any sector if any with the profit from another sector zacks equity research yndx wwwzackscom page 4 of 10,sell,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2017', 'company', 'account', '551', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '565', 'fourthquarter', '2018', 'company', 'search', 'share', 'android', 'russia', '495', 'fourth', 'quarter', 'company', 'wellpoise', 'capitalize', 'benefit', 'increase', 'penetration', 'russian', 'search', 'engine', 'market', 'introduction', 'new', 'app', 'turbo', 'page', 'alice', 'aim', 'enhance', 'search', 'result', 'online', 'advertising', 'service', 'remain', 'key', 'driver', 'yandexs', 'topline', 'growth', '2018', 'account', '805', 'total', 'revenue', 'digital', 'advertising', 'market', 'hold', 'immense', 'potential', 'global', 'spending', 'advertisement', 'increase', 'rapid', 'pace', 'report', 'media', 'agency', 'magna', 'global', 'digital', 'ad', 'spending', 'expect', 'reach', '291', 'billion', 'account', '50', 'total', 'ad', 'spending', '2020', 'past', 'year', 'mobile', 'advertising', 'play', 'important', 'role', 'drive', 'overall', 'growth', 'online', 'advertising', 'market', 'zenith', 'report', 'mobile', 'advertising', 'spend', 'expect', 'hit', '180', 'billion', '2020', 'mobile', 'anticipate', 'generate', '35', 'total', 'revenue', 'particular', 'market', 'russia', '2022', 'consequently', 'yandex', 'poised', 'reap', 'benefit', 'high', 'growth', 'market', 'vast', 'ad', 'network', 'kind', 'ad', 'format', 'robust', 'yandexdirect', 'advertising', 'placement', 'platform', 'yandexs', 'strong', 'effort', 'expansion', 'product', 'portfolio', 'continue', 'aid', 'market', 'share', 'growth', 'company', 'successful', 'exhibit', 'strong', 'doubledigit', 'topline', 'growth', 'indicate', 'good', 'management', 'execution', '2018', 'total', 'revenue', 'company', 'improve', '36', 'previous', 'year', 'revenue', 'gross', 'profit', 'company', 'grow', 'cagr', '8', 'period', 'year', 'attribute', 'strengthen', 'search', 'business', 'new', 'business', 'unit', 'name', 'taxi', 'classified', 'medium', 'service', 'company', 'effort', 'expand', 'business', 'search', 'engine', 'world', 'major', 'positive', 'company', 'significant', 'investment', 'diversify', 'business', 'company', 'operate', 'ecommerce', 'market', 'enter', 'ride', 'share', 'business', 'yandextaxi', 'auto', 'dealer', 'market', 'autoru', 'real', 'estate', 'sector', 'yandexrealty', 'job', 'search', 'market', 'yandexjob', 'travel', 'sector', 'yandextravel', 'video', 'streaming', 'market', 'robust', 'medium', 'service', 'recently', 'launch', 'car', 'rental', 'service', 'call', 'yandexdrive', 'apart', 'company', 'manage', 'foray', 'cloud', 'industry', 'launch', 'yandexcloud', 'company', 'roll', 'voice', 'assistant', 'alice', 'smart', 'speaker', 'yandexstation', 'reinforce', 'competitive', 'position', 'player', 'especially', 'google', 'russia', 'consequently', 'note', 'yandexs', 'business', 'diversify', 'help', 'overcome', 'loss', 'sector', 'profit', 'sector', 'zack', 'equity', 'research', 'yndx', 'wwwzackscom', 'page', '4', '10']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2017 company account 551 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 565 fourthquarter 2018 company search share android russia 495 fourth quarter company wellpoise capitalize benefit increase penetration russian search engine market introduction new app turbo page alice aim enhance search result online advertising service remain key driver yandexs topline growth 2018 account 805 total revenue digital advertising market hold immense potential global spending advertisement increase rapid pace report media agency magna global digital ad spending expect reach 291 billion account 50 total ad spending 2020 past year mobile advertising play important role drive overall growth online advertising market zenith report mobile advertising spend expect hit 180 billion 2020 mobile anticipate generate 35 total revenue particular market russia 2022 consequently yandex poised reap benefit high growth market vast ad network kind ad format robust yandexdirect advertising placement platform yandexs strong effort expansion product portfolio continue aid market share growth company successful exhibit strong doubledigit topline growth indicate good management execution 2018 total revenue company improve 36 previous year revenue gross profit company grow cagr 8 period year attribute strengthen search business new business unit name taxi classified medium service company effort expand business search engine world major positive company significant investment diversify business company operate ecommerce market enter ride share business yandextaxi auto dealer market autoru real estate sector yandexrealty job search market yandexjob travel sector yandextravel video streaming market robust medium service recently launch car rental service call yandexdrive apart company manage foray cloud industry launch yandexcloud company roll voice assistant alice smart speaker yandexstation reinforce competitive position player especially google russia consequently note yandexs business diversify help overcome loss sector profit sector zack equity research yndx wwwzackscom page 4 10,17,19,-0.05405405405405406,17,19,-0.05405405405405406,0.9979
426,Yandex N.V._Attachment1.pdf,YNDX,8/19/2019,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2018 the company accounted for 563 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further increased to 569 in the secondquarter 2019,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2018', 'company', 'account', '563', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'increase', '569', 'secondquarter', '2019']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2018 company account 563 share overall russian search traffic google mailru 396 34 respectively yandexs share increase 569 secondquarter 2019,1,1,0.0,1,1,0.0,0.9451
427,Yandex N.V._Attachment1.pdf,YNDX,8/19/2019,the company derives revenues majorly from online advertising which reflects the concentration of its revenues the company operates primarily in emerging markets where overall online advertising spending and internet use penetration is comparatively lower than the developed countries moreover traditional modes of advertising such as television and radio are still preferable than the online internet advertising in most of the developing countries this remains a headwind notably any customer or group of customers of the company have not even accounted for more than 10 of its revenues since 2015 yandex operates primarily in russia consequently its financial and operating activities are exposed to economic conditions of the country hence any unfavorable economic situation is bound to impact the companys fundamentals significantly russias high dependency on oil and gas exports makes its economy prone to the fluctuations in the world oil and gas prices the economy witnessed a severe downturn in 2014 and 2015 due to a sharp fall in oil prices and this led to a substantial decline in the countrys stock market and depreciation of ruble additionally strict tax laws in russia remain major concerns as the company has recorded 5 million of unrecognized tax benefits as liabilities now if the company plans to enter the global market it will face a tough competition from google which already poses a stiff challenge in russia notably the company is trading at premium in terms of priceearnings currently yandex has a trailing 12month pe ratio of 3257 which compares unfavorably with what the industry witnessed over the last year consequently valuation looks stretched from pe perspective,sell,"['company', 'derive', 'revenue', 'majorly', 'online', 'advertising', 'reflect', 'concentration', 'revenue', 'company', 'operate', 'primarily', 'emerge', 'market', 'overall', 'online', 'advertising', 'spending', 'internet', 'use', 'penetration', 'comparatively', 'low', 'develop', 'country', 'traditional', 'mode', 'advertising', 'television', 'radio', 'preferable', 'online', 'internet', 'advertising', 'develop', 'country', 'remain', 'headwind', 'notably', 'customer', 'group', 'customer', 'company', 'account', '10', 'revenue', '2015', 'yandex', 'operate', 'primarily', 'russia', 'consequently', 'financial', 'operating', 'activity', 'expose', 'economic', 'condition', 'country', 'unfavorable', 'economic', 'situation', 'bind', 'impact', 'company', 'fundamental', 'significantly', 'russia', 'high', 'dependency', 'oil', 'gas', 'export', 'make', 'economy', 'prone', 'fluctuation', 'world', 'oil', 'gas', 'price', 'economy', 'witness', 'severe', 'downturn', '2014', '2015', 'sharp', 'fall', 'oil', 'price', 'lead', 'substantial', 'decline', 'countrys', 'stock', 'market', 'depreciation', 'ruble', 'additionally', 'strict', 'tax', 'law', 'russia', 'remain', 'major', 'concern', 'company', 'record', '5', 'million', 'unrecognized', 'tax', 'benefit', 'liability', 'company', 'plan', 'enter', 'global', 'market', 'face', 'tough', 'competition', 'google', 'pose', 'stiff', 'challenge', 'russia', 'notably', 'company', 'trade', 'premium', 'term', 'priceearning', 'currently', 'yandex', 'trailing', '12month', 'pe', 'ratio', '3257', 'compare', 'unfavorably', 'industry', 'witness', 'year', 'consequently', 'valuation', 'look', 'stretch', 'pe', 'perspective']",company derive revenue majorly online advertising reflect concentration revenue company operate primarily emerge market overall online advertising spending internet use penetration comparatively low develop country traditional mode advertising television radio preferable online internet advertising develop country remain headwind notably customer group customer company account 10 revenue 2015 yandex operate primarily russia consequently financial operating activity expose economic condition country unfavorable economic situation bind impact company fundamental significantly russia high dependency oil gas export make economy prone fluctuation world oil gas price economy witness severe downturn 2014 2015 sharp fall oil price lead substantial decline countrys stock market depreciation ruble additionally strict tax law russia remain major concern company record 5 million unrecognized tax benefit liability company plan enter global market face tough competition google pose stiff challenge russia notably company trade premium term priceearning currently yandex trailing 12month pe ratio 3257 compare unfavorably industry witness year consequently valuation look stretch pe perspective,5,22,-0.6071428571428571,5,22,-0.6071428571428571,-0.3612
428,Yandex N.V._Attachment1.pdf,YNDX,12/16/2019,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2018 the company accounted for 563 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further reached 566 in the thirdquarter 2019,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2018', 'company', 'account', '563', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'reach', '566', 'thirdquarter', '2019']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2018 company account 563 share overall russian search traffic google mailru 396 34 respectively yandexs share reach 566 thirdquarter 2019,1,2,-0.25,1,2,-0.25,0.9325
429,Yandex N.V._Attachment1.pdf,YNDX,11/25/2020,yandex search remains the most significant business unit of the company and has been witnessing steady growth since its inception the search engine market continues to gain traction due to increasing penetration of internet and mobile in 2019 the company accounted for 563 share of overall russian search traffic while google and mailru was 396 and 34 respectively yandexs share further reached 593 in the thirdquarter 2020,buy,"['yandex', 'search', 'remain', 'significant', 'business', 'unit', 'company', 'witness', 'steady', 'growth', 'inception', 'search', 'engine', 'market', 'continue', 'gain', 'traction', 'increase', 'penetration', 'internet', 'mobile', '2019', 'company', 'account', '563', 'share', 'overall', 'russian', 'search', 'traffic', 'google', 'mailru', '396', '34', 'respectively', 'yandexs', 'share', 'reach', '593', 'thirdquarter', '2020']",yandex search remain significant business unit company witness steady growth inception search engine market continue gain traction increase penetration internet mobile 2019 company account 563 share overall russian search traffic google mailru 396 34 respectively yandexs share reach 593 thirdquarter 2020,1,2,-0.25,1,2,-0.25,0.9325
430,Yelp Inc._Attachment1(12).pdf,YELP,11/12/2018,yelp is benefiting from its partnership with grubhub which provides users with access to a significant number of restaurants available for food ordering on the platform revenues earned from grubhub for transactions originating on yelp platform is a positive moreover management expects the partnership to improve yelps perorder profitability further the acquisition of eat24 business by grubhub provides the company with a better return on investment yelps acquisitions of nowait february and turnstyle april are boosting its connection with business owners we note that consumerfriendly services like reservations waitlist and wifi marketing along with yelp transaction platform cash back and request a quote drive subscriptions from businesses notably the companys other services revenues increased substantially in the last reported quarter driven by growth of yelp wifi marketing platform and synergies from combining yelp reservations with nowait sales team yelp has a healthy balance sheet with about 837 million in cash and cash equivalents and marketable securities and no longterm debt the company also generated operating cash flow of 609 million in the first six months of 2018 solid liquidity and cash flow enables it to undertake share buybacks during the third quarter the company repurchased nearly 160k shares at an aggregate price of 6 million from the beginning of the year to sep 30 the company repurchased 18 million shares for 72 million,buy,"['yelp', 'benefit', 'partnership', 'grubhub', 'provide', 'user', 'access', 'significant', 'number', 'restaurant', 'available', 'food', 'order', 'platform', 'revenue', 'earn', 'grubhub', 'transaction', 'originate', 'yelp', 'platform', 'positive', 'management', 'expect', 'partnership', 'improve', 'yelps', 'perorder', 'profitability', 'acquisition', 'eat24', 'business', 'grubhub', 'provide', 'company', 'well', 'return', 'investment', 'yelp', 'acquisition', 'nowait', 'february', 'turnstyle', 'april', 'boost', 'connection', 'business', 'owner', 'note', 'consumerfriendly', 'service', 'like', 'reservation', 'waitlist', 'wifi', 'marketing', 'yelp', 'transaction', 'platform', 'cash', 'request', 'quote', 'drive', 'subscription', 'business', 'notably', 'company', 'service', 'revenue', 'increase', 'substantially', 'report', 'quarter', 'drive', 'growth', 'yelp', 'wifi', 'marketing', 'platform', 'synergy', 'combine', 'yelp', 'reservation', 'nowait', 'sale', 'team', 'yelp', 'healthy', 'balance', 'sheet', '837', 'million', 'cash', 'cash', 'equivalent', 'marketable', 'security', 'longterm', 'debt', 'company', 'generate', 'operate', 'cash', 'flow', '609', 'million', 'month', '2018', 'solid', 'liquidity', 'cash', 'flow', 'enable', 'undertake', 'share', 'buyback', 'quarter', 'company', 'repurchase', 'nearly', '160k', 'share', 'aggregate', 'price', '6', 'million', 'beginning', 'year', 'sep', '30', 'company', 'repurchase', '18', 'million', 'share', '72', 'million']",yelp benefit partnership grubhub provide user access significant number restaurant available food order platform revenue earn grubhub transaction originate yelp platform positive management expect partnership improve yelps perorder profitability acquisition eat24 business grubhub provide company well return investment yelp acquisition nowait february turnstyle april boost connection business owner note consumerfriendly service like reservation waitlist wifi marketing yelp transaction platform cash request quote drive subscription business notably company service revenue increase substantially report quarter drive growth yelp wifi marketing platform synergy combine yelp reservation nowait sale team yelp healthy balance sheet 837 million cash cash equivalent marketable security longterm debt company generate operate cash flow 609 million month 2018 solid liquidity cash flow enable undertake share buyback quarter company repurchase nearly 160k share aggregate price 6 million beginning year sep 30 company repurchase 18 million share 72 million,7,7,0.0,7,7,0.0,0.9844
431,Yelp Inc._Attachment1(2).pdf,YELP,8/28/2018,yelp is benefiting from increasing advertising revenues driven by an increase in local salesforce and transition to nonterm advertising the companys shift toward selling advertising plans without any fixed duration resulted in a robust increase in paying advertiser accounts which drove results notably in the last reported quarter paying advertiser accounts had the fastest growth in two years yelp is benefiting from its partnership with grubhub which provides users with access to a significant number of restaurants available for food ordering on the platform revenues earned from grubhub for transactions originating on yelp platform is a positive moreover management expects the partnership to improve yelps perorder profitability further the acquisition of eat24 business by grubhub provides the company with a better return on investment yelps acquisitions of nowait february and turnstyle april are boosting its connection with business owners we note that consumerfriendly services like reservations waitlist and wifi marketing along with yelp transaction platform cash back and request a quote drive subscriptions from businesses notably the companys other services revenues increased substantially in the last reported quarter driven by expansion of the customer base of nowait and turnstyle along with growth from yelp reservations yelp has a healthy balance sheet with about 803 million in cash and cash equivalents and marketable securities and no longterm debt the company also generated operating cash flow of 609 million in the first six months of 2018 solid liquidity and cash flow enables it to undertake share buybacks as of jun 30 2018 the company had 122 million remaining in its share repurchase program of 200 million authorized in july 2017,buy,"['yelp', 'benefit', 'increase', 'advertising', 'revenue', 'drive', 'increase', 'local', 'salesforce', 'transition', 'nonterm', 'advertise', 'company', 'shift', 'sell', 'advertising', 'plan', 'fix', 'duration', 'result', 'robust', 'increase', 'pay', 'advertiser', 'account', 'drive', 'result', 'notably', 'reported', 'quarter', 'pay', 'advertiser', 'account', 'fast', 'growth', 'year', 'yelp', 'benefit', 'partnership', 'grubhub', 'provide', 'user', 'access', 'significant', 'number', 'restaurant', 'available', 'food', 'order', 'platform', 'revenue', 'earn', 'grubhub', 'transaction', 'originate', 'yelp', 'platform', 'positive', 'management', 'expect', 'partnership', 'improve', 'yelps', 'perorder', 'profitability', 'acquisition', 'eat24', 'business', 'grubhub', 'provide', 'company', 'well', 'return', 'investment', 'yelp', 'acquisition', 'nowait', 'february', 'turnstyle', 'april', 'boost', 'connection', 'business', 'owner', 'note', 'consumerfriendly', 'service', 'like', 'reservation', 'waitlist', 'wifi', 'marketing', 'yelp', 'transaction', 'platform', 'cash', 'request', 'quote', 'drive', 'subscription', 'business', 'notably', 'company', 'service', 'revenue', 'increase', 'substantially', 'report', 'quarter', 'drive', 'expansion', 'customer', 'base', 'nowait', 'turnstyle', 'growth', 'yelp', 'reservation', 'yelp', 'healthy', 'balance', 'sheet', '803', 'million', 'cash', 'cash', 'equivalent', 'marketable', 'security', 'longterm', 'debt', 'company', 'generate', 'operate', 'cash', 'flow', '609', 'million', 'month', '2018', 'solid', 'liquidity', 'cash', 'flow', 'enable', 'undertake', 'share', 'buyback', 'jun', '30', '2018', 'company', '122', 'million', 'remain', 'share', 'repurchase', 'program', '200', 'million', 'authorize', 'july', '2017']",yelp benefit increase advertising revenue drive increase local salesforce transition nonterm advertise company shift sell advertising plan fix duration result robust increase pay advertiser account drive result notably reported quarter pay advertiser account fast growth year yelp benefit partnership grubhub provide user access significant number restaurant available food order platform revenue earn grubhub transaction originate yelp platform positive management expect partnership improve yelps perorder profitability acquisition eat24 business grubhub provide company well return investment yelp acquisition nowait february turnstyle april boost connection business owner note consumerfriendly service like reservation waitlist wifi marketing yelp transaction platform cash request quote drive subscription business notably company service revenue increase substantially report quarter drive expansion customer base nowait turnstyle growth yelp reservation yelp healthy balance sheet 803 million cash cash equivalent marketable security longterm debt company generate operate cash flow 609 million month 2018 solid liquidity cash flow enable undertake share buyback jun 30 2018 company 122 million remain share repurchase program 200 million authorize july 2017,8,6,0.13333333333333333,8,6,0.13333333333333333,0.991
432,Yelp Inc._Attachment1(2).pdf,YELP,5/16/2019,yelp is benefiting from increasing advertising revenues driven by an increase in local salesforce and transition to nonterm advertising the companys shift toward selling advertising plans without any fixed duration is resulting in a solid increase in paying advertiser accounts the launch of verified license to woo advertisers in november 2018 at a monthly price point of 30 is also a positive further it is witnessing strong retention rates and an improving overall retention for the costperclick cpc advertisers who adopted it the companys strategy to provide products across a range of price points will give users more ways to grow with it yelp is benefiting from its partnership with grubhub which provides users with access to a significant number of restaurants available for food ordering on the platform revenues earned from grubhub for transactions originating on yelp platform is a positive moreover management expects the partnership to improve yelps perorder profitability further the acquisition of eat24 business by grubhub provides the company with a better return on investment the company also entered into new partnerships with industry leaders including visa godaddy and google among others which will help it explore additional opportunities and expand yelps acquisitions of nowait february and turnstyle april are boosting its connection with business owners we note that consumerfriendly services like reservations waitlist and wifi marketing along with yelp transaction platform cash back and request a quote drive subscriptions from businesses notably the companys other services revenues increased substantially in the last reported quarter driven by growth of yelp wifi marketing platform and synergies from combining yelp reservations with nowait sales team yelp has a healthy balance sheet with about 626 million in cash and cash equivalents and marketable securities and no longterm debt net cash flow from operating activities in the first quarter of 2019 was 41 million during the first quarter the company repurchased nearly 28 million shares for 102 million as a result the company lowered its outstanding shares by 35 from the beginning of this year,buy,"['yelp', 'benefit', 'increase', 'advertising', 'revenue', 'drive', 'increase', 'local', 'salesforce', 'transition', 'nonterm', 'advertise', 'company', 'shift', 'sell', 'advertising', 'plan', 'fix', 'duration', 'result', 'solid', 'increase', 'pay', 'advertiser', 'account', 'launch', 'verify', 'license', 'woo', 'advertiser', 'november', '2018', 'monthly', 'price', 'point', '30', 'positive', 'witness', 'strong', 'retention', 'rate', 'improve', 'overall', 'retention', 'costperclick', 'cpc', 'advertiser', 'adopt', 'company', 'strategy', 'provide', 'product', 'range', 'price', 'point', 'user', 'way', 'grow', 'yelp', 'benefit', 'partnership', 'grubhub', 'provide', 'user', 'access', 'significant', 'number', 'restaurant', 'available', 'food', 'order', 'platform', 'revenue', 'earn', 'grubhub', 'transaction', 'originate', 'yelp', 'platform', 'positive', 'management', 'expect', 'partnership', 'improve', 'yelps', 'perorder', 'profitability', 'acquisition', 'eat24', 'business', 'grubhub', 'provide', 'company', 'well', 'return', 'investment', 'company', 'enter', 'new', 'partnership', 'industry', 'leader', 'include', 'visa', 'godaddy', 'google', 'help', 'explore', 'additional', 'opportunity', 'expand', 'yelps', 'acquisition', 'nowait', 'february', 'turnstyle', 'april', 'boost', 'connection', 'business', 'owner', 'note', 'consumerfriendly', 'service', 'like', 'reservation', 'waitlist', 'wifi', 'marketing', 'yelp', 'transaction', 'platform', 'cash', 'request', 'quote', 'drive', 'subscription', 'business', 'notably', 'company', 'service', 'revenue', 'increase', 'substantially', 'report', 'quarter', 'drive', 'growth', 'yelp', 'wifi', 'marketing', 'platform', 'synergy', 'combine', 'yelp', 'reservation', 'nowait', 'sale', 'team', 'yelp', 'healthy', 'balance', 'sheet', '626', 'million', 'cash', 'cash', 'equivalent', 'marketable', 'security', 'longterm', 'debt', 'net', 'cash', 'flow', 'operate', 'activity', 'quarter', '2019', '41', 'million', 'quarter', 'company', 'repurchase', 'nearly', '28', 'million', 'share', '102', 'million', 'result', 'company', 'lower', 'outstanding', 'share', '35', 'beginning', 'year']",yelp benefit increase advertising revenue drive increase local salesforce transition nonterm advertise company shift sell advertising plan fix duration result solid increase pay advertiser account launch verify license woo advertiser november 2018 monthly price point 30 positive witness strong retention rate improve overall retention costperclick cpc advertiser adopt company strategy provide product range price point user way grow yelp benefit partnership grubhub provide user access significant number restaurant available food order platform revenue earn grubhub transaction originate yelp platform positive management expect partnership improve yelps perorder profitability acquisition eat24 business grubhub provide company well return investment company enter new partnership industry leader include visa godaddy google help explore additional opportunity expand yelps acquisition nowait february turnstyle april boost connection business owner note consumerfriendly service like reservation waitlist wifi marketing yelp transaction platform cash request quote drive subscription business notably company service revenue increase substantially report quarter drive growth yelp wifi marketing platform synergy combine yelp reservation nowait sale team yelp healthy balance sheet 626 million cash cash equivalent marketable security longterm debt net cash flow operate activity quarter 2019 41 million quarter company repurchase nearly 28 million share 102 million result company lower outstanding share 35 beginning year,12,6,0.3157894736842105,12,6,0.3157894736842105,0.9958
433,Yelp Inc._Attachment1(3).pdf,YELP,6/21/2019,yelp is benefiting from increasing advertising revenues driven by an increase in local salesforce and transition to nonterm advertising the companys shift toward selling advertising plans without any fixed duration is resulting in a solid increase in paying advertiser accounts the launch of verified license to woo advertisers in november 2018 at a monthly price point of 30 is also a positive further it is witnessing strong retention rates and an improving overall retention for the costperclick cpc advertisers who adopted it the companys strategy to provide products across a range of price points will give users more ways to grow with it,buy,"['yelp', 'benefit', 'increase', 'advertising', 'revenue', 'drive', 'increase', 'local', 'salesforce', 'transition', 'nonterm', 'advertise', 'company', 'shift', 'sell', 'advertising', 'plan', 'fix', 'duration', 'result', 'solid', 'increase', 'pay', 'advertiser', 'account', 'launch', 'verify', 'license', 'woo', 'advertiser', 'november', '2018', 'monthly', 'price', 'point', '30', 'positive', 'witness', 'strong', 'retention', 'rate', 'improve', 'overall', 'retention', 'costperclick', 'cpc', 'advertiser', 'adopt', 'company', 'strategy', 'provide', 'product', 'range', 'price', 'point', 'user', 'way', 'grow']",yelp benefit increase advertising revenue drive increase local salesforce transition nonterm advertise company shift sell advertising plan fix duration result solid increase pay advertiser account launch verify license woo advertiser november 2018 monthly price point 30 positive witness strong retention rate improve overall retention costperclick cpc advertiser adopt company strategy provide product range price point user way grow,4,2,0.2857142857142857,4,2,0.2857142857142857,0.9709
434,Yelp Inc._Attachment1.pdf,YELP,8/27/2018,yelp faces significant competition from internet giants like google microsofts bing and facebook the amount of resources these companies have is a major threat for yelp moreover yelp depends mostly on google to drive traffic to its website the company is apprehensive about the fact that reduced traffic owing to googles practice of intentionally pushing other sites down in the search rankings on both its website and app can hamper its longterm growth prospects as yelp is highly dependent on advertising revenues a decline in user growth does not bode well this is because a decline in number of unique visitors will eventually translate into a slowdown in the number of advertisers on the platform besides google facebook and instagram are more preferred advertising platforms compared to yelp thereby posing significant threat to the company yelp has been incurring significant losses increase in operating expenses driven by an expected increase in headcount product development and sales marketing expenses remain an overhang on the bottom line the continuously declining gross margin makes us apprehensive,sell,"['yelp', 'face', 'significant', 'competition', 'internet', 'giant', 'like', 'google', 'microsoft', 'bing', 'facebook', 'resource', 'company', 'major', 'threat', 'yelp', 'yelp', 'depend', 'google', 'drive', 'traffic', 'website', 'company', 'apprehensive', 'fact', 'reduce', 'traffic', 'owe', 'google', 'practice', 'intentionally', 'push', 'site', 'search', 'ranking', 'website', 'app', 'hamper', 'longterm', 'growth', 'prospect', 'yelp', 'highly', 'dependent', 'advertising', 'revenue', 'decline', 'user', 'growth', 'bode', 'decline', 'number', 'unique', 'visitor', 'eventually', 'translate', 'slowdown', 'number', 'advertiser', 'platform', 'google', 'facebook', 'instagram', 'preferred', 'advertising', 'platform', 'compare', 'yelp', 'pose', 'significant', 'threat', 'company', 'yelp', 'incur', 'significant', 'loss', 'increase', 'operating', 'expense', 'drive', 'expect', 'increase', 'headcount', 'product', 'development', 'sale', 'marketing', 'expense', 'remain', 'overhang', 'line', 'continuously', 'decline', 'gross', 'margin', 'make', 'apprehensive']",yelp face significant competition internet giant like google microsoft bing facebook resource company major threat yelp yelp depend google drive traffic website company apprehensive fact reduce traffic owe google practice intentionally push site search ranking website app hamper longterm growth prospect yelp highly dependent advertising revenue decline user growth bode decline number unique visitor eventually translate slowdown number advertiser platform google facebook instagram preferred advertising platform compare yelp pose significant threat company yelp incur significant loss increase operating expense drive expect increase headcount product development sale marketing expense remain overhang line continuously decline gross margin make apprehensive,2,12,-0.6666666666666666,2,12,-0.6666666666666666,0.6486
435,Yelp Inc._Attachment1.pdf,YELP,3/25/2019,yelp is benefiting from its partnership with grubhub which provides users with access to a significant number of restaurants available for food ordering on the platform revenues earned from grubhub for transactions originating on yelp platform is a positive moreover management expects the partnership to improve yelps perorder profitability further the acquisition of eat24 business by grubhub provides the company with a better return on investment yelps acquisitions of nowait february and turnstyle april are boosting its connection with business owners we note that consumerfriendly services like reservations waitlist and wifi marketing along with yelp transaction platform cash back and request a quote drive subscriptions from businesses notably the companys other services revenues increased substantially in the last reported quarter driven by growth of yelp wifi marketing platform and synergies from combining yelp reservations with nowait sales team yelp has a healthy balance sheet with about 7559 million in cash and cash equivalents and marketable securities and no long term debt the company also generated operating cash flow of 1602 million in 2018 solid liquidity and cash flow enables it to undertake share buybacks during the fourth quarter the company repurchased nearly 31 million shares for 115 million the company bought back approximately 49 million shares in 2018 for 187 million the company completed a 200million repurchase authorization last november yelp announced a 250million increase in the companys earlier share repurchase program of 250 million thereby bringing the total share buyback plan to 500 million,buy,"['yelp', 'benefit', 'partnership', 'grubhub', 'provide', 'user', 'access', 'significant', 'number', 'restaurant', 'available', 'food', 'order', 'platform', 'revenue', 'earn', 'grubhub', 'transaction', 'originate', 'yelp', 'platform', 'positive', 'management', 'expect', 'partnership', 'improve', 'yelps', 'perorder', 'profitability', 'acquisition', 'eat24', 'business', 'grubhub', 'provide', 'company', 'well', 'return', 'investment', 'yelp', 'acquisition', 'nowait', 'february', 'turnstyle', 'april', 'boost', 'connection', 'business', 'owner', 'note', 'consumerfriendly', 'service', 'like', 'reservation', 'waitlist', 'wifi', 'marketing', 'yelp', 'transaction', 'platform', 'cash', 'request', 'quote', 'drive', 'subscription', 'business', 'notably', 'company', 'service', 'revenue', 'increase', 'substantially', 'report', 'quarter', 'drive', 'growth', 'yelp', 'wifi', 'marketing', 'platform', 'synergy', 'combine', 'yelp', 'reservation', 'nowait', 'sale', 'team', 'yelp', 'healthy', 'balance', 'sheet', '7559', 'million', 'cash', 'cash', 'equivalent', 'marketable', 'security', 'long', 'term', 'debt', 'company', 'generate', 'operate', 'cash', 'flow', '1602', 'million', '2018', 'solid', 'liquidity', 'cash', 'flow', 'enable', 'undertake', 'share', 'buyback', 'fourth', 'quarter', 'company', 'repurchase', 'nearly', '31', 'million', 'share', '115', 'million', 'company', 'buy', 'approximately', '49', 'million', 'share', '2018', '187', 'million', 'company', 'complete', '200million', 'repurchase', 'authorization', 'november', 'yelp', 'announce', '250million', 'increase', 'company', 'early', 'share', 'repurchase', 'program', '250', 'million', 'bring', 'total', 'share', 'buyback', 'plan', '500', 'million']",yelp benefit partnership grubhub provide user access significant number restaurant available food order platform revenue earn grubhub transaction originate yelp platform positive management expect partnership improve yelps perorder profitability acquisition eat24 business grubhub provide company well return investment yelp acquisition nowait february turnstyle april boost connection business owner note consumerfriendly service like reservation waitlist wifi marketing yelp transaction platform cash request quote drive subscription business notably company service revenue increase substantially report quarter drive growth yelp wifi marketing platform synergy combine yelp reservation nowait sale team yelp healthy balance sheet 7559 million cash cash equivalent marketable security long term debt company generate operate cash flow 1602 million 2018 solid liquidity cash flow enable undertake share buyback fourth quarter company repurchase nearly 31 million share 115 million company buy approximately 49 million share 2018 187 million company complete 200million repurchase authorization november yelp announce 250million increase company early share repurchase program 250 million bring total share buyback plan 500 million,7,7,0.0,7,7,0.0,0.9853
436,Yelp Inc._Attachment1.pdf,YELP,3/25/2019,yelp faces significant competition from internet giants like google microsofts bing and facebook the amount of resources these companies have is a major threat for yelp moreover yelp depends mostly on google to drive traffic to its website the company is apprehensive about the fact that reduced traffic owing to googles practice of intentionally pushing other sites down in the search rankings on both its website and app can hamper its longterm growth prospects as yelp is highly dependent on advertising revenues a decline in user growth does not bode well this is because a decline in number of unique visitors will eventually translate into a slowdown in the number of advertisers on the platform the companys transition to nonterm advertising which is expected to drive customer acquisition in the long run is an overhang in the short run management noted that the pace of new account growth slowed in the third quarter compared with what the company witnessed in the first half of 2018 besides google facebook and instagram are more preferred advertising platforms compared to yelp thereby posing significant threat to the company yelp has been incurring significant losses increase in operating expenses driven by an expected increase in headcount product development and sales marketing expenses remain an overhang on the bottom line the continuously declining gross margin makes us apprehensive,sell,"['yelp', 'face', 'significant', 'competition', 'internet', 'giant', 'like', 'google', 'microsoft', 'bing', 'facebook', 'resource', 'company', 'major', 'threat', 'yelp', 'yelp', 'depend', 'google', 'drive', 'traffic', 'website', 'company', 'apprehensive', 'fact', 'reduce', 'traffic', 'owe', 'google', 'practice', 'intentionally', 'push', 'site', 'search', 'ranking', 'website', 'app', 'hamper', 'longterm', 'growth', 'prospect', 'yelp', 'highly', 'dependent', 'advertising', 'revenue', 'decline', 'user', 'growth', 'bode', 'decline', 'number', 'unique', 'visitor', 'eventually', 'translate', 'slowdown', 'number', 'advertiser', 'platform', 'company', 'transition', 'nonterm', 'advertising', 'expect', 'drive', 'customer', 'acquisition', 'long', 'run', 'overhang', 'short', 'run', 'management', 'note', 'pace', 'new', 'account', 'growth', 'slow', 'quarter', 'compare', 'company', 'witness', 'half', '2018', 'google', 'facebook', 'instagram', 'preferred', 'advertising', 'platform', 'compare', 'yelp', 'pose', 'significant', 'threat', 'company', 'yelp', 'incur', 'significant', 'loss', 'increase', 'operating', 'expense', 'drive', 'expect', 'increase', 'headcount', 'product', 'development', 'sale', 'marketing', 'expense', 'remain', 'overhang', 'line', 'continuously', 'decline', 'gross', 'margin', 'make', 'apprehensive']",yelp face significant competition internet giant like google microsoft bing facebook resource company major threat yelp yelp depend google drive traffic website company apprehensive fact reduce traffic owe google practice intentionally push site search ranking website app hamper longterm growth prospect yelp highly dependent advertising revenue decline user growth bode decline number unique visitor eventually translate slowdown number advertiser platform company transition nonterm advertising expect drive customer acquisition long run overhang short run management note pace new account growth slow quarter compare company witness half 2018 google facebook instagram preferred advertising platform compare yelp pose significant threat company yelp incur significant loss increase operating expense drive expect increase headcount product development sale marketing expense remain overhang line continuously decline gross margin make apprehensive,2,15,-0.7222222222222222,2,15,-0.7222222222222222,0.7845
437,Yelp Inc._Attachment1.pdf,YELP,4/22/2019,yelp is benefiting from increasing advertising revenues driven by an increase in local salesforce and transition to nonterm advertising the companys shift toward selling advertising plans without any fixed duration is resulting in a solid increase in paying advertiser accounts the launch of verified license to woo advertisers in november 2018 at a monthly price point of 30 is also a positive further it is witnessing strong retention rates and an improving overall retention for the costperclick cpc advertisers who adopted it the companys strategy to provide products across a range of price points will give users more ways to grow with it yelp is benefiting from its partnership with grubhub which provides users with access to a significant number of restaurants available for food ordering on the platform revenues earned from grubhub for transactions originating on yelp platform is a positive moreover management expects the partnership to improve yelps perorder profitability further the acquisition of eat24 business by grubhub provides the company with a better return on investment the company also entered into new partnerships with industry leaders including visa godaddy and google among others which will help it explore additional opportunities and expand yelps acquisitions of nowait february and turnstyle april are boosting its connection with business owners we note that consumerfriendly services like reservations waitlist and wifi marketing along with yelp transaction platform cash back and request a quote drive subscriptions from businesses notably the companys other services revenues increased substantially in the last reported quarter driven by growth of yelp wifi marketing platform and synergies from combining yelp reservations with nowait sales team yelp has a healthy balance sheet with about 7559 million in cash and cash equivalents and marketable securities and no long term debt the company also generated operating cash flow of 1602 million in 2018 solid liquidity and cash flow enables it to undertake share buybacks during the fourth quarter the company repurchased nearly 31 million shares for 115 million the company bought back approximately 49 million shares in 2018 for 187 million the company completed a 200million repurchase authorization last november yelp announced a 250million increase in the companys earlier share repurchase program of 250 million thereby bringing the total share buyback plan to 500 million,buy,"['yelp', 'benefit', 'increase', 'advertising', 'revenue', 'drive', 'increase', 'local', 'salesforce', 'transition', 'nonterm', 'advertise', 'company', 'shift', 'sell', 'advertising', 'plan', 'fix', 'duration', 'result', 'solid', 'increase', 'pay', 'advertiser', 'account', 'launch', 'verify', 'license', 'woo', 'advertiser', 'november', '2018', 'monthly', 'price', 'point', '30', 'positive', 'witness', 'strong', 'retention', 'rate', 'improve', 'overall', 'retention', 'costperclick', 'cpc', 'advertiser', 'adopt', 'company', 'strategy', 'provide', 'product', 'range', 'price', 'point', 'user', 'way', 'grow', 'yelp', 'benefit', 'partnership', 'grubhub', 'provide', 'user', 'access', 'significant', 'number', 'restaurant', 'available', 'food', 'order', 'platform', 'revenue', 'earn', 'grubhub', 'transaction', 'originate', 'yelp', 'platform', 'positive', 'management', 'expect', 'partnership', 'improve', 'yelps', 'perorder', 'profitability', 'acquisition', 'eat24', 'business', 'grubhub', 'provide', 'company', 'well', 'return', 'investment', 'company', 'enter', 'new', 'partnership', 'industry', 'leader', 'include', 'visa', 'godaddy', 'google', 'help', 'explore', 'additional', 'opportunity', 'expand', 'yelps', 'acquisition', 'nowait', 'february', 'turnstyle', 'april', 'boost', 'connection', 'business', 'owner', 'note', 'consumerfriendly', 'service', 'like', 'reservation', 'waitlist', 'wifi', 'marketing', 'yelp', 'transaction', 'platform', 'cash', 'request', 'quote', 'drive', 'subscription', 'business', 'notably', 'company', 'service', 'revenue', 'increase', 'substantially', 'report', 'quarter', 'drive', 'growth', 'yelp', 'wifi', 'marketing', 'platform', 'synergy', 'combine', 'yelp', 'reservation', 'nowait', 'sale', 'team', 'yelp', 'healthy', 'balance', 'sheet', '7559', 'million', 'cash', 'cash', 'equivalent', 'marketable', 'security', 'long', 'term', 'debt', 'company', 'generate', 'operate', 'cash', 'flow', '1602', 'million', '2018', 'solid', 'liquidity', 'cash', 'flow', 'enable', 'undertake', 'share', 'buyback', 'fourth', 'quarter', 'company', 'repurchase', 'nearly', '31', 'million', 'share', '115', 'million', 'company', 'buy', 'approximately', '49', 'million', 'share', '2018', '187', 'million', 'company', 'complete', '200million', 'repurchase', 'authorization', 'november', 'yelp', 'announce', '250million', 'increase', 'company', 'early', 'share', 'repurchase', 'program', '250', 'million', 'bring', 'total', 'share', 'buyback', 'plan', '500', 'million']",yelp benefit increase advertising revenue drive increase local salesforce transition nonterm advertise company shift sell advertising plan fix duration result solid increase pay advertiser account launch verify license woo advertiser november 2018 monthly price point 30 positive witness strong retention rate improve overall retention costperclick cpc advertiser adopt company strategy provide product range price point user way grow yelp benefit partnership grubhub provide user access significant number restaurant available food order platform revenue earn grubhub transaction originate yelp platform positive management expect partnership improve yelps perorder profitability acquisition eat24 business grubhub provide company well return investment company enter new partnership industry leader include visa godaddy google help explore additional opportunity expand yelps acquisition nowait february turnstyle april boost connection business owner note consumerfriendly service like reservation waitlist wifi marketing yelp transaction platform cash request quote drive subscription business notably company service revenue increase substantially report quarter drive growth yelp wifi marketing platform synergy combine yelp reservation nowait sale team yelp healthy balance sheet 7559 million cash cash equivalent marketable security long term debt company generate operate cash flow 1602 million 2018 solid liquidity cash flow enable undertake share buyback fourth quarter company repurchase nearly 31 million share 115 million company buy approximately 49 million share 2018 187 million company complete 200million repurchase authorization november yelp announce 250million increase company early share repurchase program 250 million bring total share buyback plan 500 million,13,9,0.17391304347826086,13,9,0.17391304347826086,0.9959
438,Yelp Inc._Attachment1.pdf,YELP,9/13/2019,yelp is benefiting from increasing advertising revenues driven by an increase in local salesforce and transition to nonterm advertising the companys shift toward selling advertising plans without any fixed duration is resulting in a solid increase in paying advertiser accountsnotably its two new products verified license and business highlights added more than 25000 active paying locations in the second quarter moreover these products boosted the number of paying advertising starts in the self serve channel the launch of yelp portfolios in june is also making the management optimistic further it is witnessing strong retention rates and an improving overall retention for the costperclick cpc advertisers the companys strategy to provide products across a range of price points will give users more ways to grow with it,buy,"['yelp', 'benefit', 'increase', 'advertising', 'revenue', 'drive', 'increase', 'local', 'salesforce', 'transition', 'nonterm', 'advertise', 'company', 'shift', 'sell', 'advertising', 'plan', 'fix', 'duration', 'result', 'solid', 'increase', 'pay', 'advertiser', 'accountsnotably', 'new', 'product', 'verify', 'license', 'business', 'highlight', 'add', '25000', 'active', 'pay', 'location', 'second', 'quarter', 'product', 'boost', 'number', 'pay', 'advertising', 'start', 'self', 'serve', 'channel', 'launch', 'yelp', 'portfolio', 'june', 'make', 'management', 'optimistic', 'witness', 'strong', 'retention', 'rate', 'improve', 'overall', 'retention', 'costperclick', 'cpc', 'advertiser', 'company', 'strategy', 'provide', 'product', 'range', 'price', 'point', 'user', 'way', 'grow']",yelp benefit increase advertising revenue drive increase local salesforce transition nonterm advertise company shift sell advertising plan fix duration result solid increase pay advertiser accountsnotably new product verify license business highlight add 25000 active pay location second quarter product boost number pay advertising start self serve channel launch yelp portfolio june make management optimistic witness strong retention rate improve overall retention costperclick cpc advertiser company strategy provide product range price point user way grow,6,1,0.625,6,1,0.625,0.9716
439,Yelp Inc._Attachment1.pdf,YELP,11/17/2020,yelp is benefiting from increasing advertising revenues driven by an increase in local salesforce and transition to nonterm advertising the companys shift toward selling,buy,"['yelp', 'benefit', 'increase', 'advertising', 'revenue', 'drive', 'increase', 'local', 'salesforce', 'transition', 'nonterm', 'advertise', 'company', 'shift', 'sell']",yelp benefit increase advertising revenue drive increase local salesforce transition nonterm advertise company shift sell,1,0,0.5,1,0,0.5,0.765
440,Yelp Inc_Attachment1(5).pdf,YELP,7/8/2020,yelp is benefiting from increasing advertising revenues driven by an increase in local salesforce and transition to nonterm advertising the companys shift toward selling advertising plans without any fixed duration is resulting in a solid increase in paying advertiser accounts notably at the end of the last reported quarter subscribing locations for verified license and business highlights more than doubled on a sequential basis moreover these products boosted the number of paying advertising starts in the self serve channel the launch of yelp portfolios in june is also making the management optimistic further it is witnessing strong retention rates and an improving overall retention for the costperclick cpc advertisers the companys strategy to provide products across a range of price points will give users more ways to grow with it yelp is benefiting from its partnership with grubhub which provides users with access to a significant number of restaurants available for food ordering on the platform revenues earned from grubhub for transactions originating on yelp platform is a positive moreover management expects the partnership to improve yelps perorder profitability further the acquisition of eat24 business by grubhub provides the company with a better return on investment the company also entered into new partnerships with industry leaders including visa godaddy and google among others which will help it explore additional opportunities and expand yelp is focusing on reducing costs in an effort to stay afloat amid coronavirus crisis as part of its costreduction plan yelp fired 1000 workers and furloughed more than 1100 staff the company projects its costsaving initiatives to reduce operating expenses by 70 million in the second quarter yelps acquisitions of nowait february and turnstyle april are boosting its connection with business owners we note that consumerfriendly services like reservations waitlist and wifi marketing along with yelp transaction platform cash back and request a quote drive subscriptions from businesses notably the companys other services revenues increased substantially in the last reported quarter driven by growth in yelp reservations and yelp waitlist yelp has a strong balance sheet with ample liquidity position and less debt obligations as of mar 31 2020 the company had net cash balance of 250 million compared with 237 million at the end of december 2019 also its total debttocapital ratio of 024 is much lower than the industry average of 097 since it has net cash available on its balance sheet the existing cash can be used for pursuing strategic acquisitions investment in growth initiatives and distribution to shareholders moreover the company generates strong cash flows the company generated 41 million in operating cash flow in the first quarter of 2020 additionally to further improve its liquidity and preserve cash the company has decided to temporarily suspend its share repurchase program,sell,"['yelp', 'benefit', 'increase', 'advertising', 'revenue', 'drive', 'increase', 'local', 'salesforce', 'transition', 'nonterm', 'advertise', 'company', 'shift', 'sell', 'advertising', 'plan', 'fix', 'duration', 'result', 'solid', 'increase', 'pay', 'advertiser', 'account', 'notably', 'end', 'reported', 'quarter', 'subscribe', 'location', 'verify', 'license', 'business', 'highlight', 'double', 'sequential', 'basis', 'product', 'boost', 'number', 'pay', 'advertising', 'start', 'self', 'serve', 'channel', 'launch', 'yelp', 'portfolio', 'june', 'make', 'management', 'optimistic', 'witness', 'strong', 'retention', 'rate', 'improve', 'overall', 'retention', 'costperclick', 'cpc', 'advertiser', 'company', 'strategy', 'provide', 'product', 'range', 'price', 'point', 'user', 'way', 'grow', 'yelp', 'benefit', 'partnership', 'grubhub', 'provide', 'user', 'access', 'significant', 'number', 'restaurant', 'available', 'food', 'order', 'platform', 'revenue', 'earn', 'grubhub', 'transaction', 'originate', 'yelp', 'platform', 'positive', 'management', 'expect', 'partnership', 'improve', 'yelps', 'perorder', 'profitability', 'acquisition', 'eat24', 'business', 'grubhub', 'provide', 'company', 'well', 'return', 'investment', 'company', 'enter', 'new', 'partnership', 'industry', 'leader', 'include', 'visa', 'godaddy', 'google', 'help', 'explore', 'additional', 'opportunity', 'expand', 'yelp', 'focus', 'reduce', 'cost', 'effort', 'stay', 'afloat', 'amid', 'coronavirus', 'crisis', 'costreduction', 'plan', 'yelp', 'fire', '1000', 'worker', 'furlough', '1100', 'staff', 'company', 'project', 'costsave', 'initiative', 'reduce', 'operating', 'expense', '70', 'million', 'second', 'quarter', 'yelp', 'acquisition', 'nowait', 'february', 'turnstyle', 'april', 'boost', 'connection', 'business', 'owner', 'note', 'consumerfriendly', 'service', 'like', 'reservation', 'waitlist', 'wifi', 'marketing', 'yelp', 'transaction', 'platform', 'cash', 'request', 'quote', 'drive', 'subscription', 'business', 'notably', 'company', 'service', 'revenue', 'increase', 'substantially', 'report', 'quarter', 'drive', 'growth', 'yelp', 'reservation', 'yelp', 'waitlist', 'yelp', 'strong', 'balance', 'sheet', 'ample', 'liquidity', 'position', 'debt', 'obligation', 'mar', '31', '2020', 'company', 'net', 'cash', 'balance', '250', 'million', 'compare', '237', 'million', 'end', 'december', '2019', 'total', 'debttocapital', 'ratio', '024', 'low', 'industry', 'average', '097', 'net', 'cash', 'available', 'balance', 'sheet', 'exist', 'cash', 'pursue', 'strategic', 'acquisition', 'investment', 'growth', 'initiative', 'distribution', 'shareholder', 'company', 'generate', 'strong', 'cash', 'flow', 'company', 'generate', '41', 'million', 'operate', 'cash', 'flow', 'quarter', '2020', 'additionally', 'improve', 'liquidity', 'preserve', 'cash', 'company', 'decide', 'temporarily', 'suspend', 'share', 'repurchase', 'program']",yelp benefit increase advertising revenue drive increase local salesforce transition nonterm advertise company shift sell advertising plan fix duration result solid increase pay advertiser account notably end reported quarter subscribe location verify license business highlight double sequential basis product boost number pay advertising start self serve channel launch yelp portfolio june make management optimistic witness strong retention rate improve overall retention costperclick cpc advertiser company strategy provide product range price point user way grow yelp benefit partnership grubhub provide user access significant number restaurant available food order platform revenue earn grubhub transaction originate yelp platform positive management expect partnership improve yelps perorder profitability acquisition eat24 business grubhub provide company well return investment company enter new partnership industry leader include visa godaddy google help explore additional opportunity expand yelp focus reduce cost effort stay afloat amid coronavirus crisis costreduction plan yelp fire 1000 worker furlough 1100 staff company project costsave initiative reduce operating expense 70 million second quarter yelp acquisition nowait february turnstyle april boost connection business owner note consumerfriendly service like reservation waitlist wifi marketing yelp transaction platform cash request quote drive subscription business notably company service revenue increase substantially report quarter drive growth yelp reservation yelp waitlist yelp strong balance sheet ample liquidity position debt obligation mar 31 2020 company net cash balance 250 million compare 237 million end december 2019 total debttocapital ratio 024 low industry average 097 net cash available balance sheet exist cash pursue strategic acquisition investment growth initiative distribution shareholder company generate strong cash flow company generate 41 million operate cash flow quarter 2020 additionally improve liquidity preserve cash company decide temporarily suspend share repurchase program,16,16,0.0,16,16,0.0,0.9943
441,Yelp Inc_Attachment1.pdf,YELP,10/12/2020,yelp is benefiting from increasing advertising revenues driven by an increase in local salesforce and transition to nonterm advertising the companys shift toward selling advertising plans without any fixed duration is resulting in a solid increase in paying advertiser accounts notably at the end of the last reported quarter subscribing locations for verified license and business highlights more than doubled on a sequential basis moreover these products boosted the number of paying advertising starts in the self serve channel the launch of yelp portfolios in june is also making the management optimistic further it is witnessing strong retention rates and an improving overall retention for the costperclick cpc advertisers the companys strategy to provide products across a range of price points will give users more ways to grow with it,buy,"['yelp', 'benefit', 'increase', 'advertising', 'revenue', 'drive', 'increase', 'local', 'salesforce', 'transition', 'nonterm', 'advertise', 'company', 'shift', 'sell', 'advertising', 'plan', 'fix', 'duration', 'result', 'solid', 'increase', 'pay', 'advertiser', 'account', 'notably', 'end', 'reported', 'quarter', 'subscribe', 'location', 'verify', 'license', 'business', 'highlight', 'double', 'sequential', 'basis', 'product', 'boost', 'number', 'pay', 'advertising', 'start', 'self', 'serve', 'channel', 'launch', 'yelp', 'portfolio', 'june', 'make', 'management', 'optimistic', 'witness', 'strong', 'retention', 'rate', 'improve', 'overall', 'retention', 'costperclick', 'cpc', 'advertiser', 'company', 'strategy', 'provide', 'product', 'range', 'price', 'point', 'user', 'way', 'grow']",yelp benefit increase advertising revenue drive increase local salesforce transition nonterm advertise company shift sell advertising plan fix duration result solid increase pay advertiser account notably end reported quarter subscribe location verify license business highlight double sequential basis product boost number pay advertising start self serve channel launch yelp portfolio june make management optimistic witness strong retention rate improve overall retention costperclick cpc advertiser company strategy provide product range price point user way grow,5,2,0.375,5,2,0.375,0.9666
442,Zynga Inc_Attachment1(5).pdf,ZNGA,8/7/2020,zyngas growth is primarily driven by strength in its diversified portfolio of live services also known as forever five franchises csr racing words with friends zynga poker empires puzzles and merge dragons are the key growth drivers for the company zyngas expanding mobile gaming portfolio is expected to drive growth tremendous initial response from soft launches of games such as farmville 3 and merger magic from gram games and puzzle combat from small giant games are positives zynga had cash and cash equivalents shortterm investments of approximately 155 billion as of jun 30 2020 compared with 126 billion as of mar 31 2020 however the companys net cash of 686 million on jun 30 2020 gives an indication that its debt level is manageable the company continues to invest in developing its platform and products,sell,"['zyngas', 'growth', 'primarily', 'drive', 'strength', 'diversified', 'portfolio', 'live', 'service', 'know', 'forever', 'franchise', 'csr', 'race', 'word', 'friend', 'zynga', 'poker', 'empire', 'puzzle', 'merge', 'dragon', 'key', 'growth', 'driver', 'company', 'zyngas', 'expand', 'mobile', 'gaming', 'portfolio', 'expect', 'drive', 'growth', 'tremendous', 'initial', 'response', 'soft', 'launch', 'game', 'farmville', '3', 'merger', 'magic', 'gram', 'game', 'puzzle', 'combat', 'small', 'giant', 'game', 'positive', 'zynga', 'cash', 'cash', 'equivalent', 'shortterm', 'investment', 'approximately', '155', 'billion', 'jun', '30', '2020', 'compare', '126', 'billion', 'mar', '31', '2020', 'company', 'net', 'cash', '686', 'million', 'jun', '30', '2020', 'give', 'indication', 'debt', 'level', 'manageable', 'company', 'continue', 'invest', 'develop', 'platform', 'product']",zyngas growth primarily drive strength diversified portfolio live service know forever franchise csr race word friend zynga poker empire puzzle merge dragon key growth driver company zyngas expand mobile gaming portfolio expect drive growth tremendous initial response soft launch game farmville 3 merger magic gram game puzzle combat small giant game positive zynga cash cash equivalent shortterm investment approximately 155 billion jun 30 2020 compare 126 billion mar 31 2020 company net cash 686 million jun 30 2020 give indication debt level manageable company continue invest develop platform product,3,4,-0.125,3,4,-0.125,0.9349
443,Zynga Inc_Attachment1.pdf,ZNGA,11/6/2020,zyngas growth is primarily driven by strength in its diversified portfolio of live services also known as forever five franchises csr racing words with friends zynga poker empires puzzles and merge dragons are the key growth drivers for the company,buy,"['zyngas', 'growth', 'primarily', 'drive', 'strength', 'diversified', 'portfolio', 'live', 'service', 'know', 'forever', 'franchise', 'csr', 'race', 'word', 'friend', 'zynga', 'poker', 'empire', 'puzzle', 'merge', 'dragon', 'key', 'growth', 'driver', 'company']",zyngas growth primarily drive strength diversified portfolio live service know forever franchise csr race word friend zynga poker empire puzzle merge dragon key growth driver company,1,2,-0.25,1,2,-0.25,0.891
